<SEC-DOCUMENT>0001213900-25-038045.txt : 20250501
<SEC-HEADER>0001213900-25-038045.hdr.sgml : 20250501
<ACCEPTANCE-DATETIME>20250501070830
ACCESSION NUMBER:		0001213900-25-038045
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		115
FILED AS OF DATE:		20250501
DATE AS OF CHANGE:		20250501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NewGenIvf Group Ltd
		CENTRAL INDEX KEY:			0001981662
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			D8

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-285629
		FILM NUMBER:		25899373

	BUSINESS ADDRESS:	
		STREET 1:		13/F, PS TOWER, SUKHUMVIT 21 RD (ASOKE)
		CITY:			BANGKOK
		STATE:			W1
		ZIP:			0000
		BUSINESS PHONE:		852-2861-1666

	MAIL ADDRESS:	
		STREET 1:		1/F, PIER 2, CENTRAL
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			999077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ASPAC I Mini Acquisition Corp.
		DATE OF NAME CHANGE:	20230614
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>ea0239801-f1a1_newgen.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM F-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 01 09:22:10 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nivf="http://www.newgenivf.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">As filed with the Securities and Exchange
Commission on May 1, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b style="-keep: true">Registration No. 333-285629</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="margin: 0"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
DC 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription" id="ixv-44"><b style="-keep: true">Amendment No. 1</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form
<span style="-sec-ix-hidden: hidden-fact-0">F-1</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-63"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEWGENIVF
GROUP LIMITED</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Exact
name of registrant as specified in its charter)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-77"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>British Virgin Islands</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8090</b></span></td> <td style="width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not Applicable</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State or other jurisdiction of<br/> incorporation or organization)</i></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Primary Standard Industrial<br/> Classification Code Number)</i></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S. Employer<br/> Identification Number)</i></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-112"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wing
Fung Alfred Siu</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b style="-keep: true"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-122">36/39-36/40, 13th
Floor, PS Tower<br/>
Sukhumvit 21 Road (Asoke)</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-24160">Khlong Toei Nuea Sub-district</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine3" id="ixv-24161">Watthana District</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-24162">Bangkok</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-24163">10110</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-24164">Thailand</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tel:
<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-24165">+1 (212)</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-24166">537-4406</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address,
including zip code, and telephone number,</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>including
area code, of registrant&#8217;s principal executive offices)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cogency
</b></span><b><span style="font-size: 10pt">Global Inc.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-24167">122
East 42nd Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-24168">18th Floor</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-24169">New
York</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince" id="ixv-24170">NY</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-24171">10168</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-24172">(212)</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-24173">947-7200</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt"><i>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b><i>Copies
to:</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Steve Lin</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Han Kun Law Offices LLP</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Rooms 4301-10, 43/F.,
Gloucester Tower</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The Landmark</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>15, Queen&#8217;s Road
Central</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Hong Kong</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>+852 2820 5600</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Approximate
date of commencement of proposed sale to the public:</b> As soon as practicable after the effective date hereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If any of the securities
being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check
the following box. <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If this form is
filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If this form is
a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If this form is
a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Emerging growth
company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="ixv-245"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging
growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
7(a)(2)(B) of the Securities Act. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="ixv-253"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>The registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant
shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the Commission, acting
pursuant to said Section 8(a), may determine.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt; color: Red"><b>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt; color: Red">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 34%"><span style="font-size: 10pt; color: Red"><b>PRELIMINARY PROSPECTUS</b></span></td>
    <td style="width: 33%; text-align: center"><span style="font-size: 10pt; color: Red"><b>SUBJECT TO COMPLETION</b></span></td>
    <td style="width: 33%; text-align: right"><span style="color: Red"><b>DATED MAY 1, 2025</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt; color: Red">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">123,275,000 Class A Ordinary Shares</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NewGenIvf Group
Limited</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">This prospectus relates
to the resale by the selling securityholders identified in this prospectus (&#8220;Selling Securityholders&#8221;) of up to 123,275,000
Class A Ordinary Shares, no par value per share (&#8220;Class A Ordinary Shares&#8221;), consisting of (i) 125,000 Class A Ordinary Shares
issued to Genetics &amp; IVF Institute, Inc. (&#8220;GIVF&#8221;) in connection with the Purchase Agreement dated as of January 21, 2025,
by and between the Company and GIVF (&#8220;MicroSort Purchase Agreement&#8221;); and (ii) 150,000 Class A Ordinary Shares issued to
A SPAC Holdings Group Corp. (&#8220;ASPAC&#8221;) in connection with a consulting services agreement dated as of February 24, 2025, by
and between the Company and ASPAC (&#8220;ASPAC Agreement&#8221;); (iii) an additional 120,000,000 Class A Ordinary Shares issuable to
JAK Opportunities VI LLC upon the conversion of (a) the Remaining Additional Notes (as defined below), (b) the senior convertible notes
exchanged on August 8, 2024 (&#8220;Exchange Notes&#8221;), (c) the exercise of Series A warrants to purchase Class A Ordinary Shares
(the &#8220;Series A Warrants&#8221;), (d) the exercise of Series B warrants to purchase Class A Ordinary Shares (the &#8220;Series B
Warrants&#8221;), (e) the exercise of Series C warrants to purchase Class A Ordinary Shares (the &#8220;Exchange Warrants&#8221; and
together with the Series A Warrants and the Series B Warrants, the &#8220;Warrants&#8221;), and (f) the New CB Initial Note (as defined
below); and (iv) 3,000,000 Class A Ordinary Shares issuable by the Company to White Lion Capital, LLC (&#8220;White Lion&#8221;) in connection
with the Common Stock Purchase Agreement dated as of November 21, 2024, by and between the Company and White Lion (the &#8220;White Lion
Purchase Agreement&#8221;) (the &#8220;Resale Shares&#8221;). The Resale Shares were issued in private placements to certain Selling
Securityholders, see &#8220;<i>Item 7. Recent Sales of Unregistered Securities</i>&#8221; on page II-1 of this prospectus.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering the offer
and resale of the Resale Shares to satisfy certain registration rights we have granted. The Resale Shares will be resold from time to
time by the Selling Securityholders listed in the section titled &#8220;Selling Securityholders&#8221; beginning on page 91.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Resale Shares represent
more than the number of our outstanding Class A Ordinary Shares, and the sales of the Resale Shares, or the perception that those sales
might occur, could depress the market price of our Class A Ordinary Shares and could impair our ability to raise capital through the sale
of additional equity securities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Our registration of the
securities covered by this prospectus does not mean that the Selling Securityholders will offer or sell these securities. The Selling
Securityholders may offer all or part of the securities for resale from time to time through public or private transactions in amounts,
at prices and on terms determined at the time of offering. The Selling Securityholders may offer and sell these securities directly to
purchasers, through agents in ordinary brokerage transactions, in underwritten offerings, directly to market makers of our shares or
through any other means described in the section entitled &#8220;Plan of Distribution&#8221; herein. In connection with any sales of
securities offered hereunder, any underwriters, agents, brokers or dealers participating in such sales may be deemed to be &#8220;underwriters&#8221;
within the meaning of the Securities Act of 1933, as amended, or the &#8220;Securities Act.&#8221; White Lion is an &#8220;underwriter&#8221;
within the meaning of Section 2(a)(11) of the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The actual number of Class
A Ordinary Shares issuable to White Lion will vary depending on the then-current market price of Class A Ordinary Shares sold or issuable
to White Lion under the White Lion Purchase Agreement and are subject to the further limitations set forth in the White Lion Purchase
Agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">We are not selling any
securities under this prospectus and will not receive any of the proceeds from the sale of the Resale Shares by the Selling Securityholders.
However, we may receive gross proceeds of up to $500 million from the sale of our Class A Ordinary Shares to White Lion pursuant to the
White Lion Purchase Agreement. The actual proceeds from White Lion may be less than this amount, depending on the number of Class A Ordinary
Shares sold and the price at which the Class A Ordinary Shares are sold. In addition, we may receive proceeds from the conversion of
the Additional Notes, Exchange Notes, Warrants, New CB Initial Note which proceeds will be used for working capital and other general
corporate purposes.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders will pay all brokerage fees and
commissions and similar expenses attributable to the sales of the Resale Shares. We will pay the expenses (except brokerage fees and
commissions and similar expenses) incurred in registering the Resale Shares, including legal and accounting fees. See &#8220;Plan of
Distribution.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Our Class A Ordinary Shares
currently trade on The Nasdaq Global Market under the symbol &#8220;NIVF.&#8221; The last reported closing price of our Class A Ordinary
Shares on April 29, 2025 was $0.31.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify as a &#8220;foreign
private issuer,&#8221; as defined in Rule 405 under the U.S. Securities Act of 1933, as amended, or the Securities Act, and are a &#8220;controlled
company&#8221; as defined under the Listing Rules of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221; or the &#8220;Exchange&#8221;),
thus we are eligible for reduced public company reporting requirements, and are permitted to rely on certain exemptions from Nasdaq corporate
governance rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf Group Limited (&#8220;NewGenIvf,&#8221;
&#8220;Company,&#8221; &#8220;our,&#8221; &#8220;we,&#8221; or &#8220;us&#8221;) is a British Virgin Islands holding company with our
operations conducted through our subsidiaries in the Cayman Islands (our wholly-owned subsidiary, NewGenIvf Limited) and in Asia (Hong
Kong, Thailand, Kyrgyzstan, and the Kingdom of Cambodia). Under this holding company structure, investors are purchasing equity interests
in NewGenIvf, a British Virgin Islands holding company, and obtaining indirect ownership interests in our Cayman Islands and Asian operating
subsidiaries. Substantially all of NewGenIvf&#8217;s operations and assets are based in Thailand, Cambodia and Kyrgyzstan. As a result,
its businesses and operations are subject to the changing economic conditions prevailing from time to time in such countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On December 11, 2024,
NewGenIvf announced its entry into a binding term sheet with European Wellness Investment Holdings Limited (&#8220;EWIHL&#8221;) for
a reverse merger, in which EWIHL would, on completion, hold approximately 61.6% of NewGenIvf&#8217;s equity (the &#8220;EWIHL Proposed
Transaction"). The completion of the EWIHL Proposed Transaction is subject to, among other matters, the completion of due diligence,
the delivery of draft audited financials for the years ended 2023 and 2024 (the &#8220;Draft Financials&#8221;) of EWIHL by March 31,
2025, and the negotiation of a definitive agreement. On March 31, 2025, NewGenIvf terminated the term sheet for the EWIHL Proposed Transaction
as EWIHL had failed to produce certain draft audited financials, which were specifically required in the term sheet.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On November 21, 2024, the
Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS
Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel
(the &#8220;Panel&#8221;) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the Panel
will consider its appeal at&#160;an oral hearing&#160;on January 28, 2025 (the &#8220;Hearing&#8221;). On February 19, 2025, the Company
received written decision from the Panel, which granted an extension, allowing the Company additional time to regain compliance with
the Nasdaq Stock Market&#8217;s continued listing requirements, subject to meeting specific compliance criteria within designated timeframes.
As of the date of this prospectus, in accordance with the Panel&#8217;s extension, the Company has already made progress on its compliance
plan, including carrying out a 1-for-20 reverse stock split of its issued and unissued shares which was effected on February 11, 2025.
The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share. On February 27, 2025, the
Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company&#8217;s securities had been
at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the Company had regained
compliance with the minimum bid price rule. In addition, on February 27, 2025, the Company received a confirmation from Nasdaq that its
application to transfer its listing to the Nasdaq Capital Market had been approved and that the Company&#8217;s securities would be transferred
to the Nasdaq Capital Market at the opening of business on February 28, 2025. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><b>Investing in our Class A
Ordinary Shares involves a high degree of risk, including the risk of losing your entire investment. See &#8220;<i>Risk Factors</i>&#8221;
starting on page 25 to read about the factors you should consider before buying the Ordinary Shares.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Neither the Securities
and Exchange Commission, or the SEC, nor any state or other foreign securities commission has approved nor disapproved these securities
or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2025</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>TABLE OF CONTENTS</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 90%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_001"><span style="font-size: 10pt">About this Prospectus</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">iii</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_002"><span style="font-size: 10pt">Glossary of Defined Terms</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">iii</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_003"><span style="font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_004"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_005"><span style="font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#s_001">Management</a></td>
    <td style="text-align: center">53</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#s_002">Related Party Transactions&#160;</a></td>
    <td style="text-align: center">59</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_006"><span style="font-size: 10pt">Listing Details</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_007"><span style="font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_008"><span style="font-size: 10pt">Dividend Policy</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#aa_001">Management&#8217;s Discussion and Analysis of Financial Condition and Results of
    Operations</a></td>
    <td style="text-align: center">61</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><a href="#aa_002">Business</a></p>


</td>
    <td style="text-align: center">76</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_009"><span style="font-size: 10pt">Selling Securityholders</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">91</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_010"><span style="font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="text-align: center">93</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_011"><span style="font-size: 10pt">Description of Share Capital</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">95</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_012"><span style="font-size: 10pt">Taxation</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">98</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_013"><span style="font-size: 10pt">Legal Matters</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">104</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_014"><span style="font-size: 10pt">Experts</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">104</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_015"><span style="font-size: 10pt">Expenses</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">104</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_016"><span style="font-size: 10pt">Enforceability of Civil Liabilities</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">105</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_017"><span style="font-size: 10pt">Where You Can Find Additional Information</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">106</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>You should rely only on
the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred
you. Neither we nor the Selling Securityholder have authorized anyone to provide you with different information. Neither we nor the Selling
Securityholder are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that
the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable
document. Since the date of this prospectus, our business, financial condition, results of operations and prospects may have changed.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For investors outside of the
United States: Neither we nor the Selling Securityholder have done anything that would permit this offering or possession or distribution
of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to
inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to NewGenIvf Group Limited and its wholly owned subsidiary, NewGenIvf
Limited, a Cayman Islands company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our reporting currency is
the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus to &#8220;dollars&#8221;
or &#8220;$&#8221; are to U.S. dollars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus includes statistical,
market and industry data and forecasts which we obtained from publicly available information and independent industry publications and
reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they obtain
their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness of the information.
Although we believe that these sources are reliable, we have not independently verified the information contained in such publications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America, or
U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The number of Class A
Ordinary Shares and Class B Ordinary Shares currently issued and outstanding was 7,508,094 as of April 29, 2025. No new shares are being
issued by the Company pursuant to this offering.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>ABOUT
THIS PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">This prospectus describes
the general manner in which the Selling Securityholders identified in this prospectus may offer from time to time up to 123,275,000 Class
A Ordinary Shares through any means described in the section entitled &#8220;Plan of Distribution.&#8221; You should rely only on the
information contained in this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated
by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Securityholders have
authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should
not rely on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation
of an offer to purchase, the Resale Shares offered by this prospectus, any prospectus supplement or amendments thereto in any jurisdiction
to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should
not assume that the information contained in this prospectus, any prospectus supplement or amendments thereto, as well as information
we have previously filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), is accurate as of any date other than
the date on the front cover of the applicable document. The information contained in this prospectus is current only as of the date on
the front cover of the prospectus. Our business, financial condition, results of operations, and prospects may have changed since that
date.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If necessary, the specific
manner in which the Class A Ordinary Shares may be offered and sold will be described in a supplement to this prospectus, which supplement
may also add, update or change any of the information contained in this prospectus. To the extent there is a conflict between the information
contained in this prospectus and the prospectus supplement, you should rely on the information in the prospectus supplement, provided
that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example,
any prospectus supplement&#8212;the statement in the document having the later date modifies or supersedes the earlier statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>GLOSSARY
OF DEFINED TERMS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, unless
otherwise indicated or the context otherwise requires, references to:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;ASCA&#8221; means
A SPAC I Acquisition Corp., a British Virgin Islands business company.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;A SPAC I Mini Acquisition
Corp.&#8221; means A SPAC I Mini Acquisition Corp., a British Virgin Islands business company.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Business Combination&#8221;
means the transactions contemplated by the Merger Agreement, pursuant to which (i) ASCA reincorporated to the British Virgin Islands
by merging with and into the Company; and (ii) Merger Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being
a wholly-owned subsidiary of the Company.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;BVI&#8221; means British
Virgin Islands.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;BVI Act&#8221; means
BVI Business Companies Act (As Revised).</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Class A Ordinary Share&#8221;
means Class A ordinary shares of the Company, no par value per share.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Class B Ordinary Share&#8221;
means (x) the Company&#8217;s Class B ordinary shares with no par value per share, and (y) any shares into which such ordinary shares
shall have been changed or any shares resulting from a reclassification of such ordinary shares.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Closing&#8221; means
the consummation of the Business Combination, which occurred on April 3, 2024.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Company&#8221; means
NewGenIvf Group Limited, a British Virgin Islands business company, the surviving entity of the Business Combination.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Legacy NewGenIvf&#8221;
means NewGenIvf Limited, a Cayman Islands exempted company, which became a wholly owned subsidiary of ASCA upon the Closing.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Merger Agreement&#8221;
means the Merger Agreement entered into on February 15, 2023, and as amended on June 12, 2023 and December 6, 2023, between ASCA, A SPAC
I Mini Acquisition Corp., Merger Sub, Legacy NewGenIvf, and certain shareholders of Legacy NewGenIvf, pursuant to which the Reincorporation
Merger and Acquisition Merger were consummated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Merger Sub&#8221;
means A SPAC I Mini Sub Acquisition Corp., a Cayman Islands exempted company and former wholly-owned subsidiary of A SPAC I Mini Acquisition
Corp.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Memorandum and Articles
of Association&#8221; means the Company&#8217;s Amended and Restated Memorandum and Articles of Association, as and restated on March
4, 2025.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;NewGenIvf&#8221; means
NewGenIvf Group Limited, a British Virgin Islands business company, the surviving entity of the Business Combination, unless the context
so requires.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#8220;Ordinary Shares&#8221;
means the Class A Ordinary Shares and Class B Ordinary Shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Preferred Shares&#8221;
means preferred shares of the Company, no par value per share.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Reincorporation Merger&#8221;
means the first step of the Business Combination which occurred pursuant to the Merger Agreement, in which ASCA reincorporated to the
British Virgin Islands by merging with and into A SPAC I Mini Acquisition Corp.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Reverse Stock Split&#8221;
means the the 1-for-20 reverse stock split effected by the Company on February 11, 2025. In this registration statement, where we state
historical share and per-share numbers, we have, where appropriate, reflected a retroactive adjustment due to the Reverse Stock Split
in parentheses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<a id="a_003"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>This
summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully,
including the &#8220;Risk Factors&#8221; section and the financial statements and related notes appearing at the end of this prospectus.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Unless
the context otherwise requires, all references in this Prospectus Summary to &#8220;NewGenIvf,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
and &#8220;us&#8221; refer to Legacy NewGenIvf and its subsidiaries as they existed prior to the Closing if described in relation to
a date prior to April 3, 2024. Any references to &#8220;NewGenIvf,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; with
respect to the present time, a future time, or a date after April 3, 2024 refers to NewGenIvf, a British Virgin Islands company, and
its subsidiaries, whose existence continued after the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are an assisted reproductive
services (&#8220;ARS&#8221;) provider in Asia-Pacific. Since the opening of our first clinic in Thailand in 2014, we have established
ourselves as a long-standing ARS provider in this region. Our strategic presence in Thailand, Cambodia, and Kyrgyzstan positions us to
take advantage of opportunities across Asia-Pacific. According to China Insights Consultancy (&#8220;CIC&#8221;), from 2014 to 2022, there
was a rising number of women in the key ARS-targeted age group (ages 15 to 49) in Asia Pacific and a growing trend towards later maternal
age. The number of married women of reproductive age in Asia Pacific has risen from 816.4&#160;million in 2014 to 833.2&#160;million in
2022. Additionally, according to CIC, there was increasing social acceptance of ARS use in Asia Pacific countries such as China, India,
and Thailand during the same period. For example, the number of ARS users in China has risen from 136.8 thousand in 2017 to 184.9 thousand
in 2022 approximately and that in Japan has risen from 98.0 thousand in 2017 to 128.5 thousand in 2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">According
to CIC, the prevalence of infertility in Asia-Pacific developing countries is substantial. For example, the infertility rate in Thailand,
India and China was about 15.4%, 13.8% and 17.8%, respectively, in 2022. In India, the infertility rate in 2020 was approximately 13.1%,
representing an annual growth of 2.6%. The infertility rate in China was around 17.6% in 2020, representing an annual growth of 0.6%.
Infertility is increasingly gaining society&#8217;s attention as individuals are more openly discussing their struggles. Despite the
prevalence of infertility, access to treatment is often limited in the Asia Pacific region. According to CIC, financial challenges, costs
of treatment, and limited availability or capacity of fertility medical care are some of the main challenges in the fertility marketplace
in Asia-Pacific region. Religious, social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have
children. We believe that we can help address some of these key challenges of Asia-Pacific fertility industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>History and Development of the Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Prior
to the Business Combination, on April&#160;29, 2021, A SPAC I Acquisition Corp. (&#8220;ASCA&#8221;), was incorporated as a British Virgin
Islands business company, specifically a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition,
share purchase, recapitalization, reorganization or similar business combination with one or more target businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>The Business
Combination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
February&#160;15, 2023, ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &#8220;Merger Agreement,&#8221;
and the transactions contemplated thereunder, the &#8220;Business Combination&#8221;) with A SPAC&#160;I Mini Acquisition Corp., Merger
Sub, NewGenIvf Limited, a Cayman Islands exempted company (&#8220;Legacy NewGenIvf&#8221;) and certain shareholders of Legacy NewGenIvf.
Pursuant to the Merger Agreement, the Business Combination was effected in two steps: (i)&#160;ASCA was reincorporated to the British
Virgin Islands by merging with and into A SPAC&#160;I Mini Acquisition Corp. (such transaction, the &#8220;Reincorporation Merger&#8221;);
and (ii)&#160;Merger Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the
Company (such second step in isolation, the &#8220;Acquisition Merger&#8221;). The surviving entity of the Business Combination, together
with its subsidiaries is referred to in this prospectus as &#8220;NewGenIvf,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
or &#8220;us,&#8221; unless the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
</div><div>
</div><!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
June&#160;12, 2023, the parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the &#8220;First Amendment&#8221;),
pursuant to which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the
&#8220;Loan&#8221;) to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA
to consummate a business combination and for ASCA&#8217;s working capital, payment of professional, administrative and operational fees
and expenses, and other purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing
of the Acquisition Merger. In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan
from NewGenIvf, ASCA agreed to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&#8217;s
failure to deliver audited financial statements by no later than February&#160;28, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
December 6, 2023, the parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &#8220;Second Amendment&#8221;)
which amended and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&#8217;s board of directors following
the consummation of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf
and three (3) of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii)
provide for the conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary
Shares in connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible
assets immediately after the consummation of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
April 3, 2024, the Business Combination was consummated with the Company as the surviving entity.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>NewGenIvf&#8217;s Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">With
a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely: (i)
in vitro fertilization (&#8220;IVF&#8221;) treatment service, comprising traditional IVF and egg donation; and (ii)&#160;surrogacy and
ancillary caring services. Currently, we have three clinics: one clinic in Thailand, one clinic in Cambodia, and one clinic in Kyrgyzstan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-keep: true"><b>IVF treatment service:</b> For the&#160;years ended December&#160;31, 2024 and 2023, we generated
    approximately 100% and 78.3, respectively of our revenue from IVF treatment services. We primarily provide our clients with conventional
    IVF/intracytoplasmic sperm injection (&#8220;ICSI&#8221;) and embryo transfer services. As technology has progressively advanced,
    we have been able to, through technologies and facilities provided by MicroSort technology, help fulfill the family-balancing dreams
    of its clients and avoiding certain gender-related hereditary diseases. IVF treatment involves the performance of a series of medical
    treatment as well as procedures and eventually brings benefits to clients when embryo is successfully implanted. Revenue from IVF
    treatment is recognized at a point in time when different treatment and/or procedure completed in clinic. The completion of the various
    and procedures are evidenced by written treatment cards and reports maintained in the patient files.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="text-align: justify"><span style="-keep: true"><b>Surrogacy and ancillary caring services:</b> We also generate revenue from surrogacy services
    and related ancillary caring services in Kyrgyzstan. For the&#160;years ended December&#160;31, 2024 and 2023, we generated approximately
    Nil % and 21.7%, of our revenue from surrogacy and ancillary caring services. For surrogacy services, NewGenIvf conducts implantation
    of embryos from biological parents in surrogate mothers. In addition, NewGenIvf provides a &#8220;success guarantee&#8221; program
    for egg donation services in Cambodia and surrogacy services in Kyrgyzstan. Under this optional program, patients pay additional
    fees of approximately 40% of the original price and can have repeated attempts of IVF cycles, egg donation services and/or surrogacy
    services until the procedures are successful. The additional costs to NewGenIvf are generally limited and amount to approximately
    30% of the original costs because NewGenIvf&#8217;s clinics, together with the patients, can choose suitable egg donors and surrogate
    mothers to limit the additional costs. During the pregnancy period, NewGenIvf provides ancillary caring services including regular
    body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy and ancillary caring
    services is recognized at a point in time when the surrogate mother gives birth. Surrogacy services provide infertile couples with
    an alternative method of having children. During 2024, we did not generate any revenue from surrogacy as we went through a series
    of reorganization in Kyrgyzstan, resulting in a sale of 100% equity interest in First Fertility Bishkek Limited Liability Company
    and acquisition of 100% equity interest in Bi Clinic Limited Liability Corporation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p></div><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For the&#160;years ended
December&#160;31, 2024 and 2023, NewGenIvf&#8217;s revenue was US$5,433,375 and US$5,136,153, and its net income/(loss) was US$(474,101)&#160;and
US$108,418, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Competitive Strengths</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes that the following competitive strengths have positioned it to meet growing opportunities in the fertility market across Asia-Pacific,
and have differentiated it from its competitors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Broad-range Assisted Reproductive Service
(&#8220;ARS&#8221;) Provider Offering Comprehensive Fertility Treatment Services</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">With
almost a decade of experience in the fertility market, NewGenIvf has built a reputation in the IVF industry in Asia-Pacific. NewGenIvf
has reinforced its long-standing position through expanding its service offerings and locations to address the evolving clients&#8217;
needs or requests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s comprehensive
fertility treatment offerings in Thailand, Cambodia, and Kyrgyzstan, primarily including IVF, egg donation (in Cambodia) and surrogacy
services (in Kyrgyzstan), make it convenient for clients in Asia-Pacific market to have access to various fertility services but with
a relatively low cost, as compared with the US market. Meanwhile, the average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding
medication). Each of NewGenIvf&#8217;s clinics in Thailand, Cambodia, and Kyrgyzstan has its own specialty, and together, NewGenIvf is
able to provide more flexibility and options to its patients. For example, NewGenIvf&#8217;s Thailand clinic focuses on IVF and related
ancillary services including HIV sperm washing, egg freezing, and chromosome screening. The clinic in Cambodia specializes in providing
both IVF services and egg donation services. NewGenIvf opened the clinic in Kyrgyzstan in 2019, which broadened NewGenIvf&#8217;s services
by being legally qualified/received approval letter from The Ministry of Health of Kyrgyzstan to offer surrogacy services. As of December
31, 2024, NewGenIvf was the one of the few ARS providers in Kyrgyzstan and one of the few companies in Kyrgyzstan that is licensed to
offer surrogacy services in Kyrgyzstan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
attributes its track record of success to its experienced physicians and its ability to provide comprehensive ARS services, allowing
it to meet patients&#8217; increasing demand for advanced, high-end, and sophisticated ARS, a higher standard and a wider range of advanced
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has extensive experience serving Asia-Pacific patients and a deep understanding of their general profiles. In particular, NewGenIvf has
personnel speaking multiple languages, including nurses, facilitators, and translators, who are familiar with the health condition and
culture of Asia-Pacific patients from different countries in the region. NewGenIvf believes that it is therefore well-positioned to benefit
from market growth driven by Asia-Pacific patients travelling to its clinics for treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Attractive Market
with Significant Demand and Fast Growth</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf operates in
the ARS market in Asia Pacific, positioning it to leverage on an attractive market with compelling underlying growth potential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Built on years of experience,
NewGenIvf has established a strong reputation in its industry, which in turn attracted potential business partners to approach NewGenIvf
to negotiate cooperations and referrals. Over the years, NewGenIvf sends representatives to medical expos mostly held in the PRC to approach
potential business partners and establish new partnerships by entering into agency agreements with each agent. NewGenIvf has become a
significant partner with agents and sub-agents throughout China and India. Normally, each agency agreement has a maximum term of one
year, which is renewable upon mutual agreement. Agents typically market and promote NewGenIvf&#8217;s services by word-to-mouth referrals
and other measures and NewGenIvf pays the agents commission at a range of 10% to 25% of the treatment fees upon the completion of client&#8217;s
treatment. Normally, agents provide potential clients&#8217; contact information to the sales team of NewGenIvf, who then approach potential
clients and provide consultation on services. With its partnerships in various countries, NewGenIvf believes it is able to better benefit
from the growing market opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>


</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exclusively Owned and Licensed Technology for Family Planning and
Access to Mature Fertility Technologies</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes that its licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual
patient&#8217;s needs. These technologies include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="text-align: justify"><span style="-keep: true"><i>MicroSort Technology:</i> NewGenIvf acquired the MicroSort Technology from Genetics &amp; IVF
    Institute, Inc. (&#8220;GIVF&#8221;) pursuant to a Purchase Agreement dated January 21, 2025 between NewGenIvf and GIVF (&#8220;Purchase
    Agreement&#8221;). As such NewGenIvf exclusively owns the MicroSort Technology. Prior to the closing of the MicroSort Acquisition,
    NewGenIvf held an exclusive license granted by a division of the Genetics &amp; IVF Institute, Inc. to use MicroSort technology in
    Thailand and Cambodia. MicroSort technology is a form of pre-conception gender selection technology for humans. MicroSort technology
    aims to separate male sperm cells based on which gender chromosome they contain, which results in separated semen samples that contain
    a higher percentage of sperm cells that carry the same gender chromosome. The technology ultimately helps couples choose the gender
    of their future child by choosing semen samples that predominately contain sperm with the&#160;X chromosome for a female or Y chromosome
    for a male. Traditionally and naturally, gender selection occurs after conception, meaning after the eggs are fertilized. As a result,
    some fertilized eggs will go unused. However, with MicroSort technology, NewGenIvf is able to increase the ratio of male or female
    embryos, based on the patient&#8217;s preference. Eggs are more likely to be fertilized according to the preferences of the parents.
    Other improvements that MicroSort treatment could help achieve include prevention of certain gender-related hereditary diseases.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Preimplantation Genetic Screening (&#8220;PGS&#8221;)</i>: PGS is
    used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too
    few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid
    embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf
    by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Next-Generation Sequencing (&#8220;NGS&#8221;)</i>: NGS is a high-throughput
    technology for determining the sequence of deoxyribonucleic acid (&#8220;DNA&#8221;) or ribonucleic acid (&#8220;RNA&#8221;) to study
    genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by
    using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands
    of gene fragments simultaneously with NGS reduces time and cost associated with sequencing and increases the coverage quality and
    data output.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Preimplantation Genetic Diagnosis (&#8220;PGD&#8221;)</i>: Similar
    to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a process more enhanced than PGS since it scans for
    individual genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic
    fibrosis, where carrier status has been documented in each of the parents. By using this technique, physicians are able to check
    the genes or chromosomes for a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help
    women better achieve a healthy pregnancy. Individuals who suspect or know they carry genes for serious medical conditions may opt
    to screen for healthy embryos ahead of time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Well Established Brand with Reliable
Reputation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
founders of NewGenIvf entered the fertility market as agents in 2011 by introducing patients in need to a Thailand clinic for fertility
treatments. The founders of NewGenIvf started to operate their own clinic in Thailand in 2014 and subsequently added clinics in Cambodia
and Kyrgyzstan. Since then, NewGenIvf has attracted clients from countries throughout Asia-Pacific, including Mainland China, Hong&#160;Kong,
India, Thailand, Australia and Taiwan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
benefits from the favourable geographic locations of its clinics, especially its clinic in Thailand. Located in central Bangkok and situated
in one of the biggest shopping malls of the city, the clinic is located in close proximity to various transportation facilities and popular
tourist attractions, such as the Erawan Shrine. In this regard, NewGenIvf believes that its business has benefited from, and will continue
to benefit from, the convenience of its locations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has developed a relatively replicable and scalable operating model that supports high productivity at its assisted reproductive medical
facilities in Asia. Under this model, NewGenIvf&#8217;s medical facilities have established standardized operating procedures to select
the treatment process according to each patient&#8217;s profile. NewGenIvf&#8217;s medical and operational personnel are organized into
specialized teams according to the different stages of the treatment process and different patient profiles. When patients are initially
admitted or would like to seek additional medical services later on, they are assigned to one of the optimal medical teams, which NewGenIvf
believes is better suited after taking into account the patient&#8217;s diagnosis and preferences. NewGenIvf believes that this model
allows each team to improve its efficiency and arrange suitable physicians for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
physicians of NewGenIvf have also developed and employed an operating model that seeks to increase the effectiveness of physicians by
utilizing standardized workflows and operating procedures with teams of supporting nurses and medical assistants. This helps to increase
the number of IVF treatment cycles that physicians can perform while providing treatment customized based on patient conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">With
its established client service history, accumulated experience as well as its continuous upgrades and development of treatment models,
NewGenIvf believes that it will be able to better monetize its brands through its business.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Experienced
Management Team</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
NewGenIvf management team has considerable experience in the ARS market and the broader healthcare industry. A considerable number of
NewGenIvf&#8217;s management are physicians or laboratory technicians who possess extensive experience in the ARS industry and are experts
in their respective fields. NewGenIvf&#8217;s Chief Executive Officer, Mr.&#160;Alfred Siu, has more than 13&#160;years of experience
in the fertility service market. Dr.&#160;Wiphawee Luangtangvarodom had over 8&#160;years of experience as an obstetrician and gynecologist.
NewGenIvf&#8217;s two lab supervisors, Ms. Anussara Phinyong, and Ms. Araya Boonchaisitthipong, each had over eight&#160;years of experience
in the embryologist field. These individuals have extensive experience in managing assisted reproductive medical facilities. NewGenIvf
is also led by other members of the professional management team, who are intimately involved in the operational and financial management
of NewGenIvf&#8217;s Group. Leveraging their experience, NewGenIvf believes that it is well positioned to expand its network and aims
to become a leader in the Asia Pacific ARS market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Strategies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
vision is to provide tailored ARS solutions to fulfil patients&#8217; dreams of becoming a parent. To realize this vision, NewGenIvf
plans to adopt the following strategies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Offer Broad
Fertility Services for Fertility Tourists across Asia Pacific</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
intends to provide broad fertility services for fertility tourists seeking high quality, cost effective and comprehensive fertility solutions.
According to CIC, the demand for fertility tourism is driven by a variety of factors including the prevalence of infertility, the introduction
of the Three-Child policy in China, the improved understanding of assisted reproductive technology and increased affordability of ARS.&#160;To
address these needs, NewGenIvf plans to offer its customers a &#8220;hassle-free&#8221;, seamless and integrated ARS and hospitality
arrangement experience. To complement its fertility services, NewGenIvf intends to integrate its offerings with additional services for
traveling patients, most of whom are first-time fertility tourists, such as translation service, hotel arrangement and airport pickup
services. NewGenIvf plans to enhance its customers&#8217; experience by entering into exclusive cooperation arrangements with local premium
hospitality providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Continue to Invest in Laboratories
and Facilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes laboratories and treatment facilities are critical to supporting its future research, development and clients experience. NewGenIvf
currently operates two laboratories that offer IVF services, one in Thailand and one in Cambodia, and plans to continue to scale up its
existing laboratories. NewGenIvf plans to continue to invest in upgrading its laboratories and facilities to complement its growth and
expansion, which it believes will help NewGenIvf maintain an edge over its competitors with regard to technology, operational efficiency,
scalability, and client experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
intends to develop advanced facilities for its existing laboratories, which will be conducting research on ARS related basic science
and experiments relating to emerging technologies to improve ARS success rates and lower costs. NewGenIvf also plans to correlate its
data on patient treatment protocols to the embryo physiologic data and the pregnancy success rate-related data to identify better treatment
protocols to increase ARS success rates. NewGenIvf intends to continue to actively promote technological cooperation with tertiary institutions
to discover ways to improve its IVF success rates. Furthermore, NewGenIvf seeks to actively deploy the technology that it possesses to
expand the services it provides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has accumulated experience in treating patients over 40&#160;years old with premature ovarian failure and patients who have had recurrent
ARS implementation failure, by, for the example, injecting platelet rich plasma into the ovaries to stimulate and support growth of the
follicles. NewGenIvf is also implementing certain technological advancements relevant to the ARS industry, including microfluidics, automated
sperm analysers, time lapsed incubators, non-invasive preimplantation genetic testing (&#8220;PGT&#8221;) of cell-free DNA in spent media,
automated systems for oocyte/embryo vitrification to reduce reagent consumption and decrease labor intensity, mitochondria replacement
therapy to reconstruct oocytes by nuclear transfer of polar body genome from an MII oocyte into an enucleated donor MII cytoplasm, to
increase the number of oocytes available for the treatment of infertile women, preimplantation methylome screening. There are also breakthrough
developments in science including organ culture systems, induced pluripotent stem cells, embryonic stem cells, spermatogonial stem cells
for creation of functional gametes, but these techniques are not yet ready for human clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
also intends to develop clinically customised interior design concepts for its medical facilities, including improved service rooms,
consultation rooms, reception areas, nutrition food areas, and traditional Chinese medicine (such as acupuncture) facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Increase Brand Awareness and Market
Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
intends to maintain and strengthen its brand awareness and market share in Asia Pacific. In order to expand its reach and increase patient
numbers, NewGenIvf plans to collaborate with local hospitals, companies, premium hospitality providers and other key players in the ARS
industry in Asia Pacific. Additionally, NewGenIvf intends to increase brand awareness through social media promotions and marketing initiatives,
and is establishing its business development team with the goal of attracting new patients and partners across Asia Pacific. Meanwhile,
NewGenIvf intends to provide innovative treatment services to attract more clients. For example, NewGenIvf plans to introduce IVF mental
health services, which allows clients who fail in IVF treatments to access online consultation for further treatment plans such as egg
donation and surrogacy. These new treatments services aim to enable NewGenIvf to attract potential clients. By adopting a comprehensive
strategy to expand its market share, NewGenIvf aims to strengthen its reputation as a long-standing ARS provider and capture additional
market share of the growingly ARS market in Asia-Pacific.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
</div><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Expand Service Reach Through Acquisitions
and Partnerships</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Leveraging
its reputation and footprint in its current markets, NewGenIvf intends to expand its reach, services offering and client base through
strategic acquisitions and/or partnerships in Asia Pacific. Acquisitions of or by companies offering similar services could not only
allow NewGenIvf to diversify its client base, but also allow it to benefit from potential economies of scale and increasing efficiency
through consolidation. NewGenIvf could also leverage the acquired or acquiring company&#8217;s customer base, reputation and expertise
to further improve its offerings and operations. NewGenIvf intends to focus on ARS providers in Asia Pacific which possess all conventional
licenses and locally recognized brands. For the global market beyond Asia Pacific, NewGenIvf intends to expand its footprint through
partnerships with other IVF clinics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NewGenIvf plans
to explore expanding its client base by offering its fertility services as part of corporate benefit programs in Asia. NewGenIvf believes
that there is potential in Asia in offering fertility treatments as a benefit for employees, particularly in companies with a large number
of female employees of childbearing age. By partnering with corporate clients to provide fertility benefits, NewGenIvf can increase its
market reach, enhance its brand reputation, and drive client growth. NewGenIvf&#8217;s broad range of fertility services, including IVF
and egg freezing, can help corporate partners differentiate their employee benefits in the competitive employment landscape, which could
make them more attractive to potential employees. Additionally, by offering these services, companies can help address the growing concern
of delayed childbearing, which is becoming more common among women according to CIC.&#160;NewGenIvf plans to collaborate with potential
corporate clients to develop customized fertility benefit programs that cater to their specific needs, and to provide comprehensive support
and counselling throughout the process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Meanwhile, NewGenIvf also
intends to attract more clients by establishing its &#8220;home country gynecologist partnership program&#8221;. Under the program, NewGenIvf
may, subject to its discretion and screening process, offer treatment services to clients with reduced time requirements to be spent
overseas. Depending on local laws, the potential clients may be able to complete their treatments with gynecologists NewGenIvf partners
with, in their home countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf had entered
into a non-binding term sheet dated June 3, 2024 (the &#8220;Term Sheet&#8221;) with COVIRIX Medical Pty Ltd (&#8220;COVIRIX&#8221;)
for a proposed reverse merger (the &#8220;COVIRIX &#8220;Proposed Transaction&#8221;). However, on September 21, 2024, COVIRIX withdrew
from the Proposed Transaction, as such the Proposed Transaction was terminated with no cost to the Company.<b>&#160;</b>&#160;On December
11, 2024, NewGenIvf also announced its entry into a binding term sheet with European Wellness Investment Holdings Limited (&#8220;EWIHL&#8221;)
for a proposed reverse merger (&#8220;EWIHL Proposed Transaction&#8221;), completion of which was subject to, among other conditions,
the completion of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing. On March 31, 2025, NewGenIvf
terminated the term sheet for the EWIHL Proposed Transaction as EWIHL had failed to produce certain draft audited financials, which were
specifically required in the term sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On February 28, 2025, NewGenIvf
completed its acquisition of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&#8220;GIVF&#8221;). Pursuant to a Purchase
Agreement dated January 21, 2025 between NewGenIvf and GIVF (&#8220;Purchase Agreement&#8221;), NewGenIvf purchased all of the Assets
(as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort Business (as defined
in the Purchase Agreement) from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Class A Ordinary Shares
(&#8220;MicroSort Acquisition&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><i>White Lion Transaction</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On November 21, 2024, the Company
entered into a Common Shares Purchase Agreement (the &#8220;White Lion Purchase Agreement&#8221;) with White Lion Capital, LLC (&#8220;White
Lion&#8221;) and a related Registration Rights Agreement (the &#8220;RRA&#8221;). Pursuant to the White Lion Purchase Agreement, the Company
has the right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars ($100,000,000)
in aggregate gross purchase price of newly issued Class A Ordinary Shares, with an automatic increase to Three Hundred Million Dollars
($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase Agreement) and a further option
to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000) has been issued
and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth in the White Lion
Purchase Agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the satisfaction
of certain customary conditions including, without limitation, the effectiveness of the registration statement of which this prospectus
forms a part (the &#8220;Registration Statement&#8221;) registering the resale of the shares issuable pursuant to the White Lion Purchase
Agreement, the Company&#8217;s right to sell shares to White Lion commenced on the date of the execution of White Lion Purchase Agreement
and extends until (i) 36 months from the date of execution of the White Lion Purchase Agreement, or (ii) at the Company&#8217;s option,
until 65 months from the date of the execution of the White Lion Purchase Agreement in the event that $100,000,000 of purchases under
the White Lion Purchase Agreement have been completed prior to the 36 month anniversary of the Execution Date (the &#8220;Commitment
Period&#8221;).</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
</div><div>
</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>







</div><div style="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">During the Commitment
Period, subject to the terms and conditions of the White Lion Purchase Agreement, the Company may exercise its right to sell its Class
A Ordinary Shares to White Lion. The Company may deliver a Regular Purchase Notice (as such term is defined in the White Lion Purchase
Agreement), pursuant to which the Company can require White Lion to purchase up to a number of Ordinary Shares equal to the lesser of
(i) $3,000,000 divided by the highest closing price of the Ordinary Shares over the most recent five (5) Business Days immediately preceding
the Purchase Notice, or (ii) 40% of Average Daily Trading Volume (as such term is defined in the White Lion Purchase Agreement), subject
to a maximum Investment Limit of $3,000,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company may also deliver
a Rapid Purchase Notice (as such term is defined in the White Lion Purchase Agreement), pursuant to which the Company may require White
Lion to purchase up to a number of Ordinary Shares equal to $3,000,000 divided by the highest closing price of the Ordinary Shares over
the most recent five business days immediately prior to the receipt of the notice. White Lion may waive such limits under any notice
at its discretion and purchase additional shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The price to be paid by
White Lion for any shares that the Company requires White Lion to purchase will depend on the type of purchase notice that the Company
delivers. For shares being issued pursuant to a Regular Purchase Notice, the purchase price per share will be the lower of (i) the closing
price of Ordinary Shares prior to the receipt of the applicable Purchase Notice, or (ii) the product of (a) the lowest daily VWAP of
the Ordinary Shares during the Regular Purchase Valuation Period (as defined in the White Lion Purchase Agreement), and (b) 98%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For shares being issued
pursuant to a Rapid Purchase Notice, the Company may opt for the purchase price per share to be (i) equal to the lowest traded price
of the Ordinary Shares on the date that the notice is delivered, or (ii) 97% of the lowest traded price of the Ordinary Shares one hour
following White Lion&#8217;s written confirmation of the acceptance of the Rapid Purchase Notice.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No purchase notice shall result
in White Lion beneficially owning (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule
13d-3 thereunder) more than 4.99% (subject to increase, in the sole discretion of White Lion, to 9.99%) of the number of Class A Ordinary
Shares outstanding immediately prior to the issuance of Class A Ordinary Shares issuable pursuant to a purchase notice.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has the right
to terminate the White Lion Purchase Agreement in the event of a material breach of the White Lion Purchase Agreement by White Lion.
The White Lion Purchase Agreement also automatically terminates upon the earlier of (i) the end of the Commitment Period and (ii) the
date that the Company commences a voluntary bankruptcy proceeding, a custodian is appointed for the Company or for all or substantially
all of its property, or the Company makes a general assignment for the benefit of its creditors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In consideration for the commitments
of White Lion, as described above, the Company agreed to issue to White Lion 700,000 Class A Ordinary Shares (&#8220;Commitment Shares&#8221;).
Additional Class A Ordinary Shares may be issued to White Lion under certain conditions, including in connection with material transactions
or upon achieving specified investment thresholds. The Commitment Shares will be fully earned by White Lion regardless of termination
of the White Lion Purchase Agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The White Lion Purchase Agreement
and the RRA contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations,
warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely
for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Business Model</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">With
a focus on providing fertility treatments to fulfil couples and individuals&#8217; dreams of raising children, NewGenIvf offers mainly
two services, namely: (i)&#160;IVF treatment service, comprising traditional IVF and egg donation; and (ii)&#160;surrogacy and ancillary
caring services. The following table sets forth NewGenIvf&#8217;s revenue by service offerings and as a percentage of total revenue for
the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">IVF Treatment Service</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">100</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4,021,696</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">78.3</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Surrogacy and Ancillary Caring Services</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,114,457</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">21.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Total Revenue</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,136,153</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>IVF Treatment Service</i></b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf primarily provides
its clients with conventional IVF/ICSI and embryo transfer services. NewGenIvf is also able to, through MicroSort technology, help fulfill
the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">IVF treatments that NewGenIvf
provides address tubal factor, ovulatory dysfunction, diminished ovarian reserve, endometriosis, uterine factor, male factor, unexplained
infertility and other causes. IVF bypasses the function of the fallopian tube by achieving fertilization within a laboratory environment.
Ovarian hyper-stimulation is common with IVF treatments to recruit numerous follicles to increase the chances for success. Follicles
are retrieved trans-vaginally using a vaginal probe and ultrasound guidance. Anaesthesia is frequently used due to the number of follicles
retrieved and the resulting discomfort experienced by the patient. The eggs are identified in the follicular fluid and combined with
sperm and culture medium in culture dishes, which are placed in an incubator with a temperature and gas environment designed to mimic
the condition of the fallopian tubes. Once the embryos develop, typically over a 3-to-5-day period, they are transferred to the uterine
cavity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As a long-standing IVF
treatments provider in Asia-Pacific, NewGenIvf had completed over 4,500 cycles of IVF treatments from 2014 to 2024. For the&#160;years
ended December&#160;31, 2024 and 2023, the revenue from NewGenIvf&#8217;s IVF treatments was US$5,433,375 and US$4,021,696, respectively,
representing 100% and 78.3%&#160;of its total revenue in the corresponding periods.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">IVF Treatments
Process</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">A
typical IVF treatment process mainly includes two stages, the pre-IVF treatment stage and the IVF treatment stage. During the IVF treatment
process, NewGenIvf also provides support services such as nutrition guidance and psychological counselling. The flow chart below shows
the stages involved in a typical IVF treatment process:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">At
the pre-IVF treatment stage, clients attend an initial consultation, undergo pre-IVF tests, and undergo treatment for gynaecological
and andrological diseases, if needed. At the initial consultation, a physician reviews the clients&#8217; detailed medical history to
collect more information relating to the potential cause of their infertility. The client then undergoes various pre-IVF tests, which
may include, among other things, blood pressure, hormone level, ultrasound, infectious disease screening, uterine evaluation and male
fertility test. The physician will then design treatment plans based on the client&#8217;s medical history and results of the tests.
If the client is satisfied with treatment plan and the test results are acceptable to the physician, the physician will prescribe medications
and start stimulation treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
first step of the cycle is to boost egg production through injecting synthetic hormones. Over about one week of ovarian stimulation,
clients are monitored on a regular basis with blood test and transvaginal ultrasound. If follicles have reached at least 10 mm in size,
an additional antagonist drug will be added into the daily injection schedule. This is used to prevent ovulation before ovum pickup time.
After another few&#160;days of ovarian simulation, if follicle growth is consistent and majority of follicles are around 16 mm to 17
mm, the final injection of a human chorionic gonadotropin will be administered. The trigger injection is the final step of the stimulation
process and is for the maturation of the eggs in the follicles before they are collected. The next major step is to retrieve the eggs
with a minor surgical procedure called Trans Vaginal Follicle Aspiration conducted under anaesthesia. At the same time the male partner
collects the sperms for fertilizing the eggs in the laboratory by a process known as intracytoplasmic sperm injection. The fertilized
embryos are cultured in the laboratory for two to six&#160;days. Embryos that grow well are biopsied and tested by PGT to detect potential
genetic diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
final step is to transfer the embryos into the uterus using a catheter. Within eight&#160;days after the embryo transfer, a blood test
can be conducted to detect whether the implantation was successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MicroSort Technology</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroSort technology is a
preconception process developed by the Genetics &amp; IVF Institute, Inc (&#8220;GIVF&#8221;). that aims to improve the chances that the
baby to be conceived will be of the desired gender and prevents certain gender-related hereditary diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Semen samples usually contain
equal amounts of sperm carrying the Y chromosome (which will produce a boy), and sperm carrying the&#160;X chromosome (which will produce
a girl). During the MicroSort process, the sperm sample is washed to remove seminal liquid and nonmotile cells. After the washing, the
sample is stained with a special fluorescent material that attaches to the DNA contained in the sperm. The stained sperm cells are analyzed
one by one by a flow cytometer, in which cells pass through a laser to make the stain attach to the DNA fluoresce. The sperm containing
the&#160;X chromosome (which have more DNA and therefore more stain) will shine brighter than the sperm containing the Y chromosome.
The flow cytometer uses a special software to identify&#160;X&#160;and Y chromosome sperm based on their fluorescence signature. The
sperm carrying the chromosome that will produce the desired gender are separated from the rest of the sample -resulting in an enriched
sperm sample ready for use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="-keep: true">NewGenIvf held an exclusive
license granted by a division of GIVF, MicroSort International, to use the MicroSort technology in Thailand and Cambodia. MicroSort&#8217;s
licenses for NewGenIvf&#8217;s operation in Thailand and Cambodia were each provided under a lease and service agreement. In April 2019,
First Fertility PGS entered into a Lease and Services Agreement with MicroSort International to use MicroSort equipment in Thailand and
in March 2019, Phnom Penh Center entered into a Lease and Services Agreement with MicroSort International to use MicroSort equipment
in Cambodia (together, the &#8220;Lease and Services Agreements&#8221;). Pursuant to the Lease and Services Agreements, First Fertility
PGS and Phnom Penh Center each had the exclusive right to utilize the MicroSort equipment and to market and sell MicroSort sperm sorting
services in Thailand and Cambodia, respectively. MicroSort International was responsible for the maintenance of MicroSort equipment and
technical and engineering support. The term of each Lease and Service Agreements was initially from 2019 to 2024, which shall be automatically
renewed for one year unless a written notice of at&#160;least 180 days prior to the intended termination date is provided. The consideration
under each of the Lease and Services Agreements was US$9,000 per month after six months.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
</div><div>
</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On January 21, 2025, the
Company entered into a Purchase Agreement with Genetics&#160;&amp; IVF Institute, Inc. (&#8220;Purchase Agreement&#8221;), pursuant to which
the Company purchased all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement)
relating to the MicroSort Business (as defined in the Purchase Agreement) from Genetics &amp; IVF Institute, Inc. for a cash consideration
of $750,000 and a share consideration of 125,000 Class A Ordinary Shares (&#8220;Share Consideration&#8221;). The Purchase Agreement
is filed as Exhibit 10.30 in this registration statement. MicroSort Lab Services, LLC (&#8220;MicroSort&#8221;) was incorporated by Genetics&#160;&amp; IVF Institute, Inc. in January 2025 to hold all of the Assets (as defined in the Purchase Agreement) to be transferred to the Company
at closing. The Company&#8217;s acquisition of MicroSort was completed on February 28, 2025, and the Share Consideration was issued to
GIVF on the same day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the closing of the MicroSort Acquisition, NewGenIvf held an exclusive license granted by a division of GIVF, MicroSort International,
to use the MicroSort technology in Thailand and Cambodia. MicroSort&#8217;s licenses for NewGenIvf&#8217;s operation in Thailand and
Cambodia were each provided under a lease and service agreement. In April 2019, First Fertility PGS entered into a Lease and Services
Agreement with MicroSort International to use MicroSort equipment in Thailand and in March 2019, Phnom Penh Center entered into a Lease
and Services Agreement with MicroSort International to use MicroSort equipment in Cambodia (together, the &#8220;Lease and Services Agreements&#8221;).
Pursuant to the Lease and Services Agreements, First Fertility PGS and Phnom Penh Center each had the exclusive right to utilize the
MicroSort equipment and to market and sell MicroSort sperm sorting services in Thailand and Cambodia, respectively. MicroSort International
was responsible for the maintenance of MicroSort equipment and technical and engineering support. The term of each Lease and Service
Agreements was initially from 2019 to 2024, which shall be automatically renewed for one year unless a written notice of at&#160;least
180 days prior to the intended termination date is provided. The consideration under each of the Lease and Services Agreements was US$9,000
per month after six months from the effective date of the agreements. </span>On February 28, 2025, NewGenIvf completed its acquisition
of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&#8220;GIVF&#8221;).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The flow chart below shows
the process involved in MicroSort:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_003.jpg"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Preimplantation Genetic Screening</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">PGS
is used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too
few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos
that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving
a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Next-Generation
Sequencing</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NGS
is a high-throughput technology for determining the sequence of deoxyribonucleic acid DNA or RNA to study genetic variation associated
with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional
Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with
NGS reduces time and cost associated with sequencing and increases the coverage quality and data output.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></div><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; padding: 3pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Preimplantation Genetic Diagnosis</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a more enhanced process than PGS since it scans for individual
genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic fibrosis,
where carrier status has been documented in each of the parents. By using this technique, physicians are able to check the genes or chromosomes
for a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help women achieve a healthy pregnancy.
Individuals who suspect or know they carry genes for serious medical conditions may opt to screen for healthy embryos ahead of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Egg Freezing Service</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf also provides
egg freezing services which is a fertility preservation service that allows individuals to freeze and store their eggs for future use.
The process begins with hormonal stimulation to encourage multiple egg production, followed by a minor surgical procedure to retrieve
the eggs under sedation. The eggs are then rapidly frozen using vitrification, a technique that prevents ice crystal formation, and stored
in liquid nitrogen at ultra-low temperatures. This service is ideal for those delaying childbearing due to career, medical reasons (like
cancer treatment), or personal choice. When ready to conceive, the eggs can be thawed, fertilized with sperm, and transferred as embryos.
While success rates vary by age and clinic, egg freezing offers a proactive option for preserving fertility.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Surrogacy
and Ancillary Caring Services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf
also generated revenue from surrogacy services and related ancillary caring services in Kyrgyzstan. NewGenIvf conducts implantation of
embryos from biological parents in surrogate mothers. During the pregnancy period, NewGenIvf provides ancillary caring services including
regular body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy and ancillary caring
services is recognized when the surrogate mother gives birth. Surrogacy services provide infertile couples with an alternative method
of having children. In general, NewGenIvf provides certain discount to clients if they wish to pursue additional services such as egg
donation and surrogacy, after several cycles of IVF treatments failures due to medical reasons including, but not limited to, the poor
egg quality of aged female clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
compared to other countries, Kyrgyzstan has the following features that allow NewGenIvf to operates its surrogacy services: (i)&#160;surrogacy
is legal and regulated, which means that there are less restrictions on either intended parents or surrogate mothers, and a parent-child
relationship can be requested before the child&#8217;s birth; and (ii)&#160;the costs of operation and surrogate mother is favorable,
given the cost of living in Kyrgyzstan is relatively low.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the regular surrogacy services, NewGenIvf is also able to assist the clients with birth certificate applications and facilitate
the application of infants&#8217; passports and visas as supplemental services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the&#160;years ended December&#160;31, 2024 and 2023, the revenue from NewGenIvf&#8217;s surrogacy and ancillary caring services was
US$ Nil and US$1,114,457, respectively, representing Nil % and 21.7% of its total revenue in the corresponding periods.</span> During
2024, we did not generate any revenue from surrogacy as we went through a series of reorganization in Kyrgyzstan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
flow chart below shows the stages involved in a typical surrogacy process:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><img alt="" src="image_004.jpg" style="width: 422px; height: 500px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
Kyrgyzstan, NewGenIvf also provides ancillary fertility services when carrying out surrogacy services. These ancillary fertility services
include: (i)&#160;maternity caring service, and (ii)&#160;documentation service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p></div><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Network of Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
NewGenIvf had one administrative support office located in Hong&#160;Kong and three clinics located in Thailand, in Cambodia, and
in Kyrgyzstan, respectively. The integration of the medical facilities in Thailand help NewGenIvf provide a more seamless one-stop experience
to its clients. Set out below is an illustration of the locations of NewGenIvf&#8217;s clinics and marketing and sales office:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table sets
forth the approximate aggregate average gross floor area (&#8220;<b>G.F.A.</b>&#8221;) of each of NewGenIvf&#8217;s clinics that were
under lease and actively used for client service as of December 31, 2024</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of <br/> December&#160;31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">(Square Feet)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic"><span style="-keep: true">Thailand</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Fertility PGS Center Co., Ltd. &#8211; PS Tower<br/> (&#8220;<b>First Fertility PGS Center</b>&#8221;)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">14,750</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Fertility PGS Center Co., Ltd &#8211; Erawan Hotel <b><br/> (&#8220;First Fertility PGS Center&#8221; </b>&#8211; Not Yet Open<b>)</b></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,615</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Cambodia</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Fertility Phnom Penh Center <br/> (&#8220;<b>Phnom Penh Center</b>&#8221;)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">18,567</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Kyrgyzstan</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Bi Clinic Limited Liability Company <br/> (&#8220;Bi Clinic&#8221;)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,164</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Aggregate G.F.A</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">38,096</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
</div><div>
</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">To increase the scale
of NewGenIvf&#8217;s operations, NewGenIvf expanded its Thailand fertility services by leasing a new property for its second clinic Erawan
Consultation Clinic in May&#160;2023. Consisting of approximately 2,600 sq. ft., Erawan Consultation Clinic is expected to open in 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Currently, IVF treatments
are performed in its Thailand and Cambodia clinics, egg donation services are provided in its Cambodia clinic, and surrogacy services
are provided in its Kyrgyzstan clinic. The following table summarises the services available at NewGenIvf&#8217;s clinics:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IVF
    <br/>
    Treatments</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Surrogacy
    <br/>
    Services</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Thailand</i></b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="width: 80%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility
    PGS Center</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8730;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#215;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cambodia</i></b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phnom Penh Center</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8730;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#215;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kyrgyzstan</i></b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Bishkek
    (Disposed of on December 18, 2024)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8730;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8730;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bi Clinic (Acquired on
    December 17, 2024)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8730;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8730;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8730;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#215;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The following table sets
forth a breakdown of revenue from services performed at NewGenIvf&#8217;s medical centers for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">HK SAR</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">34,038</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.7</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Thailand</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,175,253</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">40.0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,356,903</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">26.4</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Cambodia</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">601,526</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11.1</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">621,619</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12.1</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Kyrgyzstan</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,656,596</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">48.9</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">3,123,593</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">60.8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Total Revenue</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,136,153</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Thailand Clinic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31,
2024, NewGenIvf had one clinic in Thailand. At the clinic in Thailand, NewGenIvf offers its clients customized fertility treatment
solutions including IVF/ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening by PGT,
hysteroscopy, sperm analysis, sorting, washing and freezing, and egg freezing. Its medical and operational personnel are organized
into specialized teams according to the different stages of the IVF treatment process and different patient profiles. When clients
are admitted, they are assigned to a team which NewGenIvf believes is better suited to the clients after taking into account the
clients&#8217; diagnosis and preferences. Furthermore, NewGenIvf also provides related value-added services such as nutrition
guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment. NewGenIvf prides
itself on providing quality and customized treatment to its clients on a&#160;day-to-day basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
the clinic in Thailand had 8 nurses, 8 full time lab physicians and embryologists, 14 administrative staff, totaling 30 staff members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Cambodia Clinic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf has one clinic,
Phnom Penh Center, in Cambodia. Phnom Penh Center is staffed with 4 Cambodian physician, 2 embryologists, 6 nurses and 13 other staff,
and offers similar IVF treatments as in Thailand and egg donation services. Phnom Penh Center operates under a license issued by Cambodia
MOH for the Cambodian physician, who has entered into an agreement with Phnom Penh Center for the exclusive use of such license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">After eight&#160;years
of development since its opening in 2015, Phnom Penh Center has become one of the long-standing ARS providers in Cambodia. According
to CIC, it was the first to use conventional IVF technology which led to a successful birth in 2016 in Cambodia. Since its establishment,
Phnom Penh Center achieved more than 1,800 IVF treatment cycles as of December 31, 2024. As of December 31, 2024, Phnom Penh Center&#8217;s
IVF philosophy concentrates on three key points in the treatment process: the mother&#8217;s wellbeing, the technology used to assist
mothers deliver a strong and healthy baby and the medical science used to ensure every chance of success for women in various age spectrums.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></div><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Clinic in Kyrgyzstan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
established First Fertility Bishkek in October&#160;2019 in Kyrgyzstan for its surrogacy services, as Kyrgyzstan has supply of surrogate
candidates at a relatively low cost and a more friendly legal environment for surrogacy services. In 2020, First Fertility Bishkek obtained
the license to provide ARS and surrogacy services, becoming one of the few facilities licensed to offer ARS and one of the facilities
licensed to offer surrogacy services in Kyrgyzstan as of December&#160;31, 2024, according to CIC.&#160;In addition, NewGenIvf also provide
related ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&#160;maternity
caring service, and (ii)&#160;documentation service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Physicians at First Fertility
Bishkek have expertise in sourcing surrogate mothers, techniques of embryo transfers, prenatal care, baby delivery, and postnatal care.
First Fertility Bishkek also collaborates closely with Phnom Penh Center in arranging shipment of frozen embryos. NewGenIvf hires local
physicians and local staff. NewGenIvf also provides training for newly admitted Kyrgyzstan physicians and embryologists in Thailand.
Some personnel who had relevant experience in Kyrgyzstan had also been sent from Cambodia to Kyrgyzstan to help manage such operations
from time to time. However, during 2024, Kyrgyzstan operations had been reorganized, resulting in disposal of First Fertility Bishkek
and acquisition of Bi Clinic Limited Liability Corporation in December 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
Bi Clinic had 1 full-time physician, 1 embryologist, 1 nurse, and 6 other staff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Professionals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Licensed Physicians</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
NewGenIvf employed 5 licensed physicians, among which one was based in Cambodia, one was based in Kyrgyzstan, and the other three were
based in Thailand. Most of NewGenIvf&#8217;s physicians had over 10&#160;years of experience or above. The following table summarises
the number and types of such licensed physicians as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 13%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licensed
    physician</b></span></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licenses
    and<br/>
    Approvals</b></span></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effective
    Period</b></span></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuing<br/>
    Authority</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cambodia</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.&#160;Keut Serey</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decision on permission for beauty treatment operation</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&#160;14, 2022&#160;&#8211;
    December&#160;14, 2026</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Ministry of Health of Cambodia</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Keatthisak Boonsimma</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 31801 Medical Practitioner License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April&#160;1, 2005&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royal Thai College of Obstetricians and Gynaecologists
    of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 22624/2554<br/>
    OB-Gyn License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&#160;1, 2014&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 40962/2563 Reproductive Medicine Diploma</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&#160;1, 2020&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Anurach Kulvanitchaiyanunt</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Practice License No. 11755</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 1 2025&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Wiphawee Luangtangvarodom</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 38347/2562<br/>
    OB-Gyn License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August&#160;1, 2019&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 43217/2564 Reproductive Medicine License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&#160;1, 2021&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 48510 Medical Practitioner License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April&#160;1, 2014&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kyrgyzstan</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Myrzalymbekova A.B.</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp; numero; CO170001836 Medical Certificate
    </span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 23. 2017 - Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;0002953 Medical Practitioner</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25 April 2018 - Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;11373\2565 Medical Certificate</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16 August 2024 - Indefinite
    </span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;0003447 Medical Certificate</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12 April 2023 - Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For the&#160;years ended
December&#160;31, 2024 and 2023, the majority of NewGenIvf&#8217;s clients were from China (including mainland China and Hong Kong).
The number of Thai and Cambodian local patients generally increased in 2023 and 2024 compared with earlier years due to the impact of
COVID-19 on international travel. NewGenIvf enters into a verbal contract with each of its customers that outline, among other things,
the scope of services, service fees, payment terms and rights, responsibilities and obligations of each party. Consent is obtained from
the patients prior to the provision of the various treatments. Customers are not entitled to enjoy the relevant services until outstanding
amounts have been settled pursuant to the relevant contract. Sales to individual consumers did not vary significantly and none of the
customers contribute more than 10% of NewGenIvf&#8217;s revenue for the&#160;years ended December&#160;31, 2024 and 2023.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In addition to significant
customers using NewGenIvf&#8217;s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf also has customers who
utilize the access to the freezing and storage facility and other relatively insignificant services, such as check-ups services, blood
test services and other minor services (the latter category of customers are referred to as &#8220;consultation customers&#8221;).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Sales and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For the&#160;years ended
December&#160;31, 2024 and 2023, NewGenIvf promoted brand awareness through its sales teams and, in many cases, through cooperating with
third-party agencies and partners.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
sales teams have broad experience in fertility services and are responsible for identifying potential clients and managing the overall
sales process. NewGenIvf&#8217;s sales team primarily relies on social media marketing, word-of-mouth referrals, recognition of its brand,
printed advertisements and marketing events. NewGenIvf spends marketing expenses on placing advertisements through popular social media
platforms, maintaining the official website of NewGenIvf and sending information through its official accounts on social media platforms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Supply and Procurement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s procurement
is mainly for medications, laboratory media and reagents, laboratory consumables, and blood test reagents. As of December&#160;31, 2024,
there was no supplier that individually contributed more than 10% of the Group&#8217;s trade payable. As of December 31, 2023, there
was one supplier that individually contributed more than 10% of the Group&#8217;s trade payable, accounting for 30.6% of the Group&#8217;s
trade payables in aggregate. For both the years ended December&#160;31, 2024 and 2023, no vendor contributed more than 10% of total direct
cost of the Group. NewGenIvf&#8217;s procurement team is experienced in selecting cost-effective supplies as well as selecting reliable
suppliers. NewGenIvf&#8217;s major suppliers are pharmaceutical companies.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes that it is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            value and comprehensiveness of the solutions;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">treatment
                                            that is effective and achieves desired outcomes;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">clients&#8217;
                                            experience, including dedicated patient education, clinical guidance and emotional support;
                                            and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">access
                                            to a network of high-quality fertility specialists.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
competes primarily with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably
robust and integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf&#8217;s competitors may compete
in a variety of ways, including by providing better services, having established local connections, fulfilling evolving client needs,
as well as conducting brand promotions and other marketing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</div><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
NewGenIvf may introduce new ancillary services and other companies may introduce similar fertility services as NewGenIvf&#8217;s, NewGenIvf
may become subject to additional competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
in addition to its clinics, NewGenIvf leased one property in Hong&#160;Kong with an aggregate square footage of approximately 8,000 for
its administration support offices. NewGenIvf also operates its medical facilities as described above in &#8220;&#8212;&#160;Network
of Facilities&#8221; above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Organizational Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following is a list of our principal subsidiaries and consolidated affiliated entities as of the date of this prospectus:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 26%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place
    of Formation</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 52%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf Limited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman Islands</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholly-owned subsidiary</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated on January 16, 2019</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Ltd</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, wholly owned by NewGenIvf Limited</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated on December 19, 2019</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bi Clinic LLC</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kyrgyzstan</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, wholly owned by NewGenIvf Limited</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired on December 17, 2024</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, 74% owned by Well Image Limited
    HK directly and indirectly</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated on March 6, 2014</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Ltd</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kingdom of Cambodia</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, wholly owned by NewGenIvf Limited</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated on August 10, 2015</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, 48.99% owned by Well Image
    Limited HK</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated on January 21, 2015</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited HK</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, wholly owned by NewGenIvf Limited</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated on July 11, 2008</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#28145;&#22323;&#21069;&#28023;&#35920;&#27888;&#20161;&#21295;&#20581;&#24247;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496;
    (Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, 99% owned by &#160;FFPGS (HK)
    Ltd</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated on October 24, 2024</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following is a wholly owned subsidiary being disposed of on
December 18, 2024:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Bishkek LLC</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kyrgyzstan</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indirect subsidiary, wholly owned
    by Legacy NewGenIvf</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Property, Plants and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Company leases the premises for its principal executive office located at 36/39-36/40, 13th Floor, PS Tower, Sukhumvit 21 Road (Asoke)
Khlong Toei Nuea Sub-district, Watthana District, Bangkok 10110, Thailand. This property contains approximately 14,750 square feet. The
Company leases one property in Hong&#160;Kong with an aggregate square footage of approximately 8,000 for its administration support
offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company also leases
several premises to operate its clinics in various countries. In Kyrgyzstan, the Company operates the First Fertility Bishkek Limited
Liability Company, which premises have an aggregate area of 2,368 square feet. In Kyrgyzstan, the Company operated the First Fertility
Bishkek Limited Liability Company until December 18, 2024, of which premises have an aggregate area of 2,368 square feet. The Company
operates the Bi Clinic Limited Liability Company starting from December 17, 2024 in Kyrgyzstan, which premises have an aggregate area
of 2,100 square feet. In Cambodia, the Company operates the First Fertility Phnom Penh Center, which premises have an aggregate area
of 18,567 square feet. In Thailand, the Company operates a clinic named First Fertility PGS Center Co., Ltd., which premises have an
aggregate area of 14,750 square feet.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company also leases
premises located in Thailand for its anticipated Erawan Consultation Clinic, with an aggregate area of approximately 2,500 square
feet. This property is used as the Company&#8217;s second clinic in Thailand, which is expected to open in 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>




</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Nasdaq Deficiency</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On October 8, 2024, the Company
received a deficiency letter (&#8220;Bid Price Deficiency Letter&#8221;) from the Listing Qualifications Department (the &#8220;Staff&#8221;)
of Nasdaq notifying the Company that it is currently not in compliance with the closing bid price requirement under Nasdaq Listing Rule
5450(a)(1) (the &#8220;Minimum Bid Price Rule&#8221;). The Bid Price Deficiency Letter stated that, for the preceding 30 consecutive business
days, the Company&#8217;s Class A Ordinary Shares did not meet the minimum closing bid price of $1 per share pursuant to the Minimum Bid
Price Rule. The Company has an initial compliance period of 180 calendar days, or until April 7, 2025 to regain compliance with the Minimum
Bid Price Rule. The Deficiency letter stated that if at any time the closing bid price of the Company&#8217;s Class A Ordinary Shares
is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance with
this requirement, as applicable. On February 11, 2025, the Company effected a 1-for-20 reverse stock split of its issued and unissued
shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share. On February 27, 2025,
the Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company&#8217;s securities had been
at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the Company had regained
compliance with the Minimum Bid Price Rule.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
May 24, 2024, the Company received a deficiency letter (&#8220;MVLS Deficiency Letter&#8221;) from the Staff of Nasdaq notifying the
Company that, for the preceding 35 consecutive business days, the Class A Shares did not meet the minimum $50,000,000 Market Value of
Listed Securities requirement (&#8220;MVLS Requirement&#8221;) for continued listing on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(A)
(the &#8220;MVLS Requirement,&#8221; and the Company&#8217;s non-compliance with this requirement, the &#8220;MVLS Deficiency&#8221;).
In accordance with Nasdaq Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until November
20, 2024 (the &#8220;Compliance Date&#8221;), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date,
the MVLS for the Class A Shares is at least $50,000,000 for a minimum of ten consecutive business days, the Staff will provide the Company
written confirmation of compliance with the MVLS Requirement. In the event the Company does not regain compliance with the above requirement
prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
May 24, 2024, the Company received a deficiency letter (&#8220;MVPHS Deficiency Letter&#8221;) from the Staff of Nasdaq notifying the
Company that, for the preceding 35 consecutive business days, the Company&#8217;s Class A Ordinary Shares did not meet the minimum $15,000,000
Market Value of Publicly Held Shares (&#8220;MVPHS&#8221;) requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rules
5450(b)(2)(C) (the &#8220;MVPHS Requirement,&#8221; and the Company&#8217;s non-compliance with this requirement, the &#8220;MVPHS Deficiency&#8221;).
In accordance with Nasdaq Rule 5810(c)(3)(D), the Company has until the Compliance Date to regain compliance with the MVPHS Requirement.
If, at any time before the Compliance Date, the MVPHS for the Class A Shares is at least $15,000,000 for a minimum of ten consecutive
business days, the Staff will provide the Company written confirmation of compliance with the MVPHS Requirement. In the event the Company
does not regain compliance with the above requirement prior to the expiration of the compliance period, it will receive written notification
that its securities are subject to delisting. Alternatively, the Company may apply to transfer the Company&#8217;s securities to The
Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, the
Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS
Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel
(the &#8220;Panel&#8221;) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the Panel
will consider its appeal at&#160;an oral hearing&#160;on January 28, 2025 (the &#8220;Hearing&#8221;). On February 19, 2025, the Company
received written decision from the Panel, which granted an extension, allowing the Company additional time to regain compliance with the
Nasdaq Stock Market&#8217;s (&#8220;Nasdaq&#8221; or the &#8220;Exchange&#8221;) continued listing requirements, subject to meeting specific
compliance criteria within designated timeframes. On February 11, 2025, the Company carried out a 1-for-20 reverse stock split of its
issued and unissued shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share.
On February 27, 2025, the Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company&#8217;s
securities had been at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the
Company had regained compliance with the minimum bid price rule. In addition, on February 27, 2025, the Company received a confirmation
from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved and that the Company&#8217;s securities
would be transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></div><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; padding: 3pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Capitalization and Indebtedness</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Below is the Company&#8217;s capitalization and indebtedness as
of December 31, 2024:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-keep: true">Cash and Cash equivalents</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">457,740</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">EQUITY AND LIABILITIES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="-keep: true">Share capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Subscription receivable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(204,000</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">122,505</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">Accumulated deficit</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(985,994</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total capitalization</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(609,749</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of <br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">US$</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-keep: true">Total Net Book Value</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(1,481,757</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Total Share Outstanding*</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,138,519</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="-keep: true">*</span></td><td style="text-align: justify"><span style="-keep: true">The shares as presented have been adjusted retrospectively
                                            for a Reverse Share Split effected in February 2025 of 1 share for every 20 existing share
                                            issued.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Statements of indebtedness as of December 31, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 9pt"><span style="-keep: true">Account payable</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,298,964</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Accrued liabilities and other payables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">500,729</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Contract liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">63,489</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Due to related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">154,453</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Operating lease liabilities, current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">108,526</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Convertible notes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">82,447</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Promissory note</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">500,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">Income tax payable</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">11,746</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total current liabilities</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">2,720,354</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Non-current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Lease liabilities, operating leases</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10,231</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Convertible notes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,328,916</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total non-current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,339,147</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total Indebtedness</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">5,059,501</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


</div><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<b>Dilution</b>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-keep: true">The following information is presented as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Existing shareholder</span></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">31/12/2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-keep: true">Total comprehensive income attributable to the shareholders of the company</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(498,480</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Earning per share &#8211; basic</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(1.32</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="-keep: true">- diluted</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(0.64</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Weighted average shares outstanding &#8211; Basic</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">358,108</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="-keep: true">- Diluted</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">743,323</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Subsequent
to 2024 yearend, the Company carried out 1-for-20 reverse stock split of its issued and unissued shares which was effected on February
11, 2025. The shares above have been adjusted retrospectively for this reverse stock split.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Implications
of being a &#8220;Foreign Private Issuer&#8221;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
are subject to the information reporting requirements of the Exchange Act that are applicable to &#8220;foreign private issuers,&#8221;
and under those requirements, we file reports with the SEC. As a foreign private issuer, we are not subject to the same requirements
that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain
respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, we are not required to issue
quarterly reports, proxy statements that comply with the requirements applicable to U.S. domestic reporting companies or individual executive
compensation information that is as detailed as that required of U.S. domestic reporting companies. We also have four months after the
end of each fiscal year to file our annual report with the SEC and are not required to file current reports as frequently or promptly
as U.S. domestic reporting companies. Our officers, directors and principal shareholders are exempt from the requirements to report transactions
in our equity securities and from the short-swing profit liability provisions contained in Section 16 of the Exchange Act. As a foreign
private issuer, we are not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. In addition,
as a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of those otherwise
required under the rules of Nasdaq for domestic U.S. issuers and are not required to be compliant with all Nasdaq rules as of the date
of our initial listing on Nasdaq as would domestic U.S. issuers. These exemptions and leniencies will reduce the frequency and scope
of information and protections available to you in comparison to those applicable to a U.S. domestic reporting company. We intend to
take advantage of the exemptions available to us as a foreign private issuer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Implications of Being a Controlled Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chairman of the Board
and the Chief Executive Officer, Mr. Wing Fung Alfred Siu and our Director and the Chief Marketing Officer, Ms. Hei Yue Tina Fong, who
are husband and wife, jointly owns voting power of 80.21% of our issued and outstanding ordinary shares. Therefore, Mr. Wing Fung Alfred
Siu and Ms. Hei Yue Tina Fong, as our controlling shareholders, have the ability to determine any matter required to be passed by an ordinary
resolution, which will be adopted when approved by a simple majority of votes cast by the shareholders of the Company. Our controlling
shareholders will also have the ability to control the outcome of a matter required to be passed by a special resolution, which will be
adopted when approved by not less than two-thirds&#160;of votes cast by the shareholders of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we are deemed
a &#8220;controlled company&#8221; for the purpose of the Nasdaq listing rules. As a controlled company, we are permitted to elect to
rely on certain exemptions from the obligations to comply with certain corporate governance requirements, including the requirements that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">a majority of our board of directors consist of independent
directors;</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">our director nominees be selected or recommended solely by
independent directors; and</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p></div><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; padding: 3pt; width: 98%"><p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">we have a nominating committee and a remuneration committee
that are composed entirely of independent directors with a written charter addressing the purposes and responsibilities of the committees.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we do not intend to rely on the controlled
company exemptions under the Nasdaq listing rules even if we are a controlled company, we could elect to rely on these exemptions in the
future, and if so, you would not have the same protection afforded to shareholders of companies that are subject to all of the corporate
governance requirements of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Summary of Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in our Class A Ordinary
Shares involves significant risks. You should carefully consider all of the information in this prospectus before making an investment
in our shares. Below please find a summary of the principal risks we face, organized under relevant headings. These risks are discussed
more fully in the section titled &#8220;<i>Risk Factors</i>&#8221; and in Part I, Item 3, D. Risk Factors in our most recent Annual Report
on Form 20-F.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Risks
                                            Related to NewGenIvf&#8217;s Business and Industry</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to continue
    operating as a going concern.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fertility market in
    which NewGenIvf participates is competitive, and if NewGenIvf does not continue to compete effectively, its results of operations
    could be materially and adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf has a limited
    operating history with its current platform of solutions, which makes it difficult to predict its future prospects, financial performance
    and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&#8217;s marketing
    efforts depend significantly on its ability to receive positive references from its existing clients.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf is unable
    to attract new clients, its business, financial condition and results of operations would be adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&#8217;s business
    depends on its ability to maintain its existing client demographics. Any failure to do so would harm its business, financial condition
    and results of operations.</span></td></tr>
  </table><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf fails to offer high-quality support, its reputation could
    suffer.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s failure to effectively develop and expand its marketing
    and sales capabilities could harm its ability to increase its client base and achieve broader market acceptance of solutions NewGenIvf
    provides.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf may experience net losses and may not sustain profitability
    in the future.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s future revenue may not grow at the rates it historically
    has, or at all.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s quarterly and annual results may fluctuate significantly
    and may not fully reflect the underlying performance of NewGenIvf&#8217;s business.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the estimates and assumptions NewGenIvf uses to determine the size
    of the target markets for its services are inaccurate, its future growth rate may be impacted and its business would be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf may not be able to successfully manage its growth, and if
    NewGenIvf is not able to grow efficiently, its business, financial condition and results of operations could be harmed.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p></div><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; padding: 3pt; width: 98%"><p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top"><td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf&#8217;s new solutions and services are not adopted by
    its clients, or if it fails to innovate and develop new offerings that are adopted by its clients, its revenue and results of operations
    may be adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf fails to adapt and respond effectively to the changing
    medical landscape, changing regulations, changing client needs, requirements or preferences, its offerings may become less competitive.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf fails to maintain and enhance its brand, its ability to
    expand its client base will be impaired and its business, financial condition and results of operations may suffer.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf fails to retain and motivate members of its management
    team or other key employees, or fails to attract additional qualified personnel to support its operations, its business and future
    growth prospects could be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To successfully market and sell its services and products in Asia-Pacific
    markets, NewGenIvf must address many international business risks with which NewGenIvf has limited experience.</span></td></tr>
</table>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top"><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Ethical, legal and social concerns related to the use of assisted reproductive
    technology could reduce demand for the fertility services provided by the medical facilities in NewGenIvf&#8217;s network, and thus
    may adversely affect the business, financial conditions and results of operations of the medical facilities in its network.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf is reliant on revenue from international clients.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fluctuations in exchange rates could have a material and adverse effect
    on NewGenIvf&#8217;s results of operations and the value of your investment.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Governmental control of currency conversion may limit NewGenIvf&#8217;s
    ability to utilize NewGenIvf&#8217;s net revenue effectively and affect the value of your investment.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Substantially all of NewGenIvf&#8217;s assets and operations are located
    in Thailand, Cambodia and Kyrgyzstan and they are subject to economic, legal and regulatory uncertainties in such countries.</span></td>
    </tr>
</table><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Failure to comply with the terms of future financing arrangements could
    result in default, which could have an adverse effect on NewGenIvf&#8217;s cash flow and liquidity.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf requires a significant amount of capital to fund its operations
    and growth. If NewGenIvf cannot obtain sufficient capital on acceptable terms, its business, financial condition, and prospects may
    be materially and adversely affected.</span></td>
    </tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The defects in certain leased property interests and failure to register
    certain lease agreements may materially and adversely affect NewGenIvf&#8217;s business, financial condition, results of operations,
    and prospects. </span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf currently has no insurance coverage for its operations.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf may not be successful in adapting to technological developments,
    which may affect its business and results of operations.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If its computer systems, or those of its providers, specialty pharmacies
    or other downstream vendors lag, fail or suffer security breaches, NewGenIvf may incur a material disruption of its services, which
    could materially impact its business and the results of operations.</span></td>
    </tr>

<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to comply with the filing deadlines for reports
    that we file pursuant to the Exchange Act, and our failure to timely file such reports may have material adverse consequences on
    our business.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If we are unable to continue to meet the listing requirements of Nasdaq,
    our Class A Ordinary Shares will be delisted</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Risks Related to NewGenIvf&#8217;s
Relationships with Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s business depends on its ability to maintain its network
    of high-quality fertility specialists and other healthcare providers. If NewGenIvf is unable to do so, its future growth would be
    limited and its business, financial condition and results of operations would be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The medical facilities and professionals in NewGenIvf&#8217;s network
    could become the subject of litigation, allegations and other claims, and NewGenIvf is not insured against these liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The assisted reproductive medical facilities in NewGenIvf&#8217;s network
    have limited control over the quality of the pharmaceuticals, medical equipment, medical consumables and other supplies used in its
    operations, and cannot guarantee that the products in use are not defective or counterfeit. NewGenIvf also has no control over independent
    sub-contractors and cannot guarantee the services thereof.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf loses its relationship with one or more key pharmaceutical
    manufacturers, its business and results of operations could be adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf has engaged in transactions with related parties, and such
    transactions present potential conflicts of interest that could have an adverse effect on its business and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf may be subject to claims and allegations relating to intellectual
    property and other causes.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Certain
                                    data and information in this prospectus relied on by NewGenIvf were obtained from third-party data
                                    and polls. These metrics were not independently verified by NewGenIvf and may not be accurate.</span></p>
</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Risks Related to Government Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf operates in a highly regulated industry and must comply with
    a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits applicable to NewGenIvf&#8217;s
    business may have a material and adverse impact on NewGenIvf&#8217;s business, financial condition, and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#9679;</span></td>
    <td style="text-align: justify"><span style="-keep: true">Advertising or offering of gender selection services in certain jurisdictions in which NewGenIvf
    operates could expose NewGenIvf and its directors and executive officers to significant legal and regulatory risks, including potential
    penalties.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in NewGenIvf&#8217;s effective tax rate or tax liability may
    have an adverse effect on its results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s reported financial results may be adversely affected
    by changes in accounting principles generally accepted in relevant jurisdictions.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s reported financial results may be adversely affected
    by changes in accounting principles generally accepted in relevant jurisdictions.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf&#8217;s estimates or judgments relating to its critical
    accounting policies prove to be incorrect, its results of operations could be adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">NewGenIvf
                                    is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance
                                    with such laws can subject it to criminal or civil liability and harm its business, financial condition
                                    and results of operations.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Recent Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>2025 Debt Financing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On April 1, 2025, the
Company entered into a new Securities Purchase Agreement (&#8220;2025 Securities Purchase Agreement&#8221;) with certain investors named
therein (collectively, the &#8220;Buyers&#8221;), pursuant to which, amongst other things: (i) the Company agreed to sell, at an initial
closing (and such initial closing, the &#8220;Initial Closing&#8221;) a senior convertible note (the &#8220;New CB Initial Note&#8221;)
in the aggregate original principal amount not exceeding $3,200,000, convertible into Class A Ordinary Shares pursuant to its terms;
and (ii) the Company may require each Buyer (or each Buyer may require the Company, as applicable) to participate in the sale of one
or more additional convertible notes (which aggregate original principal amount for all additional convertible notes shall not exceed
$25,600,000) (the &#8220;New CB Additional Notes&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The 2025 Securities Purchase
Agreement is filed as Exhibit 4.1 of the Company&#8217;s current report on Form 6-K dated April 3, 2025 and is incorporated by reference
herein.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>THE OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">This prospectus relates
to the resale by the Selling Securityholders identified in this prospectus of up to 123,275,000 Class A Ordinary Shares. All of the Class
A Ordinary Shares, when sold, will be sold by the Selling Securityholders. The Selling Securityholders may sell their Class A Ordinary
Shares from time to time at prevailing market prices. We will not receive any proceeds from the sale of the Class A Ordinary Shares by
the Selling Securityholders.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 35%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares currently issued and outstanding </span></td>
    <td style="width: 1%; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,508,094
    Ordinary Shares, consisting of 7,302,819 Class A Ordinary Shares and 205,275 Class B Ordinary Shares</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares offered by the Selling Securityholders </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 123,275,000 Class
    A Ordinary Shares, consisting of (i) 125,000 Class A Ordinary Shares issued pursuant to the Purchase Agreement; (ii) 150,000 Class
    A Ordinary Shares issued pursuant to the Consulting Services Agreement; (iii) 120,000,000 Class A Ordinary Shares underlying the
    Remaining Additional Notes, the Exchange Notes, the Warrants, and the New CB Initial Note; and (iv) 3,000,000
    Class A Ordinary Shares that may be issued by us to White Lion pursuant to the White Lion Purchase Agreement. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary
    Shares after this offering</b></span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 130,783,094 Ordinary
    Shares, consisting of 130,577,819 Class A Ordinary Shares and 205,275 Class B Ordinary Shares</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds </span></td>
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the securities
    offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their respective
    accounts. We will not receive any of the proceeds from such sales. However, we may receive up to $500,000,000 in gross proceeds under
    the White Lion Purchase Agreement from sales of Class A Ordinary Shares that we may elect to make to White Lion pursuant to the White
    Lion Purchase Agreement. In addition, we may receive proceeds from conversion of the Additional Notes, the Exchange Notes, the Warrants
    and the New CB Initial Note. All proceeds from the conversion of the Additional Notes, Exchange Notes, Warrants, New CB Initial
    Note and the sales of Class A Ordinary Shares to White Lion will be used for working capital and other general corporate purposes.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should read the &#8220;<i>Risk Factors</i>&#8221; section starting on page 25 of this prospectus for a discussion of factors to consider carefully before deciding to invest in our securities.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq symbol</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NIVF&#8221; (Class A Ordinary Shares); &#8220;NIVFW&#8221; (Warrants to purchase Class A Ordinary Shares).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The number of Ordinary
Shares issued and outstanding is 7,508,094 as of April 29, 2025. No new Class A Ordinary Shares will be issued by us under this offering.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>RISK
FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in our Class A Ordinary
Shares involves a high degree of risk. You should carefully consider the risks in this prospectus, the risk factors described under the
caption &#8220;<i>Risk Factors</i>&#8221; in any applicable prospectus supplement and any risk factors set forth in our other filings
with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, before
making a decision about investing in our Class A Ordinary Shares. The risks and uncertainties we have described are not the only ones
we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations.
If any risks actually occur, our business, financial condition and results of operations may be materially and adversely affected. In
such an event, the trading price of our Class A Ordinary Shares could decline and you could lose part or all of your investment.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Additionally,
we are also subject to the following risk factors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Risks Related
to NewGenIvf&#8217;s Business and Industry</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may not
be able to continue operating as a going concern.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
the Company&#8217;s cash and cash equivalents stood at approximately US$457,740. While the Company does not have immediate challenges
to settle its obligations when payments become due, the Company can make no assurance that it will have sufficient capital to bridge
potential financial and liquidity shortfalls.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company is always
closely monitoring the market for opportunities and has also been carrying out various fundraising projects to improve the Company&#8217;s
cash flow position. As of April 10, 2025, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising
the Initial Note, the First Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the
Company. A further US$2,000,000 of the Third Mandatory Additional Note was issued subsequent to the 2024 yearend and remains outstanding.
Moreover, the Company has access to an equity line of credit facility of up to US$100,000,000 from White Lion Capital, of which approximately
US$7.1 million has been drawn and become equity to date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company can make no assurance
that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one
or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there
would likely be a material adverse effect on the Company and its financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements do not reflect adjustments
that would be necessary if the going concern basis was not appropriate. If the going concern basis was not appropriate for these
consolidated financial statements, then adjustments would be necessary in the carrying value of the assets and liabilities, the
reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>The fertility
market in which NewGenIvf participates is competitive, and if NewGenIvf does not continue to compete effectively, its results of operations
could be materially and adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
market for NewGenIvf&#8217;s solutions is competitive and is likely to attract increased competition, which could make it hard for it
to succeed. NewGenIvf faces significant competition from other fertility companies and other players in the fertility market. Some of
NewGenIvf&#8217;s competitors are more established, have a longer operating history and a larger client base, benefit from greater brand
recognition and have substantially greater financial, technical and marketing resources than NewGenIvf does. NewGenIvf&#8217;s competitors
may compete with NewGenIvf in a variety of ways, including seeking to develop or integrating solutions and services that may become more
efficient or appealing to NewGenIvf&#8217;s existing and potential clients, achieving superior clinical outcomes, having access to a
network of more high-quality fertility specialists, establishing more comprehensive data reporting and sharing systems, conducting brand
promotions and other marketing activities, and making investments in and acquisitions of NewGenIvf&#8217;s business partners. While NewGenIvf
believes that one of its key competitive advantages is its ability to provide a broad range of services, and NewGenIvf does not believe
any competitors have developed a similar broad range services in Asia Pacific at this time, current or future competitors may be successful
in doing so in the future. If current or future competitors are successful at developing a similar broad range of services, NewGenIvf&#8217;s
financial performance may be negatively impacted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In addition, NewGenIvf
believes that there is growing awareness of the demand for fertility services. As the fertility services field gains more attention,
more competitors may be drawn into the market. NewGenIvf also could be adversely affected if NewGenIvf fails to identify or effectively
respond to changes in market dynamics. As a result of any of these factors, NewGenIvf may not be able to continue to compete successfully
against its current or future competitors, and this competition could result in the decrease in its clients base and market share and
the failure of its platform to continue to maintain market acceptance, which would materially and adversely affect its business, financial
condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
has a limited operating history with its current platform of solutions, which makes it difficult to predict its future prospects, financial
performance and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The predecessor entity
of the Company prior to the Business Combination in April of 2024, NewGenIvf Limited, a Cayman Islands exempted company, was established
in 2019, and although its subsidiary First Fertility PGS Center Limited launched fertility services in 2014, has a limited operating
history. As a result of its limited operating history with its current platform of solutions, as well as a limited amount of time serving
a majority of its client base, its ability to accurately forecast its future results of operations, key operating data, net revenue,
cash flows, and operating margins is limited and subject to a number of uncertainties, including its ability to plan for and model future
growth. NewGenIvf&#8217;s historical revenue growth should not be considered indicative of its future performance. Further, in future
periods, its revenue growth could slow or decline for a number of reasons, including risks, challenges and uncertainties that NewGenIvf
has encountered and may continue to encounter that are frequently experienced by companies at an early stage, slowing demand for its
solutions and fertility services in general, changes in utilization trends by its clients, general economic slowdown, an increase in
unemployment, an increase in competition, changes to health care trends and regulations, changes to science relating to the fertility
market, a decrease in the growth of the fertility market, or its failure, for any reason, to continue to take advantage of growth opportunities.
If NewGenIvf&#8217;s assumptions regarding these risks and uncertainties and its future revenue growth are incorrect or change, or if
it does not address these risks successfully, its operating and financial results could differ materially from its expectations, and
its business could suffer.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
marketing efforts depend significantly on its ability to receive positive references from its existing clients.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
marketing efforts depend significantly on its ability to call on its current clients to provide positive references to new, potential
clients. Given its limited number of long-term clients, the loss or dissatisfaction of any client could substantially harm its brand
and reputation, inhibit the market adoption of its offering and impair its ability to attract new clients and maintain existing clients.
Any of these consequences could have an adverse effect on its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>As a public
reporting company, we are subject to filing deadlines for reports that we file pursuant to the Exchange Act, and our failure to timely
file such reports may have material adverse consequences on our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In
the past, we have not been able to, and may continue to be unable to produce timely financial statements, and file these financial statements
as part of a periodic report in a timely manner with the SEC. For example, we failed to timely file with the SEC the requisite Form 20-F
for the year ended December 31, 2023. Consequently, we were not compliant with the periodic reporting requirements under the Exchange
Act at such time. We cannot guarantee that in the future our reporting will always be timely. Our failure to timely file future periodic
reports with the SEC could subject us to enforcement action by the SEC and shareholder lawsuits and could eventually result in the delisting
of our Class A Ordinary Shares from Nasdaq, regulatory sanctions from the SEC, and/or the breach of covenants in our credit facilities
or of any preferred equity or debt securities we may issue in the future, any of which could have a material adverse impact on our operations
and your investment in our Class A Ordinary Shares, and our ability to register with the SEC public offerings of our securities for our
benefit or the benefit of our security holders. Additionally, our failure to file our past periodic reports and future periodic reports
has resulted in and could result in investors not receiving adequate information regarding us with which to make investment decisions.
As a result, investors may not have access to current or timely financial information about our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If we are
unable to continue to meet the listing requirements of Nasdaq, our Class A Ordinary Shares will be delisted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On October 8, 2024, the
Company received a deficiency letter (&#8220;Bid Price Deficiency Letter&#8221;) from the Listing Qualifications Department (the &#8220;Staff&#8221;)
of Nasdaq notifying the Company that it is currently not in compliance with the closing bid price requirement under Nasdaq Listing Rule
5450(a)(1) (the &#8220;Minimum Bid Price Rule&#8221;). The Bid Price Deficiency Letter stated that, for the preceding 30 consecutive
business days, the Company&#8217;s Class A Ordinary Shares did not meet the minimum closing bid price of $1 per share pursuant to the
Minimum Bid Price Rule. The Company has an initial compliance period of 180 calendar days, or until April 7, 2025 to regain compliance
with the Minimum Bid Price Rule. The Deficiency letter stated that if at any time the closing bid price of the Company&#8217;s Class
A Ordinary Shares is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation
of compliance with this requirement, as applicable. On February 11, 2025, the Company effected a 1-for-20 reverse stock split of its
issued and unissued shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share.
On February 27, 2025, the Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company&#8217;s
securities had been at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the
Company had regained compliance with the Minimum Bid Price Rule. Notwithstanding the foregoing, if within one year of the Reverse Stock
Split, the Company&#8217;s Class A Ordinary Shares fall below $1.00 per share for 30 consecutive business days, or if within a two-year
period from the Reverse Stock Split, the Company effects one or more reverse stock splits with a cumulative ratio of 250 shares or more
to one, then Nasdaq may not provide us with an additional compliance period under its amended Listing Rule 5810(c)(3)(A)(iv) and our
common stock could be delisted immediately.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On May 24, 2024, the Company
received a MVLS Deficiency Letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of Nasdaq notifying the Company
that, for the preceding 35 consecutive business days, the Class A Shares did not meet the minimum MVLS Requirement for continued listing
on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(A). In accordance with Nasdaq Rule 5810(c)(3)(C), the Company has been provided
an initial period of 180 calendar days, or until November 20, 2024, the Compliance Date, to regain compliance with the MVLS Requirement.
If, at any time before the Compliance Date, the MVLS for the Class A Shares is at least $50,000,000 for a minimum of ten consecutive
business days, the Staff will provide the Company written confirmation of compliance with the MVLS Requirement. In the event the Company
does not regain compliance with the above requirement prior to the expiration of the compliance period, it will receive written notification
that its securities are subject to delisting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On
May 24, 2024, the Company received a MVPHS Deficiency Letter from the Staff of Nasdaq notifying the Company that, for the preceding 35
consecutive business days, the Company&#8217;s Class A Ordinary Shares did not meet the minimum $15,000,000 MVPHS Requirement for continued
listing on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(C). In accordance with Nasdaq Rule 5810(c)(3)(D), the Company has until
the Compliance Date to regain compliance with the MVPHS Requirement. If, at any time before the Compliance Date, the MVPHS for the Class
A Shares is at least $15,000,000 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation
of compliance with the MVPHS Requirement. In the event the Company does not regain compliance with the above requirement prior to the
expiration of the compliance period, it will receive written notification that its securities are subject to delisting. Alternatively,
the Company may apply to transfer the Company&#8217;s securities to The Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On November 21, 2024,
the Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the
MVPHS Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings
Panel (the &#8220;Panel&#8221;) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the
Panel will consider its appeal at&#160;an oral hearing&#160;on January 28, 2025 (the &#8220;Hearing&#8221;). On February 19, 2025, the
Company received written decision from the Panel, which granted an extension, allowing the Company additional time to regain compliance
with the Nasdaq Stock Market&#8217;s (&#8220;Nasdaq&#8221; or the &#8220;Exchange&#8221;) continued listing requirements, subject to
meeting specific compliance criteria within designated timeframes. On February 11, 2025, the Company carried out a 1-for-20 reverse stock
split of its issued and unissued shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share
into one share. On February 27, 2025, the Company received a notification letter from Nasdaq, indicating that the closing bid price of
the Company&#8217;s securities had been at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February
26, 2025, and the Company had regained compliance with the Minimum Bid Price Rule. In addition, on February 27, 2025, the Company received
a confirmation from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved and that the Company&#8217;s
securities would be transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025. On March 10, 2025, the
Company received a confirmation letter from Nasdaq confirming that it has demonstrated compliance with all of Nasdaq&#8217;s listing
requirements, as required in the Panel&#8217;s decision letter dated February 19, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-size: 10pt">If
we are unable to achieve and maintain compliance with such listing standards or other Nasdaq listing requirements in the future, our
Class A Ordinary Shares could be delisted from Nasdaq. A delisting of our Class A Ordinary Shares and our inability to list on another
national securities market could negatively impact us by: (i) reducing the liquidity and market price of our Class A Ordinary Shares;
(ii) reducing the number of investors willing to hold or acquire our Class A Ordinary Shares, which could negatively impact our ability
to raise equity financing; (iii) limiting our ability to use certain registration statements to offer and sell freely tradable securities,
thereby limiting our ability to access the public capital markets; and (iv) impairing our ability to provide equity incentives to our
employees.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
is unable to attract new clients, its business, financial condition and results of operations would be adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">To
increase its revenue, NewGenIvf must continue to attract new clients. NewGenIvf&#8217;s ability to do so depends in large part on the
success of its sales and marketing efforts, and the success of references through existing clients. Potential clients may seek out other
options; therefore, NewGenIvf must demonstrate that its solutions are valuable and superior to alternatives. If NewGenIvf fails to provide
high-quality solutions and convince clients of the benefits of its model and value proposition, NewGenIvf may not be able to attract
new clients. If the markets for NewGenIvf&#8217;s solutions decline or grow more slowly than it expects, or if the number of clients
that contract with it for its solutions declines or fails to increase as it expects, its financial results could be harmed. As the markets
in which NewGenIvf participate mature, fertility solutions and services evolve and competitors begin to enter into the market and introduce
differentiated solutions or services that are perceived to compete with its solutions, particularly if such competing solutions are adopted
by its competitors, its ability to sell its solutions could be impaired. As a result of these and other factors, NewGenIvf may be unable
to attract new clients, which would have an adverse effect on its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
business depends on its ability to maintain its existing client demographics. Any failure to do so would harm its business, financial
condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
part of its growth strategy, NewGenIvf is focused on maintaining its services within its existing client demographics. NewGenIvf mainly
competes with mid-level private clinics and hospitals, which have improved and developed their services and equipment over the&#160;years.
In addition to private clinics and hospitals already existing, foreign medical companies may also enter the markets where NewGenIvf operates.
Such foreign medical companies may be well-placed to compete with NewGenIvf due to their larger network size, reputation as global players
and access to more advanced technology and financial resources. The expansion of existing competitors in the industry may erode NewGenIvf&#8217;s
existing market share or decrease its traditional client pool. There can be no assurance that NewGenIvf will be able to compete effectively
and therefore its future business growth may suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>A significant
reduction in the utilization of NewGenIvf&#8217;s solutions could have an adverse effect on its business, financial condition and results
of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">A
significant reduction in the number of clients using NewGenIvf&#8217;s solutions could adversely affect its business, financial condition
and results of operations. Factors that could contribute to a reduction in the use of its solutions include: general economic downturn
that results in adverse financial conditions; regulatory changes; failure to adapt and respond effectively to changing medical landscape,
changing regulations, changing client needs, requirements or preferences; negative publicity, through social media or otherwise and news
coverage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If NewGenIvf fails to offer high-quality
support, its reputation could suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf relies on its client
account management personnel and the patient navigators (the &#8220;PNs&#8221;) to resolve client issues and help clients realize the
full benefits that its solutions and services provide. High-quality support is also important for the renewal and expansion of its services
to existing clients. The importance of its support functions will increase as NewGenIvf expands its business and pursue new clients. If
NewGenIvf does not help its clients quickly resolve issues and provide effective ongoing supports, its ability to maintain and expand
its offerings to existing and new clients could suffer, and its reputation with existing or potential clients could suffer. Further, to
the extent that NewGenIvf is unsuccessful in hiring, training and retaining adequate PNs and client account management personnel, its
ability to provide adequate and timely support to its clients would be negatively impacted, and its clients&#8217; satisfaction with its
solutions and services would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
                                            failure to effectively develop and expand its marketing and sales capabilities could harm
                                            its ability to increase its client base and achieve broader market acceptance of solutions
                                            NewGenIvf provides.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
ability to increase its client base and achieve broader market acceptance of solutions it provides will depend to a significant extent
on its ability to expand its marketing and sales capabilities. NewGenIvf plans to continue expanding its direct sales force and to dedicate
significant resources to sales and marketing programs, including direct sales, inside sales, targeted direct marketing, advertising,
digital marketing, e-newsletter and conference sponsorships. All of these efforts will require it to invest significant financial and
other resources. Its business and results of operations could be harmed if its sales and marketing efforts do not generate significant
increases in revenue. NewGenIvf may not achieve anticipated revenue growth from expanding its sales and marketing efforts if it is unable
to hire, develop, integrate and retain talented and effective sales personnel, if its new and existing sales personnel, on the whole,
are unable to achieve desired productivity levels in a reasonable period of time, or if its sales and marketing programs are not effective.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
may experience net losses and may not sustain profitability in the future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
experienced significant revenue decrease from 2019 to 2020, due to the impact of COVID-19. NewGenIvf is not certain whether it will obtain
sufficient levels of sales to sustain its growth or maintain profitability in the future. NewGenIvf also expects its costs and expenses
to increase in future periods, which could negatively affect its future results of operations if its revenue does not increase accordingly.
In particular, NewGenIvf intends to continue to incrementally expand its sales and client account management teams to educate potential
clients and drive new client adoption. NewGenIvf also expects to incur additional costs as it introduces new solutions and services to
enhance its comprehensive fertility offering. NewGenIvf will also face increased compliance costs associated with growth, the expansion
of its client base and being a public company. NewGenIvf&#8217;s efforts to grow its business may be costlier than it expects, and NewGenIvf
may not be able to increase its revenue enough to offset its increased operating expenses. NewGenIvf may incur significant losses in
the future for a number of reasons, including the other risks described herein, and unforeseen expenses, difficulties, complications
and delays, and other unknown events. If NewGenIvf is unable to sustain profitability, the value of its business and common stock may
significantly decrease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
future revenue may not grow at the rates it historically has, or at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has experienced growth since its business operations started in 2014. Revenue and NewGenIvf&#8217;s client base may not grow at the same
rates they historically have, or they may decline in the future. NewGenIvf&#8217;s future growth will depend, in part, on its ability
to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">continue
                                            to attract new clients and/or maintain existing clients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">price
                                            its solutions and services effectively so that it is able to attract new clients, expand
                                            sales to its existing clients and maintain profitability;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">provide
                                            its clients with client support that meets their needs, including through dedicated PNs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">maintain successful collection of applicable receivable balances;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">retain and maintain relationships with high-quality and respected fertility
    specialists;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">attract and retain highly qualified personnel to support all clients;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increase awareness of its brand and successfully compete with other
    competitors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
may not successfully accomplish all or any of these objectives, which may affect its future revenue, and which makes it difficult for
it to forecast its future results of operations. In addition, if the assumptions that NewGenIvf uses to plan its business are incorrect
or change in reaction to changes in its market, it may be difficult for it to maintain profitability. NewGenIvf&#8217;s shareholders
should not rely on its revenue for any prior quarterly or annual periods as any indication of its future revenue or revenue growth.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, NewGenIvf expects to continue to expend substantial financial and other resources on:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">sales and marketing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">technology infrastructure, including systems architecture, scalability,
    availability, performance and security; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">general administration, including increased legal and accounting expenses
    associated with being a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
investments may not result in increased revenue growth in its business. If NewGenIvf is unable to increase its revenue at a rate sufficient
to offset the expected increase in its costs, its business, financial position, and results of operations will be harmed, and NewGenIvf
may not be able to maintain profitability over the long term. Additionally, NewGenIvf may encounter unforeseen operating expenses, difficulties,
complications, delays and other unknown factors that may result in losses in future periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
its revenue growth does not meet its expectations in future periods, NewGenIvf may not maintain profitability in the future, its business,
financial position and results of operations may be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>NewGenIvf&#8217;s interim and annual
results may fluctuate significantly and may not fully reflect the underlying performance of NewGenIvf&#8217;s business.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s interim
and annual results of operations, including the levels of NewGenIvf&#8217;s revenues, expenses, net (loss)/income and other key metrics,
may vary significantly in the future due to a variety of factors, some of which are outside of NewGenIvf&#8217;s control, and period-to-period
comparisons of NewGenIvf&#8217;s operating results may not be meaningful, especially given NewGenIvf&#8217;s limited operating history.
Accordingly, the results for any one fiscal half year or any one fiscal year are not necessarily an indication of future performance.
Fluctuations in interim and/or annual financial results may adversely affect the price of NewGenIvf&#8217;s ordinary shares. Factors
that may cause fluctuations in NewGenIvf&#8217;s interim and annual financial results include:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s
                                            ability to attract new customers and maintain relationships with existing customers;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes
                                            in NewGenIvf&#8217;s products and services offered and introduction of new services and products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            amount and timing of operating expenses related to marketing and the maintenance and expansion
                                            of NewGenIvf&#8217;s business, operations and infrastructure;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">general
                                            economic, industry and market conditions; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            timing of expenses related to the development or acquisition of technologies or businesses.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If the estimates
and assumptions NewGenIvf uses to determine the size of the target markets for its services are inaccurate, its future growth rate may
be impacted and its business would be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Market
opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may
not prove to be accurate. Market opportunity estimates and growth forecasts included in this prospectus, including those NewGenIvf has
generated itself, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate,
including the risks described in this prospectus. Even if the markets in which NewGenIvf competes achieve the forecasted growth, its
business could fail to grow at similar rates, if at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
estimates of the market opportunity for its services are based on the assumption that the purpose-built, data-driven and disruptive fertility
services platform with the plan design NewGenIvf offers will be attractive to clients. Clients may pursue alternatives or may not see
the value in providing enhanced fertility-related services. In addition, NewGenIvf believes that it is expanding the size of the fertility
market as NewGenIvf enhances demand and increase awareness for fertility services. If these assumptions prove inaccurate, or if the increase
in awareness of fertility services attracts potential competitors to the market and results in greater competition, NewGenIvf&#8217;s
business, financial condition and results of operations could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">It
is difficult to predict the demand for NewGenIvf&#8217;s solutions, the entry of competitive solutions or the future growth rate and
size of the fertility market. The expansion of the fertility market depends on a number of factors, including, but not limited to: the
continued trend of individuals starting families later in life, increase in the number of single mothers by choice, adoption of non-traditional
paths to parenthood and continued de-stigmatization of infertility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
there is a reduction in demand caused by a lack of client acceptance, weakening economic conditions, data security or privacy concerns,
governmental regulation, competing offerings or otherwise, the market for its solutions and services might not continue to develop or
might develop more slowly than NewGenIvf expects, which would adversely affect its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
may not be able to successfully manage its growth, and if NewGenIvf is not able to grow efficiently, its business, financial condition
and results of operations could be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
usage of its solutions grows, NewGenIvf will need to devote additional resources to improving and maintaining its infrastructure. In
addition, NewGenIvf will need to appropriately scale its internal business systems and its client account management and services personnel
to serve its growing client base. Any failure of or delay in these efforts could result in reduced client satisfaction, resulting in
decreased sales to new clients and lower renewal and utilization rates by existing clients, which could hurt its revenue growth and its
reputation. Even if NewGenIvf is successful in these efforts, they will require the dedication of management time and attention. NewGenIvf
could also face inefficiencies or service disruptions as a result of its efforts to scale its internal infrastructure. NewGenIvf cannot
be sure that the expansion and improvements to its internal infrastructure will be effectively implemented on a timely basis, and such
failures could harm its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf&#8217;s
new solutions and services are not adopted by its clients, or if it fails to innovate and develop new offerings that are adopted by its
clients, its revenue and results of operations may be adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">To
date, NewGenIvf has derived a substantial majority of its revenue from sales of its fertility services. As NewGenIvf operates in an evolving
industry, its long-term results of operations and continued growth will depend on its ability to successfully develop and market new
successful solutions and services to its clients. If its existing clients do not value and/or are not willing to make additional payments
for such new solutions or services, it could adversely affect its business, financial condition and results of operations. If NewGenIvf
is unable to predict clients&#8217; preferences, if the markets in which NewGenIvf participates change, including in response to government
regulation, or if NewGenIvf is unable to modify its solutions and services on a timely basis, NewGenIvf may lose clients. Its results
of operations would also suffer if its innovations were not responsive to the needs of the clients, appropriately timed with market opportunity
or effectively brought to market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
fails to adapt and respond effectively to the changing medical landscape, changing regulations, changing client needs, requirements or
preferences, its offerings may become less competitive.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
market in which NewGenIvf competes is subject to a changing medical landscape and changing regulations, as well as changing client needs,
requirements and preferences. The success of its business will depend, in part, on its ability to adapt and respond effectively to these
changes on a timely basis. NewGenIvf&#8217;s business strategy may not effectively respond to these changes, and NewGenIvf may fail to
recognize and position itself to capitalize upon market opportunities. NewGenIvf may not have sufficient advance notice and resources
to develop and effectively implement an alternative strategy. There may be scientific or clinical changes that require it to change its
solutions or that make its solutions less competitive in the marketplace. If there are sensitivities to its model or its existing competitors
and new entrants create new disruptive business models and/or develop new solutions that clients prefer to its solutions, NewGenIvf may
lose clients, and its results of operations, cash flows and/or prospects may be adversely affected. The future performance of NewGenIvf&#8217;s
business will depend in large part on its ability to design and implement market appropriate strategic initiatives, some of which will
occur over several&#160;years in a dynamic industry. If these initiatives of NewGenIvf do not result in met objectives, NewGenIvf&#8217;s
results of operations could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
fails to maintain and enhance its brand, its ability to expand its client base will be impaired and its business, financial condition
and results of operations may suffer.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
growth of NewGenIvf&#8217;s business partially depends on the recognition of NewGenIvf&#8217;s brand and reputation. NewGenIvf believes
that maintaining and enhancing its brand is important to support the marketing and sale of its existing and future solutions to new clients
and expand sales of its solutions to existing clients. NewGenIvf also believes that the importance of brand recognition will increase
as competition in its market increases. Successfully maintaining and enhancing its brand will depend largely on the effectiveness of
its marketing efforts, its ability to provide reliable services that continue to meet the needs of its clients at competitive prices,
its ability to maintain its clients&#8217; trust, its ability to continue to develop new solutions, and its ability to successfully differentiate
its platform from competitive solutions and services. NewGenIvf&#8217;s brand promotion activities may not generate client awareness
or yield increased revenue, and even if they do, any increased revenue may not offset the expenses NewGenIvf incurs in building its brand.
If NewGenIvf fails to successfully promote and maintain its brand, its business, financial condition and results of operations may suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
fails to retain and motivate members of its management team or other key employees, or fails to attract additional qualified personnel
to support its operations, its business and future growth prospects could be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
success and future growth depend largely upon the continued services of its management team and its other key employees. From time to
time, there may be changes in its executive management team or other key employees resulting from the hiring or departure of these personnel.
Its executive officers and other key employees are employed on an at-will basis, which means that these personnel could terminate their
employment with it at any time. The loss of one or more of its executive officers, or the failure by its executive team to effectively
work with its employees and lead its company, could harm its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
addition, to execute its growth plan, NewGenIvf must attract and retain highly qualified personnel. Competition for these personnel is
intense, especially for experienced medical officers and scientific staffs and sales and client account management personnel. There is
no guarantee NewGenIvf will be able to attract such personnel or that competition among potential employers will not result in increased
salaries or other benefits. From time to time, NewGenIvf has experienced, and NewGenIvf expects to continue to experience, difficulty
in hiring and retaining employees with appropriate qualifications. Many of the companies with which NewGenIvf competes for experienced
personnel have greater resources than NewGenIvf has. If NewGenIvf hires employees from competitors or other companies, their former employers
may attempt to assert that these employees or NewGenIvf has breached their legal obligations, resulting in a diversion of its time and
resources. In addition, prospective and existing employees often consider the value of the equity awards they receive in connection with
their contribution to the company. If the perceived value of its equity awards declines, experiences significant volatility, or increases
such that prospective employees believe there is limited upside to the value of its equity awards, it may adversely affect its ability
to recruit and retain key employees. If NewGenIvf fails to attract new personnel or fails to retain and motivate its current personnel,
its business and future growth prospects could be harmed.

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Furthermore,
in order to attract and retain key personnel and employees, the compensation amounts for NewGenIvf&#8217;s executive officers may change
significantly after consummation of the Business Combination, although there are currently no agreements in place relating to any such
post Business Combination compensation arrangements. As a result, NewGenIvf&#8217;s expenses associated with the compensation may increase,
which may also have an adverse effect on its results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s Share
Incentive Plan allows NewGenIvf to enhance its ability to attract and retain exceptionally qualified individuals and agents and to encourage
them to acquire a proprietary interest in the company&#8217;s growth and performance. Competition for highly skilled personnel and agents
is often intense and NewGenIvf may incur significant costs or may not be successful in attracting, integrating, or retaining qualified
personnel and agents to fulfill NewGenIvf&#8217;s current or future needs. NewGenIvf believes that the granting of share-based awards
is of significant importance to NewGenIvf&#8217;s ability to attract and retain agents, key personnel and employees, and NewGenIvf will
continue to grant share-based awards in the future. In addition, NewGenIvf may, with the approval of its Compensation Committee and the
Board, revise the terms of, and increase the size of, its share incentive plan, to ensure that it is able to attract and retain agents,
key personnel and employees. On March 31, 2025, NewGenIvf&#8217;s Board approved certain amendments to its Share Incentive Plan, including
the increase of the size of the share incentive plan to 20% of the outstanding shares of the Company from time to time. As a result,
NewGenIvf&#8217;s expenses associated with share-based compensation may increase, which may have an adverse effect on NewGenIvf&#8217;s
results of operations. The amended share incentive plan is available as Exhibit 4.32.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>To successfully
market and sell its services and products in Asia-Pacific markets, NewGenIvf must address many international business risks with which
NewGenIvf has limited experience.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
business is subject to risks in connection with changes in international, national and local economic and market conditions, including
the effects of global financial crises, effects of terrorist acts and war and global pandemics. Such economic changes could negatively
impact infertile couples&#8217; abilities to pay for fertility treatments around the world.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
strategy is to increase its international presence in Asia-Pacific countries and its international sales are subject to a number of risks,
including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increased competition as a result of more products and procedures receiving
    regulatory approval or otherwise free to market in international markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">longer accounts receivable payment cycles and difficulties in collecting
    accounts receivable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reduced or varied protection for intellectual property rights in some
    countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">export restrictions, trade regulations, and foreign tax laws;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">fluctuations in currency exchange rates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">foreign certification and regulatory clearance or approval requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>   <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">customs clearance and shipping delays;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">political, social, and economic instability abroad, terrorist attacks,
    and security concerns in general;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">preference for locally provided services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potentially adverse tax consequences, including the complexities of
    foreign value-added tax systems;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the burdens of complying with a wide variety of foreign laws and different
    legal standards; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increased financial accounting and reporting burdens and complexities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
one or more of these risks are realized, its business, financial condition and results of operations could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Ethical,
legal and social concerns related to the use of assisted reproductive technology could reduce demand for the fertility services provided
by the medical facilities in NewGenIvf&#8217;s network, and thus may adversely affect the business, financial conditions and results
of operations of the medical facilities in its network.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Patient
sentiment and distrust of the use of assisted reproductive technology may lead to less demand for fertility services. Assisted reproductive
technologies, including genetic testing, technologies used for surrogacy and egg donation and gender selection, have raised ethical,
legal and social issues regarding privacy and the appropriate uses of the resulting information. Government authorities could, for social
or other purposes, limit or regulate the use of assisted reproductive technology to certain conditions. Similarly, these concerns may
lead patients to refuse to use, or physicians to be reluctant to order, assisted reproductive services even if permissible. These and
other ethical, legal and social concerns may limit market acceptance of fertility services or reduce patient demand for such services,
either of which could have a material adverse effect on the business, financial condition and results of operations of the medical facilities
in NewGenIvf&#8217;s network, and NewGenIvf itself.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
is reliant on revenue from international clients.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Fertility
services revenue from international clients are an important part of NewGenIvf&#8217;s revenue, though NewGenIvf is expanding rapidly
into the local markets. The number of international clients travelling to Thailand, Cambodia and Kyrgyzstan to seek fertility services
may, however, be affected by a number of factors, including the economic status of the foreign client&#8217;s country of origin, the
relative exchange rate of the client&#8217;s home currency to the relevant authorities, which may affect the cost of treatment, natural
disasters, pandemics like COVID-19, and political tension or acts of terrorism in such countries and the region. For example, the COVID-19
has had resulted in a number of countries declaring a state of emergency and a number of countries, including the countries in Asian
Pacific, imposing extensive travel restrictions, which in turn caused a decrease in the numbers of internal clients traveling to Thailand,
Cambodia or Kyrgyzstan for treatments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
events could cause a postponement or a reduction in the number of clients traveling to Thailand, Cambodia or Kyrgyzstan, and could in
turn affect revenues from international clients, which is the significant contributor in terms of volume. A decline in the medical tourism
industry may have a material adverse effect on NewGenIvf&#8217;s financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Fluctuations
in exchange rates could have a material and adverse effect on NewGenIvf&#8217;s results of operations and the value of your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s reporting
currency is U.S.&#160;dollars. The functional currency of NewGenIvf and its subsidiaries include Hong&#160;Kong dollar (&#8220;HK$&#8221;),
Thai baht (&#8220;THB&#8221;), and United&#160;States dollar (&#8220;USD&#8221;). Accordingly, fluctuations in the value of HK$, and
THB relative to the USD could affect its results of operations due to translational remeasurements. As its international operations expand,
an increasing portion of its revenue and operating expenses may be denominated in non- HK$, and THB currencies. Accordingly, NewGenIvf&#8217;s
revenue and operating expenses will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. If
NewGenIvf is not able to successfully hedge against the risks associated with currency fluctuations, NewGenIvf&#8217;s business, financial
condition and results of operations could be materially adversely affected.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Governmental
control of currency conversion may limit NewGenIvf&#8217;s ability to utilize NewGenIvf&#8217;s net revenue effectively and affect the
value of your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
revenue and expenses for its businesses are substantially denominated in THB, which are currently not freely convertible currencies.
A portion of such revenue must be converted into other currencies in order to meet its foreign currency obligations. For example,
NewGenIvf&#8217;s subsidiaries will need to obtain foreign currency to make payments of declared dividends, if any, on its
shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Under
the existing foreign exchange regulations in Thailand, NewGenIvf will be able to make current account foreign exchange transactions.
However, in the future, governments may take measures, at its discretion, to restrict access to foreign currencies for capital account
and current account transactions under certain circumstances. If such measures are implemented, NewGenIvf may not be able to pay dividends
in foreign currencies to holders of its shares. Foreign exchange transactions under its capital account are subject to significant foreign
exchange controls and require certain approvals. These limitations could affect our ability to obtain foreign exchange through offshore
financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
value of the THB against the U.S.&#160;dollar and other currencies fluctuates, and is subject to changes resulting from policies of the
Thailand and other governments, and depends to a large extent on domestic and international economic and political developments as well
as supply and demand in the local market. For example, the Bank of Thailand, which is the central bank of Thailand, is responsible for
formulating and implementing monetary policies in the country to maintain the price stability and promote economic stability and sustainable
growth. The Bank of Thailand imposes (four) measures in preventing THB fluctuation. Those are measures to limit THB liquidity, to curb
capital inflows, to limit the flows on Non-resident Bank Account and Non-resident Baht for Securities, and to limit the flows on Non-Deliverable
Forward transactions. With an increased floating range of the THB&#8217;s value against foreign currencies and a more market-oriented
mechanism for determining the mid-point exchange rates, the THB may further appreciate or depreciate significantly in value against the
U.S.&#160;dollar or other foreign currencies in the long-term, depending on the fluctuation of the basket of currencies against which
it is currently valued, or it may be permitted to enter into a full float, which may also result in a significant appreciation or depreciation
of the THB against the U.S.&#160;dollar or other foreign currencies. It cannot be assured that THB will not experience significant appreciation
or depreciation against the U.S.&#160;dollar or other foreign currencies in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Furthermore,
NewGenIvf is also currently required to obtain approvals before converting significant sums of foreign currencies into THB. All of these
factors could materially and adversely affect its business, results of operations, financial condition and prospects, and could reduce
the value of, and dividends payable on, its shares in foreign currency terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Sales of
a substantial number of our securities in the public market by the Selling Securityholders and/or by our existing securityholders could cause
the price of our Ordinary Shares to decrease significantly.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Selling Securityholders
can resell, under this prospectus, up to 123,275,000 Class A Ordinary Shares. The securities being offered in this prospectus represent
a substantial percentage of our issued and outstanding Class A Ordinary Shares, and the sale of such securities in the public market
by the Selling Securityholders, or the perception that those sales might occur, could depress the market price of our Class A Ordinary
Shares, and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the
effect that such sales may have on the prevailing market price of our Class A Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Our dual-class voting structure may
limit your ability to influence corporate matters and could discourage others from pursuing any change of control transactions that holders
of our Class A Ordinary Shares may view as beneficial.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Our authorized and issued
ordinary shares are divided into Class A Ordinary Shares and Class B Ordinary Shares. Each Class A Ordinary Share is entitled to one
(1) vote, while each Class B Ordinary Share is entitled to one hundred (100) votes with all Ordinary Shares voting together as a single
class on most matters. Each Class B Ordinary Share is convertible into one Class A Ordinary Share at any time by the holder thereof,
while Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. Only Class A Ordinary Shares
are listed and traded on NASDAQ, and we intend to maintain the dual-class voting structure. Mr. Wing Fung Alfred Siu and Ms. Hei Yue
Tina Fong beneficially own all of the issued Class B Ordinary Shares. As of the date of this prospectus, these Class B Ordinary Shares constitute
approximately 2.73% of our total issued and outstanding shares and 73.76% of the aggregate voting power of our total issued and outstanding
shares due to the disparate voting powers associated with our dual-class share structure. As a result of the dual-class share structure
and the concentration of control, holders of Class B Ordinary Shares have considerable influence over matters such as decisions regarding
election of directors and other significant corporate actions. Such holders may take actions that are not in the best interest of us
or our other shareholders. This concentration of control may discourage, delay, or prevent a change in control of us, which could have
the effect of depriving our other shareholders of the opportunity to receive a premium for their shares as part of a sale of us and may
reduce our share price. This concentrated control will limit the ability of holders of Class A Ordinary Shares to influence corporate
matters and could discourage others from pursuing any potential merger, takeover, or other change of control transactions that holders
of Class A Ordinary Shares may view as beneficial.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Substantially
all of NewGenIvf&#8217;s assets and operations are located in Thailand, Cambodia and Kyrgyzstan and they are subject to economic, legal
and regulatory uncertainties in such countries.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Substantially
all of NewGenIvf&#8217;s operations and assets are based in Thailand, Cambodia and Kyrgyzstan.&#160;As a result, its businesses and operations
are subject to the changing economic conditions prevailing from time to time in such countries. Since 2020, Thailand&#8217;s economy
has been experiencing a slowdown. According to the National Economic and Social Development Board of Thailand (the &#8220;NESDB&#8221;)
the GDP growth rate of Thailand declined to minus 6.1% in 2020 and slightly recovered to 1.6% in 2021 and 2.6% in 2022. Under such conditions,
the NESDB projected that Thailand&#8217;s economy will only grow by 3.0% to 4.0% in 2023, lower than the previously growth
in historical&#160;years. Meanwhile, Cambodia&#8217;s post-pandemic economic recovery has gained momentum, but remains uneven. Traditional
growth drivers, especially manufacturing and agricultural commodities exports, have fully recovered. However, while travel and tourism
have improved, the sector remains well below pre-COVID-19 levels. The subsequent impact also caused the vendors and customers preference
change, lower the willingness travelling to Kyrgyzstan for surrogacy services. The economy is projected to grow, underpinned by merchandise
exports and domestic economic activity. Foreign direct investment, while diversified, remains affected by China&#8217;s related COVID-19
policies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf also derives
a substantial portion of its revenue from Chinese clients and as such, its maintenance of PRC-sourced revenues and access to new and
existing clients from the PRC are also subject to the economic conditions of China. However, the near-term growth prospects of the PRC
economy are unclear due to the uncertain effects of ongoing economic stress caused by policies to contain the COVID-19 pandemic, trade
and national security policies, and the elevated levels of private and public indebtedness, among others. According to the National Statistics
Bureau of the PRC, growth rate of China&#8217;s GDP for the year 2022 slowed down to 3.0% on a year-on-year basis compared to the growth
rate of approximately 8.4% for the year 2021. In 2023, China&#8217;s GDP grew 5.2% while China&#8217;s 2024 GDP growth rate was 5%. A
prolonged downturn in the PRC economy generally could materially and adversely affect NewGenIvf&#8217;s results of operations.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Factors
that may adversely affect the economy and conditions in such countries include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">political instability (e.g., Thailand&#8217;s national election in
    May&#160;2023);&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">global economic conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">exchange rate fluctuations and the exchange control policy of the banks;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a prolonged period of inflation or increase in regional interest rates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in taxation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in government policies affecting import and export volumes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">decline in tourism;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">natural disasters, including tsunamis, earthquakes, fires, floods,
    drought and similar events;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a potential recurrence or outbreak of avian influenza, severe acute
    respiratory syndrome or other infectious or contagious diseases like COVID-19 in Asian countries, and governmental policies to address
    such outbreak;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">scarcity of credit or other financing, resulting in lower demand for
    products and services provided by companies in the region;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increases in oil prices and other commodity prices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">decreased consumer confidence;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">other external recessions or potential economic downturns in the United&#160;States,
    Asia or other parts of the world; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">other regulatory, political or economic developments in or affecting
    the countries.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
economic conditions in Thailand, Cambodia, Kyrgyzstan and China are also affected by global economic conditions. The global credit markets
have experienced, and may continue to experience, volatility and liquidity disruptions, which have resulted in the consolidation, failure
or near failure of a number of institutions in the banking and insurance industries. There remains a concern that a return of the debt
crisis in Europe, the political unrest in the Middle East and Eastern Europe as well as rumors or threats or actual terrorist attacks
or conflicts in the Middle East, Southeast Asia, Eastern Europe or other regions will impinge upon the health of the global financial
system. These or other such events could adversely affect NewGenIvf&#8217;s business, financial condition, results of operations and
prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">There
is no assurance that the economies and social conditions of Thailand, Cambodia, Kyrgyzstan and China will meet current projections or
improve in the future. Any instability or economic downturn could have a material adverse effect on NewGenIvf&#8217;s business, financial
condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Failure to
comply with the terms of future financing arrangements could result in default, which could have an adverse effect on NewGenIvf&#8217;s
cash flow and liquidity.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
may from time to time enter into credit facilities and debt financing arrangements containing financial and other covenants that could,
among other things, restrict NewGenIvf&#8217;s business and operations. If NewGenIvf breaches any of these covenants, including the failure
to maintain certain financial ratios, NewGenIvf&#8217;s lenders may be entitled to accelerate NewGenIvf&#8217;s debt obligations. Any
default under the credit facility could result in the repayment of these loans prior to maturity as well as the inability to obtain additional
financing, which in turn may have a material adverse effect on NewGenIvf&#8217;s cash flow and liquidity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
requires a significant amount of capital to fund its operations and growth. If NewGenIvf cannot obtain sufficient capital on acceptable
terms, its business, financial condition, and prospects may be materially and adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
requires a significant amount of capital and resources for its operations and continued growth. NewGenIvf expects to make significant
investments to fund operations, laboratory upgrades, among other things, which may significantly increase NewGenIvf&#8217;s net cash
used in operating activities. In addition, NewGenIvf will continue to invest in laboratory and facilities which are fundamental to NewGenIvf&#8217;s
business operation and future growth. However, NewGenIvf cannot assure you that these investments will generate the optimal returns,
if at all. To date, NewGenIvf has historically funded its cash requirements primarily through operational, capital contributions from
its shareholders and short-term or long-term borrowings. If these resources are insufficient to satisfy NewGenIvf&#8217;s cash requirements,
NewGenIvf may seek to raise funds through additional equity offering or debt financing or additional bank facilities. NewGenIvf&#8217;s
ability to obtain additional capital in the future, however, is subject to a number of uncertainties, including those relating to its
future business development, financial condition, and results of operations, general market conditions for financing activities by companies
in its industry, and macro-economic and other conditions in Thailand, Cambodia, Kyrgyzstan and globally. If NewGenIvf cannot obtain sufficient
capital on acceptable terms to meet its capital needs, NewGenIvf may not be able to execute its growth strategies, and NewGenIvf&#8217;s
business, financial condition, and prospects may be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>The defects
in certain leased property interests and failure to register certain lease agreements may materially and adversely affect NewGenIvf&#8217;s
business, financial condition, results of operations, and prospects. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
leases premises in Thailand, Cambodia and Kyrgyzstan in various locations. With respect to property leased by First Fertility PGS Center
in Thailand, the lessors did not have or provide NewGenIvf with property ownership certificates or other documents evidencing their rights
to lease such premises to First Fertility PGS Center. Therefore, NewGenIvf cannot assure that it will not be subject to any challenges,
lawsuits, or other actions taken against First Fertility PGS Center with respect to its leased premises for which the relevant lessors
do not have valid title or right to lease. If First Fertility PGS Center&#8217;s lessors&#8217; right to lease premises is successfully
challenged by any third party, First Fertility PGS Center&#8217;s lease agreements may not be enforceable and NewGenIvf may be forced
to vacate the premises and relocate to a different location. Under such circumstances, NewGenIvf expects to incur relocation costs of
up to THB3 million and expects that there would not be material business interruption costs, if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, the failure of the lessor to provide sufficient legal evidence of its right to lease the premises has prevented First Fertility
PGS Center from registering the clinic with the Bangkok Metropolitan Authority (&#8220;BMA&#8221;) as required under the Public Health
Act B.E. 2535 (1992) (the &#8220;PHA&#8221;). Under Section 71 of the PHA, First Fertility PGS Center and its directors are subject to
imprisonment of up to 6 (six) months and a fine of up to THB50,000, or both. The BMA could also order First Fertility PGS Center to stop
operating the clinic which would require relocation of the clinic if First Fertility PGS Center could not make the necessary registration.
Under such circumstances, First Fertility PGS Center expects to incur relocation costs of up to THB3 million and expects that there would
not be material business interruption costs, if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Only one of NewGenIvf&#8217;s
directors or officers, namely Ms. Fong, Hei Yue Tina, is also a director of First Fertility PGS Center. NewGenIvf believes that if First
Fertility PGS Center&#8217;s directors, including Ms.&#160;Fong, are found guilty of the above offence and subject to imprisonment, the
resulting impact on NewGenIvf&#8217;s business, results of operations and financial conditions would be limited, as Ms. Fong has limited
involvement in the day-to-day management of First Fertility PGS Center&#8217;s operations and Mr. Siu, Wing Fung Alfred and the other
directors and officers of NewGenIvf and its subsidiaries would be able to keep operating the group&#8217;s and First Fertility PGS Center&#8217;s
activities with limited disruptions. Further, a second clinic has been set up in a separate location which will mitigate the risk of
interruptions to operations.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
currently has no insurance coverage for its operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
assisted reproductive medical facilities in NewGenIvf&#8217;s network are exposed to potential liabilities that are inherent to the provision
of services. Medical and other liabilities may not be fully covered by insurance and the medical facilities may face claims in excess
of the insurance coverage or claims which are not covered by insurance due to other policy limitations or exclusions or where the medical
facilities in NewGenIvf&#8217;s network have failed to comply with the terms of the policy. Any uninsured risks may result in substantial
costs and the diversion of resources, which could adversely affect its results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
insurance industries in Thailand, Cambodia and Kyrgyzstan are still at early stages of development, and insurance companies in Thailand,
Cambodia and Kyrgyzstan currently offer limited business-related insurance products. NewGenIvf does not currently maintain insurance.
NewGenIvf cannot assure you that the medical facilities in its network will be able to obtain and/or maintain medical liability insurance
on acceptable terms or without substantial premium increases or at all in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, as NewGenIvf&#8217;s business expands, the cost for each medical facility in its network and NewGenIvf to maintain an adequate
level of insurance may become increasingly high. NewGenIvf cannot ensure that the medical facilities in its network will be able to locate
or purchase appropriate insurance to cover the expanding operations in time, on commercially reasonable terms or at all. Any significant
uninsured loss could have material and adverse effects on the financial condition and results of operations of the medical facilities
in NewGenIvf&#8217;s network, and thus may affect its business, results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Moreover,
NewGenIvf does not currently maintain professional malpractice liability insurance for its physicians and nurses. As a result, NewGenIvf
may be subject to medical disputes and claims arising under relevant laws from time to time, which could cause substantial damage to
NewGenIvf if not covered by professional malpractice liability insurance. Any dispute with clients, or any legal proceeding involving
the physicians of the medical facilities or medical professionals, regardless of its merit or eventual outcome, could result in significant
legal costs and financial and/or reputational damages to the medical facilities and NewGenIvf and materially and adversely affect the
business, financial condition and results of operations of the medical facilities in NewGenIvf&#8217;s network, and further affect its
business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
may not be successful in adapting to technological developments, which may affect its business and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">It
is possible that new technologies could be developed or scientific advances made by NewGenIvf&#8217;s competitors, or elsewhere and licensed
to NewGenIvf&#8217;s competitors, which cannot be replicated by NewGenIvf without significant capital expenditure or at all, or that
replace or reduce the requirement for assisted reproductive services, ultrasound or specialized diagnostics. The consequences for NewGenIvf
of the development of new technologies could include lower or loss of revenues, loss of market position and reduced prospects of NewGenIvf.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If its computer
systems, or those of its providers, specialty pharmacies or other downstream vendors lag, fail or suffer security breaches, NewGenIvf
may incur a material disruption of its services, which could materially impact its business and the results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
businesses in Thailand, Cambodia and Kyrgyzstan are increasingly dependent on critical, complex and interdependent information technology
systems to support business processes as well as internal and external communications. NewGenIvf&#8217;s success is therefore dependent
in part on its ability to secure, integrate, develop, redesign and enhance its (or contract with vendors to provide) technology systems
that support its business strategy initiatives and processes in a compliant, secure, and cost and resource efficient manner. If NewGenIvf
or its providers, specialty pharmacies or other downstream vendors have an issue with its or their respective technology systems, it
may result in a disruption to its operations or downstream disruption to its relationships with its clients or its selective network
of high-quality fertility specialists. Additionally, if NewGenIvf chooses to insource any of the services currently handled by a third
party, it may result in technological or operational disruptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, despite the implementation of security measures, its internal computer systems, and those of its provider clinics, specialty
pharmacies or other downstream vendors, are potentially vulnerable to damage from malicious intrusion, malware, computer viruses, unauthorized
access, natural disasters, terrorism, war and telecommunication and electrical failures. While NewGenIvf is not aware that it has experienced
any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in its operations,
it could result in a material disruption to its ability to operate and deliver its solutions. In addition, to the extent that any disruption
or security breach were to result in a loss or inappropriate disclosure of confidential information, NewGenIvf could incur liability.
See &#8220;&#8212;<i>&#160;Risks Related to Government Regulation&#160;&#8212;&#160;NewGenIvf operates in a highly regulated industry
and must comply with a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits
applicable to NewGenIvf&#8217;s business may have a material and adverse impact on NewGenIvf&#8217;s business, financial condition, and
results of operations&#160;&#8212;&#160;Data Protection and Breaches</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Risks Related to NewGenIvf&#8217;s
Relationships with Third Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
business depends on its ability to maintain its network of high-quality fertility specialists and other healthcare providers. If NewGenIvf
is unable to do so, its future growth would be limited and its business, financial condition and results of operations would be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
performance and success is dependent upon its continued ability to maintain a credentialed network of high-quality fertility specialists,
including its senior management team, other key employees, as well as research and development and operation maintenance personnel, many
of whom are difficult to replace. Fertility specialists could refuse to contract, demand higher payments or take other actions that could
result in higher medical costs, less attractive service for its clients or difficulty meeting regulatory or accreditation requirements.
Identifying high-quality fertility specialists, credentialing and negotiating contracts with them and evaluating, monitoring and maintaining
its network, requires significant time and resources. Competition in the healthcare industry for qualified employees is intense. NewGenIvf
may need to offer higher compensation and other benefits in order to attract and retain key personnel in the future, which could increase
NewGenIvf&#8217;s compensation expenses, including stock-based compensation. NewGenIvf&#8217;s continued ability to compete effectively
depends on NewGenIvf&#8217;s ability to attract new employees and to retain and motivate NewGenIvf&#8217;s existing employees. If NewGenIvf
is not successful in maintaining its relationships with top fertility specialists, these fertility specialists may refuse to renew their
contracts with it, and potential competitors may be effective in onboarding these or other high-quality fertility specialists to create
a similarly high-quality network. There may be additional shifts in the fertility specialty provider space as the fertility market matures,
and high-quality fertility specialists may become more demanding in re-negotiating to remain in its network. Its ability to develop and
maintain satisfactory relationships with high-quality fertility specialists also may be negatively impacted by other factors not associated
with it, such as regulatory changes impacting providers or consolidation activity among hospitals, physician groups and healthcare providers.
In addition, certain organizations of physicians, such as practice management companies (which group together physician practices for
administrative efficiency), may change the way in which healthcare providers do business with it and may compete directly with it, which
could adversely affect its business, financial condition and results of operations. NewGenIvf intends to grant, and may continue to grant,
options and other types of awards, which may result in increased share-based compensation expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s Share
Incentive Award will allow NewGenIvf to enhance its ability to attract and retain exceptionally qualified individuals and agents and
to encourage them to acquire a proprietary interest in the company&#8217;s growth and performance. Competition for highly skilled personnel
and agents is often intense and NewGenIvf may incur significant costs or may not be successful in attracting, integrating, or retaining
qualified personnel and agents to fulfill NewGenIvf&#8217;s current or future needs. NewGenIvf believes that the granting of share-based
awards is of significant importance to NewGenIvf&#8217;s ability to attract and retain agents, key personnel and employees, and NewGenIvf
will continue to grant share-based awards in the future. In addition, NewGenIvf may, with the approval of its Compensation Committee
and the Board, revise the terms of, and increase the size of, its share incentive plan, to ensure that it is able to attract and retain
agents, key personnel and employees. On March 31, 2025, NewGenIvf&#8217;s Board approved certain amendments to its Share Incentive Plan,
including the increase of the size of the share incentive plan to 20% of the outstanding shares of the Company from time to time. As
a result, NewGenIvf&#8217;s expenses associated with share-based compensation may increase, which may have an adverse effect on NewGenIvf&#8217;s
results of operations. The amended share incentive plan is available as Exhibit 4.32.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Meanwhile,
the retirement or loss of certain specialists, scientific staff or other key personnel, the activities of competitors, the introduction
of a competing service that is perceived to be superior to the services provided by NewGenIvf, or other events which impact NewGenIvf&#8217;s
reputation could adversely affect NewGenIvf&#8217;s relationships with fertility specialists. For example, one specialist who was previously
engaged by NewGenIvf brought a lawsuit against NewGenIvf regarding disputed remuneration, which resulted in a settlement for NewGenIvf
to compensate the specialist with a sum of approximately US$98,000. Also, fertility specialists&#8217; relationship with NewGenIvf could
affect their behaviors in recommending NewGenIvf&#8217;s services or referring patients to NewGenIvf, which could in turn adversely impact
the number of patients treated by NewGenIvf and adversely impact on its financial performance, market position and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, the perceived value of NewGenIvf&#8217;s solutions and its reputation may be negatively impacted if the services provided by
fertility specialists or other healthcare providers are not satisfactory to NewGenIvf&#8217;s clients, including as a result of error
that could result in litigation. For example, if fertility specialist or other healthcare provider releases sensitive information of
its clients, it could incur additional expenses and give rise to litigation against NewGenIvf. Any such issue with one of its providers
may expose it to public scrutiny, adversely affect its brand and reputation, expose it to litigation or regulatory action, and otherwise
make its operations vulnerable. Further, if its services result in less than favorable outcomes, this could cause it to fail to meet
its contractually guaranteed specified service metrics, and NewGenIvf could be obligated to provide the client with a fee reduction or
a second chance for free, depending on their contract terms. The failure to maintain its selective network of high-quality fertility
specialists or the failure of those specialists to meet and exceed its clients&#8217; expectation, may result in a loss of or inability
to grow or maintain its client base, which could adversely affect its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>The medical
facilities and professionals in NewGenIvf&#8217;s network could become the subject of litigation, allegations and other claims, and NewGenIvf
is not insured against these liabilities.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
relies on the physicians and other medical professionals of the assisted reproductive medical facilities in its network to make proper
clinical decisions regarding the diagnosis and treatment of clients. However, NewGenIvf does not have full and direct control over every
step of clinical activities undertaken at each of the medical facilities. In addition, physicians and medical professionals outside NewGenIvf&#8217;s
network may introduce patients to NewGenIvf and conduct medical treatments and/or procedures for such patients in NewGenIvf&#8217;s facilities.
NewGenIvf enters into independent contractor agreements with such physicians and medical professionals and treats such patients as NewGenIvf&#8217;s
own patients. As such, NewGenIvf will have to bear any liabilities arising from their medical treatments and/or procedures conducted
in NewGenIvf&#8217;s facilities. Any incorrect clinical decision or malpractice on the part of physicians and other medical professionals
(including those from outside of its network), or any failure by the medical facilities in its network to properly manage their clinical
activities may result in unsatisfactory treatment outcomes, patient injury or even death, which could lead to disputes with patients
and/or their families or the medical professionals, including those from outside its network. In its experience, moreover, clients of
fertility treatments tend to be more demanding on the medical services received. In addition, the relevant laws governing medical disputes
and claims grant claimants liberal rights in bringing claims against physicians and other medical professionals practicing in the jurisdiction.
As a result, the medical facilities in its network may be subject to medical disputes and claims arising under relevant laws, from time
to time, which could generate substantial damages imposed on such facilities if not covered by professional liability insurance. Any
dispute with its patients and/or their families or the medical professionals, including those from outside its network, or any legal
proceeding involving the physicians of the medical facilities or medical professionals, including those from outside its network, regardless
of its merit or eventual outcome, could result in significant legal costs and reputational damage to the medical facilities and materially
and adversely affect the business, financial condition and results of operations of the medical facilities in its network, and further
affect its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>The assisted
reproductive medical facilities in NewGenIvf&#8217;s network have limited control over the quality of the pharmaceuticals, medical equipment,
medical consumables and other supplies used in its operations, and cannot guarantee that the products in use are not defective or counterfeit.
NewGenIvf also has no control over independent sub-contractors and cannot guarantee the services thereof.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
assisted reproductive medical facilities in NewGenIvf&#8217;s network procure a variety of pharmaceuticals, medical equipment, consumables
and other supplies in NewGenIvf&#8217;s operations from third-party suppliers. As the medical facilities in NewGenIvf&#8217;s network
do not engage in the direct manufacture of such supplies, NewGenIvf cannot assure you that such supplies are free of defects and meet
relevant quality standards or, in the case of imported supplies, verify the origin of such products. In addition, there may be counterfeit
pharmaceutical products manufactured without proper licenses or approvals or fraudulently mislabeled with respect to their content or
manufacturer in the pharmaceutical markets. In some cases these products are very similar in appearance to the authentic products. The
quality control checks and processes may not be able to identify all counterfeit pharmaceutical products in the inventory. Any sale of
such products by the medical facilities in NewGenIvf&#8217;s network, regardless of its knowledge as to their authenticity, may subject
the medical facilities to administrative sanctions, civil claims, negative publicity or reputational damage. NewGenIvf cannot assure
you that the medical facilities in our network will be able to successfully claim full indemnity from such manufacturers of counterfeit
pharmaceutical products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
also cannot assure you that the medical facilities in our network will not encounter incidents relating to defective products, or
that such incidents will not materially and adversely affect our network of medical facilities. If the products provided by
NewGenIvf&#8217;s suppliers are defective, of poor quality or are otherwise unsafe or ineffective, the medical facilities in
NewGenIvf&#8217;s network could be subject to liability claims, complaints or adverse publicity, any of which would materially and
adversely affect its results of operations and reputation. NewGenIvf cannot assure you that the medical facilities in
NewGenIvf&#8217;s network will find suitable replacement suppliers on commercially acceptable terms or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
suppliers are also subject to extensive laws, rules and regulations. If any suppliers violate applicable laws, rules and regulations,
NewGenIvf&#8217;s reputation or procurement may be materially and adversely affected. In addition, the medical facilities in NewGenIvf&#8217;s
network may be exposed to reputational damages or even liabilities for defective goods provided by the suppliers or negative publicity
associated with any suppliers, and the business and results of operations of the medical facilities in NewGenIvf&#8217;s network and
NewGenIvf could suffer as a result.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Independent
sub-contractors and/or agents that work with NewGenIvf are also subject to extensive laws, rules, and regulations. If any sub-contractor
and/or agent violates any applicable laws, rules, regulations or breaches any agreements, NewGenIvf&#8217;s reputation may be materially
and adversely affected and NewGenIvf may be penalized by regulatory or other parties. In addition, NewgenIvf&#8217;s clients may engage
Newgen&#8217;s sub-contractors and/or agents for ongoing services or additional services following the termination of contracts with
NewGenIvf. NewGenIvf has no control over the services provided by sub-contractors and cannot assure the quality of such services or ensure
compliance with applicable laws, rules and regulations. In addition, the services provided by independent sub-contractors may expose
NewGenIvf to public scrutiny, adversely affect its brand and reputation, expose it to litigation or regulatory action, and otherwise
make its operations vulnerable if such independent sub-contractors fail to meet their contractual obligations or to comply with applicable
laws or regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
loses its relationship with one or more key pharmaceutical manufacturers, its business and results of operations could be adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
maintains contractual relationships with select pharmaceutical manufacturers in Thailand, Cambodia and Kyrgyzstan. The consolidation
of pharmaceutical manufacturers, the shortages of drugs provided by such manufacturers, the termination or material alteration of its
contractual relationships, or its failure to renew such contracts could have a material adverse effect on its business and results of
operations. Adoption of new laws, rules or regulations or changes in, or new interpretations of, existing laws, rules or regulations,
relating to any of these programs could materially adversely affect its business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
has engaged in transactions with related parties, and such transactions present potential conflicts of interest that could have an adverse
effect on its business and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has entered into a number of transactions with related parties. NewGenIvf may in the future enter into additional transactions with its
related parties. Interests of these related parties may not necessarily be aligned with NewGenIvf&#8217;s or The Company&#8217;s interests
and the interests of its other shareholders. For example, conflicts of interest may arise in connection with decisions regarding the
transaction arrangements which may be less favorable to NewGenIvf than similar arrangements negotiated with unaffiliated third parties.
Conflicts of interest may also arise in connection with the exercise of contractual remedies, such as the treatment of events of default.
As a result, those related party transactions, individually or in the aggregate, may have an adverse effect on NewGenIvf&#8217;s business
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
may be subject to claims and allegations relating to intellectual property and other causes.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
may from time to time receive claims that NewGenIvf infringes on the intellectual property rights of others. Moreover, NewGenIvf may
be subject to claims by third parties who maintain that NewGenIvf&#8217;s service providers&#8217; technology infringes third-party&#8217;s
intellectual property rights. If NewGenIvf fails to successfully defend against such claim or does not prevail in such litigation, it
could be required to modify, redesign or cease operating, pay monetary amounts as damages or enter into royalty or licensing arrangements
with the valid intellectual property holders. Any royalty or licensing arrangements that NewGenIvf may seek in such circumstances may
not be available to it on commercially reasonable terms or at all. Also, if NewGenIvf acquires technology licenses from third parties,
NewGenIvf&#8217;s exposure to infringement actions may increase because NewGenIvf must rely upon these third parties to verify the origin
and ownership of such technology. This exposure to liability could result in disruptions in NewGenIvf&#8217;s business that could materially
and adversely affect NewGenIvf&#8217;s results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Some
of NewGenIvf&#8217;s employees may previously employed at other companies, including NewGenIvf&#8217;s competitors. NewGenIvf may hire
additional personnel to expand its development team and technical support team as its business grows. To the extent these employees were
involved in the development of content or technology similar to NewGenIvf&#8217;s at their former employers, NewGenIvf may become subject
to claims that these employees or NewGenIvf has appropriated these employees&#8217; former employers&#8217; proprietary information or
intellectual properties. If NewGenIvf fails to successfully defend such claims against itself, NewGenIvf may be exposed to liabilities
which could have a material adverse effect on its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is currently not a party to any material legal or administrative proceedings but may subject to legal or administrative actions for defamation,
negligence, copyright and trademark infringement, unfair competition, breach of service terms, or other purported injuries resulting
from the content NewGenIvf provides or the nature of NewGenIvf&#8217;s services. Such legal and administrative actions, with or without
merits, may be expensive and time-consuming and may result in significant diversion of resources and management attention from NewGenIvf&#8217;s
business operations. Furthermore, such legal or administrative actions may adversely affect NewGenIvf&#8217;s brand image and reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Certain data
and information in this prospectus relied on by NewGenIvf were obtained from third-party data and polls. These metrics were not independently
verified by NewGenIvf and may not be accurate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Certain
numbers and information in this prospectus were obtained and provided from numerous sources including management data, third-party data
or numbers generally estimated by calculating infertile couples, fertility tourism number, etc. to generally assess potential customer
numbers in Asia-Pacific countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
metrics were not independently verified. Such databases, third-party information, and calculations may not accurately reflect actual
statistics or numbers and NewGenIvf does not have access to specific rating numbers. Similarly, any statistical data in any third-party
publications also include projections based on a number of assumptions. If any one or more of the assumptions underlying the market data
is later found to be incorrect, actual results may differ from the projections based on these assumptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Risks Related
to Government Regulation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
operates in a highly regulated industry and must comply with a significant number of complex and evolving requirements. Any lack of requisite
approvals, licenses, or permits applicable to NewGenIvf&#8217;s business may have a material and adverse impact on NewGenIvf&#8217;s
business, financial condition, and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
operations of NewGenIvf are subject to various laws, rules and regulations at the national, regional and local levels in Thailand, Cambodia,
Kyrgyzstan and other applicable jurisdictions. Such laws and regulations mainly relate to (i)&#160;the licensing of local and foreign
medical professionals, nursing professionals, medical technology professionals, pharmaceutical professions and other applicable licensing;
(ii)&#160;the licensing, registration, and accreditation of medical facilities, laboratories, including but not limited to the licensing,
registration, and accreditation of persons performing related activities; (iii)&#160;the privacy and security of confidential patient
medical records; (iv)&#160;the corporate practice of medicine; (v)&#160;healthcare fraud and abuse laws; (vi)&#160;the donation and transplantation
of human cells, tissues and organs; (vii)&#160;potential prohibition on surrogacy or providing intermediary assistance in surrogacy;
and (viii)&#160;licensing and approval of the accommodation provided as parts of the services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has attempted to structure its operations to comply with laws, regulations and other requirements applicable to it directly and to its
clients and vendors, but there can be no assurance that its operations will not be challenged or impacted by regulatory authorities or
enforcement initiatives, or that the relevant authorities in each jurisdiction could impose higher standards or requirements, which NewGenIvf
may have difficulty to adhere to, e.g. Medical Facilities Act B.E. 2541 (1998)&#160;and Protection of a Child Born by Medically Assisted
Reproductive Technology Act B.E. 2558 (2015)&#160;for Thailand jurisdiction, Law on Reproduction Rights and on Guarantees of Their Realization
of July&#160;4, 2015 No. 148, Law on status of medical worker of May 28, 2013 No. 81 and Temporary Regulation on Procedure of Licensing
Private Medical Activity approved by the resolution of government of April&#160;4, 2017 No. 203 for Kyrgyz Republic. NewGenIvf in the
future may become involved in governmental investigations, audits, reviews and assessments. Any determination by a court or agency that
NewGenIvf&#8217;s solutions or services violate, or cause its clients to violate, applicable laws, regulations or other requirements
could subject it or its clients to civil, criminal, or administrative penalties. Such a determination also could require it to change
or terminate portions of its business, disqualify it from serving clients that do business with government entities, or cause it to refund
some or all of its service fees or otherwise compensate its clients. In addition, failure to satisfy laws, regulations or other requirements
could adversely affect demand for its solutions and could force it to expend significant capital, research and development and other
resources to address the failure. Even an unsuccessful challenge by regulatory and other authorities or parties could be expensive and
time-consuming, could result in loss of business, exposure to adverse publicity, and injury to its reputation and could adversely affect
its ability to retain and attract clients. If NewGenIvf fails to comply with applicable laws, regulations and other requirements, its
business, financial condition and results of operations could be adversely affected. Such non-compliance could also require significant
investment to address and may prove costly. There are several additional state statutes, regulations, guidance and contractual provisions
related to or impacting the healthcare industry that may apply to its business activities directly or indirectly, including, but not
limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b><i>&#9679;</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Licensing and Licensed Personnel. </i></b>Many countries have
    licensure or registration requirements for entities acting as a medical services provider. The scope of these laws differs from country
    to country, and the application of such laws to the activities of fertility treatment is often unclear. Given the nature and scope
    of the solutions and services that NewGenIvf provides, it is required to maintain the License to Operate Medical Facility Business
    (Sor.Por.7), the License to Manage Medical Facility Business (Sor.Por.19), License to Certify the Standard of Service relating to
    Medically Assisted Reproductive Technology (KorThorPhor.9), and personnel licenses, i.e., license of medical professionals, nursing
    professionals, medical technology professionals, pharmaceutical professions and other applicable licenses in Thailand, Approval on
    Opening of Medical Clinic, Approval on Opening of Pharmacy and relevant approvals to conduct IVF, embryo implant and/or transfer
    activities issued by the Ministry of Health of Cambodia (&#8220;Cambodia MOH&#8221;) in Cambodia and licenses to carry out private
    medical activities (including diagnostics and treatment gynecological diseases, supervision of pregnant women before childbirth,
    IVF in outpatient and&#160;day hospital conditions (for four (4) beds)) in Kyrgyzstan, respectively, and to ensure that such licenses
    and registrations are in good standing on an annual basis. NewGenIvf is licensed, has licensure applications pending before appropriate
    regulatory bodies, is exempt from licensure or registration, or is otherwise authorized under such laws in those countries in which
    it provides its services. These licenses require it to comply with the rules and regulations of the governmental bodies that issued
    such licenses. NewGenIvf&#8217;s failure to comply with such rules and regulations could result in criminal and/ or administrative
    penalties, the suspension of a license, or the loss of a license, all of which could negatively impact its business. First Fertility
    PGS had provided arrangements of accommodation without additional charges for its patients without a tourism license in Thailand,
    all of which was subsequently ceased in early 2023. Pursuant to the Tourism Business and Guide Act 2551 (2008) of Thailand, a maximum
    fine of THB500,000 may be imposed on First Fertility PGS as a result of the above activity without a tourism license in Thailand.
    NewGenIvf is unable to predict, however, how its services may be viewed by regulators over time, how these laws and regulations will
    be interpreted, or the full extent of their applicable. If a regulatory authority in any country determines that the nature of its
    business requires that NewGenIvf be licensed under applicable laws, it may need to restructure its business or it may need to comply
    with any related requirements, such as obtaining relevant license, paying additional regulatory fees and/or penalties for previous
    non-compliance with relevant licensing requirements, which could adversely affect its results of operation. Additionally, in extreme
    case, NewGenIvf may need to cease operations until it is able to obtain appropriate licensure, which may adversely affect its revenue
    for a period of time that it cannot estimate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Patients&#8217; Right Protection. </i></b>There has been an increased
    awareness of patients&#8217; rights in Thailand, Cambodia and Kyrgyzstan, especially with the issuance of the Constitution of the
    Kingdom of Thailand, the Act on Court Proceedings for Consumer Cases B.E. 2551 (2008)&#160;(as amended), National Health Act B.E.
    2550 (2007), and other applicable laws in Thailand, the Civil Code dated December&#160;8, 2017 as amended by the Law on Implementation
    of the Civil Code dated May&#160;31, 2011, Law on Management of Donation and Transplantation of Human Cells, Tissues, and Organs
    (2016)&#160;and Sub-Decree No. 61 on the Code of Medical Ethics (2003) in Cambodia and Constitution of Kyrgyzstan of May&#160;5,
    2021, Civil Code, Part&#160;I of May&#160;8, 1996 No. 15, Law on Health Protection of Civilians of Kyrgyzstan of January&#160;9,
    2005 No. 6, Law on Reproduction Rights and on Guarantees of their Realization of July&#160;4, 2015 No. 148, Law on status of medical
    worker of May 28, 2013 No. 81 and other relevant applicable laws in Kyrgyzstan, which enables consumers and patients to file suits
    more easily against healthcare service providers. Furthermore, treatment of more complex medical conditions has no guaranteed positive
    outcome, which subjects it to an increased likelihood of medical malpractice suits. Such lawsuits could result in hefty compensation
    payments or damage to NewGenIvf&#8217;s reputation, which may have a material adverse effect on its business, financial condition,
    results of operations and prospects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">Meanwhile,
Thailand is considering enacting a Patient Protection Bill &#160;(the &#8220;Bill&#8221;). The Bill, if issued, is intended to alleviate
disputes between patients and healthcare providers, which have an impact on the healthcare system in Thailand as a whole. The compensation
outlined in the Bill will assist patients in claiming damages, thereby fostering a positive relationship between patients and healthcare
providers. Consequently, the rate of disputes is expected to decrease. The provisions under the Bill would require healthcare providers
to compensate patients in a timely manner, sometimes without requiring proof of wrongdoing. The Bill also contemplates setting up a patient
protection fund for damages to patients pursuant to which healthcare providers have to make mandatory contributions according to the
rules determined by a patient protection committee. Failure by it to comply with applicable rules and regulations could result in penalties,
the loss of regulatory permits and damage to NewGenIvf&#8217;s business reputation, each of which could have a material adverse effect
on its financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">Furthermore,
the Protection of A Child Born By Medically Assisted Reproductive Technology Act B.E. 2558 (2015)&#160;of Thailand was promulgated with
the intention to appropriately designate the legitimate parenthood status of a child born using medically assisted reproductive technology
and regulate any medical scientific research on embryology and medically assisted reproductive technologies to prevent the misuse of
medically assisted reproductive technologies. NewGenIvf is therefore under the supervision of a Committee of the Protection for Children
Born through Medically Assisted Reproductive Technology, which is a committee established to control, inspect, supervise and formulate
various policies relating to such acts. In Cambodia and Kyrgyzstan, all health establishments, including private medical clinics, are
under the supervision of the Cambodia MOH and the Ministry of Health of Kyrgyzstan, respectively, which each governs and regulates the
operation of medical clinics and activities of medical practitioners in respective countries. In particular, the Medical Council of Cambodia,
Cambodian Council of Nurses, Cambodian Midwives Council and the Pharmaceutical Council of Cambodia, all assist the Cambodia MOH to supervise
and monitor the practice of health professionals in Cambodia. IVF/embryo implant/transfer activities are subject to an approval by the
Cambodia MOH.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Privacy and Security Requirements. </i></b>There are numerous
    laws and regulations related to the privacy and security of health information in each country. In particular, regulations promulgated
    pursuant to the Personal Data Protection Act B.E. 2562 (2019)&#160;of Thailand (&#8220;PDPA&#8221;), Law on Data of Personal Character
    of April&#160;14, 2008 No. 58 of Kyrgyzstan (&#8220;Data Protection Law&#8221;), as well as Regulation of Registration of Personal
    Data Holders (Owners) approved by the Resolution of the Cabinet of Ministers of KR of November&#160;18, 2022, Offences Code No. 128
    of October&#160;28, 2021 of Kyrgyzstan establish privacy and security standards in each country that limit the collection, use, and/
    or disclosure of certain individually identifiable health information, whether directly or indirectly (excluding the information
    of the deceased person) and require the implementation of administrative, physical and technological safeguards to protect the privacy
    of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information.
    The privacy regulations established under the PDPA and Data Protection Law also provide patients with rights related to understanding
    and controlling how their protected health information is collected, used and/ or disclosed. As a provider of services to entities
    subject to the PDPA and Data Protection Law, NewGenIvf is directly subject to certain provisions of the regulations. To the extent
    permitted by applicable privacy regulations and contracts with its clients, NewGenIvf is permitted to use and disclose protected
    health information to perform its services and for other limited purposes, but other uses and disclosures, such as marketing communications,
    require written authorization from the patient or must meet an exception specified under the privacy regulations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">NewGenIvf
also has downstream entities which provide it with services and are also subject to applicable regulations. If NewGenIvf or any of its
downstream entities are unable to properly protect the privacy and security of protected health information entrusted to it, it could
be found to have breached its contracts with its clients and be subject to investigation by the relevant supervision institution, i.e.,
the Office of the Personal Data Protection Committee of Thailand (the Government Authority under the PDPA), the Cambodia MOH and the
State Data Protection Agency under the Cabinet of Ministers of Kyrgyzstan (the &#8220;Agency&#8221;). In the event the Office of the
Personal Data Protection Committee or the Agency finds that NewGenIvf has failed to comply with applicable privacy and security standards,
it could face civil, criminal, and/ or administrative penalties. In addition, the Office of the Personal Data Protection Committee performs
compliance audits in order to proactively enforce the privacy and security standards. The Office of the Personal Data Protection Committee
has become an increasingly active regulator and has signaled its intention to continue this trend. The Office of the Personal Data Protection
Committee has the discretion to impose penalties and may require companies to enter into resolution agreements and corrective action
plans which impose ongoing compliance requirements. The Office of the Personal Data Protection Committee&#8217;s enforcement activity,
or audit related to incident regarding it or its downstream entity, can result in financial liability and reputational harm, and responses
to such enforcement activity can consume significant internal resources. Although NewGenIvf has implemented and maintain policies, processes
and compliance program infrastructure to assist it in complying with these laws and regulations and its contractual obligations, NewGenIvf
cannot provide assurance regarding how these laws and regulations will be interpreted, enforced or applied to its operations. In associated
with enforcement activities and potential contractual liabilities, its ongoing efforts to comply with evolving laws and regulations might
also require it to make costly system purchases and/or modifications or otherwise divert significant resources to compliance initiatives
from time to time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b><i>&#9679;</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Other Privacy and Security Requirements. </i></b>In addition,
    numerous other laws govern the collection, dissemination, use, access to and confidentiality of personal information. For example,
    the Law on E-Commerce of Cambodia (2019)&#160;places an obligation on those who electronically store private information to use all
    means to ensure that the information is protected by security safeguards in every reasonable circumstance to avoid the loss, access,
    use, modification, leakage, or disclosure of the information, except with the consent of the data owner or other lawfully authorized
    party. The Law on E-Commerce also prohibits individuals from dishonestly accessing, downloading, copying, extracting, leaking, deleting,
    modifying, or otherwise interfering with data stored by other persons. Applicable laws are contributing to increased enforcement
    activity and may also be subject to interpretation by various courts and other governmental authorities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">Certain
of NewGenIvf&#8217;s solutions and services involve the transmission and storage of client data in various jurisdictions, which subjects
the operation of those solutions and services to privacy or data protection laws and regulations in those jurisdictions. While NewGenIvf
believes those solutions and services comply with current regulatory and security requirements in the jurisdictions in which it provides
these solutions and services, there can be no assurance that such requirements will not change or that it will not otherwise be subject
to legal or regulatory actions. The laws and regulations are rapidly evolving and changing, and could have an adverse impact on its operations.
These laws and regulations are subject to uncertainty in how they may be interpreted and enforced by government authorities and regulators.
The costs of compliance with, and the other burdens imposed by, these and other laws or regulatory actions may increase its operational
costs, prevent it from providing its solutions, and/or impact its ability to invest in or jointly develop its solutions. NewGenIvf also
may face audits or investigations by one or more government agencies relating to its compliance with these laws and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">An
adverse outcome under any such investigation or audit could result in fines, penalties, other liability, or could result in adverse publicity
or a loss of reputation, and adversely affect NewGenIvf&#8217;s business. Any failure or perceived failure by it or by NewGenIvf&#8217;s
solutions to comply with these laws and regulations may subject it to legal or regulatory actions, damage its reputation or adversely
affect its ability to provide its solutions in the jurisdiction that has enacted the applicable law or regulation. Moreover, if these
laws and regulations change, or are interpreted and applied in a manner that is inconsistent with its policies and processes or the operation
of its solutions NewGenIvf may need to expend resources in order to change its business operations, policies and processes or the manner
in which it provides its solutions. This could adversely affect NewGenIvf&#8217;s business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Data Protection and Breaches. </i></b>In recent&#160;years, there
    have been a number of well-publicized data breaches involving the improper dissemination of personal information of individuals both
    within and outside of the healthcare industry. Pursuant to the applicable data protection law of Thailand, the PDPA requires businesses
    to notify the data subjects and/or the government authorities upon the occurrence of a data breach. The laws are not consistent,
    and compliance in the event of a widespread data breach is costly. Each country also constantly amending existing laws, requiring
    attention to frequently changing regulatory requirements. Most countries require holders of personal information to maintain safeguards
    and take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals.
    In some countries, these laws are limited to electronic data, but they increasingly are enacting or considering stricter and broader
    requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">Despite
NewGenIvf&#8217;s security management efforts with respect to physical and technological safeguards, employee training, vendor (and sub-vendor)
controls and contractual relationships, its infrastructure, data or other operation centers and systems used in its business operations,
including the internet and related systems of its vendors (including vendors to whom NewGenIvf outsources data hosting, storage and processing
functions) are vulnerable to, and may from time to time experience, unauthorized access to data and/or breaches of confidential information
due to a variety of causes. Techniques used to obtain unauthorized access to or compromise systems change frequently, are becoming increasingly
sophisticated and complex, and are often not detected until after an incident has occurred. As a result, NewGenIvf might not be able
to anticipate these techniques, implement adequate preventive measures, or immediately detect a potential compromise. If its security
measures, some of which are managed by third parties, or the security measures of its service providers or vendors, are breached or fail,
it is possible that unauthorized or illegal access to or acquisition, disclosure, use or processing of personal information, confidential
information, or other sensitive client or employee data, including protected health information, may occur. A security breach or failure
could result from a variety of circumstances and events, including third-party action, human negligence or error, malfeasance, employee
theft or misuse, phishing and other social engineering schemes, computer viruses, attacks by computer hackers, failures during the process
of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, and
catastrophic events. If NewGenIvf&#8217;s security measures, or those of its service providers or vendors, were to be breached or fail,
its reputation could be severely damaged, adversely affecting client or investor confidence. As a result, clients may curtail their use
of or stop using its offering and its business may suffer. In addition, NewGenIvf could face litigation, damages for contract breach,
penalties and regulatory actions for violation of laws or regulations applicable to data protection and significant costs for remediation
and for measures to prevent future occurrences. In addition, any potential security breach could result in increased costs associated
with liability for stolen assets or information, repairing system damage that may have been caused by such breaches, incentives offered
to clients or other business partners in an effort to maintain the business relationships after a breach and implementing measures to
prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies, training employees
and engaging third-party experts and consultants. Negative publicity may also result from real, threatened or perceived security breaches
affecting it or its industry or clients, which could cause it to lose clients or partners and adversely affect its operations and future
prospects. NewGenIvf may not carry insurance or maintain coverage sufficient to compensate for all liability and such insurance may not
be available for renewal on acceptable terms or at all, and in any event, insurance coverage would not address the reputational damage
that could result from a security incident.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Fraud and Abuse Laws. </i></b>NewGenIvf may be impacted directly
    and indirectly by certain fraud and abuse laws, including the Act Supplementing the Constitution Relating to the Prevention and Suppression
    of Corruption B.E. 2561 (2018)&#160;of Thailand, the Penal Code of Thailand, the Criminal Code of Cambodia, the Offences Code of
    October&#160;28, 2021 No. 128 of Kyrgyzstan, the Criminal Code of October&#160;28, 2021, No. 17 of Kyrgyzstan and the Law on prevention
    of corruption of August&#160;8, 2021 No. 153 of Kyrgyzstan. Because the solutions and services NewGenIvf provides are not reimbursed
    by government healthcare payors, such fraud and abuse laws generally do not directly apply to its business, however, some laws may
    be applicable. The laws, regulations and other requirements in this area are both broad and vague and judicial interpretation can
    also be inconsistent. NewGenIvf reviews its practices with regulatory experts in an effort to comply with all applicable laws, regulatory
    and other requirements. However, NewGenIvf is unable to predict how these laws, regulations and other requirements will be interpreted
    or the full extent of their application, particularly to services that are not directly reimbursed by healthcare programs. Any determination
    by a regulatory authority that any of NewGenIvf&#8217;s activities or those of its clients or vendors violate any of these laws or
    regulations could subject NewGenIvf to civil or criminal penalties, require it to enter into corporate integrity agreements or similar
    agreements with ongoing compliance obligations, disqualify it from providing services to clients and/or have an adverse impact on
    its business, financial condition and results of operations. Even an unsuccessful challenge by a regulatory authority of NewGenIvf&#8217;s
    activities could result in adverse publicity and could require a costly response from it.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Consumer Protection Laws. </i></b>Consumer protection laws are
    being applied increasingly by the Office of the Consumer Protection Board in Thailand and by the Cambodia Ministry of Health to regulate
    the collection, use, storage and disclosure of personal or health information, through websites or otherwise, and, in Cambodia, by
    the Consumer Protection Competition and Fraud Repression Directorate-General, to regulate the presentation of website content. Courts
    may also adopt the standards for fair information practices, which concern consumer notice, choice, security and access.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Restrictions on Communication. </i></b>Communications with NewGenIvf&#8217;s
    clients increasingly may be subject to and restricted by laws and regulations governing communications via telephone, fax, text,
    and email. NewGenIvf also uses email and social media platforms as marketing tools. For example, NewGenIvf maintains social media
    accounts. As laws and regulations rapidly evolve to govern the use of these platforms and devices, the failure by it, its employees
    or third parties acting at its direction to abide by applicable laws and regulations in the use of these platforms and devices could
    adversely impact its business, financial condition and results of operations or subject it to fines or other penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b><i>&#9679;</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Advertisement Laws. </i></b>NewGenIvf&#8217;s advertisement and
    announcements, in particular, the messages releasing on the Internet related to medical facilities may subject to the laws and regulations
    of relevant jurisdictions (and potential prohibition in Cambodia on commercial advertisement of private medical services).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">For
example, in Thailand, NewGenIvf shall apply for and obtain the approval and/ or pre-approval from the relevant authority for the images,
and text used in advertisements or announcements which shall be in accordance with the Medical Facility Act B.E. 2541 (1998)&#160;(and
its amendments) and the Notification of the Department of Health Services Support on Rules, Procedures, Conditions, and Costs of Advertisements
or Announcements of Healthcare Facilities B.E. 2562 (2019)&#160;(and its amendments) and the Operational Manual for Approval of Advertisements
or Announcements relating to Healthcare Facilities. If such approval was not obtained by NewGenIvf, it could lead to significant liabilities
and consequences, which could adversely impact NewGenIvf&#8217;s business, financial condition and results of operations or subject its
sales and marketing director to personal liabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">For
Cambodia, Prakas 028 on Advertisement of Private Medical, Paramedical and Medical Aid Practices dated August&#160;23, 2004 issued by
the Cambodia MOH prohibits commercial advertising of private medical services. Advertisement of private health care services is only
allowed for any advertisements within the professional framework not affecting the ethics of private medical services and such advertisement
requires a permit from the Cambodia MOH.&#160;In addition, the Royal Government of Cambodia has recently issued Sub-Decree 232 on the
Management of Commercial Advertisements of Goods and Services on November&#160;4, 2022 to provide the legal framework for the management
of commercial advertising of goods and services for all types, forms and means in Cambodia. In light of this Sub-Decree, in addition
to the permit requirement of the Cambodia MOH, a person wishing to advertise their goods and/or services in Cambodia may also apply for
a compliance certificate from the Ministry of Commerce, which certifies that advertising text or content complies with the Law on Consumer
Protection or other applicable regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">For
Kyrgyzstan, the Law on Advertisements of December&#160;24, 1998, No. 155 requires that if the activities of the advertiser subject to
licensing, the advertisement of such advertiser must include the license number and the name of the authority that issued the license,
except for radio advertising, where it is sufficient to state &#8220;licensed activity&#8221; on the territory of Kyrgyzstan. In advertising
goods (including works and services), and other objects of advertising, cost indicators must be stated in the national currency. There
are also other requirements established in relation to size, frequency, cost and other features of advertisements via different types
of media.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">New
laws and regulations relevant to the fertility services may be introduced in the future, or the current applicable regulations may otherwise
be amended or replaced requiring the assisted reproductive medical facilities in its network to conduct business with additional oversight
and regulatory compliance. If NewGenIvf fails to obtain the necessary licenses, permits and approvals, NewGenIvf may be subject to fines,
confiscation of revenues generated from incompliance operations, or the suspension of relevant operations. NewGenIvf may also experience
adverse publicity arising from such non-compliance with government regulations that negatively impacts its brand. NewGenIvf may experience
difficulties or failures in obtaining the necessary approvals, licenses, and permits for new spaces or new service offerings. If NewGenIvf
fails to obtain the material licenses, NewGenIvf&#8217;s business activities could be severely delayed. In addition, there can be no
assurance that NewGenIvf will be able to obtain, renew, and/or convert all of the approvals, licenses, and permits required for its existing
business operations upon their expiration in a timely manner, in a cost-efficient manner or at all, which could adversely affect NewGenIvf&#8217;s
business operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, considerable uncertainties exist in relation to the interpretation and implementation of existing and future laws and regulations
governing NewGenIvf&#8217;s business activities. NewGenIvf could be found not in compliance with any future laws and regulations or of
the laws and regulations currently in effect due to changes in the relevant authorities&#8217; interpretation of those laws and regulations.
It is possible that different interpretations or enforcement of these regulations could subject the current or past practices to allegations
of impropriety or illegality or require the medical facilities in its network to implement changes in the facilities, equipment, personnel
or services, or increase capital expenditure and operating expenses. If NewGenIvf fails to complete, obtain, or maintain any of the required
licenses or approvals or make the necessary filings, NewGenIvf may be subject to various penalties, such as confiscation of unlawful
gains, the imposition of fines, revocation of licenses, and the discontinuation or restriction of NewGenIvf&#8217;s operations. Any such
penalties or changes in policies, regulations, or enforcement by government authorities may disrupt NewGenIvf&#8217;s operations and
materially and adversely affect NewGenIvf&#8217;s business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Legal or
regulatory restriction, government regulation, industry standards and other requirements create risks and challenges with respect to
NewGenIvf&#8217;s compliance efforts and its business strategies and could adversely impact NewGenIvf&#8217;s business and limited the
growth of NewGenIvf&#8217;s operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
healthcare industry is highly regulated and subject to frequently changing laws, regulations, industry standards and other requirements.
Many healthcare laws and regulations are complex, and their application to specific solutions, services and relationships may not be
clear. In particular, many existing healthcare laws and regulations, when enacted, did not anticipate the solutions and services that
NewGenIvf provides, and these laws and regulations may be applied to its solutions and services in ways that NewGenIvf does not anticipate.
Efforts to reform or revise aspects of the healthcare industry or to revise or create additional legal or and regulatory requirements
could impact its operations, the use of its solutions and services, and its ability to market new solutions and services, or could create
unexpected liabilities for it. NewGenIvf also may be impacted by laws, industry standards and other requirements that are not specific
to the healthcare industry, such as consumer protection laws and payment card industry standards. These requirements may impact its operations
and, if not followed, could result in fines, penalties and other liabilities and adverse publicity and injury to its reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span>

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">There
is a risk that existing or future laws may be interpreted in a manner that is not consistent with the healthcare industry&#8217;s current
practices and could have an adverse effect on NewGenIvf&#8217;s business, financial condition, results of operations and growth prospects.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Advertising or offering of gender
selection services in certain jurisdictions in which NewGenIvf operates could expose the Company and its directors and executive
officers to significant legal and regulatory risks, including potential penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The marketing or provision
of gender selection services in certain jurisdictions in which we operate is subject to stringent legal restrictions. In particular,
in Hong Kong, under the Human Reproductive Technology Ordinance (Cap. 561 of the Laws of Hong Kong), gender selection for non-medical
purposes is prohibited. Violation of these provisions may result in criminal liability. Any person found guilty of advertising or offering
gender selection services in Hong Kong may, on a first conviction, face a fine of up to HKD 25,000 and imprisonment for up to 6 months.
If we, our representatives, or our sub-contractors inadvertently violate, or are alleged to violate, these laws, we could face significant
financial penalties, reputational harm, and potential legal proceedings. Even if we do not directly market our gender selection services
in Hong Kong, promotional activities conducted by third parties, affiliates, or other associates on our behalf could also expose us to
liability under these laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Additionally, increased
scrutiny or enforcement actions by regulatory authorities in the jurisdictions in which we operate, including Hong Kong, could result
in adverse publicity, increased compliance costs, and significant disruption of our business operations in the region. As a result, any
failure to comply with applicable laws and regulations related to gender selection services could have a material adverse effect on our
business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Significant tariffs or other restrictions
imposed on imports by the U.S. and related countermeasures taken by impacted countries could have a material adverse effect on our operations
and financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If significant tariffs
or other restrictions are imposed on imports by the U.S. and related countermeasures are taken by foreign countries, our business, including
results of operations, cash flows and financial condition, may be adversely affected. In January 2025, during the initial days of U.S.
President Trump's second term, the U.S. announced the imposition of additional substantial tariffs on imports from various countries,
including China, Canada and Mexico, and the subject countries have imposed or indicated their intention to impose counter measures. In
February 2025, the U.S. imposed tariffs of 10% on all imported goods from China, followed by an additional 10% tariff in March 2025.
The U.S. also imposed a 25% tariff on all steel and aluminum imports, beginning in March 2025. On February 13, 2025, President Trump
ordered his trade advisers to come up with &#8220;reciprocal&#8221; tariffs on U.S. trade partners to retaliate against taxes, tariffs,
regulations and subsidies and on April 2, 2025, announced new tariffs on many U.S. trading partners, including a universal baseline tariff
of 10% on all imported goods, and country specific tariffs such as an additional 34% tax on imports from China (leading to an effective
rate of 54% when combined with existing tariffs) and 20% on products from the E.U. Specific products that are being tariffed, such as
automobiles, were to be exempted from the new tariffs, and tariffs on products such as pharmaceutical drugs were to be announced at a
later date. Following a period of market turbulence, on April 9, 2025, President Trump announced a 90-day pause to the tariffs announced
on April 2, 2025 for most countries. Countries subject to the pause on the tariffs are still to be subject to the baseline 10% tariff.
This consequently lowers the tariff rate for the E.U., Japan, and South Korea, among other countries. However, U.S. President Trump announced
an increased tariff rate against Chinese imports of a minimum 145%. These and other tariffs and countermeasures could increase the cost
of equipment necessary for our operations, disrupt global supply chains and create additional operational challenges. Additionally, ongoing
trade tensions and uncertainty regarding future trade policies could negatively impact global economic conditions and consumer confidence,
further affecting our business performance.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Any litigation
against NewGenIvf could be costly and time-consuming to defend and could harm its business, financial condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has in the past and may in the future become subject to regulatory actions, litigation, disputes, or claims of various types, legal proceedings
and claims that arise in the ordinary course of business, such as claims brought by its clients or vendors in connection with commercial
disputes or employment claims made by its current or former employees, as well as claims brought by relevant regulatory authorities or
NewGenIvf&#8217;s competitors, patients, employees, or other third parties against NewGenIvf. NewGenIvf is unable to predict the outcome
of any of these legal proceedings. Such regulatory actions, disputes, allegations, complaints, or legal proceedings may damage NewGenIvf&#8217;s
reputation, evolve into litigation, or otherwise have a material adverse impact on NewGenIvf&#8217;s reputation and business. Such proceedings
might result in substantial costs, regardless of the outcome, and may significantly divert management&#8217;s attention and resources
from operating NewGenIvf&#8217;s business, which might seriously harm its business, financial condition and results of operations. Insurance
might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims, and might
not continue to be available on terms acceptable to it. A claim brought against it that is uninsured or underinsured could result in
unanticipated costs, potentially harming its business, financial condition and results of operations. The outcomes of actions NewGenIvf
institutes may not be successful or favorable to NewGenIvf. Lawsuits against NewGenIvf may also generate negative publicity that significantly
harms NewGenIvf&#8217;s reputation, which may adversely affect NewGenIvf&#8217;s client base. NewGenIvf may also need to pay damages
or settle lawsuits with a substantial amount of cash.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-size: 10pt"><b><i>Acquisitions,
strategic investments, partnerships, or alliances could be difficult to identify, pose integration challenges, divert the attention of
management, disrupt NewGenIvf&#8217;s business, dilute stockholder value, and adversely affect its business, financial condition and
results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
may in the future seek to acquire or invest in businesses, joint ventures, products and services, or technologies that it believes could
complement or expand its platform, enhance its technical capabilities, or otherwise offer growth opportunities. Any such acquisition
or investment may divert the attention of management and cause NewGenIvf to incur various expenses in identifying, investigating and
pursuing suitable opportunities, whether or not the transactions are completed, and may result in unforeseen operating difficulties and
expenditures. In particular, NewGenIvf may encounter difficulties assimilating or integrating the businesses, technologies, products
and services, personnel or operations of the acquired companies, particularly if the key personnel of the acquired company choose not
to work for it, they are operationally difficult to integrate, or NewGenIvf has difficulty retaining the clients of any acquired business
due to changes in ownership, management or otherwise. These transactions may also disrupt its business, divert its resources, and require
significant management attention that would otherwise be available for development of its existing business and may not benefit NewGenIvf&#8217;s
business strategy, may not generate sufficient revenues to offset the associated acquisition costs or may not otherwise result in the
intended benefits. Any such transactions that NewGenIvf is able to complete may not result in any synergies or other benefits it had
expected to achieve, which could result in impairment charges that could be substantial. In addition, NewGenIvf may not be able to find
and identify desirable acquisition targets or business opportunities or be successful in entering into an agreement with any particular
strategic partner. These transactions could also result in dilutive issuances of equity securities or the incurrence of debt, which could
adversely affect its results of operations. In addition, if the resulting business from such a transaction fails to meet NewGenIvf&#8217;s
expectations, or it fails to successfully integrate such businesses into its own, its business, financial condition and results of operations
may be adversely affected or it may be exposed to unknown risks or liabilities. Even when NewGenIvf identifies an appropriate acquisition
or investment target, it may not be able to negotiate the terms of the acquisition or investment successfully, obtain financing for the
proposed transaction, or integrate the relevant businesses into its existing business and operations. Strategic investments or acquisitions
will involve risks commonly encountered in business relationships, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulties in assimilating and integrating the operations, personnel,
    systems, data, technologies, products and services of the acquired business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability of the acquired technologies, products or businesses to achieve
    expected levels of revenue, profitability, productivity or other benefits;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulties in retaining, training, motivating and integrating key
    personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">diversion of management&#8217;s time and resources from NewGenIvf&#8217;s
    normal daily operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulties in maintaining uniform standards, controls, procedures
    and policies within the combined organizations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulties in retaining relationships with customers, employees and
    suppliers of the acquired business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">risks of entering markets in which NewGenIvf have limited or no prior
    experience;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory risks, including remaining in good standing with existing
    regulatory bodies or receiving any necessary pre-closing or post-closing approvals, as well as being subject to new regulators with
    oversight over an acquired business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">assumption of contractual obligations that contain terms that are not
    beneficial to NewGenIvf, require it to license or waive intellectual property rights or increase its risk for liability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to further successfully develop the acquired technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">liability for activities of the acquired business before the acquisition,
    including intellectual property infringement claims, violations of laws, commercial disputes, tax liabilities and other known and
    unknown liabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential disruptions to NewGenIvf&#8217;s ongoing businesses; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unexpected costs and unknown risks and liabilities associated with
    strategic investments or acquisitions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Even
if the transaction is consummated, NewGenIvf may only have limited control over the companies in which it only has minority stake, it
cannot ensure that these companies will always comply with applicable laws and regulations in their business operations. Non-compliance
of regulatory requirements by NewGenIvf&#8217;s investees may cause substantial harm to NewGenIvf&#8217;s reputations and the value of
NewGenIvf&#8217;s investment. In addition, if the resulting business from such a transaction fails to meet NewGenIvf&#8217;s expectations,
or it fails to successfully integrate such businesses into its own, its business, financial condition and results of operations may be
adversely affected or it may be exposed to unknown risks or liabilities. If NewGenIvf is unable to effectively address these challenges,
its ability to execute acquisitions as a component of its long-term strategy will be impaired, which could have an adverse effect on
its growth. As a result of the above, NewGenIvf&#8217;s strategies may not be successfully implemented beyond the current markets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Any
investment might not achieve the synergies, operational or financial benefits it expects and may adversely impact NewGenIvf&#8217;s operating
results. In addition, NewGenIvf cannot assure you that any future investment in or acquisition of new businesses or technology will lead
to the successful development of new or enhanced products and services or that any new or enhanced products and services, if developed,
will achieve market acceptance, or prove to be profitable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Changes in
NewGenIvf&#8217;s effective tax rate or tax liability may have an adverse effect on its results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
effective tax rate could increase due to several factors, including, but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in the relative amounts of income before taxes in the various
    jurisdictions in which NewGenIvf operates that have differing statutory tax rates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in tax laws, tax treaties, and regulations or the interpretation
    of them;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes to its assessment about its ability to realize its deferred
    tax assets that are based on estimates of its future results, the prudence and feasibility of possible tax planning strategies, and
    the economic and political environments in which NewGenIvf does business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the outcome of future tax audits, examinations, or administrative appeals;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">limitations or adverse findings regarding its ability to do business
    in some jurisdictions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Any
of these developments could have an adverse effect on its results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
reported financial results may be adversely affected by changes in accounting principles generally accepted in relevant jurisdictions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Accounting
principles generally accepted in Thailand, Cambodia and Kyrgyzstan are subject to interpretation by the relevant supervision institutions,
and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations
could have a significant effect on NewGenIvf&#8217;s reported results of operations and could affect the reporting of transactions already
completed before the announcement of a change. The adoption of new or revised accounting principles may require it to make changes to
its systems, processes and control, which could have a significant effect on its reported financial results, cause unexpected financial
reporting fluctuations, retroactively affect previously reported results or require it to make costly changes to its operational processes
and accounting systems upon or following the adoption of these standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf&#8217;s
estimates or judgments relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely
affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect
the amounts reported in NewGenIvf&#8217;s consolidated financial statements and accompanying notes appearing elsewhere in this prospectus.
NewGenIvf bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances,
as provided in the section titled &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations
of NewGenIvf&#160;&#8212;&#160;Critical Accounting Policies, Judgments and Estimates</i>.&#8221; The results of these estimates form
the basis for making judgments about the carrying values of assets, liabilities and equity, and the amount of revenue and expenses that
are not readily apparent from other sources. Significant estimates and judgments used in preparing NewGenIvf&#8217;s consolidated financial
statements include those related to the determination of fair value of its Class A Ordinary Shares and Warrants and revenue recognition
relating to services rendered but for which no claim has yet been reported, among other things. NewGenIvf&#8217;s results of operations
may be adversely affected if its assumptions change or if actual circumstances differ from those in its assumptions, which could cause
its results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the market price
of its Class A Ordinary Shares and Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it
to criminal or civil liability and harm its business, financial condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is subject to the Anti-Money Laundering Act B.E. 2542 (1999)&#160;of Thailand, the Act Supplementing the Constitution Relating to the
Prevention and Suppression of Corruption B.E. 2561 (2018)&#160;of Thailand, and the Penal Code of Thailand, domestic bribery laws, and
other anticorruption and anti-money laundering laws in the countries in which it conducts activities. Anti-corruption and anti-bribery
laws have been enforced aggressively in recent&#160;years and are interpreted broadly to generally prohibit companies, their employees
and their third-party intermediaries from authorizing, offering, or providing, directly or indirectly, improper payments or benefits
to recipients in the public or private sector. If NewGenIvf expands its business and sales and to the public sector, it may engage with
business partners and third-party intermediaries to market its services and to obtain for it the necessary permits, licenses, and other
regulatory approvals. In addition, NewGenIvf or its third-party intermediaries may have direct or indirect interactions with officials
and employees of government agencies or state-owned or affiliated entities. NewGenIvf can be held liable for the corrupt or other illegal
activities of these third-party intermediaries, its employees, representatives, contractors, partners and agents, even if it does not
explicitly authorize such activities. Detecting, investigating, and resolving actual or alleged violations of anti-corruption laws can
require a significant diversion of time, resources, and attention from senior management. In addition, noncompliance with anti-corruption,
anti-bribery, or anti-money laundering laws could subject it to whistleblower complaints, investigations, prosecution, enforcement actions,
sanctions, settlements, fines, damages, other civil or criminal penalties or injunctions, suspension or debarment from contracting with
certain persons, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas or investigations are
launched, or governmental or other sanctions are imposed, or if NewGenIvf does not prevail in any possible civil or criminal proceeding,
its business, financial condition and results of operations could be harmed. In addition, responding to any action will likely result
in a materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional
fees, which could adversely affect its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">For
more information about our SEC filings, please see &#8220;<i>Where You Can Find More Information</i>&#8221; and &#8220;<i>Incorporation
by Reference</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Some
of the statements made under &#8220;<i>Prospectus Summary</i>,&#8221; &#8220;<i>Risk Factors</i>,&#8221; &#8220;<i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations</i>,&#8221; &#8220;<i>Business</i>&#8221; and elsewhere in this
prospectus constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; &#8220;intends&#8221; or &#8220;continue,&#8221; or the negative
of these terms or other comparable terminology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements
that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating
to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that
address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements
on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our
                                            planned level of revenues and capital expenditures;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to market and sell our products and services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our plans to continue to invest in research and development to develop
    technology for both existing and new products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to maintain our relationships with suppliers, manufacturers
    and other partners;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to maintain or protect the validity of our intellectual
    property and know-how;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to retain key executive members;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to internally develop and protect new inventions and intellectual
    property;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to expose and educate the industry about the use of our
    services and products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our expectations regarding our tax classifications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">interpretations of current laws and the passages of future laws; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact of the coronavirus (COVID-19) pandemic and resulting government
    actions on us, our manufacturers, suppliers and facilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our
or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those anticipated
by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading &#8220;<i>Risk
Factors</i>&#8221; and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking
statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="s_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>MANAGEMENT</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth information regarding our executive officers and directors as of the date of this prospectus.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 35%; border-bottom: black 1.5pt solid; padding-right: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="white-space: nowrap; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 55%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wing Fung Alfred Siu</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors, Chief Executive
    Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hei Yue Tina Fong</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chief Marketing Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hok Man Jefferson Au</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Florianna Ann Chi Wan Chan</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chun Wa Tam</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ho Fai Chung</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Wing Fung Alfred Siu</i></b><i>.&#160;</i>NewGenIvf&#8217;s
co-founder, Mr. Wing Fung Alfred Siu, has served as the Chairman of the Board and the Chief Executive Officer of NewGenIvf (before the
Closing, Legacy NewGenIvf) since 2019. Prior to establishing Legacy NewGenIvf in 2019, Mr.&#160;Siu served as a director of First Fertility
PGS Center Co., Ltd. since 2014. Mr.&#160;Siu received his master&#8217;s degree in science and bachelor&#8217;s degree in science from
Stanford University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Hei Yue Tina Fong.&#160;</i></b>Ms.
Fong has served as a Director and the Chief Marketing Officer of NewGenIvf (before the Closing, Legacy NewGenIvf) since 2019. Prior to
establishing NewGenIvf in 2019, Ms. Fong served as a director of First Fertility PGS Center Co., Ltd. since 2014. Ms. Fong received her
bachelor&#8217;s degree in marketing from Indiana University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Ho Fai
Chung</i></b>. Mr. Chung has served as NewGenIvf&#8217;s Chief Financial Officer since October 10, 2024. Mr. Chung has over 30 years
of working experience in Asia. He is a certified public accountant in the U.S. Born in Hong Kong, Mr. Chung holds a Bachelor of Law
degree from University of London and a Master&#8217;s degree in Accounting and Finance from Lancaster University (UK). Mr. Chung
also holds a Master&#8217;s degree in International and Public Affairs from Hong Kong University. He started his career with Price
Waterhouse (&#8220;PwC&#8221;) in Hong Kong and then joined a number of companies to take up financial control as well as general
management jobs in industries including fashion, office products, telecommunications/internet and advertising. He had worked and
based in China, Taiwan, Singapore and Malaysia before and had extensive regional financial controlling exposure in Asia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Hok Man Jefferson Au</i></b>.
Mr. Au has served as NewGenIvf&#8217;s independent director since April 3, 2024. Mr. Au has served as the Assistant Financial Controller
and the Company Secretary at Coolpoint Innonism Holding Limited since May 2017 and a director of JWMG CPA Limited, Certified Public Accountants
since August 2014. He previously worked as the audit supervisor at Clement C.W. Chan &amp; Co., Certified Public Accountants from September
2010 to March 2014. Mr. Au obtained his honours diploma in accounting from Hong Kong Shue Yan University (formerly known as Hong Kong
Shue Yan College) and received his Master of Science in professional accountancy from the University of London. Mr. Au is a member of
the Hong Kong Institute of Certified Public Accountants and an associate of the Association of Chartered Certified Accountants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true"><b><i>Florianna Ann Chi
Wan Chan</i></b> has served as NewGenIVF&#8217;s independent director since April 15, 2025. Ms Chan has over 20 years of experience in
project management, real estate development, and luxury hospitality, she is a proven leader in driving growth and operational excellence.
Since 2015, Ms. Chan has led Lab Concept Company Limited, a subsidiary of The Lane Crawford Joyce Group, where she successfully restructured
operations, spearheaded rebranding, and digitized processes, achieving significant revenue growth. Previously, she held senior roles
at VCC Company Limited, Eton Properties, and Crown Macau, excelling in real estate development, marketing, and VIP services. She holds
a Bachelor of Hospitality Management from Central Queensland University in Australia and an Advanced Diploma from William Angliss Institute
of TAFE. Fluent in Cantonese, Mandarin, and English, Ms. Chan brings a deep understanding of Asia Pacific markets and a strategic vision
that will drive the Company&#8217;s continued growth and success.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Tam Chun Wa</i></b>.
Mr. Tam has served as NewGenIvf&#8217;s independent director since November 29, 2024. Mr. Tam is currently the chief financial officer,
the company secretary, and the authorised representative of China Asia Valley Group Limited since December 2023. Mr. Tam was appointed
as an independent non-executive director of Green Energy Group Limited on 24 August 2011. Mr. Tam was also the chief financial officer,
the company secretary and the authorised representative of Perfect Group International Holdings Limited from February 2017 to November
2023. The shares of these three companies are listed on the Main Board of the Stock Exchange with stock codes 63, 979 and 3326 respectively.
He was the executive director of Chinasing Investment Holdings Limited from February 2009 to August 2015, a company whose shares were
listed on the Main Board of Singapore Exchange Limited. Mr. Tam obtained a Master degree of Business Administration from the University
of Sydney. Mr. Tam is also a member of Hong Kong Institute of Certified Public Accountants, CPA (Australia) and Institute of Singapore
Chartered Accountants. Mr. Tam has more than 30 years in the areas of auditing, accounting, tax, investment banking and company secretarial
work.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Election of Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive officers are
appointed by, and serve at the discretion of, the Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Wing Fung Alfred Siu
and Ms. Hei Yue Tina Fong are husband and wife. Other than as disclosed in this prospectus, none of the directors or executive officers
has a family relationship as defined in Item 401 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Involvement in Certain
Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the best of our knowledge,
none of our directors or executive officers has, during the past ten years, been involved in any legal proceedings described in subparagraph
(f) of Item 401 of Regulation S-K. Our directors and officers have not been involved in any transactions with us or any of our affiliates
or associates which are required to be disclosed pursuant to the rules and regulations of the SEC.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Diversity Matrix
of Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
the diversity statistics of the Board, as required by Rule 5606 of the Nasdaq Listing Rules:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Board Diversity Matrix as at the
    date of this prospectus</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="5">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Country of Principal Executive Offices:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign Private Issuer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Disclosure Prohibited Under Home Country Law</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Number of Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Female</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Male</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Non-Binary</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-keep: true">Did Not <br/>
    Disclose <br/>
    Gender</b></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">Part I: Gender Identity</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Directors</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="-keep: true">2</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="-keep: true">3</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Part II: Demographic Background</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Underrepresented Individual in Home Country Jurisdiction</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">LGBTQ+</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Did Not Disclose Demographic Background</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#8212;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table sets
forth the amount of compensation, including base salary, discretionary bonus, equity compensation, contractual benefits and contributions
to defined contribution plans, which was paid, earned and/or accrued during the fiscal years ended December 31, 2024 and 2023, for each
of the officers and directors for Legacy NewGenIvf prior to the Business Combination.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Name</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025<br/> Compensation<br/> US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024<br/> Compensation<br/> US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Directors and Officers</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Wing Fung Alfred Siu</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">190,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">125,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Hei Yue Tina Fong</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">190,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">125,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">380,000</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">250,000</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Board Practices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><b>Committees
of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We established three committees
under the Board: an audit committee (&#8220;Audit Committee&#8221;), a Compensation Committee (&#8220;Compensation Committee&#8221;)
and a nominating and corporate governance committee (&#8220;Nominating and Corporate Governance Committee). We have adopted a charter
for each of the three committees. Each committee&#8217;s members and functions are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true"><i>Audit Committee</i>.
Our Audit Committee consists of Mr. Hok Man Jefferson Au, Ms, Florianna Ann Chi Wan Chan, and Mr. Tam Chun Wa. We have determined that
all of these individuals satisfy the &#8220;independence&#8221; requirements of NASDAQ Rule 5605 and Rule 10A-3 under the Exchange Act.
Our Board has determined that Mr. Hok Man Jefferson Au qualifies as an audit committee financial expert and has the accounting or financial
management expertise as required under Item 407(d)(5)(ii) and (iii) of Regulation S-K. The audit committee will oversee our accounting
and financial reporting processes and the audits of the financial statements of our company. The Audit Committee will be responsible
for, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            clear hiring policies for employees or former employees of the independent auditors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and recommending to the Board for approval, the appointment, reappointment or removal of
                                            the independent auditor, after considering its annual performance evaluation of the independent
                                            auditor;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
                                            the remuneration and terms of engagement of the independent auditor and pre-approving all
                                            auditing and non-auditing services permitted to be performed by the Company&#8217;s independent
                                            auditors at least annually;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            a written report from the Company&#8217;s independent auditor describing matters relating
                                            to its independence and quality control procedures;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            with the independent registered public accounting firm any audit problems or difficulties
                                            and management&#8217;s response;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
                                            with the Company&#8217;s independent auditor, among other things, the audits of the financial
                                            statements, including whether any material information should be disclosed, in addition to
                                            issues regarding accounting and auditing principles and practices;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and approving all proposed related party transactions, as defined in Item&#160;404 of Regulation&#160;S-K
                                            under the Securities Act;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and recommending the financial statements for inclusion within the Company&#8217;s quarterly
                                            earnings releases and to the Board for inclusion in its annual reports;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
                                            the annual audited financial statements with management and the independent registered public
                                            accounting firm;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            policies with respect to risk assessment and risk management;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            the adequacy and effectiveness of the Company&#8217;s accounting and internal control policies
                                            and procedures and any special steps taken to monitor and control major financial risk exposures;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
                                            reviewing and reassessing the adequacy of the committee charter;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
                                            annual audit plans, and undertaking an annual performance evaluation of the internal audit
                                            function;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            and overseeing procedures for the handling of complaints and whistleblowing;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting
                                            separately and periodically with management, the internal auditors and the independent registered
                                            public accounting firm;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
                                            compliance with the Company&#8217;s code of business conduct and ethics, including reviewing
                                            the adequacy and effectiveness of its procedures to ensure proper compliance;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting
                                            periodically to the Board; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            other matters that are specifically delegated to the Company&#8217;s Audit Committee by the
                                            Board from time to time.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the audit committee&#8217;s
current charter is available at our corporate website at www.newgenivf.com.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true"><i>Compensation Committee</i>.
Our Compensation Committee (&#8220;Compensation Committee&#8221;) consists of Mr. Wing Fung Alfred Siu, Ms. Hei Yue Tina Fong, and Ms
Florianna Ann Chi Wan Chan. The Chairman of the Compensation Committee is Mr. Siu. The Company has determined that Ms. Chan satisfies
the &#8220;independence&#8221; requirements of Rule&#160;5605(c)(2)&#160;of the Nasdaq Stock Market Listing Rules. The Compensation Committee
assists the Board in reviewing and approving compensation structure, including all forms of compensation relating to the Company&#8217;s
directors and executive officers. The Company&#8217;s Chief Executive Officer may not be present at any committee meeting during which
their compensation is deliberated upon. The Compensation Committee is responsible for, among other things:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and evaluating the Company&#8217;s executive compensation and benefits policies generally;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and recommending any incentive compensation or equity plans, programs or other similar arrangements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
                                            reviewing and reassessing the adequacy of the Compensation Committee charter;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
                                            compensation consultant, legal counsel or other adviser only after taking into consideration
                                            all factors relevant to that person&#8217;s independence from management;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting
                                            periodically to the Board; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            other matters that are specifically delegated to the Compensation Committee by the Board
                                            from time to time.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Compensation
Committee&#8217;s current charter is available at our corporate website at: www.newgenivf.com.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Nominating and Corporate
Governance Committee</i>. The Company&#8217;s Nominating and Corporate Governance Committee consist of Mr. Wing Fung Alfred Siu, Ms.
Hei Yue Tina Fong, and Mr. Hok Man Jefferson Au. The Chairman of the Nominating and Corporate Governance Committee is Mr. Siu. The Company
has determined that Mr. Au satisfies the &#8220;independence&#8221; requirements of Rule&#160;5605(c)(2)&#160;of the Nasdaq Stock Market
Listing Rules. The Nominating and Corporate Governance Committee assists the Board of Directors in selecting individuals qualified to
become the Company&#8217;s directors and in determining the composition of the Board of Directors and its committees. The Nominating
and Corporate Governance Committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            nominees to the Board for election or re-election to the Board, or for appointment to fill
                                            any vacancy or newly created directorships on the Board;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            periodically with the Board the current composition of the Board with regards to characteristics
                                            such as judgment, experience, expertise, diversity and background;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            to the Board of criteria with respect to nomination or appointment of members of its Board
                                            of Directors and chairs and members of its committees or other corporate governance matters
                                            as may be required pursuant to any SEC or Nasdaq Stock Market Listing Rules, or otherwise
                                            considered desirable and appropriate;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            to the Board the names of directors to serve as members of the Audit Committee and the Compensation
                                            Committee, as well as of the Nominating and Corporate Governance Committee itself;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
                                            and reassessing the adequacy of the committee charter;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
                                            compliance with the corporate governance guidelines and code of business conduct and ethics;
                                            and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
                                            and leading the self-evaluation of the Board in its performance and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness
                                            as a whole.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Nominating
and Corporate Governance Committee&#8217;s current charter is available at our corporate website at www.newgenivf.com.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Duties and Functions
of Directors</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the laws of the British
Virgin Islands, the Company&#8217;s directors owe fiduciary duties to the Company, including duty to act honestly and in good faith in
what the directors believe to be in the best interests of the company, duty to exercise powers for a proper purpose and directors shall
not act, or agree to act, in a matter that contravenes the BVI Act or the Memorandum and Articles of Association, duty to exercise the
care, diligence and skill that a reasonable director would exercise in the circumstances, and duty to avoid conflicts of interest. In
fulfilling their duty of care to the Company, the Company&#8217;s directors must ensure compliance with the Company&#8217;s Memorandum
and Articles of Association, as amended and restated from time to time. The Company has the right to seek damages if a duty owed by its
directors is breached. In limited exceptional circumstances, a shareholder may have the right to seek damages in the Company&#8217;s
name if a duty owed by the Company&#8217;s directors is breached. The functions and powers of the Board include, among other things,
(i)&#160;convening shareholder meetings at such times and in such manner and places as the director considers necessary or desirable,
(ii)&#160;declaring dividends, (iii)&#160;appointing directors or officers and determining their terms of offices and responsibilities,
and (iv)&#160;approving the transfer of shares of the Company, including the registering of such shares in the Company&#8217;s share
register.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Terms of Directors
and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s officers are elected by and serve at the discretion
of the Board. Each director holds office for the term fixed by the resolution of shareholders or the resolution of directors appointing
him until such time as his successor takes office or until the earlier of his death, resignation or removal from office by resolution
of directors with or without cause or be removed by the shareholders for cause only by a resolution approved at a duly convened and constituted
meeting of the shareholders of the Company by the affirmative vote of not less than 75% of the votes of the shares entitled to vote thereon
which were present at the meeting and were voted. The directors may at any time appoint any person to be a director either to fill a vacancy
or as an addition to the existing directors. Where the directors appoint a person as director to fill a vacancy, the term shall not exceed
the term that remained when the person who has ceased to be a director ceased to hold office. A vacancy in relation to directors occurs
if a director dies or otherwise ceases to hold office prior to the expiration of his term of office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Interested Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director may, subject to
any separate requirements for Audit Committee approval under applicable laws or applicable Nasdaq Stock Market Listing Rules, vote on
a matter relating to the transaction in which he or she is interested, provided that the interest of any directors in such transaction
is disclosed by him or her to all other directors.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Director Agreements&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into director
agreements with our directors, which require us to maintain director and officer liability insurance for our directors, provide reimbursements
for business related travel and accommodation and other reasonable expenses, and an annual remuneration of between $20,000 to $25,000
for our independent directors, and $240,000 for our executive directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf had 76 full-time
employees, of which 64 are based in Thailand, Cambodia and Kyrgyzstan. NewGenIvf aims to attract and retain employees with the skills,
and experience necessary to implement its growth strategy. The following table sets forth the number of its employees in Thailand, Cambodia
and Kyrgyzstan by function as of December 31, 2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Function</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number&#160;of <br/> employees</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">Thailand</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="-keep: true">Medical professionals</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">16</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Administrative staff and others</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-keep: true">Sub-total</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="-keep: true">Cambodia</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Medical professionals</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Administrative staff and others</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">13</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-keep: true">Sub-total</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">25</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="-keep: true">Kyrgyzstan</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Medical professionals</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Administrative staff and others</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-keep: true">Sub-total</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">9</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="-keep: true">China</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Administrative staff and others</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span style="-keep: true">Hong&#160;Kong</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Administrative staff and others</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">76</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we maintain
a good working relationship with our employees and we have not experienced any significant labor disputes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Share Ownership</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as specifically noted,
the following table sets forth information with respect to the beneficial ownership of our ordinary shares as of the date of this annual
report by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our directors and executive officers; and</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our principal shareholders who beneficially own more than 5% of our total outstanding
                                            ordinary shares;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The calculations in the
table below are based on <span style="background-color: white">7,508,094</span> ordinary shares outstanding, including <span style="background-color: white">7,302,819
</span> Class A Ordinary Shares and 205,275 Class B Ordinary Shares, as of April 28, 2025.&#160;Unless otherwise indicated, each person
has sole investment and voting power with respect to all shares shown as beneficially owned. The term &#8220;beneficial owner&#8221;
of securities refers to any person who, even if not the record owner of the securities, has or shares the underlying benefits of ownership.
These benefits include the power to direct the voting or the disposition of the securities or to receive the economic benefit of ownership
of the securities. A person also is considered to be the &#8220;beneficial owner&#8221; of securities that the person has the right to
acquire within 60 days by option or other agreement. Beneficial owners include persons who hold their securities through one or more
trustees, brokers, agents, legal representatives or other intermediaries, or through companies in which they have a &#8220;controlling
interest&#8221;, which means the direct or indirect power to direct the management and policies of the entity. The Company&#8217;s directors
and executive officers do not have different voting rights than other shareholders of the Company.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Name of Beneficial Owner</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Class A Ordinary shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Class B Ordinary Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">% of Total Ordinary Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">% of Voting Power</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left; width: 52%"><span style="-keep: true">Directors and Named Executive
    Officers:</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="-keep: true">&#160;</span></td><td style="text-align: right; width: 9%"><span style="-keep: true">&#160;</span></td><td style="text-align: left; width: 1%"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="-keep: true">&#160;</span></td><td style="text-align: right; width: 9%"><span style="-keep: true">&#160;</span></td><td style="text-align: left; width: 1%"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="-keep: true">&#160;</span></td><td style="text-align: right; width: 9%"><span style="-keep: true">&#160;</span></td><td style="text-align: left; width: 1%"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="-keep: true">&#160;</span></td><td style="text-align: right; width: 9%"><span style="-keep: true">&#160;</span></td><td style="text-align: left; width: 1%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Wing Fung Alfred Siu</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">88,975</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1.19</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">31.97</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Hei Yue Tina Fong</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">116,300</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1.55</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">41.79</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Hok Man Jefferson Au</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Florianna Ann Chi Wan Chan</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Ho Fai Chung</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">All Directors and Executive Officers as Group</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">205,275</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2.74</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">73.76</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="s_002"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>RELATED
PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Related Party Transactions</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of related parties
of the Company is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 49%"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap; width: 2%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Siu, Wing Fung Alfred and Ms. Fong, Hei Yue
    Tina*</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders and directors</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harcourt Limited</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled by Mr. Siu</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">Ms. Fong is the spouse of Mr. Siu&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i style="-keep: true">Transaction with
Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Historically, certain
amount of cash provided by operating activities was distributed to Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong, resulting in amount
due from them. For the year ended December 31, 2023, the largest aggregate amount due from Mr. Siu, Wing Fung Alfred and Ms. Fong, Hei
Yue Tina was US$2,240,872. Mr. Siu and Ms.&#160;Fong had repaid the outstanding amounts due pursuant to the terms and conditions of the
repayment agreement dated August 14, 2023. As of December 31, 2024, the aggregate balance of amount due to Mr. Siu and Ms. Fong was US$92,651.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In addition, NewGenIvf
also recorded remuneration to its directors, Mr. Siu and Ms. Fong. The remuneration to Mr. Siu, Wing Fung Alfred was US$125,000 and US$190,000
during the year ended December 31, 2023 and 2024, respectively. The remuneration during the years ended December 31, 2023 and 2024 was
all in the nature of the fair value of the services provided by Mr. Siu and Ms. Fong. Mr. Siu Wing Fung also entered into agreement to
waive the balance of due from the Company US$88,151 in 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>LISTING
DETAILS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Class A Ordinary Shares
currently trade on Nasdaq under the symbol &#8220;NIVF.&#8221; As of the date of this prospectus, our only listed class of securities
are our Class A Ordinary Shares. All of our Class A Ordinary Shares, including those to be offered by the Selling Securityholder pursuant
to this prospectus, have the same rights and privileges. For more information, see &#8220;<i>Description of Share Capital&#8212;Ordinary
Shares</i>.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>USE
OF PROCEEDS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">All of the Resale Shares
will be sold by the Selling Securityholders for their own accounts. We will not receive any proceeds from the resale of the Resale Shares.
However, we may receive gross proceeds of up to $500 million from the sale of our Ordinary Shares to White Lion pursuant to the White
Lion Purchase Agreement. The actual proceeds from White Lion may be less than this amount, depending on the number of Class A Ordinary
Shares sold and the price at which the Class A Ordinary Shares are sold. In addition, we may receive proceeds of up to $42,433,500 from
the conversion of the Additional Notes, Exchange Notes, Warrants, New CB Initial Note which proceeds will be used for working capital
and other general corporate purposes. We will also bear the costs incurred in connection with this prospectus and the registration of
the Resale Shares.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>DIVIDEND
POLICY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared or paid
any cash dividend on our Class A Ordinary Shares as of the date of this prospectus. We currently intend to retain any future earnings
and do not expect to pay any dividends in the near future. Any further determination to pay dividends on our ordinary shares would be
at the discretion of our Board of Directors, subject to applicable laws, and would depend on our financial condition, results of operations,
capital requirements, general business conditions, and other factors that our Board of Directors may deem relevant.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>
</div><div><a id="aa_001"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>The
following discussion and analysis of our results of operations and financial condition should be read together with our consolidated
financial statements and the notes thereto and other financial information, which are included elsewhere in this registration statement.
Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;).
In addition, our financial statements and the financial information included in this registration statement reflect our organizational
transactions and have been prepared as if our current corporate structure had been in place throughout the relevant periods.<b>&#160;</b></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>This
section contains forward-looking statements. These forward-looking statements are subject to various factors, risks and uncertainties
that could cause actual results to differ materially from those reflected in these forward-looking statements. Further, as a result of
these factors, risks and uncertainties, the forward-looking events may not occur. Relevant factors, risks and uncertainties include,
but are not limited to, those discussed in the section entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and elsewhere in this
registration statement. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect management&#8217;s
beliefs and opinions as of the date of this registration statement. We are not obligated to publicly update or revise any forward -looking
statements, whether as a result of new information, future events or otherwise. See &#8220;Cautionary Note Regarding Forward-Looking
Statements.&#8221;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is an assisted reproductive services (&#8220;ARS&#8221;) provider in Asia Pacific. Since the establishment of its first clinic in Thailand
in 2014, it has established itself as a long-standing ARS provider in the region. NewGenIvf&#8217;s mission is to assist couples and
individuals across Asia Pacific, regardless of fertility challenges that they may face, to fulfil their dreams of building families and
to increase their access to fertility treatments. Its strategic presence in Thailand, Cambodia, and Kyrgyzstan positions the company
to take advantage of opportunities across Asia Pacific.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is still in the early stage of materializing its long-term objective of building a comprehensive, sophisticated and high-end ARS platform
for its clients and providing personalized solutions based on NewGenIvf&#8217;s brands and client-generated services. NewGenIvf plans
to offer full fertility services for fertility tourists across Asia Pacific, continue to invest in laboratories and facilities updates,
increase its brand awareness and market share, as well as expand service reach through acquisitions and partnerships, which NewGenIvf
believes will help expand its client base and enhance expertise attraction, and in turn strengthen NewGenIvf&#8217;s monetization capabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Key Factors Affecting NewGenIvf&#8217;s
Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
results of operation are principally affected by the following factors:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Regulatory environment</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
ARS market in Asia-Pacific region is highly regulated. The implementation and enforcement of laws, regulations and government policies
in Thailand, Cambodia, Kyrgyzstan and other applicable jurisdictions significantly impact the design, pricing and sale of fertility services
and cost of compliance for clinics across Asia Pacific. Medical facilities providing fertility services generally must be filed and registered
with the relevant supervision institutions and such filing and registration must be renewed periodically. Any change in laws, regulations
or policies in relation to such filing or registration could affect NewGenIvf&#8217;s ability and plans to launch new services and renew
registration for existing services. The regulatory framework for medical facilities and services, especially those involving ARS, is,
and will continue, evolving. Any changes in the applicable regulatory frameworks in the jurisdictions where NewGenIvf operates may materially
affect its financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Growth and competitive landscape
of Asia Pacific&#8217;s ARS market</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
revenue has historically been primarily derived from clients in Asia Pacific. As such, NewGenIvf&#8217;s financial performance and future
growth depend primarily on the demand for ARS, as well as changes in its competitive landscape, in Asia Pacific. Population growth, infertility
rates, and demand for facility treatments in the region will ultimately determine the demand for NewGenIvf&#8217;s services. According
to CIC, infertility is increasingly becoming prevalent globally, primarily driven by increasing average age of first birth, as well as
various lifestyle and environmental factors. Driven by an increased infertility rate and growing demand for children without birth defects,
resulting from improving living standards and improved awareness about birth defects and prevention, the global ARS market is expected
to continue to grow. Furthermore, according to CIC, a growing number of governments around the world has granted legal recognition to
same-sex marriages, which brings more desires for having children to form a complete family. According to CIC, because of the fertility
rate and recent government incentive policies, such as the Three-child Policy of China in 2021, the ARS market increased significantly
in Asia Pacific. Leveraging its status as a long-standing ARS provider in Asia Pacific, NewGenIvf expects to continue to be well positioned
to capture the expected growth in the demand for ARS in the area.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of the date of this
prospectus, NewGenIvf owns and uses MicroSort technology in Thailand and Cambodia, which is a form of pre-conception gender selection
technology for humans. While NewGenIvf expects to benefit from first-mover advantages for this technology in the two regions, market
entry by potential competitors or faster-than-expected development of potential competitors may affect its market position and demand
for its services and cause downward pricing pressure on its treatments, which may in turn materially and adversely affect its results
of operations. Meanwhile, ARS market could also be affected by the macroeconomic environment and geopolitical events. Uncertainty in
the macroeconomic environment, resulting from a range of events and trends, including the rise in global inflation and interest rates,
supply chain disruptions, geopolitical pressures, including the unknown impact of current and future trade regulations, changes in Asian-Pacific
relations, fluctuation in foreign exchange rates, and associated global economic conditions may result in volatility in ARS market and
NewGenIvf&#8217;s operating performance. For example, NewGenIvf derives a substantial portion of its revenue from Chinese clients and
as such, its failure to maintain PRC-sourced revenues and access to new and existing clients from the PRC could materially and adversely
affect its results of operations and competitive position. However, the near-term growth prospects of the PRC economy are unclear due
to the uncertain effects of ongoing economic stress caused by policies to contain the COVID-19 pandemic, trade and national security
policies, and the elevated levels of private and public indebtedness, among others. According to the National Statistics Bureau of the
PRC, growth rate of China&#8217;s GDP for the year 2022 slowed down to 3.0% on a year-on-year basis compared to the growth rate of approximately
8.4% for the year 2021. In the second quarter of 2023, China&#8217;s GDP grew only 0.8% on a quarter basis, a significant slowdown from
the 2.2% quarter growth registered in the first quarter of 2023. A prolonged downturn in the PRC economy generally could materially and
adversely affect NewGenIvf&#8217;s results of operations and there is a significant likelihood that NewGenIvf&#8217;s actual results
over the time periods and under the scenarios covered by the projections would be different. However, according to World Bank Group,
China&#8217;s GDP grew 5.2% and 3% in 2023 and 2022 respectively. In 2024, according to National Bureau of Statistics of China, China
GDP grew 5%. NewGenIvf believes that if recovery of the PRC economy is sustainable, it might increase the demand for NewgenIvf&#8217;s
services and therefore in turn affect NewGenIvf&#8217;s results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Fluctuation
of costs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
costs primarily include clinic costs, cost of goods sold, selling and marketing expenses and general and administrative expenses, details
of which are set out below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><i>Clinic
    costs.</i> <span style="font-style: normal">NewGenIvf&#8217;s clinic costs primarily consisted of sub-contracting charges, office
    supplies and staff salaries and bonus, most of which are recognized during the provision of surrogacy services. Its clinic costs
    represented approximately 48.8%, 55.7% of its revenue for the&#160;years ended December 31, 2024 and 2023, respectively. As NewGenIvf
    gradually expands the scale of its operation and presence in Asia Pacific, its clinic costs are expected to increase in the foreseeable
    future, which will affect its profitability.</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><i>Cost
    of goods sold.</i> <span style="font-style: normal">NewGenIvf&#8217;s cost of goods sold primarily consisted of purchase and direct
    cost for IVF treatment services and surrogacy and ancillary caring services, most of which are recognized during the provision of
    IVF treatment services. Its cost of goods sold represented approximately 11.6% and 11.6% of the revenue for the&#160;years ended
    December&#160;31, 2024 and 2023, respectively. NewGenIvf expects its cost of goods sold to increase in the foreseeable future as
    it gradually grows its revenues and expand its sales network.</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><i>Selling
    and marketing expenses.</i> <span style="font-style: normal">NewGenIvf&#8217;s selling and marketing expenses primarily consisted
    of social media expense. Its selling and marketing expenses represented approximately 3.8% and 0.4% of its revenue for the&#160;years
    ended December 31, 2024 and 2023, respectively. NewGenIvf expects its selling and marketing expenses to increase as it plans to expand
    its sales and scale its operation in Asia-Pacific.</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General and administrative
    expenses.</i> NewGenIvf&#8217;s general and administrative expenses primarily consisted of depreciation in operating lease right-of-use
    (&#8220;ROU&#8221;) assets, l and staff salaries&#160;and director fees. Its general and administrative expenses represented approximately
    51.2% and 24.5% of its revenue for the&#160;years ended December 31, 2024 and 2023, respectively. NewGenIvf expects its general and
    administrative expenses to increase in line with its expansion plan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
expects its cost structure to evolve as it develops and expands its business. As NewGenIvf continues to develop new services and technologies,
NewGenIvf expects to incur additional costs in relation to its raw materials procurement, production and sales and marketing, among other
things. Moreover, to support NewGenIvf&#8217;s business growth, it expects to increase its headcount, particularly for its lab and nurse
team, and incur higher staff costs as a result.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Ability to maintain trust of clients
and reputation in the industry</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
success of NewGenIvf&#8217;s business will depend to a large extent on its ability to gain broad acceptance of its services from clients.
Reputation is crucial in keeping existing clients and attracting new clients. NewGenIvf&#8217;s reputation depends on a number of factors,
including for example the success, effectiveness, quality and pricing of its services, service offerings of its competitors, the effectiveness
of its marketing efforts to drive awareness and the demand for fertility services, which eventually will affect its ability to maintain
clients and attract new clients. Therefore, NewGenIvf&#8217;s success will depend to a large extent on its ability to maintain its reputation
in the industry and its clients&#8217; trust, which would affect the number of its clients and treatment cycles that will in turn affect
its revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes that the medical facilities in its network are increasingly recognized among clients, for their service quality, technological
expertise and patient experience. NewGenIvf also hopes to keep its clients by providing discounts in treatment services and via the &#8220;success
guarantee&#8221; program for egg donation services in Cambodia and surrogacy services in Kyrgyzstan, which provides treatments to clients
until a success is achieved.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Based
on its increasingly recognized reputation, NewGenIvf believes that there is substantial opportunity to continue to grow its revenue through
attracting new clients. NewGenIvf&#8217;s addressable market is couples who want to have children, egg freezing patients, LGBT groups
and couples with genetic abnormalities, particularly those in Asia Pacific. NewGenIvf believes that its current client base represents
a small percentage of its total market opportunity. NewGenIvf intends to attract new clients by, among other things, making significant
investments in sales and marketing to engage, educate and drive awareness of the unmet need of fertility treatment among its potential
clients and by its customer-reference discounts mechanism. Additionally, NewGenIvf believes that its expanding presence has resulted
in a heightened awareness of the need to offer fertility services and the value it provides to its clients, which it believes will help
facilitate its growth. In addition, NewGenIvf is continuously utilizing its established client relationships to evaluate other potential
services that could benefit its clients and simultaneously drive its growth.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>International traveling conditions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
revenue from international clients is a critical component of NewGenIvf&#8217;s revenue. International traveling to Thailand, Cambodia
and Kyrgyzstan may be affected by a number of factors, including local and global political, economic and cultural conditions. Furthermore,
an outbreak, or threatened outbreak, of any severe contagious disease may also in turn significantly reduce the demand of traveling.
For example, the COVID-19 pandemic has had resulted in a number of countries declaring a state of emergency and a number of countries,
including the countries in Asian Pacific, imposing extensive travel restrictions. NewGenIvf&#8217;s revenue in the year 2021 was significantly
adversely affected due to the impact from COVID-19 travel restrictions. In addition, a Chinese crime thriller, <i>No More Bets</i>, which
has grossed more than $500 million at the international box office since its August 2023 release and which tells the harrowing story
of characters being lured and kidnapped into a violent scam ring in an unnamed Southeast Asian country after accepting lucrative overseas
job offers, and the continuing social media coverage may have brought fears and safety concerns to Chinese tourists of being scammed
and kidnapped in Thailand&#160;and&#160;Cambodia. In addition, in October 2023, a 14-year-old with a gun opened fire in a luxury shopping
mall in downtown Bangkok, killing two people and injuring five in one of Thailand&#8217;s most popular tourist destinations. These conditions
may cause NewGenIvf difficulty in attracting clients from the PRC to travel to Thailand, Cambodia and Kyrgyzstan for NewGenIvf&#8217;s
services, which could materially and adversely affect NewGenIvf&#8217;s operations and financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Given
the uncertainty of the local and global conditions and the countries&#8217; future policy regarding international traveling, all of which
are beyond NewGenIvf&#8217;s control, NewGenIvf&#8217;s results of operation may be materially and adversely affected by any changes
in international travelling conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Key Components of Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
revenues were derived from two types of services: IVF treatment services and surrogacy and ancillary caring services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table sets
forth a breakdown of NewGenIvf&#8217;s revenue by the types of services, in absolute amounts and as percentages of total revenue, for
the periods indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IVF
    treatment services<sup>(1)</sup></span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">100.0</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4,021,696</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">78.3</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Surrogacy and ancillary caring services</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,114,457</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">21.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Total revenues</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,136,153</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Include
    an insignificant amount of revenue derived from consultation customers who used NewGenIvf&#8217;s non-IVF treatment and insignificant
    services, such as check-ups services, blood test services and other minor services.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
generated revenue from facilities located in various geographic regions. The following table sets forth a breakdown of NewGenIvf&#8217;s
revenue based on the locations where the revenue originated, in absolute amounts and as percentages of total revenue, for the periods
indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">HK SAR</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">34,038</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.7</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Kyrgyzstan</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,656,596</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">48.9</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,123,593</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">60.8</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Cambodia</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">601,526</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11.1</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">621,619</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12.1</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Thailand</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,175,253</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">40.0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,356,903</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">26.4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Total revenues</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,136,153</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s revenue
results are affected by, among others, changes in sales price and the fluctuation of foreign currency rates with US dollars. A 5% change
in sales price would cause 5% change in NewGenIvf&#8217;s revenue. Based on the breakdown of the revenue contribution in terms of currencies
used by customers for 2024, a 5% change in foreign currency rates with US dollars would cause approximately 2.4% change in NewGenIvf&#8217;s
revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>IVF treatment
services</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf
generated revenue from IVF treatment services provided at facilities that NewGenIvf operated in Thailand and Cambodia. In addition, NewGenIvf
also recognized revenues from IVF treatments included in surrogacy services performed in Kyrgyzstan. NewGenIvf&#8217;s revenue from IVF
treatment service amounted to US$5,433,375 and US$4,021,696, representing approximately 100% and 78.3% of its total revenues in 2024
and 2023, respectively.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">IVF treatment involves
the performance of a series of medical treatment and procedures and eventually brings benefits to clients when embryo is successfully
implanted. Revenue from IVF treatment is recognized at a point in time when different treatment and/or procedure completed in clinic.
The completion of the respective treatments and/or procedures are evidenced by treatment cards and reports maintained in the patient
files indicating successful completion of respective promised obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Surrogacy and ancillary caring services</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf also generated
revenue of US$1,114,457 from surrogacy and related ancillary caring services, approximately 21.7% of its total revenue in 2023, provided
at facilities that NewGenIvf operated in Kyrgyzstan. In 2024, due to the reorganization of the Kyrgyzstan operations, NewGenIvf did not
generate any revenue from surrogacy and related ancillary caring services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
surrogacy and ancillary caring services, embryo from intending parents is implanted in the surrogate mother sub-contracted by NewGenIvf.
During the pregnancy period of the surrogate mother, NewGenIvf provides ancillary caring services including maternity caring services
such as regular body check and provision of vitamins, supplements and medicines to surrogate mothers, documentation service, and hotel
accommodation services. Revenue from surrogacy and ancillary caring services is recognized at a point in time when the surrogate mother
gives birth.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Cost of revenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth a breakdown of NewGenIvf&#8217;s cost of revenue by the nature of the cost, in absolute amounts and as percentages
of total cost of revenues, for the periods indicated.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">Cost of revenues</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Cost of goods sold</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">629,620</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">17.5</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">594,984</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">17.2</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Clinic costs</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,976,861</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">82.5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,859,384</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">82.8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Total cost of revenues</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">3,606,481</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">3,454,368</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>Cost
of goods sold. </i>Cost of goods sold primarily consisted of purchase and direct cost for IVF treatment services and surrogacy and ancillary
caring services. NewGenIvf&#8217;s cost of goods was mostly recognized during the provision of IVF treatment services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>Clinic
costs. </i>Clinic costs primarily consisted of sub-contracting charges, office supplies and staff salaries and bonus. The largest portion
of clinic costs was sub-contracting charges, representing fees paid to agents who recruited surrogate mothers and assisted in the documentation,
consulting and medical treatment arrangement throughout treatment procedure. NewGenIvf&#8217;s clinic costs of goods were mostly recognized
during the provision of surrogacy services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Gross profit and gross margin</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table sets
forth NewGenIvf&#8217;s gross profit in absolute amounts and its gross margin as percentages of total revenues, for the periods indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Gross profit</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,826,894</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">33.6</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,681,785</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">32.7</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><span style="-keep: true">Revenues</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">&#8212;</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">5,136,153</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">&#8212;</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
expects that gross profit and gross margin will continue to be affected by various factors including the geographic locations where treatments
are performed, as well as the pricing with its clients, agent subcontracting charges and the costs of the supplies provided by major
pharmaceutical companies, all of which are negotiated separately.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Operating expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s operating
expenses consist primarily of selling and marketing expenses and general and administrative expenses. NewGenIvf&#8217;s selling and marketing
expenses are primarily social media expenses. NewGenIvf&#8217;s general and administrative expenses mainly include depreciation in operating
lease ROU assets, and staff salaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Other income</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s other
income consists primarily of partial waiver of promissory note</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Interest expense</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s interest
expense is incurred in relation to its interest-bearing convertible bonds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Taxation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>British Virgin Islands</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is incorporated in the British Virgin Islands and is not subject to tax on income or capital gains under current British Virgin Islands
law. In addition, upon payment of dividends to shareholders, no British Virgin Islands withholding tax will be imposed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Hong&#160;Kong</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Under
the two-tiered profits tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong profits tax in respect of profits
arising in or derived from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits
above HK$2&#160;million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime
will continue to be taxed at a flat rate of 16.5%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Accordingly,
the Hong&#160;Kong profits tax is calculated at 8.25% on the first HK$2&#160;million of the estimated assessable profits and at 16.5%
on the remaining estimated assessable profits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Thailand</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
companies incorporated in Thailand are taxed on worldwide income. A company incorporated outside of Thailand is taxed on its profits
arising from or in consequence of the business carried on in Thailand. The Thailand corporate income tax rate is 20%. A foreign company
not carrying on business in Thailand is subject to a final withholding tax on certain types of assessable income (e.g., interest, dividends,
royalties, rentals, and service fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%,
while other rates may apply under the provisions of a double tax treaty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Cambodia</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
standard rate of corporate income tax for companies and permanent establishments in Cambodia who are classified as medium and large taxpayers
is 20%. For companies and permanent establishments who are classified as small taxpayers, the corporate income tax rates are progressive
rates from 0% to 20%. In view of the annual turnover of the company, which ranges from KHR1 billion to KHR6 billion for service and commercial
sectors, the company is considered a medium-sized company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Kyrgyzstan</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is subject to a corporate income tax on its aggregate annual income earned worldwide. Non-resident legal entities carrying out business
activities through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that
permanent establishments. Profit tax is calculated at a rate of 10% of aggregate annual income less allowed deductions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Year ended<br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold"><span style="-keep: true">Revenues</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-keep: true">5,136,153</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Cost of revenues</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(3,606,481</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(3,454,368</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Gross profit</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1,826,894</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">1,681,785</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Operating expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Selling and marketing expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(206,314</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(18,030</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">General and administrative expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,651,075</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(1,259,364</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Auditor&#8217;s fees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(130,000</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(362,149</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Total operating
    expenses</b></span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(2,987,389</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(1,639,543</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Operating (loss) income</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(1,160,495</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">42,242</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Other income (expenses), net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Other income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">971,391</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">111,837</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Interest income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,953</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">518</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Interest expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(778,656</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(46,179</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Total other income (expenses), net</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">199,688</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">66,176</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">(Loss) Income before taxes</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(960,807</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">108,418</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Tax income (expense)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">486,706</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#8212;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net (loss) income</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(474,101</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">108,418</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Less: net income attributable to non-controlling interests</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">50,542</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(21,775</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Net (loss) income attributable to the shareholders of the Company</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(524,643</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">130,193</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Other comprehensive (loss) income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Foreign currency translation adjustment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">32,529</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(22,704</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Total comprehensive (loss) income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(441,572</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">85,714</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Less: Total comprehensive (loss) income attributable to non-controlling interests</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">56,908</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(27,621</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Total comprehensive (loss) income attributable to the shareholders of the Company</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(498,480</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">113,335</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Earnings per share&#160;&#8211;&#160;basic</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(1.32</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3.53</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="-keep: true">&#8211;&#160;diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(0.64</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3.53</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Weighted average shares outstanding * &#8211; basic</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">358,108</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30,757</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="-keep: true">- diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">743,323</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">30,757</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
    to 2024 yearend, the Company carried out a 1-for-20 reverse stock split of its issued and unissued shares which was effected on
    February 11, 2025. The shares above have been adjusted retrospectively for this reverse stock split.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>Year Ended December&#160;31, 2024 Compared with Year Ended
December&#160;31, 2023</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Revenue</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="-keep: true">NewGenIvf&#8217;s revenue
increased by approximately 5.8% from US$5,136,153 in 2023 to US$5,433,375 in 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">IVF treatment services</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s IVF
treatment service revenue increased by approximately 35.1% from US$4,021,696 in 2023 to 5,433,375 in 2024. This increase was primarily
the result of our continued expansion of clinics in Thailand and clinic in Kyrgyzstan focusing on IVF services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Surrogacy and ancillary caring services</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s surrogacy
and ancillary caring services revenue decreased by approximately 100.0% from US$1,114,457 in 2023 to US$ Nil in 2024. This decrease was
primarily the result of temporary cessation of surrogacy business due to the reorganization of Kyrgyzstan business operation.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Cost of revenue</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s cost
of revenue increased by approximately 4.4% from US$3,454,368 in 2023 to 3,606,481 in 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Cost of goods sold</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s cost
of goods sold increased by approximately 5.8% from US$594,984 in 2023 to US$629,620 in 2024, primarily attributed to the increase on
procurement costs. The increase in IVF treatment services, directly leading to increase in cost of goods sold.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Clinic costs</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s clinic
costs increased by approximately 4.1% from US$2,859,384 in 2023 to US$2,976,861 in 2024, primarily due to the relocation arrangement,
certain daily operating schedules stopped, resulting in the clinic&#8217;s service being temporarily ceased.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Gross profit</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s gross
profit increased by approximately 8.6% from US$1,681,785 in 2023 to US$1,826,894 in 2024 to, primarily attributable to a reorganizing
of our cooperation model with subcontractors and the increased efficiency of our marketing services, resulting in a decrease in unit
service costs per customer, directly leading to increases in gross profit margins.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s gross
margin slightly increased from 32.7% in 2023 to 33.6% in 2024.<b>&#160;</b></span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i><b>&#160;</b></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Operating expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s operating
expenses increased by approximately 82.2% from US$1,639,543 in 2023 to US$2,987,389 in 2024, primarily attributable to (i) professional
fees of US$769,820 incurred in 2024 being related to business combination with ACSA and the convertible note financing; (ii) license
fee of US$123,000 in 2024 related to the use of MicroSort technology; and (iii) staff and director salary and personnel cost of US$888,861
in 2024 due to enlargement of sales force and administrative staff to implement our business expansion pan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Other income</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s other
income increased from US$111,837 in 2023 to US$971,391 in 2024, primarily attributable to a partial waiver of promissory note and legal
fee payable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Interest expense</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s interest
expense increased from US$46,179 in 2023 to US$778,656 in 2024 as a result of more interest expenses on convertible note issuance in
2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Tax income (expense)&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf made no provision
for income taxes in 2024 and 2023. Thailand&#8217;s taxable income in 2024, if any, would be offset by the tax loss carryforward from
previous years. With the disposition of First Fertility Bishkek LLC in 2024, income tax liabilities, if any, in Kyrgyzstan would be borne
by the new shareholder of First Fertility Bishkek LLC. There was no assessable income generated from Hong Kong and Cambodia.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">During the year ended
December 31, 2024 excess provision of US$486,706 was reversed as they are no longer deemed to be payable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Net income </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s incurred
a net loss of US$474,101 in 2024 while there was a net income of US$108,418 in 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Liquidity
                                            and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Cash flows and working capital</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s principal
sources of liquidity have been cash flows generated from its business operations and external financing via various instruments. As of
December&#160;31, 2024 and 2023, NewGenIvf had US$457,740 and US$54,104, respectively, in cash and cash equivalents. NewGenIvf had working
capital (defined as total current assets deducted by total current liabilities) of a surplus of $452,391 and US$79,000, respectively,
as of December&#160;31, 2024 and 2023.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
NewGenIvf owed US$154,453 to shareholders. Nevertheless, NewGenIvf is able to generate sufficient cash flow from its business operations
and financing activities to operate and grow its business.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
continually seeks to monetize from positive cash flow contracts and increase revenue from its operating activities. NewGenIvf monitors
its current and expected liquidity requirements to help ensure that it maintains sufficient cash balances to meet its existing and reasonably
likely long-term liquidity needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
intends to finance its future working capital requirements and capital expenditures from cash generated from operating activities, in
addition to funds raised from financing activities. NewGenIvf may, however, require additional cash due to changing business conditions
or other future developments, including any investments or acquisitions it may decide to pursue. If its existing cash is insufficient
to meet its requirements, NewGenIvf may seek to issue debt or equity securities or obtain additional credit facilities. Financing may
be unavailable in the amounts NewGenIvf needs or on terms acceptable to it, if at all. Issuance of additional equity securities, including
convertible debt securities, would dilute NewGenIvf&#8217;s earnings per share. The incurrence of debt would divert cash for working
capital and capital expenditures to service debt obligations and could result in operating and financial covenants that restrict NewGenIvf&#8217;s
operations and its ability to pay dividends to its shareholders. If NewGenIvf is unable to obtain additional equity or debt financing
as required, its business operations and prospects may suffer. Please see &#8220;<i>Risk Factors &#8212; Risks Relating to NewGenIvf&#8217;s
Business and Industry&#160;&#8212; NewGenIvf requires a significant amount of capital to fund its operations and growth. If NewGenIvf
cannot obtain sufficient capital on acceptable terms, its business, financial condition, and prospects may be materially and adversely
affected</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table presents NewGenIvf&#8217;s selected consolidated cash flow data for the periods indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Year ended <br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; font-style: italic"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"><span style="-keep: true">US$</span></td><td style="font-weight: bold; font-style: italic"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-keep: true">Net cash used in operating activities</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(8,264,074</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(1,766,135</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Net cash used in investing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(53,045</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(69,848</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Net cash provided by financing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">8,675,790</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,881,493</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Net increase in cash and cash equivalents</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">358,671</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">45,510</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Effect of foreign currency translation on cash and cash equivalents</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">44,965</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(18,962</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Cash and cash equivalents, beginning of year</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">54,104</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">27,556</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Cash and cash equivalents, end of year</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">457,740</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">54,104</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Operating activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Net cash used in operating
activities was US$8,264,074 for the year ended December&#160;31, 2024. The difference between NewGenIvf&#8217;s net loss of US$474,101
for the year ended December 31, 2024 and the net cash used in operating activities was primarily attributable to (i)&#160;an increase
of agent&#8217;s receivable of US$1,191,795, (ii)&#160;a cash deposit of US$1,000,000 with a digital trading platform and settlement
of charges in relation to the de-spac and business reorganisation.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Net
cash used in operating activities was US$1,766,135 for the year ended December 31, 2023. The difference between NewGenIvf&#8217;s net
profit of US$108,418 for the year ended December 31, 2023 and the net cash used in operating activities was primarily attributable to
refund of payment from clients from the contract liabilities and the expenses spent on the legal and professional cost which was capitalized
in the book of 2023.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Investing activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Net cash used in investing
activities in 2024 was US$53,045, primarily representing purchase of plant and equipment.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Net
cash used in investing activities in 2023 was US$69,848, primarily representing purchase of plant and equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Financing activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Net cash provided by financing
activities in 2024 was US$8,675,790, primarily representing issuance of share capital utilizing equity line of credit, convertible note
issuance and proceeds from issuance of promissory notes all totaling to an amount of $8,583,597.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Net cash provided by financing
activities in 2023 was US$1,881,493, primarily representing amounts advanced to shareholder and repayment of prior loans from related
parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Contractual Obligations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table sets
forth NewGenIvf&#8217;s main contractual obligations and commitments as of December 31, 2024 and December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Operating lease</span></td><td style="font-weight: bold; font-style: italic"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"><span style="-keep: true">US$</span></td><td style="font-weight: bold; font-style: italic"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 10pt"><span style="-keep: true">- Payable less than 1 years</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">111,321</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">209,303</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">- Payable 1 &#8211; 2 years</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10,300</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">111,613</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">- Payable 2.- 5 years</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">10,373</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">121,621</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">331,289</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Finance; lease</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Lease liabilities &#8211; current portion</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,446</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.25in; padding-left: 0.5in"><span style="-keep: true">-</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Convertible bonds-</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">2025</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">516,250</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">2026</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">457,250</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">2027</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">457,250</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">2028</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">507,250</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">2029</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">3,269,625</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">5,207,625</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
convertible bonds have the option of being converted to Class A ordinary shares at the discretion of the holder, any time after issuance.
The conversion, however, is subject to certain terms and conditions, including the requirement of the shareholdings not to exceed 9.99%
of the Company&#8217;s shares. As of December 31, 2024, this criterion has been met.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Off-Balance Sheet Commitments and
Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties, nor any
derivative contracts that are indexed to its shares and classified as shareholder&#8217;s equity or that are not reflected in its consolidated
financial statements. Furthermore, NewGenIvf does not have any retained or contingent interest in assets transferred to an unconsolidated
entity that serves as credit, liquidity or market risk support to such entity. NewGenIvf does not have any variable interest in any unconsolidated
entity that provides financing, liquidity, market risk or credit support to it or engages in leasing, hedging or product development
services with it.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Holding Company Structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
Group Limited is a holding company with no material operations of its own. NewGenIvf Group Limited conducts all of its operations through
its subsidiaries. As a result, NewGenIvf Group Limited&#8217;s ability to pay dividends depends upon dividends paid by its subsidiaries.
If our subsidiaries or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing their debt
may restrict their ability to pay dividends to the Company.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
Group Limited is permitted under BVI law to provide funding to its subsidiaries in Hong&#160;Kong, Thailand, Cambodia and Kyrgyzstan
through loans or capital contributions without restrictions on the amount of the funds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, the Company&#8217;s subsidiaries are currently permitted to pay dividends to the Company in accordance with relevant laws and
regulations. Payment of dividends requirements in a company incorporated under the laws of Thailand is governed by the Civil and Commercial
Code of Thailand. For example, the company may not declare dividends if the company has incurred losses, the company must appropriate
to a reserved fund at each dividend contribution of dividend of at least one-twentieth of the profits until the fund reaches one-tenth
of the capital, or the dividends payment must be made to the shareholders within one (1)&#160;month from the dividend declaration date.
On the capital remittance or payment of dividends to the shareholders from outside of Thailand, it is regulated by the regulations issued
by the Bank of Thailand, including the Exchange Control Act B.E. 2485 (1942). The fund remittance from Thailand to a foreign jurisdiction
may require an approval from the Bank of Thailand or require notifying the Bank of Thailand for such transfer, depending on the types
of the remittance transactions, through the commercial bank in the country. For a company incorporated under the laws of Kyrgyzstan,
under Kyrgyz regulations of dividends (net profit), the dividends can be paid once a year depending on the results of the financial year
of the company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Quantitative and Qualitative Disclosure
about Market Risk</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Accounts receivable</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
order to minimize the credit risk, NewGenIvf&#8217;s management team monitors and ensures that follow-up action is taken to recover overdue
debts. NewGenIvf considers the probability of default upon initial recognition of the asset and whether there has been a significant
increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit
risk, NewGenIvf compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date
of initial recognition. It considers available reasonable and supportive forwarding-looking information, such as GDP growth rate and
nominal GDP per capita. Based on the impairment assessment performed by NewGenIvf, the directors considered the loss allowance for account
receivables as of December&#160;31, 2023 and December&#160;31, 2022 is $19 and $26, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and cash equivalents</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings. The credit
risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating
agencies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Deposits
and other receivables, amount due from shareholders and loan to A SPAC I</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
assessed the impairment for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on internal
credit rating and ageing of these debtors which, in the opinion of the directors, have no significant increase in credit risk since initial
recognition. Based on the impairment assessment performed by the Company, the directors consider the loss allowance for deposits and
other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2023 is $14, $17,818 and Nil, respectively. The
loss allowance for deposits and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2022 is $141, $17,059
and Nil, respectively. The loss allowance for deposits and other receivables and amount due from shareholders as of December&#160;31,
2021 was $115 and $6,312 and Nil, respectively.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Cash flow
interest rate risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is exposed to cash flow interest rate risk through the changes in interest rates related mainly to its variable-rates bank balances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
currently does not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk.
The directors monitor NewGenIvf&#8217;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Sensitivity
analysis</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
sensitivity analysis below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period
and had been applied to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is
used when reporting interest rate risk internally to key management personnel and represents management&#8217;s assessment of the reasonably
possible change in interest rates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
interest rates had been 1% higher or lower and all other variables were held constant, NewGenIvf&#8217;s post tax loss for the&#160;years
ended December&#160;31, 2023 and 2022 would have increased or decreased by approximately US$122 and US$275, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Foreign currency
risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Foreign
currency risk is the risk that the holding of foreign currency assets will affect NewGenIvf&#8217;s financial position as a result of
a change in foreign currency exchange rates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
monetary assets and liabilities are mainly denominated in HK$ and THB which are the same as the functional currencies of the relevant
group entities. Hence, in the opinion of the directors of NewGenIvf, the currency risk of US$ is considered insignificant. NewGenIvf
currently does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related
foreign currency exposure closely and will consider hedging significant foreign currency exposures should the need arise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Economic and political risks</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
operations are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, NewGenIvf&#8217;s business, financial condition, and
results of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
operations in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks not typically associated
with companies in North America and Western Europe. These include risks associated with, among other things, the political, economic
and legal environment and foreign currency exchange. NewGenIvf&#8217;s results may be adversely affected by changes in the political
and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies with respect to laws and regulations,
anti-inflationary measures, currency conversion, remittances abroad, and rates and methods of taxation, among other things.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Travel restriction risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">International
clients contribute a large portion of NewGenIvf&#8217;s revenue. International clients need to travel to Thailand, Cambodia and Kyrgyzstan
for treatment services, where NewGenIvf&#8217;s operations are mainly conducted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">International
traveling to Thailand, Cambodia and Kyrgyzstan may be affected by a number of factors, including local and global political and economic
conditions. Furthermore, an outbreak, or threatened outbreak, of any severe contagious disease may also in turn significantly reduce
the demand of traveling or cause extensive travel restrictions. NewGenIvf&#8217;s results may be materially and adversely affected if
travel restriction was imposed or difficulties in cross-border flow arose.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Inflation risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Management
of NewGenIvf monitors changes in prices levels. Historically inflation has not materially impacted NewGenIvf&#8217;s consolidated financial
statements; however, significant increases in the price of labor that cannot be passed to NewGenIvf&#8217;s customers could adversely
impact its results of operations.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Critical Accounting Policies, Judgments
and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
prepares its financial statements in conformity with U.S.&#160;GAAP, which requires NewGenIvf to make judgments, estimates and assumptions.
NewGenIvf continually evaluates these estimates and assumptions based on the most recently available information, its historical experience
and various other assumptions that NewGenIvf&#8217;s management believes to be reasonable under the circumstances. Since the use of estimates
is an integral component of the financial reporting process, actual results could differ from its expectations as a result of changes
in NewGenIvf&#8217;s estimates. Some of NewGenIvf&#8217;s accounting policies require a higher degree of judgment than others in their
application and require NewGenIvf to make significant accounting estimates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
selection of critical accounting policies, the judgments and other uncertainties affecting application of those policies and the sensitivity
of reported results to changes in conditions and assumptions are factors that should be considered when reviewing NewGenIvf&#8217;s financial
statements. NewGenIvf&#8217;s management believes the following accounting policies involve the most significant judgments and estimates
used in the preparation of their financial statements.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i><span style="text-decoration:underline">Going Concern</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The going concern assumption
is a fundamental principle in the preparation of financial statements, and it is management&#8217;s responsibility to evaluate whether
there are any conditions or events that raise substantial doubt about the Company&#8217;s ability to continue operating for the foreseeable
future. Management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern for the financial year ending 2024
has been addressed in the foregoing paragraph.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company is always
closely monitoring the market for opportunities and has also been carrying out various fundraising projects to improve the Company&#8217;s
cash flow position. As of April 10, 2025, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising
the Initial Note, the First Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the
Company. A further $2,000,000 of the Third Mandatory Additional Note are was issued subsequent to year end and remains outstanding. Moreover,
the Company has access to an equity line of credit facility of up to $100,000,000 from White Lion Capital, of which approximately $7.1
million has been drawn and become equity to date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company can make no
assurance that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at
all. If one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall,
there would likely be a material adverse effect on the Company and its financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The consolidated financial
statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i><span style="text-decoration:underline">Equity Line of Credit </span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company entered into
an equity line of credit agreement with White Lion Capital in November 2024. As part of the agreement, the Company is required to pay
a commitment fee of 700,000 shares to the White Lion Capital. The commitment fee is a cost incurred to secure the equity line of credit.
The relevant US GAAP guidance for this treatment can be found in ASC 340-10-S99-1, which states that costs incurred to raise capital
should be recorded as a reduction of Additional Paid in Capital (&#8220;APIC&#8221;) and shall be excluded from the determination of
net income or the results of operations under all circumstances. The commitment fee of 700,000 shares was directly offset against APIC.
The financing arrangement resulting from the commitment fee is that of equity financing and not debt financing in characteristics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The commitment fee paid
in the form of shares, are recorded at fair value of the shares issued, determined based on the market price of the shares at the date
of issuance. The fair market value of the shares is recorded as APICs (since we do not have par value), and APIC &#8211; deferred cost
of financing, both of which are presented in the Statement of Equity. The APIC &#8211; deferred financing cost is amortised over the
term of the facility and credited into APIC. There is no impact nevertheless on the total equity of the Company and for purposes of presentation
in the Statement of Equity, APIC and APIC &#8211; deferred financing cost are not segregated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"></b></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i><span style="text-decoration:underline">Principles of consolidation and basis of preparation </span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company balances and transactions have been eliminated in consolidation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The business combination
transaction between Legacy NewGenIvf and SPAC I was accounted for as a reverse recapitalization under ASC 805, Business Combinations,
with NewGenIvf Group Limited, and deemed to be the accounting acquirer. As SPAC I did not meet the definition of a business under ASC
805, the transaction was not treated as a business combination. Instead, it was accounted for as a recapitalization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Accordingly, the consolidated
assets, liabilities and results of operations of the accounting acquirer will become the historical financial statements of the Company,
and the accounting acquirer&#8217;s assets, liabilities and results of operations will be consolidated with the Company beginning on
the acquisition date. The Legacy NewGenIvf was the legal acquiree but deemed to be the accounting acquirer. The Company was the legal
acquirer but deemed to be the accounting acquiree in the reverse merger. The historical financial statements prior to the acquisition
are those of the accounting acquirer (Legacy NewGenivf). After completion of the Merger Transaction, the Company&#8217;s consolidated
financial statements include the assets and liabilities, the operations and cash flow of the accounting acquirer. Any excess of the value
of shares issued by the Company over the net book value of the accounting acquirer will be recognized as a reduction to equity (APIC).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i><span style="text-decoration:underline">Revenue recognition </span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company adopted ASC
Topic 606, Revenue from Contracts with Customers. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(1)</span></td><td style="text-align: justify"><span style="-keep: true">identify its contracts with customers;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(2)</span></td><td style="text-align: justify"><span style="-keep: true">identify its performance obligations under those contracts;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(3)</span></td><td style="text-align: justify"><span style="-keep: true">determine the transaction prices of those contracts;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(4)</span></td><td style="text-align: justify"><span style="-keep: true">allocate the transaction prices to its performance obligations
in those contracts; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(5)</span></td><td style="text-align: justify"><span style="-keep: true">recognize revenue when each performance obligation under
those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the
consideration expected in exchange for those services.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company enters into
verbal agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify
the scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior
to each promised service or bundle of services that are inter dependent. All the contracts have commercial substance, and it is probable
that the Company will collect considerations from its customers for service component as settlement is predominantly required prior to
performance of the promised service.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company derives its
revenues from two sources: (1) revenue from IVF treatment, and (2) revenue from surrogacy and ancillary caring services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i><span style="text-decoration:underline">Revenue from IVF treatment </span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In vitro fertilization
(&#8220;IVF&#8221;) treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to
become embryo. Fertilized embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a
series of medical treatment as well as procedures and brings benefits to clients as the service of bundles service is completed. Revenue
from IVF treatment is recognized at a point in time when different treatment and/or procedure or bundles thereof, are completed in clinic.
The full completion of the various procedures and treatments are evidenced by treatment cards and reports included within the patient
files indicating successful completion of the service.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i><span style="text-decoration:underline">Revenue from surrogacy and ancillary caring services </span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of
vitamins, supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation
where a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate
mother gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments
across pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result
of operations can be found in Note 8 below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i><span style="text-decoration:underline">Revenue from egg freezing and storage facility </span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company provides access
to the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the
customer, the Company makes available access to the facility with no further substantial involvement. Revenue is recognized at a point
in time when the facility is made available to the customer at the agreed consideration by the provision of specific address within the
facility as maintained in the patient file. The receipt of consideration is assured as payment is required upfront.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i><span style="text-decoration:underline">Principal versus agency considerations </span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company follows the
guidance provided in ASC 606, Revenue from Contracts with Customers, for determining whether the Company is the principal or an agent
in arrangements with customers that involve another party that contributes to the provision of services to a customer. In these instances,
the Company determines whether it has promised to provide the service itself (as principal) or to arrange for the specified service to
be provided by another party (as an agent). This determination is a matter of judgment that depends on the facts and circumstances of
each arrangement. The Company recognizes revenue from the performance of the procedures and treatment on a gross basis as the Company
is responsible for the fulfillment, controls the delivery of the promised service, and has full discretion in establishing prices and
therefore is the principal in the arrangement.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Lease</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf
adopted ASU 2016-02, &#8220;Leases&#8221; (Topic 842). Lease terms used to calculate the present value of lease payments generally do
not include any options to extend, renew, or terminate the lease, as NewGenIvf does not have reasonable certainty at lease inception
that these options will be exercised. NewGenIvf generally considers the economic life of its operating lease ROU assets to be comparable
to the useful life of similar owned assets. NewGenIvf has elected the short-term lease exception, therefore operating lease ROU assets
and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee.
The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
there were $98,570 ROU assets and $118,757 in lease liabilities based on the present value of the future minimum rental payments of leases,
respectively. NewGenIvf&#8217;s management believes that using an incremental borrowing rate of the minimum loan rate and Hong Kong Dollar
Best Lending Rate (&#8220;BLR&#8221;) minus 0.125% was the most indicative rate of NewGenIvf&#8217;s borrowing cost for the calculation
of the present value of the lease payments; the rate used by NewGenIvf was 6.6% and 5.5% respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, there were $283,847 ROU assets and $326,107 in lease liabilities based on the present value of the future minimum
rental payments of leases, respectively. NewGenIvf&#8217;s management believes that using an incremental borrowing rate of the Hong Kong
Dollar Best Lending Rate (&#8220;BLR&#8221;) minus 0.125%&#160;&#160;&#160;was the most indicative rate of NewGenIvf&#8217;s borrowing
cost for the calculation of the present value of the lease payments; the rate used by NewGenIvf was 5.0%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
instruments</i></b></span><span style="font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
financial instruments, including cash and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities
and amounts due from (to) shareholders, have carrying amounts that approximate their fair values due to their short maturities. ASC Topic&#160;820,
&#8220;Fair Value Measurements and Disclosures&#8221; requires disclosing the fair value of financial instruments held by NewGenIvf.
ASC Topic&#160;825, &#8220;Financial Instruments&#8221; defines fair value and establishes a three-level valuation hierarchy for disclosures
of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated
balance sheets for cash and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities and amounts
due from (to) shareholders each qualify as financial instruments and are a reasonable estimate of their fair values because of the short
period between the origination of such instruments and their expected realization and their current market rate of interest. NewGenIvf
analyzes all financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities
from Equity&#8221; and ASC&#160;815. See &#8220;<i>Note&#160;2 &#8212; Summary of Significant Accounting Policies</i>&#8221; for details.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Recent accounting pronouncements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The FASB has introduced
expanded income tax disclosure requirements under ASU 2023-09 to improve transparency. Companies will now need to provide a detailed
reconciliation of their effective tax rate, breaking down federal, state, and foreign taxes, as well as specific categories like tax
credits and foreign earnings. Additionally, businesses must disclose income taxes paid by jurisdiction, offering investors greater clarity
on tax obligations. These changes apply to both public and private companies, with annual reporting periods beginning after December
15, 2024 (2025 for calendar-year entities). This update aims to reduce ambiguity in tax reporting and align disclosures with investor
needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">A major shift in digital
asset accounting, ASU 2023-08 requires companies to measure certain crypto assets (e.g., Bitcoin, Ethereum) at fair value rather than
applying the previous impairment-only model. This means entities must recognize quarterly fair value adjustments in their financial statements,
increasing volatility in reported earnings but improving transparency. The standard applies to fiscal years beginning after December
15, 2024, and impacts both corporate treasuries and investment firms holding cryptocurrencies. This change aligns GAAP closer to fair
value accounting seen in other investment holdings, addressing criticisms of the old impairment approach.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="aa_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an assisted reproductive
services (&#8220;ARS&#8221;) provider in Asia-Pacific. Since the opening of our first clinic in Thailand in 2014, we have established
ourself as a long-standing ARS provider in this region. Our strategic presence in Thailand, Cambodia, and Kyrgyzstan positions us to
take advantage of opportunities across Asia-Pacific. According to China Insights Consultancy (&#8220;CIC&#8221;), from 2014 to 2022,
there was a rising number of women in the key ARS-targeted age group (ages 15 to 49) in Asia Pacific and a growing trend towards later
maternal age. The number of married women of reproductive age in Asia Pacific has risen from 816.4&#160;million in 2014 to 833.2&#160;million
in 2022. Additionally, according to CIC, there was increasing social acceptance of ARS use in Asia Pacific countries such as China, India,
and Thailand during the same period. For example, the number of ARS users in China has risen from 136.8 thousand in 2017 to 184.9 thousand
in 2022 approximately and that in Japan has risen from 98.0 thousand in 2017 to 128.5 thousand in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to CIC, the prevalence
of infertility in Asia-Pacific developing countries is substantial. For example, the infertility rate in Thailand, India and China was
about 15.4%, 13.8% and 17.8%, respectively, in 2022. In India, the infertility rate in 2020 was approximately 13.1%, representing an
annual growth of 2.6%. The infertility rate in China was around 17.6% in 2020, representing an annual growth of 0.6%. Infertility is
increasingly gaining society&#8217;s attention as individuals are more openly discussing their struggles. Despite the prevalence of infertility,
access to treatment is often limited in the Asia Pacific region. According to CIC, financial challenges, costs of treatment, and limited
availability or capacity of fertility medical care are some of the main challenges in the fertility marketplace in Asia-Pacific region.
Religious, social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have children. We believe that
we can help address some of these key challenges of Asia-Pacific fertility industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>History and Development of the Company</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Business Combination,
on April&#160;29, 2021, A SPAC I Acquisition Corp. (&#8220;ASCA&#8221;), was incorporated as a British Virgin Islands business company,
specifically a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or similar business combination with one or more target businesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Business Combination</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February&#160;15, 2023,
ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &#8220;Merger Agreement,&#8221; and the
transactions contemplated thereunder, the &#8220;Business Combination&#8221;) with A SPAC&#160;I Mini Acquisition Corp., Merger Sub,
NewGenIvf Limited, a Cayman Islands exempted company (&#8220;Legacy NewGenIvf&#8221;) and certain shareholders of Legacy NewGenIvf. Pursuant
to the Merger Agreement, the Business Combination was effected in two steps: (i)&#160;ASCA was reincorporated to the British Virgin Islands
by merging with and into A SPAC&#160;I Mini Acquisition Corp. (such transaction, the &#8220;Reincorporation Merger&#8221;); and (ii)&#160;Merger
Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the Company (such second
step in isolation, the &#8220;Acquisition Merger&#8221;). The surviving entity of the Business Combination, together with its subsidiaries
is referred to in this prospectus as &#8220;NewGenIvf,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us,&#8221;
unless the context otherwise requires.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&#160;12, 2023, the
parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the &#8220;First Amendment&#8221;), pursuant to
which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the &#8220;Loan&#8221;)
to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA&#8217;s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from NewGenIvf, ASCA agreed
to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&#8217;s failure to deliver audited
financial statements by no later than February&#160;28, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 6, 2023, the
parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &#8220;Second Amendment&#8221;) which
amended and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&#8217;s board of directors following
the consummation of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf
and three (3) of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii)
provide for the conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary
Shares in connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible
assets immediately after the consummation of the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 3, 2024, the Business
Combination was consummated with the Company as the surviving entity.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NewGenIvf&#8217;s Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With a focus on providing
fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely: (i) in vitro fertilization
(&#8220;IVF&#8221;) treatment service, comprising traditional IVF and egg donation; and (ii)&#160;surrogacy and ancillary caring services.
Currently, we have three clinics: one clinic in Thailand, one clinic in Cambodia, and one clinic in Kyrgyzstan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>IVF treatment service: </b>For the&#160;years
    ended December&#160;31, 2024 and 2023, we generated approximately 100% and 78.3% respectively of our revenue from IVF treatments.
    We primarily provide our clients with conventional IVF/intracytoplasmic sperm injection (&#8220;ICSI&#8221;) and embryo transfer
    services. As technology has progressively advanced, we have been able to, through technologies and facilities provided by MicroSort
    technology, help fulfill the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases. IVF
    treatment involves the performance of a series of medical treatment and procedures that are not separately distinct and only brings
    benefits to clients when embryo is successfully implanted, therefore revenue from IVF treatment is recognized at a point in time
    when it is completed in clinic. The completion of this treatment is evidenced by a written IVF report indicating successful embryo
    implantation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Surrogacy and ancillary caring services: </b>We also generate
    revenue from surrogacy services and related ancillary caring services in Kyrgyzstan. For the&#160;years ended December&#160;31, 2024
    and 2023, we generated approximately Nil % and 21.7%, of our revenue from surrogacy and ancillary caring services. For surrogacy
    services, NewGenIvf conducts implantation of embryos from biological parents in surrogate mothers. In addition, NewGenIvf provides
    a &#8220;success guarantee&#8221; program for egg donation services in Cambodia and surrogacy services in Kyrgyzstan. Under this
    optional program, patients pay additional fees of approximately 40% of the original price and can have repeated attempts of IVF cycles,
    egg donation services and/or surrogacy services until the procedures are successful. The additional costs to NewGenIvf are generally
    limited and amount to approximately 30% of the original costs because NewGenIvf&#8217;s clinics, together with the patients, can
    choose suitable egg donors and surrogate mothers to limit the additional costs. During the pregnancy period, NewGenIvf provides ancillary
    caring services including regular body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from
    surrogacy and ancillary caring services is recognized at a point in time when the surrogate mother gives birth. Surrogacy services
    provide infertile couples with an alternative method of having children. During 2024, we did not generate any revenue from Surrogacy
    as we went through a series of reorganization in Kyrgyzstan, resulting in a sale of 100% equity interest in First Fertility Bishkek
    Limited Liability Company and acquisition of 100% equity interest in Bi Clinic Limited Liability Corporation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For the&#160;years ended
December&#160;31, 2024 and 2023, NewGenIvf&#8217;s revenue was US$5,433,375 and US$5,136,153, and its net income/(loss) was US$(474,101)&#160;and
US$108,418, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to CIC, NewGenIvf&#8217;s
core market for fertility services is substantial and growing rapidly, driven by, among other things, societal and cultural shifts, such
as people starting families later in life and other health-related challenges which could impact couples&#8217; and individuals&#8217;
ability to have children. In addition, NewGenIvf believes that continued overall de-stigmatization of infertility will help drive better
access to, and stronger demand for, fertility treatment services, thereby further enabling the expansion of NewGenIvf&#8217;s addressable
market. According to CIC, the market size of fertility treatments in Asia Pacific was increasing steadily and the potential size of the
Asia fertility market is expected to reach US$37.4&#160;billion by 2030. NewGenIvf believes its market opportunity is substantial and
is continuing to grow as a result of the rising demand for fertility services, the lack of adequate offerings in the market and the increasing
awareness of the challenges of infertility.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competitive Strengths</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that the
following competitive strengths have positioned it to meet growing opportunities in the fertility market across Asia-Pacific, and have
differentiated it from its competitors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Broad-range ARS Provider Offering Comprehensive
Fertility Treatment Services</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With almost a decade of experience
in the fertility market, NewGenIvf has built a reputation in the IVF industry in Asia-Pacific. NewGenIvf has reinforced its long-standing
position through expanding its service offerings and locations to address the evolving clients&#8217; needs or requests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s comprehensive
fertility treatment offerings in Thailand, Cambodia, and Kyrgyzstan, primarily including IVF, egg donation (in Cambodia) and surrogacy
services (in Kyrgyzstan), make it convenient for clients in Asia-Pacific market to have access to various fertility services but with
a relatively low cost, as compared with the US market. Meanwhile, the average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding
medication). Each of NewGenIvf&#8217;s clinics in Thailand, Cambodia, and Kyrgyzstan has its own specialty, and together, NewGenIvf is
able to provide more flexibility and options to its patients. For example, NewGenIvf&#8217;s Thailand clinic focus on IVF and related
ancillary services including HIV sperm washing, egg freezing, and chromosome screening. The clinic in Cambodia specializes in providing
both IVF services and egg donation services. NewGenIvf opened the clinic in Kyrgyzstan in 2019, which broadened NewGenIvf&#8217;s services
by being legally qualified/received approval letter from The Ministry of Health of Kyrgyzstan to offer surrogacy services. As of December
31, 2024, NewGenIvf was the one of the few ARS providers in Kyrgyzstan and one of the few companies in Kyrgyzstan that is licensed to
offer surrogacy services in Kyrgyzstan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf attributes its
track record of success to its experienced physicians and its ability to provide comprehensive ARS services, allowing it to meet patients&#8217;
increasing demand for advanced, high-end, and sophisticated ARS, a higher standard and a wider range of advanced services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has extensive experience
serving Asia-Pacific patients and a deep understanding of their general profiles. In particular, NewGenIvf has personnel speaking multiple
languages, including nurses, facilitators, and translators, who are familiar with the health condition and culture of Asia-Pacific patients
from different countries in the region. NewGenIvf believes that it is therefore well-positioned to benefit from market growth driven
by Asia-Pacific patients travelling to its clinics for treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Attractive Market with Significant Demand
and Fast Growth</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf operates in
the ARS market in Asia Pacific, positioning it to leverage on an attractive market with compelling underlying growth potential.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Built on years of experience,
NewGenIvf has established a strong reputation in its industry, which in turn attracted potential business partners to approach NewGenIvf
to negotiate cooperations and referrals. Over the years, NewGenIvf sends representatives to medical expos mostly held in the PRC to approach
potential business partners and establish new partnerships by entering into agency agreements with each agent. NewGenIvf has become a
significant partner with approximately 90 fertility service agents in China as well as in India. Normally, each agency agreement has
a maximum term of one year, which is renewable upon mutual agreement. Agents typically market and promote NewGenIvf&#8217;s services
by word-to-mouth referrals and other measures and NewGenIvf pays the agents commission at a range of 10% to 25% of the treatment fees
upon the completion of client&#8217;s treatment. Normally, agents provide potential clients&#8217; contact information to the sales team
of NewGenIvf, who then approach potential clients and provide consultation on services. With its partnerships in various countries, NewGenIvf
believes it is able to better benefit from the growing market opportunities.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exclusively Owned and
Licensed Technology for Family Planning and Access to Mature Fertility Technologies</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that its
licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patient&#8217;s
needs. These technologies include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>MicroSort Technology:</i> NewGenIvf acquired the MicroSort Technology
    from Genetics &amp; IVF Institute, Inc. (&#8220;GIVF&#8221;) pursuant to a Purchase Agreement dated January 21, 2025 between NewGenIvf
    and GIVF (&#8220;Purchase Agreement&#8221;). As such NewGenIvf exclusively owns the MicroSort Technology. Prior to the closing of
    the MicroSort Acquisition, NewGenIvf held an exclusive license granted by a division of the Genetics &amp; IVF Institute, Inc. to
    use MicroSort technology in Thailand and Cambodia. MicroSort technology is a form of pre-conception gender selection technology for
    humans. MicroSort technology aims to separate male sperm cells based on which gender chromosome they contain, which results in separated
    semen samples that contain a higher percentage of sperm cells that carry the same gender chromosome. The technology ultimately helps
    couples choose the gender of their future child by choosing semen samples that predominately contain sperm with the&#160;X chromosome
    for a female or Y chromosome for a male. Traditionally and naturally, gender selection occurs after conception, meaning after the
    eggs are fertilized. As a result, some fertilized eggs will go unused. However, with MicroSort technology, NewGenIvf is able to increase
    the ratio of male or female embryos, based on the patient&#8217;s preference. Eggs are more likely to be fertilized according to
    the preferences of the parents. Other improvements that MicroSort treatment could help achieve include prevention of certain gender-related
    hereditary diseases.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Preimplantation Genetic Screening (&#8220;PGS&#8221;)</i>: PGS is
    used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too
    few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid
    embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf
    by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Next-Generation Sequencing (&#8220;NGS&#8221;)</i>: NGS is a high-throughput
    technology for determining the sequence of deoxyribonucleic acid (&#8220;DNA&#8221;) or ribonucleic acid (&#8220;RNA&#8221;) to study
    genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by
    using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands
    of gene fragments simultaneously with NGS reduces time and cost associated with sequencing and increases the coverage quality and
    data output.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Preimplantation Genetic Diagnosis (&#8220;PGD&#8221;)</i>: Similar
    to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a process more enhanced than PGS since it scans for
    individual genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic
    fibrosis, where carrier status has been documented in each of the parents. By using this technique, physicians are able to check
    the genes or chromosomes for a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help
    women better achieve a healthy pregnancy. Individuals who suspect or know they carry genes for serious medical conditions may opt
    to screen for healthy embryos ahead of time.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Well Established Brand with Reliable Reputation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The founders of NewGenIvf
entered the fertility market as agents in 2011 by introducing patients in need to a Thailand clinic for fertility treatments. The founders
of NewGenIvf started to operate their own clinic in Thailand in 2014 and subsequently added clinics in Cambodia and Kyrgyzstan. Since
then, NewGenIvf has attracted clients from countries throughout Asia-Pacific, including Mainland China, Hong&#160;Kong, India, Thailand,
Australia and Taiwan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf benefits from the
favourable geographic locations of its clinics, especially its clinic in Thailand. Located in central Bangkok and situated in one of
the biggest shopping malls of the city, the clinic is located in close proximity to various transportation facilities and popular tourist
attractions, such as the Erawan Shrine. In this regard, NewGenIvf believes that its business has benefited from, and will continue to
benefit from, the convenience of its locations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has developed a
relatively replicable and scalable operating model that supports high productivity at its assisted reproductive medical facilities in
Asia. Under this model, NewGenIvf&#8217;s medical facilities have established standardized operating procedures to select the treatment
process according to each patient&#8217;s profile. NewGenIvf&#8217;s medical and operational personnel are organized into specialized
teams according to the different stages of the treatment process and different patient profiles. When patients are initially admitted
or would like to seek additional medical services later on, they are assigned to one of the optimal medical teams, which NewGenIvf believes
is better suited after taking into account the patient&#8217;s diagnosis and preferences. NewGenIvf believes that this model allows each
team to improve its efficiency and arrange suitable physicians for patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The physicians of NewGenIvf
have also developed and employed an operating model that seeks to increase the effectiveness of physicians by utilizing standardized
workflows and operating procedures with teams of supporting nurses and medical assistants. This helps to increase the number of IVF treatment
cycles that physicians can perform while providing treatment customized based on patient conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With its established client
service history, accumulated experience as well as its continuous upgrades and development of treatment models, NewGenIvf believes that
it will be able to better monetize its brands through its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Experienced Management Team</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NewGenIvf management
team has considerable experience in the ARS market and the broader healthcare industry. A considerable number of NewGenIvf&#8217;s management
are physicians or laboratory technicians who possess extensive experience in the ARS industry and are experts in their respective fields.
NewGenIvf&#8217;s Chief Executive Officer, Mr.&#160;Alfred Siu, has more than 13&#160;years of experience in the fertility service market.
Dr.&#160;Wiphawee Luangtangvarodom had over 8&#160;years of experience as an obstetrician and gynecologist. NewGenIvf&#8217;s two lab
supervisors, Ms. Anussara Phinyong, and Ms. Araya Boonchaisitthipong, each had over eight&#160;years of experience in the embryologist
field. These individuals have extensive experience in managing assisted reproductive medical facilities. NewGenIvf is also led by other
members of the professional management team, who are intimately involved in the operational and financial management of NewGenIvf&#8217;s
Group. Leveraging their experience, NewGenIvf believes that it is well positioned to expand its network and aims to become a leader in
the Asia Pacific ARS market.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Strategies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s vision
is to provide tailored ARS solutions to fulfil patients&#8217; dreams of becoming a parent. To realize this vision, NewGenIvf plans to
adopt the following strategies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Offer Broad Fertility Services for Fertility
Tourists across Asia Pacific</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to provide
broad fertility services for fertility tourists seeking high quality, cost effective and comprehensive fertility solutions. According
to CIC, the demand for fertility tourism is driven by a variety of factors including the prevalence of infertility, the introduction
of the Three-Child policy in China, the improved understanding of assisted reproductive technology and increased affordability of ARS.&#160;To
address these needs, NewGenIvf plans to offer its customers a &#8220;hassle-free&#8221;, seamless and integrated ARS and hospitality
arrangement experience. To complement its fertility services, NewGenIvf intends to integrate its offerings with additional services for
traveling patients, most of whom are first-time fertility tourists, such as translation service, hotel arrangement and airport pickup
services. NewGenIvf plans to enhance its customers&#8217; experience by entering into exclusive cooperation arrangements with local premium
hospitality providers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Continue to Invest in Laboratories and Facilities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes laboratories
and treatment facilities are critical to supporting its future research, development and clients experience. NewGenIvf currently operates
two laboratories that offer IVF services, one in Thailand and one in Cambodia, and plans to continue to scale up its existing laboratories.
NewGenIvf plans to continue to invest in upgrading its laboratories and facilities to complement its growth and expansion, which it believes
will help NewGenIvf maintain an edge over its competitors with regard to technology, operational efficiency, scalability, and client
experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to develop
advanced facilities for its existing laboratories, which will be conducting research on ARS related basic science and experiments relating
to emerging technologies to improve ARS success rates and lower costs. NewGenIvf also plans to correlate its data on patient treatment
protocols to the embryo physiologic data and the pregnancy success rate-related data to identify better treatment protocols to increase
ARS success rates. NewGenIvf intends to continue to actively promote technological cooperation with tertiary institutions to discover
ways to improve its IVF success rates. Furthermore, NewGenIvf seeks to actively deploy the technology that it possesses to expand the
services it provides.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has accumulated
experience in treating patients over 40&#160;years old with premature ovarian failure and patients who have had recurrent ARS implementation
failure, by, for the example, injecting platelet rich plasma into the ovaries to stimulate and support growth of the follicles. NewGenIvf
is also implementing certain technological advancements relevant to the ARS industry, including microfluidics, automated sperm analysers,
time lapsed incubators, non-invasive preimplantation genetic testing (&#8220;PGT&#8221;) of cell-free DNA in spent media, automated systems
for oocyte/embryo vitrification to reduce reagent consumption and decrease labor intensity, mitochondria replacement therapy to reconstruct
oocytes by nuclear transfer of polar body genome from an MII oocyte into an enucleated donor MII cytoplasm, to increase the number of
oocytes available for the treatment of infertile women, preimplantation methylome screening. There are also breakthrough developments
in science including organ culture systems, induced pluripotent stem cells, embryonic stem cells, spermatogonial stem cells for creation
of functional gametes, but these techniques are not yet ready for human clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also intends to
develop clinically customised interior design concepts for its medical facilities, including improved service rooms, consultation rooms,
reception areas, nutrition food areas, and traditional Chinese medicine (such as acupuncture) facilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Increase Brand Awareness and Market Share</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to maintain
and strengthen its brand awareness and market share in Asia Pacific. In order to expand its reach and increase patient numbers, NewGenIvf
plans to collaborate with local hospitals, companies, premium hospitality providers and other key players in the ARS industry in Asia
Pacific. Additionally, NewGenIvf intends to increase brand awareness through social media promotions and marketing initiatives, and establishing
its business development team with the goal of attracting new patients and partners across Asia Pacific. Meanwhile, NewGenIvf intends
to provide innovative treatment services to attract more clients. For example, NewGenIvf plans to introduce IVF mental health services,
which allows clients who fail in IVF treatments to access online consultation for further treatment plans such as egg donation and surrogacy.
These new treatments services aim to enable NewGenIvf to attract potential clients. By adopting a comprehensive strategy to expand its
market share, NewGenIvf aims to strengthen its reputation as a long-standing ARS provider and capture additional market share of the
growingly ARS market in Asia-Pacific.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Expand Service Reach Through Acquisitions and Partnerships</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Leveraging its reputation
and footprint in its current markets, NewGenIvf intends to expand its reach, services offering and client base through strategic acquisitions
and/or partnerships in Asia Pacific. Acquisitions of or by companies offering similar services could not only allow NewGenIvf to diversify
its client base, but also allow it to benefit from potential economies of scale and increasing efficiency through consolidation. NewGenIvf
could also leverage the acquired or acquiring company&#8217;s customer base, reputation and expertise to further improve its offerings
and operations. NewGenIvf intends to focus on ARS providers in Asia Pacific which possess all conventional licenses and locally recognized
brands. For the global market beyond Asia Pacific, NewGenIvf intends to expand its footprint through partnerships with other IVF clinics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NewGenIvf plans
to explore expanding its client base by offering its fertility services as part of corporate benefit programs in Asia. NewGenIvf believes
that there is potential in Asia in offering fertility treatments as a benefit for employees, particularly in companies with a large number
of female employees of childbearing age. By partnering with corporate clients to provide fertility benefits, NewGenIvf can increase its
market reach, enhance its brand reputation, and drive client growth. NewGenIvf&#8217;s broad range of fertility services, including IVF
and egg freezing, can help corporate partners differentiate their employee benefits in the competitive employment landscape, which could
make them more attractive to potential employees. Additionally, by offering these services, companies can help address the growing concern
of delayed childbearing, which is becoming more common among women according to CIC.&#160;NewGenIvf plans to collaborate with potential
corporate clients to develop customized fertility benefit programs that cater to their specific needs, and to provide comprehensive support
and counselling throughout the process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Meanwhile, NewGenIvf also
intends to attract more clients by establishing its &#8220;home country gynecologist partnership program&#8221;. Under the program, NewGenIvf
may, subject to its discretion and screening process, offer treatment services to clients with reduced time requirements to be spent
overseas. Depending on local laws, the potential clients may be able to complete their treatments with gynecologists NewGenIvf partners
with, in their home countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf had entered
into a non-binding term sheet dated June 3, 2024 (the &#8220;Term Sheet&#8221;) with COVIRIX Medical Pty Ltd (&#8220;COVIRIX&#8221;)
for a proposed reverse merger (the &#8220;Proposed Transaction&#8221;). However, on September 21, 2024, COVIRIX withdrew from the Proposed
Transaction, as such the Proposed Transaction was terminated with no cost to the Company. On December 11, 2024, NewGenIvf also announced
its entry into a binding term sheet with European Wellness Investment Holdings Limited (&#8220;EWIHL&#8221;) for a proposed reverse merger
(&#8220;EWIHL Proposed Transaction&#8221;), completion of which was subject to, among other conditions, the completion of due diligence,
the negotiation of a definitive agreement, and obtaining adequate financing. On March 31, 2025, NewGenIvf terminated the term sheet for
the EWIHL Proposed Transaction as EWIHL had failed to produce certain draft audited financials, which were specifically required in the
term sheet.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 28, 2025, NewGenIvf
completed its acquisition of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&#8220;GIVF&#8221;). Pursuant to a Purchase
Agreement dated January 21, 2025 between NewGenIvf and GIVF (&#8220;Purchase Agreement&#8221;), NewGenIvf purchased all of the Assets
(as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort technology (as
described below from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Class A Ordinary Shares (&#8220;MicroSort
Acquisition&#8221;).&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>White Lion Transaction</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, the
Company entered into a Common Shares Purchase Agreement (the &#8220;White Lion Purchase Agreement&#8221;) with White Lion Capital, LLC
(&#8220;White Lion&#8221;) and a related Registration Rights Agreement (the &#8220;RRA&#8221;). Pursuant to the White Lion Purchase Agreement,
the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars
($100,000,000) in aggregate gross purchase price of newly issued Class A Ordinary Shares, with an automatic increase to Three Hundred
Million Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase Agreement)
and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000)
has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth
in the White Lion Purchase Agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the satisfaction
of certain customary conditions including, without limitation, the effectiveness of the Registration Statement registering the resale
of the shares issuable pursuant to the White Lion Purchase Agreement, the Company&#8217;s right to sell shares to White Lion commenced
on the date of the execution of White Lion Purchase Agreement and extends until (i) 36 months from the date of execution of the White
Lion Purchase Agreement, or (ii) at the Company&#8217;s option, until 65 months from the date of the execution of the White Lion Purchase
Agreement in the event that $100,000,000 of purchases under the White Lion Purchase Agreement have been completed prior to the 36 month
anniversary of the Execution Date (the &#8220;Commitment Period&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">During the Commitment
Period, subject to the terms and conditions of the White Lion Purchase Agreement, the Company may exercise its right to sell its Class
A Ordinary Shares to White Lion. The Company may deliver a Regular Purchase Notice (as such term is defined in the White Lion Purchase
Agreement), pursuant to which the Company can require White Lion to purchase up to a number of Ordinary Shares equal to the lesser of
(i) $3,000,000 divided by the highest closing price of the Ordinary Shares over the most recent five (5) Business Days immediately preceding
the Purchase Notice, or (ii) 40% of Average Daily Trading Volume (as such term is defined in the White Lion Purchase Agreement), subject
to a maximum Investment Limit of $3,000,000.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company may also deliver
a Rapid Purchase Notice (as such term is defined in the White Lion Purchase Agreement), pursuant to which the Company may require White
Lion to purchase up to a number of Ordinary Shares equal to $3,000,000 divided by the highest closing price of the Ordinary Shares over
the most recent five business days immediately prior to the receipt of the notice. White Lion may waive such limits under any notice
at its discretion and purchase additional shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The price to be paid by
White Lion for any shares that the Company requires White Lion to purchase will depend on the type of purchase notice that the Company
delivers. For shares being issued pursuant to a Regular Purchase Notice, the purchase price per share will be the lower of (i) the closing
price of Ordinary Shares prior to the receipt of the applicable Purchase Notice, or (ii) the product of (a) the lowest daily VWAP of
the Ordinary Shares during the Regular Purchase Valuation Period (as defined in the White Lion Purchase Agreement), and (b) 98%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For shares being issued
pursuant to a Rapid Purchase Notice, the Company may opt for the purchase price per share to be (i) equal to the lowest traded price
of the Ordinary Shares on the date that the notice is delivered, or (ii) 97% of the lowest traded price of the Ordinary Shares one hour
following White Lion&#8217;s written confirmation of the acceptance of the Rapid Purchase Notice.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No purchase notice shall result
in White Lion beneficially owning (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule
13d-3 thereunder) more than 4.99% (subject to increase, in the sole discretion of White Lion, to 9.99%) of the number of Class A Ordinary
Shares outstanding immediately prior to the issuance of Class A Ordinary Shares issuable pursuant to a purchase notice.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has the right
to terminate the White Lion Purchase Agreement in the event of a material breach of the White Lion Purchase Agreement by White Lion.
The White Lion Purchase Agreement also automatically terminates upon the earlier of (i) the end of the Commitment Period and (ii) the
date that the Company commences a voluntary bankruptcy proceeding, a custodian is appointed for the Company or for all or substantially
all of its property, or the Company makes a general assignment for the benefit of its creditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration for the commitments
of White Lion, as described above, the Company has agreed that it will issue to White Lion 700,000 Class A Ordinary Shares (&#8220;Commitment
Shares&#8221;). Additional Ordinary Shares may be issued to White Lion under certain conditions, including in connection with material
transactions or upon achieving specified investment thresholds. The Commitment Shares will be fully earned by White Lion regardless of
termination of the White Lion Purchase Agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The White Lion Purchase Agreement
and the RRA contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations,
warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely
for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Model</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With a focus on providing
fertility treatments to fulfil couples and individuals&#8217; dreams of raising children, NewGenIvf offers mainly two services, namely:
(i)&#160;IVF treatment service, comprising traditional IVF and egg donation; and (ii)&#160;surrogacy and ancillary caring services. The
following table sets forth NewGenIvf&#8217;s revenue by service offerings and as a percentage of total revenue for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-keep: true">IVF Treatment Service</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">100.0</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4,021,696</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">78.3</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Surrogacy and Ancillary Caring Services</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,114,457</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">21.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total Revenue</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,433,375</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">5,136,153</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>IVF Treatment Service</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf primarily provides
its clients with conventional IVF/ICSI and embryo transfer services. NewGenIvf is also able to, through MicroSort technology, help fulfill
the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IVF treatments that NewGenIvf
provides address tubal factor, ovulatory dysfunction, diminished ovarian reserve, endometriosis, uterine factor, male factor, unexplained
infertility and other causes. IVF bypasses the function of the fallopian tube by achieving fertilization within a laboratory environment.
Ovarian hyper-stimulation is common with IVF treatments to recruit numerous follicles to increase the chances for success. Follicles
are retrieved trans-vaginally using a vaginal probe and ultrasound guidance. Anaesthesia is frequently used due to the number of follicles
retrieved and the resulting discomfort experienced by the patient. The eggs are identified in the follicular fluid and combined with
sperm and culture medium in culture dishes, which are placed in an incubator with a temperature and gas environment designed to mimic
the condition of the fallopian tubes. Once the embryos develop, typically over a 3-to-5-day period, they are transferred to the uterine
cavity. According to CIC, the average clinical pregnancy success rates, using 5-day incubation, averaged approximately 64.6% (with no
PGT) for IVF, with live birth rate at approximately 28.7%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As a long-standing IVF
treatments provider in Asia-Pacific, NewGenIvf had completed over 4,500 cycles of IVF treatments from 2014 to 2024. For the&#160;years
ended December&#160;31, 2024 and 2023, the revenue from NewGenIvf&#8217;s IVF treatments was US$5,433,375 and US$4,021,696, respectively,
representing 100% and 78.3%&#160;of its total revenue in the corresponding periods.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IVF Treatments Process</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A typical IVF treatment process
mainly includes two stages, the pre-IVF treatment stage and the IVF treatment stage. During the IVF treatment process, NewGenIvf also
provides support services such as nutrition guidance and psychological counselling. The flow chart below shows the stages involved in
a typical IVF treatment process:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_006.jpg" style="height: 249px; width: 624px"/><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the pre-IVF treatment
stage, clients attend an initial consultation, undergo pre-IVF tests, and undergo treatment for gynaecological and andrological diseases,
if needed. At the initial consultation, a physician reviews the clients&#8217; detailed medical history to collect more information relating
to the potential cause of their infertility. The client then undergoes various pre-IVF tests, which may include, among other things,
blood pressure, hormone level, ultrasound, infectious disease screening, uterine evaluation and male fertility test. The physician will
then design treatment plans based on the client&#8217;s medical history and results of the tests. If the client is satisfied with treatment
plan and the test results are acceptable to the physician, the physician will prescribe medications and start stimulation treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first step of the cycle
is to boost egg production through injecting synthetic hormones. Over about one week of ovarian stimulation, clients are monitored on
a regular basis with blood test and transvaginal ultrasound. If follicles have reached at least 10 mm in size, an additional antagonist
drug will be added into the daily injection schedule. This is used to prevent ovulation before ovum pickup time. After another few&#160;days
of ovarian simulation, if follicle growth is consistent and majority of follicles are around 16 mm to 17 mm, the final injection of a
human chorionic gonadotropin will be administered. The trigger injection is the final step of the stimulation process and is for the
maturation of the eggs in the follicles before they are collected. The next major step is to retrieve the eggs with a minor surgical
procedure called Trans Vaginal Follicle Aspiration conducted under anaesthesia. At the same time the male partner collects the sperms
for fertilizing the eggs in the laboratory by a process known as intracytoplasmic sperm injection. The fertilized embryos are cultured
in the laboratory for two to six&#160;days. Embryos that grow well are biopsied and tested by PGT to detect potential genetic diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The final step is to transfer
the embryos into the uterus using a catheter. Within eight&#160;days after the embryo transfer, a blood test can be conducted to detect
whether the implantation was successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MicroSort Technology</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroSort technology is a
preconception process developed by the Genetics and IVF Institute, Inc. that aims to improve the chances that the baby to be conceived
will be of the desired gender and prevents certain gender-related hereditary diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Semen samples usually contain
equal amounts of sperm carrying the Y chromosome (which will produce a boy), and sperm carrying the&#160;X chromosome (which will produce
a girl). During the MicroSort process, the sperm sample is washed to remove seminal liquid and nonmotile cells. After the washing, the
sample is stained with a special fluorescent material that attaches to the DNA contained in the sperm. The stained sperm cells are analyzed
one by one by a flow cytometer, in which cells pass through a laser to make the stain attach to the DNA fluoresce. The sperm containing
the&#160;X chromosome (which have more DNA and therefore more stain) will shine brighter than the sperm containing the Y chromosome.
The flow cytometer uses a special software to identify&#160;X&#160;and Y chromosome sperm based on their fluorescence signature. The
sperm carrying the chromosome that will produce the desired gender are separated from the rest of the sample -resulting in an enriched
sperm sample ready for use.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf held an exclusive
license granted by a division of GIVF, MicroSort International, to use the MicroSort technology in Thailand and Cambodia. MicroSort&#8217;s
licenses for NewGenIvf&#8217;s operation in Thailand and Cambodia were each provided under a lease and service agreement. In April 2019,
First Fertility PGS entered into a Lease and Services Agreement with MicroSort International to use MicroSort equipment in Thailand and
in March 2019, Phnom Penh Center entered into a Lease and Services Agreement with MicroSort International to use MicroSort equipment
in Cambodia (together, the &#8220;Lease and Services Agreements&#8221;). Pursuant to the Lease and Services Agreements, First Fertility
PGS and Phnom Penh Center each had the exclusive right to utilize the MicroSort equipment and to market and sell MicroSort sperm sorting
services in Thailand and Cambodia, respectively. MicroSort International was responsible for the maintenance of MicroSort equipment and
technical and engineering support. The term of each Lease and Service Agreements was initially from 2019 to 2024, which shall be automatically
renewed for one year unless a written notice of at least 180 days prior to the intended termination date is provided. The consideration
under each of the Lease and Services Agreements was US$9,000 per month after six months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 28, 2025, NewGenIvf
completed its acquisition of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&#8220;GIVF&#8221;). Pursuant to a Purchase
Agreement dated January 21, 2025 between NewGenIvf and GIVF (&#8220;Purchase Agreement&#8221;), NewGenIvf purchased all of the Assets
(as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort technology from
GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Ordinary Shares (&#8220;MicroSort Acquisition&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the closing of the
MicroSort Acquisition, NewGenIvf held an exclusive license granted by a division of GIVF, MicroSort International, to use the MicroSort
technology in Thailand and Cambodia. MicroSort&#8217;s licenses for NewGenIvf&#8217;s operation in Thailand and Cambodia were each provided
under a lease and service agreement. In April 2019, First Fertility PGS entered into a Lease and Services Agreement with MicroSort International
to use MicroSort equipment in Thailand and in March 2019, Phnom Penh Center entered into a Lease and Services Agreement with MicroSort
International to use MicroSort equipment in Cambodia (together, the &#8220;Lease and Services Agreements&#8221;). Pursuant to the Lease
and Services Agreements, First Fertility PGS and Phnom Penh Center each had the exclusive right to utilize the MicroSort equipment and
to market and sell MicroSort sperm sorting services in Thailand and Cambodia, respectively. MicroSort International was responsible for
the maintenance of MicroSort equipment and technical and engineering support. The term of each Lease and Service Agreements was initially
from 2019 to 2024, which shall be automatically renewed for one year unless a written notice of at&#160;least 180 days prior to the intended
termination date is provided. The consideration under each of the Lease and Services Agreements was US$9,000 per month after six months
from the effective date of the agreements. MicroSort International was entitled to a down payment of US$15,000 per agreement and the aggregated
amounts received by it under the agreements was US$328,500.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The flow chart below shows
the process involved in MicroSort:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preimplantation Genetic Screening</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PGS is used in parallel with
an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in a developing
embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher chance of
implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate
of 70.9% and reducing miscarriage rates by 26.6%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next-Generation Sequencing</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NGS is a high-throughput
technology for determining the sequence of deoxyribonucleic acid DNA or RNA to study genetic variation associated with diseases or other
biological phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing
determines the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with NGS reduces time
and cost associated with sequencing and increases the coverage quality and data output.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Preimplantation Genetic Diagnosis</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to PGS, PGD is also
used in parallel with an IVF treatment cycle. But PGD is a more enhanced process than PGS since it scans for individual genes. PGD is
the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic fibrosis, where carrier
status has been documented in each of the parents. By using this technique, physicians are able to check the genes or chromosomes for
a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help women achieve a healthy pregnancy.
Individuals who suspect or know they carry genes for serious medical conditions may opt to screen for healthy embryos ahead of time.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Surrogacy and Ancillary Caring Services</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also generated
revenue from surrogacy services and related ancillary caring services in Kyrgyzstan. NewGenIvf conducts implantation of embryos from
biological parents in surrogate mothers. During the pregnancy period, NewGenIvf provides ancillary caring services including regular
body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy and ancillary caring services
is recognized when the surrogate mother gives birth. Surrogacy services provide infertile couples with an alternative method of having
children. In general, NewGenIvf provides certain discount to clients if they wish to pursue additional services such as egg donation
and surrogacy, after several cycles of IVF treatments failures due to medical reasons including, but not limited to, the poor egg quality
of aged female clients.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As compared to other countries,
Kyrgyzstan has the following features that allow NewGenIvf to operates its surrogacy services: (i)&#160;surrogacy is legal and regulated,
which means that there are less restrictions on either intended parents or surrogate mothers, and a parent-child relationship can be
requested before the child&#8217;s birth; and (ii)&#160;the costs of operation and surrogate mother is favourable, given the cost of
living in Kyrgyzstan is relatively low.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the regular
surrogacy services, NewGenIvf is also able to assist the clients with birth certificate applications and facilitate the application of
infants&#8217; passports and visas as supplemental services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For the&#160;years ended
December&#160;31, 2024 and 2023, the revenue from NewGenIvf&#8217;s surrogacy and ancillary caring services was US$ Nil and US$1,114,457,
respectively, representing Nil % and 21.7% of its total revenue in the corresponding periods. During 2024, we did not generate any revenue
from surrogacy as we went through a series of reorganization in Kyrgyzstan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The flow chart below shows
the stages involved in a typical surrogacy process:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Kyrgyzstan, NewGenIvf
also provides ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&#160;maternity
caring service, and (ii)&#160;documentation service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Network of Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 20243,
NewGenIvf had one administrative support office located in Hong&#160;Kong and three clinics located in Thailand, in Cambodia, and
in Kyrgyzstan, respectively. The integration of the medical facilities in Thailand help NewGenIvf provide a more seamless one-stop experience
to its clients. Set out below is an illustration of the locations of NewGenIvf&#8217;s clinics and marketing and sales office:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth the approximate aggregate average gross floor area (&#8220;<b>G.F.A.</b>&#8221;) of each of NewGenIvf&#8217;s clinics that were
under lease and actively used for client service as of December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of <br/> December&#160;31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">(Square Feet)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic"><span style="-keep: true">Thailand</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Fertility PGS Center Co., Ltd. &#8211; PS Tower<br/> (&#8220;<b>First Fertility PGS Center</b>&#8221;)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">14,750</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Fertility PGS Center Co., Ltd &#8211; Erawan Hotel <b><br/> (&#8220;First Fertility PGS Center&#8221; </b>&#8211; Not Yet Open<b>)</b></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,615</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Cambodia</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Fertility Phnom Penh Center <br/> (&#8220;<b>Phnom Penh Center</b>&#8221;)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">18,567</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Kyrgyzstan</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Bi Clinic Limited Liability Company <br/> (&#8220;Bi Clinic&#8221;)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,164</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Aggregate G.F.A</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">38,096</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To increase the scale of
NewGenIvf&#8217;s operations, NewGenIvf expanded its Thailand fertility services by leasing a new property for its second clinic Erawan
Consultation Clinic in May&#160;2023. Consisting of approximately 2,500 sq. ft., Erawan Consultation Clinic is expected to open in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, IVF treatments
are performed in its Thailand and Cambodia clinics, egg donation services are provided in its Cambodia clinic, and surrogacy services
are provided in its Kyrgyzstan clinic. The following table summarises the services available at NewGenIvf&#8217;s clinics:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>IVF <br/>
    Treatments</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Surrogacy <br/>
    Services</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td><span style="font-size: 10pt"><b><i>Thailand</i></b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="width: 68%; padding-left: 9pt"><span style="font-size: 10pt">First Fertility PGS Center</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">&#8730;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">&#215;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td><span style="font-size: 10pt"><b><i>Cambodia</i></b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Phnom Penh Center</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8730;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#215;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td><span style="font-size: 10pt"><b><i>Kyrgyzstan</i></b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">First Fertility Bishkek (Disposed of on December 18, 2024)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8730;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8730;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt"><span style="-keep: true">BiClinic (Acquired on December 17, 2024)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8730;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8730;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#8730;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Yes</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#215;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth a breakdown of revenue from services performed at NewGenIvf&#8217;s medical centers for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the Year ended December&#160;31,</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK
    SAR</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,038</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.7</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,175,253</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.0</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,356,903</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.4</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cambodia</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">601,526</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">621,619</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kyrgyzstan</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,656,596</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48.9</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,123,593</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60.8</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    Revenue</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5,433,375</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5,136,153</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Thailand Clinic</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
NewGenIvf had one clinic in Thailand. At the clinic in Thailand, NewGenIvf offers its clients customized fertility treatment solutions
including IVF/ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening by PGT, hysteroscopy, sperm
analysis, sorting, washing and freezing, and egg freezing. Its medical and operational personnel are organized into specialized teams
according to the different stages of the IVF treatment process and different patient profiles. When clients are admitted, they are assigned
to a team which NewGenIvf believes is better suited the clients after taking into account the clients&#8217; diagnosis and preferences.
Furthermore, NewGenIvf also provides related value-added services such as nutrition guidance, psychological counselling, acupuncture,
and translation interpreters to supplement the IVF treatment. NewGenIvf prides itself on providing quality and customized treatment to
its clients on a&#160;day-to-day basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
the clinic in Thailand had six 8 nurses, 8 full time lab physicians and embryologists, 14 administrative staff, totaling 30 staff members.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cambodia Clinic</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has one clinic,
Phnom Penh Center, in Cambodia. Phnom Penh Center is staffed with one Cambodian physician, three embryologists, five nurses and twelve
other staff, and offers similar IVF treatments as in Thailand and egg donation services. Phnom Penh Center operates under a license issued
by Cambodia MOH for the Cambodian physician, who has entered into an agreement with Phnom Penh Center for the exclusive use of such license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">After eight&#160;years
of development since its opening in 2015, Phnom Penh Center has become one of the long-standing ARS providers in Cambodia. According
to CIC, it was the first to use conventional IVF technology which led to a successful birth in 2016 in Cambodia. Since its establishment,
Phnom Penh Center achieved more than 1,600 IVF treatment cycles as of December 31, 2024. As of December 31, 2024, Phnom Penh Center&#8217;s
IVF philosophy concentrates on three key points in the treatment process: the mother&#8217;s wellbeing, the technology used to assist
mothers deliver a strong and healthy baby and the medical science used to ensure every chance of success for women in various age spectrums.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Clinic in Kyrgyzstan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf established
First Fertility Bishkek in October&#160;2019 in Kyrgyzstan for its surrogacy services, as Kyrgyzstan has supply of surrogate candidates
at a relatively low cost and a more friendly legal environment for surrogacy services. In 2020, First Fertility Bishkek obtained the
license to provide ARS and surrogacy services, becoming one of the few facilities licensed to offer ARS and one of the facilities licensed
to offer surrogacy services in Kyrgyzstan as of December&#160;31, 2024, according to CIC.&#160;In addition, NewGenIvf also provide related
ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&#160;maternity caring
service, and (ii)&#160;documentation service.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Physicians at First Fertility
Bishkek have expertise in sourcing surrogate mothers, techniques of embryo transfers, prenatal care, baby delivery, and postnatal care.
First Fertility Bishkek also collaborates closely with Phnom Penh Center in arranging shipment of frozen embryos. NewGenIvf hires local
physicians and local staff. NewGenIvf also provides training for newly admitted Kyrgyzstan physicians and embryologists in Thailand.
Some personnel who had relevant experience in Kyrgyzstan had also been sent from Cambodia to Kyrgyzstan to help manage such operations
from time to time. However, during 2024, Kyrgyzstan operations had been reorganized, resulting in disposal of First Fertility Bishkek
and acquisition of Bi Clinic Limited Liability Corporation in December 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
Bi Clinic had 1 full-time physician, 1 embryologist, 1 nurse, and 6 other staff.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Professionals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Licensed Physicians</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
NewGenIvf contracted with five licensed physicians, among which one was based in Cambodia, one was based in Kyrgyzstan, and the other
three were based in Thailand. Most of NewGenIvf&#8217;s physicians had over 10&#160;years of experience or above. The following table
summarises the number and types of such licensed physicians as of December 31, 2024.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 20%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licensed
    physician</b></span></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licenses
    and<br/>
    Approvals</b></span></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effective
    Period</b></span></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuing<br/>
    Authority</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cambodia</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.&#160;Keut Serey</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decision on permission for beauty treatment operation</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&#160;14, 2022&#160;&#8211;
    December&#160;14, 2026</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Ministry of Health of Cambodia</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Keatthisak Boonsimma</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 31801 Medical Practitioner License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April&#160;1, 2005&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royal Thai College of Obstetricians and Gynaecologists
    of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 22624/2554<br/>
    OB-Gyn License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&#160;1, 2014&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">Number 40962/2563 Reproductive Medicine Diploma</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">July&#160;1, 2020&#160;&#8211;
                                   Indefinite</span></p></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">Medical Council of Thailand</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Anurach Kulvanitchaiyanunt</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Practice License No. 11755</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 1 2025&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Wiphawee Luangtangvarodom</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 38347/2562<br/>
    OB-Gyn License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 1, 2019&#160;&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 43217/2564 Reproductive Medicine License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&#160;1, 2021&#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number 48510 Medical Practitioner License</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April&#160;1, 2014 &#8211;
    Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kyrgyzstan</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr Myrzalymbekova A.B.</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp; numero; CO170001836 Medical Certificate
    </span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 23. 2017 - Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;0002953 Medical Practitioner</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25 April 2018 - Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;11373\2565 Medical Certificate</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16 August 2024 - Indefinite
    </span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number &amp;numero;0003447 Medical Certificate</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12 April 2023 - Indefinite</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Council of Kyrgyzstan</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Customers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For the&#160;years ended
December&#160;31, 2024 and 2023, the majority of NewGenIvf&#8217;s clients were from China (including mainland China and Hong Kong).
The number of Thai and Cambodian local patients generally increased in 2023 and 2024 compared with earlier years due to the impact
of COVID-19 on international travel. NewGenIvf enters into a service agreement with each of its customers that outline, among other things,
the scope of services, service fees, payment terms and rights, responsibilities and obligations of each party. Consent is obtained from
the patients prior to the provision of the various treatments. Customers are not entitled to enjoy the relevant services until outstanding
amounts have been settled pursuant to the relevant contract. Sales to individual consumers did not vary significantly and none of the
customers contribute more than 10% of NewGenIvf&#8217;s revenue for the&#160;years ended December&#160;31, 2024 and 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In addition to significant
customers using NewGenIvf&#8217;s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf also has customers who
utilize the access to the freezing and storage facility and other relatively insignificant services, such as check-ups services, blood
test services and other minor services (the latter category of customers are referred to as &#8220;consultation customers&#8221;).</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to significant
customers using NewGenIvf&#8217;s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf also has customers who
only use its relatively insignificant services, such as check-ups services, blood test services and other minor services (the latter
category of customers are referred to as &#8220;consultation customers&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales and Marketing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For the&#160;years ended
December&#160;31, 2024 and 2023, NewGenIvf promoted brand awareness through its sales teams and, in many cases, through cooperating
with third-party agencies and partners.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s sales teams have broad experience in fertility services
and are responsible for identifying potential clients and managing the overall sales process. NewGenIvf&#8217;s sales team primarily relies
on social media marketing, word-of-mouth referrals, recognition of its brand, printed advertisements and marketing events. NewGenIvf spends
marketing expenses on placing advertisements through popular social media platforms, maintaining the official website of NewGenIvf and
sending information through its official accounts on social media platforms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Supply and Procurement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">NewGenIvf&#8217;s procurement
is mainly for medications, laboratory media and reagents, laboratory consumables, and blood test reagents. As of December&#160;31, 2023,
there was one supplier that individually contributed more than 10% of the Group&#8217;s trade payable, accounting for 30.6% of the Group&#8217;s
trade payables. For both the years ended December&#160;31, 2024 and 2023, no vendor contributed more than 10% of total direct cost of
the Group. NewGenIvf&#8217;s procurement team is experienced in selecting cost-effective supplies as well as selecting reliable suppliers.
NewGenIvf&#8217;s major suppliers are pharmaceutical companies.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that it
is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the value and comprehensiveness of the solutions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">treatment that is effective and achieves desired outcomes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clients&#8217; experience, including dedicated patient education, clinical
    guidance and emotional support; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">access to a network of high-quality fertility specialists.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf competes primarily
with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably robust and
integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf&#8217;s competitors may compete in a variety
of ways, including by providing better services, having established local connections, fulfilling evolving client needs, as well as conducting
brand promotions and other marketing activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As NewGenIvf may introduce
new ancillary services and other companies may introduce similar fertility services as NewGenIvf&#8217;s, NewGenIvf may become subject
to additional competition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of December 31, 2024,
in addition to its clinics, NewGenIvf leased one property in Hong&#160;Kong with an aggregate square footage of approximately 8,000 for
its administration support offices. NewGenIvf also operates its medical facilities as described above in &#8220;&#8212;&#160;Network
of Facilities&#8221; above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SELLING
SECURITYHOLDER</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">This prospectus relates
to the possible resale from time to time by the Selling Securityholders of up to 123,275,000 Class A Ordinary Shares, which includes
(i) 125,000 Class A Ordinary Shares issued to Genetics and IVF Institute pursuant to the MicroSort Purchase Agreement; (ii) 150,000 Class
A Ordinary Shares issued to ASPAC pursuant to the Consulting Services Agreement; (iii) 120,000,000 Class A Ordinary Shares issuable upon
the conversion of (a) the Remaining Additional Notes (as defined below), (b) the senior convertible notes exchanged on August 8, 2024
(&#8220;Exchange Notes&#8221;), (c) the exercise of Series A warrants to purchase Class A Ordinary Shares (the &#8220;Series A Warrants&#8221;),
(d) the exercise of Series B warrants to purchase Class A Ordinary Shares (the &#8220;Series B Warrants&#8221;), (e) the exercise of
Series C warrants to purchase Class A Ordinary Shares (the &#8220;Exchange Warrants&#8221; and together with the Series A Warrants and
the Series B Warrants, the &#8220;Warrants&#8221;), and (f) the New CB Initial; and (iv) 3,000,000 Class A Ordinary Shares issuable by
the Company to White Lion Capital, LLC (&#8220;White Lion&#8221;) in connection with the Common Stock Purchase Agreement dated as of
November 21, 2024, by and between the Company and White Lion (the &#8220;White Lion Purchase Agreement&#8221;). We are registering the
Resale Shares to satisfy certain registration rights that we have granted to the Selling Securityholders.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Securityholders may from time to time
offer and sell any or all of the securities set forth below pursuant to this prospectus. When we refer to the &#8220;Selling Securityholders&#8221;
in this prospectus, we mean the persons listed in the tables below, and the pledgees, donees, transferees, assignees, successors and others
who later come to hold any of the Selling Securityholders&#8217; interest in our securities after the date of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The table below presents
information regarding the Selling Securityholders and the Resale Shares that they may offer from time to time under this prospectus.
This table is prepared based on information known to us as of April 29, 2025. The number of shares in the column &#8220;Maximum Number
of Ordinary Shares to be Sold Pursuant to this Prospectus&#8221; represents all of the Class A Ordinary Shares that the Selling Securityholder
may offer under this prospectus. The Selling Securityholder may sell some, all or none of its shares in this offering. We do not know
how long the Selling Securityholder will hold the shares before selling them, and we currently have no agreements, arrangements or understandings
with the Selling Securityholder regarding the sale of any of the shares.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Beneficial ownership is
determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes Class A Ordinary Shares with
respect to which a Selling Securityholder has voting and investment power. The percentage of Class A Ordinary Shares beneficially owned
by the Selling Securityholder prior to the offering shown in the table below is based on an aggregate of 7,302,819 Ordinary Shares outstanding
as of April 29, 2025. The fourth column assumes the sale of all of the shares offered by the Selling Securityholder pursuant to this
prospectus.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may require the
Selling Securityholder to suspend the sales of the Resale Shares offered by this prospectus upon the occurrence of any event that makes
any statement in this prospectus or the Registration Statement untrue in any material respect or that requires the changing of statements
in these documents in order to make statements in those documents not misleading.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="-keep: true">Under the terms of the Remaining Additional
Notes and the Warrants, Selling Securityholder may not convert the Remaining Additional Notes or exercise the Warrants to the extent
(but only to the extent) such Selling Remaining Additional or any of its affiliates would beneficially own a number of shares of our
ordinary shares which would exceed 9.99% of the outstanding shares of the Company (the &#8220;Maximum Percentage&#8221;). The number
of shares in the second column reflects these limitations. The Selling Securityholder may sell all, some or none of their shares in this
offering. See &#8220;Plan of Distribution.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Name of Selling Securityholders</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Ordinary <br/> Shares <br/> Beneficially
    <br/> Owned<br/> Prior to <br/> Offering<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"/><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Percentage&#160;of
    <br/> Ordinary Shares Beneficially Owned <br/> Prior to<br/> Offering<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Maximum <br/> Number of <br/> Ordinary<br/>
    Shares <br/> to be <br/> Sold<br/> Pursuant to<br/> this<br/> Prospectus</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Ordinary
    <br/> Shares Beneficially Owned<br/> Immediately<br/> After Sale of <br/> Maximum<br/> Number&#160;of Shares <br/> in this<br/> Offering<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Percentage&#160;of<br/>
    Ordinary Shares Beneficially Owned Immediately<br/> After <br/> Sale of<br/> Maximum<br/> Number&#160;of Shares<br/> in this<br/> Offering<sup>(1)(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">JAK Opportunities
    VI LLC <sup>(3)</sup></span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">833,306</span></td><td style="width: 1%; text-align: left"><sup style="-keep: true">(7)</sup>&#160;</td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">9.99</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">120,000,000</span></td><td style="width: 1%; text-align: left"><sup style="-keep: true">(8)</sup>&#160;</td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;0</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">White Lion Capital LLC <sup>(4)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,000,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Genetics &amp; IVF Institute,
    Inc. <sup>(5)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">125,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">A SPAC (Holdings) Limited <sup>(6)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">150,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="-keep: true">The applicable percentage of beneficial ownership is calculated based on the
    total number of ordinary shares issued and outstanding, being 7,508,094 shares as of the date of this prospectus.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="-keep: true">(2)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="-keep: true">Represents the amount of ordinary shares that will be held by the Selling Securityholder
    after completion of this offering based on the assumptions that (a) all ordinary shares, including all ordinary shares underlying
    the Notes and Warrants, registered for sale by the registration statement of which this prospectus is part of will be sold, and (b)
    no other shares of ordinary shares are acquired or sold by the Selling Securityholder prior to completion of this offering.&#160;&#160;However,
    the Selling Securityholder is not obligated to sell all or any portion of the ordinary shares offered pursuant to this prospectus.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Selling Securityholder, JAK Opportunities VI LLC (&#8220;JAK VI&#8221;), is wholly-owned by ATW Opportunities Master Fund II, L.P. (the &#8220;Fund&#8221;). ATW Partners Opportunities Management, LLC serves as the investment manager to the Fund (the &#8220;Adviser&#8221;). The Fund and the Adviser may be deemed to have shared voting and dispositive power with respect to the shares of common stock beneficially owned by the Selling Securityholder and may be deemed to be the beneficial owner of these shares. Antonio Ruiz-Gimenez and Kerry Propper serve as the managing members of the Adviser (the &#8220;Managing Members&#8221;). The Managing Members, in their capacity as Managing Members of the Adviser, may also be deemed to have investment discretion and voting power over the shares of common stock beneficially owned by the Selling Securityholder. The Fund, the Adviser and the Managing Members each disclaim any beneficial ownership of such holdings. The address of this Selling Securityholder is c/o ATW Partners Opportunities Management, LLC, 1 Pennsylvania Plaza, Suite 4810, New York, NY 10119.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">(4)</td>
    <td style="text-align: justify">The business address of White Lion is 17631 Ventura Blvd, Suite 1008, Encino, CA 91316</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(5)</td>
    <td>The business address of Genetics &amp; IVF Institute, Inc. is 3015 Williams Drive, Fairfax VA 22031, USA </td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(6) </td>
    <td style="text-align: justify">The business address of A SPAC (Holdings) Limited is Ritter House, Wickhams Cay, II, PO Box 3170, Road Town, Tortola VG1110, British Virgin Islands.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">(7)</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">This column lists the number of our ordinary
    shares beneficially owned by this Selling Securityholder as of April 30, 2025 after giving effect to the Maximum Percentage (as defined
    in the paragraph above). Without regard to the Maximum Percentage, as of April 30, 2025, this Selling Shareholder would beneficially
    own an aggregate of 132,201,241 of our Ordinary Shares (of which 120,000,000 shares are being registered for resale under this prospectus),
    consisting of (i) 26,823,440 shares underlying the <span style="background-color: white">Fourth Tranche Note</span> held by this
    Selling Securityholder, convertible at an alternate conversion price of $0.2388, (ii) 105,377801 shares underlying the <span style="background-color: white">Additional
    Remaining Notes</span> to be acquired by this Selling Securityholder, convertible at an alternate conversion price of $0.2388, (iii)
    11,328,695 shares underlying the Series A Warrants held by this Selling Securityholder, currently exercisable at an exercise price
    of $[_], (iv) 74,257 shares underlying the Series B Warrants held by this Selling Securityholder, the exercise price of the Series
    B Warrants was prepaid, except for a nominal exercise price of $0.001 per share, and (v) 3,266,091 shares underlying the Exchange
    Warrants held by this Selling Shareholder.&#160;</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="-keep: true">(8)</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In accordance with the terms of the Registration
    Rights Agreement (as defined below) with this Selling Securityholder, for purposes of the calculations of ordinary shares to be sold
    by this Selling Securityholder pursuant to the prospectus we are assuming (i) an event of default under the <span style="background-color: white">Fourth
    Tranche Note and the Additional Remaining Notes</span> has not occurred and the issuance of 250% of the ordinary shares underlying
    the <span style="background-color: white">Fourth Tranche Note</span>, assuming that (x) all Additional Notes issuable under the Securities
    Purchase Agreement (as defined below) have been issued and (y) the Notes, including payment of 14.75% interest on the Notes through
    the fifty-four (54) month anniversary of the issuance date of such Notes, are converted in full at an alternate conversion price
    of $0.2388 per share, without regard to any limitations set forth therein and (ii) the issuance of the maximum amount of ordinary
    shares underlying the Warrants, exercised in full at the applicable exercise price without regard to any limitations set forth therein.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;&#160;</span></p><div>



</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PLAN OF DISTRIBUTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are registering the Class
A Ordinary Shares previously issued and the Class A Ordinary Shares issuable upon conversion of the Notes and exercise of the Warrants,
to permit the resale of these Class A Ordinary Shares by the holders of these securities from time to time after the date of this prospectus.
We will not receive any of the proceeds from the sale by the Selling Securityholders of the Class A Ordinary Shares, although we will
receive (i) the exercise price of any Warrants not exercised by the Selling Securityholders on a cashless exercise basis, and (ii) gross
proceeds of up to $500 million from the sale of our Class A Ordinary Shares to White Lion pursuant to the White Lion Purchase Agreement.
We will bear all fees and expenses incident to our obligation to register the Selling Securityholder&#8217;s Class A Ordinary Shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Selling Securityholders
may sell all or a portion of the Class A Ordinary Shares held by them and offered hereby from time to time directly or through one or
more underwriters, broker-dealers or agents. If the Class A Ordinary Shares are sold through underwriters or broker-dealers, the Selling
Securityholders will be responsible for underwriting discounts or commissions or agent&#8217;s commissions. The Class A Ordinary Shares
may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined
at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions,
pursuant to one or more of the following methods:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">on any national securities exchange
or quotation service on which the securities may be listed or quoted at the time of sale;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">in the over-the-counter market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">in transactions other than on
these exchanges or systems or in the over-the-counter market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">ordinary brokerage transactions
and transactions in which the broker-dealer solicits purchasers;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">through the writing or settlement
of options, whether such options are listed on an options exchange or otherwise;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">block trades in which the broker-dealer
will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">purchases by a broker-dealer
as principal and resale by the broker-dealer for its account;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">an exchange distribution in
accordance with the rules of the applicable exchange;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">privately negotiated transactions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">short sales made after the date
this registration statement is declared effective by the SEC;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">broker-dealers may agree with
the selling securityholders to sell a specified number of such shares at a stipulated price per share;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">a combination of any such methods
of sale; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">any other method permitted pursuant
to applicable law.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Selling Securityholders
may also sell Class A Ordinary Shares under Rule 144 promulgated under the Securities Act, if available, rather than under this prospectus.
In addition, the Selling Securityholders may transfer the Class A Ordinary Shares by other means not described in this prospectus. If
the Selling Securityholders effect such transactions by selling Class A Ordinary Shares to or through underwriters, broker-dealers or
agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from
the Selling Securityholders or commissions from purchasers of the Class A Ordinary Shares for whom they may act as an agent or to whom
they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be
in excess of those customary in the types of transactions involved). In connection with sales of the Class A Ordinary Shares or otherwise,
the Selling Securityholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the Class
A Ordinary Shares in the course of hedging in positions they assume. The Selling Securityholders may also sell Class A Ordinary Shares
short and deliver Class A Ordinary Shares covered by this prospectus to close out short positions and to return borrowed shares in connection
with such short sales. The Selling Securityholders may also loan or pledge Class A Ordinary Shares to broker-dealers that in turn may
sell such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Selling Securityholders
may pledge or grant a security interest in some or all of the Class A Ordinary Shares owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell the Ordinary Shares from time to time pursuant to this
prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if
necessary, the list of Selling Securityholders to include the pledgee, transferee or other successors in interest as Selling Securityholders
under this prospectus. The Selling Securityholders also may transfer and donate the Class A Ordinary Shares in other circumstances in
which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus. To the extent required by the Securities Act and the rules and regulations thereunder, the Selling Securityholders and any
broker-dealer participating in the distribution of the shares may be deemed to be &#8220;underwriters&#8221; within the meaning of the
Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting
commissions or discounts under the Securities Act. At the time a particular offering of the shares is made, a prospectus supplement, if
required, will be distributed which will set forth the aggregate amount of Class A Ordinary Shares being offered and the terms of the
offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation
from the Selling Securityholders and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Under the securities laws of
some states, the Class A Ordinary Shares may be sold in such states only through registered or licensed brokers or dealers. In addition,
in some states, the Class A Ordinary Shares may not be sold unless such shares have been registered or qualified for sale in such state
or an exemption from registration or qualification is available and is complied with.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">There can be no assurance that
any Selling Securityholders will sell any or all of the Class A Ordinary Shares registered pursuant to the registration statement, of
which this prospectus forms a part.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Selling Securityholders
and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act, and the rules and
regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the
timing of purchases and sales of any of the shares by the Selling Securityholders and any other participating person. To the extent applicable,
Regulation M may also restrict the ability of any person engaged in the distribution of the Class A Ordinary Shares to engage in market-making
activities with respect to the shares. All of the foregoing may affect the marketability of the Class A Ordinary Shares and the ability
of any person or entity to engage in market-making activities with respect to the Class A Ordinary Shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We will pay all expenses of
the registration of the Class A Ordinary Shares, estimated to be $1,867.30 in total, including, without limitation, SEC filing fees and
expenses of compliance with state securities or &#8220;blue sky&#8221; laws; provided, however, that a Selling Securityholders will pay
all underwriting discounts and selling commissions if any. We will indemnify the Selling Securityholders against liabilities, including
some liabilities under the Securities Act in accordance with the Registration Rights Agreement, or the Selling Securityholders will be
entitled to contribution. We may be indemnified by the Selling Securityholders against civil liabilities, including liabilities under
the Securities Act, that may arise from any written information furnished to us by the Selling Securityholders specifically for use in
this prospectus, in accordance with the related registration rights agreements or we may be entitled to contribution.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Once sold under the registration
statement, of which this prospectus forms a part, the Class A Ordinary Shares will be freely tradable in the hands of persons other than
our affiliates.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>DESCRIPTION
OF SHARE CAPITAL</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Class A and Class B Ordinary Shares </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><span style="-keep: true">The Memorandum and Articles
of Association authorize the issuance of a maximum of 400,000,000 Class A Ordinary Shares, 99,950,000 Class B Ordinary Shares and 50,000
preferred shares with no par value (&#8220;Preferred Shares&#8221;). As of the date of this prospectus, we have 7,508,094 Class A Ordinary
Shares outstanding, 205,275 Class B Ordinary Shares outstanding, and no Preferred Shares outstanding. All of our outstanding Class A
Ordinary Shares are validly issued, and fully paid. Our Class A Ordinary Shares and Class B Ordinary Shares are not subject to any preemptive
right.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">Hei Yue Tina
Fong and Wing Fung Alfred Siu control the voting power of all of the outstanding Class&#160;B Ordinary Shares. Although Ms. Fong and Mr.
Siu control the voting power of all of the outstanding Class&#160;B Ordinary Shares, their control over those shares is not permanent
and is subject to reduction or elimination at any time or after certain periods as a result of a variety of factors. As further described
below, upon any transfer of Class&#160;B Ordinary Shares by a holder thereof to any person which is not a Permitted Transferee of such
holder, those shares will automatically and immediately convert into Class&#160;A Ordinary Shares. In addition, all Class&#160;B Ordinary
Shares will automatically convert to Class&#160;A Ordinary Shares in other events described below. See &#8220;&#8212; Optional and Mandatory
Conversion.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends<i>.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of our Class A
Ordinary Shares and Class B Ordinary Shares are entitled to such dividends as may be declared by its Board of Directors subject to its
Memorandum and Articles of Association and applicable law. No dividend may be declared and paid unless the Board of Directors determine
that, immediately after the payment, the value of the Company assets will exceed its liabilities and the Company will be able to pay its
debts as and when they fall due. Holders of Class A ordinary shares and Class B ordinary shares will be entitled to the same amount of
dividends, if declared.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Voting Rights</b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">Holders
of Class A Ordinary Shares and Class B Ordinary Shares have the right to receive notice of, attend, speak and vote at general meetings
of the shareholders. In respect of all matters upon which holders of our shares are entitled to vote, each Class&#160;A Ordinary Share
are entitled to one (1)&#160;vote and each Class&#160;B Ordinary Share are entitled to one hundred (100)&#160;votes. At any meeting of
shareholders a resolution put to the vote of the meeting shall be decided by way of a poll and not by way of a show of hands.</span><span style="background-color: white">
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A meeting of the shareholders
is duly constituted if, at the commencement of the meeting, there are present in person or by proxy not less than 50 per cent of the votes
of the shares entitled to vote on resolutions of the shareholders to be considered at the meeting. As a BVI business company, the Company
is not obliged by the BVI Act to call shareholders&#8217; annual general meetings. The Memorandum and Articles of Association provide
that the Company may (but is not obliged to) in each calendar year hold a general meeting as its annual general meeting in which case
the Company will specify the meeting as such in the notices calling it, and the annual general meeting will be held at such time and place
as may be determined by its directors. Each general meeting, other than an annual general meeting, shall be an extraordinary general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders&#8217; annual
general meetings and any other general meetings of the Company&#8217;s shareholders may be convened by any director or, upon a requisition
of shareholders holding at the date of deposit of the requisition not less than 30 percent of the votes attaching to the issued and outstanding
shares entitled to vote at general meetings in respect of the matter for which the meeting is requested, in which case the directors are
obliged to convene such meeting and to put the resolutions so requisitioned to a vote at such meeting; however, the Memorandum and Articles
of Association do not provide its shareholders with any right to put any proposals before any annual general meetings or any extraordinary
general meetings not called by such shareholders. Advance notice of at least ten (10) days and not more than sixty (60) days is required
for the convening of the Company&#8217;s annual general meeting and other general meetings unless such notice is waived in accordance
with its articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any resolution to be passed
at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the shares cast by those
shareholders entitled to vote who are present in person or by proxy at a general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Conversion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to any applicable
adjustment pursuant to the Memorandum and Articles of Association, each Class B Ordinary Share is convertible into one (1) Class A Ordinary
Share at any time at the option of the holder thereof. The right to convert shall be exercisable by the holder of the Class B Ordinary
Share delivering a written notice to the Company that such holder elects to convert a specified number of Class B Ordinary Shares into
Class A Ordinary Shares. In no event shall Class A Ordinary Shares be convertible into Class B Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidation.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted by the BVI Act
and the Memorandum and Articles of Association, the Company may be voluntarily liquidated under Part XII of the BVI Act by resolution
of directors and resolution of shareholders if the Company&#8217;s assets exceed the Company&#8217;s liabilities and the Company is able
to pay the Company&#8217;s debts as they fall due. The Company may also be wound up in circumstances where the Company is insolvent in
accordance with the terms of the BVI Insolvency Act (As Revised).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company is wound up
and the assets available for distribution among the Company&#8217;s shareholders are more than sufficient to repay all amounts paid to
the Company on account of the issue of shares immediately prior to the winding up, the excess shall be distributable pari passu among
those shareholders in proportion to the amount paid up immediately prior to the winding up on the shares held by them, respectively. If
the Company is wound up and the assets available for distribution among the shareholders as such are insufficient to repay the whole of
the amounts paid to the Company on account of the issue of shares, those assets shall be distributed so that, to the greatest extent possible,
the losses shall be borne by the shareholders in proportion to the amounts paid up immediately prior to the winding up on the shares held
by them, respectively. If the Company is wound up, the liquidator appointed by the Company may, in accordance with the BVI Act, divide
among the Company&#8217;s shareholders in specie or kind the whole or any part of the Company&#8217;s assets (whether they shall consist
of property of the same kind or not) and may, for such purpose, set such value as the liquidator deems fair upon any property to be divided
and may determine how such division shall be carried out as between the shareholders or different classes of shareholder</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Redemption, Repurchase and Surrender
of Ordinary Shares.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may issue shares
on terms that such shares are subject to redemption, at the Company&#8217;s option or at the option of the holders thereof, on such terms
and in such manner as may be determined, before the issue of such shares, by the Board of Directors. The Company may also repurchase
any of its shares provided that the Company may not purchase, redeem or otherwise acquire its own shares without the consent of the shareholder
whose Shares are to be purchased, redeemed or otherwise acquired unless the Company is permitted or required by the Act or any other
provision in the Memorandum or Articles to purchase, redeem or otherwise acquire the Shares without such consent.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Variations of Rights of Shares.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the Company&#8217;s
share are divided into different classes or series of shares, the rights attached to any class or series of shares (unless otherwise
provided by the terms of issue of the shares of that class or series), whether or not the Company is being wound-up, may be varied by
a resolution passed at a meeting by the holders of more than fifty percent of the issued shares of that class that have voted (and are
entitled to vote thereon) in relation to any such resolution, unless otherwise provided by the terms of issue of such class. The rights
conferred upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of
the shares of that class, be deemed to be varied by the creation or issue of further shares ranking pari passu with such existing class
of shares.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Inspection of Books and Records. </b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our Class A Ordinary
Shares and Class B Ordinary Shares have no general right under BVI law to inspect or obtain copies of the Company&#8217;s list of shareholders
or its corporate records. However, the Company will provide its shareholders with annual audited financial statements. See &#8220;Where
You Can Find Additional Information.&#8221;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Issuance of Additional Shares.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The
Memorandum and Articles of Association authorize the Board of Directors to issue additional Class A or Class B Ordinary Shares from time
to time as the Board of Directors shall determine, to the extent of available authorized but unissued shares. The Memorandum and Articles
of Association also authorize the Board of Directors to establish from time to time one or more series of preferred shares and to determine,
with respect to any series of preferred shares, the terms and rights of that series, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the designation of the series;</td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"/><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">the
                                            number of shares of the series;</td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"/><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">the
                                            dividend rights, dividend rates, conversion rights, voting rights; and</td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"/><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">the
                                            rights and terms of redemption and liquidation preferences.</td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors may
issue preferred shares without action by its shareholders to the extent authorized but unissued. Issuance of these shares may dilute
the voting power of holders of Class A Ordinary Shares and Class B Ordinary Shares.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-Takeover Provisions</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some provisions of the Memorandum
and Articles of Association may discourage, delay or prevent a change of control of the Company or management that shareholders may consider
favorable, including (i) provisions that authorize the Board of Directors to issue preferred shares in one or more series and to designate
the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by its shareholders;
and (ii) provisions providing that directors may not be removed by the shareholders except for cause.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Preferred Shares</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable law
and the Memorandum and Articles of Association, the Board of Directors may issue Preferred Shares with such preferred rights as they
shall determine. The rights, privileges, restrictions and conditions attaching to the Preferred Shares shall be stated in the Memorandum
and Articles of Association, which shall be amended accordingly prior to the issue of such Preferred Shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>TAXATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>The
following is a general summary of the material U.S. federal income tax consequences relevant to an investment in our Ordinary Shares.
The discussion is not intended to be, nor should it be construed as, legal or tax advice to any particular prospective purchaser. The
discussion is based on laws and relevant interpretations thereof as of the date of this annual report, all of which are subject to change
or different interpretations, possibly with retroactive effect. The discussion does not address U.S. state or local tax laws. You should
consult your own tax advisors with respect to the consequences of acquisition, ownership and disposition of our Ordinary Shares.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">This
discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed),
administrative rulings of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing
interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of
all potential U.S.&#160;federal income tax considerations that may apply to a securityholder of the Company as a result of the ownership
and disposition of the Company Securities. In addition, this discussion does not address all aspects of U.S.&#160;federal income taxation
that may be relevant to particular holders nor does it take into account the individual facts and circumstances of any particular holder
that may affect the U.S.&#160;federal income tax consequences to such holder, and accordingly, is not intended to be, and should not
be construed as, tax advice. This discussion does not address the U.S.&#160;federal 3.8% Medicare tax imposed on certain net investment
income or any aspects of U.S.&#160;federal taxation other than those pertaining to the income tax, nor does it address any tax consequences
arising under any U.S.&#160;state and local, or non-U.S.&#160;tax laws, or, except as discussed here, any tax reporting obligations of
a holder of the Company Securities. Holders should consult their own tax advisors regarding such tax consequences in light of their particular
circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">No
ruling has been requested or will be obtained from the IRS regarding the U.S.&#160;federal income tax consequences discussed below; thus,
there can be no assurance that the IRS will not challenge the U.S.&#160;federal income tax treatment described below or that, if challenged,
such treatment will be sustained by a court.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">This
summary is limited to considerations relevant to U.S.&#160;Holders that hold the Company Securities as &#8220;capital assets&#8221; within
the meaning of section 1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S.&#160;federal
income taxation that may be important to holders in light of their individual circumstances, including holders subject to special treatment
under the U.S.&#160;tax laws, such as, for example:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">banks or other financial institutions, underwriters, or insurance companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">traders in securities who elect to apply a mark-to-market method of
    accounting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">real estate investment trusts and regulated investment companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">tax-exempt organizations, qualified retirement plans, individual retirement
    accounts, or other tax- deferred accounts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expatriates or former citizens or long-term residents of the United&#160;States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">subchapter S corporations, partnerships or other pass-through entities
    or investors in such entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any holder that is not a U.S.&#160;Holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">dealers or traders in securities, commodities or currencies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">grantor trusts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons subject to the alternative minimum tax;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">U.S.&#160;persons whose &#8220;functional currency&#8221; is not the
    U.S.&#160;dollar;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who receive stock of the Company through the issuance of restricted
    share under an incentive plan or through a tax-qualified retirement plan or otherwise as compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">U.S.&#160;shareholders of controlled foreign corporations, as those
    terms are defined in Sections 951(b)&#160;and 957(a), respectively;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who own (directly or through attribution) 5% or more (by vote
    or value) of the outstanding Class A Ordinary Shares (excluding treasury shares);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">holders holding ASCA securities, or, after the Business Combination,
    the Company Securities, as a position in a &#8220;straddle,&#8221; as part of a &#8220;synthetic security&#8221; or &#8220;hedge,&#8221;
    as part of a &#8220;conversion transaction,&#8221; or other integrated investment or risk reduction transaction.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
used in this prospectus, the term &#8220;U.S.&#160;Holder&#8221; means a beneficial owner of the Company Securities, that is, for U.S.&#160;federal
income tax purposes:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an individual who is a citizen or resident of the United&#160;States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a corporation (or other entity that is classified as a corporation
    for U.S.&#160;federal income tax purposes) that is created or organized in or under the laws of the United&#160;States or any State
    thereof or the District of Columbia;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an estate the income of which is subject to U.S.&#160;federal income
    tax regardless of its source; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a trust (i)&#160;if a court within the United&#160;States is able to
    exercise primary supervision over the administration of the trust and one or more U.S.&#160;persons have the authority to control
    all substantial decisions of the trust, or (ii)&#160;that has a valid election in effect under applicable Treasury Regulations to
    be treated as a U.S.&#160;person for U.S.&#160;federal income tax purposes.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S.&#160;federal income tax
purposes, holds the Company Securities, the U.S.&#160;federal income tax treatment of a partner in such partnership will generally depend
on the status of the partner and the activities of the partnership. A holder that is a partnership and the partners in such partnership
should consult their own tax advisors with regard to the U.S.&#160;federal income tax consequences of ownership and disposition of the
Company Securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">THIS
SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S.&#160;FEDERAL INCOME TAX CONSEQUENCES OF
OWNERSHIP AND DISPOSITION OF THE COMPANY SECURITIES.&#160;IN ADDITION, THE U.S.&#160;FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS
OF THE COMPANY SECURITIES MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT AND
INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S.&#160;FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE.&#160;HOLDERS
OF THE COMPANY SECURITIES SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE OWNERSHIP AND
DISPOSITION OF THE COMPANY SECURITIES, INCLUDING THE APPLICABILITY AND EFFECTS OF U.S.&#160;FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Distribution on the Class A Ordinary
Shares</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Subject
to the PFIC rules discussed below &#8220;&#8212;&#160;Passive Foreign Investment Company Status,&#8221; the gross amount of any distribution
on the Class A Ordinary Shares that is made out of the Company&#8217;s current and accumulated earnings and profits (as determined for
U.S.&#160;federal income tax purposes) will generally be taxable to a U.S.&#160;Holder as ordinary dividend income on the date such distribution
is actually or constructively received by such U.S.&#160;Holder. Any such dividends paid to corporate U.S.&#160;Holders generally will
not qualify for the dividends-received deduction that may otherwise be allowed under the Code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends
received by non-corporate U.S.&#160;Holders, including individuals, from a &#8220;qualified foreign corporation&#8221; may be eligible
for reduced rates of taxation, provided that certain holding period requirements and other conditions are satisfied. For these purposes,
a non-U.S.&#160;corporation will be treated as a qualified foreign corporation with respect to dividends paid by that corporation on
shares that are readily tradable on an established securities market in the United&#160;States. U.S.&#160;Treasury Department guidance
indicates that shares listed on Nasdaq will be considered readily tradable on an established securities market in the United&#160;States.
Even if the Class A Ordinary Shares are listed on Nasdaq, there can be no assurance that the Class A Ordinary Shares will be considered
readily tradable on an established securities market in future&#160;years. Non-corporate U.S.&#160;Holders that do not meet a minimum
holding period requirement or that elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Section&#160;163(d)(4)
of the Code (dealing with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation regardless
of the Company&#8217;s status as a qualified foreign corporation. In addition, the rate reduction will not apply to dividends if the
recipient of a dividend is obligated to make related payments with respect to positions in substantially similar or related property.
This disallowance applies even if the minimum holding period has been met. Finally, the Company will not constitute a qualified foreign
corporation for purposes of these rules if it is a PFIC for the taxable year in which it pays a dividend or for the preceding taxable
year. See the discussion below under &#8220;&#8212;&#160;Passive Foreign Investment Company Status.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
amount of any dividend paid in foreign currency will be the U.S.&#160;dollar value of the foreign currency distributed by the Company,
calculated by reference to the exchange rate in effect on the date the dividend is includible in the U.S.&#160;Holder&#8217;s income,
regardless of whether the payment is in fact converted into U.S.&#160;dollars on the date of receipt. Generally, a U.S.&#160;Holder should
not recognize any foreign currency gain or loss if the foreign currency is converted into U.S.&#160;dollars on the date the payment is
received. However, any gain or loss resulting from currency exchange fluctuations during the period from the date the U.S.&#160;Holder
includes the dividend payment in income to the date such U.S.&#160;Holder actually converts the payment into U.S.&#160;dollars will be
treated as ordinary income or loss. That currency exchange income or loss (if any) generally will be income or loss from U.S.&#160;sources
for foreign tax credit limitation purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">To
the extent that the amount of any distribution made by the Company on the Class A Ordinary Shares exceeds the Company&#8217;s current
and accumulated earnings and profits for a taxable year (as determined under U.S.&#160;federal income tax principles), the distribution
will first be treated as a tax-free return of capital, causing a reduction in the adjusted basis of the U.S.&#160;Holder&#8217;s the
Class A Ordinary Shares, and to the extent the amount of the distribution exceeds the U.S.&#160;Holder&#8217;s tax basis, the excess
will be taxed as capital gain recognized on a sale or exchange as described below under &#8220;&#8212;&#160;Sale, Exchange, Redemption
or Other Taxable Disposition of the Company Securities.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Sale, Exchange, Redemption or Other
Taxable Disposition of the Company Securities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Subject
to the discussion below under &#8220;&#8212;&#160;Passive Foreign Investment Company Status,&#8221; a U.S.&#160;Holder will generally
recognize gain or loss on any sale, exchange, redemption, or other taxable disposition of the Class A Ordinary Shares and the Warrants
in an amount equal to the difference between the amount realized on the disposition and such U.S.&#160;Holder&#8217;s adjusted tax basis
in such the Class A Ordinary Shares or Warrants. Any gain or loss recognized by a U.S.&#160;Holder on a taxable disposition of the Class
A Ordinary Shares or Warrants will generally be capital gain or loss and will be long-term capital gain or loss if the holder&#8217;s
holding period in the Class A Ordinary Shares or Warrants exceeds one year at the time of the disposition. Preferential tax rates may
apply to long-term capital gains of non-corporate U.S.&#160;Holders (including individuals). The deductibility of capital losses is subject
to limitations. Any gain or loss recognized by a U.S.&#160;Holder on the sale or exchange of the Class A Ordinary Shares or the Warrants
will generally be treated as U.S.&#160;source gain or loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Exercise or
Lapse of a Warrant</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Except
as discussed below with respect to the cashless exercise of a Warrant, a U.S.&#160;Holder generally will not recognize gain or loss upon
the acquisition of an ordinary share of the Company on the exercise of a Warrant for cash. A U.S.&#160;Holder&#8217;s tax basis in an
ordinary share received upon exercise of the Warrant generally will be an amount equal to the sum of the U.S.&#160;Holder&#8217;s tax
basis in the Warrant exchanged therefor and the exercise price. The U.S.&#160;Holder&#8217;s holding period for an ordinary share received
upon exercise of the Warrant will begin on the date following the date of exercise (or possibly the date of exercise) of the Warrants
and will not include the period during which the U.S.&#160;Holder held the Warrants. If a Warrant is allowed to lapse unexercised, a
U.S.&#160;Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the Warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
tax consequences of a cashless exercise of a warrant are not clear under current tax law. A cashless exercise may be tax-free, either
because the exercise is not a gain realization event or because the exercise is treated as a recapitalization for U.S.&#160;federal income
tax purposes. In either tax-free situation, a U.S.&#160;Holder&#8217;s basis in the Class A Ordinary Shares received would equal the
holder&#8217;s basis in the Warrant. If the cashless exercise were treated as not being a gain recognition event, a U.S.&#160;Holder&#8217;s
holding period in the Class A Ordinary Shares would be treated as commencing on the date following the date of exercise (or possibly
the date of exercise) of the Warrant. If the cashless exercise were treated as a recapitalization, the holding period of the Class A
Ordinary Share would include the holding period of the Warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">It
is also possible that a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In
such event, a U.S.&#160;Holder would recognize gain or loss with respect to the portion of the exercised Warrants treated as surrendered
to pay the exercise price of the Warrants (the &#8220;surrendered warrants&#8221;). The U.S.&#160;Holder would recognize capital gain
or loss with respect to the surrendered warrants in an amount generally equal to the difference between (i)&#160;the fair market value
of the Class A Ordinary Shares that would have been received with respect to the surrendered warrants in a regular exercise of the Warrants
and (ii)&#160;the sum of the U.S.&#160;Holder&#8217;s tax basis in the surrendered warrants and the aggregate cash exercise price of
such warrants (if they had been exercised in a regular exercise). In this case, a U.S.&#160;Holder&#8217;s tax basis in the Class A Ordinary
Shares received would equal the U.S.&#160;Holder&#8217;s tax basis in the Warrants exercised plus (or minus) the gain (or loss) recognized
with respect to the surrendered warrants. A U.S.&#160;Holder&#8217;s holding period for the Class A Ordinary Shares would commence on
the date following the date of exercise (or possibly the date of exercise) of the Warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Due
to the absence of authority on the U.S.&#160;federal income tax treatment of a cashless exercise, there can be no assurance which, if
any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly,
U.S.&#160;Holders should consult their tax advisors regarding the tax consequences of a cashless exercise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Passive Foreign
Investment Company Status</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Certain
adverse U.S.&#160;federal income tax consequences could apply to a U.S.&#160;Holder if the Company or any of its subsidiaries is treated
as a PFIC for any taxable year during which the U.S.&#160;Holder holds the Company Securities. A non-U.S.&#160;corporation will be classified
as a PFIC for any taxable year (a)&#160;if at least 75% of its gross income in a taxable year, including its pro rata share of the gross
income of any entity in which it is considered to own at least 25% of the interest by value, is passive income, or (b)&#160;if at least
50% of its assets in a taxable year of the foreign corporation, ordinarily determined based on fair market value and averaged quarterly
over the year, including its pro rata share of the assets of any entity in which it is considered to own at least 25% of the interest
by value, are held for the production of, or produce, passive income. Passive income generally includes dividends, interest, rents and
royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive
assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
the Company is not a PFIC in the 2024 taxable year, such U.S.&#160;Holder would likely recognize gain (but not loss if the Reincorporation
Merger qualifies as a &#8220;reorganization&#8221;) upon the exchange of ASCA securities for The Company securities pursuant to the Reincorporation
Merger. The gain (or loss) would be computed as described above under &#8220;&#8212;&#160;If the Reincorporation Merger Does Not Qualify
as a Reorganization.&#8221; Any such gain recognized by such U.S.&#160;Holder on the exchange of ASCA securities for The Company securities
would be allocated ratably over the U.S.&#160;Holder&#8217;s holding period for the ASCA securities. Such amounts allocated for the current
taxable year and any taxable year prior to the first taxable year in which ASCA was a PFIC would be treated as ordinary income, and not
as capital gain, in the U.S.&#160;Holder&#8217;s taxable year, and such amounts allocated to each other taxable year beginning with the
year that ASCA became a PFIC would be taxed at the highest tax rate in effect for each year to which the gain was allocated, together
with a special interest charge on the tax attributable to each such year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Whether
the Company is a PFIC for any taxable year is a factual determination that depends on, among other things, the composition of the Company&#8217;s
income and assets, the market value of its assets, and potentially the composition of the income and assets of one or more of the Company&#8217;s
subsidiaries and the market value of their assets in that year. Whether a Company subsidiary is a PFIC for any taxable year is likewise
a factual determination that depends on, among other things, the composition of the subsidiary&#8217;s income and assets and the market
value of such assets in that year. One or more changes in these factors may cause the Company and/or one or more of its subsidiaries
to become a PFIC for a taxable year even though it has not been a PFIC for one or more prior taxable years. Whether the Company or a
subsidiary is treated as a PFIC for U.S.&#160;federal income tax purposes is a factual determination that must be made annually at the
close of each taxable year and, thus, is subject to significant uncertainty. Moreover, there can be no assurance that the Company will
timely provide a PFIC annual information statement for 2024 or going forward. The failure to provide such information on an annual basis
could preclude U.S.&#160;Holders from making or maintaining a &#8220;qualified electing fund&#8221; election under Section&#160;1295
of the Code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
the Company were determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S.&#160;Holder
of Class A Ordinary Shares, the U.S.&#160;Holder did not make a valid &#8220;mark-to-market&#8221; election, such U.S.&#160;Holder generally
will be subject to special rules&#160;with respect to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any gain recognized by the U.S.&#160;Holder on the sale or other disposition
    of the Company Securities (including a redemption treated as a sale or exchange); and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any &#8220;excess distribution&#8221; made to the U.S.&#160;Holder
    (generally, any distributions to such U.S.&#160;Holder during a taxable year of the U.S.&#160;Holder that are greater than 125% of
    the average annual distributions received by such U.S.&#160;Holder in respect of the Class A Ordinary Shares during the three preceding
    taxable&#160;years of such U.S.&#160;Holder or, if shorter, such U.S.&#160;Holder&#8217;s holding period for such ordinary shares).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Under
these rules:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the U.S.&#160;Holder&#8217;s gain or excess distribution will be allocated
    ratably over the U.S.&#160;Holder&#8217;s Company Securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amount allocated to the U.S.&#160;Holder&#8217;s taxable year in
    which the U.S.&#160;holder recognized gain or received the excess distribution, or to the period in the U.S.&#160;Holder&#8217;s
    holding period before the first&#160;day of the Company&#8217;s first taxable year in the Company is a PFIC, will be taxed as ordinary
    income;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amount allocated to other taxable&#160;years (or portions thereof)
    of the U.S.&#160;Holder and included in its holding period will be taxed at the highest tax rate in effect for that year and applicable
    to the&#160;U.S.&#160;Holder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the interest charge generally applicable to underpayments of tax will
    be imposed in respect of the tax attributable to each such other taxable year of the U.S.&#160;Holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Although
a determination as to the Company&#8217;s PFIC status will be made annually, an initial determination that the Company is a PFIC will
generally apply for subsequent&#160;years to a U.S.&#160;Holder who held Company Securities while the Company was a PFIC, whether or
not the Company meets the test for PFIC status in those subsequent&#160;years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
a U.S.&#160;Holder, at the close of its taxable year, owns shares in a PFIC that are treated as marketable stock, the U.S.&#160;Holder
may make a mark-to-market election with respect to such shares for such taxable year. If the U.S.&#160;Holder makes a valid mark-to-market
election for the first taxable year of the U.S.&#160;Holder in which the U.S.&#160;Holder holds (or is deemed to hold) the Class A Ordinary
Shares and for which the Company is determined to be a PFIC, such holder generally will not be subject to the PFIC rules&#160;described
above in respect to the Class A Ordinary Shares as long as such shares continue to be treated as marketable stock. Instead, in general,
the U.S.&#160;Holder will include as ordinary income each year that the Company is treated as a PFIC the excess, if any, of the fair
market value of its Class A Ordinary Shares at the end of its taxable year over the adjusted basis in its Class A Ordinary Shares. The
U.S.&#160;Holder also will be allowed to take an ordinary loss in respect of the excess, if any, of the adjusted basis of its Class A
Ordinary Shares over the fair market value of its Class A Ordinary Shares at the end of its taxable year (but only to the extent of the
net amount of previously recognized income as a result of the mark-to-market election). The U.S.&#160;Holder&#8217;s adjusted tax basis
in its Class A Ordinary Shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale
or other taxable disposition of the Class A Ordinary Shares in a taxable year in which the Company is treated as a PFIC will be treated
as ordinary income. Special tax rules may also apply if a U.S.&#160;Holder makes a mark-to-market election for a taxable year after the
first taxable year in which the U.S.&#160;Holder holds (or is deemed to hold) its Class A Ordinary Shares and for which the Company is
treated as a PFIC.&#160;Currently, a mark-to-market election may not be made with respect to the Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
mark-to-market election is available only for stock that is regularly traded on a national securities exchange that is registered with
the SEC, including Nasdaq (on which the Company Securities are traded), or on a foreign exchange or market that the IRS determines has
rules&#160;sufficient to ensure that the market price represents a legitimate and sound fair market value. Such stock generally will
be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at
least 15&#160;days during each calendar quarter, but no assurances can be given in this regard with respect to the Class A Ordinary Shares.
U.S.&#160;Holders should consult their own tax advisors regarding the availability and tax consequences of a mark-to-market election
in respect of the Class A Ordinary Shares under their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
the Company is a PFIC and, at any time, has a foreign subsidiary that is classified as a PFIC, U.S.&#160;Holders generally would be deemed
to own a portion of the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge
described above if the Company were to receive a distribution from, or dispose of all or part of the Company&#8217;s interest in, the
lower-tier PFIC (even though such U.S.&#160;Holder would not receive the proceeds of those distributions or dispositions) or the U.S.&#160;Holders
otherwise were deemed to have disposed of an interest in the lower-tier PFIC.&#160;A mark-to-market election generally would not be available
with respect to such lower-tier PFIC.&#160;U.S.&#160;Holders are urged to consult their own tax advisors regarding the tax issues raised
by lower-tier PFICs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">A
U.S.&#160;Holder that owns (or is deemed to own) shares in a PFIC during any taxable year of the U.S.&#160;Holder, may have to file an
IRS Form&#160;8621 (whether or not a mark-to-market election is or has been made) with such U.S.&#160;Holder&#8217;s U.S.&#160;federal
income tax return and provide any such other information as may be required by the U.S.&#160;Treasury Department. Failure to do so, if
required, will extend the statute of limitations until such required information is furnished to the IRS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
rules&#160;dealing with PFICs and mark-to-market elections are very complex and are affected by various factors in addition to those
described above. Accordingly, U.S.&#160;Holders of Company Securities should consult their own tax advisors concerning the application
of the PFIC rules&#160;to the Company Securities under the U.S. Holders&#8217; particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Information Reporting and Backup
Withholding</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
general, information reporting requirements may apply to dividends received by U.S.&#160;Holders of the Class A Ordinary Shares (including
constructive dividends), and the proceeds received on sale or other taxable disposition of the Class A Ordinary Shares or Warrants effected
within the United&#160;States (and, in certain cases, outside the United&#160;States), in each case, other than U.S.&#160;Holders that
are exempt recipients (such as corporations). Backup withholding (currently at a rate of 24%) may apply to such amounts if the U.S.&#160;Holder
fails to provide an accurate taxpayer identification number (generally on an IRS Form&#160;W-9 provided to the paying agent or the U.S.&#160;Holder&#8217;s
broker) or is otherwise subject to backup withholding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Certain
U.S.&#160;Holders holding specified foreign financial assets with an aggregate value in excess of the applicable dollar threshold are
required to report information to the IRS relating to the Company Securities, subject to certain exceptions (including an exception for
the Company Securities held in accounts maintained by U.S.&#160;financial institutions), by attaching a complete IRS Form&#160;8938,
Statement of Specified Foreign Financial Assets, with their tax return, for each year in which they hold the Company Securities. In addition
to these requirements, U.S.&#160;Holders may be required to annually file FinCEN Report 114 (Report of Foreign Bank and Financial Accounts)
with the U.S.&#160;Department of Treasury. U.S.&#160;Holders should consult their own tax advisors regarding information reporting requirements
relating to their ownership of the Company Securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against
a holder&#8217;s U.S.&#160;federal income tax liability, if any, provided the required information is timely furnished to the IRS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>This summary
does not contain a detailed description of all the United States federal income tax consequences that may be applicable to you in light
of your particular circumstances and, except as set forth below with respect to PRC tax considerations, does not address the effects
of any state, local or non-United States tax laws. If you are considering the purchase, ownership or disposition of our Ordinary Shares,
you should consult your own tax advisors concerning the United States federal income tax consequences to you in light of your particular
situation as well as any consequences arising under the laws of any other taxing jurisdiction.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>LEGAL
MATTERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Certain legal matters
as to U.S. federal securities law concerning this offering will be passed upon for us by Han Kun Law Offices LLP. Certain legal matters
as to BVI law will be passed upon for us by Ogier. Han Kun Law Offices LLP may rely upon Ogier with respect to matters governed by BVI
law.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>EXPERTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The financial statements
of NewGenIvf Limited as of December 31, 2024 and 2023 included in this prospectus have been so included in reliance on the report of
J &amp; S Associate (&#8220;J &amp; S&#8221;), an independent registered public accounting firm, given on the authority of said firm
as an expert in auditing and accounting. For the years ended December 31, 2022 included in this prospectus have been so included in reliance
on the report of WWC, P.C., an independent registered public accounting firm, given on the authority of said firm as an expert in auditing
and accounting.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>EXPENSES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are the estimated
expenses of the issuance and distribution of the securities being registered under the Registration Statement of which this prospectus
forms a part, all of which will be paid by us. With the exception of the SEC registration fee, all amounts are estimates and may change:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-keep: true">SEC registration fee</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">6,021</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Printer fees and expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">1,500</span></td><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Legal fees and expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">30,000</span></td><td style="text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Miscellaneous</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">42,521</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">This
                                            is an estimate.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>ENFORCEABILITY
OF CIVIL LIABILITIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
are incorporated under the laws of the British Virgin Islands with limited liability. We are incorporated in the British Virgin Islands
because of certain benefits associated with being a British Virgin Islands company, such as political and economic stability, an effective
judicial system, a favorable tax system, the absence of exchange control or currency restrictions and the availability of professional
and support services. However, the British Virgin Islands has a less developed body of securities laws as compared to the United States
and provides protections for investors to a lesser extent. In addition, British Virgin Islands companies may not have standing to sue
before the federal courts of the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Substantially
all of our assets are located outside the United States. In addition, a majority of our directors and officers are nationals and/or residents
of countries other than the United States, and all or a substantial portion of such persons&#8217; assets are located outside the United
States. As a result, it may be difficult for investors to effect service of process within the United States upon us or such persons
or to enforce against them or against us, judgments obtained in United States courts, including judgments predicated upon the civil liability
provisions of the securities laws of the United States or any state thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
have appointed Cogency Global Inc., as our agent to receive service of process with respect to any action brought against us in the United
States District Court for districts in the State of New York under the federal securities laws of the United States or of any State of
the United States or any action brought against us in the Supreme Court of the State of New York under the securities laws of the State
of New York.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">The British
Virgin Islands courts are unlikely:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify; padding-right: 1pt">to recognize
                                            or enforce against the Company, judgments of courts of the U.S. based on certain civil liability
                                            provisions of U.S. securities laws where that liability is in respect of penalties, taxes,
                                            fines or similar fiscal or revenue obligations of the company; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">to impose
                                            liabilities against the Company, in original actions brought in the British Virgin Islands,
                                            based on certain civil liability provisions of U.S. securities laws that are penal in nature.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">There
is no statutory enforcement in the British Virgin Islands of judgments obtained in the U.S., however, the courts of the British Virgin
Islands will in certain circumstances recognize such a foreign judgment and treat it as a cause of action in itself which may be sued
upon as a debt at common law so that no retrial of the issues would be necessary, provided that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the U.S. court issuing the judgment had jurisdiction in the matter
    and the company either submitted to such jurisdiction or was resident or carrying on business within such jurisdiction and was duly
    served with process;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the judgment is final and for a liquidated sum;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the judgment given by the U.S. court was not in respect of penalties,
    taxes, fines or similar fiscal or revenue obligations of the company;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">in obtaining judgment there was no fraud on the part of the person
    in whose favor judgment was given or on the part of the court;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recognition or enforcement of the judgment in the British Virgin Islands
    would not be contrary to public policy; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the proceedings pursuant to which judgment was obtained were not contrary
    to natural justice.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-size: 10pt">In
appropriate circumstances, a British Virgin Islands Court may give effect in the British Virgin Islands to other kinds of final foreign
judgments such as declaratory orders, orders for performance of contracts and injunctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form F-1 under the Securities Act relating to this registration of the Ordinary Shares to be sold by the
Selling Securityholders. This prospectus, which is part of the Registration Statement, does not contain all of the information contained
in the Registration Statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is
included in the Registration Statement. Statements made in this prospectus concerning the contents of any contract, agreement or other
document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of
these documents. If we filed any of these documents as an exhibit to the Registration Statement, you may read the document itself for
a complete description of its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the periodic
reporting and other information requirements of the Exchange Act as applicable to a &#8220;Foreign Private Issuer,&#8221; and we will
file annual reports and other information from time to time with the SEC in accordance with such requirements. Our filings with the SEC
are also available to the public through the SEC&#8217;s website at <i>www.sec.gov</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements,
and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained
in Section&#160;16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial
statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at www.newgenivf.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus.
We have included our website address in this prospectus solely as an inactive textual reference. We will post on our website any materials
required to be so posted on such website under applicable corporate or securities laws and regulations, including, posting any XBRL interactive
financial data required to be filed with the SEC and any notices of general meetings of our shareholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">123,275,000 Ordinary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b><img alt="" src="image_001.jpg"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>NewGenIvf
Group Limited</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>PROSPECTUS</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 114 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>PART II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>INFORMATION NOT
REQUIRED IN PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Item 6. Indemnification
of Directors, Officers and Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">British
Virgin Islands law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for
indemnification of officers and directors, except to the extent any such provision may be held by the British Virgin Islands courts
to be contrary to public policy, such as to provide indemnification against willful default, civil fraud or the consequences of
committing a crime. Under our Memorandum and Articles of Association, we may indemnify our directors, officers and liquidators
against all expenses, including legal fees, and against all judgments, fines and amounts paid in settlement and reasonably incurred
in connection with civil, criminal, administrative or investigative proceedings to which they are party or are threatened to be made
a party by reason of their acting as our director, officer or liquidator. To be entitled to indemnification, these persons must have
acted honestly and in good faith with a view to the best interest of the registrant and, in the case of criminal proceedings, they
must have had no reasonable cause to believe their conduct was unlawful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Insofar
as indemnification for liabilities arising under the&#160;Securities Act of 1933&#160;may be permitted to directors, officers or persons
controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the&#160;Securities Act&#160;and is therefore unenforceable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Item 7. Recent
Sales of Unregistered Securities</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Set
forth below are the sales of all securities by the Company since the closing of the Business Combination which were not registered under
the Securities Act. The Company believes that each of such issuances was exempt from registration under the Securities Act in reliance
on Section&#160;4(a)(2)&#160;of the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 3, 2024, the Company
issued to certain investors 295,000 Class A Ordinary Shares which were converted from the ordinary shares of Legacy NewGenIvf pursuant
to the terms of the Securities Purchase Agreement by and between A SPAC I Mini Acquisition Corp. and certain investors named therein (the
&#8220;February Buyers&#8221;) on February 29, 2024. Pursuant to this Securities Purchase Agreement, A SPAC I Mini Acquisition Corp agreed
to issue and sell to the February Buyers, in a private placement, an aggregate of up to $3,500,000 principal amount of convertible notes,
consisting of one or more tranches: (i) an initial tranche of an aggregate principal amount of promissory notes of up to $1,750,000 and
including an original issue discount of up to aggregate $122,500, and (ii) subsequent tranches of an aggregate principal amount of promissory
notes of up to $1,750,000 and including an original issue discount of up to aggregate $122,500. The closing of the Initial Tranche took
place on April 3, 2024. The Company also closed on a subsequent tranche of the aforementioned promissory notes in the principal amount
of $250,000 by issuing and selling to the February Buyers shortly after the closing of the Business Combination, resulting in an aggregate
principal amount of notes of $2,000,000 sold to the February Buyers. The form of these promissory notes is included as Exhibit 4.2 of
the Form 6-K filed on April 4, 2024. The aforementioned Securities Purchase Agreement is included as Exhibit 4.1 of the Form 6-K filed
on April 4, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><span style="text-decoration:underline">2024 Debt Financing</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 7, 2024, the Company
entered into a Securities Purchase Agreement (&#8220;Securities Purchase Agreement&#8221;) with certain investors named therein (collectively,
the &#8220;Buyers&#8221;), pursuant to which, amongst other things: (i) the Company agreed to sell, at an initial closing (and such initial
closing, the &#8220;Initial Closing&#8221;), (a) a senior convertible note (the &#8220;Initial Note&#8221;) in the aggregate original
principal amount not exceeding $1,100,000, convertible into Class A Ordinary Shares pursuant to its terms, (b) a warrant to purchase 1,325,301
Class A Ordinary Shares (such warrant, the &#8220;Series A Warrant&#8221;), and (c) a warrant to purchase 180,722 Class A Ordinary Shares
(the &#8220;Series B Warrant&#8221;); and (ii) the Company may require each Buyer (or each Buyer may require the Company, as applicable)
to participate in the sale of (a) one or more additional convertible notes (which aggregate original principal amount for all additional
convertible notes shall not exceed $9,500,000) (the &#8220;Additional Notes&#8221;) and (b) related Warrants.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Securities Purchase Agreement
is filed as Exhibit 4.1 of the Company&#8217;s current report on Form 6-K dated August 16, 2024 and is incorporated by reference herein.
The Initial Note is filed as Exhibit 10.25 of this registration statement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in connection
with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with certain holders of its convertible
promissory notes (the &#8220;Existing Notes&#8221; and each of such amendment and exchange agreements, an &#8220;Amendment and Exchange
Agreement&#8221;), pursuant to which the Company exchanged the Existing Notes by issuing, among other things, (i) senior convertible notes
in the aggregate principal amount of $2,700,000 (the &#8220;Exchange Notes&#8221;, and, together with the Initial Note and the Additional
Notes, the &#8220;Notes&#8221;) and (b) a series of warrants to initially acquire up to a certain number of Class A Ordinary Shares to
the holders of the Existing Notes set forth therein (the &#8220;Exchange Warrants&#8221; and the Series A Warrants and the Series B Warrants,
the &#8220;Warrants&#8221;). The Exchange Notes are in substantially similar form to the Initial Notes, which are discussed further below.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Exchange Warrants expire
nine years after the issuance date and are initially exercisable for an aggregate of 3,253,012 Class A Ordinary Shares, subject to adjustment
as provided therein. The Exchange Warrants may be exercised at any time after the exchange date, subject to the Maximum Percentage (as
defined in the Exchange Warrants). The initial exercise price of the Exchange Warrants is $0.913 per share, subject to adjustment as provided
therein. If at the time of exercise of the Exchange Warrants, there is no effective registration statement registering our Class A Ordinary
Shares underlying such warrants, such warrants may be exercised on a cashless basis pursuant to their terms. The form of the Amendment
and Exchange Agreement, the form of Exchange Notes, and the form of Exchange Warrants are filed as Exhibits 4.2, 4.3, and 4.4 to the Form
6-K dated August 16, 2024, and are incorporated herein by reference.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Initial Closing</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 12, 2024, the Company
and the Buyers consummated the Initial Closing. The Initial Note sold in connection with the Securities Purchase Agreement bears an interest
rate of 14.75% per annum and is convertible into the Company&#8217;s Class A Ordinary Shares as follows: the Conversion Amount (as defined
in the Initial Note) into validly issued, fully paid and non-assessable Class A Ordinary Shares at the Conversion Rate (as defined in
the Initial Note); subject to adjustment as provided therein. No fractional Class A Ordinary Shares are issuable upon any such conversion.
A holder may convert the Initial Notes at any time after the initial issuance date of such Initial Note, subject to the Maximum Percentage.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
form of the Initial Note is included as Exhibit A of the Securities Purchase Agreement filed as Exhibit 4.1 in the Form 6-K dated August
15, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Initial Closing, the
Company also sold to the Buyers Series A Warrants to purchase an aggregate 1,325,301 Class A Ordinary Shares and Series B Warrants to
purchase an aggregate 180,722 Class A Ordinary Shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>Series
A Warrants</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Series A Warrants expire nine years after the issuance date and are initially exercisable for an aggregate of 1,325,301 Class A Ordinary
Shares (the &#8220;Series A Warrant Shares&#8221;), subject to adjustment as provided therein. The initial exercise price of the Series
A Warrants is $0.913 per share, subject to adjustment as provided therein. If at the time of exercise of the Series A Warrants, there
is no effective registration statement registering the shares of our Ordinary Shares underlying such warrants, such warrants may be exercised
on a cashless basis pursuant to their terms.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>Series
B Warrants</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series B Warrants expire
nine years after the issuance date and are initially exercisable for an aggregate of 180,722 Ordinary Shares, subject to adjustment as
provided therein. The Series B Warrants may be exercised at any time on or after February 12, 2025 (the &#8220;Initial Exercise Eligibility
Date&#8221;), subject to the Maximum Percentage. The initial exercise price of the Series B Warrants was prepaid, except for a nominal
exercise price of $0.001 per share, subject to adjustment as provided therein.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
form of the Series A Warrant and form of the Series B Warrant are included as Exhibit B of the Securities Purchase Agreement included
as Exhibit 4.1 in the Form 6-K filed on August 16, 2024, which is incorporated herein by reference.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Second Tranche</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 28, 2024, the Company
closed on the second tranche of the 2024 Debt Financing pursuant to the terms of the Securities Purchase Agreement. Under the second tranche,
the Company sold the First Mandatory Additional Note in the aggregate principal amount of $500,000. The First Mandatory Additional Note
is in substantially similar form to the Initial Note. Upon issuance of the First Mandatory Additional Note, the number of Class A Ordinary
Shares issuable upon exercise of the Series A Warrant automatically increased to 2,236,446 (equivalent to 111,822 Class A Ordinary Shares
post Reverse Stock Split). The First Mandatory Additional Note is included as Exhibit 4.1 in the Form 6-K filed on August 30, 2024, which
is incorporated herein by reference.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Third Tranche</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 11, 2024,&#160;the
Company <span style="background-color: white">closed on the third tranche of the 2024 Debt Financing pursuant to the terms of the Securities
Purchase Agreement. Under the third tranche, the Company sold the Second Mandatory Additional Note in the aggregate principal amount of
$1,500,000. The Second Mandatory Additional Note is in substantially similar form to the Initial Note. </span>Upon issuance of the First
Mandatory Additional Note, the number of Class A Ordinary Shares issuable upon exercise of the Series A Warrant automatically increased
to 5,874,383 (equivalent to 293,719 Class A Ordinary Shares post Reverse Stock Split). <span style="background-color: white">The Second
Mandatory Additional Note is included as Exhibit 4.1 in the Form 6-K filed on November 15, 2024, which is incorporated herein by reference.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Fourth Tranche</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On April 2, 2024,&#160;the
Company <span style="background-color: white">closed on the fourth tranche of the 2024 Debt Financing pursuant to the terms of the Securities
Purchase Agreement. Under the fourth tranche, the Company sold a senior convertible note (the &#8220;Fourth Tranche Note&#8221;) in the
original principal amount of $2,000,000. The Fourth Tranche Note is in substantially similar form to the Initial Note. </span>Upon issuance
of the note, the number of Class A Ordinary Shares issuable upon exercise of the Series A Warrant automatically increased to 7,961,189
(on a post Reverse Stock Split basis). <span style="background-color: white">The Fourth Tranche Note is included as Exhibit 4.1 in the
Form 6-K filed on April 3, 2025, which is incorporated herein by reference.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Between November 7, 2024
and the date of this prospectus, the Company received gross proceeds of $6,450,000 and issued an aggregate of 4,761,660 Class A Ordinary
Shares (on a post-reverse stock split basis) to the Buyers.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">


</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Company may receive
up to approximately $33,891,289 in additional net proceeds from the 2024 Debt Financing if (i) $6,975,000 in net proceeds are received
if all remaining Additional Notes in the aggregate principal amount of $7,500,000 (together with the <span style="background-color: white">Fourth
Tranche Note,</span> the &#8220;Remaining Additional Notes&#8221;) issuable pursuant to the Securities Purchase Agreement are sold and
(ii) the Series A Warrants are increased by 10,157,580 assuming that (A) all Remaining Additional Notes are sold and (B) an Additional
Share Price is equal to $1.3513 and (iii) all of the Warrants are exercised in full, based on the following assumptions (x) approximately
$23,909,021 in net proceeds are received from the exercise of the Series A Warrants, assuming that the Series A Warrants are exercised
in full at an exercise price of $1.8258 and the number of Ordinary Shares issuable upon exercise of the Series A Warrants equals 13,095,093,
(y) approximately $1,485 in net proceeds are received from the exercise of the Series B Warrants, assuming that the Series B Warrants
are exercised in full at an exercise price of $0.020 per share, and (z) approximately $3,005,784 in net proceeds are received from the
exercise of the Exchange Warrants, assuming that the Exchange Warrants are exercised in full at an exercise price of $1.8258. The foregoing
is subject to adjustment as set forth in the respective Notes and Warrants, as applicable.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">White Lion Equity Line of Credit</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, the Company entered into
a Common Shares Purchase Agreement (the &#8220;White Lion Purchase Agreement&#8221;) with White Lion Capital, LLC (&#8220;White Lion&#8221;)
and a related Registration Rights Agreement (the &#8220;RRA&#8221;). Pursuant to the White Lion Purchase Agreement, the Company has the
right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars ($100,000,000)
in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to Three Hundred Million Dollars ($300,000,000)
upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase Agreement) and a further option to increase
to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000) has been issued and sold to
White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth in the White Lion Purchase
Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration statement filed on December 5,
2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On December 10, 2024,
700,000 Class A Ordinary Shares (equivalent to 35,000 Class A Ordinary Shares post Reverse Stock Split) were issued to White Lion, in
consideration for White Lion&#8217;s commitment pursuant to the White Lion Purchase Agreement. In addition, on December 12, 2024, the
Company issued 3,800,000 Class A Ordinary Shares (equivalent to 190,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase
price of $1,572,186. On December 24, 2024, the Company issued 500,000 Class A Ordinary Shares (equivalent to 25,000 Class A Ordinary
Shares post Reverse Stock Split) for a purchase price of $160,050. On December 31, 2024, the Company issued 600,000 Class A Ordinary
Shares (equivalent to 30,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $204,000. On January 2, 2025,
the Company issued 300,000 Class A Ordinary Shares (equivalent to 15,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase
price of $111,000. On January 3, 2025, the Company issued 600,000 Class A Ordinary Shares (equivalent to 30,000 Class A Ordinary Shares
post Reverse Stock Split) for a purchase price of $240,600. On January 6, 2025, the Company issued 300,000 Class A Ordinary Shares (equivalent
to 15,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $112,500. On January 7, 2025, the Company issued
300,000 Class A Ordinary Shares (equivalent to 15,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $111,000.
On January 8, 2025, the Company issued 400,000 Class A Ordinary Shares (equivalent to 20,000 Class A Ordinary Shares post Reverse Stock
Split) for a purchase price of $140,000. On January 13, 2025, the Company issued 300,000 Class A Ordinary Shares (equivalent to 15,000
Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $102,000. On January 14, 2025, the Company issued 1,800,000
Class A Ordinary Shares (equivalent to 90,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $526,689. Between
January 15, 2025 to January 17, 2025, the Company issued 1,200,000 Class A Ordinary Shares (equivalent to 60,000 Class A Ordinary Shares
post Reverse Stock Split) for a purchase price of $365,250. Between January 21, 2025 to January 23, 2025, the Company issued 4,000,000
Class A Ordinary Shares (equivalent to 200,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $1,181,898.
On February 3, 2025, the Company issued 2,000,000 Class A Ordinary Shares (equivalent to 100,000 Class A Ordinary Shares post Reverse
Stock Split) for a purchase price of $280,000. On February 7, 2025, the Company issued 4,000,000 Class A Ordinary Shares (equivalent
to 200,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $431,068. On February 10, 2025, the Company issued
7,000,000 Class A Ordinary Shares (equivalent to 350,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $802,821.
On February 20, 2025, the Company issued 125,000 Class A Ordinary Shares (on a post-Reverse Stock Split basis) for a purchase price of
$261,822. On February 28, 2025, the Company issued 100,000 Class A Ordinary Shares (on a post-Reverse Stock Split basis) for a purchase
price of $190,120. On March 3, 2025, the Company issued 25,000 Class A Ordinary Shares (on a post-Reverse Stock Split basis) for a purchase
price of $34,678. On April 3, 2025, the Company issued 325,000 Class A Ordinary Shares (on a post-Reverse Stock Split basis) for a purchase
price of $302,240. The Company received gross proceeds of $7,129,921 and issued an aggregate of 1,930,000 Class A Ordinary Shares (on
a post-Reverse Stock Split basis) to White Lion.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">MicroSort Acquisition</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On January 21, 2025, the
Company entered into a Purchase Agreement with Genetics &amp; IVF Institute, Inc. (&#8220;Purchase Agreement&#8221;), pursuant to which
the Company purchased all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement)
relating to the MicroSort Business (as defined in the Purchase Agreement) from Genetics &amp; IVF Institute, Inc. for a cash consideration
of $750,000 and a share consideration of 125,000 Class A Ordinary Shares (&#8220;Share Consideration&#8221;). The Purchase Agreement
is filed as Exhibit 10.30 in this registration statement. MicroSort Lab Services, LLC (&#8220;MicroSort&#8221;) was incorporated by Genetics&#160;&amp; IVF Institute, Inc. in January 2025 to hold all of the Assets (as defined in the Purchase Agreement) to be transferred to the Compay
at closing. The Company&#8217;s acquisition of MicroSort was completed on February 28, 2025, and the Share Consideration was issued to
GIVF on the same day.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">ASPAC Consulting Services Agreement</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 24, 2025, the
Company entered into a Consulting Services Agreement with A SPAC (Holdings) Group Corp (&#8220;ASPAC&#8221;), pursuant to which the Company
engaged ASPAC for the provision of certain consulting services. It was agreed that the Company would provide consideration in the form
of cash and shares. On March 3, 2025, the Company issued the 150,000 Class A Ordinary Shares to ASPAC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Financial Statement
Schedules:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">All
financial statement schedules have been omitted because either they are not required, are not applicable or the information required
therein is otherwise set forth in the Company&#8217;s financial statements and related notes thereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Item 8. Exhibits
and Financial Statement Schedules</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="white-space: nowrap; vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Exhibit No.&#160; </b></span></td>
    <td style="white-space: nowrap; vertical-align: top; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: justify"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023_aspac1miniacq.htm#T702">Amended
    and Restated Memorandum and Articles of Association of PubCo (incorporated by reference to Annex B of PubCo&#8217;s registration
    statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390025033966/ea023590401ex1-1_newgenivf.htm"><span style="-keep: true">Amended and Restated Memorandum and Articles of Association of the Company
                                    dated March 31, 2025 (incorporated by reference to Exhibit 1.1 of the Company&#8217;s annual report on Form 20-F filed with the SEC
on April 22, 2025)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex2-1_newgen.htm">Specimen
    Class A Ordinary Share Certificate of the Company (incorporated by reference to Exhibit 2.1 of the report on Form 20-F filed with
    the Securities and Exchange Commission on April 9, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex2-2_newgen.htm">Specimen
    Warrant Certificate of the Company (incorporated by reference to Exhibit 2.2 of the report on Form 20-F filed with the Securities
    and Exchange Commission on April 9, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000110465922025006/tm225054d14_ex4-2.htm">Warrant
    Agreement, dated February 14, 2022, by and between ASCA and Continental Stock Transfer &amp; Trust Company (incorporated by reference
    to Exhibit 4.2 to ASCA&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 18, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000121390023087023/ff42023a1ex4-7_aspac1.htm">Form
    of Assumption of Warrant Agreement (incorporated by reference to Exhibit 4.7 to the Company&#8217;s registration statement on Form
    F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">5.1*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="ea023980101ex5-1_newgen.htm"><span style="font-size: 10pt">Opinion of Ogier</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023012495/ea173753ex2-1_aspac1acq.htm">Merger
    Agreement, dated as of February 15, 2023, by and among ASCA, NewGenIvf Limited, certain shareholders of NewGenIvf Limited, A SPAC
    I Mini Acquisition Corp., and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&#8217;s Current
    Report on Form 8-K filed with the Securities and Exchange Commission on February 16, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023048612/ea180200ex2-1_aspac1acq.htm">First
    Amendment to the Merger Agreement, dated June 12, 2023, by and among ASCA, NewGenIvf Limited, Principal Shareholders, A SPAC I Mini
    Acquisition Corp. and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&#8217;s Current Report
    on Form 8-K filed with the Securities and Exchange Commission on June 13, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023093702/ea189487ex2-1_aspac1acq.htm">Second
    Amendment to the Merger Agreement, dated December 6, 2023, by and among ASCA, NewGenIvf Limited, Principal Shareholders, A SPAC I
    Mini Acquisition Corp. and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&#8217;s Current
    Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex2-1_aspac1.htm">Third
    Amendment to the Merger Agreement, dated March 1, 2024, by and among ASCA, NewGenIvf Limited, Principal Shareholders, A SPAC I Mini
    Acquisition Corp. and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&#8217;s Current Report
    on Form 8-K filed with the Securities and Exchange Commission on March 6, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.5</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000110465922025006/tm225054d14_ex10-5.htm">Stock
    Escrow Agreement, dated February 14, 2022 by and between ASCA and Continental Stock Transfer &amp; Trust Company (incorporated by
    reference to Exhibit 10.5 to ASCA&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February
    18, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.6</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023012495/ea173753ex10-1_aspac1acq.htm">Voting
    and Support Agreement, dated as of February 15, 2023, by and among A SPAC I Acquisition Corp., A SPAC I Mini Acquisition Corp., NewGenIvf
    Limited, and certain shareholders of NewGenIvf Limited (incorporated by reference to Exhibit 10.1 to ASCA&#8217;s Current Report
    on Form 8-K filed with the Securities and Exchange Commission on February 16, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.7</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023012495/ea173753ex10-2_aspac1acq.htm">Form
    of Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to ASCA&#8217;s Current Report on
    Form 8-K filed with the Securities and Exchange Commission on February 16, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.8</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex4-8_newgen.htm">Form
    of Lock-Up Agreement (incorporated by reference to exhibit 4.8 of the Company&#8217;s report on Form 20-F filed with the SEC on April
    9, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.9</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-1_aspac1.htm">Securities
    Purchase Agreement, dated February 29, 2024, by and among ASCA, The Company, Legacy NewGenIvf, the Buyers and Merger Sub (incorporated
    by reference to Exhibit 10.1 to ASCA&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March
    6, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.10</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-2_aspac1.htm">Form
    of Note between The Company and the Buyers (incorporated by reference to Exhibit 10.2 to ASCA&#8217;s Current Report on Form 8-K
    filed with the Securities and Exchange Commission on March 6, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.11</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-3_aspac1.htm">Acknowledgement
    Agreement, dated March 1, 2024, by and among ASCA, Legacy NewGenIvf and Chardan (incorporated by reference to Exhibit 10.3 to ASCA&#8217;s
    Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2024)</a></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-size: 10pt">10.12</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-19_aspac1.htm">Power
    Generator Lease Contract, dated January 10, 2021, between BD &amp; H TECH Co., LTD. and First Fertility Phnom Penh Ltd (English Translation)
    (incorporated by reference to Exhibit 10.19 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed
    with the Securities and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.13</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-20_aspac1.htm">Property
    Lease Contract, dated June 22, 2020, between SOK HEANG and First Fertility Phnom Penh Ltd (English Translation) (incorporated by
    reference to Exhibit 10.20 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-size: 10pt">10.14</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 90%"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-21_aspac1.htm">MicroSort
    Lease and Services Agreement, dated March 29, 2019, between First Fertility Phnom Penh Ltd and MicroSort International (incorporated
    by reference to Exhibit 10.21 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.15</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-22_aspac1.htm">Management
    and Administrative Services Agreement, dated November 1, 2022, between First Fertility PGS Center Ltd and Med Holdings Ltd (incorporated
    by reference to Exhibit 10.22 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.16</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-23_aspac1.htm">MicroSort
    Lease and Services Agreement, dated April, 8, 2019, between First Fertility PGS Center Ltd. and MicroSort International (incorporated
    by reference to Exhibit 10.23 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.17</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-24_aspac1.htm">Medical
    Consulting Service Agreement, dated January 1, 2021, between First Fertility PGS Center Ltd and First Fertility Phnom Penh Ltd (incorporated
    by reference to Exhibit 10.24 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.18</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-25_aspac1.htm">Receivables
    Purchase Agreement, dated December, 28, 2022, between First Fertility PGS Center Ltd and Mr. Siu, Wing Fung Alfred (incorporated
    by reference to Exhibit 10.25 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.19</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-26_aspac1.htm">Master
    Services Agreement, dated December 21, 2022, between First Fertility PGS Center Ltd and First Fertility Phnom Penh Ltd (incorporated
    by reference to Exhibit 10.26 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.20</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-27_aspac1.htm">Form
    of Agreement for Storage of Embryos, Eggs, and Sperms Service between First Fertility PGS Center Ltd and Reproductive Expert Co Ltd
    (incorporated by reference to Exhibit 10.27 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed
    with the Securities and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.21</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex4-21_newgen.htm">Form
    of NewGenIvf Group Limited 2024 Share Incentive Plan (incorporated by reference to exhibit 4.21 of the Company&#8217;s report on
    Form 20-F filed with the SEC on April 9, 2024)</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.22</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-1_aspac1.htm">Securities
    Purchase Agreement between A SPAC I Mini Acquisition Corp. and JAK Opportunities VI LLC dated February 29, 2024 (incorporated by
    reference to Exhibit 4.1 of the Company&#8217;s current report on Form 6-K filed with the SEC on April 4, 2024)</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.23</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-2_aspac1.htm">Form
    of Note between A SPAC I Mini Acquisition Corp. and JAK Opportunities VI LLC dated February 29, 2024 (incorporated by reference to
    Exhibit 4.2 of the Company&#8217;s current report on Form 6-K filed with the SEC on April 4, 2024)</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.24</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024069887/ea021151801ex4-1_newgen.htm">Securities
    Purchase Agreement between the Company and certain buyers dated August 7, 2024 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s
    current report on Form 6-K filed with the SEC on August 16, 2024)</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.25</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024076330/ea021292701ex10-25_newgen.htm"><span style="font-size: 10pt">Form
    of Note between the Company and JAK Opportunities VI LLC dated August 7, 2024 (incorporated by reference to Exhibit 10.25 of the
    Company&#8217;s registration statement on Form F-1 (File No. 333-281964), filed with the Securities and Exchange Commission on September
    6, 2024</span></a></td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.26</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024074614/ea021297701ex4-1_newgen.htm">Form
    of Note between the Company and JAK Opportunities VI LLC dated August 28, 2024 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s
    current report on Form 6-K filed with the SEC on August 30, 2024)</a>&#160;</span></td></tr>


<tr style="background-color: White">
    <td style="vertical-align: top">10.27</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024101682/ea022147001ex10-27_newgen.htm">Common
    Stock Purchase Agreement between the Company and White Lion Capital, LLC dated November 21, 2024</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">10.28</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024101682/ea022147001ex10-28_newgen.htm">Registration
    Rights Agreement between the Company and White Lion Capital, LLC dated November 21, 2024</a></td></tr>

<tr style="background-color: White">
    <td style="vertical-align: top">10.29</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024099047/ea022145801ex4-1_newgen.htm">Form
    of Note between the Company and JAK Opportunities VI LLC dated November 11, 2024 (incorporated by reference to Exhibit 4.1 of the
    Company&#8217;s current report on Form 6-K filed with the SEC on November 15, 2024)</a></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">10.30**</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390025021404/ea023310401ex10-30_newgen.htm">Purchase Agreement between the Company and Genetics and IVF Institute, Inc. dated January 21, 2025</a></td></tr>
<tr style="background-color: White">
    <td style="vertical-align: top">10.31**</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390025021404/ea023310401ex10-31_newgen.htm">Consulting Services Agreement between the Company and A SPAC (Holdings) Limited dated February 24, 2025</a></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="-keep: true">10.32</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390025028370/ea023707201ex4-1_newgen.htm">Securities Purchase Agreement between the Company and certain buyers dated April 1, 2025 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s current report on Form 6-K filed with the SEC on April 3, 2025)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000121390025033966/ea023590401ex8-1_newgenivf.htm"><span style="-keep: true">List of Subsidiaries (incorporated by reference to Exhibit 8.1 of the Company&#8217;s annual report on Form 20-F filed with the SEC on April 22, 2025)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent Letter from WWC, P.C.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent Letter from J&amp;S Associate PLT</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><a href="ea023980101ex5-1_newgen.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ogier (included in Exhibit 5.1)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#p_001">Power of Attorney</a></span></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024070853/ea021122901ex97-1_newgen.htm">Clawback
    Policy of the Company. (incorporated by reference to Exhibit 97.1 of the Company&#8217;s annual report on Form 20-F filed with the
    SEC on August 20, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline
    XBRL and contained in Exhibit 101)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><a href="ea023980101ex-fee_newgen.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee Table</span></a></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.3in">*</td><td>Filed herewith.</td></tr><tr style="vertical-align: top">
<td><span style="-keep: true">**</span></td><td><span style="-keep: true">Previously filed.</span></td></tr>
                                                             </table><div>
</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="-keep: true">***</span></td><td style="text-align: justify"><span style="-keep: true">To be filed by amendment.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Item 9. Undertakings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">The undersigned
                                            Registrant hereby undertakes:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify">(1)</td><td style="text-align: justify">To
                                            file, during any period in which offers or sales are being made, a post-effective amendment
                                            to this registration statement:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">i.</td><td style="text-align: justify">To
                                            include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">ii.</td><td style="text-align: justify">To
                                            reflect in the prospectus any facts or events arising after the effective date of the registration
                                            statement (or the most recent post-effective amendment thereof) which, individually or in
                                            the aggregate, represent a fundamental change in the information set forth in the registration
                                            statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
                                            offered (if the total dollar value of securities offered would not exceed that which was
                                            registered) and any deviation from the low or high end of the estimated maximum offering
                                            range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
                                            424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change
                                            in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration
                                            Fee&#8221; table in the effective registration statement;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">iii.</td><td style="text-align: justify">To
                                            include any material information with respect to the plan of distribution not previously
                                            disclosed in the registration statement or any material change to such information in the
                                            registration statement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify">(2)</td><td style="text-align: justify">That,
                                            for the purpose of determining any liability under the Securities Act of 1933, each such
                                            post-effective amendment shall be deemed to be a new registration statement relating to the
                                            securities offered therein, and the offering of such securities at that time shall be deemed
                                            to be the initial bona fide offering thereof.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify">(3)</td><td style="text-align: justify">To
                                            remove from registration by means of a post-effective amendment any of the securities being
                                            registered which remain unsold at the termination of the offering.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify">(4)</td><td style="text-align: justify">To
                                            file a post-effective amendment to the registration statement to include any financial statements
                                            required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous
                                            offering. Financial statements and information otherwise required by Section 10(a)(3) of
                                            the Act need not be furnished, provided that the registrant includes in the prospectus, by
                                            means of a post-effective amendment, financial statements required pursuant to this paragraph
                                            (a)(4) and other information necessary to ensure that all other information in the prospectus
                                            is at least as current as the date of those financial statements. Notwithstanding the foregoing,
                                            with respect to registration statements on Form F-3, a post-effective amendment need not
                                            be filed to include financial statements and information required by Section 10(a)(3) of
                                            the Act or Item 8.A of Form 20-F if such financial statements and information are contained
                                            in periodic reports filed with or furnished to the Commission by the registrant pursuant
                                            to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated
                                            by reference in the Form F-3.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify">(5)</td><td style="text-align: justify">That,
                                            for the purpose of determining liability of the Registrant under the Securities Act of 1933
                                            to any purchaser in the initial distribution of the securities:</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in">The undersigned Registrant undertakes
that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities
to such purchaser:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 13.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">(i)</td><td style="text-align: justify">Any
                                            preliminary prospectus or prospectus of the undersigned Registrant relating to the offering
                                            required to be filed pursuant to Rule&#160;424;</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">(ii)</td><td style="text-align: justify">Any
                                            free writing prospectus relating to the offering prepared by or on behalf of the undersigned
                                            registrant or used or referred to by the undersigned Registrant;</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">(iii)</td><td style="text-align: justify">The
                                            portion of any other free writing prospectus relating to the offering containing material
                                            information about the undersigned registrant or its securities provided by or on behalf of
                                            the undersigned Registrant; and</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">(iv)</td><td style="text-align: justify">Any
                                            other communication that is an offer in the offering made by the undersigned Registrant to
                                            the purchaser.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify">(b)</td><td style="text-align: justify">Insofar
                                            as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
                                            to directors, officers and controlling persons of the registrant pursuant to the foregoing
                                            provisions, or otherwise, the registrant has been advised that in the opinion of the U.S.
                                            Securities and Exchange Commission such indemnification is against public policy as expressed
                                            in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
                                            against such liabilities (other than the payment by the registrant of expenses incurred or
                                            paid by a director, officer or controlling person of the registrant in the successful defense
                                            of any action, suit or proceeding) is asserted by such director, officer or controlling person
                                            in connection with the securities being registered, the registrant will, unless in the opinion
                                            of its counsel the matter has been settled by controlling precedent, submit to a court of
                                            appropriate jurisdiction the question of whether such indemnification by it is against public
                                            policy as expressed in the Act and will be governed by the final adjudication of such issue.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify">(c)</td><td style="text-align: justify">The
                                            undersigned Registrant hereby undertakes that:</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">i.</td><td style="text-align: justify">That
                                            for purposes of determining any liability under the Securities Act of 1933, the information
                                            omitted from the form of prospectus filed as part of this registration statement in reliance
                                            upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to
                                            Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this
                                            registration statement as of the time it was declared effective</td>
</tr></table><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">ii.</td><td style="text-align: justify">That
                                            for the purpose of determining any liability under the Securities Act of 1933, each post-effective
                                            amendment that contains a form of prospectus shall be deemed to be a new registration statement
                                            relating to the securities offered therein, and the offering of such securities at that time
                                            shall be deemed to be the initial <i>bona fide</i> offering thereof.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="p_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-indent: 27.55pt"><span style="-keep: true">Pursuant to
the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by
the undersigned, thereunto duly authorized, on May 1, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-size: 10pt"><b>NEWGENIVF GROUP LIMITED</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 36%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 60%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap"><span style="font-size: 10pt"><i>/s/ Wing Fung Alfred Siu</i></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Wing Fung Alfred Siu</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">POWER OF ATTORNEY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">KNOW ALL PERSONS BY THESE
PRESENTS, that each of the undersigned constitutes and appoints Wing Fung Alfred Siu, his true and lawful&#160;attorneys-in-fact&#160;and
agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities,
to sign this Registration Statement on Form&#160;F-1,&#160;or other appropriate form, and all amendments thereto, including post-effective
amendments, of NewGenIvf Group Limited, and to file the same, with all exhibits thereto, and other document in connection therewith,
with the Securities and Exchange Commission, granting unto said&#160;attorneys-in-fact&#160;and agents, each acting alone, full power
and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to
all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that any such&#160;attorney-in-fact&#160;and
agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1pt 0pt 0.4pt; text-indent: 27.55pt">Pursuant to
the requirements of the Securities Act of 1933, this registration statement on Form F-1 has been signed by the following
persons in the capacities and on the dates indicated.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 35%; border-bottom: black 1.5pt solid"><b style="-keep: true">Signature</b></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><b style="-keep: true">Title</b></td>
    <td style="width: 1%; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><b style="-keep: true">Date</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><i style="-keep: true">/s/ Wing Fung Alfred Siu</i></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">Chief Executive Officer and Director,</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">May 1, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">Wing Fung Alfred Siu</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">(Principal Executive Officer)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><i style="-keep: true">/s/ Hei Yue Tina Fong</i></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">Director, Chief Marketing Officer</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">May 1, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">Hei Yue Tina Fong</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><i style="-keep: true">/s/ Hok Man Jefferson Au</i></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">Independent Director</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">May 1, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="-keep: true">Hok Man Jefferson Au</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><i style="-keep: true">/s/ Florianna Ann Chi Wan Chan</i></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">Independent Director</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">May 1, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-top: black 1.5pt solid"><span style="-keep: true">Florianna Ann Chi Wan Chan</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><i style="-keep: true">/s/ Tam Chun Wa</i></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">Independent Director</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">May 1, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">Tam Chun Wa</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="-keep: true">/s/ <i>Ho Fai Chung</i></span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">Chief Financial Officer</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">May 1, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">Ho Fai Chung</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURE OF
AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.55pt"><span style="-keep: true">Pursuant to the Securities
Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America of NewGenIvf Group Limited,
has signed this registration statement in New York, NY on May 1, 2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt"><b>COGENCY GLOBAL INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-size: 10pt"><i>/s/ Colleen A. De Vries</i></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Name:&#160;</span></td>
    <td><span style="font-size: 10pt">Colleen A. De Vries</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Senior Vice President on behalf of Cogency Global Inc.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 91%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#fin_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB ID: 6732)</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#fin_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB ID: 6743)</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#fin_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#fin_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Income (Loss) for the&#160;Years Ended December 31, 2024, 2023 and 2022</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit) for the&#160;Years Ended December 31, 2024, 2023 and 2022</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the&#160;Years Ended December 31, 2024, 2023 and 2022</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#fin_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></a></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 126; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors and Shareholders of NewgenIvf Limited</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have audited the accompanying
consolidated balance sheet of NewgenIvf Limited and its subsidiaries (collectively, the &#8220;Company&#8221;) as of December 31, 2023,
the related consolidated statements of operations and comprehensive income, shareholders&#8217; equity, and cash flows for the year ended
December 31, 2023, and the related notes to the consolidated financial statements and schedule (collectively, the financial statements).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with accounting principles
generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Material Uncertainty relating to Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompany financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the
Company had bank balance of $54,104 as of December 31, 2023 and for the year ended December 31, 2023, the Company had operating cash outflows
of $1,766,135.&#160;This raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard
to these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result
from the outcome of this uncertainty. Our opinion is not modified in respect of this matter.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We conducted our audit in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audit included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 40%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Onestop Assurance PAC</span></td>
    <td style="width: 60%; font-size: 10pt">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Singapore</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 16, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors and Shareholders of NewgenIvf Group Limited</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have audited the accompanying
consolidated balance sheet of Newgenivf Group Limited and its subsidiaries (collectively, the &#8220;Company&#8221;) as of December 31,
2024, the related consolidated statements of operations and comprehensive income, shareholders&#8217; equity, and cash flows for the year
ended December 31, 2024, and the related notes to the consolidated financial statements and schedule (collectively, the financial statements).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles
generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Substantial Doubt about the Company&#8217;s Ability to Continue
as a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3, the Company
has generated a loss and suffered from an accumulated deficit of $985,994 as of December 31, 2024 and a deficit in shareholders&#8217;
equity of $1,481,757 as of that date. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
Management&#8217;s plans with regards to these matters are also described in Note 3 to the financial statements. These financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We conducted our audit in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audit included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ J&amp;S Associate PLT</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Firm ID: 6743</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kuala Lumpur, Malaysia</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 22, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP
LIMITED<br/> CONSOLIDATED BALANCE SHEETS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF DECEMBER 31, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023**</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-24174">457,740</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">54,104</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-24176">49,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">9,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-24178">80,813</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:InventoryNet" scale="0" unitRef="usd">126,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Deposits, other receivables and deferred legal &amp; IPO cost, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-24180">195,446</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">512,581</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Deposit with a digital asset trading platform</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="0" unitRef="usd" id="ixv-24182">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Receivable from agents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:ReceivableFromAgents" scale="0" unitRef="usd" id="ixv-24183">1,191,795</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Prepayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-24184">197,706</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">1,262,228</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Loan to A SPAC I</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_9_fact" name="nivf:LoanToASPAC" scale="0" unitRef="usd">140,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Due from shareholders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_10_fact" name="nivf:DueFromShareholders" scale="0" unitRef="usd">354,285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-24188">3,172,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">2,458,836</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-24190">273,096</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">162,157</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Right-of-use assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-24192">98,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">283,847</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Prepayments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd" id="ixv-24194">33,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd">1,582,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-24196">404,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd">2,028,160</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-24198">3,577,744</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:Assets" scale="0" unitRef="usd">4,486,996</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-24200">1,298,964</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">172,626</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accrued liabilities and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24202">500,729</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_18_fact" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">241,613</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-24204">63,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd">7,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24206">154,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Operating lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-24207">108,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_20_fact" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">207,128</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Finance lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_21_fact" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" unitRef="usd">6,446</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-24210">82,447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Promissory note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-24211">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-24212">11,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_22_fact" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd">486,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24214">2,720,354</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_23_fact" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">1,122,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Operating lease liabilities, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-24216">10,231</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_24_fact" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">118,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Convertible notes, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="0" unitRef="usd" id="ixv-24218">2,328,916</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-24219">2,339,147</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_25_fact" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd">118,979</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-24221">5,059,501</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_26_fact" name="us-gaap:Liabilities" scale="0" unitRef="usd">1,241,435</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 0.25in">Ordinary shares, <span style="-sec-ix-hidden: hidden-fact-12"><span style="-sec-ix-hidden: hidden-fact-13">no</span></span> par value, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-24223"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" id="ix_27_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">1,138,519</ix:nonFraction></ix:nonFraction>* and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">507,469</ix:nonFraction></ix:nonFraction>* shares issued and outstanding as of December 31, 2024 and 2023 respectively</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-24229">204,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_28_fact" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd">127,564</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-24231">122,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_29_fact" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">4,331,815</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-24233">985,994</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_30_fact" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">461,351</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated other comprehensive (loss) income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-24235">18,875</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_31_fact" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd">7,288</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Equity attributable to the shareholders of the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-24237">1,048,614</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_32_fact" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">3,735,612</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-24239">433,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_33_fact" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd">490,051</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24241">1,481,757</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_34_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">3,245,561</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-24243">3,577,744</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_35_fact" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">4,486,996</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify; font-size: 10pt"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares as presented have been adjusted retrospectively for a Reverse Share Split effected in February 2025 of 1 share for every 20 existing share issued</span></ix:footnote></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="text-align: justify; font-size: 10pt"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></ix:footnote></td></tr> </table><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP
LIMITED<br/> CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)<br/> FOR THE YEARS ENDED DECEMBER 31, 2024, 2023
AND 2022<br/> (Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24245">5,433,375</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24246">5,136,153</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24247">5,944,190</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-24248">3,606,481</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-24249">3,454,368</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-24250">4,406,421</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24251">1,826,894</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24252">1,681,785</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24253">1,537,769</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-24254">206,314</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-24255">18,030</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-24256">36,194</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24257">2,781,075</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24258">1,621,513</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24259">1,102,870</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-24260">2,987,389</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-24261">1,639,543</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-24262">1,139,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating (loss) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24263">1,160,495</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-24264">42,242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-24265">398,705</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expenses), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-24266">971,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-24267">111,837</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-24268">23,019</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-24269">6,953</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-24270">518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-24271">21</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="0" unitRef="usd" id="ixv-24272">778,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="0" unitRef="usd" id="ixv-24273">46,179</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="0" unitRef="usd" id="ixv-24274">77,757</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-24275">199,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-24276">66,176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-24277">54,717</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">(Loss) Income before taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24278">960,807</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24279">108,418</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24280">343,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-24281">486,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-24282">208,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net (loss) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24283">474,101</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-24284">108,418</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-24285">135,847</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: net income (loss) attributable to non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24286">50,542</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24287">21,775</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24288">322,820</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net (loss) income attributable to the shareholders of the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24289">524,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd" id="ixv-24290">130,193</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd" id="ixv-24291">458,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-24292">32,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24293">22,704</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24294">1,920</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total comprehensive (loss) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24295">441,572</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" unitRef="usd" id="ixv-24296">85,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" unitRef="usd" id="ixv-24297">133,927</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: total comprehensive (loss) income attributable to non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24298">56,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24299">27,621</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24300">323,458</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total comprehensive (loss) income attributable to the shareholders of the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24301">498,480</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24302">113,335</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24303">457,385</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Earnings per share&#160;&#8211;&#160;basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24304">1.32</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-24305">3.53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-24306">4.72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#8211; diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24307">0.64</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-24308">3.53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-24309">4.72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average shares outstanding *- basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" id="ix_36_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">358,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" id="ix_37_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">30,757</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" id="ix_38_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">28,797</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">- diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24313">743,323</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24314">30,757</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24315">28,797</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Adjusted
retrospectively for reverse stock split&#160;that was effected in February 2025 of 1 share for every 20 existing share issued.</span></ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP
LIMITED<br/> CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY (DEFICIT)<br/> FOR THE YEARS ENDED DECEMBER 31,
2024,&#160;2023 AND 2022<br/> (Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Subscription<br/> receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Additional <br/> paid-in <br/> capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> other<br/> comprehensive<br/> income/(loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> attributable<br/> to the<br/> shareholders<br/> of the<br/> Company</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non- controlling<br/> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 26.2%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January&#160;1, 2022**</td><td style="width: 0.4%">&#160;</td>
    <td style="width: 0.4%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" id="ix_39_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">507,469</ix:nonFraction></td><td style="width: 0.4%; text-align: left">&#160;</td><td style="width: 0.4%">&#160;</td>
    <td style="width: 0.4%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;</td><td style="width: 0.4%; text-align: left">&#160;</td><td style="width: 0.4%">&#160;</td>
    <td style="width: 0.4%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="width: 0.4%; text-align: left">&#160;</td><td style="width: 0.4%">&#160;</td>
    <td style="width: 0.4%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" id="ix_40_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">263,421</ix:nonFraction></td><td style="width: 0.4%; text-align: left">&#160;</td><td style="width: 0.4%">&#160;</td>
    <td style="width: 0.4%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" id="ix_41_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">1,050,211</ix:nonFraction></td><td style="width: 0.4%; text-align: left">)</td><td style="width: 0.4%">&#160;</td>
    <td style="width: 0.4%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" id="ix_42_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">10,852</ix:nonFraction></td><td style="width: 0.4%; text-align: left">&#160;</td><td style="width: 0.4%">&#160;</td>
    <td style="width: 0.4%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" id="ix_43_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">775,938</ix:nonFraction></td><td style="width: 0.4%; text-align: left">)</td><td style="width: 0.4%">&#160;</td>
    <td style="width: 0.4%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24321">138,972</ix:nonFraction></td><td style="width: 0.4%; text-align: left">)</td><td style="width: 0.4%">&#160;</td>
    <td style="width: 0.4%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24322">914,910</ix:nonFraction></td><td style="width: 0.4%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-24323">458,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-24324">458,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24325">322,820</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-24326">135,847</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign currency translation&#160;adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24327">1,282</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24328">1,282</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24329">638</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24330">1,920</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Capital injection by directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-24331">240,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-24332">240,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-24333">240,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Issuance of shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" sign="-" unitRef="usd" id="ixv-24334">319,872</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24335">961,538</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24336">641,666</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24337">641,666</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, December&#160;31, 2022**</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" id="ix_44_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">507,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" id="ix_45_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">319,872</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" id="ix_46_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">1,464,959</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" id="ix_47_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">591,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" id="ix_48_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">9,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" id="ix_49_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">563,113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" id="ix_50_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">462,430</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" id="ix_51_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">100,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January&#160;1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24346">507,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24347">319,872</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24348">1,464,959</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24349">591,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24350">9,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24351">563,113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24352">462,430</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24353">100,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-24354">130,193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-24355">130,193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24356">21,775</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-24357">108,418</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign currency translation&#160;adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24358">16,858</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24359">16,858</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24360">5,846</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24361">22,704</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Settlement of subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-24362">192,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-24363">192,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-24364">192,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Issuance of shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24365">2,866,856</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24366">2,866,856</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24367">2,866,856</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, December&#160;31, 2023**</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c38" decimals="INF" format="ixt:num-dot-decimal" id="ix_52_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">507,469</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" id="ix_53_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">127,564</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" id="ix_54_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">4,331,815</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" id="ix_55_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">461,351</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" id="ix_56_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">7,288</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" id="ix_57_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">3,735,612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" id="ix_58_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">490,051</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_59_fact" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">3,245,561</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January&#160;1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24376">507,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24377">127,564</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24378">4,331,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24379">461,351</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24380">7,288</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24381">3,735,612</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24382">490,051</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24383">3,245,561</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net (loss) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24384">524,643</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24385">524,643</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-24386">50,542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24387">474,101</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign currency translation&#160;adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-24388">26,163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-24389">26,163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-24390">6,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-24391">32,529</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Reverse capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueReverseCaptialization" scale="0" sign="-" unitRef="usd" id="ixv-24392">6,028,690</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueReverseCaptialization" scale="0" sign="-" unitRef="usd" id="ixv-24393">6,028,690</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueReverseCaptialization" scale="0" sign="-" unitRef="usd" id="ixv-24394">6,028,690</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Settlement of subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-24395">127,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-24396">127,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-24397">127,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Remeasurement of share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" sign="-" unitRef="usd" id="ixv-24398">2,766,856</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" sign="-" unitRef="usd" id="ixv-24399">2,766,856</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" sign="-" unitRef="usd" id="ixv-24400">2,766,856</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Issuance of shares under ELOC/Note Conversion arrangement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-24401">631,050</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="usd" id="ixv-24402">204,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">) </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-24403">4,586,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-24404">4,382,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-24405">4,382,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, December&#160;31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24406">1,138,519</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24407">204,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24408">122,505</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24409">985,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24410">18,875</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24411">1,048,614</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24412">433,143</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24413">1,481,757</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The no of shares as presented have been adjusted retrospectively for a Reverse Share Split effected in February 2025 of 1 share for every 20 existing share issued.</span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="text-align: justify; font-size: 10pt"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></ix:footnote></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP
LIMITED<br/> CONSOLIDATED STATEMENTS OF CASH FLOWS<br/> FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022<br/> (Stated in US
Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023**</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022**</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net (loss) income</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24414">474,101</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_60_fact" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">108,418</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_61_fact" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">135,847</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Depreciation of plant and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-24417">19,502</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_62_fact" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">31,173</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_63_fact" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">100,533</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-24420">186,762</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_64_fact" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">198,535</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_65_fact" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">203,411</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Loss on disposal of plant and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_66_fact" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd">114,013</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortisation of share-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:AmortisationOfShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-24424">33,334</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Non cash discount on convertible notes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:NonCashDiscountOnConvertibleNotes" scale="0" unitRef="usd" id="ixv-24425">402,500</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Provision of expected credit loss allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_67_fact" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" unitRef="usd">625</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_68_fact" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" unitRef="usd">10,777</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest expense</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-24428">778,656</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_69_fact" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">46,179</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Waiver of related party balance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_70_fact" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd">88,151</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Gain on lease modification</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnTerminationOfLease" scale="0" unitRef="usd" id="ixv-24431">13,092</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Gain on promissory note</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:GainOnPromissoryNote" scale="0" unitRef="usd" id="ixv-24432">953,861</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Directors&#8217; remuneration</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_71_fact" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">240,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Legal and professional fee</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_72_fact" name="us-gaap:LegalFees" scale="0" unitRef="usd">27,320</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">(Gain on) Provision for income taxes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-24435">486,706</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_73_fact" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">208,141</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-24437">39,871</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_74_fact" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd">1,166</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_75_fact" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd">129,922</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Inventories</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-24440">45,451</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_76_fact" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">80,665</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_77_fact" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">7,219</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Deposit and other receivables, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd" id="ixv-24443">2,000,851</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_78_fact" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd">448,266</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_79_fact" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd">15,197</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-24446">1,126,338</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_80_fact" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">71,362</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_81_fact" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">58,752</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accrued liabilities and other payables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-24449">6,750,587</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_82_fact" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd">51,167</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_83_fact" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">190,689</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Contract liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-24452">55,552</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_84_fact" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" sign="-" unitRef="usd">1,352,231</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_85_fact" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd">548,010</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating lease liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-24455">204,846</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_86_fact" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd">230,433</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_87_fact" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd">175,132</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Finance lease liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_88_fact" name="us-gaap:IncreaseDecreaseInFinanceReceivables" scale="0" unitRef="usd">19,476</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Tax paid</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" unitRef="usd" id="ixv-24459">11,746</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_89_fact" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" sign="-" unitRef="usd">12,170</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash (used in) provided by operating activities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-24461">8,264,074</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_90_fact" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">1,766,135</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_91_fact" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd">1,710,901</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITY</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchase of plant and equipment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-24464">53,045</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_92_fact" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">69,848</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_93_fact" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">94,452</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activity</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-24467">53,045</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_94_fact" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">69,848</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_95_fact" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">94,452</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amount due from A SPAC I</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:ProceedsFromAmountDueFromASPACI" scale="0" sign="-" unitRef="usd" id="ixv-24470">140,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_96_fact" name="nivf:ProceedsFromAmountDueFromASPACI" scale="0" unitRef="usd">140,000</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd" id="ixv-24472">6,446</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_97_fact" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd">9,317</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_98_fact" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd">19,476</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other borrowings, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="0" unitRef="usd" id="ixv-24475">8,583,597</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_99_fact" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="0" unitRef="usd">128,204</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of shares (net of reverse capitalization effect)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_100_fact" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">192,308</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest paid</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:PaymentofInterest" scale="0" unitRef="usd" id="ixv-24478">677,663</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_101_fact" name="nivf:PaymentofInterest" scale="0" unitRef="usd">24,704</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amount with related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-24480">508,738</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_102_fact" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">1,863,206</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_103_fact" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" sign="-" unitRef="usd">1,742,509</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Subscription receivable</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:SubscriptionReceivable" scale="0" sign="-" unitRef="usd" id="ixv-24483">127,564</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-24484">8,675,790</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_104_fact" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">1,881,493</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_105_fact" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" sign="-" unitRef="usd">1,633,781</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase/(decrease) in cash and cash equivalents</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-24487">358,671</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_106_fact" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd">45,510</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_107_fact" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">17,332</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of foreign currency translation on cash and cash equivalents</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24490">44,965</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_108_fact" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd">18,962</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_109_fact" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">16,124</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of year</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24493">54,104</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" id="ix_110_fact" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">27,556</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" id="ix_111_fact" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">28,764</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Cash and cash equivalents, end of year</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24496">457,740</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_112_fact" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">54,104</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" id="ix_113_fact" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">27,556</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Supplementary cash flow information:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxes paid</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_114_fact" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">12,170</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest paid</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-24500">768,068</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_115_fact" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">24,704</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_116_fact" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">55,469</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="text-align: justify; font-size: 10pt"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2024, no cash was exchanged in respect
of these transactions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in">a.</td><td>$2,650,000 of convertible debt was converted into equity.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reversal arising from remeasurement of share-based compensation</span><span style="font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif">within prepayment amounting to $2,739,856.</span></span></td></tr>
  </table><div>



</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fin_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-20269"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION AND PRINCIPAL ACTIVITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to the Business Combination,
on April 29, 2021, A SPAC I Acquisition Corp. (&#8220;ASCA&#8221;), was incorporated as a British Virgin Islands business company, specifically
a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or similar business combination with one or more target businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>The Business Combination</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 15, 2023,
ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &#8220;Merger Agreement,&#8221; and
the transactions contemplated thereunder, the &#8220;Business Combination&#8221;) with A SPAC I Mini Acquisition Corp., Merger Sub,
NewGenIvf Limited, a Cayman Islands exempted company (&#8220;Legacy NewGenIvf&#8221;) and certain shareholders of Legacy NewGenIvf.
Pursuant to the Merger Agreement, the Business Combination was effected in two steps: (i) ASCA was reincorporated to the British
Virgin Islands by merging with and into A SPAC I Mini Acquisition Corp. (such transaction, the &#8220;Reincorporation Merger&#8221;)
 and then the listed company was renamed as NewGenIvf Group
Limited; and (ii) Merger Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the
Company (such second step in isolation, the &#8220;Acquisition Merger&#8221;). The surviving entity of the Business Combination,
together with its subsidiaries is referred to in this prospectus as &#8220;NewGenIvf,&#8221; the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us,&#8221; unless the context otherwise requires.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 12, 2023, the
parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the &#8220;First Amendment&#8221;), pursuant to
which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-24503">560,000</ix:nonFraction> (the &#8220;Loan&#8221;)
to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA&#8217;s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" unitRef="usd" id="ixv-24504">140,000</ix:nonFraction> as part of the Loan from Legacy NewGenIvf, ASCA
agreed to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&#8217;s failure to deliver audited
financial statements by no later than February 28, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 6, 2023, the
parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &#8220;Second Amendment&#8221;) which amended
and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&#8217;s board of directors following the consummation
of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf and three (3)
of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii) provide for the
conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary Shares in
connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $<ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="nivf:NetTangibleAssets" scale="0" unitRef="usd" id="ixv-24505">5,000,000</ix:nonFraction> in net tangible assets immediately
after the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 3, 2024, the Business
Combination was consummated with the Company as the surviving entity.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is an organization chart of the
Company and its subsidiaries as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg" style="height: 322px; width: 700px"/>&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" id="ixv-20306"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s subsidiaries are detailed
in the table as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenivf Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td> <ix:nonNumeric contextRef="c88" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-20331"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Cayman Islands company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on 16 January, 2019</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24506">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c88" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-20339"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td> <ix:nonNumeric contextRef="c89" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-20346"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24507">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c89" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-20354"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td> <ix:nonNumeric contextRef="c90" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-20361"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24508">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c90" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-20369"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <ix:nonNumeric contextRef="c91" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-20376"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c91" decimals="2" format="ixt:num-dot-decimal" id="ix_117_fact" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure">49</ix:nonFraction>%*</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c91" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-20384"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <ix:nonNumeric contextRef="c92" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-20391"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24510">74</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c92" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-20399"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <ix:nonNumeric contextRef="c93" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-20406"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Cambodia company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24511">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c93" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-20414"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bi Clinic Ltd (&#8220;FFBi&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <ix:nonNumeric contextRef="c94" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-20421"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;A Kyrgyzstan company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;Incorporated on December 16, 2021</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;Acquired on December 17, 2024</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24512">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c94" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-20430"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment, surrogacy and ancillary caring services</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd. (&#8220;SZ QianHai&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <ix:nonNumeric contextRef="c95" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-20437"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;A Shenzhen China, PRC company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;Incorporated on October 24, 2024</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24513">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<ix:nonNumeric contextRef="c95" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-24514">Marketing and administrative services</ix:nonNumeric></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than <ix:nonFraction contextRef="c62" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-24515">50</ix:nonFraction>% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></ix:footnote></td></tr> </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">According to Thailand&#8217;s
Foreign Business Act (the &#8220;FBA&#8221;), the majority shareholdings of limited company incorporated in Thailand is required to be
owned by Thai nationals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With reference to the capital
structure and voting rights structure of ordinary shares and preference shares (the &#8220;Share Structure&#8221;) of Med Holdings and
FFC, all the preference share capital shall be owned by a Thai national. No preference shares, however, have been issued to date. The
ordinary shares and preference shares have the same rights and status in all respects except for the distribution of profits by way of
dividends with details as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" unitRef="pure" id="ixv-24516">15</ix:nonFraction>% of the total amount of dividends declared from time to time;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After allocation of dividends as per (a)&#160;above, the rest of the dividends shall be distributed equally amongst the holders of ordinary shares according to their shareholding ratio;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of preferred shares shall be entitled to dividends only in respect of the&#160;years for which the Company has declared a dividend payment, and there shall be no cumulative dividends; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends allocated to the holders of preferred shares in each year shall be limited at the rate as stated in (a)&#160;only. No additional dividends shall be paid to the holders of preferred shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based upon the management&#8217;s
judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board meeting, the Company accounts
for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings and FFC by exercising its majority
voting power in any board meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 17, 2024, the Company entered into a non-binding term sheet
(the &#8220;Non-Binding Term Sheet&#8221;) with European Wellness Investment Holdings Limited (&#8220;EWIHL&#8221;) for (i) the potential
acquisition of the entire equity interest of EWIHL by the Company for a consideration of US$<ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd" id="ixv-24517">268,000,000</ix:nonFraction> to be payable by issuing <ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24518">53,600,000</ix:nonFraction>
ordinary shares of the of the Company to the shareholder(s) of EWIHL or its associate and (ii) the fund-raising activity by the Company
from public or private shareholders, and in a form mutually acceptable to the parties, including structured equity investment for up to
US$<ix:nonFraction contextRef="c65" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" unitRef="usd" id="ixv-24519">30</ix:nonFraction> million. On December 11, 2024, NewGenIvf announced its entry into a binding term sheet with European Wellness Investment Holdings
Limited (&#8220;EWIHL&#8221;) for the above proposed reverse merger, completion of which was subject to, among other conditions, the completion
of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May 24, 2024, the Company
received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying
the Company of its non-compliance with two (2) listing requirements for continued listing on Nasdaq pursuant to Nasdaq Listing Rules.
On November 21, 2024, a delisting notice was received from the continued non-compliance. The Company had filed to appeal the delisting
determination and undertook several strategic actions to regain compliance with Nasdaq&#8217;s listing require. On February 27, 2025.
received approval for the transfer the Company&#8217;s securities from the Nasdaq Global Market to the Nasdaq Capital Market and on March
10, 2025 its compliance with the listing requirements thereof.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 3, 2024, the Company announced the execution of a non-binding
term sheet (the &#8220;Term Sheet&#8221;) regarding a proposed reverse merger (the &#8220;Proposed Transaction&#8221;) with pharmaceutical
company COVIRIX Medical Pty Ltd (&#8220;COVIRIX&#8221;). The consideration was to be settled by way of the issuance of issue <ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24520">102,890,000</ix:nonFraction>
of its ordinary shares to the shareholder(s) of COVIRIX or their respective nominees (the &#8220;COVIRIX Shareholders&#8221;) in exchange
for <ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-24521">100</ix:nonFraction>% equity interest of COVIRIX, at a deemed price per share of US$<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24522">6</ix:nonFraction>, representing an aggregate amount of US$<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="nivf:AggregateAmount" scale="0" unitRef="usd" id="ixv-24523">617,340,000</ix:nonFraction>. Simultaneously,
it is proposed that COVIRIX undertakes to introduce investors to raise US$<ix:nonFraction contextRef="c66" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyCommittedCapital" scale="6" unitRef="usd" id="ixv-24524">6</ix:nonFraction> million at US$<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24525">6</ix:nonFraction> per share for NIVF, in a form mutually acceptable
to both NewGen and COVIRIX. Following stockholder approval of the Proposed Transaction, COVIRIX Shareholders are expected to hold approximately
<ix:nonFraction contextRef="c69" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-24526">85.8</ix:nonFraction>% equity interest in NewGen. However, on September 21, 2024, COVIRIX withdrew from the Proposed Transaction, as such the Proposed
Transaction was terminated with no cost to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">On August 7, 2024, the
Company entered into a Securities Purchase Agreement with certain investors named therein (collectively, the &#8220;Buyers&#8221;), pursuant
to which, amongst other things: (i) the Company agreed to sell, at an initial closing with JAK Opportunities VI LLC (&#8220;JAK&#8221;
and such initial closing, the &#8220;Initial Closing&#8221;), pursuant to which the Company agreed to sell to JAK (a) a senior convertible
note (the &#8220;Initial Note&#8221;) in the aggregate original principal amount of $<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-24527">1,100,000</ix:nonFraction>, and which terms are further set forth
below under the subheading &#8220;(ii) Initial Closing with JAK&#8221;, (b) a warrant to purchase <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24528">1,325,301</ix:nonFraction> Class A Ordinary Shares of
the Company, no par value (&#8220;Class A Shares&#8221; and such warrant, the Series A Warrant), and (c) a warrant to purchase <ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24529">180,722</ix:nonFraction>
Class B Ordinary Shares of the Company, no par value (&#8220;Class B Shares&#8221; and such warrant, the Series B Warrant, and the Series
B Warrants, together with the Series A Warrants, the &#8220;Warrants&#8221;); and (ii) the Company may require each Buyer (or each Buyer
may require the Company, as applicable) to participate in the sale of (a) one or more additional convertible notes (which aggregate original
principal amount for all additional convertible notes shall not exceed $<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-24530">9,500,000</ix:nonFraction>) (the &#8220;Additional Notes,&#8221; and, together
with the Initial Note, the &#8220;Notes&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 12, 2024, the Company
and JAK consummated the Initial Closing. The Initial Note sold to JAK in connection with the Securities Purchase Agreement bears an interest
rate of <ix:nonFraction contextRef="c74" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure" id="ixv-24531">14.75</ix:nonFraction>% per annum and is convertible into the Company&#8217;s Class A Shares as follows: the Conversion Amount (as defined below)
into validly issued, fully paid and non-assessable Class A at the Conversion Rate determined by dividing the aggregate of the principal
sum plus the interest rates (including late interest charges, if any) and the Make-Whole Amount, if any, by conversion price of $<ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-24532">0.83</ix:nonFraction>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the Initial Closing, the
Company also sold to JAK a Series A Warrant to purchase <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24533">1,325,301</ix:nonFraction> Class A Shares and a Series B Warrant to purchase <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24534">180,722</ix:nonFraction> Class B Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, in connection
with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with certain holders of its convertible
promissory notes (the &#8220;Existing Notes&#8221; and each of such amendment and exchange agreements, &#8220;Amendment and Exchange Agreement&#8221;),
pursuant to which the Company will exchange the Existing Notes by issuing, among other things, (i) senior convertible notes in the aggregate
principal amount of $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-24535">2,700,000</ix:nonFraction> (the &#8220;Exchange Notes&#8221;) and (b) a series of warrants to initially acquire up to a certain number
of ordinary shares to the holders of the Existing Notes set forth therein or in the Amendment and Exchange Agreement (the &#8220;Exchange
Warrants&#8221;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 28, 2024, the Company
consummated the second tranche of its debt financing under the terms of the Securities Purchase Agreement. At the closing of the second
tranche, the Company sold to JAK Opportunities VI LLC (&#8220;JAK&#8221;) a senior convertible note (the &#8220;Note&#8221;) in the principal
amount of $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-24536">500,000</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 11, 2024, the Company consummated the third tranche of
its debt financing under the terms of the Securities Purchase Agreement (&#8220;SPA&#8221;) referenced in the current report on Form 6-K
filed with the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) on August 16, 2024. The Form 6-K filed with the
SEC on August 16, 2024 is incorporated by reference herein. Pursuant to the terms of the SPA, the Company may elect at the second additional
mandatory closing to sell and the institutional investor party to the SPA shall be required to purchases, subject to certain conditions,
an additional note (&#8220;Second Additional Mandatory Note&#8221;) in the principal amount of $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-24537">1,500,000</ix:nonFraction>, after the effective date of
the Registration Statement (as defined in the SPA). The sale of the Second Additional Mandatory Note resulted in $<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-24538">1,395,000</ix:nonFraction> of gross proceeds
to the company before fees and expenses. The Notes bears an interest rate of <ix:nonFraction contextRef="c80" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure" id="ixv-24539">14.75</ix:nonFraction>% per annum and may be adjustable from time to time
pursuant to its terms, with maturity at the <ix:nonNumeric contextRef="c81" format="ixt-sec:duryear" name="nivf:MaturityTerm" id="ixv-24540">4.5</ix:nonNumeric> years anniversary of the date of issuance, subject to extension at the option of the holders
in certain circumstances. The Second Additional Note are convertible at any time, at an initial conversion price of $<ix:nonFraction contextRef="c82" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-24541">0.658</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November. 18, 2024, the
Company entered into a binding term sheet (the &#8220;Term Sheet&#8221;) with White Lion Capital, LLC, (&#8220;White Lion&#8221;) a California-based
institutional investor focused on high-growth, early-stage public companies, setting out the principal terms and conditions for a $<ix:nonFraction contextRef="c83" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-24542">100</ix:nonFraction>
million equity line of credit, expandable to $<ix:nonFraction contextRef="c83" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-24543">500</ix:nonFraction> million. Pursuant to the Term Sheet, NewGen will have the option, but not the obligation,
to sell to White Lion up to $<ix:nonFraction contextRef="c84" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockHeldBySubsidiary" scale="6" unitRef="usd" id="ixv-24544">100.0</ix:nonFraction> million in shares of common stock over an initial 36-month period, with the potential to increase to
$<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="nivf:CommonStockPotentialValue" scale="6" unitRef="usd" id="ixv-24545">300.0</ix:nonFraction> million upon substantial M&amp;A or merger activity, and further to $<ix:nonFraction contextRef="c86" decimals="-5" format="ixt:num-dot-decimal" name="nivf:MergerActivityDrawn" scale="6" unitRef="usd" id="ixv-24546">500.0</ix:nonFraction> million after $<ix:nonFraction contextRef="c87" decimals="-5" format="ixt:num-dot-decimal" name="nivf:MergerActivityDrawn" scale="6" unitRef="usd" id="ixv-24547">250.0</ix:nonFraction> million has been drawn.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 29, 2024, the
Company appointed Tam, Chun Wa to the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). Mr. Tam will serve as an independent
director. In addition, Mr. Tam has been named to the Audit Committee of the Board. Following the appointment of Mr. Tam, the Board consists
of five members.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-20556"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-20561"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Principles of consolidation and basis of preparation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c0_cont_2" id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c0_cont_3" id="_ConsolidationPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management has prepared the
accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the United&#160;States
of America (&#8220;U.S.&#160;GAAP&#8221;). The Company maintains its general ledger and journals with the accrual method accounting.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c0_cont_4" id="_ConsolidationPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The business combination
transaction between Legacy NewGenIvf and SPAC I was accounted for as a reverse recapitalization under ASC 805, Business Combinations,
with NewGenIvf Group Limited, and deemed to be the accounting acquirer. As SPAC I did not meet the definition of a business under ASC
805, the transaction was not treated as a business combination. Instead, it was accounted for as a recapitalization.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, the consolidated assets, liabilities
and results of operations of the accounting acquirer will become the historical financial statements of the Company, and the accounting
acquirer&#8217;s assets, liabilities and results of operations will be consolidated with the Company beginning on the acquisition date.
The Legacy NewGenIvf was the legal acquiree but deemed to be the accounting acquirer. The Company was the legal acquirer but deemed to
be the accounting acquiree in the reverse merger. The historical financial statements prior to the acquisition are those of the accounting
acquirer (Legacy NewGenivf). After completion of the Share Exchange Transaction, the Company&#8217;s consolidated financial statements
include the assets and liabilities, the operations and cash flow of the accounting acquirer. Any excess of the value of shares issued
by the Company over the net book value of the accounting acquirer will be recognized as a reduction to equity (APIC).</p></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-20597"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of estimates</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-20604"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency translation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#8220;$&#8221;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#8220;HK$&#8221;).
Med Holdings and FFC use Thai baht (&#8220;THB&#8221;) as their functional currencies. First Fertility Phnom Penh Limited and Bi Clinic
Ltd (&#8220;FFBi&#8221;) uses United&#160;States dollar (&#8220;USD&#8221;) as their functional currencies. Shenzhen Qianhai Fengtai Renhui
Health Technology Co., Ltd. (&#8220;SZ QianHai&#8221;) uses Chinese Renminbi (&#8220;CNY&#8221;) as its functional currency.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Monetary assets and liabilities denominated in currencies other than the functional currency
are translated into the functional currency using the applicable exchange rates at the balance sheet dates</span>. <span style="font-family: Times New Roman, Times, Serif">Translation
gains and losses are recognized in the consolidated statements of operations and comprehensive income as other comprehensive income or
loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The value of foreign currencies
including, the HK$, THB and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#8217;s financial condition in terms of reporting
in USD.&#160;<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" id="ixv-24548">The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock-c0_cont_1"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Period-end</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">$: HK$</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c103" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24549">7.8000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c104" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24550">7.8000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c105" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24551">7.8000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: HK$</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24552">7.8000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24553">7.8000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24554">7.8000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Period-end</td><td>&#160;</td>
    <td style="text-align: center">$: THB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24555">34.3353</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24556">34.2265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24557">34.6153</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: THB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c112" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24558">35.2262</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24559">34.7867</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24560">35.1428</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Period-end</td><td>&#160;</td>
    <td style="text-align: center">$: RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24561">7.2994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24562">7.0971</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24563">6.9091</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24564">7.1946</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24565">7.0835</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-24566">6.4569</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-20736"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cash and cash equivalents</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_1" escape="true" name="nivf:DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" id="ixv-20743"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Deposits, other receivables and deferred legal
&amp; IPO cost, net</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_2" id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deposits, other receivables and deferred Initial Public Offering (&#8220;IPO&#8221;)
cost, net primarily include deposits paid to suppliers, prepaid expenses, the prepaid professional fee which meets the definition of deferred
IPO cost, and a cash deposit of US$<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="0" unitRef="usd" id="ixv-24567">1,000,000</ix:nonFraction> with OSL Group, a digital asset trading platform listed in Hong Kong Stock Exchange, for
the Company&#8217;s future digital asset diversification strategy.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_3" id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to additional paid-in capital upon the completion of the Initial Public Offering.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Legal and professional fees
incurred in connection with issuing convertible debt are deferred and amortized over the life of the debt. These costs are presented as
a direct deduction from the carrying amount of the debt liability on the balance sheet (per ASC 835-30).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-20756"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share based compensation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company accounts for stock-based compensation
in accordance with ASC Topic 718-10, <i>Compensation-Stock Compensation</i>, which requires the measurement and recognition of compensation
expense for all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees
based on fair values of the shares to be issued estimated at grant date. The stock-based compensation expense recognized during the period
is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period.</p></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Fair value is determined based on the estimated
market prices of the Company&#8217;s Common Stock at the respective issuance date in accordance with ASC 718, taking into consideration
the volatility of the market price of the shares, the terms of the instruments and the conditions upon which they were granted.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-20782"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and equipment, net</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Plant and equipment are stated
at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" scale="-2" unitRef="pure" id="ixv-24568">0</ix:nonFraction>%. <ix:nonNumeric contextRef="c0" continuedAt="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock-c0_cont_1" escape="true" name="nivf:ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" id="ixv-24569">The estimated useful lives of the plan and equipment are as follows:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 81%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c121" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24570">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c122" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24571">5</ix:nonNumeric>&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-102">the lesser of useful life or&#160;term of lease</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical instruments</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c124" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24572">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c125" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24573">10</ix:nonNumeric>&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor vehicle</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c126" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24574">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c127" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24575">5</ix:nonNumeric>&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c128" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24576">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c129" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24577">5</ix:nonNumeric>&#160;years</span></td></tr> </table></ix:continuation></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#8217;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-20827"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of&#160;long-lived&#160;assets</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_2" id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-20838"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Inventories</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete inventory
will be made based primarily on products approaching expiry period and forecasts of product demand. The excess balance above the product
demand as determined by this analysis becomes the basis for excess inventory charge and the written-down&#160;value of the inventory becomes
its cost. Written-down&#160;inventory would not be reversed if market conditions improve.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DebtPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock" id="ixv-20845"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other borrowings</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_DebtPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nivf_ConvertibleInstrumentsPolicyTextBlock-c0_cont_1" escape="true" name="nivf:ConvertibleInstrumentsPolicyTextBlock" id="ixv-20852"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Convertible Instruments</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="nivf_ConvertibleInstrumentsPolicyTextBlock-c0_cont_2" id="nivf_ConvertibleInstrumentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Convertible Instruments are
categorized as equity or debt based on the terms of the notes. Convertible Notes are recorded at amounts equal to the proceeds of the
issuance, including the embedded conversion feature, and net of discounts and unamortized debt issuance in accordance with ASC 480-10-55-44
on the consolidated balance sheets. An evaluation of all conversion, purchase and redemption features contained in a debt instrument is
performed to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is recorded
separately as a derivative liability at its fair value, calculated using the Black-Scholes model.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="nivf_ConvertibleInstrumentsPolicyTextBlock-c0_cont_3" id="nivf_ConvertibleInstrumentsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Debt issuance and offering
costs are amortized over the contractual term of the Convertible Notes, to the consolidated statements of operations in accordance with
ASC 835-30-45-1A.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:continuation id="nivf_ConvertibleInstrumentsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The convertible notes are
subsequently recorded at amortized cost, with interest expense recognized using the effective interest method. The derivative liability,
if any is remeasured at fair value at each reporting date and any gain or loss on fair value is recognized in the statement of comprehensive
income.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nivf_PromissoryNotesPolicyTextBlock-c0_cont_1" escape="true" name="nivf:PromissoryNotesPolicyTextBlock" id="ixv-20865"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Promissory Notes</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<ix:continuation id="nivf_PromissoryNotesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Promissory notes, originated from ASCA&#8217;s transaction and being
taken over by NewGenIVF Group Limited upon merger, are of non-interest bearing and recorded at original cost. They are subsequently measured
at amortised cost, with interest expense recognized using the effective interest method in the consolidated statement of income.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityPolicyTextBlock" id="ixv-20887"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary shares</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_StockholdersEquityPolicyTextBlock-c0_cont_2" id="_StockholdersEquityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s ordinary
shares are stated at no par value. The difference between the consideration received, net of issuance cost, is recorded in additional
paid-in&#160;capital.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_StockholdersEquityPolicyTextBlock-c0_cont_3" id="_StockholdersEquityPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 21, 2025, the
Board of Directors of the Company approved a reverse stock split of all of the Company&#8217;s issued and unissued shares, including the
Class A ordinary shares with no par value (the &#8220;Class A Ordinary Shares&#8221;), Class B ordinary shares with no par value and preferred
shares with no par value, at an exchange ratio of one (1) share for twenty (<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-24578">20</ix:nonFraction>) shares (the &#8220;Reverse Stock Split&#8221;). Upon the
opening of the market on February 11, 2025, the Company&#8217;s Class A Ordinary Shares will begin trading on the Nasdaq Global Market
(&#8220;Nasdaq&#8221;) on a post-Reverse Stock Split basis.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_StockholdersEquityPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with ASC 505,
the reverse stock split is to be accounted for retrospectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-20900"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC Topic&#160;606,
Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using the full retrospective
method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had been applied to all prior
periods. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;) treatment and surrogacy
and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its contracts with customers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its performance obligations under those contracts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction prices of those contracts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction prices to its performance obligations in those contracts; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services are inter dependant. All the contracts have commercial substance, and it is probable that
the Company will collect considerations from its customers for service component as settlement is predominantly required prior to performance
of the promised service.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company derives its revenues
from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from IVF treatment</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In vitro fertilization (&#8220;IVF&#8221;) treatment is an assisted
reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized embryo is then implanted
to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment as well as procedures and
brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized at a point in time
when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the various procedures and
treatments are evidenced by treatment cards and reports included within the patient files indicating successful completion of the service.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from surrogacy and ancillary caring
services</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. The Company collects approximately <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="nivf:RevenueRate" scale="-2" unitRef="pure" id="ixv-24579">40</ix:nonFraction>% of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result of operations
can be found in Note&#160;8 below.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from egg freezing and storage facility</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides access
the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the customer,
the Company makes available access to the facility with no further substantial involvement. Revenue is recognized at a point in time when
the facility is made available to the customer at the agreed consideration by the provision of specific address within the facility as
maintained in the patient file. The receipt of consideration is assured as payment is required upfront.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Principal versus agency considerations</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company follows the guidance provided in ASC 606, Revenue from
Contracts with Customers, for determining whether the Company is the principal or an agent in arrangements with customers that involve
another party that contributes to the provision of services to a customer. In these instances, the Company determines whether it has promised
to provide the service itself (as principal) or to arrange for the specified service to be provided by another party (as an agent). This
determination is a matter of judgment that depends on the facts and circumstances of each arrangement. The Company recognizes revenue
from the performance of the procedures and treatment on a gross basis as the Company is responsible for the fulfillment, controls the
delivery of the promised service, and has full discretion in establishing prices and therefore is the principal in the arrangement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract related assets and
liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_15" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Account receivables, net</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_16" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#8217;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#8217;s customers&#8217; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_17" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contract liabilities</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_18" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#8217;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_19" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expected credit loss</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ASU No.&#160;2016-13, Financial
Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of credit
losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due to the
entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective interest
rate of the financial asset.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PostemploymentBenefitPlansPolicy-c0_cont_1" escape="true" name="us-gaap:PostemploymentBenefitPlansPolicy" id="ixv-21046"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Retirement benefits</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_PostemploymentBenefitPlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-21053"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Segment information</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines its
reportable segments using the management approach based on internal reporting used by the Chief Operating Decision Maker (&#8220;CODM&#8221;),
comprising the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), for decision-making, resource allocation, and performance
assessment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company does not distinguish
revenues, costs, or expenses by segments, operational or geographical, but reports them in aggregate. Based on this assessment, management
has determined that the Company operates as a single reportable segment under ASC 280. Accordingly, all required segment financial information
is included in the consolidated financial statements. However, we segregate IVF revenue from surrogacy revenue as these two revenue types
are critical to our business.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s CODM
is Mr. Siu Wing Fund Alfred, its CEO. Geographic disclosures of long-lived assets and revenue from external customers as of December 31,
2024 and 2023 are presented in Note 15.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;<b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-21067"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Leases</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company measured the
lease in accordance to ASU&#160;2016-02, &#8220;Leases&#8221; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of <span style="-sec-ix-hidden: hidden-fact-103">twelve</span>&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-21090"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income Taxes</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the differences
are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not realizable
or recoverable in the future.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions in
income tax expense.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ixv-21100"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Comprehensive Income</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;<i>Comprehensive Income</i>. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-21109"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Earnings per share</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company computes earnings
per share (&#8220;EPS&#8221;) following ASC Topic&#160;260, &#8220;Earnings per share&#8221;. Basic EPS is measured as the income or loss
available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents the dilutive
effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and or warrants; the
dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive effect of
options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those that increase
income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive securities
that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2024, 2023 and 2022.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nivf_RelatedPartiesPolicyTextBlock-c0_cont_1" escape="true" name="nivf:RelatedPartiesPolicyTextBlock" id="ixv-21116"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Related parties</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_RelatedPartiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-21123"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Commitments and contingencies</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the normal course of business,
the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range
of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency if it determines
it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors in making
these assessments including historical and the specific facts and circumstances of each matter.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nivf_NonControllingInterestsPolicyTextBlock-c0_cont_1" escape="true" name="nivf:NonControllingInterestsPolicyTextBlock" id="ixv-21130"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Non-controlling&#160;interests</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_NonControllingInterestsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-21137"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of risks</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of credit risk</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers. Furthermore, the risk is mitigated by ascertaining upfront payments for
services prior to their performance.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_5" id="_ConcentrationRiskCreditRisk-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of customers</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_6" id="_ConcentrationRiskCreditRisk-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, one and two customers respectively which individually contributed more than 10% of trade receivable, and accounted for <span style="-sec-ix-hidden: hidden-fact-104">89%</span> and <ix:nonFraction contextRef="c99" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-24580">96.3</ix:nonFraction>%
of the Company&#8217;s trade receivable respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_7" id="_ConcentrationRiskCreditRisk-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of the customers contributed
more than 10% of revenue for&#160;years ended December&#160;31, 2024 and 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_8" id="_ConcentrationRiskCreditRisk-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of suppliers</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_9" id="_ConcentrationRiskCreditRisk-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, nil and one supplier respectively which individually contributed more than 10% of trade payable, accounted for <span style="-sec-ix-hidden: hidden-fact-105">nil</span> % and <ix:nonFraction contextRef="c101" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-24581"><ix:nonFraction contextRef="c102" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-24582">30.6</ix:nonFraction></ix:nonFraction>% of
the Company&#8217;s trade payable respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For both the years ended
December 31, 2024 and 2023, no vendor contributed more than 10% of total purchases of the Company.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-21192"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Financial instruments</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net, loan
to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that approximate
their fair values due to their short maturities. ASC Topic&#160;820, &#8220;Fair Value Measurements and Disclosures&#8221; requires disclosing
the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#8220;Financial Instruments&#8221; defines fair value
and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts and
other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify as financial
instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments
and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8212;&#160;inputs to the valuation methodology used quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#160;&#8212;&#160;inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#8217;s full term</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#160;&#8212;&#160;inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities from Equity&#8221;
and ASC&#160;815.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-21244"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recently issued accounting pronouncements </span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FASB has introduced expanded
income tax disclosure requirements under ASU 2023-09 to improve transparency. Companies will now need to provide a detailed reconciliation
of their effective tax rate, breaking down federal, state, and foreign taxes, as well as specific categories like tax credits and foreign
earnings. Additionally, businesses must disclose income taxes paid by jurisdiction, offering investors greater clarity on tax obligations.
These changes apply to both public and private companies, with annual reporting periods beginning after December 15, 2024 (2025 for calendar-year
entities). This update aims to reduce ambiguity in tax reporting and align disclosures with investor needs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A major shift in digital
asset accounting, ASU 2023-08 requires companies to measure certain crypto assets (e.g., Bitcoin, Ethereum) at fair value rather than
applying the previous impairment-only model. This means entities must recognize quarterly fair value adjustments in their financial statements,
increasing volatility in reported earnings but improving transparency. The standard applies to fiscal years beginning after December 15,
2024, and impacts both corporate treasuries and investment firms holding cryptocurrencies. This change aligns GAAP closer to fair value
accounting seen in other investment holdings, addressing criticisms of the old impairment approach.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="ixv-21260"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 3 &#8212; GOING CONCERN.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated financial statements have been prepared
assuming that the Company will continue as a going concern. The Company has generated a loss and suffered from an accumulated deficit
of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-24583">985,994</ix:nonFraction> as of December 31, 2024. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
Management&#8217;s plans with regards to these include but not limited to issuance of share through equity line of credit with White Lion
Capital and conversion of JAK&#8217;s promissory notes. These financial statements do not include any adjustments that might result from
the outcome of this uncertainty.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company closely monitors
the market for opportunities and has also been carrying out various fundraising projects to improve the Company&#8217;s cash flow position.
As of this report date, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising the Initial Note,
the First Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the Company. A further
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityAverageOutstandingAmount" scale="0" unitRef="usd" id="ixv-24584">2,000,000</ix:nonFraction> of the Third Mandatory Additional Note was issued subsequent to year end and remains outstanding. Moreover, the Company has
access to an equity line of credit facility of up to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityPeriodicPayment" scale="0" unitRef="usd" id="ixv-24585">100,000,000</ix:nonFraction> from White Lion Capital, of which approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="6" unitRef="usd" id="ixv-24586">7.1</ix:nonFraction> million has been
drawn and become equity to date. As of this report date, the Company holds $<ix:nonFraction contextRef="c2" decimals="-4" format="ixt:num-dot-decimal" name="nivf:CashInBank" scale="6" unitRef="usd" id="ixv-24587">2.48</ix:nonFraction>m cash in bank and a cash deposit of $<ix:nonFraction contextRef="c2" decimals="-9" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssets" scale="9" unitRef="usd" id="ixv-24588">1</ix:nonFraction>m with a trading
platform company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company can make no assurance
that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one
or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there
would likely be a material adverse effect on the Company and its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial
statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><ix:nonNumeric contextRef="c0" continuedAt="_AccountsAndNontradeReceivableTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsAndNontradeReceivableTextBlock" id="ixv-21277"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 4 &#8212;&#160;ACCOUNTS RECEIVABLE, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="ixv-21282"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accounts receivable, net consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd" id="ixv-24589">49,264</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd" id="ixv-24590">9,393</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-24591">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-24592">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-24593">49,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-24594">9,374</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_AccountsAndNontradeReceivableTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="ixv-21343"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">As of the end of each of the financial year, the
aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Within 90&#160;days</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-24595">49,245</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-24596">9,374</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-24597">49,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-24598">9,374</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" id="ixv-21381"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24599">19</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24600">26</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Reversal of expected credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-24601">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24602">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24603">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-21433"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 5 &#8212;&#160;INVENTORIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-21438"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Inventories consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Medicines, consumables and reagents for clinical and laboratory analyses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd" id="ixv-24604">80,813</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd" id="ixv-24605">126,264</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-24606">80,813</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-24607">126,264</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OtherCurrentAssetsTextBlock-c0_cont_1" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-21478"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 6 &#8212;&#160;DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND
DEFERRED IPO COST, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-21483"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Other receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesGrossCurrent" scale="0" unitRef="usd" id="ixv-24608">121,533</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesGrossCurrent" scale="0" unitRef="usd" id="ixv-24609">15,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:Deposit" scale="0" unitRef="usd" id="ixv-24610">73,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:Deposit" scale="0" unitRef="usd" id="ixv-24611">123,008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Deferred initial public offering &#8220;IPO&#8221; cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrent" scale="0" unitRef="usd" id="ixv-24612">373,677</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-24613">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-24614">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-24615">195,446</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-24616">512,581</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Deposit with a digital asset trading platform</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositAssets" scale="0" unitRef="usd" id="ixv-24617">1,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Receivable from agents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:ReceivableFromAgents" scale="0" unitRef="usd" id="ixv-24618">1,191,795</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt">Prepayments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-24619">197,706</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-24620">1,262,228</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline">Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Prepayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:OtherPrepaidExpenseNonCurrent" scale="0" unitRef="usd" id="ixv-24621">33,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:OtherPrepaidExpenseNonCurrent" scale="0" unitRef="usd" id="ixv-24622">1,582,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd" id="ixv-24623">33,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd" id="ixv-24624">1,582,156</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Included in prepayment is
an amount of $<span><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-24625">22,000</ix:nonFraction></span> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-24626">2,839,536</ix:nonFraction> as of December 31, 2024 and 2023 respectively, being
share-based compensation cost paid to consultants for services ranging from three to <ix:nonNumeric contextRef="c138" format="ixt-sec:durwordsen" name="nivf:ServicesRanging" id="ixv-24627">ten years</ix:nonNumeric> and with termination clauses of <ix:nonNumeric contextRef="c137" continuedAt="nivf_TerminationClauses-c137_cont_1" format="ixt-sec:durwordsen" name="nivf:TerminationClauses" id="ixv-24628">one</ix:nonNumeric> to
<ix:nonNumeric contextRef="c138" format="ixt-sec:durwordsen" name="nivf:TerminationClauses" id="ixv-24629"><ix:nonNumeric contextRef="c137" format="ixt-sec:durwordsen" name="nivf:ServicesRanging" id="ixv-24630">three<ix:continuation id="nivf_TerminationClauses-c137_cont_1"> years</ix:continuation></ix:nonNumeric></ix:nonNumeric> respectively without any penalties. During the year, the scope of service was amended and accordingly the excess compensation
was reversed against Additional Paid in Capital and the remaining value of service is recognized over the period of service in the Statement
of Income.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" id="ixv-21680"><ix:continuation id="_OtherCurrentAssetsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-24632">14</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-24633">141</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Reversal of provision (Provision)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision" scale="0" unitRef="usd" id="ixv-24634">10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision" scale="0" unitRef="usd" id="ixv-24635">127</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-24636">4</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-24637">14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-21731"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 7 &#8212;&#160;PROPERTY AND EQUIPMENT, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-21736"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Plant and equipment, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>At cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Building improvement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24638">196,929</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24639">92,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24640">25,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24641">250,493</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24642">785,776</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24643">844,809</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24644">142,936</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24645">142,936</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24646">361,385</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24647">150,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24648">1,512,416</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24649">1,481,364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-24650">1,239,320</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-24651">1,319,207</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-24652">273,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-24653">162,157</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Depreciation expenses for
the&#160;years ended December 31, 2024 and 2023 were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-24654">19,502</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-24655">31,173</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="-sec-ix-hidden: hidden-fact-110"><span style="-sec-ix-hidden: hidden-fact-111">No</span></span> impairment loss was recorded for the&#160;years
ended December&#160;31, 2024, and 2023.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-21851"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 8 &#8212;&#160;ACCRUED LIABILTIES AND OTHER
PAYABLES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-21856"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued liabilities and other payables consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24656">201,455</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24657">43,633</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:CustomerDeposit" scale="0" unitRef="usd" id="ixv-24658">6,349</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-24659">4,361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-24660">7,349</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Independent director fee payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:IndependentDirectorFeePayable" scale="0" unitRef="usd" id="ixv-24661">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compensation payable (Note&#160;1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_118_fact" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="0" unitRef="usd">100,802</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_119_fact" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="0" unitRef="usd">144,015</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-24664">167,762</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-24665">46,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24666">500,729</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24667">241,613</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0%">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><ix:footnote id="ix_6_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represents a claim relating to an employee of
the subsidiary. On April 23, 2023, a settlement agreement was entered into with the employee, with compensation payable over 12 instalments
commencing April 2023.</span></ix:footnote></td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="ixv-21969"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 9 &#8212;&#160;CONTRACT LIABILITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="ixv-21974"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Contract liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-24668">7,937</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-24669">1,360,168</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" scale="0" unitRef="usd" id="ixv-24670">75,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" scale="0" unitRef="usd" id="ixv-24671">112,006</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recognized to revenue during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" sign="-" unitRef="usd" id="ixv-24672">19,788</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" sign="-" unitRef="usd" id="ixv-24673">122,662</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Refund to customers (Note 1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_120_fact" name="us-gaap:ContractWithCustomerRefundLiability" scale="0" unitRef="usd">1,341,575</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-24675">63,489</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-24676">7,937</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0%">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><ix:footnote id="ix_7_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund to customers are in relation to China-based clients who prepaid
for surrogacy and ancillary caring services but requested for refund of fees so that they may appoint their own surrogate mothers in countries
in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service
contract with those clients.</span></ix:footnote></td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-22055"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 10 &#8212;&#160;CONVERTIBLE NOTES, PROMISSORY NOTES, DERIVATIVE
LIABILITY AND WARRANTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" id="ixv-22061"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Convertible notes, at amortised cost are as follows:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Convertible notes at amortised cost</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsGross" scale="0" unitRef="usd" id="ixv-24677">3,059,595</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: Deferred debt issuance cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedAmortizationDeferredFinanceCosts" scale="0" unitRef="usd" id="ixv-24678">648,232</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Convertible notes, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-24679">2,411,363</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>The convertible notes are repayable as follows:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Current liability</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-24680">82,447</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="0" unitRef="usd" id="ixv-24681">2,328,916</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-24682">2,411,363</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#160;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="ixv-22177"><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0">As of December 31, 2024, the Company had the following outstanding
convertible notes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Principal</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><b>Conversion</b></td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Coupon</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Issuance</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Maturity</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Note Holders</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td> <td>&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Price</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left">JAK &amp; affiliated holders</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd" id="ixv-24683">50,000</ix:nonFraction></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-24684">0.830</ix:nonFraction></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="4" format="ixt:num-dot-decimal" name="nivf:DebtInstrumentCouponRatePercentage" scale="-2" unitRef="pure" id="ixv-24685">14.75</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center"><ix:nonNumeric contextRef="c162" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-24686">April 3, 2024</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center"><ix:nonNumeric contextRef="c162" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-24687">October 2, 2028</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">JAK &amp; affiliated holders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd" id="ixv-24688">1,100,000</ix:nonFraction></td> <td>&#160;</td> <td>&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-24689">0.830</ix:nonFraction></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="4" format="ixt:num-dot-decimal" name="nivf:DebtInstrumentCouponRatePercentage" scale="-2" unitRef="pure" id="ixv-24690">14.75</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c164" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-24691">August&#160;3, 2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c164" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-24692">February 2, 2029</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">JAK &amp; affiliated holders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd" id="ixv-24693">500,000</ix:nonFraction></td> <td>&#160;</td> <td>&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-24694">0.950</ix:nonFraction></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="4" format="ixt:num-dot-decimal" name="nivf:DebtInstrumentCouponRatePercentage" scale="-2" unitRef="pure" id="ixv-24695">14.75</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c166" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-24696">August 30, 2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c166" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-24697">March 1, 2029</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">JAK &amp; affiliated holders</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd" id="ixv-24698">1,500,000</ix:nonFraction></td> <td>&#160;</td> <td>&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c167" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-24699">0.686</ix:nonFraction></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c167" decimals="4" format="ixt:num-dot-decimal" name="nivf:DebtInstrumentCouponRatePercentage" scale="-2" unitRef="pure" id="ixv-24700">14.75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c168" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentIssuanceDate1" id="ixv-24701">November 11, 2024</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c168" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-24702">May 10, 2029</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd" id="ixv-24703">3,150,000</ix:nonFraction></td> <td>&#160;</td> <td>&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">During the year ended December 31, 2024, a total
of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd" id="ixv-24704">5,800,000</ix:nonFraction> of convertible promissory notes were issued with a discount of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nivf:convertiblePromissoryNoteDiscountPercentage" scale="-2" unitRef="pure" id="ixv-24705">7</ix:nonFraction>%. These Notes are to be settled by way of cash or may be
converted to Class A ordinary shares. The conversion of these notes are subject to certain criterions as mentioned in the Convertible
Note Agreements, which include a beneficiary cap of <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeCapInterestRate" scale="-2" unitRef="pure" id="ixv-24706">9.9</ix:nonFraction>% of shareholdings in the Company by JAK.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
$<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd" id="ixv-24707">2,650,000</ix:nonFraction> of convertible notes were converted into <ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-24708">7,020,975</ix:nonFraction> ordinary shares by the note holder, thereby increasing our shareholder equity
by the same amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The effective interest expense calculated at <ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="0" unitRef="usd" id="ixv-24709">16.96</ix:nonFraction> % amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-24710">765,177</ix:nonFraction>
and $<span style="-sec-ix-hidden: hidden-fact-131">nil</span> for the year ended December 31, 2024 and December 31, 2023 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="nivf:ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" id="ixv-22312"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The transaction costs incurred
on issuance of the Notes are capitalized and amortised over the term of the Notes as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs on issuance of Notes</span></td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at beginning of the year</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add: capitalized during the year</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestCostsCapitalized" scale="0" unitRef="usd" id="ixv-24711">929,500</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: amortized during the year</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-24712">281,268</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-24713">648,232</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="ixv-22394"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth the Company&#8217;s contractual obligations as of December 31, 2024 relating to the convertible notes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Convertible bonds-</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-24714">516,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" unitRef="usd" id="ixv-24715">457,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" unitRef="usd" id="ixv-24716">457,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInFourthYear" scale="0" unitRef="usd" id="ixv-24717">507,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2029</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligationDueInFifthYear" scale="0" unitRef="usd" id="ixv-24718">3,269,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligation" scale="0" unitRef="usd" id="ixv-24719">5,207,625</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="nivf:ScheduleOfPromissoryNotesTableTextBlock" id="ixv-22445"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Promissory Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Balance at beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesIssued1" scale="0" unitRef="usd" id="ixv-24720">1,453,861</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Waiver of liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfLiability" scale="0" unitRef="usd" id="ixv-24721">953,861</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; padding-bottom: 4pt">Ending balance</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd" id="ixv-24722">500,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
the Company has outstanding non-interest-bearing unsecured promissory notes with a total principal balance of US$<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-24723">500,000</ix:nonFraction>, which was settled
fully in February 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Derivative liability </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to ASC 815, a derivative liability had
arisen from the issuance of convertible bonds which have the option of being converted to or exchanged for Class A ordinary shares at
any time from date of issuance. The derivative liability is assessed to be a debt requiring to be bifurcated from the host contract and
recorded at the fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">However, the conversion
to ordinary shares is subject to certain terms and criteria as set within the Agreement, which includes restriction of conversion if the
shareholdings by the note holder before and after the conversion exceeds <ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="nivf:PercentageOfConversionExceeds" scale="-2" unitRef="pure" id="ixv-24724">9.99</ix:nonFraction>%, as revised. As of December 31, 2024, the threshold has
been met, and accordingly the derivative is assessed to have no value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Free standing instruments &#8211; warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The convertible bond agreements as mentioned above
granted the note holders <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24725">6,174,690</ix:nonFraction> series A warrant, <ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24726">180,722</ix:nonFraction> series B warrant and <ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24727">3,253,012</ix:nonFraction> series C warrant, allowing the warrant holders
to purchase additional Class A ordinary shares at an exercise price of $<ix:nonFraction contextRef="c156" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24728">0.913</ix:nonFraction>, $<ix:nonFraction contextRef="c157" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24729">0.001</ix:nonFraction> and $<ix:nonFraction contextRef="c158" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24730">0.924</ix:nonFraction> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The exercise of these warrants
is subject to a <ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ProductWarrantyLiquidationProceedsPercentage" scale="-2" unitRef="pure" id="ixv-24731">9.99</ix:nonFraction>% beneficial cap, as revised, which restricts the holder from exceeding shareholdings in excess of the cap in the
Company. As of December 31, 2024, the threshold has been met, and accordingly the derivative is assessed to have no value.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-22543"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 11 &#8212;&#160;LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has various operating
leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The Company&#8217;s management believes
that the interest rate of <ix:nonFraction contextRef="c175" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-24732">6.6</ix:nonFraction>% and <ix:nonFraction contextRef="c176" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-24733">5.5</ix:nonFraction>% was the most indicative rate of the Company&#8217;s borrowing cost for the calculation of the
present value of the lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024 and 2023, the right-of-use&#160;assets
totaled $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-24734">98,570</ix:nonFraction>, and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-24735">283,847</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-22552"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024 and 2023, lease liabilities
consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Operating lease</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lease liabilities&#160;&#8211;&#160;current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-24736">108,526</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-24737">207,128</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities&#160;&#8211;&#160;non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-24738">10,231</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-24739">118,979</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-24740">118,757</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-24741">326,107</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Finance lease</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lease liabilities&#160;&#8211;&#160;current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-24742">6,446</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-22626"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is a schedule of future minimum
payments under operating leases as of December&#160;31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Not later than 1 year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-24743">111,321</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Between 1 to 2&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-24744">10,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-24745">121,621</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-24746">2,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total operating lease liabilities, net of interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-24747">118,757</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other lease information is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-24748">2.75</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-24749">0.92</ix:nonNumeric>&#160;years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Weighted-average discount rate&#160;&#8211;&#160;operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-24750">5</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-24751">5</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term lease cost</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" unitRef="usd" id="ixv-24752">234,767</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" unitRef="usd" id="ixv-24753">114,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, there were $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-24754">98,570</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-24755">283,847</ix:nonFraction> right of use (&#8220;ROU&#8221;) assets and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-24756">118,757</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-24757">326,107</ix:nonFraction> lease liabilities based on the
present value of the future minimum rental payments of leases, respectively. The Company&#8217;s management believes that using an incremental
borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate (&#8220;BLR&#8221;) minus <ix:nonFraction contextRef="c2" decimals="5" format="ixt:num-dot-decimal" name="nivf:IndicativeRateOfBorrowingCost" scale="-2" unitRef="pure" id="ixv-24758">0.125</ix:nonFraction>%&#160;was the
most indicative rate of the Company&#8217;s borrowing cost for the calculation of the present value of the lease payments; the rate used
by the Company was <ix:nonFraction contextRef="c177" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-24759">6.6</ix:nonFraction>% and <ix:nonFraction contextRef="c178" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-24760">5.5</ix:nonFraction>% respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-22727"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Ordinary shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As at December&#160;31, 2023
and December 31, 2024, the Company is authorized to issue <ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-24761"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-24762">10,000,000</ix:nonFraction></ix:nonFraction> ordinary shares. Each ordinary share is entitled to <ix:nonNumeric contextRef="c0" name="us-gaap:CommonStockVotingRights" id="ixv-24763">one</ix:nonNumeric> vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board
of Directors of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The equity of the Company
as of December 31, 2024 and 2023 represents <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24764">1,138,519</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24765">507,469</ix:nonFraction> ordinary shares with par value of $<span style="-sec-ix-hidden: hidden-fact-133"><span style="-sec-ix-hidden: hidden-fact-134">Nil</span></span>. The number of shares as above
have taken into consideration the reverse stock split effected on February 11, 2025 at an exchange ratio of one (1) share for twenty (20)
shares. Pursuant to ASC 505 the reverse stock split has been applied retrospectively.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c0_cont_1" escape="true" name="nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock" id="ixv-22755"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional paid-in capital</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance as at January 1,2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-24766">1,464,959</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of shares&#160;as compensation for services (<i>Note 1</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_121_fact" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">2,866,856</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-24768">4,331,815</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of shares through Equity Line of Credit (<i>Note 2</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_123_fact" name="nivf:StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" scale="0" unitRef="usd">1,936,236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of shares through conversion of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd" id="ixv-24770">2,650,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease in subscription receivable due to reduction of work by professionals <i>(Note 1)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_122_fact" name="nivf:DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" scale="0" unitRef="usd">2,766,856</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Combination (<i>Note 3</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_124_fact" name="nivf:ReverseCapitalization" scale="0" unitRef="usd">6,028,690</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Balance as at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-24773">122,505</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">- the number of shares below have been amended to apply the
reverse stock split in February 2025 retrospectively.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 1:&#160;<ix:footnote id="ix_8_footnote" xml:lang="en-US">On January 10, 2023, the Company issued <ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-24775">1,365</ix:nonFraction> ordinary
shares to professional party for consulting service of <ix:nonNumeric contextRef="c179" format="ixt-sec:duryear" name="nivf:ConsultingServiceTerm" id="ixv-24776">10</ix:nonNumeric> years, increasing the additional paid-in capital by $<ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAdditionalCapital" scale="0" unitRef="usd" id="ixv-24777">812,300</ix:nonFraction>. On December 4,
2023, the Company issued additional <ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-24778">3,450</ix:nonFraction> shares to DoubleClick Services Limited for consulting service of <ix:nonNumeric contextRef="c181" format="ixt-sec:duryear" name="nivf:ConsultingServiceTerm" id="ixv-24779">10</ix:nonNumeric> years, increasing the additional
paid-in capital by $<ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAdditionalCapital" scale="0" unitRef="usd" id="ixv-24780">2,054,556</ix:nonFraction>. During 2024, the service scope and duration were reduced and the service value was adjusted accordingly
pursuant to addendums to respective agreements</ix:footnote></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Note 2:</span> On November 21, 2024, the Company
entered into a Common Shares Purchase Agreement (the &#8220;White Lion Purchase Agreement&#8221;) with White Lion Capital, LLC (&#8220;White
Lion&#8221;) and a related Registration Rights Agreement (the &#8220;RRA&#8221;). Pursuant to the White Lion Purchase Agreement, the Company
has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One
Hundred Million Dollars ($<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" sign="-" unitRef="usd" id="ixv-24781">100,000,000</ix:nonFraction>) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to
Three Hundred Million Dollars ($<ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" sign="-" unitRef="usd" id="ixv-24782">300,000,000</ix:nonFraction>) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase
Agreement) and a further option to increase to Five Hundred Million Dollars ($<ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" sign="-" unitRef="usd" id="ixv-24783">500,000,000</ix:nonFraction>) after Two Hundred and Fifty Million Dollars
($<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" sign="-" unitRef="usd" id="ixv-24784">250,000,000</ix:nonFraction>) has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions
set forth in the White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration
statement filed on December 5, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 10, 2024, <ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24785">35,000</ix:nonFraction> Class A Ordinary
Shares were issued to White Lion amounting $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24786">276,850</ix:nonFraction>, in consideration for White Lion&#8217;s commitment pursuant to the White Lion Purchase
Agreement. In addition, on December 12, 2024, pursuant to this Agreement, the Company issued <ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24787">9,500</ix:nonFraction> Class A Ordinary Shares for a purchase
price of $<ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24788">1,572,186</ix:nonFraction>. On December 24, 2024, the Company issued <ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24789">25,000</ix:nonFraction> Class A Ordinary Shares for a purchase price of $<ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24790">160,050</ix:nonFraction>. On December
31, 2024, the Company issued <ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24791">30,000</ix:nonFraction> Class A Ordinary Shares for a purchase price of $<ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-24792">204,000</ix:nonFraction>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Note 3: <ix:footnote id="ix_10_footnote" xml:lang="en-US">Upon de-spac business combination, additional paid-in capital
and capital reserve of Legacy NewGenIvf was combined with additional paid-in capital and accumulated net losses of the A SPAC I Acquisition
Corp and added into the additional paid-in capital of NewGenIvf Group upon the reverse take-over.</ix:footnote></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CompensationAndEmployeeBenefitPlansTextBlock-c0_cont_1" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-22839"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 13 &#8212;&#160;EMPLOYEE BENEFIT PLANS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>HK SAR</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at <ix:nonFraction contextRef="c191" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ManagementAndServiceFeesRate" scale="-2" unitRef="pure" id="ixv-24794">5</ix:nonFraction>% of the employees&#8217;
basic salaries on monthly basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Thailand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is obliged to
make social security payments within the first 15&#160;days of the month over which it is accrued. In 2024, the Company and its employees
are each required to make contributions to the scheme calculated at <ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" unitRef="pure" id="ixv-24795">5</ix:nonFraction>% of the employee&#8217;s salary with a cap of <span style="-sec-ix-hidden: hidden-fact-137"><span style="-sec-ix-hidden: hidden-fact-138">THB750</span></span> per month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cambodia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Every business employing
one or more workers must register its business and workers with the National Social Security Fund (the &#8220;NSSF&#8221;) for the Occupational
Risk Scheme (for work-related&#160;accidents and occupational diseases), the Health Care Scheme and the Pension Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once registered, the business
must pay to the NSSF:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to <ix:nonFraction contextRef="c193" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" unitRef="pure" id="ixv-24796">0.8</ix:nonFraction>% of each worker&#8217;s monthly average wages (between $<ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" unitRef="usd" id="ixv-24797">0.40</ix:nonFraction> and $<ix:nonFraction contextRef="c195" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" unitRef="usd" id="ixv-24798">2.40</ix:nonFraction> per month per worker) for the Occupational Risk Scheme.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to <ix:nonFraction contextRef="c196" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" unitRef="pure" id="ixv-24799">2.6</ix:nonFraction>% of a worker&#8217;s monthly average wages (between $<ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" unitRef="usd" id="ixv-24800">1.30</ix:nonFraction> and $<ix:nonFraction contextRef="c198" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" unitRef="usd" id="ixv-24801">7.80</ix:nonFraction> per month per worker) for the Health Care Scheme.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of <ix:nonFraction contextRef="c199" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" unitRef="pure" id="ixv-24802">2</ix:nonFraction>% (total of <ix:nonFraction contextRef="c200" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" unitRef="pure" id="ixv-24803">4</ix:nonFraction>%) of the contributable wage for the first five&#160;years. The contributable wage for the Pension Scheme ranges from between <span style="-sec-ix-hidden: hidden-fact-136">KHR400,000</span> (approximately $<ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="0" unitRef="usd" id="ixv-24804">100</ix:nonFraction>) up to <span style="-sec-ix-hidden: hidden-fact-135">KHR1,200,000</span> (approximately $<ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="0" unitRef="usd" id="ixv-24805">300</ix:nonFraction>).</span></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation id="_CompensationAndEmployeeBenefitPlansTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Kyrgyzstan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at <ix:nonFraction contextRef="c203" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ManagementAndServiceFeesRate" scale="-2" unitRef="pure" id="ixv-24806">15</ix:nonFraction>% and <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ManagementAndServiceFeesRate" scale="-2" unitRef="pure" id="ixv-24807">8</ix:nonFraction>%, respectively
of the employees&#8217; basic salaries on monthly basis.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-22919"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;PROVISION FOR INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cayman Islands</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NewGenIvf Limited was incorporated
in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law. In addition, upon payment
of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>HK SAR</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" name="nivf:ProfitTaxDescription" id="ixv-24808">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived from
Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, the HK SAR profits
tax is calculated at <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-24809">8.25</ix:nonFraction>% on the first HK$<ix:nonFraction contextRef="c204" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" unitRef="hkd" id="ixv-24810">2</ix:nonFraction>&#160;million of the estimated assessable profits and at <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" scale="-2" unitRef="pure" id="ixv-24811">16.5</ix:nonFraction>% on the remaining estimated
assessable profits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Thailand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The companies incorporated
in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from or in consequence of the
business carried on in Thailand. The corporate income tax (CIT) rate is <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" scale="-2" unitRef="pure" id="ixv-24812">20</ix:nonFraction>%. A foreign company not carrying on business in Thailand is
subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends, royalties, rentals, and service
fees) paid from or in Thailand. The rate of tax is generally <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" unitRef="pure" id="ixv-24813">15</ix:nonFraction>%, except for dividends, which is <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nivf:EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" scale="-2" unitRef="pure" id="ixv-24814">10</ix:nonFraction>%, while other rates may apply under
the provisions of a double tax treaty (DTT).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cambodia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The standard rate of corporate
income tax (&#8220;CIT&#8221;) for companies and permanent establishments who are classified as medium and large taxpayers is <ix:nonFraction contextRef="c205" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" scale="-2" unitRef="pure" id="ixv-24815">20</ix:nonFraction>%. For
companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive rates from <ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-24816">0</ix:nonFraction>% to <ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-24817">20</ix:nonFraction>%. In view
of the annual turnover of the company, the annual turnover ranges from <span style="-sec-ix-hidden: hidden-fact-152">KHR1</span>&#160;billion to <span style="-sec-ix-hidden: hidden-fact-153">KHR6</span>&#160;billion for service and commercial
sectors, the company shall consider as the medium-sized&#160;company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Kyrgyzstan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company is subject to
a corporate income tax on their aggregate annual income earned worldwide. Non-resident&#160;legal entities carrying out business activities
through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that permanent
establishments. During the year, excess tax payable of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:DeemedExcessTaxPayable" scale="0" unitRef="usd" id="ixv-24818">486,706</ix:nonFraction> were deemed to be no longer payable and reversed accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Profit tax is calculated
at a rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" unitRef="pure" id="ixv-24819">10</ix:nonFraction>% of aggregate annual income less allowed deductions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-22960"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Significant components of
the provisions for income taxes for the year ended December&#160;31, 2024, and 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Current tax provision Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: justify">Over provision of tax in prior year Kyrgyzstan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-24820">486,706</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: justify">Current tax provision Cambodia</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total tax (income) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-24821">486,706</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-23024"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-bottom: 1.5pt">(Loss) Income before taxes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24822">960,807</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24823">108,418</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24824">343,988</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax credit (expense) at the effective tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-24825">179,863</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" unitRef="usd" id="ixv-24826">10,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-24827">124,591</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax effect on non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="0" sign="-" unitRef="usd" id="ixv-24828">81,323</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="0" sign="-" unitRef="usd" id="ixv-24829">39,173</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax effect on non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" unitRef="usd" id="ixv-24830">129,814</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" unitRef="usd" id="ixv-24831">369,101</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-24832">131,991</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-24833">28,441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax effect on utilization of tax losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" sign="-" unitRef="usd" id="ixv-24834">127,521</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" sign="-" unitRef="usd" id="ixv-24835">36,369</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax losses unable to be utilized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" unitRef="usd" id="ixv-24836">126,902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Over provision of tax in prior year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" scale="0" sign="-" unitRef="usd" id="ixv-24837">486,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Tax (income) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-24838">486,706</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-24839">208,141</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax asset, net</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-23191"><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">Significant components of deferred tax assets,
net were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">&#8211; Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-24840">160,432</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-24841">28,441</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-24842">160,432</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-24843">28,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, the Company had net operating loss carry forward of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-24844">972,316</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-24845">164,721</ix:nonFraction>. The Company believes it is less likely than not that
its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry forward. As a result, the
Company provided <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nivf:PercentageOfAllowanceOnDeferredTaxAssets" scale="-2" unitRef="pure" id="ixv-24846">100</ix:nonFraction>% allowance on deferred tax assets on net operating loss.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-23258"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 15 &#8212;&#160;DISAGGREGATED REVENUES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="ixv-23263"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s main business operations are
to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">IVF treatment service</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24847">5,433,375</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24848">4,021,696</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24849">2,819,163</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Surrogacy, ancillary caring and other services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24850">1,114,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24851">3,125,027</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24852">5,433,375</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24853">5,136,153</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24854">5,944,190</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="ixv-23328"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Geographical information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers originated from</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24855">34,038</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24856">2,656,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24857">3,123,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24858">5,060,973</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24859">601,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24860">621,619</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24861">377,608</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24862">2,175,253</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24863">1,356,903</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24864">505,609</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24865">5,433,375</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24866">5,136,153</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24867">5,944,190</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisaggregationOfRevenueTableTextBlock-c0_cont_1" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="ixv-23424"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The revenue information above is based on the
locations where the revenue originated.</p></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_RevenueFromContractWithCustomerTextBlock-c0_cont_1"><ix:continuation id="_DisaggregationOfRevenueTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Long-lived assets located at</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24868">3,081</ix:nonFraction></td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24869">584</ix:nonFraction></td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="width: 1%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>China</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24870">8,370</ix:nonFraction></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24871">22,513</ix:nonFraction></td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24872">47,902</ix:nonFraction></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24873">137,472</ix:nonFraction></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24874">229,085</ix:nonFraction></td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24875">312,313</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24876">307,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24877">254,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24878">371,666</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24879">446,004</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24880">506,343</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s long-lived&#160;assets consist
of plant and equipment, net and operating leases right-of-use&#160;assets, net.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-23553"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 16 &#8212;&#160;RISKS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">A. Credit risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Accounts receivable</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to minimize the
credit risk, the management of the Company monitors and ensures that follow-up&#160;action is taken to recover overdue debts. The Company
considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk
on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Company compares
the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition.
It considers available reasonable and supportive forward-looking&#160;information, such as GDP growth rate and nominal GDP per capita.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account receivables as of December
31, 2024 and 2023 to be $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-24881"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-24882">19</ix:nonFraction></ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash and cash equivalents</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The credit risk on liquid
funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&#160;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Deposits and other receivables, amount due
from shareholders and loan to A SPAC I</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company assessed the
impairment for deposits and other receivables, due from shareholders individually based on internal credit rating and ageing of these
debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition. Based on the impairment
assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables, due from shareholders
as of December&#160;31, 2024 is $<ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-24883">4</ix:nonFraction>, and $<ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-24884">17,818</ix:nonFraction>, respectively. The loss allowance for deposits and other receivables, due from shareholders
as of December&#160;31, 2023 is $<ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-24885">14</ix:nonFraction>, and $<ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-24886">17,818</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">B.&#160;Interest
risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cash flow interest rate risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is exposed to
cash flow interest rate risk through the changes in interest rates related mainly to the Company&#8217;s variable-rates&#160;bank balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company currently does
not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk. The directors
monitor the Company&#8217;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sensitivity analysis</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The sensitivity analysis
below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period and had been applied
to the exposure to interest rates for financial instruments in existence at that date. <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" unitRef="pure" id="ixv-24887">1</ix:nonFraction>% increase or decrease is used when reporting
interest rate risk internally to key management personnel and represents management&#8217;s assessment of the reasonably possible change
in interest rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If interest rates had been
<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nivf:InterestRateOtherVariablesPercentage" scale="-2" unitRef="pure" id="ixv-24888">1</ix:nonFraction>% higher or lower and all other variables were held constant, the Company&#8217;s net (loss) income for the&#160;years ended December
31, 2024 and 2023 would have increased or decreased by approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPensionPlanObligations" scale="0" unitRef="usd" id="ixv-24889">26,894</ix:nonFraction> and$<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPensionPlanObligations" scale="0" unitRef="usd" id="ixv-24890">541</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Foreign currency risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign currency risk is
the risk that the holding of foreign currency assets will affect the Company&#8217;s financial position as a result of a change in foreign
currency exchange rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s monetary
assets and liabilities are mainly denominated in HK$, THB and RMB which are the same as the functional currencies of the relevant group
entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered insignificant. The Company currently
does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related foreign currency
exposure closely and will consider hedging significant foreign currency exposures should the need arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">C. Economic and political
risks</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s operations
are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&#8217;s business, financial condition, and results
of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s operations
in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include risks associated with,
among others, the political, economic and legal environment and foreign currency exchange. The Company&#8217;s results may be adversely
affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies
with respect to laws and regulations, anti-inflationary&#160;measures, currency conversion, remittances abroad, and rates and methods
of taxation, among other things including natural disasters and wars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">D. Inflation risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management monitors changes
in prices levels. Historically inflation has not materially impacted the Company&#8217;s consolidated financial statements; however, significant
increases in the price of labor that cannot be passed to the Company&#8217;s customers could adversely impact the Company&#8217;s results
of operations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-23629"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 17 &#8212;&#160;RELATED PARTY BALANCES AND TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-23634"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The summary of amount due from and due to related
parties as the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Due from shareholders consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 30%; text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c234" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-24891">Shareholders and directors</ix:nonNumeric></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-24892">404,549</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-24893">354,285</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Due to a related party consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c237" id="ix_125_fact" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Shareholders and directors (note 1)</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" id="ix_126_fact" name="nivf:DueToARelatedParty" scale="0" unitRef="usd">497,200</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Harcourt Limited</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c239" id="ix_127_fact" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">A related party (note&#160;2)</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" id="ix_128_fact" name="nivf:DueToARelatedParty" scale="0" unitRef="usd">61,802</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">JAK &amp; affiliated holders</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c242" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-24898">5% or more shareholder</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueToARelatedParty" scale="0" sign="-" unitRef="usd" id="ixv-24899">3,150,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:</span>
</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:footnote id="ix_11_footnote" xml:lang="en-US">Ms. Fong is the spouse of Mr.&#160;Siu. The due to shareholders balance
as of December 31, 2024 was $<ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24901">92,651</ix:nonFraction> while the due from shareholders balance as of December 31, 2023 was $<ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-24902">354,285</ix:nonFraction>.</ix:footnote></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><ix:footnote id="ix_12_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</span></ix:footnote></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" id="ixv-23776"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The balance due from shareholders consist of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Due from/ (to)shareholders/ related party</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueFromtoshareholdersRelatedParty" scale="0" sign="-" unitRef="usd" id="ixv-24903">154,453</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueFromtoshareholdersRelatedParty" scale="0" unitRef="usd" id="ixv-24904">372,103</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24905">17,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:AccountsReceivableAfterAllowanceForCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-24906">154,453</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:AccountsReceivableAfterAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-24907">354,285</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="ixv-23825"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24908">17,818</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24909">17,059</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Reversal of Provision / (Provision)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-24910">17,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-24911">759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24912">17,818</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" id="ixv-23874"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Directors&#8217; remuneration to Mr.&#160;Siu Wing Fung, Alfred</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd" id="ixv-24913">190,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd" id="ixv-24914">125,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd" id="ixv-24915">120,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd" id="ixv-24916">190,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd" id="ixv-24917">125,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd" id="ixv-24918">120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Waiver of related party balance of Mr. Siu Wing Fung, Alfred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" sign="-" unitRef="usd" id="ixv-24919">88,151</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Coupon interest expense  to JAK Opportunities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd" id="ixv-24920">308,751</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Conversion of convertible note to shares to JAK Opportunities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd" id="ixv-24921">2,650,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ShortTermDebtTextBlock" id="ixv-23974"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 18 &#8212;&#160;LOAN TO A SPAC&#160;I</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June&#160;12, 2023, NewGenIvf
Limited (the &#8220;Legacy NewGenIvf&#8221;) and A SPAC&#160;I Acquisition Corp (&#8220;A SPAC&#160;I&#8221;) entered into a First Amendment
to Merger Agreement, pursuant to which the Legacy NewGenIvf agreed to provide non-interest&#160;bearing loans in an aggregate principal
amount of up to $<ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" scale="0" unitRef="usd" id="ixv-24922">560,000</ix:nonFraction> (the &#8220;Loan&#8221;) to A SPAC&#160;I to fund amounts required to further extend the period of time available
for A SPAC&#160;I to consummate a business combination, and for working capital and payment of professional, administrative and operational
expenses, and other purposes as mutually agreed by A SPAC&#160;I and the Legacy NewGenIvf. The Loan will only become repayable upon the
closing of the Acquisition Merger. As of December 31, 2023, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd" id="ixv-24923">140,000</ix:nonFraction> was outstanding under the loan. The Legacy NewGenIvf completed the
business combination with A SPAC I Acquisition Corp on April 3, 2024. After the combination, the balance of loan to ACSA was eliminated
in the subsequent period.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-23983"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 19 &#8212;&#160;COMMITMENTS &amp; <span style="text-transform: uppercase">CONTINGENCIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, the Company was not a party to any legal or administrative proceedings. As of December 31, 2024, the Company had commitment as described
in Notes 10 and 11 to the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is also committed
to honor its obligations pursuant to the convertible note agreements as described in Note 10</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="nivf:DisposalOfSubsidiaryTextBlock" id="ixv-24007"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 20 &#8212;&#160;<span style="text-transform: uppercase">DISPOSAL
OF SUBSIDIARY</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 18, 2024, the
Company completed the sale of its First Fertility Bishkek LLC to an unrelated third party for total consideration of US$<ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="0" unitRef="usd" id="ixv-24924">11</ix:nonFraction>, consisting
of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As part of the disposal,
all the outstanding account payables and receivables as well as all outstanding balances between the First Fertility Bishkek LLC and Harcourt,
FFPGS, and the Director were transferred to the Seller. Any tax liabilities in Kyrgyzstan arising from the transfer of these balances
shall be borne by the Buyer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">The following table summarizes the financial impact
of the disposal:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration received: Cash of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="0" unitRef="usd" id="ixv-24925">11</ix:nonFraction> </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt">Net assets acquired of&#160;$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd" id="ixv-24926">486,706</ix:nonFraction></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reversal of excess tax of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" scale="0" unitRef="usd" id="ixv-24927">486,706</ix:nonFraction></span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The disposal was accounted for in accordance with ASC 810, Consolidation.
As a result, the Company deconsolidated First Fertility Bishkek LLC and recognized a write back of tax (after netting against the cash
consideration received) in the amount of US$<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-24928">486,706</ix:nonFraction> in the consolidated statements of operations for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">The disposal did not represent a strategic shift
and, therefore, was not classified as a discontinued operation under ASC 205-20.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="ixv-24048"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 21 &#8212;&#160;<span style="text-transform: uppercase">BUSINESS
ACQUISITION</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">On December 17, 2024, the Company acquired Bi
Clinic Ltd (&#8220;Bi Clinic&#8221;), which holds a license for the provision of IVF treatment, surrogacy, and ancillary caring services,
for total consideration of $<ix:nonFraction contextRef="c262" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd" id="ixv-24929">15,000</ix:nonFraction>. The acquisition enhances the Company&#8217;s position in healthcare fertility sector. The transaction
was accounted for as a business combination under ASC 805, Business Combinations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">At the acquisition date, Bi Clinic had not yet
commenced revenue-generating activities but had established the necessary regulatory approvals and licensing framework to operate as an
IVF and surrogacy service provider. These approvals, along with the Company&#8217;s planned integration of medical personnel and operational
processes, provide the necessary inputs and substantive processes required to meet the definition of a business under ASC 805.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">Since Bi Clinic had no other assets or liabilities,
the entire purchase price was allocated to intangible assets, specifically the IVF license and regulatory approvals. No goodwill was recognized
in connection with the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">As Bi Clinic had no prior operations, its financial
results have been included in the consolidated financial statements from the acquisition date, with no historical revenue or expenses
impacting the Company&#8217;s consolidated results. Pro forma financial information has been omitted, as the acquisition is not considered
material to the Company&#8217;s financial results.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-24065"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 22 &#8212;&#160;SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluated subsequent
events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon
this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or
disclosure in the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 11, 2025, the
Company carried out a <ix:nonNumeric contextRef="c263" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-24930">1-for-20</ix:nonNumeric> reverse stock split of its issued and unissued shares. The effect of the reverse stock split was to consolidate
every 20 issued and unissued shares into one share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 24, 2025, the
Company entered into a Consulting Services Agreement with A SPAC (Holdings) Group Corp (&#8220;ASPAC&#8221;), pursuant to which the Company
engaged ASPAC for the provision of certain consulting services. It was agreed that the Company would provide consideration in the form
of cash and shares. On March 3, 2025, the Company issued the <ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24931">150,000</ix:nonFraction> Class A Ordinary Shares to ASPAC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 27, 2025, the
Company received a confirmation from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved
and that the Company&#8217;s securities were transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025.
On March 10, 2025, the Company received a confirmation letter from Nasdaq confirming that it has demonstrated compliance with all of Nasdaq&#8217;s
listing requirements, including shareholder equity of more than $<ix:nonFraction contextRef="c265" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOther" scale="6" unitRef="usd" id="ixv-24932">2.5</ix:nonFraction>m, as required in the Panel&#8217;s decision letter dated February
19, 2025</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 28, 2025, the
Company completed its acquisition of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&#8220;GIVF&#8221;). Pursuant to
a Purchase Agreement dated January 21, 2025 between the Company and GIVF (&#8220;Purchase Agreement&#8221;), the Company purchased all
of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort
technology from GIVF for a cash consideration of $<ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="nivf:CashConsideration" scale="0" unitRef="usd" id="ixv-24933">750,000</ix:nonFraction> and a share consideration of <ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24934">125,000</ix:nonFraction> Ordinary Shares (&#8220;MicroSort Acquisition&#8221;).
Under the terms of the agreement, the Company acquired the technology for US$<ix:nonFraction contextRef="c268" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" unitRef="usd" id="ixv-24935">5</ix:nonFraction> million, which was satisfied through a combination of US$<ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" unitRef="usd" id="ixv-24936">750,000</ix:nonFraction>
in cash and the issuance of <ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24937">2,500,000</ix:nonFraction> ordinary shares (as was adjusted to <ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-24938">125,000</ix:nonFraction> ordinary shares after the Reverse Stock Split on February
11, 2025) at a deemed value of US$<ix:nonFraction contextRef="c271" decimals="2" format="ixt:num-dot-decimal" name="nivf:DeemedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24939">1.70</ix:nonFraction> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 18, 2025, the
Company entered into a cooperation agreement with FERTILITY GROUP LLC (&#8220;BOBCARE&#8221;) to jointly develop fertility services in
the Kyrgyzstan market. The collaboration aims to combine NewGen&#8217;s technical expertise in fertility treatments with BOBCARE&#8217;s
market resources in the region. This strategic partnership is anticipated to contribute to NewGen&#8217;s market presence over the next
three years, improving the competitive position of both parties in the Kyrgyzstan market. Both companies will work together on several
initiatives, including enhancing clinical protocols and patient management systems, knowledge exchange between fertility specialists,
coordinated marketing and brand-building activities in Kyrgyzstan, and developing specialized fertility treatment options for the regional
market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 31, 2025, the Company
terminated the binding term sheet with healthcare company European Wellness Investment Holdings Limited (&#8220;EWIHL&#8221;) regarding
their previously announced reverse merger transaction. On the grounds of non fulfilment of certain criteria as contained in the term sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 31, 2025, the Company&#8217;s Board approved certain amendments
to its Share Incentive Plan of 2024, the awards of which are valid for a period of <ix:nonNumeric contextRef="c272" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-24940">10</ix:nonNumeric> years from March 28, 2025, whereby the maximum aggregate
number of shares with respect to which Awards may be granted under the Plan shall be <ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-24941">1,054,260</ix:nonFraction> Shares, which may be increased from time
to time as determined by the Board or Committee of the Board, in an amount equal to <ix:nonFraction contextRef="c272" decimals="2" format="ixt:num-dot-decimal" name="nivf:OutstandingPercentage" scale="-2" unitRef="pure" id="ixv-24942">20</ix:nonFraction>% of the then outstanding ordinary shares of the
Company at the time of such increase. Shares may be made available from Shares held in treasury or authorized but unissued shares of the
Company not reserved for any other purpose. To date, no shares have been awarded under this Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">On April 1, 2025, the
Company entered into a new Securities Purchase Agreement (&#8220;2025 Securities Purchase Agreement&#8221;) with JAK, pursuant to which,
amongst other things: (i) the Company agreed to sell, at an initial closing, a senior convertible note in the aggregate original principal
amount of $<ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-24943">3,200,000</ix:nonFraction>, convertible into Class A Ordinary Shares pursuant to its terms; and (ii) the Company may require JAK (or JAK may
require the Company, as applicable) to participate in the sale of one or more additional convertible notes (which aggregate original
principal amount for all additional convertible notes shall not exceed $<ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-24944">25,600,000</ix:nonFraction>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 2, 2025, the Company
consummated the fourth tranche of its debt financing under the terms of its existing Securities Purchase Agreement with the investor,&#160;At
the closing of the fourth tranche, the Company sold&#160;to&#160;the investor a senior convertible note in the principal amount of $<ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-24945">2,000,000</ix:nonFraction>.
The Note&#160;bears an interest rate of <ix:nonFraction contextRef="c276" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-24946">14.75</ix:nonFraction>% per annum and may be adjustable from time to time pursuant to its terms. The funding from
these arrangements with the investor is intended to be used to finance the establishment of a fertility clinic in Dubai.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span>Mr.
Yip Eng Jeremy Foo, a director of NewGenIvf Group Limited (the &#8220;Company&#8221;), has resigned from the Board of Directors of the
Company, the Audit Committee of the Company, and the Compensation Committee of the Company due to personal reasons, effective April 4,
2025. Mr. Foo&#8217;s resignation did not result from any disagreement with the Board or the Company on any matter relating to the Company&#8217;s
operations, policies or practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ms. Florianna Ann Chi Wan
Chan will be appointed as a director of the Company, effective April 15, 2025, to fill the vacancy on the Audit Committee and the Compensation
Committee created by Mr. Foo&#8217;s resignation. Ms Chan has over 20 years of experience in project management, real estate development,
and luxury hospitality, and is a proven leader in driving growth and operational excellence. Since 2015, Ms. Chan has led Lab Concept
Company Limited, a subsidiary of The Lane Crawford Joyce Group, where she successfully restructured operations, spearheaded rebranding,
and digitized processes, achieving significant revenue growth. Previously, she held senior roles at VCC Company Limited, Eton Properties,
and Crown Macau, excelling in real estate development, marketing, and VIP services. She holds a Bachelor of Hospitality Management from
Central Queensland University in Australia and an Advanced Diploma from William Angliss Institute of TAFE. Fluent in Cantonese, Mandarin,
and English, Ms. Chan brings a deep understanding of Asia Pacific markets and a strategic vision that will drive the Company&#8217;s
continued growth and success.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 15, 2025, the Board
of Directors approved another reverse stock split of all of the Company&#8217;s issued and unissued shares, including the Class A ordinary
shares with no par value (the &#8220;Class A Ordinary Shares&#8221;), Class B ordinary shares with no par value and preferred shares with
no par value, at an exchange ratio of one (1) share for ten (10) shares. The Company expects that the Reverse Stock Split will become
effective on or around May 2, 2025, and that its Class A Ordinary Shares will begin trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
on a post-Reverse Stock Split basis on such date. The Reverse Stock Split is intended for the Company to remain compliant with a minimum
bid price of $<ix:nonFraction contextRef="c277" decimals="2" format="ixt:num-dot-decimal" name="nivf:BidPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24947">1.00</ix:nonFraction> per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No fractional shares will
be issued in connection with the Reverse Stock Split. Instead, the Company will issue one full post-Reverse Stock Split Class A Ordinary
Share to any shareholder at a participant level who would have been entitled to receive a fractional share as a result of the process.
After the Reverse Stock Split, all options, warrants and other convertible securities of the Company outstanding immediately prior to
the Reverse Stock Split will be adjusted by dividing the number of Class A Ordinary Shares into which the options, warrants and other
convertible securities are exercisable or convertible by ten (10) in accordance with the terms of the plans, agreements or arrangements
governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subsequent to the year end
and to the date of this report, $<ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-24948">3,150,000</ix:nonFraction> convertible notes outstanding as of December 31, 2024 had been converted to additional <ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares" id="ixv-24949">2,594,252</ix:nonFraction>
Class A ordinary shares while Promissory Notes of $<ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd" id="ixv-24950">500,000</ix:nonFraction> outstanding as of December 31, 2024 were settled. A further <ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-24951">1,660,000</ix:nonFraction> shares
totaling $<ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-24952">5,193,763</ix:nonFraction> were issued under the Equity Line of Credit with White Lion.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than the events mentioned
above, there have been no other subsequent events noted till the date of these financial statements.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:Reclassifications" id="ixv-24137"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 23 &#8212;&#160;RECLASSIFICATION
AND COMPARATIVE FIGURES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">Certain prior year amounts
have been reclassified to conform to the current year&#8217;s presentation. These include the re-presentation of share-based compensation
to consultants pursuant to service agreements. In the prior year, compensation for future services to be rendered were recorded as subscription
receivables in the Statement of Equity. In the current year, these compensation for services has been reclassified and measured at the
fair value of the shares issued as compensation at grant date in accordance with ASC 718. This reclassification had no effect on previously
reported&#160;net&#160;income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">The comparative figures in the consolidated balance sheets, statement
of equity, consolidated statements of cash flows, together with the accompanying notes, where relevant reflect those of the Company after
the reverse takeover and reorganization process in 2024, and accordingly differs from those audited and reported on by the predecessor
auditor on NewGenIvf Limited, the legal acquiree and accounting acquirer, arising from the application of ASC 805, which requires retrospective
application. The difference mainly impacts the equity in the consolidated balance sheets, the statement of equity and the consolidated
statements of cash flows, including the relevant notes.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white">F-32</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">F-1/A</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:DepositsAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="nivf:ReceivableFromAgents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="nivf:LoanToASPAC" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="nivf:DueFromShareholders" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-7" name="us-gaap:ConvertibleNotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-8" name="us-gaap:OtherNotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-9" name="us-gaap:ConvertibleLongTermNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-10" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-11" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-12" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-13" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-14" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-15" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-16" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-17" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-18" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-19" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-20" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-21" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-22" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-23" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-25" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-26" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-32" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-33" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-34" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-35" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-36" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-37" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-38" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-39" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-40" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-41" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-42" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-43" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-44" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-45" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-46" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-50" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-51" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-52" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-53" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-54" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-55" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-56" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-57" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-58" name="nivf:StockIssuedDuringPeriodValueReverseCaptialization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-59" name="nivf:StockIssuedDuringPeriodValueReverseCaptialization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-60" name="nivf:StockIssuedDuringPeriodValueReverseCaptialization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-61" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-62" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-63" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-64" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-65" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-66" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-67" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-68" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-69" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-70" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-72" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-73" name="nivf:AmortisationOfShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-74" name="nivf:AmortisationOfShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-75" name="nivf:NonCashDiscountOnConvertibleNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-76" name="nivf:NonCashDiscountOnConvertibleNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-77" name="us-gaap:ProvisionForOtherCreditLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-78" name="us-gaap:InterestExpenseDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-79" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-80" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-81" name="us-gaap:GainLossOnTerminationOfLease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-82" name="us-gaap:GainLossOnTerminationOfLease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-83" name="nivf:GainOnPromissoryNote" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-84" name="nivf:GainOnPromissoryNote" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-85" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-86" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-87" name="us-gaap:LegalFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-88" name="us-gaap:LegalFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-89" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-90" name="us-gaap:IncreaseDecreaseInFinanceReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-91" name="us-gaap:IncreaseDecreaseInFinanceReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-92" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-93" name="nivf:ProceedsFromAmountDueFromASPACI" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-94" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-95" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-96" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-97" name="nivf:PaymentofInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-98" name="nivf:SubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-99" name="nivf:SubscriptionReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-100" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-101" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c123" id="hidden-fact-102" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember</ix:nonNumeric>
<ix:nonNumeric contextRef="c2" id="hidden-fact-103" name="us-gaap:LesseeOperatingLeaseTermOfContract">P12M</ix:nonNumeric>
<ix:nonFraction contextRef="c98" id="hidden-fact-104" name="us-gaap:ConcentrationRiskPercentage1" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-105" name="us-gaap:ConcentrationRiskPercentage1" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c134" id="hidden-fact-106" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-107" name="us-gaap:DeferredCostsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-108" name="us-gaap:DepositAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-109" name="nivf:ReceivableFromAgents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-110" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-111" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-112" name="nivf:CustomerDeposit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-113" name="nivf:IndependentDirectorFeePayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-114" name="us-gaap:ContractWithCustomerRefundLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-115" name="us-gaap:DeferredFinanceCostsGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-116" name="us-gaap:AccumulatedAmortizationDeferredFinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-117" name="us-gaap:DeferredFinanceCostsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-118" name="us-gaap:ConvertibleNotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-119" name="us-gaap:ConvertibleLongTermNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-120" name="us-gaap:ConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-121" name="us-gaap:DeferredFinanceCostsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-122" name="us-gaap:DeferredFinanceCostsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-123" name="us-gaap:InterestCostsCapitalized" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-124" name="us-gaap:AmortizationOfFinancingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-125" name="us-gaap:DeferredFinanceCostsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-126" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-127" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c173" id="hidden-fact-128" name="us-gaap:NotesIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c173" id="hidden-fact-129" name="nivf:WaiverOfLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-130" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-131" name="us-gaap:InterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-132" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_9_footnote" xml:lang="en-US">On November 21, 2024, the Company entered into a Common Shares Purchase Agreement (the &#8220;White Lion Purchase Agreement&#8221;) with White Lion Capital, LLC (&#8220;White Lion&#8221;) and a related Registration Rights Agreement (the &#8220;RRA&#8221;). Pursuant to the White Lion Purchase Agreement, the Company has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One Hundred Million Dollars ($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to Three Hundred Million Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase Agreement) and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000) has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth in the White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration statement filed on December 5, 2024.
On December 10, 2024, 35,000 Class A Ordinary Shares were issued to White Lion amounting $276,850, in consideration for White Lion&#8217;s commitment pursuant to the White Lion Purchase Agreement. In addition, on December 12, 2024, pursuant to this Agreement, the Company issued 9,500 Class A Ordinary Shares for a purchase price of $1,572,186. On December 24, 2024, the Company issued 25,000 Class A Ordinary Shares for a purchase price of $160,050. On December 31, 2024, the Company issued 30,000 Class A Ordinary Shares for a purchase price of $204,000.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Additional Paid-in Capital-->
<ix:nonFraction contextRef="c2" id="hidden-fact-133" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-134" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c202" decimals="0" id="hidden-fact-135" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="kzt">1200000</ix:nonFraction>
<ix:nonFraction contextRef="c201" decimals="0" id="hidden-fact-136" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="kzt">400000</ix:nonFraction>
<ix:nonFraction contextRef="c175" decimals="0" id="hidden-fact-137" name="us-gaap:SpecialAssessmentBond" unitRef="thb">750</ix:nonFraction>
<ix:nonFraction contextRef="c176" decimals="0" id="hidden-fact-138" name="us-gaap:SpecialAssessmentBond" unitRef="thb">450</ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-139" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c207" id="hidden-fact-140" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c209" id="hidden-fact-141" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c210" id="hidden-fact-142" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c211" id="hidden-fact-143" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-144" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-145" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-146" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-147" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-148" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-149" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-150" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-151" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" decimals="-9" id="hidden-fact-152" name="nivf:AnnualTurnover" unitRef="khr">1000000000</ix:nonFraction>
<ix:nonFraction contextRef="c138" decimals="-9" id="hidden-fact-153" name="nivf:AnnualTurnover" unitRef="khr">6000000000</ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-154" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c191" id="hidden-fact-155" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-156" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c219" id="hidden-fact-157" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c228" id="hidden-fact-158" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c229" id="hidden-fact-159" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-160" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c220" id="hidden-fact-161" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c241" id="hidden-fact-162" name="nivf:DueToARelatedParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c244" id="hidden-fact-163" name="nivf:DueToARelatedParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-164" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-165" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c251" id="hidden-fact-166" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c253" id="hidden-fact-167" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c255" id="hidden-fact-168" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c256" id="hidden-fact-169" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c258" id="hidden-fact-170" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c259" id="hidden-fact-171" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-25128">0001981662</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-25129">true</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="nivf-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_4_fact ix_5_fact ix_6_fact ix_7_fact hidden-fact-1 hidden-fact-2 ix_8_fact ix_9_fact ix_10_fact ix_11_fact ix_12_fact ix_13_fact ix_14_fact ix_15_fact ix_16_fact ix_17_fact ix_18_fact ix_19_fact hidden-fact-5 ix_20_fact ix_21_fact hidden-fact-7 hidden-fact-8 ix_22_fact ix_23_fact ix_24_fact hidden-fact-9 ix_25_fact ix_26_fact hidden-fact-11 ix_27_fact ix_2_fact ix_3_fact hidden-fact-13 ix_28_fact ix_29_fact ix_30_fact ix_31_fact ix_32_fact ix_33_fact ix_34_fact ix_35_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_36_fact ix_37_fact ix_38_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_39_fact hidden-fact-15 ix_40_fact ix_41_fact ix_42_fact ix_43_fact ix_44_fact hidden-fact-32 ix_45_fact ix_46_fact ix_47_fact ix_48_fact ix_49_fact ix_50_fact ix_51_fact ix_52_fact ix_53_fact ix_54_fact ix_55_fact ix_56_fact ix_57_fact ix_58_fact ix_59_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_60_fact ix_61_fact ix_62_fact ix_63_fact ix_64_fact ix_65_fact hidden-fact-72 ix_66_fact hidden-fact-73 hidden-fact-74 hidden-fact-75 hidden-fact-76 ix_67_fact ix_68_fact ix_69_fact hidden-fact-78 ix_70_fact hidden-fact-80 hidden-fact-81 hidden-fact-82 hidden-fact-83 hidden-fact-84 hidden-fact-86 ix_71_fact ix_72_fact hidden-fact-88 hidden-fact-89 ix_73_fact ix_74_fact ix_75_fact ix_76_fact ix_77_fact ix_78_fact ix_79_fact ix_80_fact ix_81_fact ix_82_fact ix_83_fact ix_84_fact ix_85_fact ix_86_fact ix_87_fact hidden-fact-91 ix_88_fact hidden-fact-92 ix_89_fact ix_90_fact ix_91_fact ix_92_fact ix_93_fact ix_94_fact ix_95_fact ix_96_fact hidden-fact-93 ix_97_fact ix_98_fact hidden-fact-94 ix_99_fact ix_100_fact hidden-fact-96 ix_101_fact hidden-fact-97 ix_102_fact ix_103_fact hidden-fact-98 hidden-fact-99 ix_104_fact ix_105_fact ix_106_fact ix_107_fact ix_108_fact ix_109_fact ix_110_fact ix_111_fact ix_112_fact ix_113_fact hidden-fact-101 ix_114_fact ix_115_fact ix_116_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_117_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_118_fact ix_119_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-114 ix_120_fact" toRefs="ix_7_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_121_fact ix_122_fact" toRefs="ix_8_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_123_fact" toRefs="ix_9_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_124_fact" toRefs="ix_10_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_125_fact ix_126_fact" toRefs="ix_11_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_127_fact ix_128_fact hidden-fact-162" toRefs="ix_12_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nivf:NewGenIvfLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-12</xbrli:startDate>
    <xbrli:endDate>2023-06-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:SubsidiarieMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nivf:EWIHLMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-17</xbrli:startDate>
    <xbrli:endDate>2024-04-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-17</xbrli:startDate>
    <xbrli:endDate>2024-04-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-03</xbrli:startDate>
    <xbrli:endDate>2024-06-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:COVIRIXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:NewGenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:AdditionalNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nivf:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConversionRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesAWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesBWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKOpportunitiesVILLCJAKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SecondAdditionalMandatoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SecondAdditionalMandatoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-16</xbrli:startDate>
    <xbrli:endDate>2024-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SecondAdditionalNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:WhiteLionCapitalLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-18</xbrli:startDate>
    <xbrli:endDate>2024-11-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-18</xbrli:startDate>
    <xbrli:endDate>2024-11-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-18</xbrli:startDate>
    <xbrli:endDate>2024-11-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:NewGenivfLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FFPGSHKLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:WellImageLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:MedHoldingsLimitedMedHoldingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPGSCenterLimitedFFCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPhnomPenhLimitedFFPPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:BiClinicLtdFFBiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:OSLGroupMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91Jey1KbBNr08lrF9bNZYdTx/rA/SBVS10LyurQW5OboqYQWmZFkzLw3/d47HSjYGzqO9ETKAZNCuSd9bzJkSVkcGU94k1fhDc4tXQqjibaNNszh6F9ORmGKLPAlHqyPWSx7sNc84Mf0+16i2rCxXhF9zTDRtTnZMKL3YCBUcInLdH] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">nivf:ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesAWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesBWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesCWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:FreeStandingInstrumentsWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nivf:BestLendingRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nivf:BestLendingRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:ProfessionalPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-10</xbrli:startDate>
    <xbrli:endDate>2023-01-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:ProfessionalPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:DoubleClickServicesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-04</xbrli:startDate>
    <xbrli:endDate>2023-12-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:DoubleClickServicesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nivf:NewGenIvfLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-21</xbrli:startDate>
    <xbrli:endDate>2024-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nivf:MAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-21</xbrli:startDate>
    <xbrli:endDate>2024-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nivf:WhiteLionPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-21</xbrli:startDate>
    <xbrli:endDate>2024-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-21</xbrli:startDate>
    <xbrli:endDate>2024-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-10</xbrli:startDate>
    <xbrli:endDate>2024-12-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-12</xbrli:startDate>
    <xbrli:endDate>2024-12-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-24</xbrli:startDate>
    <xbrli:endDate>2024-12-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-31</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:OverProvisionOfTaxInPriorYearKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:OverProvisionOfTaxInPriorYearKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKOPPORTUNITIESVILLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKOPPORTUNITIESVILLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKOPPORTUNITIESVILLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:FirstFertilityBishkekLLCFFBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nivf:BiClinicLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-17</xbrli:startDate>
    <xbrli:endDate>2024-12-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-11</xbrli:startDate>
    <xbrli:endDate>2025-02-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-03</xbrli:startDate>
    <xbrli:endDate>2025-03-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-10</xbrli:startDate>
    <xbrli:endDate>2025-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-28</xbrli:startDate>
    <xbrli:endDate>2025-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nivf:MicroSortAcquisitionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-28</xbrli:startDate>
    <xbrli:endDate>2025-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nivf:NewGenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:GeneticsIVFInstituteIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-28</xbrli:startDate>
    <xbrli:endDate>2025-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-28</xbrli:startDate>
    <xbrli:endDate>2025-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-02</xbrli:startDate>
    <xbrli:endDate>2025-04-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="thb">
  <xbrli:measure>iso4217:THB</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="kzt">
  <xbrli:measure>iso4217:KZT</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="hkd">
  <xbrli:measure>iso4217:HKD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="khr">
  <xbrli:measure>iso4217:KHR</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea023980101ex5-1_newgen.htm
<DESCRIPTION>OPINION OF OGIER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="5" STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">NewGenIvf Group Limited<BR>
Ritter House, Wickham Cay II<BR>
P.O. Box 3170<BR>
Road Town<BR>
Tortola, VG1110<BR>
British Virgin Islands</P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D: +852 3656 6054 / +852 3656 6010</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.7pt; text-align: justify; text-indent: -14.7pt"><B>E: nathan.powell@ogier.com<BR>
rachel.huang@ogier.com</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference: NMP/RYH/509512.00013</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>30 April 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sirs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NewGenIvf Group Limited (Company number: 2116988) (the Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel as to British Virgin
Islands law to the Company in connection with the Company&rsquo;s registration statement filed with the Securities and Exchange Commission
(the <B>Commission</B>) under the United States Securities Act of 1933, as amended (the <B>Securities Act</B>), on Form F-1, such registration
statement including all amendments or supplements to such form filed with the Commission (the <B>Registration Statement</B>). The Registration
Statement relates to the resale by the selling securityholders (the <B>Selling Securityholders</B>) identified in the Registration Statement
of up to 123,275,000 class A ordinary shares with no par value of the Company (the <B>Class A Shares</B>) consisting of (i) 125,000 Class
A Shares issued to Genetics &amp; IVF Institute, Inc. (<B>GIVF</B>) in connection with the Purchase Agreement dated as of 21 January
2025, by and between the Company and GIVF (the <B>MicroSort Purchase Agreement</B>); (ii) 150,000 Class A Shares issued to A SPAC Holdings
Group Corp. (<B>ASPAC</B>) in connection with a consulting services agreement dated as of 24 February 2025, by and between the Company
and ASPAC (the <B>ASPAC Agreement</B>); (iii) an additional 120,000,000 Class A Shares issuable to JAK Opportunities VI LLC in connection
with a Securities Purchase Agreement dated 7 August 2024 (the <B>First Securities Purchase Agreement) </B>and another Securities Purchase
Agreement dated 1 April 2025 <B>(</B>the <B>Second Securities Purchase Agreement</B>) upon (a) the conversion of the Notes (as defined
in Schedule 1) and (b) the exercise of the Warrants (as defined in Schedule 1); and (iv) 3,000,000 Class A Shares issuable by the Company
to White Lion Capital, LLC in connection with the Common Stock Purchase Agreement dated 21 November 2024 by and between the Company and
White Lion Capital, LLC (the <B>CSPA</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are furnishing this opinion as Exhibits 5.1
and 23.3 to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>1</B></TD><TD STYLE="text-align: justify"><B>Documents</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">For the purposes of
giving this opinion, we have examined originals, copies, or drafts of the documents set forth in Schedule 1. In addition, we have examined
the corporate and other documents and conducted the searches listed in Schedule 1. We have not made any searches or enquiries concerning,
and have not examined any documents entered into by or affecting the Company, or any other person, save for the searches, enquiries and
examinations expressly referred to in Schedule 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 8pt; vertical-align: bottom">
    <TD STYLE="font-size: 8pt; width: 41%">
    <P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 0">Ogier</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Providing advice on British Virgin Islands, Cayman Islands and Guernsey
    laws</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Floor 11 Central Tower</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">28 Queen&rsquo;s Road Central</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Central</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Hong Kong</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">T +852 3656 6000</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">F +852 3656 6001</P>
    <P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 0">ogier.com</P></TD>
    <TD STYLE="font-size: 8pt; width: 15%">
    <P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 0">Partners</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Nicholas Plowman</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Nathan Powell</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Anthony Oakes</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Oliver Payne</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Kate Hodson</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">David Nelson</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Justin Davis</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Joanne Collett</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Dennis Li</P></TD>
    <TD STYLE="font-size: 8pt; width: 15%">
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Cecilia Li**</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Rachel Huang**</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Yuki Yan**</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Florence Chan*<SUP>&Dagger;</SUP></P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Richard Bennett**<SUP>&Dagger;</SUP></P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">James Bergstrom<SUP>&Dagger;</SUP></P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">Marcus Leese<SUP>&Dagger;</SUP></P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="font-size: 8pt; width: 29%">
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">* admitted in New Zealand</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">** admitted in England and Wales</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&Dagger;</SUP> not ordinarily resident in Hong Kong</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>2</B></TD><TD STYLE="text-align: justify"><B>Assumptions</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">In giving this opinion we have relied
upon the assumptions set forth in this paragraph 2 without having carried out any independent investigation or verification in respect
of those assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">all original documents examined by us are authentic and complete;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">all copies of documents examined by us (whether in facsimile, electronic or other form) conform to the
originals and those originals are authentic and complete;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">all signatures, seals, dates, stamps and markings (whether on original or copy documents) are genuine;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">each of the Certificate of Incumbency and the Registers (each as defined in Schedule 1) is accurate and
complete as at the date of this opinion;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">all copies of the Documents (as defined in Schedule 1) are true and correct copies and the Documents conform
in every material respect to the latest drafts of the same produced to us and, where any of the Documents have been provided to us in
successive drafts marked-up to indicate changes to such documents, all such changes have been so indicated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">the Directors Resolutions (as defined in Schedule 1) remain in full force and effect and each of the directors
of the Company has acted in good faith with a view to the best interests of the Company and has exercised the standard of care, diligence
and skill that is required of him or her in approving the transactions approved in the Directors Resolutions and each of the directors
does not have a financial interest in or other relationship to a party of the transactions approved in the Directors Resolutions which
has not been properly disclosed in the Directors Resolutions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">all parties to any of the Documents other than the Company (and other than any party that is an individual)
are duly incorporated, formed or organised (as applicable), validly existing and in good standing under all relevant laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">all parties to any of the Documents (other than the Company) have the capacity, power and authority to
exercise their rights and perform their obligations under such Documents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">each of the Documents have been or, as the case may be, will be duly authorised, executed and unconditionally
delivered by or on behalf of all parties to it in accordance with all applicable laws (other than, in the case of the Company, the laws
of the British Virgin Islands);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">the Form of Note Document will be signed on behalf of the Company by the person(s) authorised by the Company
in the Director Resolutions, dated and unconditionally delivered on behalf of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">the Form of Note Document will be duly executed, dated and delivered by all parties thereto in materially
the same form as the last draft examined by us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">the obligations expressed to be assumed by the Company and by the other parties in each of the Documents
constitute legal, valid, binding and enforceable obligations of such parties under all applicable laws (other than the laws of the British
Virgin Islands);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">none of the opinions expressed herein will be adversely affected by the laws or public policies of any
jurisdiction other than the British Virgin Islands. In particular, but without limitation to the previous sentence:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the laws or public policies of any jurisdiction other than the British Virgin Islands will not adversely
affect the capacity or authority of the Company; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">neither the execution or delivery of the Documents nor the exercise by any party to the Documents of its
rights or the performance of its obligations under them contravene those laws or public policies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">there are no agreements, documents or arrangements (other than the documents expressly referred to in
this opinion as having been examined by us) that materially affect or modify the Documents or the transactions contemplated by them or
restrict the powers and authority of the Company in any way;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">the issue of any Class A Shares (including any Class A Shares to be issued upon the conversion of the
Notes or the exercise of the Warrants) pursuant to the Documents at the time of issuance, whether as principal issue or on the conversion,
exchange or exercise of any Notes or Warrants, would not result in the Company exceeding its authorised number of shares; and upon the
issue of any Class A Shares, the Company would receive consideration for the full issue price thereof which should be equal to at least
the par value thereof and that such issuance would be duly registered, and would continue to be registered, in the Company&rsquo;s register
of members;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">there are no circumstances or matters of fact existing which may properly form the basis for an application
for an order for rectification of the register of members of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">the certificates for the Class A Shares will conform to the specimen as set out thereof and upon issuance
will have been duly countersigned by the transfer agent and duly registered by the registrar for the Class A Shares, or, if uncertificated,
valid book-entry notations for the issuance of the Class A Shares in uncertificated form will have been duly made in the share register
of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">no invitation has been or will be made by or on behalf of the Company to the public in the British Virgin
Islands to subscribe for the Class A Shares, the Notes or the Warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">at the time of the issuance of the Class A Shares (including any Class A Shares to be issued upon the
conversion of the Notes or the exercise of the Warrants) in accordance with its terms:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Company would not have been struck off and dissolved or placed in liquidation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the issue price for each Class A Share issued would not be less than the par value of such share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify">the information and documents disclosed by the searches of the Public Records (as defined in Schedule
1) was and is accurate, up-to-date and remains unchanged as at the date hereof and there is no information or document which has been
delivered for registration by any party (other than the Company), or which is required by the laws of the British Virgin Islands to be
delivered for registration by any party (other than the Company), which was not included and available for inspection in the Public Records;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD STYLE="text-align: justify">the Company has complied with, or will comply with when due, its obligations to file (unless the Company
is within one of the statutory exceptions to the obligations to file) a financial return, its register of directors, its register of members
and its beneficial ownership information pursuant to the BVI Business Companies Act, 2004 (the <B>BCA</B>); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">there is no provision of the law of any jurisdiction, other than the British Virgin Islands, which would
have any implication in relation to the opinions expressed herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>3</B></TD><TD STYLE="text-align: justify"><B>Opinions</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">On the basis of the
examinations and assumptions referred to above and subject to the qualifications set forth in Schedule 2 and the limitations set forth
below, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B>Corporate status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company is a company duly incorporated with limited liability under the BCA and validly existing in
good standing under the laws of the British Virgin Islands. It is a separate legal entity and is subject to suit in its own name.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.9pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.9pt; text-align: justify; text-indent: 0in"><B>Authorised number
of shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Company is authorised to issue a maximum of 500,000,000 shares with no par value divided into three
classes of shares as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">400,000,000 class A ordinary shares with no par value;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">99,950,000 class B ordinary shares with no par value; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">50,000 preferred shares with no par value.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.9pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.9pt; text-align: justify; text-indent: 0in"><B>Valid issuance
of Class A Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The issue and allotment of the Class A Shares (including the issuance of the Class A Shares by the Company
upon the conversion of the Notes or the exercise of the Warrants) to be offered and sold by the Selling Securityholders pursuant to the
provisions of the Documents (as applicable) have been duly authorised, and the Class A Shares, when issued by the Company upon:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-decoration: none">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; text-decoration: none">payment in full of the consideration as set out
in the Documents (as applicable) and in accordance with the terms set out in the Documents (as applicable) and in accordance with the
Directors Resolutions and its then effective memorandum and articles of association; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-weight: normal; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="text-decoration: none; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="text-decoration: none; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; text-decoration: none">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; text-decoration: none">the entry of those Class A Shares as fully paid
on the register of members of the Company, shall be validly
issued, fully paid and non-assessable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"><FONT STYLE="font-weight: normal; text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>4</B></TD><TD STYLE="text-align: justify"><B>Limitations</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">We offer no opinion:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">in relation to the laws of any jurisdiction other than the British Virgin Islands (and we have not made
any investigation into such laws) and we express no opinion as to the meaning, validity, or effect of references in the documents reviewed
to statutes, rules, regulations, codes or judicial authority of any jurisdiction other than the British Virgin Islands;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">in relation to any representation or warranty made or given by the Company in the documents reviewed or,
save as expressly set out herein, as to whether the Company will be able to perform its obligations under the documents reviewed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">as to the commerciality of the transactions envisaged in the documents reviewed or, save as expressly
stated in this opinion, whether the documents reviewed and the transaction envisaged therein achieve the commercial, tax, legal, regulatory
or other aims of the parties to the documents reviewed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">as to whether the acceptance, execution or performance of the obligations of the Company under the documents
reviewed will result in the breach of or infringe any other agreement, deed or document (other than the Company&rsquo;s memorandum and
articles of association) entered into by or binding on the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">as to the rights, title or interest of the Company to or in, or the existence of, any property or assets
that are the subject of the documents reviewed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>5</B></TD><TD STYLE="text-align: justify"><B>Governing law of this opinion</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">This opinion is:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">governed by, and shall be construed in accordance with, the laws of the British Virgin Islands;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">limited to the matters expressly stated herein; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">confined to, and given on the basis of, the laws and practice in the British Virgin Islands at the date
hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">Unless otherwise indicated, all references in this opinion to specific British Virgin Islands legislation
shall be to such legislation as amended to, and as in force at, the date hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>6</B></TD><TD STYLE="text-align: justify"><B>Reliance</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the
reference to our firm under the headings &ldquo;<I>Legal Matters</I>&rdquo; of the Registration Statement. In the giving of our consent,
we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the
Rules and Regulations of the Commission thereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">6.2</TD><TD STYLE="text-align: justify">This opinion may be used only in connection with the Class A Shares by the Company while the Registration
Statement is effective. With the exception of your professional advisers (acting only in that capacity), it may not be relied upon by
any person, other than persons entitled to rely upon it pursuant to the provisions of the Securities Act, without our prior written consent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%">Yours faithfully</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">/s/ Ogier</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Ogier</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Documents examined</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">1</TD><TD STYLE="text-align: justify">The constitutional documents and public records of the Company obtained from the Registry of Corporate
Affairs in the British Virgin Islands on 3 July 2024 (the <B>Company Registry Records</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2</TD><TD STYLE="text-align: justify">The public information revealed from a search of the electronic records of the Civil Division and the
Commercial Division of the Registry of the High Court and of the Court of Appeal (Virgin Islands) Register, each from 1 January 2000,
as maintained on the Judicial Enforcement Management System (the <B>High Court Database</B>) by the Registry of the High Court of the
Virgin Islands on 3 July 2024 (the <B>Court Records</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">3</TD><TD STYLE="text-align: justify">The Company Registry Records and the Court Records each as updated by update searches on 30 April 2025
(the Company Registry Records and the Court Records together, and as updated, the <B>Public Records</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">4</TD><TD STYLE="text-align: justify">The certificate of incumbency dated 3 April 2025 issued by the Company&rsquo;s registered agent in
respect of the Company (the <B>Certificate of Incumbency</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">5</TD><TD STYLE="text-align: justify">A copy of the register of directors of the Company dated 20 December 2024 (the <B>Register of Directors</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">6</TD><TD STYLE="text-align: justify">A copy of the register of charges of the Company printed on 30 January 2023 (together with the Register of Directors,
the <B>Registers</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">7</TD><TD STYLE="text-align: justify">Written resolutions of the sole director of the Company dated 14 February 2023, 4 January 2024, 1 March
2024 and 27 March 2024 and written resolutions of the directors of the Company dated 12 August 2024 and 21 August 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">8</TD><TD STYLE="text-align: justify">Written resolutions of the board of directors of the Company dated 20 November 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">9</TD><TD STYLE="text-align: justify">Written resolutions of the board of directors
of the Company dated 13 February 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">10</TD><TD STYLE="text-align: justify">Written resolutions of the board of directors of the Company
dated 1 April 2025 and another written resolutions of the board of directors of the Company dated 1 April 2025 (items 7 to 10 collectively
referred to as the <B>Directors Resolutions</B>).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">11</TD><TD STYLE="text-align: justify">The Registration Statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">12</TD><TD STYLE="text-align: justify">The CSPA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">13</TD><TD STYLE="text-align: justify">The ASPAC Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">14</TD><TD STYLE="text-align: justify">The MicroSort Purchase Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15</TD><TD STYLE="text-align: justify">The First Securities Purchase Agreement, pursuant to which, additional convertible notes convertible into
Class A Shares may be issued to the investors named therein pursuant to its terms (the <B>Additional Notes</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16</TD><TD STYLE="text-align: justify">The Second Securities Purchase Agreement, pursuant to which, convertible note convertible into Class A
Shares may be issued to the investors named therein at an initial closing and additional convertible notes convertible into Class A Shares
may be issued to the investors named therein pursuant to its terms (together, the <B>2025 SPA Notes</B>, and together with the Additional
Notes, the First Exchange Note, the Second Exchange Note, the Initial Note, the Second Note, the Third Note and the Fourth Note, the <B>Notes</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17</TD><TD STYLE="text-align: justify">The certificate of senior convertible note in respect of a senior convertible promissory note initially
issued by the Company on 4 April 2024 and exchanged by the Company on 8 August 2024 convertible into the Class A Shares (the <B>First
Exchange Note</B>) dated 8 August 2024 and executed by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18</TD><TD STYLE="text-align: justify">The certificate of senior convertible note in respect of a senior convertible promissory note initially
issued by the Company on 3 April 2024 and exchanged by the Company on 8 August 2024 convertible into the Class A Shares (the <B>Second
Exchange Note</B>) dated 8 August 2024 and executed by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19</TD><TD STYLE="text-align: justify">The certificate of senior convertible note convertible into Class A Shares dated 12 August 2024 and executed
by the Company (the <B>Initial Note</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20</TD><TD STYLE="text-align: justify">The certificate of senior convertible note convertible into Class A Shares dated 28 August 2024 and executed
by the Company (the <B>Second Note</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21</TD><TD STYLE="text-align: justify">The certificate of senior convertible note convertible into Class A Shares dated 11 November 2024 and
executed by the Company (the <B>Third Note</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">22</TD><TD STYLE="text-align: justify">The certificate of senior convertible note convertible into Class A Shares dated 3 April 2025 and executed
by the Company (the <B>Fourth Note</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23</TD><TD STYLE="text-align: justify">The certificate of series A warrant to purchase ordinary shares constituting a series A warrant issued
by the Company on 12 August 2024 (the <B>Series A Warrant</B>) dated 12 August 2024 and executed by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">24</TD><TD STYLE="text-align: justify">The certificate of series B warrant to purchase ordinary shares constituting a series B warrant issued
by the Company on 12 August 2024 (the <B>Series B Warrant</B>) dated 12 August 2024 and executed by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">25</TD><TD STYLE="text-align: justify">The certificate of series C warrant to purchase ordinary shares constituting a series C warrant initially
issued by the Company on 4 April 2024 and exchanged by the Company on 8 August 2024 dated 8 August 2024 and executed by the Company (together
with the Series A Warrant and the Series B Warrant, the <B>Warrants</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">26</TD><TD STYLE="text-align: justify">A form of the certificate of senior convertible note in respect of the Additional Notes to be executed
by the Company, substantially in the form attached to the First Securities Purchase Agreement (the <B>2024 SPA Form of Note Document</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">27</TD><TD STYLE="text-align: justify">A form of the certificate of senior convertible note in respect of the 2025 SPA Notes to be executed by
the Company, substantially in the form attached to the Second Securities Purchase Agreement (together with the 2024 SPA Form of Note Document,
the <B>Form of Note Document</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
11 &ndash; 27 are collectively referred to as the <B>Documents</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Qualifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Good standing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">1</TD><TD STYLE="text-align: justify">Under the BCA an annual fee must be paid in respect of the Company to the Registry of Corporate Affairs.
Failure to pay the annual fees by the relevant due date will render the Company liable to a penalty fee in addition to the amount of the
outstanding fees. If the license fee and/or any penalty fee remains unpaid from the due date, the Company will be liable to be struck
off and dissolved from the Register of Companies in the British Virgin Islands.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2</TD><TD STYLE="text-align: justify">Under the BCA, a copy of the Company&rsquo;s register of directors which is complete must be filed by the Company
at the Registry of Corporate Affairs. Failure to make this filing will render the Company liable to a penalty fee and if the filing is
not made within the requisite time period or any penalty fee remains unpaid from the due date, the Company will be liable to be struck
off and dissolved from the Register of Companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">3</TD><TD STYLE="text-align: justify">Under the BCA, an annual financial return, in the prescribed form, must be filed by the Company with its
registered agent in respect of each year for which one is due within the timeframe prescribed by the BCA for that year (unless the Company
is within one of the statutory exceptions to the obligation to file). Failure to make this filing when due will render the Company liable
to a penalty fee and where the Company is liable to the maximum penalty and has not filed its annual return, the Company will be liable
to be struck off and dissolved from the Register of Companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">4</TD><TD STYLE="text-align: justify">Under the BCA, unless the Company is within one of the statutory exceptions to the obligation to file
and is compliant with any conditions for the relevant exception(s) to apply, a copy of the Company&rsquo;s register of members which is complete
and certain prescribed beneficial ownership information for the Company must be filed by the Company at the Registry of Corporate Affairs.
Failure to make these filings will render the Company liable to penalty fees and if the filings are not made within the requisite time
period or any penalty fee remains unpaid from the due date, the Company will be liable to be struck off and dissolved from the Register
of Companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">5</TD><TD STYLE="text-align: justify">For the purposes of this opinion &ldquo;in good standing&rdquo; means only that as of the date of this opinion
it appears from our searches of the Public Records and on the basis of certain of the assumptions made in paragraph 2 being correct the
Company is in good standing. We have made no enquiries into the Company&rsquo;s good standing with respect to any other filings or payment of
fees, or both, that it may be required to make under the laws of the British Virgin Islands other than the BCA. We have made no enquiries
into whether the copy of the register of directors, the copy of the register of members or the Company&rsquo;s beneficial ownership information
filed at the Registry of Corporate Affairs matches the details set out on the Certificate of Incumbency or whether the annual return filed
by the Company with its Registered Agent is in the prescribed form as required pursuant to the BCA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Non-assessable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">6</TD><TD STYLE="text-align: justify">In this opinion, the phrase &ldquo;non-assessable&rdquo; means, with respect to the Class A Shares in
the Company, that a shareholder shall not, solely by virtue of its status as a shareholder, be liable for additional assessments or calls
on the Class A Shares by the Company or its creditors (except in exceptional circumstances, such as involving fraud, the establishment
of an agency relationship or an illegal or improper purpose or other circumstance in which a court may be prepared to pierce or lift the
corporate veil).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Register of members</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">7</TD><TD STYLE="text-align: justify">Under the BCA, the entry of the name of a person in the register of members as a holder of a share in
a company is <I>prima facie</I> evidence that legal title in the share vests in that person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Public Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">8</TD><TD STYLE="text-align: justify">The Public Records and our searches thereof may not reveal the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">in the case of the Company Registry Records, details of matters which have not been lodged for registration
or have been lodged for registration but not actually registered at the time of our search or notifications made to the Registrar of Corporate
Affairs by the registered agent of any failure by the Company to file its register of directors, register of members, beneficial ownership
information and/or annual return as required and within the time frame prescribed by the BCA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">in the case of the Court Records, details of proceedings which have been filed but not actually entered
in the High Court Database at the time of our search;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">whether an application for the appointment of a liquidator or a receiver has been presented to the High
Court of the British Virgin Islands or whether a liquidator or a receiver has been appointed out of court, or whether any out of court
dissolution, reconstruction or reorganisation of the Company has been commenced; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">any originating process (including an application to appoint a liquidator) in respect of the Company in
circumstances where the High Court of the British Virgin Islands has prior to the issuance of such process ordered that such process upon
issuance be anonymised (whether on a temporary basis or otherwise),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">and the following
points should also be noted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">e.</TD><TD STYLE="text-align: justify">the Court Records reflect the information accessible remotely on the High Court Database, we have not
conducted a separate search of the underlying Civil Cause Book (the <B>Civil Cause Book</B>) or the Commercial Cause Book (the <B>Commercial
Cause Book</B>) at the Registry of the High Court of the British Virgin Islands. Although the High Court Database should reflect the content
of the Civil Cause Book and the Commercial Cause Book, neither the High Court Database nor the Civil Cause Book or Commercial Cause Book
is updated every day, and for that reason neither facility can be relied upon to reveal whether or not a particular entity is a party
to litigation in the British Virgin Islands;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">f.</TD><TD STYLE="text-align: justify">the High Court Database is not updated if third parties or noticed parties are added to or removed from
the proceedings after their commencement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">g.</TD><TD STYLE="text-align: justify">while it is a requirement under Section 118 of the Insolvency Act 2003 of the British Virgin Islands that
notice of the appointment of a receiver be registered with the Registry of Corporate Affairs, however, it should be noted that failure
to file a notice of appointment of a receiver does not invalidate the receivership but gives rise to penalties on the part of the receiver
and the absence of a registered notice of appointment of a receiver is not conclusive as to there being no existing appointment of a receiver
in respect of the Company or its assets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Economic substance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">9</TD><TD STYLE="text-align: justify">We have not undertaken any enquiry and express no view as to the compliance of the Company with the Economic
Substance (Companies and Limited Partnerships) Act 2018.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">9</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>3
<FILENAME>ea023980101ex-fee_newgen.htm
<DESCRIPTION>FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 107 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form F-1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NewGenIvf Group Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Newly Registered Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Security <BR>Type</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Security</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Class</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Title<SUP>(1)</SUP></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Fee <BR>Calculation <BR>or Carry <BR>Forward <BR>Rule</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Amount <BR>Registered</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Proposed <BR>Maximum <BR>Offering <BR>Price <BR>Per Unit</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Maximum <BR>Aggregate <BR>Offering <BR>Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Fee <BR>Rate</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amount of</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registration</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fee<SUP>(4)</SUP></P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 18.5%; text-align: left">Fees To Be Paid</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 17%">Class A Ordinary Shares, no par value</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">123,275,000</TD><TD STYLE="padding-bottom: 4pt; white-space: nowrap; width: 0.5%; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">0.319</TD><TD STYLE="padding-bottom: 4pt; white-space: nowrap; width: 0.5%; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1.5%; text-align: center">US$</TD>
    <TD STYLE="width: 6.5%; text-align: right">39,324,725</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">0.00015310</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center; width: 1.5%">US$</TD>
    <TD STYLE="text-align: right; width: 6.5%">6,020.62</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Fees Previously Paid</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; vertical-align: top">Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; text-align: center">Rule 457(c)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">9,275,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; text-align: center">US$</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right">12,196,625</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">0.00015310</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center">US$</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,867.30</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: center">Net Fee Due</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 4pt double; text-align: center">US$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">4,153.32</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), an indeterminable number of additional securities are also being registered to prevent dilution resulting from stock splits, stock dividends or similar transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents up to an aggregate of 123,275,000 Class A ordinary shares, no par value of NewGenIvf Group Limited., a British Virgin Islands holding company (the &ldquo;Company&rdquo;) consisting of (i) 125,000 Ordinary Shares issued to Genetics &amp; IVF Institute, Inc. (&ldquo;GIVF&rdquo;) in connection with the Purchase Agreement dated as of January 21, 2025, by and between the Company and GIVF (&ldquo;MicroSort Purchase Agreement&rdquo;); and (ii) 150,000 Ordinary Shares issued to A SPAC Holdings Group Corp. (&ldquo;ASPAC&rdquo;) in connection with a consulting services agreement dated as of February 24, 2025, by and between the Company and ASPAC (&ldquo;ASPAC Agreement&rdquo;); (iii) an additional 120,000,000 Ordinary Shares issuable to JAK Opportunities VI LLC upon the conversion of (a) the Remaining Additional Notes (as defined below), (b) the senior convertible notes exchanged on August 8, 2024 (&ldquo;Exchange Notes&rdquo;), (c) the exercise of Series A warrants to purchase Ordinary Shares (the &ldquo;Series A Warrants&rdquo;), (d) the exercise of Series B warrants to purchase Ordinary Shares (the &ldquo;Series B Warrants&rdquo;), (e) the exercise of Series C warrants to purchase Ordinary Shares (the &ldquo;Exchange Warrants&rdquo; and together with the Series A Warrants and the Series B Warrants, the &ldquo;Warrants&rdquo;), and (f) the senior convertible notes to be sold by the Company to JAK Opportunities VI LLC in the as agreed in the Securities Purchase Agreement dated April 1, 2025; and (iv) 3,000,000 Ordinary Shares issuable by the Company to White Lion Capital, LLC (&ldquo;White Lion&rdquo;) in connection with the Common Stock Purchase Agreement dated as of November 21, 2024, by and between the Company and White Lion (the &ldquo;White Lion Purchase Agreement&rdquo;).</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the common stock on the Nasdaq Global Market on April 28, 2025, in accordance with Rule 457(c) of the Securities Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Calculated pursuant to Rule 457 of the Securities Act by multiplying the proposed maximum aggregate offering price of securities to be registered by 0.00015310.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P +(# 2(  A$! Q$!_\0
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ME1T9D,I8'@?.<\?2G:/<7M*W6)H'4[4+$1,A\X9CY^]ZU-!<)<('C(93W!K
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+=10)*P4444#/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y G # 2(  A$! Q$!_\0
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M%% !1110 4444 %%%% !1110 4444 >8_$'_ )#D/_7'^M<G76?$'_D-P_\
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M-<F*JJ$;=6>OE6%]M5YI?"C=LK<6T"Q@ $#M5SM313J\;U/L$%%%% PHHHH
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M2'N!V%><?X8K;\/>))]#D,9!ELV.60<[3[5ABL/S>_$[,NS!4?W=38]<4*%
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MI/:@ R*,BFD=ZY&X^(>EVMS+;O#.7B<HV%[BI<DMS&K7ITDG-V.QS2<5Q?\
MPLK2?^>-Q_WS1_PLK2?^>%Q_WS2]I$Y_[0PW\Z.TXI<UQ7_"RM)_YX7'_?-'
M_"RM)_YX7'_?-'M(]P_M##?SH[7-&:XK_A96D_\ /"X_[YJ>Q\>Z;J-]#9Q1
M3AY6V@LM"G%Z%1QV'D[*:.NR**8..*<*L[!:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I,BF3R"&%Y&SA5)(%<;_PLG2N<07''^S2<DMS"KB*5
M'^([';9HKB?^%E:3_P \;C_OFC_A96E?\\;C_OBH]I'N8_7\-_.CMJ,UQ/\
MPLK2O^>-Q_WQ2_\ "RM)_P">-QG_ ':?M(]P^OX;^=':YHS7%?\ "RM(_P">
M%Q_WS2?\+*TD'_4W'_?-'M(B_M##?SH[:C-<5_PLK2O^>-Q_WS6WH/B&U\01
M2R6J.HB8*=XQS34D]C2GBZ-5\L)79M9HI*6J.H**** "BBB@ HHHH **** "
MBBB@!IK@?B'J5[8SV0M+F2 ,&W;#UKOSUKS?XG?\?-A_NM45':.AYV92E'#2
M<78Y+^W]8 '_ !,;K_OJC_A(-8_Z"=S_ -]5F\9YZ9&:ZH/HJ2QM+]E,(;,8
M09;;MYW?C7&I/N?)TIU*F\[?,Q_^$@UC&?[3N<?[U']OZQWU&Y_[ZK1DDT:Z
MMFNHXH;<HCHT3?>9N-K?SKG!T''.*')K6X595:>G/?YGIOP[O[V^COOM=S)/
MM<;2YS@8KNZ\\^&'^JU#_>6O0Z[*;O'4^NRZ3EAHML****L[PHHHH P]5\3:
M7HTT<-[<;)7&X *3Q5'_ (6!X?QG[6?^^#3/$G@R+Q#>Q7373PM&NT*%!K''
MPLAQ_P A.7_O@5K%0MJ>M0IX!TTZLFF;?_"P/#__ #]G_ODT?\+ \/\ _/V?
M^^36)_PJR+_H)R_]\"C_ (57#_T$Y?\ O@4[4S?V65_SO[C;_P"%@>'_ /G[
M/_?)H_X6!X?_ .?L_P#?)K$_X57#_P!!.7_O@4?\*KA_Z"<O_? HM3%[++/Y
MW]QM_P#"P/#_ /S]G_ODT?\ "P/#_P#S]G_ODUB?\*KA_P"@G+_WP*/^%60_
M]!.7_O@46IA[++/YW]QM_P#"P/#_ /S]G_O@TUO'_A\*=MT2<?W36-_PJR'_
M *"4O_? I&^%L0!(U&5CZ%!1:F/V65W7OR.J\/>)+/Q!;>9;L%D4D-$>H]\5
MN5R/A#PBF@[KB=P][("&(Z!<\"NNK.5KZ'E8E4E4:HN\0HHHJ3G"BBB@ IO>
MG44 -;[M>"ZM_P AJ_\ ^OA_YU[TW2O#I[0WWB>ZM@VS?.YW8STK"ML>!G2;
MA!+N%OI"SZ5'<B8"667RTC/ SZ^]6T\+S^6QDF7>,[ !PW^%5H]&N96Q%,IA
MC?AB<;3UR!3Y-/UEVED:X\QEQN(D]:YTM#Q807VHL='X5U"7)B>)QT)R1@_C
M4=GHC7*MF3#+.86VC(&!G)J6?3M64I(+TNS@ $28'L![TRTT^\2[N;5+MHEW
M!)"O\1(STIJP.$.;X65;_2I]/1'E9"'./E[5-X8_Y&:P_P"NE27=O)>2R&>^
MR80 H(^7T_.CP]&T/BRSB?[R3;3CH:27O*Q,86KQ:74]L7FE[T"BN\^[%HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** *NH?\>%Q_US/\J\"]?J:]
M^O\ _CPN/^N;?RKPBSM6OKO[.C;6()R?:N:OT/FL[3;@D0'@5NS>'2/+6"X!
M<Q"1RW09Z# Y_&JIT&]*H5"%G7<%W?G4@TO58F\V.=3*5Q\LGS$8K!>9XU.D
MU\<;DS^&9A"A69=^ 7#<[1SGZU#+X:OX;62X8Q>3&#ELYZ4)8:PHWQ7#,P^Z
M!)RWKBF76GZI;6DLD\C>2!\XWYSGK5:&KA"WP,E@\/R7,*O')@M$CJ67Y23G
MC]*S;VSDL;DP2E2V <KT.:T66^TRSL;G[6_E-\WE\D)Z47.F23W+%;PSRY5G
M8I@JK#.?I2=NA$J::M!:F/WQ7I'PQ_X\+[_KJ/Y5PVH:<+&.-TF\Y7.!@8%=
MU\,?^0??\_\ +4?RJZ*]\Z\KBXXI)^9WHI:04M=A]B%%%% !1110 4444 %%
M%% !1110 G>O-_B=_P ?-A_NM7I!KS;XG?\ 'S8?[K5G5^$\S-/]UD<%4UHE
MN]W&MTYCA)^9E'(J$_R/-= VCVBZ5#<1PO/))%F3$F/*XZD5QI,^/HTW-F'<
M+"ES(L#%X@Q",1@D5'72W6AV$6D-=Q[E<19 9^6;CGZ5S/;/7/>E)6T%5I.#
MU/1?AA_JM0_WEKT.O//A?_JM0_WEKT.NVG\*/L\L_P!U@%%%%:'HA1110 W\
M*/<4 <4O2@+"9HS2T4"$S1FES1TH 3-9/BC4IM'\+:IJ, !FMK9Y$R.-P'%:
MDLJ0QM)(P5%4LQ/8#J:\/\<>/=>\7:+J=KX2TZ4:+#$_VO4IEVB1!U"9[=:0
M'J?@C6+G7_!>E:I> "YN8 \FT8!/M705X#\/_'/B#P9X=TU/$>FRS>&YHP;:
M_@7=Y"^C8[5[Q;7$5W;17$#AX94#HX_B4C(- R90!TI:2C-%P%HI,T9HN M%
M)FC-%P%H-)FC-%P$/2O"=0F>WU^\EC;:ZSO@_C7NQP:Q9?"FASRO))IT1=V+
M,<'DFLZD>9'F9AA)XF*4':QX\FIW:!@DP4,<D*,4+JEX X6Y(W')XZFO8/\
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MXT/,H)ZQ81RF;VDCUC-%>/ZIKFJ1:-<21WTRN'3#!O6L"WU[Q+=2;+>_NY7
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MUXGVQMO&1C/'%:UCXBA(D%[&C<2.JXSN8\K^56?^$CTR6UM()X)7$6S(VC'
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MNQ9F.2<U4(+L15KSMRWN3+_R#Y/^NP_E5ZRUD6EE';FW\S8Q&XC/!/2J*_\
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MU.J.#I15D>1GX4ZKT^W6WUP:/^%4ZM_S_P!MGUP:]<P*.*/KU?N5]5I'D?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $- A # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBD)P*
M&J,4,,UBMJ%]=3RQZ=;Q-%"VQGF<C+=P, ]*:VHZA9%6O[:$P$@%X7)VY[D$
M#BJY&<[KQ3ZV[F_12 Y&12U)T!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK9^2U<'+C:'QO' ;:<],=LUW.G7D6H6,%Y!DQ3QB1,]0#VI#+M%%% !1110
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M;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^$)U;^ZE'_"$ZM_=2O4LF@T?6ZO</[+P_8\UM_"_B&VXAN'0>BN:=/X8\07
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MP6O_ !=U[7O%8T[P7>VT%F$RLER%7>>I)+=* /H:C-?/!U_XL G_ (GNC?\
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M%G_(NS_5?YBMTUB>*(S+X>NMH)*@-^1%3+8WCN<Y$!&4;.%*@%6[U%,H$]D
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MUH/_ '[>I/"_Q+T#7= M;^XU&UM+AUQ+#+*%96'7\*VO^$S\-?\ 0>T__O\
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M!<NR[ON\YXY&<\4V[T+Q=-:R1-J4DR2HRO&\BKVR,$ $'- $SZ/XK\Q NHY
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M#PU)--2#55)NH?D:7<#YGO6Q7&Z'IGBFVUR&XU*\$MH8-LD9DR%?V']:[*@
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M3[?X4^B@"+RE\T2%$W@8#8Y ],U+110 4444 %%%% !1110 AKEK7_DIU_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M****  ]*Y:VBD'Q*OI3&WEG38@'QQG>>,UU!Z4@X.*+@.HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )F @8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBD- ')WGC4?VG=V&CZ1>:O-9\7+6Q54C;^
M[N8C+8["M'1_$MIK/A^35XX+F".+>LL4R;71D^\,=Z\V\'^*[/P+K>K^&?%
M:PEGOY+FWNY%Q',KG(RW]37I^I/;R^&KZ6U:-XGM9&5H\8;*GGB@!/#>OV?B
M?0;;5[ 2"VN 2@E7#<$@Y'X5)KNM6OA_29=2O Y@B*AMBY/) '\ZY3X,?\DI
MT?Z2?^AM5WXH?\B#?_[\7_HQ: -+Q3XKL/".DIJ%_'/)%)*L2K"@9BS=!@D5
MGZAX^M]'@6ZU;1=7LK,D!KF2%61,]VVL2!7._&]E3P/8,S *-1@))[<]:O\
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M8*#C!]^]:\LD=M;O)(0D42%F/8*!FO$M?M[FRATKXG;&%R-1\R<>EFQVJ#[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]7_.C[1-_P ]7_[ZIKHT<A1NH[TVO.<I+2YUI(D\^8_\M7_[Z-'GRC_EJ_\
MWT:CHI<[[CY42>?+_P ]7_[Z-'GR_P#/5_\ OHU'12YGW"R)//E_YZO_ -]&
MCSY?^>K_ /?1J.BB[[A9#_.E_P">C_\ ?1H\Z7_GH_\ WT:911S,+(?YTO\
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MV4S:;;R'J4%6J@LX?(LXHO[B@'ZU/7$]R@HHHI %%%% !1110 4444 %%%%
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M_P!*D;_B6+IWS(IPHS\W^]S^%0R?#BRD,S?;KDS-%;I%,Q#/$T/W6R>I/?-
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M_!<O].IQ0!H7WB>UT^:U2YMKA5NIHX(9,#:S/T&<_G5C1M>LM;2=K5G#03O
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M'. H]34&E:SIVMV(O=,O(;JV)($D39&1UH OT50;5;$0K*+A&5BP7;SN*]<
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MC/\ +F@#%?P_>M9PA;R1;J-%#2"0E68#&2IZY/7UIXT?4A<;C=IM-U#/\N<
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M2K\_01<K3;#Q/;7$3M=XMF625 3]TB,\G/TJT=?TU?+!GYD=508)R6&5_,4
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M*SCXN3RW=+*0B.TBNV&[G:YQ@>XJMHGBB>[2XBDB>XG269E"@*3&K  #U/-
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M-TGF1L""OL:NU0O=02QN;&!HV=KN;RE*_P )VELG\ : (6T&P,OF"-@1*LH
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M$FKC3H;-%WF<1SN#M8(H((QV)./PJ6WUB^3PU:ZA+&LTH<"Z4*057."0/44
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MVB@+'IEG<I=VL<\9RKC-3UQ_A;4?*F-C(WR/S&?0UUXIDBT444 %%%(3@9H
MR-3@$<@D7 W]1[U1J>\N//N"1]T<+4%6CAFTY.P4444$!1110 4444 %%%%
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ML)A]8@<517;?\(GI_K-_WU1_PBFG_P#37_OJCV$@^L0.)HKM_P#A%-/])?\
MOJC_ (173O23_ONCV$@^L1.(HKN/^$5T[^[)_P!]4#PMIH_AD_[ZH]A(/K,#
MAZ*[G_A%]-_N/_WU2_\ "+Z9_P \W_[Z-'U>0?68'"\]!R>U=WX?T[[#8JS@
M>;)\S'V["G1^'--AD618B2IR,L36L.E;4J7+N8U:W,K1 =*6BBN@YB*XF2WA
M>:0X5!DFO.;Z\>^O)+A_XC\J^@[5WVI6 U&W\AY71"<G;WK)'A"T_P">\I'X
M4 F<?178_P#"(V6?];+^8IW_  B-E_SUF_,4BKG&45VG_")6/_/2?\Q_A1_P
MB5A_STG_ #'^% 7.+HKM?^$2L/[\W_?0_P *3_A$]/\ [TW_ 'U_]:@+G%T5
MVO\ PB>G^L__ 'W_ /6H_P"$4T[UF_[[_P#K4!<XJBNV'A33O^FW_??_ -:C
M_A%-._Z:_P#?= 7.)HKM_P#A%=.])?\ ONC_ (173?[LG_?= 7.(HKN/^$5T
MW^[)_P!]TO\ PB^F_P#/.3_ON@+G#4=.:[H>&-,_YY/_ -]TH\,Z8#GR6_%C
M0%RIX6TWR+8W<H_>2C"^RUT0Z4B(L:!%&%48 IU,D**** "BBB@ HHHH ***
M* "BBB@!*:S*BEF( '<TX]*P[RZ:>4J#^[4\#U]Z:1G.?*B[)JD:G"*6]^E1
MC5N>8N/8UFT4['/[61NP7<4_"MAO0]:L5S:L48,IPPZ&MNSN/M$.3PPX-)HV
MIU.;1EJBBBD;!1110 4444 %%%% !1110 4444 %%%% !1110 E(2 "3T]Z;
M(ZQHSL<*HR3Z5P^L:[-?R-' YCMAQ@'&[W)K.<U$TA3<WH=;+K&GV[%9+J,'
MTSFEAU:QN&"Q7,9;T)P:\YQ1QZ=/PKG^L/L=/U9=&>I@^]+7$:-K\MK*L%RY
M>!N QZJ:[52&4$'(/I73":DKHYJE-P=F.HHHJS,**** "BBB@ HHHH ****
M"BBB@ HHHH ***Q]=UD:9"$CPUQ)]P'M[F@#2GN8+9=T\J1CU8XJF-=TS=C[
M6F:X*>XEN9#)/(TC'G)J/\J15CTZ*>*==T,BR#U4YJ0=*\SMKJ>SE$MO(4<>
M_!^OK7<Z-JR:G;9/RS)]]?ZTQ-&I1110(**** "BBB@ HHHH **** "BBB@
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M667S=1C2.0 C"A.!CCWK<HH 11M15!R ,9I:*:S!<9(&>![T .HHHH ****
M,S7M(BU[1+S2KB62.&ZC,;M']X ^F:S+_P %:5JG_(162Z(M#:1ER!Y:<'C
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MQSV)^E9XT;4HM5LK>5FGA-O<B1\D("[90'W%;]YKUC8I.\K_ "0HK,PYSN.
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M&XB2([E&#OSZKTKI)9HK:%I)76.-!R3P *E5@RA@00>0?6@#E9+[Q$NFBY6
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %: ET# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVT=G9PV\,2QQQH%"+T6IZXIU)29VPI1BA%&% I:**S-0HHHH **** "BBB@
MHHHH **** "BBB@ HI#34E20D(ZL1U .<4 /KC/'*$36$N25RR8[ ^M=G6=K
M6EIJVGO;L<./FC.>C#I5PERR3(J1YHM'FM%7YM"U>WDV263/QG=$=P-9X.1G
M\,&O4C.,MCR90E'<6BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BFR2)
M$NZ1U1?5CBA9$?&UU.?0U/,KVN%AU%%%4 56OQNMPA)"O(JMCN">:LU7O?\
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M_"1:IG/]FVV?^NY_PJK2'@$D\4?V+A.P?VI5[(M_\)%JG_0.M_\ O^?\*/\
MA(M5_P"@=;_]_P _X5261C$LK0RI&_*L4.&%"R(_"NI/UJ(Y1@I;?F6\PQ"W
MB7O^$BU3_H'6_P#W_/\ A1_PD6J_] ZW_P"_Y_PJI15_V)A.Q']J5>R+?_"1
M:I_T#K?_ +_G_"D_X2+5#_S#;;_O^?\ "JM%']B83L']J5>R+7_"1:I_T#K;
M_O\ G_"D'B#4@,#3+4#T$W_UJK44_P"Q<+V#^U*O9%O_ (2+5?\ H'6__?\
M/^%1MXHU!3AK*T!]#<?_ %JJRHSQ,BOL8C ;TJM:1H&DA:)"T>/F Z__ %ZE
MY+A>PUF=7LC53Q-J,@REA:M]+C/]*9/KNK3PO"+.WA+@KO\ -+;<]\8JD]G;
MR'<8P#ZKQ3&\VU^8%I81U4_>7Z>M-9-A8N]@>9U7LD36\(M[>.%22$7&3WJ2
MFHZR(&1@RGH13J]E))61Y<FY-MD]E?76G/*UJZKYJ[7W+GCV/:K.B:V=+UB(
MR^;Y,X*3EG+*#_"PST]ZSZ3&1@\BLIT8R-85I0.HM?'T<]PXDLF$"2&-I$;/
M0]0.XK9O=>2/2SJ&GB*[BB^:8>9M95[X'K[5Y\ !TXJ(VZ&Y6?#$@%60-A74
M]016,L,K:&T,2[^\>K:=J5KJEE'=VDHDBD ((ZCV/I5NO)](OY=(U!+N)98H
M7.V2-A\LB>H]Q7J5M=0WD"SV\BR1,,AE-<DX.)UPFI$U%%%0:%'5-*M]6M3!
M.O3E''5#ZBO/-1TVYTFZ\BY&0?\ 5R@?*X_Q]J]1/2JE_8P:A:/;W"!D;\P?
M45K3JN#\C&K24UYGEQZ''-=CX/L1%!]JBU RQR+A[<#B-JY[6=$N=)<K(QDM
MGX29>"/8^AKH?!$=J;*1HX-ES&?+DDS_ *SN"?>MZ\U**:.>A!QFTSIYH8[B
M%X9D5XW&&5AD$5FQ:$MK;2V]G>7,$;8* /N\L_[.>WM6M17&=Q%;I+' BS2^
M9(!AGQC=^%2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 5[RS@O[9[:X0/$_537&:KX4NX;QFTV+S+8@'8S\J?09[5W=)BKA.4'H1.
MG&:LSRVZT^^L'"75K(N1N!0%ACZBJRNK]#G^E>M$#'/2O/?%2QC7T>'R?+:'
M&8L9R#SNQ772KN3LSCJT%%71D4445V'&1/*XD*I$9-J[GQ_"*LZ7:K-$MY<?
M/(6.Q2,*GT']:992I!J+^8Q02J%7CAB/4UL9&!Z=L5\KF>+JJ3I;(ZZ4%:Y$
M;: KM,,>,YQMK/DTATN%:TN#%#@YC8;AGMCVK5HKR*6)JTG>$C5Q3W,Q=*9D
M)ENI Y/_ "SZ >U-DTNY4XM[A3&?^>HR1^/>M6@=:V6/Q"E?F%R1[&?8Z>]G
M-)(\B-N7;M1<#Z_6M"LRWUB.>*ZE\LJMOD-D\D@]O:E&J-+;6LUO$KF=MNQF
MP0>_Y5SU'.I+FEN:*#6AI450.J1?;+JW"Y-O'OS_ 'B.HJ*/68WL8;HQ,(Y&
M*@=6Z9Y%9\K'R,U**SEU3=):CRL)<*#N)Z$]J;)JCP07LL\*JMN^Q0K9+FCE
M8<C-.CZ]*RKC7(K<PGRRR2QAP^> 2<8-:M)IH3BUN9KZ-"\S,)9%3JB*<;3Z
MC_"J>HZ;,NG7+27>55,@*F"?K6]VJEJP_P")1=?]<ZZXXVNE92*H1C[6/J9S
M++:1QB=2T9 Q*HXZ=_2GB1"VT.I8C. ><5KH UNBL 04 (/?BLC4X+;>MO;P
M"*XX?S8Q@JM>S@LTG-JG)79S5Z2YFQ'D6, L>IP .I/H*T8-"U"Y3>TB6H[*
MR[F/U]*KZ+)8V,N+Z(/+O+)=L,XSZ^E=;!<P7()@F20#KM;.*Z,9C*T'RQ5C
MLPN%I27-)W.8N='OK6+S"$G4?>$6<CWQ6=(RM&Z.DJJ1M.8V&/TKO0*" 1@@
M$>]<T,SJ15I*YT3RZFW>.AC^'KR2ZL/*D3(@PBR8X<59OM'M+V)AY21RGE94
M&"I]:OJH4 *  .PI:X'5?/S1T.U4ER\LM3CI=,U* [7M#+S@-$00??VIW]DZ
MKY8;[(F?[OF#(KK_ ,:3VKM69UK6.3^SJ-SAGWPOLGB>)LXPXXS]>E+7:3V\
M-U$8IXUD0]585F'PWI^X%/.CQV$A(_6NNEFJM^\1R5,L=_<9SK,$4LQP!U)I
M2EPL*S/:3K"W1]N?TZUTT.@Z=$.8/-;.=TAW5I#I[5-3-7?W$73RQ6]]G!^?
M&'V,VQ^NUQM)_.H+:16NKA5Y7(.X=*U?$T4?]M1R3A#&UO@;AW!K/26!$"HR
MA0. O05Z="NJL%-GG5Z/LYN*)J*3.1D=*6NLYBH\+V[--;@D'EXNQ]Q[U/%-
M',BNC @]L\U)4+VD#DL8EW'J1P:5ADU%5?)FMUS;R%T'_+.3D_@:FCF22,.K
M#;[GI1<+$E%5OMT);C>5S@N%^4'ZU9H$;>A36MW;OHE\N?,):V<C[I],]JJV
M=W?>&-2D@925!_>P_P +C^\OO6:7:+$J':\9#*?<5V>N:7/K.E6M[#%MO$C#
M%#U8$<BN.HE&5GLSMIMSC=;HW[&_M]0M5N+9PR-^8/H:M5QGA;3D&F+>:9,\
M-T&*W$4CED=@><CL:[%22!NZXYKCEH[([8NZ'4444AF;K4;OI=P4C$N$),1&
M?,]JK>%+"2PT&%9XQ'<29DD [$]ORK4O%5[.9'("LA!)]Z6UB$-K%$"2$0+D
MG.:=]+"MK<FHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH R?$L_V?0;I]LQ&S#-"0&4>O->9VRC9O!!5P"O<X^M=GXM
MLM<NE=8&6;36V[H(T_> CKD]Q7) C)4#:5ZJ1@C\*[<,EN<.);V%HHHKM.(:
MZ+(-KJ&'7!I+2Z>UU..Q2&21)Q^[5>2'] .PHD)"' R>@KT+0-!T_3+."6&-
M)+CR\-.3N)SR<'TKS\;3IU(<LD=6'@Y.YF0^'=0EA\QWBB;M&>?S-4KNSGL+
M@0W&PEEW*R="*WO$&O#2X_)BW?:F *_)D =S]:YN::ZO+I+B:YW_ ";=NP"O
MF\53HTX\JW.R22"@#-,E?RXG<#.U2<4X6%Q/:M))=;0Z9585P>GK7%0P\ZWP
MD)7(!]E,Y@ B\T#)7'..M/:V@<JQA3*G(XZ&J7AW18KNTU*225_,M9=T)D.T
M[@.<^H(J[#.DZ;UR#_$K#!4^]:8C#2HV&TT+Y,9.?+3G/;UZTHAC7I&@YSP*
M?17)=DW9%]GAW*WE)N3[IQ]VG&)#G*+R=QX[^M/HHN%V1&WA(VF)"/0BI:**
M5PNV%4M6/_$HNO\ KG5VLS7I9HM)G\J(.I7#G/W1ZU45=V1K0_B1]0NKJYAD
MMHH"@#0[CN&<]*K2-<7$\<DPB4H",IG+ ]JB'VJ9X)99(SL3;A5QQZ58K[#
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MJK7A35Y,4(R;]TSAJ&J6<FR[M!(O)\Q3U _K5RVUFRN5!6782,X<8Q5CR;R
M$(ZW*YZ2'##\:JM;V=Q,8YX!#<$8V^H]1V-*GB*=3X65.#7Q(FDAECF-S:;&
MWCYXR<!_<'UJA=V5EJI.PFVO-I7!&"?KZCZ58LM*DLKO>MW(\ 4@1-ZU<NH[
M=X2]R%"ISO/!7Z&NC<RO9Z$1\VPTQ0%:YEC4 Y_B]3]*PYH3/=-.ETBR2?\
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ML4A\<6XMHK@V[!'5RQW#"%>@/UK6YR<DCK:*C@E\Z".3&-ZAL?6I*9 4444
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MU0TRX@U!YKV$/C<8E9QC('I[9H TA1110 4444 %%%% !1110 4444 %%%%
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M$0("\ ,W;WXK7@EN[-0EK/B/KY<@W ?3TJ9TXS5I(2DXO1EM]+U)?N7%N_\
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M=A17'_V[K_\ SQT__OIJ/[=U_P#YXZ?_ -]-2]G/L'M*?\R.PHKC_P"W=?\
M^>.G_P#?34?V[K__ #QT_P#[Z:CV<^P>TI_S(["BN/\ [=U__GCI_P#WTU']
MNZ__ ,\=/_[Z:CV<^P>TI_S(["BN/_M[7_\ GCI__?34?V[K^/\ 4Z?_ -]-
M1[*?8/:4_P"9'845Q_\ ;NO_ //'3_\ OIJ/[=U_M#8?]]-1[*?8/:4_YD=A
M17'_ -O:]_SQT_\ [Z:C^WM?_P">.G_]]-1[.?8/:4_YD=A17'_V[K__ #QT
M_P#[Z:C^W=?_ .>.G_\ ?34>RGV#VE/^9'845Q_]NZ__ ,\M/_[Z:C^W=?\
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M6=E?:V8P8UA(B7/+XZYKH<8^R3ZG,I2]K9;'8WUA;:C9R6EU&'A<8*UACP=
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M)BC%%WW"YS?_  A\7_02OO\ OL?X4?\ "'Q?]!.^_P"^Q_A728HQ1=A<YO\
MX0^+_H)WW_?8_P */^$/B_Z"=]_WV/\ "NDQ1BB[[A<YO_A#XO\ H)7W_?8_
MPH_X0^+_ *"=]_WV/\*Z3%&*+ON%SF_^$/B_Z"=]_P!]C_"C_A#XO^@G??\
M?8_PKI,48HNPN<W_ ,(?%_T$[[_OL?X4?\(?%_T$[[_OL?X5TF*,47?<+G-_
M\(?%_P!!.^_[['^%'_"'Q?\ 03OO^^Q_A728HQ1=]PN<T?!T)&&U._(/4"0#
M^E;6G:;;:79):VB%(E]3DD]R3W-6\4M+<=PHHHH$%%%% "'@4%@ 23@4IK'\
M3N\?AR]9&*MLQD'GDBIE+E394(\TE'N/?Q)HZ.4;4(,@X/S4G_"3:-_T$(?^
M^JP8X+2UL58PQ+%'&&)VC@8IL,ME/LV0K\_*[HL9KPGFTND3O^JTUI=G0?\
M"3:-_P!!"'\Z/^$FT;_H(0_G6*Z6D:,[K J*,DD#@5',]C;VXN)$B\HD ,J
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M;;&?*AQZX%-"6;2O$%@,B %EP,CZTO[7E_('U6GW9M_\)-HW_00A_P"^J/\
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MS:D.230ZBDR/449'K6IF<?JNFVVJ^.H+:\1I(19%@F\@9W>U7QX*T#_GR/\
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ME971ULOB3R)-DEE-R"591D'VJSIFN)J=PT26TT>T9+.,"J1\6Z=Q_H][_P"
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M9?\ PD>C?]!.U_[^"GQ:]I4\JQ1:A;/(QPJAQDT<\>XN278T:*,T59(4444
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MB/\ T14$@RN^(#CUJ20:<D;2.EJ%52Q.U>@ZUE7F@RM:6T%LQQ'$ROYDA/)
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M_P" XH_X1C5O^@\W_@.M=711]2H?RA]9J=SE/^$8U;_H/'_P'6C_ (1C5O\
MH/'_ ,!Q75T4?4J'\H?6:G<Y3_A&-6_Z#Q_\!Q_C1_PC&K?]!X_^ XKJZ*7U
M*A_*'UFIW.4_X1C5O^@\?_ =:0^$KR?]W>ZQ)+;G[\:1A"P],UUE%-8.@G=1
M%]9J=R..(11+&@PJ@ #T%2445UF 4444 %%%% !1110 4444 %%%% !1110
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M4)-'G,LXB6-8Y)5D#9P>!TQ42:)=1^6V(W:,H0K'@XSFCECW#GJ=C?5T) #
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$T ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &* ]T# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR"B@4I&*+AI82BBBF%E:["BBB@- HHHI,- HHHH$K7"BBB@>@4444!H%%%%
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M** "BBB@ HHHH **** "BBB@ HHHH **** .,^(/_(*B_P!\5YOWKTCXA?\
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MQ14<GH.E:4:<D[LRQM>,H6B0X]\T4<=A]?K17H=#R%I$****D04444 %%%%
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MC2L.I:2EKG.X****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKN/^$*C_ +S4?\(5'_>:CZW /[)K'#_A1^%=Q_PA4?\ >:C_ (0J/^\U'UN
M?V36.'_"C\*[C_A"H_[S4?\ "%1_WFH^MP#^R:QP_P"%'X5W'_"%1_WFH_X0
MJ/\ O-1];@']DUCA_P */PKN/^$*C_O-1_PA4?\ >:CZW /[)K'#_A1^%=Q_
MPA4?]YJ/^$*C_O-1];@']DUCA_PH_"NX_P"$*C_O-1_PA4?]YJ/K< _LFL</
M^%'X5W'_  A4?]YJ/^$*C_O-1];@']DUCA_PH_"NX_X0J/\ O-1_PA4?]YJ/
MK< _LFL</^%'X5W'_"%1_P!YJ/\ A"H_[S4?6X!_9-8X?\*/PKN/^$*C_O-1
M_P (5'_>:CZW /[)K'#_ (4?A7<?\(5'_>:C_A"H_P"\U'UN ?V36.'_  H_
M"NX_X0J/^\U'_"%1_P!YJ/K< _LFL</^%'X5W'_"%1_WFH_X0J/^\U'UN ?V
M36.'_"C\*[C_ (0J/^\U'_"%1_WFH^MP#^R:QP_X4?A7<?\ "%1_WFH_X0J/
M^\U'UN ?V36.'_"C\*[C_A"H_P"\U'_"%1_WFH^MP#^R:QP_X4?A7<?\(5'_
M 'FH_P"$*C_O-1];@']DUCA_PH_"NX_X0J/^\U'_  A4?]YJ/K< _LFL</\
MA1^%=Q_PA4?]YJ/^$*C_ +S4?6X!_9-8X?\ "C\*[C_A"H_[S4?\(5'_ 'FH
M^MP#^R:QP_X4?A7<?\(5'_>:C_A"H_[S4?6X!_9-8X?\**[C_A"X_P"\:/\
MA"X_[QH^MP'_ &16L</D*W&>:Z?PSI6]A(XY/2M-?!<:D'!./>NDTO2A:A..
M%KFJXA26AWX#+G1E>H7[*W$,:X&*NTBC@4M>>?0(.U+112ZC"BBBF 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 -]L4FQ?04ZB@!NP>@HV#T%.HH ;L'H*-@]!3J*!:#=@]!1L'H*=10
M&@W8/04;!Z"G44 -V#T%&P>@IU% :#=@]!1L'H*=10 W8/04;!Z"G44 -V#T
M%&P>@IU% :#=@]!1L'H*=10 W8/04;!Z"G44 -V#T%&P>@IU% #=@]!1L'H*
M=10 W8/04;!Z"G44 -V#T%&P>@IU% #=@]!1L'H*=10 W8/04;!Z"G44 -V#
MT%&P>@IU% #=@]!1L'H*=10 W8/04;!Z"G44 -V#T%&P>@IU% #=@]!1L'H*
M=10 W8/04;!Z"G44 -V#T%&P>@IU% #=@]!1L'H*=10 W8/04;!Z"G44 -V#
MT%&P>@IU% #=@]!1L'H*=10 W8/04;!Z"G44 -V#T%&P>@IU% #=@]!1L'H*
M=10 W8/04;!Z"G44 -V#T%&P>@IU% QNQ0.E*H [8I:* %I ,4M% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "
M44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "
M44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "
M44M% "44M% "44M% "44M% "44M% "44M% "44M% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4@I:3/% !12=:,CUIAHA:6F_K1^%(!:*3\*/PH"XM
M%)GVHR:!7L+2TW/%.% PHHHH **** "BBB@ HHHH ***,T %%(32 YH%<=12
M9HS0,6BDS1F@!:*3-&: %HI,T9H 6BDS1GVH%<6BDS1F@8M%)D^E+0 4444
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MXB:H/^6"T?\ "QM3_P">"UQY''#'([9I4C>0XC#N>^*YE4D>)''XF6TCK_\
MA8VI_P#/!:/^%C:G_P \%KD1'(6*[)-P[8ZTA5E)#AUQUR.E/GD'U[%=V=?_
M ,+&U/\ YX+1_P +#U/KY"XKCRI#;6W*>V:3@@X9L_6DJDEN*68XBUN8[O3/
M'VH7FJP6DD*A7.#7I2'<H->&:$<Z_:$YSN%>YQC$8KIIR<CZ/*Z]2K!N;N/H
MHHK4]<**** "BBB@ HHHH ;FBDSGH:0'/!Q1<5GNAV*6DS1F@=[BT4F:,T7
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M6XEA#,UQ)\I9JBNM*OXA*]R S#E_4>]2[,55J4;11G]AZT#J:O0:1?7, F"
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M3A?8I8"A_*<7_P *XTW_ )ZS?G1_PK?3,8\R7\Z[3-&:/9Q[%?4:'\IQ]O\
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M:3/0*,_YQ7G_ /PL&4=;:E_X6!+D#[-R>E'U6J8_VIA^YW^?\XHS_G%>?_\
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MFWUBT@>XB$LCK(."<U)'KUD=V[]WL;[P_BI^TJ+[(O8T&K<QSWV.ZVF40,$
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M3/;Y:]:MI"^ISHPX4<5?\M/[HI/'270/[$@]5(\7_LS4,8-K(6]=II/[+O\
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MY_S[R9_W:]:\J/\ N#\J/*C_ +@_*C^S5W#^UG_*>2#3KS:2;9_^^:7^S[O
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M%% !1110 4444 %%%% !1110 4444 %)@4M% "8'I1@>E+10 F!Z48'I2T4
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M&'\J^XS?[ TC_H%V?_?A?\*/[ TC_H&6?_?A?\*TJ*+(/8P_E7W&;_8&D?\
M0,L_^_"_X4?V!I'_ $#+/_OPO^%:5%%D'L8?RK[C-_L#2/\ H&6?_?A?\*5=
M"TE6#+IMF&'0B%>/TK1HHL@]C#^5?<(%     %.HHH- HHHH **** "BBB@
MHHHH **** "C%%% %2YL+2\ %U:PS =/,0-C\ZK_ -@:3_T#+3_ORO\ A6C2
MTK&3A"6K2,W^P-(_Z!EG_P!^%_PH_L#2/^@79_\ ?A?\*TJ*=D/V,/Y5]QF_
MV!I'_0+L_P#OPO\ A1_8&D?] NS_ ._"_P"%:5%%D'L8?RK[C-_L#2/^@79_
M]^%_PH_L#2/^@79_]^%_PK2HHL@]C#^5?<9O]@:1_P! NS_[\+_A1_8&D?\
M0+L_^_"_X5I4460>QA_*ON,W^P-(_P"@79_]^%_PH_L#2/\ H%V?_?A?\*TJ
M*+(/8P_E7W&;_8&D?] NS_[\+_A1_8&D?] NS_[\+_A6E119![&'\J^XS?[
MTC_H%V?_ 'X7_"C^P-(_Z!EG_P!^%_PK2HHL@]C#^5?<9O\ 8&D?] NS_P"_
M"_X4?V!I'_0+L_\ OPO^%:5%%D'L8?RK[C-_L#2/^@79_P#?A?\ "C^P-(_Z
M!=G_ -^%_P *TJ*+(/8P_E7W&;_8&D?] NS_ ._"_P"%']@:1_T"[/\ [\+_
M (5I4460>QA_*ON,W^P-(_Z!EG_WX7_"C^P-(_Z!=G_WX7_"M*BBR#V,/Y5]
MPR*&.",1Q1JB#HJC %/I:*#0**** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &S [(# 2(  A$! Q$!_\0
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M7_!5^OO^@#X _P"'EG[.O_1.?V__ /Q4[_P5-_\ H-Z/^'EG[.O_ $3G]O\
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M=(DWRND:;F&Z1U1<LP!LT ? '_#RS]G7_HG/[?\ _P"*G?\ @J;_ /0;T?\
M#RS]G7_HG/[?_P#XJ=_X*F__ $&]??\ 10!\ ?\ #RS]G7_HG/[?_P#XJ=_X
M*F__ $&]>_\ P,_:=^$/[11\46WPZN_B!IGB#P5_8D_BGP'\8O@G\;/V<OBG
MH^C>)_[7C\*^+KGX2_M#_#SX6_$Q_ 'BZ]\-^+=&\(?$6#PG-X%\5^(O WQ
M\->'O$6I>(/ 'C/3=#^@*^ /AU_RE-_;$_[, _X)M?\ K17_  5:H ^_Z***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA'>>&+W1/A_=^*I_&UQH?@+Q=XU^&,TGBB[\9W/Q$O=6.N?#CQ%X5\0K)?\
MC>[N/$FH6Z:JMG?ZE*9;RVG0*B@'S_\ &OPS:Q_%_P#8Y^$M_HOA*S^#_B[Q
M[\7O%WC[0--T*/1?#'CKXM^'O ^J>//!VE:AX:A:XTZ]M-6\27GCWXPW5GK-
MWJ<ESXQ\":+K-VVJZM;'48O._C!\0_$OPQ^*_P"VIXR^%WPB^$>@_&+P-^R1
MX ^)9^*7B'Q%XEUZT^)FC>']3^,K_#GPIX\\#:%X9\%WEE)H][X=^(-E-KME
M\0M9O--TK5M 6VBU:".32M)^\/'OPN\#_$[PU:^$_&^CS:QI>G:AI>L:1=1Z
MSKVD>)?#^O:(Q;2/$OAKQGHFIZ;XP\,^*=-+2_8_%&@:[IWB" 7%TL>I!;NY
M$OGVL?LP?!O7]$^)N@ZUH_B[4[?XQ>&=/\%_$/5;SXL?%N;Q;K7A#2HM4BL/
M"]EXY;QS_P )IX:\/VW]NZ[.ND>%M?T6P:\US6[^2![W5]1N+D ^5=9_:#_:
M;\,>$_VI=?U#5_@MXDUG]E6VTCQ;JVA:1\+/'/ABU^(/AK4/"EO\8K[PQI,]
MW\9/&FH:7JEI\--7LO 6B^-C;7-EK7Q.T;5_%UUX'TSPW<)X"LO.?'7[;/[0
M>E? S5_BGX8L_@]'K6F^&/V\M8ATCQ%X&\;7&GW=]^RS\4;WPYX"AN&T_P"*
MEE=Z?;Z_X6TV:S\8HC:A,?$-W'KNC2:=IUDWAF^^^-3_ &9_@UK'BK3/&FI>
M'-:N?$-AX8T7P9?W!^(/Q&BL/&OACPW<75UX=TGXJ:%!XMBT'XPPZ#<7^IS:
M++\5=,\97.EOJ^LFQG@_MC4_M?SK\9/^"=WP<\=>#?C#9_#1)/AE\3/BOI7Q
M;TZW\?:[KGQ;^)/AWP1)\=X+6W^+;^%/A9-\8?"?AG0-)\9S6R^)-3\(>$[K
MPKX/N?B"L'Q!U#0K_P 3+=W=Z >@? /Q_P#M W/Q<^+_ ,&OC_J/PF\:-X;\
M&_##XH^!?'?PF^'OC/X8:;-X6^)^H?$+0KCP'XL\)>,OB7\7Q>>)?"FJ?#J\
MO%\7Z1XRLK#Q+HOB*PAG\$^&[O1Y[K7.1_8DBLO"G[!?PEMO#LFC>#X[#P%K
M=GX>>*PL+?2-)U2[\0Z];:*MOI0-G8S%]7N;5+?3$,(U"ZFCLT_>W*@_2WPX
M^$.A?#[P=<^&DO-;U35==L4A\7^*[GQ?\2-3\0ZU?O8&RGGT[Q1XU\>>-_B#
MH&FVGF7!\,:1#XZO%\'PS>3H5Y;R(;A_*_ 7[%'[//PTT_X::+X2T3XC0>&_
MA!<R7GP^\(:Y^T!^T'XQ\$:)<M;7MI#-=>"/&/Q2U[PEXA;3XM1O'T;_ (27
M1M8&AW,WVW1Q8WD<4\8!^;FI_%3XE?'G_@G_ *>/&OB7P3XIUCP%HG[#&J>/
M]=UWP+=WOB#Q1XX\:ZG\"_BO=:S9>7XZAL?#>I0:/XOT58-971[V"37GU2_L
M-.LK.&/2(/W07H/H/Y5\4)_P3O\ V2X]/MM'7P%XR.C6_ASPYX1GT1_CQ^T#
M)H>M>'/!7B*\\5> =*\4Z-)\4FTSQ?!\-]:OIY?AB_BFTUB?X:V"6FB^!)?#
M^B:?8:=;?:RJ$547=A%"C<S.V%  W.Y9W; Y9F9F/+$DDT .HHHH *^ /AU_
MRE-_;$_[, _X)M?^M%?\%6J^_P"O@#X=?\I3?VQ/^S /^";7_K17_!5J@#[_
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$W@0?GM_PV3^PIX-^#WACX ?"K_@H9_P3"U:U^%/[7>D?'?P[JOC[]OCX,>
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M_P#/&H ^_P"BO@#_ (>Q?\$LO^DEG[ '_B9'[.O_ ,\:C_A[%_P2R_Z26?L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"NW"4Z491I/EDIWJN,?9PJSORTIV_8ZBBBOESV HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /@#XH_M+_M3?\-3^._V:/V:/V<O@!\4/^%8? #X"_'3QKXU^.G[6/Q%
M_9__ .2__$7]IGP!X<\+>%O#G@#]C?\ ::_MO^Q?^&9M>U;6];U;7O#/_(S:
M186&D7?V2\O*/^%C?\%3?^C-_P!@#_Q99^T5_P#2G:/AS_RE-_;'_P"S /\
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M)WP\^#GAJR^,/@_P;XJU+XZZ#KOQ"\#>(/!/A76[;Q%\(=2\+:';:_H&J_\
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MGZ%XF\9>'_$$6KZ3I@!S7_"QO^"IO_1F_P"P!_XLL_:*_P#I3M<-HZ?\%%=
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M!(VKKX:2+PZNH1K"D-RNA(NCK+&RZ:/L8AKZHK(L^ /^%C?\%3?^C-_V /\
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MM8?%NAZ/& /_ .%C?\%3?^C-_P!@#_Q99^T5_P#2G:/^%C?\%3?^C-_V /\
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MOV;=:N;FVMM%\4:=J>G>)M+EBU2RN;.[M&^X*^ /AY_RE-_:]_[, _X)Q_\
MK17_  5.H ^_Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X ^'/_*4W]L?_
M +, _P"":O\ ZT5_P5?K[_KX ^'/_*4W]L?_ +, _P"":O\ ZT5_P5?K[_H
M**** "O'=<^'_C/4?CAX"^)^F>-O#VF^#O"W@'QYX+\0>!;SP-?:GKWB.Y\9
MZQX-UFVUC3?'47CC3+/PY'HLW@JRB.F3>!_$!U*.^OB^H6C?93;^Q44 ?"$G
M[#VF^#?"7B'1?@)\1+SX5:U'^T>O[3?PMDUKPX?'O@3X9^+=1TA=%\9>"HO
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M+!<O ;F.WM1+]GC]NHHH **** "O@#X=?\I3?VQ/^S /^";7_K17_!5JOO\
MKX ^'7_*4W]L3_LP#_@FU_ZT5_P5:H ^_P"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O@#_@FK_R;W\3?^S_ /\
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M% !1110 4444 %%%% !1110 4444 %%%% 'P!\.?^4IO[8__ &8!_P $U?\
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M<T ??]? 'PZ_Y2F_MB?]F ?\$VO_ %HK_@JU1_PZ=_X)9?\ 2-/]@#_Q#?\
M9U_^=S7O_P #/V3OV6/V7SXH/[-'[-/[/_[.Y\<?V(/&I^!GP:^'7PD/B\>&
MO[7_ .$<'BC_ (0#PYX?_P"$@_L#^W]=_L3^UOM?]E?VUJ_V#R/[2O/. /H"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "O@#_ ()J_P#)O?Q-_P"S_P#_ (*L?^O/OVO:^_Z^(?%O_!,K_@FYX_\
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M:\SIJ:IN>UK*<HQWO=K2VI^E-%? '_#IW_@EE_TC3_8 _P#$-_V=?_G<T?\
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MEAZT*#J.NYSEAX8A\M*E":C&$ZM*,;RGK*[=DDEJV<3_ ,-.^%_^B7_M(_\
MB.7Q?_\ F4H_X:=\+_\ 1+_VD?\ Q'+XO_\ S*5](T5M]<R3_H15_P#P_P"-
M_P#G41[#,/\ H94__#9AO_FP^;O^&G?"_P#T2_\ :1_\1R^+_P#\RE'_  T[
MX7_Z)?\ M(_^(Y?%_P#^92OI&BCZYDG_ $(J_P#X?\;_ /.H/89A_P!#*G_X
M;,-_\V'S=_PT[X7_ .B7_M(_^(Y?%_\ ^92C_AIWPO\ ]$O_ &D?_$<OB_\
M_,I7TC11]<R3_H15_P#P_P"-_P#G4'L,P_Z&5/\ \-F&_P#FP^;O^&G?"_\
MT2_]I'_Q'+XO_P#S*4?\-.^%_P#HE_[2/_B.7Q?_ /F4KZ1HH^N9)_T(J_\
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MZ$5?_P /^-_^=0>PS#_H94__  V8;_YL/F[_ (:=\+_]$O\ VD?_ !'+XO\
M_P RE'_#3OA?_HE_[2/_ (CE\7__ )E*^D:*/KF2?]"*O_X?\;_\Z@]AF'_0
MRI_^&S#?_-A\W?\ #3OA?_HE_P"TC_XCE\7_ /YE*/\ AIWPO_T2_P#:1_\
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MZYDG_0BK_P#A_P ;_P#.H/89A_T,J?\ X;,-_P#-A\W?\-.^%_\ HE_[2/\
MXCE\7_\ YE*/^&G?"_\ T2_]I'_Q'+XO_P#S*5](T4?7,D_Z$5?_ ,/^-_\
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MK+<*E]7>+II-1>*LJK]M"G.I?FEAZ4*.B5WY#_PT[X7_ .B7_M(_^(Y?%_\
M^92C_AIWPO\ ]$O_ &D?_$<OB_\ _,I7TC17S/US)/\ H15__#_C?_G4>S[#
M,/\ H94__#9AO_FP^;O^&G?"_P#T2_\ :1_\1R^+_P#\RE'_  T[X7_Z)?\
MM(_^(Y?%_P#^92OI&BCZYDG_ $(J_P#X?\;_ /.H/89A_P!#*G_X;,-_\V'S
M=_PT[X7_ .B7_M(_^(Y?%_\ ^92C_AIWPO\ ]$O_ &D?_$<OB_\ _,I7TC11
M]<R3_H15_P#P_P"-_P#G4'L,P_Z&5/\ \-F&_P#FP^;O^&G?"_\ T2_]I'_Q
M'+XO_P#S*4?\-.^%_P#HE_[2/_B.7Q?_ /F4KZ1HH^N9)_T(J_\ X?\ &_\
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M &D?_$<OB_\ _,I1_P -.^%_^B7_ +2/_B.7Q?\ _F4KZ1HH^N9)_P!"*O\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,KGXP>
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M%<!U!1110 4444 %%%% !1110 4444 %%%% 'B.H_M%?"+1M2^-.F:WXCO\
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M_P#U!QQRXS_=Y?\ 7W"_^IN".XHHHKE.H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@".:58(99W$K)#%)*ZPPS7,S+&I=A%;V\<MQ/*0I$<,$4D
MTKX2*-W95/@.C_M-_"KQ-X-\">-/"EWXC\0V_P 4/%WBKP)\/?#R>$M?\.^,
MO$_BGP1=^+[7Q;IB>%_&MEX7U30/^$?C\!^++W5+SQ;%X?L;2TT@F6Y6XO\
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MX1[2-8L/"JRZM>V26WB;6KZT\&ZG9:AI6K:/XBU'2M:T:]U#\T?#/COPS9^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&:QF&GA*CJT,96C62IU)SDXTZC=*4[J/M85(1YN1R91117RA[04444 %%%%
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M],5_7,? #_DA'P6_[)/\._\ U$=(KV5_R3D_^R@I?^J*N<#_ .1K'_L63_\
M5C3/7****\8[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#Y@_;"^/GBK]FOX(-\2O OP]\/\ Q2\;:M\8/V9_@IX.\$>+/B#J/PK\*ZEX
MJ_:9_:5^$G[-OA[4/$WQ T?X>?%C5_#7A_PUJ_Q8L_%&LW6E_#GQ=J-QIVC7
M-A8Z4]S=Q30^/_\ "QO^"IO_ $9O^P!_XLL_:*_^E.T?\%+/^3=?AS_V?_\
M\$G?_7IO[&]??] 'P!_PL;_@J;_T9O\ L ?^++/VBO\ Z4[1_P +&_X*F_\
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M^VV-E:W8!X=_PL;_ (*F_P#1F_[ '_BRS]HK_P"E.T?\+&_X*F_]&;_L ?\
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M^-_'7A7XQWGCW4/$]]J>@?M-?'CP?I4'B_\ X1+^V]&\+^&O&=QI_AS0I/\
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M !R7_"QO^"IO_1F_[ '_ (LL_:*_^E.T?\+&_P""IO\ T9O^P!_XLL_:*_\
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MDFC6*Z9I+:G=)_P2;$MW_9VGH+.S$S,+>#*1A0S9W/\ A8W_  5-_P"C-_V
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M8QBK1C&*O*5HQ45S2DY2E:*2YI2;E)VO*3<I-MMOYS_X6-_P5-_Z,W_8 _\
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M0? '_"QO^"IO_1F_[ '_ (LL_:*_^E.T?\+&_P""IO\ T9O^P!_XLL_:*_\
MI3M??]% 'P!_PL;_ (*F_P#1F_[ '_BRS]HK_P"E.UT'[.7[1WQ]\>_'[XY?
MLY_M&? OX/\ P@\;?"+X/_L[?&O2M5^"G[1GC3]H7PMXL\+?M!>-/VF/ MEI
M^H7OCK]F/]F75O#'B#PQJW[-&MW-U:VVB>*-.U33O$^E2Q:K97-G=VC?;]?
M'PZ_Y2F_MB?]F ?\$VO_ %HK_@JU0!]_T444 %%%% 'Q!^T?^T=\?? /Q\^!
M?[.O[.GP,^$'Q?\ &_Q@^$7[17QHU35/C7^T7XT_9Z\*^$_"W[/?C+]F?P1?
M6%A?>!?V9/VFM7\3^(/$^K?M+Z)<6EI<:'X8T[3-.\,:K--JMY<WEI:+S_\
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M;P'X@L?"WCO5WT3X5?"SQGJMO%X(UW4M/LO%L%Q:17F@?;;.?4;>"VO+6:8
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MPY:0>)[VR^)/B:[D\32V%IJ_ACP_H_AS2[FTU[47\&GBGX&_&Z?]HOQ)\>?
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M5[J<>F2VUIJ=]JE[:S:K>^_JRNJNC*Z,H964AE96&596&05(((()!!R.*6@
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MP9I$/Q7N;/X<_$+7O&GPSTOQ)XS\2?9/%FD>,(;V\AO?"MIXGEN?&EY]YT4
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MKMEX9\1R7NG:A:ZOX6T2^@>R3ULLJE0S*"[;4!(!=@K.54'EF"*S8&3M5FZ
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M7A6;PZW@;PN_A^^>]U6_\>^+D\0#6[J634;1(-+\/G1K?9I\SZS(K:B_NE%
M'P3X4_9D_:4\)^&?B7X0T_\ ::^&MMI?Q6^-7Q!^)WB36-,_9O\ $>G^,M*\
M+_$KQ-)K6O\ @OPAK,G[2%]H^C:W9Z3*_A_0?'FH>&=<DTY=FL3^&K[5(TE'
M#V7["_Q<T3X;^%/ 7AO]I#PGI4T'[,U_^R1\1=2G^ ^J:GIWC'X4:7%JUG\,
M?$/AO0I_CE$_@CXN^ M/\0^(X+[Q7>:QXS\$^,+CQ#J,]]\,=.@MM"L]%_2Z
MB@#\T?V>/#%UX*_X*(_M)>#;W54UV[\)?\$U/^"6GAFYUN/3QI*:O-H7QS_X
M*J:6^IKI8O-0&G_;FM3<FR6^NUMC*85N)50.?TNKX ^'/_*4W]L?_LP#_@FK
M_P"M%?\ !5^OO^@#X ^'/_*4W]L?_LP#_@FK_P"M%?\ !5^OO^O@#X<_\I3?
MVQ_^S /^":O_ *T5_P %7Z^_Z "BBB@ HHHH ^4/B+\$_C3K?Q[TGXX?#;XN
M_"_P>="^#?B[X4:9X8\<? SQ7\1,W'B[Q3X.\5W?B*^UK0?V@/A?]IAM+SP5
MIUM;Z);Z39.UM=7OF:R96@D@XKX3_L:7'P;\2?LZWOACXG?VGX9^"'AOX_V/
MB#3?$_@^?4O%'Q \5?M%^,M)^(7C7Q-:^)[#QEI&B^"M/M?%VF2W6D>%[?P3
MKUI9Z7?2Z3#?Q)!:W,7W)10!\N>+?@/X[LOC%K'QL^!GQ-\,_#CQ)X\\.>'O
M"_Q:\/>/?AGJ/Q3\%>.;;P6=3_X0KQ+8Z;H7Q+^$^O>%O'>@VNLZCH4^NP>)
MM4T;7/#+V&F:MX7N+S1-$U;3O./V@?V3_BA\<?[%EC^.?A70KRU^!W[0_P '
M=:NM9^"]YXC^WR_M#Z;X;TO5M<T:#1?BWX'BT73/"%IX:L[?PWH&H#Q'J=Q
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MQG/% 'S5^T)\$O'_ ,6V^!\G@+XG>&_A\_P@^+NA_%74/^$M^&VI_$T>,_\
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M"IO_ $>1^P!_XK3_ &BO_IL55H?A9_P5!MIKRYM_VOO^">]O<:A-'<W\\/\
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M_BKXE>-=$O-/L?A]J,?A/2--&D^%)?#'@#X,:YH9\.?%*UTGQKJ.D^;]-?\
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MV /_ !6G^T5_]-BH ^_Z*^ /^%<_\%3?^CR/V /_ !6G^T5_]-BH_P"%<_\
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M^ ?#>C^#? G[4'_!-[P5X0\/6::?H'A7PE_P2X^/'ASPWH=@C,Z6.CZ'H_\
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M?^"IO_1Y'[ '_BM/]HK_ .FQ56M?A9_P5!L4DBLOVOO^">]G'-<W5[+':_\
M!,S]H6W26\OKB2[O;N1(O^"KZ*]S>74TMS=3L#+<7$LDTKO([,0#]"**^ /^
M%<_\%3?^CR/V /\ Q6G^T5_]-BH_X5S_ ,%3?^CR/V /_%:?[17_ --BH ^_
MZ*^ /^%<_P#!4W_H\C]@#_Q6G^T5_P#38J/^%<_\%3?^CR/V /\ Q6G^T5_]
M-BH ^_Z*^ /^%<_\%3?^CR/V /\ Q6G^T5_]-BH_X5S_ ,%3?^CR/V /_%:?
M[17_ --BH ^_Z^ /AU_RE-_;$_[, _X)M?\ K17_  5:H_X5S_P5-_Z/(_8
M_P#%:?[17_TV*N@_9R_9Q^/O@+X_?'+]HS]HSXZ?!_XO^-OB[\'_ -G;X*:5
MI7P4_9S\:?L]>%O"?A;]GWQI^TQXZLM0U"R\=?M.?M-:MXG\0>)]6_:7UNVN
MKJVUOPOIVEZ=X8TJ*+2KVYO+N[4 ^WZ*** "BBB@#X ^)'_*4O\ 8U_[,&_X
M*4_^M"_\$I:^_P"OR9T_X.?MA_M >*?V<?VU/AU^TI^SY\-_'>@_ ?XR?#JQ
M\)?$7]D?Q[\7?!T7@[]HKQ3^SWX[\3QHOA']L+X$ZX?$.CZU^SCX-@TC6+G5
M[K3SIFI^(+>YT%[JXLKZQ]G_ .%<_P#!4W_H\C]@#_Q6G^T5_P#38J[,PP4\
MNQN)P-6M0K5L)5J8>M/#3J3HQKT9SI5J49U*.'E)T:M*I3E)4_9RE&].=2#C
M-\^%Q$<7AZ6)A"K3IUX1JTXUHQC-TYQC.G-QA4JJ*G"<9I.?,D[3C&2<5]_T
M5\ ?\*Y_X*F_]'D?L ?^*T_VBO\ Z;%1_P *Y_X*F_\ 1Y'[ '_BM/\ :*_^
MFQ5QG0??]%? '_"N?^"IO_1Y'[ '_BM/]HK_ .FQ4?\ "N?^"IO_ $>1^P!_
MXK3_ &BO_IL5 '5^/=&USPK^W!\(_B[J<NJ2_#G5_P!FWXR_!X)96UUJ46G_
M !%?QK\-_B?H]K%I.EV=WJMYJ?BSPAX,\7KIZPQ7 N+CPE%I5FBZMJEA::I^
M?OA/P#9:5^R1^Q_KTO@;]KE/&VD?M2_ V]\0>"[OPK^V=>/X<A\-?'6V\4>*
M=9\0_!.ZT^XTOPSX*TKPW;W>J0:]JW@?3O!,>RV_L>^-^UBC?9UW\+/^"H-_
M#]FO_P!K[_@GO>V_G6UQY%W_ ,$S/VA;F'[197,5Y9S^5-_P5?=/.M+RW@N[
M:7;O@N88IXF26-'6S_PKG_@J;_T>1^P!_P"*T_VBO_IL5 'P/\5_A#K/C?\
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MTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX+_\D>^%7_9./!'_ *C6F4_XR?\ )(?BK_V3?QS_ .HQJE,^"_\ R1[X5?\
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M%I8?#&ZO[QX;2WE>.SL+6ZOKN0+;V=M<7,L4+]'_ ,%+/^3=?AS_ -G_ /\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _ [3OV>_@%^TI^T!_P $L_ O[1?P
M/^$'Q]\$:5_P3@_;^\6:7X.^-?PT\%_%3PKIOBFP^-7_  2YTBQ\2V'A[QUH
MNNZ19^(+/2==UO2[36;>SCU&WT[6=5LH;E+;4+N*;[R_X=._\$LO^D:?[ '_
M (AO^SK_ /.YKYL^ ?\ R=5_P3"_[1@_\%"?_5]?\$I*_9*O8XB_Y*#/O^QW
MF_\ ZM,P.#*O^17EG_8NP/\ ZAX8^ /^'3O_  2R_P"D:?[ '_B&_P"SK_\
M.YKRC_A@?_@CFOQL'[/<_P#P3A_85M/B?-\.'^+&GZ9=?L*_!*'1=8\$0>((
MO"U_?Z3XM/PI/A:]U+2];GMK;4_#::N/$EE;7=IJDNDC2;J"^D_5:ORU_:W\
M7>$M#^-\?Q-\*ZK%XJ^,_P"R5HWP5^+6L?"WP9<VNN_$G5_@YXSU_P",GPV^
M+>FIX-T_[3X@U&%_ WC%O&>E:7;6R3ZEXE\*^$#$LS36<-SXYWE#PK^P7_P1
MP\:_%;XH?!CPW_P3C_85O_'/P;L?!E]\0H)/V%/@G8Z)I"_$"QO]2\+6UEXF
MO_A1;:#XAO+RRTO4);R#P[J&JG1Y;2:RUEK"_7[+77>/?^":?_!)3X;>"/%W
MQ"\4_P#!-;]A"+PUX(\-ZSXK\02Z3^P_\"=?U*'1M T^XU/4IK+1=$^%M_JV
MISQ6=M-(EI86=Q<RE<)&>2/G-OB2OPF\9_MRQ:;XUT:?XKZ!\%/V2_&_Q<T[
MPWJLFO\ C#PGI6O?$CXP>(/C_P"([?P]X?URW\;I;_#OP9XUUK5K5M(NK+7M
M'TFW\/\ ]CW-G>OHQ/'_ !"^-OP@CT/]H[PEK'[55WX]^#_Q?_9S^+?C/]G[
MQ5H?Q2\96'PR\>?%>Z\.ZCX>^)?P@^"?CZT^)WB74_B)J_A6.P\&ZY8?"[3/
M&7BF:PUWX@>--(\%Z':1^'-=T+PZ ?0_CG]A#_@CM\._A-:_&OQ'_P $UOV'
MO^$#NK3PA>K<Z/\ L*? O7]82W\<ZAI&E>'7;0-&^&%[J\AN=2UW2K2X6VM9
MS8FZ-S=^396]U<P:L_\ P3V_X)#6WQ:T;X*3_P#!-#]AV/QWKW@#6OB;IT/_
M  PS\!I-"?PCX=UO0_#FLW4WB:+X9R:%;ZC9:UXDT.S.B2WRZQ<)J,=]:65Q
MIL%W>6]W]JCQ?X2TC_@FAH>N:UXXT?P7HFI^#/V:8;'Q9J>K:'H\%G-<^,_A
MC<PW=G=>)DET=KZTMK>XU&*WU&TO+<+93/>V,]M#<Q5X/^TIXYU#X=?M%J/"
M?[1GB+XF>.;C]B?QGK\6AO?_  JE\?:;\,-2_:$_9[O/'?B?X>:)\(/ _@KQ
M;?ZO??"?3O'^M>%-1L(-8OY;WPV-0\* 7NG3EP#W+QS_ ,$\/^"0GP[UKX:Z
M!XF_X)L_L+0ZC\6?&W_"OO!IL/V&?@9J=C/XF_X1O7_%?V;5M5L?A;-IF@0/
MHOAG6)[>YUF[LDO9[;['8_:;IO*&/X__ &"O^"/_ ,.?%'ASP5K7_!,G]B[4
MO%/BWPK\0/%_AO1O"_[ OP7\23ZSIOPUT[3]3\265A/I7PIGLY_$,D6JZ?#H
MOAM+DZYK=Q<@:?8S0PW,T/E_C#X@^"V_:+^ >I^!/C/I/CC]G/QE^T=\!M;^
M'>MW_P 6&^(7AI_BK+\&?VJ_#_Q'TCX<>+-;UW6?M.EOHD?PCO=>\.:+K5_I
MNF>+_$3WXL].UWQ9J@U'Y^^-G[0/@+Q=X<\&>,K_ .-&M^'OC[X1_9V_X* :
M?\7=)LOC#XV\*^)_@9\9])\"Z5=VWA;4='TSQA9I\)-=L?%/AYK7X?/##X;N
M?%_A_3%OO"4NL^'M2N)+H _2>V_X)2?\$L+JVM[E/^"9_P"P/$MQ#%.L5S^Q
MA^SS;7,:RHL@CN+>;X;I-!,@8++#*BR1.&1U#*0)_P#AT[_P2R_Z1I_L ?\
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MI]I=7DD-O)\E?M+?\$L?V5/'W@[]G+QW^RK\ /AY^S]X%U#X@^#=1^)GA?\
M9_\ @?H'PTG\5?"WXCOHB77B;4?!'PX\-:3))XMT.&'28/[3U'2A=Z%H6J:K
M?>(KF#3O#GE6OWIX]^(^A_\ #N;XE?$;Q9)K/@G1Q^R]\1;S5G^(WBVW\4ZM
MILG_  @NNZ?LO_' N)XO&@O;\QQ:!XF@EFE\96MWI6HVD4EQJT4!^8/CE^V1
M^S[HW[*_P)\)^$_VE/"%E\3+^7]E;5-,M?AQ\9K'2]=TWP[8_$GX4Z;XMO\
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MO#NI7$_PM\3V/C/2'@EM-,\%7ZF0T_VLOB/\1]2\&_#KP/\ $ZU^'/C7P_\
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M1=FGQSI//<?*?_!)W_E%E_P33_[, _8W_P#6=?AS0!]_T444 %%%% !1110
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MMK>ZN[==(\5Q:WHCP7EY#)ISQW=RLORQ_P %+/\ DW7X<_\ 9_\ _P $G?\
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M#>OO^B@#X _X>6?LZ_\ 1.?V_P#_ ,5._P#!4W_Z#>C_ (>6?LZ_]$Y_;_\
M_%3O_!4W_P"@WK[_ ** /PE^"O[:L7[/.C/\$? GPF_:7\3_  /T#6M?D^%O
MC;Q+_P $U?\ @L)H7Q!\">#O$FMZGK]EX*USX8:5_P $[-9\.^.8/AU/JDNB
M>'-7LOBYX#E\3>%[/2+#4K#P]JEC=ZWJF%\(OVE/ OA/3_@G\/\ QK\/OVN[
MKP)^RKXR\1^)?@UXJ\.?\$OO^"NTWBSQWI\_@SX@^ ?!6F>/_!VH?L%:=I'@
M>Z\,^%_B)=66N:AHOCCXB1^+-2T*VUNVL?"Z:O+HVE?OO10!^/'PJ_X*;Z^_
MBFQM_C?\(OVC8/"DWP?\%W>HW?PI_P""5G_!8.\O=.^.L5_J$7Q%TJSNO%_[
M&MC)K'PUO+";2;KP1>2^']%\06#V.J1Z^U^^I6<>G>,6/[>OC+P-\6_VKOB#
MX(_9^^.'B6R^+FN^ ;WX6)XJ_8._X+-^%KJPL_!GPZTCP6T_Q T_2/\ @E7X
MLB@N;G4[*[UH6'AS6=0B>PEMM'.IP7"2ZR_[W44 ?SO_  G_ &IKSPA9?"=O
M&/PP_:7U?6_#/[7?QQ^//CC4-(_X)R?\%@(X+SPE\5?#_P 6+2SET&VD_P""
M9EC'<^+8M9^):2:EX<N4T70;2RTV66Q\4W<EQ%90\3JW[0NJZE\*-/\  J_!
M_P#:%AU;_AES]K?X'W]R?^"?O_!8]].M_%'Q[U_PQ?\ A#4[.4?\$MEN;W0=
M-L=#N6\23S6FGZA:74L%OI>FZQ"9+N/^E:B@#^;.X^/:VUGXUO+#X1_M :YJ
MJ?'+X+_M"^#?#OBW_@FG_P %?KWP=XRU;0/@!X1^ 7Q3^%7Q!5O^":%[<>&-
M!CT?1M;U[X>_$O1=.\;:A=:]=:!>Z[\,]&@T:[L-5S_&/[0OB34]'^,?A7PM
M\)?C#H_ACX_ZI\'/B-JVGQ?\$R/^"PVB0_!/QS\-=8\''6_ /@^QT3_@FD(/
MBUX%\1^'O >A&T\;ZS/\(]=TOQIJ?BWQ+/X#U#3-9LO#.C?TN44 ?G^O_!2S
M]G<JI?X;_M_*Y4;E7_@D_P#\%3G4-CY@K']C5"R@Y 8HI(Y*J3@+_P /+/V=
M?^B<_M__ /BIW_@J;_\ 0;U]_P!% 'P!_P /+/V=?^B<_M__ /BIW_@J;_\
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M&]??]% 'P!_P\L_9U_Z)S^W_ /\ BIW_ (*F_P#T&]'_  \L_9U_Z)S^W_\
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M3\-?!G@S3]8,NN6TWA#25M+O1I=8^S:Y:?8R)\7(T6-%^&RHBJB*H\3!550
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M1:O=Z+7HMD4445XQWA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?-G['G_)KWP,_P"R=>'O
M_245])U\V?L>?\FO? S_ +)UX>_])17TG7L<1?\ )09]_P!CO-__ %:9@<&5
M?\BO+/\ L78'_P!0\,%%%%>.=X4444 %%%% !1110 4444 %>1?%+_D-_!?_
M +*W!_ZKKXBUZ[7D7Q2_Y#?P7_[*W!_ZKKXBUZ&5_P"_4O\ KUC?_5;F9RXS
M_=Y_X\/_ .I>#/7:***\\Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#YN_9._P"2,V__ &4OX\?^KU^(]?2-?-W[
M)W_)&;?_ +*7\>/_ %>OQ'KZ1KV>(?\ D?9Q_P!C'$_G1.#*O^1;@/\ L$H_
ME,****\8[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU&SMIHH&^'GQ#19I(IID=(F9T59&4(690"2P!]RK\B_^"D?_  3NF_:\\>?
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M1<DI.*BVDVTBBBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^;OV3O\ DC-O_P!E+^/'_J]?B/7TC7S=^R=_R1FW_P"R
ME_'C_P!7K\1Z^D:]GB'_ )'V<?\ 8QQ/YT3@RK_D6X#_ +!*/Y3"BBBO&.\*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@'4/@MX0_;W_P""1?B;PE\9(/B7XA_: ^)E[^WQ\&OAG?:=\0/B=(]CJ?\
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MA=9VOA+Q'XMAU;XS:38:GM\.0:E%X>&AV"^!]0^),,/B/5=,TO6KS1FNHI7
M/!?^'L7_  2R_P"DEG[ '_B9'[.O_P \:C_A[%_P2R_Z26?L ?\ B9'[.O\
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MCIFBZ+I\$MS>:C?W,S*D%M##!*V]N7*&.,/)A" ?$G_#V+_@EE_TDL_8 _\
M$R/V=?\ YXU'_#V+_@EE_P!)+/V /_$R/V=?_GC5]\I<P2+ R2H1=1B6W!8*
M\R%!)NC1MKMA&#, N5!RP%<G\0_'_A/X5>!O%?Q(\=ZLFA^#_!6A:AXB\0ZH
M\-Q=-:Z9IL#3SF"SLXI[V_O)MJV]CIUC;W%]J%[+!965O/=3PQ. ?&7_  ]B
M_P""67_22S]@#_Q,C]G7_P">-1_P]B_X)9?])+/V /\ Q,C]G7_YXU>_'XS>
M+].\1_"C2O$WP3\8:-H_Q>UB\T73]<MM>\'ZN_PYO;;PAK_B^WM/B_IL.L6W
M]A7>KQZ%)H6E-X OOB?I+>()TL=3UC2XI+"YU'WR.:&8RB*:*4P2&&81R(YA
MF55<Q2A23'($=&,;X8*ZL1A@2 >"? S]K+]E?]J ^*!^S1^TO^S_ /M$'P.-
M%/C0? SXR_#KXMGP@/$G]K#PZ?% \ ^(_$!T :^=!UT:*=6^R?VK_8NK?8?/
M_LZ\\GZ KX ^'G_*4W]K_P#[, _X)P_^M%?\%4:^_P"@ HHHH **R]<UO2?#
M6BZQXCUZ_M]*T/0-+U#6]9U.[?R[73M)TJTFOM1O[F3!V6]G9P37$SX.V.-C
M@XQ7A/PN_:(TSXB^(/#'AK4?"'B+P-JGQ ^%MM\:OAY:^(6LWN/$'P_EO]-T
MZ_CU*"U<MH'C7PQ+KWA:?Q9X5D-_;Z7;>+M -EKVK77]MVFB 'T517R;XI_:
M]\ ^#KWQ3JWB#3=2T_X4>!OBE9?!7QC\6KBXM(] T+X@7NE6%ZTDM@2;J?P5
MIFMZKIGP]UGQ5'-]HT_XC7AT+^P9](L-6\1Z?RVK_MQ^ _"'A,^+/B%X2\2^
M!X=<^$VC_&;X<Z3K=_X;L-3\<^&?$/B3P_X.TCPR]QK.K:-H7A3XC1^*/&?@
M'2M>\/\ B'6K?P]H1\>^&KBX\8SQ1^(SX> /MNBOCG7?VL]2\)P^%M(\4? O
MQ[IWQ,\6>&OB3\0[7X5V7BGX7:SKVB_"SX4VFD3^*?''B;Q+8^-#\/M/6\O]
M>T+P_P"&-&T[Q;K%SJ^N^(M$2[N-)TB'Q7K/A3W;X4?$QOBIHFL:\O@KQ7X(
MM]*\4Z[X3CL?%\OA:74;^[\-7(TS6;ZU?P?XD\6:*^G6VMQ:CHJ2QZU+.]]I
M-^LMO;K'&90#U"BBB@ HHHH **** "BBB@ HHHH ^;?V2N?@;H3GEY?%OQ8G
ME;O)-<?%KQO-/*Y_BDEFD>61CRSNS$DDFOI*OFW]DG_DA?A[_L:/BE_ZM7QK
M7TE7L\1?\C_.O^QIC?\ T[%?DE]R.#*O^19E_P#V!T/_ $AA1117C'>%%%%
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M+49/T@_LOXO_ /0\_#;_ ,-3XH_^?+1_9?Q?_P"AY^&W_AJ?%'_SY:/JD/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC]@#_P 5I_M%?_38J/\ A7/_  5-_P"CR/V /_%:?[17_P!-BKYH]8^_Z*^
M/^%<_P#!4W_H\C]@#_Q6G^T5_P#38J/^%<_\%3?^CR/V /\ Q6G^T5_]-BH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ )@# 2(  A$! Q$!_\0
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>nivf-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 01 09:22:09 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.newgenivf.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nivf="http://www.newgenivf.com/20241231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="nivf-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nivf-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nivf-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nivf-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet" id="nivf_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals" id="nivf_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConsolidatedIncomeStatement" id="nivf_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ShareholdersEquityType2or3" id="nivf_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConsolidatedCashFlow" id="nivf_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivities" id="nivf_r_OrganizationandPrincipalActivities">
        <link:definition>006 - Disclosure - Organization and Principal Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies" id="nivf_r_SummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/GoingConcern" id="nivf_r_GoingConcern">
        <link:definition>008 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccountsReceivableNet" id="nivf_r_AccountsReceivableNet">
        <link:definition>009 - Disclosure - Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/Inventories" id="nivf_r_Inventories">
        <link:definition>010 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" id="nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet">
        <link:definition>011 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/PropertyandEquipmentNet" id="nivf_r_PropertyandEquipmentNet">
        <link:definition>012 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables" id="nivf_r_AccruedLiabiltiesandOtherPayables">
        <link:definition>013 - Disclosure - Accrued Liabilties and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ContractLiabilities" id="nivf_r_ContractLiabilities">
        <link:definition>014 - Disclosure - Contract Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants" id="nivf_r_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants">
        <link:definition>015 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/Leases" id="nivf_r_Leases">
        <link:definition>016 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/Equity" id="nivf_r_Equity">
        <link:definition>017 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlans" id="nivf_r_EmployeeBenefitPlans">
        <link:definition>018 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxes" id="nivf_r_ProvisionforIncomeTaxes">
        <link:definition>019 - Disclosure - Provision for Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DisaggregatedRevenues" id="nivf_r_DisaggregatedRevenues">
        <link:definition>020 - Disclosure - Disaggregated Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/Risks" id="nivf_r_Risks">
        <link:definition>021 - Disclosure - Risks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions" id="nivf_r_RelatedPartyBalancesandTransactions">
        <link:definition>022 - Disclosure - Related Party Balances and Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/LoantoaSPACI" id="nivf_r_LoantoaSPACI">
        <link:definition>023 - Disclosure - Loan to a SPAC I</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/CommitmentsContingencies" id="nivf_r_CommitmentsContingencies">
        <link:definition>024 - Disclosure - Commitments &amp; Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DisposalofSubsidiary" id="nivf_r_DisposalofSubsidiary">
        <link:definition>025 - Disclosure - Disposal of Subsidiary</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/BusinessAcquisition" id="nivf_r_BusinessAcquisition">
        <link:definition>026 - Disclosure - Business Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SubsequentEvents" id="nivf_r_SubsequentEvents">
        <link:definition>027 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ReclassificationandComparativeFigures" id="nivf_r_ReclassificationandComparativeFigures">
        <link:definition>028 - Disclosure - Reclassification and Comparative Figures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccountingPoliciesByPolicy" id="nivf_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables" id="nivf_r_OrganizationandPrincipalActivitiesTables">
        <link:definition>996001 - Disclosure - Organization and Principal Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables" id="nivf_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccountsReceivableNetTables" id="nivf_r_AccountsReceivableNetTables">
        <link:definition>996003 - Disclosure - Accounts Receivable, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/InventoriesTables" id="nivf_r_InventoriesTables">
        <link:definition>996004 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" id="nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables">
        <link:definition>996005 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/PropertyandEquipmentNetTables" id="nivf_r_PropertyandEquipmentNetTables">
        <link:definition>996006 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables" id="nivf_r_AccruedLiabiltiesandOtherPayablesTables">
        <link:definition>996007 - Disclosure - Accrued Liabilties and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ContractLiabilitiesTables" id="nivf_r_ContractLiabilitiesTables">
        <link:definition>996008 - Disclosure - Contract Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables" id="nivf_r_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables">
        <link:definition>996009 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/LeasesTables" id="nivf_r_LeasesTables">
        <link:definition>996010 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/EquityTables" id="nivf_r_EquityTables">
        <link:definition>996011 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables" id="nivf_r_ProvisionforIncomeTaxesTables">
        <link:definition>996012 - Disclosure - Provision for Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DisaggregatedRevenuesTables" id="nivf_r_DisaggregatedRevenuesTables">
        <link:definition>996013 - Disclosure - Disaggregated Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables" id="nivf_r_RelatedPartyBalancesandTransactionsTables">
        <link:definition>996014 - Disclosure - Related Party Balances and Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails" id="nivf_r_OrganizationandPrincipalActivitiesDetails">
        <link:definition>996015 - Disclosure - Organization and Principal Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable" id="nivf_r_ScheduleofCompanysSubsidiariesTable">
        <link:definition>996016 - Disclosure - Organization and Principal Activities - Schedule of Company&#8217;s Subsidiaries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails" id="nivf_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996017 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" id="nivf_r_ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable">
        <link:definition>996018 - Disclosure - Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment" id="nivf_r_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment">
        <link:definition>996019 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/GoingConcernDetails" id="nivf_r_GoingConcernDetails">
        <link:definition>996020 - Disclosure - Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable" id="nivf_r_ScheduleofAccountsReceivableNetTable">
        <link:definition>996021 - Disclosure - Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" id="nivf_r_ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable">
        <link:definition>996022 - Disclosure - Accounts Receivable, Net - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable" id="nivf_r_ScheduleofMovementAllowancesforExpectedCreditLossTable">
        <link:definition>996023 - Disclosure - Accounts Receivable, Net - Schedule of Movement Allowances for Expected Credit Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable" id="nivf_r_ScheduleofInventoriesTable">
        <link:definition>996024 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails" id="nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails">
        <link:definition>996025 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" id="nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable">
        <link:definition>996026 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable" id="nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable">
        <link:definition>996027 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Movement of Allowances for Expected Credit Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/PropertyandEquipmentNetDetails" id="nivf_r_PropertyandEquipmentNetDetails">
        <link:definition>996028 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable" id="nivf_r_ScheduleofPlantandEquipmentNetTable">
        <link:definition>996029 - Disclosure - Property and Equipment, Net - Schedule of Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable" id="nivf_r_ScheduleofAccruedLiabiltiesandOtherPayablesTable">
        <link:definition>996030 - Disclosure - Accrued Liabilties and Other Payables - Schedule of Accrued Liabilties and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable" id="nivf_r_ScheduleofContractLiabilitiesTable">
        <link:definition>996031 - Disclosure - Contract Liabilities - Schedule of Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails" id="nivf_r_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails">
        <link:definition>996032 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91Jey1KbBNr08lrF9bNZYdTx/rA/SBVS10LyurQW5OboqYQWmZFkzLw3/d47HSjYGzqO9ETKAZNCuSd9bzJkSVkcGU94k1fhDc4tXQqjibaNNszh6F9ORmGKLPAlHqyPWSx7sNc84Mf0+16i2rCxXhF9yHYx5TYTSiZPuoLcG6k6Nm] CSR-->
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable" id="nivf_r_ScheduleofConvertibleNotesTable">
        <link:definition>996033 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable" id="nivf_r_ScheduleofOutstandingConvertibleNotesTable">
        <link:definition>996034 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Outstanding Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable" id="nivf_r_ScheduleofTransactionCostsonIssuanceofNotesTable">
        <link:definition>996035 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Transaction Costs on Issuance of Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofContractualObligationsTable" id="nivf_r_ScheduleofContractualObligationsTable">
        <link:definition>996036 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Contractual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable" id="nivf_r_ScheduleofPromissoryNotesTable">
        <link:definition>996037 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/LeasesDetails" id="nivf_r_LeasesDetails">
        <link:definition>996038 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable" id="nivf_r_ScheduleofLeaseLiabilitiesTable">
        <link:definition>996039 - Disclosure - Leases - Schedule of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" id="nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable">
        <link:definition>996040 - Disclosure - Leases - Schedule of Future Minimum Payments under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/EquityDetails" id="nivf_r_EquityDetails">
        <link:definition>996041 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable" id="nivf_r_ScheduleofAdditionalPaidinCapitalTable">
        <link:definition>996042 - Disclosure - Equity - Schedule of Additional Paid-in Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails" id="nivf_r_EmployeeBenefitPlansDetails">
        <link:definition>996043 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails" id="nivf_r_ProvisionforIncomeTaxesDetails">
        <link:definition>996044 - Disclosure - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable" id="nivf_r_ScheduleoftheProvisionsforIncomeTaxesTable">
        <link:definition>996045 - Disclosure - Provision for Income Taxes - Schedule of the Provisions for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable" id="nivf_r_ScheduleofIncomeTaxesTable">
        <link:definition>996046 - Disclosure - Provision for Income Taxes - Schedule of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable" id="nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable">
        <link:definition>996047 - Disclosure - Provision for Income Taxes - Schedule of Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable" id="nivf_r_ScheduleofBusinessOperationsTable">
        <link:definition>996048 - Disclosure - Disaggregated Revenues - Schedule of Business Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable" id="nivf_r_ScheduleofGeographicalInformationTable">
        <link:definition>996049 - Disclosure - Disaggregated Revenues - Schedule of Geographical Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable" id="nivf_r_ScheduleofRevenueInformationBasedontheLocationsTable">
        <link:definition>996050 - Disclosure - Disaggregated Revenues - Schedule of Revenue Information Based on the Locations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/RisksDetails" id="nivf_r_RisksDetails">
        <link:definition>996051 - Disclosure - Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails" id="nivf_r_RelatedPartyBalancesandTransactionsDetails">
        <link:definition>996052 - Disclosure - Related Party Balances and Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable" id="nivf_r_ScheduleofAmountDuefromandDuetoRelatedPartiesTable">
        <link:definition>996053 - Disclosure - Related Party Balances and Transactions - Schedule of Amount Due from and Due to Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable" id="nivf_r_ScheduleofBalanceDuefromShareholdersTable">
        <link:definition>996054 - Disclosure - Related Party Balances and Transactions - Schedule of Balance Due from Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0" id="nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable0">
        <link:definition>996055 - Disclosure - Related Party Balances and Transactions - Schedule of Movement of Allowances for Expected Credit Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable" id="nivf_r_ScheduleofConsolidatedFinancialStatementsTable">
        <link:definition>996056 - Disclosure - Related Party Balances and Transactions - Schedule of Consolidated Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/LoantoaSPACIDetails" id="nivf_r_LoantoaSPACIDetails">
        <link:definition>996057 - Disclosure - Loan to a SPAC I (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DisposalofSubsidiaryDetails" id="nivf_r_DisposalofSubsidiaryDetails">
        <link:definition>996058 - Disclosure - Disposal of Subsidiary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/BusinessAcquisitionDetails" id="nivf_r_BusinessAcquisitionDetails">
        <link:definition>996059 - Disclosure - Business Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SubsequentEventsDetails" id="nivf_r_SubsequentEventsDetails">
        <link:definition>996060 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:element name="ScheduleOfCompanySSubsidiariesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfCompanySSubsidiariesAbstract"/>
  <xs:element name="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfAccountsReceivableNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAccountsReceivableNetAbstract"/>
  <xs:element name="ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract"/>
  <xs:element name="ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract"/>
  <xs:element name="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract"/>
  <xs:element name="ScheduleOfPlantAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfPlantAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfConvertibleNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfConvertibleNotesAbstract"/>
  <xs:element name="ScheduleOfOutstandingConvertibleNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfOutstandingConvertibleNotesAbstract"/>
  <xs:element name="ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract"/>
  <xs:element name="ScheduleOfContractualObligationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfContractualObligationsAbstract"/>
  <xs:element name="ScheduleOfPromissoryNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfPromissoryNotesAbstract"/>
  <xs:element name="ScheduleOfAdditionalPaidInCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAdditionalPaidInCapitalAbstract"/>
  <xs:element name="ScheduleOfTheProvisionsForIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
  <xs:element name="ScheduleOfBusinessOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfBusinessOperationsAbstract"/>
  <xs:element name="ScheduleOfGeographicalInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfGeographicalInformationAbstract"/>
  <xs:element name="ScheduleOfRevenueInformationBasedOnTheLocationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfRevenueInformationBasedOnTheLocationsAbstract"/>
  <xs:element name="ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="CurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_CurrentAbstract"/>
  <xs:element name="NonCurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NonCurrentAbstract"/>
  <xs:element name="AtCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_AtCostAbstract"/>
  <xs:element name="ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract"/>
  <xs:element name="TheConvertibleNotesAreRepayableAsFollowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract"/>
  <xs:element name="ConvertibleBondsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConvertibleBondsAbstract"/>
  <xs:element name="DueFromShareholdersConsistOfTheFollowingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueFromShareholdersConsistOfTheFollowingAbstract"/>
  <xs:element name="DueToARelatedPartyConsistOfTheFollowingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract"/>
  <xs:element name="ReceivableFromAgents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_ReceivableFromAgents"/>
  <xs:element name="LoanToASPAC" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_LoanToASPAC"/>
  <xs:element name="DueFromShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueFromShareholders"/>
  <xs:element name="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
  <xs:element name="StockIssuedDuringPeriodValueReverseCaptialization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_StockIssuedDuringPeriodValueReverseCaptialization"/>
  <xs:element name="AmortisationOfShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AmortisationOfShareBasedCompensationExpense"/>
  <xs:element name="NonCashDiscountOnConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_NonCashDiscountOnConvertibleNotes"/>
  <xs:element name="WaiverOfRelatedPartyBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_WaiverOfRelatedPartyBalance"/>
  <xs:element name="GainOnPromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_GainOnPromissoryNote"/>
  <xs:element name="ProceedsFromAmountDueFromASPACI" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_ProceedsFromAmountDueFromASPACI"/>
  <xs:element name="PaymentofInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_PaymentofInterest"/>
  <xs:element name="SubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_SubscriptionReceivable"/>
  <xs:element name="DisposalOfSubsidiaryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DisposalOfSubsidiaryTextBlock"/>
  <xs:element name="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock"/>
  <xs:element name="ConvertibleInstrumentsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConvertibleInstrumentsPolicyTextBlock"/>
  <xs:element name="PromissoryNotesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_PromissoryNotesPolicyTextBlock"/>
  <xs:element name="RelatedPartiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_RelatedPartiesPolicyTextBlock"/>
  <xs:element name="NonControllingInterestsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NonControllingInterestsPolicyTextBlock"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock"/>
  <xs:element name="ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock"/>
  <xs:element name="ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock"/>
  <xs:element name="ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock"/>
  <xs:element name="ScheduleOfPromissoryNotesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfPromissoryNotesTableTextBlock"/>
  <xs:element name="ScheduleOfAdditionalPaidinCapitalTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock"/>
  <xs:element name="ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable"/>
  <xs:element name="AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable"/>
  <xs:element name="AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable"/>
  <xs:element name="Deposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_Deposit"/>
  <xs:element name="OtherPrepaidExpenseNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_OtherPrepaidExpenseNonCurrent"/>
  <xs:element name="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable"/>
  <xs:element name="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems"/>
  <xs:element name="AllowancesForExpectedCreditLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AllowancesForExpectedCreditLoss"/>
  <xs:element name="AllowancesForExpectedCreditLossReversalOfProvisionProvision" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
  <xs:element name="CustomerDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_CustomerDeposit"/>
  <xs:element name="IndependentDirectorFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_IndependentDirectorFeePayable"/>
  <xs:element name="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable"/>
  <xs:element name="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems"/>
  <xs:element name="DebtInstrumentCouponRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nivf_DebtInstrumentCouponRatePercentage"/>
  <xs:element name="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable"/>
  <xs:element name="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems"/>
  <xs:element name="WaiverOfLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_WaiverOfLiability"/>
  <xs:element name="EquityScheduleofAdditionalPaidinCapitalDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit"/>
  <xs:element name="DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals"/>
  <xs:element name="ReverseCapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_ReverseCapitalization"/>
  <xs:element name="ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear"/>
  <xs:element name="DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable"/>
  <xs:element name="DueToARelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueToARelatedParty"/>
  <xs:element name="DueFromtoshareholdersRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueFromtoshareholdersRelatedParty"/>
  <xs:element name="AccountsReceivableAfterAllowanceForCreditLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AccountsReceivableAfterAllowanceForCreditLoss"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems"/>
  <xs:element name="OrganizationandPrincipalActivitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_OrganizationandPrincipalActivitiesDetailsTable"/>
  <xs:element name="NetTangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_NetTangibleAssets"/>
  <xs:element name="AggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AggregateAmount"/>
  <xs:element name="MaturityTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MaturityTerm"/>
  <xs:element name="CommonStockPotentialValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_CommonStockPotentialValue"/>
  <xs:element name="MergerActivityDrawn" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_MergerActivityDrawn"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="RevenueRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nivf_RevenueRate"/>
  <xs:element name="CashInBank" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_CashInBank"/>
  <xs:element name="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable"/>
  <xs:element name="ServicesRanging" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ServicesRanging"/>
  <xs:element name="TerminationClauses" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_TerminationClauses"/>
  <xs:element name="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable"/>
  <xs:element name="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems"/>
  <xs:element name="convertiblePromissoryNoteDiscountPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_convertiblePromissoryNoteDiscountPercentage"/>
  <xs:element name="PercentageOfConversionExceeds" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nivf_PercentageOfConversionExceeds"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_LeasesDetailsTable"/>
  <xs:element name="IndicativeRateOfBorrowingCost" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nivf_IndicativeRateOfBorrowingCost"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_EquityDetailsTable"/>
  <xs:element name="ConsultingServiceTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConsultingServiceTerm"/>
  <xs:element name="EmployeeBenefitPlansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_EmployeeBenefitPlansDetailsTable"/>
  <xs:element name="ProvisionforIncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_ProvisionforIncomeTaxesDetailsTable"/>
  <xs:element name="ProfitTaxDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ProfitTaxDescription"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent"/>
  <xs:element name="AnnualTurnover" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AnnualTurnover"/>
  <xs:element name="DeemedExcessTaxPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DeemedExcessTaxPayable"/>
  <xs:element name="PercentageOfAllowanceOnDeferredTaxAssets" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_PercentageOfAllowanceOnDeferredTaxAssets"/>
  <xs:element name="RisksDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_RisksDetailsTable"/>
  <xs:element name="InterestRateOtherVariablesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_InterestRateOtherVariablesPercentage"/>
  <xs:element name="RelatedPartyBalancesandTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_RelatedPartyBalancesandTransactionsDetailsTable"/>
  <xs:element name="DisposalofSubsidiaryDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_DisposalofSubsidiaryDetailsTable"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax"/>
  <xs:element name="BusinessAcquisitionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_BusinessAcquisitionDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_SubsequentEventsDetailsTable"/>
  <xs:element name="CashConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_CashConsideration"/>
  <xs:element name="DeemedValuePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DeemedValuePerShare"/>
  <xs:element name="OutstandingPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OutstandingPercentage"/>
  <xs:element name="BidPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nivf_BidPricePerShare"/>
  <xs:element name="ASPACIMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ASPACIMember"/>
  <xs:element name="AdditionalNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_AdditionalNotesMember"/>
  <xs:element name="BestLendingRateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_BestLendingRateMember"/>
  <xs:element name="BiClinicLtdFFBiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_BiClinicLtdFFBiMember"/>
  <xs:element name="BiClinicLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_BiClinicLtdMember"/>
  <xs:element name="COVIRIXMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_COVIRIXMember"/>
  <xs:element name="ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember"/>
  <xs:element name="ConversionRateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConversionRateMember"/>
  <xs:element name="ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConvertibleNoteMember"/>
  <xs:element name="ConvertibleNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConvertibleNotesMember"/>
  <xs:element name="ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember"/>
  <xs:element name="CurrentTaxProvisionCambodiaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_CurrentTaxProvisionCambodiaMember"/>
  <xs:element name="CurrentTaxProvisionKyrgyzstanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_CurrentTaxProvisionKyrgyzstanMember"/>
  <xs:element name="CustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_CustomerMember"/>
  <xs:element name="CustomerTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_CustomerTwoMember"/>
  <xs:element name="DirectorsRemunerationToMrSiuWingFungAlfredMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
  <xs:element name="DirectorsRemunerationToMsFongHeiYueTinaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
  <xs:element name="DoubleClickServicesLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DoubleClickServicesLimitedMember"/>
  <xs:element name="EWIHLMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_EWIHLMember"/>
  <xs:element name="FFPGSHKLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_FFPGSHKLimitedMember"/>
  <xs:element name="FirstFertilityBishkekLLCFFBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_FirstFertilityBishkekLLCFFBMember"/>
  <xs:element name="FirstFertilityPGSCenterLimitedFFCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
  <xs:element name="FirstFertilityPhnomPenhLimitedFFPPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
  <xs:element name="FreeStandingInstrumentsWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_FreeStandingInstrumentsWarrantsMember"/>
  <xs:element name="GeneticsIVFInstituteIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_GeneticsIVFInstituteIncMember"/>
  <xs:element name="HKSARMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_HKSARMember"/>
  <xs:element name="HarcourtLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_HarcourtLimitedMember"/>
  <xs:element name="HealthCareSchemeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_HealthCareSchemeMember"/>
  <xs:element name="IVFTreatmentServiceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_IVFTreatmentServiceMember"/>
  <xs:element name="JAKAffiliatedHoldersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_JAKAffiliatedHoldersMember"/>
  <xs:element name="JAKAffiliatedHoldersOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_JAKAffiliatedHoldersOneMember"/>
  <xs:element name="JAKAffiliatedHoldersThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_JAKAffiliatedHoldersThreeMember"/>
  <xs:element name="JAKAffiliatedHoldersTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_JAKAffiliatedHoldersTwoMember"/>
  <xs:element name="JAKOPPORTUNITIESVILLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_JAKOPPORTUNITIESVILLCMember"/>
  <xs:element name="JAKOpportunitiesVILLCJAKMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_JAKOpportunitiesVILLCJAKMember"/>
  <xs:element name="MAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MAMember"/>
  <xs:element name="MedHoldingsLimitedMedHoldingsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MedHoldingsLimitedMedHoldingsMember"/>
  <xs:element name="MedicalInstrumentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MedicalInstrumentsMember"/>
  <xs:element name="MicroSortAcquisitionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MicroSortAcquisitionMember"/>
  <xs:element name="MotorVehiclesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MotorVehiclesMember"/>
  <xs:element name="MovementOfAllowancesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MovementOfAllowancesMember"/>
  <xs:element name="MrSiuWingFungAlfredMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MrSiuWingFungAlfredMember"/>
  <xs:element name="MsFongHeiYueTinaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MsFongHeiYueTinaMember"/>
  <xs:element name="NewGenIvfLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NewGenIvfLimitedMember"/>
  <xs:element name="NewGenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NewGenMember"/>
  <xs:element name="NewGenivfLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NewGenivfLimitedMember"/>
  <xs:element name="OSLGroupMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OSLGroupMember"/>
  <xs:element name="OccupationalRiskSchemeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OccupationalRiskSchemeMember"/>
  <xs:element name="OverProvisionOfTaxInPriorYearKyrgyzstanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember"/>
  <xs:element name="PensionSchemeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_PensionSchemeMember"/>
  <xs:element name="PeriodAverageMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_PeriodAverageMember"/>
  <xs:element name="PeriodEndMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_PeriodEndMember"/>
  <xs:element name="ProfessionalPartyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ProfessionalPartyMember"/>
  <xs:element name="PromissoryNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_PromissoryNotesMember"/>
  <xs:element name="SecondAdditionalMandatoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SecondAdditionalMandatoryNoteMember"/>
  <xs:element name="SecondAdditionalNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SecondAdditionalNoteMember"/>
  <xs:element name="SecuritiesPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SecuritiesPurchaseAgreementMember"/>
  <xs:element name="SeniorConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SeniorConvertibleNoteMember"/>
  <xs:element name="SeniorConvertibleNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SeniorConvertibleNotesMember"/>
  <xs:element name="SeriesAWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SeriesAWarrantMember"/>
  <xs:element name="SeriesBWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SeriesBWarrantMember"/>
  <xs:element name="SeriesCWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SeriesCWarrantMember"/>
  <xs:element name="ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember"/>
  <xs:element name="SubsidiarieMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SubsidiarieMember"/>
  <xs:element name="SuppliersOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SuppliersOneMember"/>
  <xs:element name="SuppliersTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SuppliersTwoMember"/>
  <xs:element name="SurrogacyAncillaryCaringAndOtherServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
  <xs:element name="TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"/>
  <xs:element name="UnsecuredPromissoryNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_UnsecuredPromissoryNotesMember"/>
  <xs:element name="WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember"/>
  <xs:element name="WellImageLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_WellImageLimitedMember"/>
  <xs:element name="WhiteLionCapitalLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_WhiteLionCapitalLLCMember"/>
  <xs:element name="WhiteLionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_WhiteLionMember"/>
  <xs:element name="WhiteLionPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_WhiteLionPurchaseAgreementMember"/>
  <xs:element name="Within90DaysMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_Within90DaysMember"/>
  <xs:element name="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
  <xs:element name="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems"/>
  <xs:element name="DisposalOfSubsidiaryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DisposalOfSubsidiaryAbstract"/>
  <xs:element name="GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_GoingConcernAbstract"/>
  <xs:element name="ProvisionsForIncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ProvisionsForIncomeTaxesLineItems"/>
  <xs:element name="ScheduleOfBalanceDueFromShareholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>nivf-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 01 09:22:09 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedBalanceSheet" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedIncomeStatement" roleURI="http://www.newgenivf.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedCashFlow" roleURI="http://www.newgenivf.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAccountsReceivableNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofInventoriesTable" roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofPlantandEquipmentNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAccruedLiabiltiesandOtherPayablesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofConvertibleNotesTable" roleURI="http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofContractualObligationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofContractualObligationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofLeaseLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofIncomeTaxesTable" roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable" roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofBalanceDuefromShareholdersTable" roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable"/>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_ReceivableFromAgents" xlink:href="nivf-20241231.xsd#nivf_ReceivableFromAgents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="nivf_ReceivableFromAgents" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_LoanToASPAC" xlink:href="nivf-20241231.xsd#nivf_LoanToASPAC"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="nivf_LoanToASPAC" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholders" xlink:href="nivf-20241231.xsd#nivf_DueFromShareholders"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="nivf_DueFromShareholders" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherIncome" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_AmortisationOfShareBasedCompensationExpense" xlink:href="nivf-20241231.xsd#nivf_AmortisationOfShareBasedCompensationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nivf_AmortisationOfShareBasedCompensationExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_NonCashDiscountOnConvertibleNotes" xlink:href="nivf-20241231.xsd#nivf_NonCashDiscountOnConvertibleNotes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nivf_NonCashDiscountOnConvertibleNotes" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InterestExpenseDebt" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_LegalFees" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91Jey1KbBNr08lrF9bNZYdTx/rA/SBVS10LyurQW5OboqYQWmZFkzLw3/d47HSjYGzqO9ETKAZNCuSd9bzJkSVkcGU94k1fhDc4tXQqjibaNNszh6F9ORmGKLPAlHqyPWSx7sNc84Mf0+16i2rCxXhF9yBgtxzlph0oafR35fKueI7] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="13" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="14" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="15" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalance" xlink:href="nivf-20241231.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nivf_WaiverOfRelatedPartyBalance" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nivf_GainOnPromissoryNote" xlink:href="nivf-20241231.xsd#nivf_GainOnPromissoryNote"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nivf_GainOnPromissoryNote" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="20" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="21" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="22" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInFinanceReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables" order="23" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_ProceedsFromAmountDueFromASPACI" xlink:href="nivf-20241231.xsd#nivf_ProceedsFromAmountDueFromASPACI"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nivf_ProceedsFromAmountDueFromASPACI" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nivf_PaymentofInterest" xlink:href="nivf-20241231.xsd#nivf_PaymentofInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nivf_PaymentofInterest" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nivf_SubscriptionReceivable" xlink:href="nivf-20241231.xsd#nivf_SubscriptionReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nivf_SubscriptionReceivable" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofInventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_Deposit" xlink:href="nivf-20241231.xsd#nivf_Deposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="nivf_Deposit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <loc xlink:type="locator" xlink:label="nivf_OtherPrepaidExpenseNonCurrent" xlink:href="nivf-20241231.xsd#nivf_OtherPrepaidExpenseNonCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="nivf_OtherPrepaidExpenseNonCurrent" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_CustomerDeposit" xlink:href="nivf-20241231.xsd#nivf_CustomerDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="nivf_CustomerDeposit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_IndependentDirectorFeePayable" xlink:href="nivf-20241231.xsd#nivf_IndependentDirectorFeePayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="nivf_IndependentDirectorFeePayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofContractualObligationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFourthYear" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFifthYear" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" xlink:href="nivf-20241231.xsd#nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" order="7" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableAfterAllowanceForCreditLoss" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableAfterAllowanceForCreditLoss"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromtoshareholdersRelatedParty" xlink:href="nivf-20241231.xsd#nivf_DueFromtoshareholdersRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nivf_AccountsReceivableAfterAllowanceForCreditLoss" xlink:to="nivf_DueFromtoshareholdersRelatedParty" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nivf_AccountsReceivableAfterAllowanceForCreditLoss" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>nivf-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 01 09:22:09 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedBalanceSheet" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedIncomeStatement" roleURI="http://www.newgenivf.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ShareholdersEquityType2or3" roleURI="http://www.newgenivf.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedCashFlow" roleURI="http://www.newgenivf.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_OrganizationandPrincipalActivities" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivities"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_GoingConcern" roleURI="http://www.newgenivf.com/role/GoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccountsReceivableNet" roleURI="http://www.newgenivf.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_Inventories" roleURI="http://www.newgenivf.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_PropertyandEquipmentNet" roleURI="http://www.newgenivf.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccruedLiabiltiesandOtherPayables" roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ContractLiabilities" roleURI="http://www.newgenivf.com/role/ContractLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants" roleURI="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_Leases" roleURI="http://www.newgenivf.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_Equity" roleURI="http://www.newgenivf.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_EmployeeBenefitPlans" roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ProvisionforIncomeTaxes" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DisaggregatedRevenues" roleURI="http://www.newgenivf.com/role/DisaggregatedRevenues"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_Risks" roleURI="http://www.newgenivf.com/role/Risks"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_RelatedPartyBalancesandTransactions" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_LoantoaSPACI" roleURI="http://www.newgenivf.com/role/LoantoaSPACI"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_CommitmentsContingencies" roleURI="http://www.newgenivf.com/role/CommitmentsContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DisposalofSubsidiary" roleURI="http://www.newgenivf.com/role/DisposalofSubsidiary"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_BusinessAcquisition" roleURI="http://www.newgenivf.com/role/BusinessAcquisition"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SubsequentEvents" roleURI="http://www.newgenivf.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ReclassificationandComparativeFigures" roleURI="http://www.newgenivf.com/role/ReclassificationandComparativeFigures"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccountingPoliciesByPolicy" roleURI="http://www.newgenivf.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_OrganizationandPrincipalActivitiesTables" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccountsReceivableNetTables" roleURI="http://www.newgenivf.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_InventoriesTables" roleURI="http://www.newgenivf.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_PropertyandEquipmentNetTables" roleURI="http://www.newgenivf.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccruedLiabiltiesandOtherPayablesTables" roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ContractLiabilitiesTables" roleURI="http://www.newgenivf.com/role/ContractLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables" roleURI="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_LeasesTables" roleURI="http://www.newgenivf.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_EquityTables" roleURI="http://www.newgenivf.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ProvisionforIncomeTaxesTables" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DisaggregatedRevenuesTables" roleURI="http://www.newgenivf.com/role/DisaggregatedRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_RelatedPartyBalancesandTransactionsTables" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofCompanysSubsidiariesTable" roleURI="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" roleURI="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAccountsReceivableNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofMovementAllowancesforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofInventoriesTable" roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofPlantandEquipmentNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAccruedLiabiltiesandOtherPayablesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofContractLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofConvertibleNotesTable" roleURI="http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofOutstandingConvertibleNotesTable" roleURI="http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofTransactionCostsonIssuanceofNotesTable" roleURI="http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofContractualObligationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofContractualObligationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofPromissoryNotesTable" roleURI="http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofLeaseLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAdditionalPaidinCapitalTable" roleURI="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleoftheProvisionsforIncomeTaxesTable" roleURI="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofIncomeTaxesTable" roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable" roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofBusinessOperationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofGeographicalInformationTable" roleURI="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofRevenueInformationBasedontheLocationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAmountDuefromandDuetoRelatedPartiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofBalanceDuefromShareholdersTable" roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable0" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofConsolidatedFinancialStatementsTable" roleURI="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_OrganizationandPrincipalActivitiesDetails" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_GoingConcernDetails" roleURI="http://www.newgenivf.com/role/GoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_PropertyandEquipmentNetDetails" roleURI="http://www.newgenivf.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails" roleURI="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_LeasesDetails" roleURI="http://www.newgenivf.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_EquityDetails" roleURI="http://www.newgenivf.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_EmployeeBenefitPlansDetails" roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ProvisionforIncomeTaxesDetails" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_RisksDetails" roleURI="http://www.newgenivf.com/role/RisksDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_RelatedPartyBalancesandTransactionsDetails" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_LoantoaSPACIDetails" roleURI="http://www.newgenivf.com/role/LoantoaSPACIDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DisposalofSubsidiaryDetails" roleURI="http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_BusinessAcquisitionDetails" roleURI="http://www.newgenivf.com/role/BusinessAcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SubsequentEventsDetails" roleURI="http://www.newgenivf.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#DocumentAndEntityInformation" roleURI="http://www.newgenivf.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositsAssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ReceivableFromAgents" xlink:href="nivf-20241231.xsd#nivf_ReceivableFromAgents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nivf_ReceivableFromAgents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_LoanToASPAC" xlink:href="nivf-20241231.xsd#nivf_LoanToASPAC"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nivf_LoanToASPAC" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholders" xlink:href="nivf-20241231.xsd#nivf_DueFromShareholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nivf_DueFromShareholders" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNotesPayableCurrent" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrent" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterest" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="37" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20241231.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueReverseCaptialization" xlink:href="nivf-20241231.xsd#nivf_StockIssuedDuringPeriodValueReverseCaptialization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nivf_StockIssuedDuringPeriodValueReverseCaptialization" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AmortisationOfShareBasedCompensationExpense" xlink:href="nivf-20241231.xsd#nivf_AmortisationOfShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nivf_AmortisationOfShareBasedCompensationExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NonCashDiscountOnConvertibleNotes" xlink:href="nivf-20241231.xsd#nivf_NonCashDiscountOnConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nivf_NonCashDiscountOnConvertibleNotes" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalance" xlink:href="nivf-20241231.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nivf_WaiverOfRelatedPartyBalance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_GainOnPromissoryNote" xlink:href="nivf-20241231.xsd#nivf_GainOnPromissoryNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nivf_GainOnPromissoryNote" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_LegalFees" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInFinanceReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ProceedsFromAmountDueFromASPACI" xlink:href="nivf-20241231.xsd#nivf_ProceedsFromAmountDueFromASPACI"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nivf_ProceedsFromAmountDueFromASPACI" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PaymentofInterest" xlink:href="nivf-20241231.xsd#nivf_PaymentofInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nivf_PaymentofInterest" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SubscriptionReceivable" xlink:href="nivf-20241231.xsd#nivf_SubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nivf_SubscriptionReceivable" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="38" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/GoingConcern" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_GoingConcernAbstract" xlink:href="nivf-20241231.xsd#nivf_GoingConcernAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_GoingConcernAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccountsReceivableNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/Inventories" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ContractLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DisaggregatedRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/Risks" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/LoantoaSPACI" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/CommitmentsContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DisposalofSubsidiary" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DisposalOfSubsidiaryAbstract" xlink:href="nivf-20241231.xsd#nivf_DisposalOfSubsidiaryAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_DisposalOfSubsidiaryTextBlock" xlink:href="nivf-20241231.xsd#nivf_DisposalOfSubsidiaryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DisposalOfSubsidiaryAbstract" xlink:to="nivf_DisposalOfSubsidiaryTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/BusinessAcquisition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ReclassificationandComparativeFigures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Reclassifications" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Reclassifications"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_Reclassifications" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleInstrumentsPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_ConvertibleInstrumentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_ConvertibleInstrumentsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PromissoryNotesPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_PromissoryNotesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_PromissoryNotesPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_RelatedPartiesPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_RelatedPartiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_RelatedPartiesPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NonControllingInterestsPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_NonControllingInterestsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_NonControllingInterestsPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccountsReceivableNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/InventoriesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ContractLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfPromissoryNotesTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfPromissoryNotesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="nivf_ScheduleOfPromissoryNotesTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DisaggregatedRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenivfLimitedMember" xlink:href="nivf-20241231.xsd#nivf_NewGenivfLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_NewGenivfLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FFPGSHKLimitedMember" xlink:href="nivf-20241231.xsd#nivf_FFPGSHKLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FFPGSHKLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WellImageLimitedMember" xlink:href="nivf-20241231.xsd#nivf_WellImageLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_WellImageLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MedHoldingsLimitedMedHoldingsMember" xlink:href="nivf-20241231.xsd#nivf_MedHoldingsLimitedMedHoldingsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_MedHoldingsLimitedMedHoldingsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPGSCenterLimitedFFCMember" xlink:href="nivf-20241231.xsd#nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FirstFertilityPGSCenterLimitedFFCMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" xlink:href="nivf-20241231.xsd#nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_BiClinicLtdFFBiMember" xlink:href="nivf-20241231.xsd#nivf_BiClinicLtdFFBiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_BiClinicLtdFFBiMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember" xlink:href="nivf-20241231.xsd#nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntercompanyForeignCurrencyBalanceLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntercompanyForeignCurrencyBalanceNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntercompanyForeignCurrencyBalanceNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" xlink:to="srt_CurrencyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_HKD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_THB" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_THB"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_THB" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CNY" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PeriodEndMember" xlink:href="nivf-20241231.xsd#nivf_PeriodEndMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:to="nivf_PeriodEndMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PeriodAverageMember" xlink:href="nivf-20241231.xsd#nivf_PeriodAverageMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:to="nivf_PeriodAverageMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_Within90DaysMember" xlink:href="nivf-20241231.xsd#nivf_Within90DaysMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="nivf_Within90DaysMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MovementOfAllowancesMember" xlink:href="nivf-20241231.xsd#nivf_MovementOfAllowancesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="nivf_MovementOfAllowancesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofInventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_Deposit" xlink:href="nivf-20241231.xsd#nivf_Deposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="nivf_Deposit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ReceivableFromAgents" xlink:href="nivf-20241231.xsd#nivf_ReceivableFromAgents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="nivf_ReceivableFromAgents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OtherPrepaidExpenseNonCurrent" xlink:href="nivf-20241231.xsd#nivf_OtherPrepaidExpenseNonCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="nivf_OtherPrepaidExpenseNonCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:to="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLoss" xlink:href="nivf-20241231.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:to="nivf_AllowancesForExpectedCreditLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:href="nivf-20241231.xsd#nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:to="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MedicalInstrumentsMember" xlink:href="nivf-20241231.xsd#nivf_MedicalInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nivf_MedicalInstrumentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CustomerDeposit" xlink:href="nivf-20241231.xsd#nivf_CustomerDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nivf_CustomerDeposit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_IndependentDirectorFeePayable" xlink:href="nivf-20241231.xsd#nivf_IndependentDirectorFeePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nivf_IndependentDirectorFeePayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerRefundLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesMember" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_ConvertibleNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKAffiliatedHoldersMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_JAKAffiliatedHoldersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKAffiliatedHoldersOneMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_JAKAffiliatedHoldersOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKAffiliatedHoldersTwoMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_JAKAffiliatedHoldersTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKAffiliatedHoldersThreeMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_JAKAffiliatedHoldersThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DebtInstrumentCouponRatePercentage" xlink:href="nivf-20241231.xsd#nivf_DebtInstrumentCouponRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="nivf_DebtInstrumentCouponRatePercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:to="us-gaap_InterestCostsCapitalized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofContractualObligationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfContractualObligationsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfContractualObligationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInFourthYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInFifthYear" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligation" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:to="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PromissoryNotesMember" xlink:href="nivf-20241231.xsd#nivf_PromissoryNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_PromissoryNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:to="us-gaap_NotesIssued1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfLiability" xlink:href="nivf-20241231.xsd#nivf_WaiverOfLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:to="nivf_WaiverOfLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable" xlink:href="nivf-20241231.xsd#nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" xlink:href="nivf-20241231.xsd#nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" order="2" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91Jey1KbBNr08lrF9bNZYdTx/rA/SBVS10LyurQW5OboqYQWmZFkzLw3/d47HSjYGzqO9ETKAZNCuSd9bzJkSVkcGU94k1fhDc4tXQqjibaNNszh6F9ORmGKLPAlHqyPWSx7sNc84Mf0+16i2rCxXhF9y9eCTU/ZkTexnsgjUqI/SY] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" xlink:href="nivf-20241231.xsd#nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ReverseCapitalization" xlink:href="nivf-20241231.xsd#nivf_ReverseCapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nivf_ReverseCapitalization" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ProvisionsForIncomeTaxesLineItems" xlink:href="nivf-20241231.xsd#nivf_ProvisionsForIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_ProvisionsForIncomeTaxesLineItems" xlink:to="nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionKyrgyzstanMember" xlink:href="nivf-20241231.xsd#nivf_CurrentTaxProvisionKyrgyzstanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nivf_CurrentTaxProvisionKyrgyzstanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember" xlink:href="nivf-20241231.xsd#nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionCambodiaMember" xlink:href="nivf-20241231.xsd#nivf_CurrentTaxProvisionCambodiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nivf_CurrentTaxProvisionCambodiaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionsForIncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" xlink:href="nivf-20241231.xsd#nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_IVFTreatmentServiceMember" xlink:href="nivf-20241231.xsd#nivf_IVFTreatmentServiceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nivf_IVFTreatmentServiceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" xlink:href="nivf-20241231.xsd#nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KG" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KH" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TH" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KG" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KH" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TH" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MrSiuWingFungAlfredMember" xlink:href="nivf-20241231.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_MrSiuWingFungAlfredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MsFongHeiYueTinaMember" xlink:href="nivf-20241231.xsd#nivf_MsFongHeiYueTinaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_MsFongHeiYueTinaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HarcourtLimitedMember" xlink:href="nivf-20241231.xsd#nivf_HarcourtLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_HarcourtLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKAffiliatedHoldersMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_JAKAffiliatedHoldersMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToARelatedParty" xlink:href="nivf-20241231.xsd#nivf_DueToARelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nivf_DueToARelatedParty" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromtoshareholdersRelatedParty" xlink:href="nivf-20241231.xsd#nivf_DueFromtoshareholdersRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="nivf_DueFromtoshareholdersRelatedParty" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableAfterAllowanceForCreditLoss" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableAfterAllowanceForCreditLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="nivf_AccountsReceivableAfterAllowanceForCreditLoss" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:href="nivf-20241231.xsd#nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:href="nivf-20241231.xsd#nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:href="nivf-20241231.xsd#nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKOPPORTUNITIESVILLCMember" xlink:href="nivf-20241231.xsd#nivf_JAKOPPORTUNITIESVILLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_JAKOPPORTUNITIESVILLCMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember" xlink:href="nivf-20241231.xsd#nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalance" xlink:href="nivf-20241231.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nivf_WaiverOfRelatedPartyBalance" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MedicalInstrumentsMember" xlink:href="nivf-20241231.xsd#nivf_MedicalInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nivf_MedicalInstrumentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MotorVehiclesMember" xlink:href="nivf-20241231.xsd#nivf_MotorVehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nivf_MotorVehiclesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_OrganizationandPrincipalActivitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="nivf_OrganizationandPrincipalActivitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_RangeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_OwnershipAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SecuritiesPurchaseAgreementMember" xlink:href="nivf-20241231.xsd#nivf_SecuritiesPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nivf_SecuritiesPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SeriesAWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesAWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nivf_SeriesAWarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SeriesBWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesBWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nivf_SeriesBWarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKOpportunitiesVILLCJAKMember" xlink:href="nivf-20241231.xsd#nivf_JAKOpportunitiesVILLCJAKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_JAKOpportunitiesVILLCJAKMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenIvfLimitedMember" xlink:href="nivf-20241231.xsd#nivf_NewGenIvfLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="nivf_NewGenIvfLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SeniorConvertibleNotesMember" xlink:href="nivf-20241231.xsd#nivf_SeniorConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_SeniorConvertibleNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AdditionalNotesMember" xlink:href="nivf-20241231.xsd#nivf_AdditionalNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_AdditionalNotesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ConversionRateMember" xlink:href="nivf-20241231.xsd#nivf_ConversionRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_ConversionRateMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SecondAdditionalMandatoryNoteMember" xlink:href="nivf-20241231.xsd#nivf_SecondAdditionalMandatoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_SecondAdditionalMandatoryNoteMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SecondAdditionalNoteMember" xlink:href="nivf-20241231.xsd#nivf_SecondAdditionalNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_SecondAdditionalNoteMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WhiteLionCapitalLLCMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionCapitalLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_WhiteLionCapitalLLCMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_EWIHLMember" xlink:href="nivf-20241231.xsd#nivf_EWIHLMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nivf_EWIHLMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsidiarieMember" xlink:href="nivf-20241231.xsd#nivf_SubsidiarieMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_SubsidiarieMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_COVIRIXMember" xlink:href="nivf-20241231.xsd#nivf_COVIRIXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_COVIRIXMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenMember" xlink:href="nivf-20241231.xsd#nivf_NewGenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_NewGenMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_LongTermDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NetTangibleAssets" xlink:href="nivf-20241231.xsd#nivf_NetTangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="nivf_NetTangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AggregateAmount" xlink:href="nivf-20241231.xsd#nivf_AggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="nivf_AggregateAmount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_InvestmentCompanyCommittedCapital" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MaturityTerm" xlink:href="nivf-20241231.xsd#nivf_MaturityTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="nivf_MaturityTerm" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_LineOfCredit" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockHeldBySubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockHeldBySubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_CommonStockHeldBySubsidiary" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CommonStockPotentialValue" xlink:href="nivf-20241231.xsd#nivf_CommonStockPotentialValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="nivf_CommonStockPotentialValue" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MergerActivityDrawn" xlink:href="nivf-20241231.xsd#nivf_MergerActivityDrawn"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="nivf_MergerActivityDrawn" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SuppliersTwoMember" xlink:href="nivf-20241231.xsd#nivf_SuppliersTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="nivf_SuppliersTwoMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SuppliersOneMember" xlink:href="nivf-20241231.xsd#nivf_SuppliersOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="nivf_SuppliersOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OSLGroupMember" xlink:href="nivf-20241231.xsd#nivf_OSLGroupMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_OSLGroupMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CustomerMember" xlink:href="nivf-20241231.xsd#nivf_CustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="nivf_CustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CustomerTwoMember" xlink:href="nivf-20241231.xsd#nivf_CustomerTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="nivf_CustomerTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_Deposits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueRate" xlink:href="nivf-20241231.xsd#nivf_RevenueRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="nivf_RevenueRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/GoingConcernDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_GoingConcernAbstract" xlink:href="nivf-20241231.xsd#nivf_GoingConcernAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_GoingConcernAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_GoingConcernAbstract" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_GoingConcernAbstract" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_GoingConcernAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CashInBank" xlink:href="nivf-20241231.xsd#nivf_CashInBank"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_GoingConcernAbstract" xlink:to="nivf_CashInBank" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_GoingConcernAbstract" xlink:to="us-gaap_DepositsAssets" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:to="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ServicesRanging" xlink:href="nivf-20241231.xsd#nivf_ServicesRanging"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:to="nivf_ServicesRanging" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_TerminationClauses" xlink:href="nivf-20241231.xsd#nivf_TerminationClauses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:to="nivf_TerminationClauses" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNoteMember" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_ConvertibleNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_UnsecuredPromissoryNotesMember" xlink:href="nivf-20241231.xsd#nivf_UnsecuredPromissoryNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_UnsecuredPromissoryNotesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember" xlink:href="nivf-20241231.xsd#nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SeriesAWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesAWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nivf_SeriesAWarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SeriesBWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesBWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nivf_SeriesBWarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SeriesCWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesCWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nivf_SeriesCWarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_CommonClassAMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FreeStandingInstrumentsWarrantsMember" xlink:href="nivf-20241231.xsd#nivf_FreeStandingInstrumentsWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nivf_FreeStandingInstrumentsWarrantsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_convertiblePromissoryNoteDiscountPercentage" xlink:href="nivf-20241231.xsd#nivf_convertiblePromissoryNoteDiscountPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="nivf_convertiblePromissoryNoteDiscountPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCapInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCapInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_DerivativeCapInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PercentageOfConversionExceeds" xlink:href="nivf-20241231.xsd#nivf_PercentageOfConversionExceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="nivf_PercentageOfConversionExceeds" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyLiquidationProceedsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_LeasesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="nivf_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_LeasesDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_LeasesDetailsTable" xlink:to="dei_LegalEntityAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_BestLendingRateMember" xlink:href="nivf-20241231.xsd#nivf_BestLendingRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nivf_BestLendingRateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_IndicativeRateOfBorrowingCost" xlink:href="nivf-20241231.xsd#nivf_IndicativeRateOfBorrowingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="nivf_IndicativeRateOfBorrowingCost" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsTable" xlink:href="nivf-20241231.xsd#nivf_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nivf_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ProfessionalPartyMember" xlink:href="nivf-20241231.xsd#nivf_ProfessionalPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_ProfessionalPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DoubleClickServicesLimitedMember" xlink:href="nivf-20241231.xsd#nivf_DoubleClickServicesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_DoubleClickServicesLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WhiteLionMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_WhiteLionMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenIvfLimitedMember" xlink:href="nivf-20241231.xsd#nivf_NewGenIvfLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nivf_NewGenIvfLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MAMember" xlink:href="nivf-20241231.xsd#nivf_MAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nivf_MAMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WhiteLionPurchaseAgreementMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nivf_WhiteLionPurchaseAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockNoParValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ConsultingServiceTerm" xlink:href="nivf-20241231.xsd#nivf_ConsultingServiceTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nivf_ConsultingServiceTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAdditionalCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_OtherAdditionalCapital" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_EmployeeBenefitPlansDetailsTable" xlink:href="nivf-20241231.xsd#nivf_EmployeeBenefitPlansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="nivf_EmployeeBenefitPlansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EmployeeBenefitPlansDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EmployeeBenefitPlansDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EmployeeBenefitPlansDetailsTable" xlink:to="srt_RangeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PensionSchemeMember" xlink:href="nivf-20241231.xsd#nivf_PensionSchemeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nivf_PensionSchemeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OccupationalRiskSchemeMember" xlink:href="nivf-20241231.xsd#nivf_OccupationalRiskSchemeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nivf_OccupationalRiskSchemeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HealthCareSchemeMember" xlink:href="nivf-20241231.xsd#nivf_HealthCareSchemeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nivf_HealthCareSchemeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TH" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KH" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KG" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementAndServiceFeesRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementAndServiceFeesRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_ManagementAndServiceFeesRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SpecialAssessmentBond" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SpecialAssessmentBond"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_SpecialAssessmentBond" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ProvisionforIncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="nivf_ProvisionforIncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KH" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HKSARMember" xlink:href="nivf-20241231.xsd#nivf_HKSARMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="nivf_HKSARMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ProfitTaxDescription" xlink:href="nivf-20241231.xsd#nivf_ProfitTaxDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="nivf_ProfitTaxDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" xlink:href="nivf-20241231.xsd#nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AnnualTurnover" xlink:href="nivf-20241231.xsd#nivf_AnnualTurnover"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="nivf_AnnualTurnover" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DeemedExcessTaxPayable" xlink:href="nivf-20241231.xsd#nivf_DeemedExcessTaxPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="nivf_DeemedExcessTaxPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:href="nivf-20241231.xsd#nivf_PercentageOfAllowanceOnDeferredTaxAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="nivf_PercentageOfAllowanceOnDeferredTaxAssets" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/RisksDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_RisksDetailsTable" xlink:href="nivf-20241231.xsd#nivf_RisksDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="nivf_RisksDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_RisksDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ASPACIMember" xlink:href="nivf-20241231.xsd#nivf_ASPACIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nivf_ASPACIMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_InterestRateOtherVariablesPercentage" xlink:href="nivf-20241231.xsd#nivf_InterestRateOtherVariablesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="nivf_InterestRateOtherVariablesPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPensionPlanObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_IncreaseDecreaseInPensionPlanObligations" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_RelatedPartyBalancesandTransactionsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_RelatedPartyBalancesandTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nivf_RelatedPartyBalancesandTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/LoantoaSPACIDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DisposalofSubsidiaryDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_DisposalofSubsidiaryDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DisposalofSubsidiaryDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="nivf_DisposalofSubsidiaryDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_DisposalofSubsidiaryDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityBishkekLLCFFBMember" xlink:href="nivf-20241231.xsd#nivf_FirstFertilityBishkekLLCFFBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_FirstFertilityBishkekLLCFFBMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" xlink:href="nivf-20241231.xsd#nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_BusinessAcquisitionDetailsTable" xlink:href="nivf-20241231.xsd#nivf_BusinessAcquisitionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="nivf_BusinessAcquisitionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_BusinessAcquisitionDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_BiClinicLtdMember" xlink:href="nivf-20241231.xsd#nivf_BiClinicLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nivf_BiClinicLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsequentEventsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nivf_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WhiteLionMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_WhiteLionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_GeneticsIVFInstituteIncMember" xlink:href="nivf-20241231.xsd#nivf_GeneticsIVFInstituteIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_GeneticsIVFInstituteIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:href="nivf-20241231.xsd#nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SeniorConvertibleNoteMember" xlink:href="nivf-20241231.xsd#nivf_SeniorConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_SeniorConvertibleNoteMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesMember" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_ConvertibleNotesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PromissoryNotesMember" xlink:href="nivf-20241231.xsd#nivf_PromissoryNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_PromissoryNotesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MicroSortAcquisitionMember" xlink:href="nivf-20241231.xsd#nivf_MicroSortAcquisitionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nivf_MicroSortAcquisitionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenMember" xlink:href="nivf-20241231.xsd#nivf_NewGenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nivf_NewGenMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CashConsideration" xlink:href="nivf-20241231.xsd#nivf_CashConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nivf_CashConsideration" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DeemedValuePerShare" xlink:href="nivf-20241231.xsd#nivf_DeemedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nivf_DeemedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OutstandingPercentage" xlink:href="nivf-20241231.xsd#nivf_OutstandingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nivf_OutstandingPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_BidPricePerShare" xlink:href="nivf-20241231.xsd#nivf_BidPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nivf_BidPricePerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherNotesPayable" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeTermOfLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="us-gaap_UsefulLifeTermOfLeaseMember" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="15" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>nivf-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 01 09:22:09 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity attributable to the shareholders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">(Loss) Income before taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">(Loss) Income before taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income attributable to the shareholders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total comprehensive (loss) income attributable to the shareholders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Ordinary shares ,shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Principal Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis_lbl" xml:lang="en-US">Intra-Entity Foreign Currency Balance by Description [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_GoingConcernAbstract" xlink:href="nivf-20241231.xsd#nivf_GoingConcernAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_GoingConcernAbstract_lbl" xml:lang="en-US">Going Concern [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_GoingConcernAbstract" xlink:to="nivf_GoingConcernAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US">Accounts Receivable, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Total accounts receivable net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis_lbl" xml:lang="en-US">Financial Asset, Aging [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Balance at beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1" xml:lang="en-US">Less: allowance for expected credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract_lbl" xml:lang="en-US">Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAbstract_lbl" xml:lang="en-US">Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Deposits, prepayment, other receivables and deferred IPO cost, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Deposits, other receivables and deferred legal &amp; IPO cost, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLoss" xlink:href="nivf-20241231.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="nivf_AllowancesForExpectedCreditLoss_lbl" xml:lang="en-US">Balance at beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLoss" xlink:to="nivf_AllowancesForExpectedCreditLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="nivf_AllowancesForExpectedCreditLoss_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLoss" xlink:to="nivf_AllowancesForExpectedCreditLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Plant and equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accrued Liabilties and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Schedule of Accrued Liabilities and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilties and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract_lbl" xml:lang="en-US">Contract Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_DepositContractsLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xml:lang="en-US">Schedule of Contract Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Balance at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl0" xml:lang="en-US">Balance at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfConvertibleNotesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfConvertibleNotesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfConvertibleNotesAbstract_lbl" xml:lang="en-US">Schedule of Convertible Notes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfConvertibleNotesAbstract" xlink:to="nivf_ScheduleOfConvertibleNotesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Convertible notes, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl0" xml:lang="en-US">Balance at beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl1" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl1" xml:lang="en-US">Convertible notes outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract_lbl" xml:lang="en-US">Schedule of Transaction Costs on Issuance of Notes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:to="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfContractualObligationsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfContractualObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfContractualObligationsAbstract_lbl" xml:lang="en-US">Schedule of Contractual Obligations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfContractualObligationsAbstract" xlink:to="nivf_ScheduleOfContractualObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Balance at beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Total operating lease liabilities, net of interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Payments under Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl" xml:lang="en-US">Employee Benefit Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Provision for Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract_lbl" xml:lang="en-US">Schedule of Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Tax (income) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">(Gain on) Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Tax income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US">Total tax (income) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Disaggregated Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Balances and Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfBalanceDueFromShareholdersAbstract_lbl" xml:lang="en-US">Schedule of Balance Due from Shareholders [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="nivf_ScheduleOfBalanceDueFromShareholdersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableAfterAllowanceForCreditLoss" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableAfterAllowanceForCreditLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="nivf_AccountsReceivableAfterAllowanceForCreditLoss_lbl" xml:lang="en-US">Total shareholders amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableAfterAllowanceForCreditLoss" xlink:to="nivf_AccountsReceivableAfterAllowanceForCreditLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract_lbl" xml:lang="en-US">Schedule of Movement of Allowances for Expected Credit Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US">LOAN TO A SPAC I [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments &amp; Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DisposalOfSubsidiaryAbstract" xlink:href="nivf-20241231.xsd#nivf_DisposalOfSubsidiaryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DisposalOfSubsidiaryAbstract_lbl" xml:lang="en-US">Disposal of Subsidiary [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisposalOfSubsidiaryAbstract" xlink:to="nivf_DisposalOfSubsidiaryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Business Acquisition [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Reclassification and Comparative Figures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposit with a digital asset trading platform</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ReceivableFromAgents" xlink:href="nivf-20241231.xsd#nivf_ReceivableFromAgents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ReceivableFromAgents_lbl" xml:lang="en-US">Receivable from agents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ReceivableFromAgents" xlink:to="nivf_ReceivableFromAgents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_LoanToASPAC" xlink:href="nivf-20241231.xsd#nivf_LoanToASPAC"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_LoanToASPAC_lbl" xml:lang="en-US">Loan to A SPAC I</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LoanToASPAC" xlink:to="nivf_LoanToASPAC_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholders" xlink:href="nivf-20241231.xsd#nivf_DueFromShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueFromShareholders_lbl" xml:lang="en-US">Due from shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholders" xlink:to="nivf_DueFromShareholders_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl0" xml:lang="en-US">Prepayment, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Due to shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Lease liabilities &#8211; current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liabilities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Lease liabilities &#8211; current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Lease liabilities &#8211; non-current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl0" xml:lang="en-US">Non-current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, no par value, 10,000,000 shares authorized and 1,138,519* and 507,469* shares issued and outstanding as of December 31, 2024 and 2023 respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockNoParValue_lbl0" xml:lang="en-US">Ordinary shares with par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: net income (loss) attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: total comprehensive (loss) income attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings per share &#8211; basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">&#8211; diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding - basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">- diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Capital injection by directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20241231.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl" xml:lang="en-US">Settlement of subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueReverseCaptialization" xlink:href="nivf-20241231.xsd#nivf_StockIssuedDuringPeriodValueReverseCaptialization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_StockIssuedDuringPeriodValueReverseCaptialization_lbl" xml:lang="en-US">Reverse capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueReverseCaptialization" xlink:to="nivf_StockIssuedDuringPeriodValueReverseCaptialization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Remeasurement of share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of shares under ELOC/Note Conversion arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of shares under ELOC/Note Conversion arrangement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation of plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AmortisationOfShareBasedCompensationExpense" xlink:href="nivf-20241231.xsd#nivf_AmortisationOfShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AmortisationOfShareBasedCompensationExpense_lbl" xml:lang="en-US">Amortisation of share based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AmortisationOfShareBasedCompensationExpense" xlink:to="nivf_AmortisationOfShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NonCashDiscountOnConvertibleNotes" xlink:href="nivf-20241231.xsd#nivf_NonCashDiscountOnConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NonCashDiscountOnConvertibleNotes_lbl" xml:lang="en-US">Non cash discount on convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonCashDiscountOnConvertibleNotes" xlink:to="nivf_NonCashDiscountOnConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xml:lang="en-US">Provision of expected credit loss allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Directors&#8217; remuneration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal and professional fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Tax paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xml:lang="en-US">Other borrowings, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of shares (net of reverse capitalization effect)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Amount with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of foreign currency translation on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplementary cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US">Subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalance" xlink:href="nivf-20241231.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_WaiverOfRelatedPartyBalance_lbl" xml:lang="en-US">Waiver of related party balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalance" xlink:to="nivf_WaiverOfRelatedPartyBalance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_WaiverOfRelatedPartyBalance_lbl0" xml:lang="en-US">Transactions with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalance" xlink:to="nivf_WaiverOfRelatedPartyBalance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US">Gain on lease modification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_GainOnPromissoryNote" xlink:href="nivf-20241231.xsd#nivf_GainOnPromissoryNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_GainOnPromissoryNote_lbl" xml:lang="en-US">Gain on promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_GainOnPromissoryNote" xlink:to="nivf_GainOnPromissoryNote_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Deposit and other receivables, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInFinanceReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables_lbl" xml:lang="en-US">Finance lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProceedsFromAmountDueFromASPACI" xlink:href="nivf-20241231.xsd#nivf_ProceedsFromAmountDueFromASPACI"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_ProceedsFromAmountDueFromASPACI_lbl" xml:lang="en-US">Amount due from A SPAC I</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProceedsFromAmountDueFromASPACI" xlink:to="nivf_ProceedsFromAmountDueFromASPACI_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Finance lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PaymentofInterest" xlink:href="nivf-20241231.xsd#nivf_PaymentofInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_PaymentofInterest_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PaymentofInterest" xlink:to="nivf_PaymentofInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SubscriptionReceivable" xlink:href="nivf-20241231.xsd#nivf_SubscriptionReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_SubscriptionReceivable_lbl" xml:lang="en-US">Subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubscriptionReceivable" xlink:to="nivf_SubscriptionReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xml:lang="en-US">Subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive income/(loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Total attributable to the shareholders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non- controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND PRINCIPAL ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl" xml:lang="en-US">Background</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl" xml:lang="en-US">Ownership %</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl" xml:lang="en-US">Principal activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl" xml:lang="en-US">Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xml:lang="en-US">Currency exchange rates, period-end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of the Plan and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" xlink:to="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">GOING CONCERN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl" xml:lang="en-US">ACCOUNTS RECEIVABLE, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Receivable, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Accounts receivable , net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Movement Allowances for Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Reversal of expected credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Reversal of Provision / (Provision)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Medicines, consumables and reagents for clinical and laboratory analyses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND DEFERRED IPO COST, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentAbstract" xlink:href="nivf-20241231.xsd#nivf_CurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CurrentAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentAbstract" xlink:to="nivf_CurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_Deposit" xlink:href="nivf-20241231.xsd#nivf_Deposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_Deposit_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_Deposit" xlink:to="nivf_Deposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred initial public offering &#8220;IPO&#8221; cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">Deposit with a digital asset trading platform</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NonCurrentAbstract" xlink:href="nivf-20241231.xsd#nivf_NonCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NonCurrentAbstract_lbl" xml:lang="en-US">Non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonCurrentAbstract" xlink:to="nivf_NonCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OtherPrepaidExpenseNonCurrent" xlink:href="nivf-20241231.xsd#nivf_OtherPrepaidExpenseNonCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OtherPrepaidExpenseNonCurrent_lbl" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherPrepaidExpenseNonCurrent" xlink:to="nivf_OtherPrepaidExpenseNonCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Movement of Allowances for Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:href="nivf-20241231.xsd#nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl" xml:lang="en-US">Reversal of provision (Provision)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:to="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AtCostAbstract" xlink:href="nivf-20241231.xsd#nivf_AtCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AtCostAbstract_lbl" xml:lang="en-US">At cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AtCostAbstract" xlink:to="nivf_AtCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Plant and equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED LIABILTIES AND OTHER PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilties and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CustomerDeposit" xlink:href="nivf-20241231.xsd#nivf_CustomerDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CustomerDeposit_lbl" xml:lang="en-US">Customer deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CustomerDeposit" xlink:to="nivf_CustomerDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Withholding tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_IndependentDirectorFeePayable" xlink:href="nivf-20241231.xsd#nivf_IndependentDirectorFeePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_IndependentDirectorFeePayable_lbl" xml:lang="en-US">Independent director fee payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IndependentDirectorFeePayable" xlink:to="nivf_IndependentDirectorFeePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US">Compensation payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">CONTRACT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Contract Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Recognized to revenue during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES, PROMISSORY NOTES, DERIVATIVE LIABILITY AND WARRANTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract_lbl" xml:lang="en-US">Convertible notes, at amortised cost are as follows:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract" xlink:to="nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Convertible notes at amortised cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedAmortizationDeferredFinanceCosts_lbl" xml:lang="en-US">Less: Deferred debt issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="us-gaap_AccumulatedAmortizationDeferredFinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract" xlink:href="nivf-20241231.xsd#nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract_lbl" xml:lang="en-US">The convertible notes are repayable as follows:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract" xlink:to="nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_DebtInstrumentCouponRatePercentage" xlink:href="nivf-20241231.xsd#nivf_DebtInstrumentCouponRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DebtInstrumentCouponRatePercentage_lbl" xml:lang="en-US">Coupon Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DebtInstrumentCouponRatePercentage" xlink:to="nivf_DebtInstrumentCouponRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuanceDate1_lbl" xml:lang="en-US">Issuance Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuanceDate1" xlink:to="us-gaap_DebtInstrumentIssuanceDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock_lbl" xml:lang="en-US">Schedule of Transaction Costs on Issuance of Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" xlink:to="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestCostsCapitalized_lbl" xml:lang="en-US">Add: capitalized during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsCapitalized" xlink:to="us-gaap_InterestCostsCapitalized_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Schedule of Contractual Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleBondsAbstract" xlink:href="nivf-20241231.xsd#nivf_ConvertibleBondsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ConvertibleBondsAbstract_lbl" xml:lang="en-US">Convertible bonds-</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleBondsAbstract" xlink:to="nivf_ConvertibleBondsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xml:lang="en-US">2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfPromissoryNotesTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfPromissoryNotesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfPromissoryNotesTableTextBlock_lbl" xml:lang="en-US">Schedule of Promissory Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfPromissoryNotesTableTextBlock" xlink:to="nivf_ScheduleOfPromissoryNotesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Issued during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfLiability" xlink:href="nivf-20241231.xsd#nivf_WaiverOfLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_WaiverOfLiability_lbl" xml:lang="en-US">Waiver of liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfLiability" xlink:to="nivf_WaiverOfLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average lease term &#8211; operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate &#8211; operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short term lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments under Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Not later than 1 year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Between 1 to 2 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl" xml:lang="en-US">Schedule of Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:to="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of shares as compensation for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Shares issued value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" xlink:href="nivf-20241231.xsd#nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit_lbl" xml:lang="en-US">Issuance of shares through Equity Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" xlink:to="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Issuance of shares through conversion of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">PROVISION FOR INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of the Provisions for Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Tax credit (expense) at the effective tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Tax effect on non-taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Tax effect on non-deductible expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Tax effect on utilization of tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Tax losses unable to be utilized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" xlink:href="nivf-20241231.xsd#nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear_lbl" xml:lang="en-US">Over provision of tax in prior year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" xlink:to="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">DISAGGREGATED REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Schedule of Business Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Geographical Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenue Information Based on the Locations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Long-lived assets, total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">RISKS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Amount Due from and Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" xlink:href="nivf-20241231.xsd#nivf_DueFromShareholdersConsistOfTheFollowingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract_lbl" xml:lang="en-US">Due from shareholders consist of the following:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" xlink:to="nivf_DueFromShareholdersConsistOfTheFollowingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Relationship</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract" xlink:href="nivf-20241231.xsd#nivf_DueToARelatedPartyConsistOfTheFollowingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract_lbl" xml:lang="en-US">Due to a related party consist of the following:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract" xlink:to="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl" xml:lang="en-US">Schedule of Balance Due from Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:to="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromtoshareholdersRelatedParty" xlink:href="nivf-20241231.xsd#nivf_DueFromtoshareholdersRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueFromtoshareholdersRelatedParty_lbl" xml:lang="en-US">Due from/ (to)shareholders/ related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromtoshareholdersRelatedParty" xlink:to="nivf_DueFromtoshareholdersRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Movement of Allowances for Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">LOAN TO A SPAC I</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS &amp; CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DisposalOfSubsidiaryTextBlock" xlink:href="nivf-20241231.xsd#nivf_DisposalOfSubsidiaryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DisposalOfSubsidiaryTextBlock_lbl" xml:lang="en-US">DISPOSAL OF SUBSIDIARY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisposalOfSubsidiaryTextBlock" xlink:to="nivf_DisposalOfSubsidiaryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS ACQUISITION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Reclassifications" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Reclassifications"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Reclassifications_lbl" xml:lang="en-US">RECLASSIFICATION AND COMPARATIVE FIGURES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Less: allowance for expected credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0" xml:lang="en-US">Allowance for account receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Less: allowance for expected credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ContractWithCustomerRefundLiability_lbl" xml:lang="en-US">Refund to customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiability" xlink:to="us-gaap_ContractWithCustomerRefundLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Less: amortized during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" xlink:href="nivf-20241231.xsd#nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals_lbl" xml:lang="en-US">Decrease in subscription receivable due to reduction of work by professionals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" xlink:to="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ReverseCapitalization" xlink:href="nivf-20241231.xsd#nivf_ReverseCapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_ReverseCapitalization_lbl" xml:lang="en-US">Business Combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ReverseCapitalization" xlink:to="nivf_ReverseCapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToARelatedParty" xlink:href="nivf-20241231.xsd#nivf_DueToARelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_DueToARelatedParty_lbl" xml:lang="en-US">Due to a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToARelatedParty" xlink:to="nivf_DueToARelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenivfLimitedMember" xlink:href="nivf-20241231.xsd#nivf_NewGenivfLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NewGenivfLimitedMember_lbl" xml:lang="en-US">NewGenivf Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NewGenivfLimitedMember" xlink:to="nivf_NewGenivfLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_FFPGSHKLimitedMember" xlink:href="nivf-20241231.xsd#nivf_FFPGSHKLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_FFPGSHKLimitedMember_lbl" xml:lang="en-US">FFPGS (HK) Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FFPGSHKLimitedMember" xlink:to="nivf_FFPGSHKLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WellImageLimitedMember" xlink:href="nivf-20241231.xsd#nivf_WellImageLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_WellImageLimitedMember_lbl" xml:lang="en-US">Well Image Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WellImageLimitedMember" xlink:to="nivf_WellImageLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MedHoldingsLimitedMedHoldingsMember" xlink:href="nivf-20241231.xsd#nivf_MedHoldingsLimitedMedHoldingsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MedHoldingsLimitedMedHoldingsMember_lbl" xml:lang="en-US">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedHoldingsLimitedMedHoldingsMember" xlink:to="nivf_MedHoldingsLimitedMedHoldingsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPGSCenterLimitedFFCMember" xlink:href="nivf-20241231.xsd#nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_FirstFertilityPGSCenterLimitedFFCMember_lbl" xml:lang="en-US">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityPGSCenterLimitedFFCMember" xlink:to="nivf_FirstFertilityPGSCenterLimitedFFCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" xlink:href="nivf-20241231.xsd#nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_FirstFertilityPhnomPenhLimitedFFPPMember_lbl" xml:lang="en-US">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" xlink:to="nivf_FirstFertilityPhnomPenhLimitedFFPPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_BiClinicLtdFFBiMember" xlink:href="nivf-20241231.xsd#nivf_BiClinicLtdFFBiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_BiClinicLtdFFBiMember_lbl" xml:lang="en-US">Bi Clinic Ltd (&#8220;FFBi&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BiClinicLtdFFBiMember" xlink:to="nivf_BiClinicLtdFFBiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember" xlink:href="nivf-20241231.xsd#nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember_lbl" xml:lang="en-US">Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd. (&#8220;SZ QianHai&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember" xlink:to="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_HKD_lbl" xml:lang="en-US">HK [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_HKD" xlink:to="currency_HKD_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PeriodEndMember" xlink:href="nivf-20241231.xsd#nivf_PeriodEndMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PeriodEndMember_lbl" xml:lang="en-US">Period End [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PeriodEndMember" xlink:to="nivf_PeriodEndMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PeriodAverageMember" xlink:href="nivf-20241231.xsd#nivf_PeriodAverageMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PeriodAverageMember_lbl" xml:lang="en-US">Period Average [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PeriodAverageMember" xlink:to="nivf_PeriodAverageMember_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_THB" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_THB"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_THB_lbl" xml:lang="en-US">THB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_THB" xlink:to="currency_THB_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_CNY_lbl" xml:lang="en-US">RMB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CNY" xlink:to="currency_CNY_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_Within90DaysMember" xlink:href="nivf-20241231.xsd#nivf_Within90DaysMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_Within90DaysMember_lbl" xml:lang="en-US">Within 90 days [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_Within90DaysMember" xlink:to="nivf_Within90DaysMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MovementOfAllowancesMember" xlink:href="nivf-20241231.xsd#nivf_MovementOfAllowancesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MovementOfAllowancesMember_lbl" xml:lang="en-US">Movement of Allowances [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MovementOfAllowancesMember" xlink:to="nivf_MovementOfAllowancesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingImprovementsMember_lbl" xml:lang="en-US">Building improvement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_MedicalInstrumentsMember" xlink:href="nivf-20241231.xsd#nivf_MedicalInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MedicalInstrumentsMember_lbl" xml:lang="en-US">Medical instruments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedicalInstrumentsMember" xlink:to="nivf_MedicalInstrumentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nivf_MedicalInstrumentsMember_lbl0" xml:lang="en-US">Medical Instruments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedicalInstrumentsMember" xlink:to="nivf_MedicalInstrumentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Motor vehicle [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKAffiliatedHoldersMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_JAKAffiliatedHoldersMember_lbl" xml:lang="en-US">JAK &amp; affiliated holders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKAffiliatedHoldersMember" xlink:to="nivf_JAKAffiliatedHoldersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKAffiliatedHoldersOneMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_JAKAffiliatedHoldersOneMember_lbl" xml:lang="en-US">JAK &amp; affiliated holders One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKAffiliatedHoldersOneMember" xlink:to="nivf_JAKAffiliatedHoldersOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKAffiliatedHoldersTwoMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_JAKAffiliatedHoldersTwoMember_lbl" xml:lang="en-US">JAK &amp; affiliated holders Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKAffiliatedHoldersTwoMember" xlink:to="nivf_JAKAffiliatedHoldersTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKAffiliatedHoldersThreeMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_JAKAffiliatedHoldersThreeMember_lbl" xml:lang="en-US">JAK &amp; affiliated holders Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKAffiliatedHoldersThreeMember" xlink:to="nivf_JAKAffiliatedHoldersThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesMember" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesMember" xlink:to="nivf_ConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PromissoryNotesMember" xlink:href="nivf-20241231.xsd#nivf_PromissoryNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PromissoryNotesMember_lbl" xml:lang="en-US">Promissory Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PromissoryNotesMember" xlink:to="nivf_PromissoryNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionKyrgyzstanMember" xlink:href="nivf-20241231.xsd#nivf_CurrentTaxProvisionKyrgyzstanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CurrentTaxProvisionKyrgyzstanMember_lbl" xml:lang="en-US">Current tax provision Kyrgyzstan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentTaxProvisionKyrgyzstanMember" xlink:to="nivf_CurrentTaxProvisionKyrgyzstanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember" xlink:href="nivf-20241231.xsd#nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember_lbl" xml:lang="en-US">Over provision of tax in prior year Kyrgyzstan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember" xlink:to="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionCambodiaMember" xlink:href="nivf-20241231.xsd#nivf_CurrentTaxProvisionCambodiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CurrentTaxProvisionCambodiaMember_lbl" xml:lang="en-US">Current tax provision Cambodia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentTaxProvisionCambodiaMember" xlink:to="nivf_CurrentTaxProvisionCambodiaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_IVFTreatmentServiceMember" xlink:href="nivf-20241231.xsd#nivf_IVFTreatmentServiceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_IVFTreatmentServiceMember_lbl" xml:lang="en-US">IVF treatment service [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IVFTreatmentServiceMember" xlink:to="nivf_IVFTreatmentServiceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" xlink:href="nivf-20241231.xsd#nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SurrogacyAncillaryCaringAndOtherServicesMember_lbl" xml:lang="en-US">Surrogacy, ancillary caring and other services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" xlink:to="nivf_SurrogacyAncillaryCaringAndOtherServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_HK_lbl" xml:lang="en-US">HK SAR [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_HK_lbl0" xml:lang="en-US">HK [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl0"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KG_lbl" xml:lang="en-US">Kyrgyzstan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KG" xlink:to="country_KG_lbl"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KH_lbl" xml:lang="en-US">Cambodia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KH" xlink:to="country_KH_lbl"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_TH_lbl" xml:lang="en-US">Thailand [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_TH" xlink:to="country_TH_lbl"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CN_lbl" xml:lang="en-US">China [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MrSiuWingFungAlfredMember" xlink:href="nivf-20241231.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MrSiuWingFungAlfredMember_lbl" xml:lang="en-US">Mr. Siu Wing Fung, Alfred (&#8220;Mr. Siu&#8221;) and Ms. Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MrSiuWingFungAlfredMember" xlink:to="nivf_MrSiuWingFungAlfredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MsFongHeiYueTinaMember" xlink:href="nivf-20241231.xsd#nivf_MsFongHeiYueTinaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MsFongHeiYueTinaMember_lbl" xml:lang="en-US">Ms. Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MsFongHeiYueTinaMember" xlink:to="nivf_MsFongHeiYueTinaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_HarcourtLimitedMember" xlink:href="nivf-20241231.xsd#nivf_HarcourtLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_HarcourtLimitedMember_lbl" xml:lang="en-US">Harcourt Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HarcourtLimitedMember" xlink:to="nivf_HarcourtLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:href="nivf-20241231.xsd#nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember_lbl" xml:lang="en-US">Directors&#8217; remuneration to Mr. Siu Wing Fung, Alfred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:to="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:href="nivf-20241231.xsd#nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember_lbl" xml:lang="en-US">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:to="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:href="nivf-20241231.xsd#nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember_lbl" xml:lang="en-US">Waiver of related party balance of Mr. Siu Wing Fung, Alfred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:to="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKOPPORTUNITIESVILLCMember" xlink:href="nivf-20241231.xsd#nivf_JAKOPPORTUNITIESVILLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_JAKOPPORTUNITIESVILLCMember_lbl" xml:lang="en-US">Coupon interest payable to JAK Opportunities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKOPPORTUNITIESVILLCMember" xlink:to="nivf_JAKOPPORTUNITIESVILLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember" xlink:href="nivf-20241231.xsd#nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember_lbl" xml:lang="en-US">Conversion of convertible note to shares to JAK Opportunities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember" xlink:to="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xml:lang="en-US">Stock Conversion Description [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Aggregate loans principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Receipt of loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NetTangibleAssets" xlink:href="nivf-20241231.xsd#nivf_NetTangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NetTangibleAssets_lbl" xml:lang="en-US">Net tangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NetTangibleAssets" xlink:to="nivf_NetTangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Equity investment percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividends preference shares rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Consideration amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0" xml:lang="en-US">Total consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl1" xml:lang="en-US">Business combination agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Equity investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Percentage of equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Deemed price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AggregateAmount" xlink:href="nivf-20241231.xsd#nivf_AggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AggregateAmount_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AggregateAmount" xlink:to="nivf_AggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyCommittedCapital_lbl" xml:lang="en-US">Investors amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyCommittedCapital" xlink:to="us-gaap_InvestmentCompanyCommittedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Total principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US">Original principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant to purchase shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Convertible warrant shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MaturityTerm" xlink:href="nivf-20241231.xsd#nivf_MaturityTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MaturityTerm_lbl" xml:lang="en-US">Maturity, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MaturityTerm" xlink:to="nivf_MaturityTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockHeldBySubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockHeldBySubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockHeldBySubsidiary_lbl" xml:lang="en-US">Common stock selling value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockHeldBySubsidiary" xlink:to="us-gaap_CommonStockHeldBySubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CommonStockPotentialValue" xlink:href="nivf-20241231.xsd#nivf_CommonStockPotentialValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CommonStockPotentialValue_lbl" xml:lang="en-US">Common stock potential value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CommonStockPotentialValue" xlink:to="nivf_CommonStockPotentialValue_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MergerActivityDrawn" xlink:href="nivf-20241231.xsd#nivf_MergerActivityDrawn"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MergerActivityDrawn_lbl" xml:lang="en-US">Merger activity drawn</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MergerActivityDrawn" xlink:to="nivf_MergerActivityDrawn_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Cash deposit (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Salvage value percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Reverse stock split shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Ordinary shares reverse stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueRate" xlink:href="nivf-20241231.xsd#nivf_RevenueRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_RevenueRate_lbl" xml:lang="en-US">Contract revenue rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueRate" xlink:to="nivf_RevenueRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl" xml:lang="en-US">Remains outstanding balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment_lbl" xml:lang="en-US">Line of credit facility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CashInBank" xlink:href="nivf-20241231.xsd#nivf_CashInBank"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CashInBank_lbl" xml:lang="en-US">Cash in bank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CashInBank" xlink:to="nivf_CashInBank_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Cash deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl" xml:lang="en-US">Prepayment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ServicesRanging" xlink:href="nivf-20241231.xsd#nivf_ServicesRanging"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ServicesRanging_lbl" xml:lang="en-US">Service ranging</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ServicesRanging" xlink:to="nivf_ServicesRanging_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_TerminationClauses" xlink:href="nivf-20241231.xsd#nivf_TerminationClauses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_TerminationClauses_lbl" xml:lang="en-US">Termination clauses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TerminationClauses" xlink:to="nivf_TerminationClauses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_convertiblePromissoryNoteDiscountPercentage" xlink:href="nivf-20241231.xsd#nivf_convertiblePromissoryNoteDiscountPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_convertiblePromissoryNoteDiscountPercentage_lbl" xml:lang="en-US">Convertible promissory note discount percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_convertiblePromissoryNoteDiscountPercentage" xlink:to="nivf_convertiblePromissoryNoteDiscountPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCapInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCapInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeCapInterestRate_lbl" xml:lang="en-US">Percentage of beneficiary cap</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCapInterestRate" xlink:to="us-gaap_DerivativeCapInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xml:lang="en-US">Carrying amount of the convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PercentageOfConversionExceeds" xlink:href="nivf-20241231.xsd#nivf_PercentageOfConversionExceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PercentageOfConversionExceeds_lbl" xml:lang="en-US">Percentage of conversion exceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PercentageOfConversionExceeds" xlink:to="nivf_PercentageOfConversionExceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyLiquidationProceedsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl" xml:lang="en-US">Percentage of exercise warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_IndicativeRateOfBorrowingCost" xlink:href="nivf-20241231.xsd#nivf_IndicativeRateOfBorrowingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_IndicativeRateOfBorrowingCost_lbl" xml:lang="en-US">Indicative rate of borrowing cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IndicativeRateOfBorrowingCost" xlink:to="nivf_IndicativeRateOfBorrowingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Voting rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares with par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of shares for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConsultingServiceTerm" xlink:href="nivf-20241231.xsd#nivf_ConsultingServiceTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ConsultingServiceTerm_lbl" xml:lang="en-US">Consulting service term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConsultingServiceTerm" xlink:to="nivf_ConsultingServiceTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAdditionalCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAdditionalCapital_lbl" xml:lang="en-US">Increase in paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAdditionalCapital" xlink:to="us-gaap_OtherAdditionalCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Consideration amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementAndServiceFeesRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementAndServiceFeesRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManagementAndServiceFeesRate_lbl" xml:lang="en-US">Scheme calculated rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementAndServiceFeesRate" xlink:to="us-gaap_ManagementAndServiceFeesRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US">Percentage of employee&apos;s salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SpecialAssessmentBond" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SpecialAssessmentBond"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SpecialAssessmentBond_lbl" xml:lang="en-US">Special concession amount (in Baht)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SpecialAssessmentBond" xlink:to="us-gaap_SpecialAssessmentBond_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Contribution equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US">Average wages per month (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Contributable wage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProfitTaxDescription" xlink:href="nivf-20241231.xsd#nivf_ProfitTaxDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ProfitTaxDescription_lbl" xml:lang="en-US">Profit tax rate description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProfitTaxDescription" xlink:to="nivf_ProfitTaxDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Profit tax percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US">Estimated assessable profits (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl" xml:lang="en-US">Remaining estimated percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic_lbl" xml:lang="en-US">Corporate income tax, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xml:lang="en-US">General tax rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" xlink:href="nivf-20241231.xsd#nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent_lbl" xml:lang="en-US">Other rates provisions percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" xlink:to="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Progressive rates percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AnnualTurnover" xlink:href="nivf-20241231.xsd#nivf_AnnualTurnover"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AnnualTurnover_lbl" xml:lang="en-US">Annual turnover ranges (in Riels)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AnnualTurnover" xlink:to="nivf_AnnualTurnover_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DeemedExcessTaxPayable" xlink:href="nivf-20241231.xsd#nivf_DeemedExcessTaxPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DeemedExcessTaxPayable_lbl" xml:lang="en-US">Deemed excess tax payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DeemedExcessTaxPayable" xlink:to="nivf_DeemedExcessTaxPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xml:lang="en-US">Aggregate annual income percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:href="nivf-20241231.xsd#nivf_PercentageOfAllowanceOnDeferredTaxAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl" xml:lang="en-US">Percentage of allowance on deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:to="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) interest risk rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_InterestRateOtherVariablesPercentage" xlink:href="nivf-20241231.xsd#nivf_InterestRateOtherVariablesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_InterestRateOtherVariablesPercentage_lbl" xml:lang="en-US">Interest rate other variables, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_InterestRateOtherVariablesPercentage" xlink:to="nivf_InterestRateOtherVariablesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPensionPlanObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations_lbl" xml:lang="en-US">Increased (decreased) amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:to="us-gaap_IncreaseDecreaseInPensionPlanObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl" xml:lang="en-US">Outstanding under the loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xml:lang="en-US">Total consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" xlink:href="nivf-20241231.xsd#nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax_lbl" xml:lang="en-US">Reversal of excess tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" xlink:to="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityOther_lbl" xml:lang="en-US">Shareholder equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CashConsideration" xlink:href="nivf-20241231.xsd#nivf_CashConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CashConsideration_lbl" xml:lang="en-US">Cash consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CashConsideration" xlink:to="nivf_CashConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Business combination cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DeemedValuePerShare" xlink:href="nivf-20241231.xsd#nivf_DeemedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DeemedValuePerShare_lbl" xml:lang="en-US">Deemed value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DeemedValuePerShare" xlink:to="nivf_DeemedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Valid period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Awarded shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OutstandingPercentage" xlink:href="nivf-20241231.xsd#nivf_OutstandingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OutstandingPercentage_lbl" xml:lang="en-US">Outstanding amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OutstandingPercentage" xlink:to="nivf_OutstandingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Bears an interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_BidPricePerShare" xlink:href="nivf-20241231.xsd#nivf_BidPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_BidPricePerShare_lbl" xml:lang="en-US">Bid price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BidPricePerShare" xlink:to="nivf_BidPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Promissory notes outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation and basis of preparation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl" xml:lang="en-US">Deposits, other receivables and deferred legal &amp; IPO cost, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Other borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleInstrumentsPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_ConvertibleInstrumentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ConvertibleInstrumentsPolicyTextBlock_lbl" xml:lang="en-US">Convertible Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleInstrumentsPolicyTextBlock" xlink:to="nivf_ConvertibleInstrumentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PromissoryNotesPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_PromissoryNotesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PromissoryNotesPolicyTextBlock_lbl" xml:lang="en-US">Promissory Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PromissoryNotesPolicyTextBlock" xlink:to="nivf_PromissoryNotesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xml:lang="en-US">Retirement benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91Jey1KbBNr08lrF9bNZYdTx/rA/SBVS10LyurQW5OboqYQWmZFkzLw3/d47HSjYGzqO9ETKAZNCuSd9bzJkSVkcGU94k1fhDc4tXQqjibaNNszh6F9ORmGKLPAlHqyPWSx7sNc84Mf0+16i2rCxXhF9zW9j4/a5D3QtQ8xj7KO/pD] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_RelatedPartiesPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_RelatedPartiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_RelatedPartiesPolicyTextBlock_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RelatedPartiesPolicyTextBlock" xlink:to="nivf_RelatedPartiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NonControllingInterestsPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_NonControllingInterestsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NonControllingInterestsPolicyTextBlock_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonControllingInterestsPolicyTextBlock" xlink:to="nivf_NonControllingInterestsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of risks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MotorVehiclesMember" xlink:href="nivf-20241231.xsd#nivf_MotorVehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MotorVehiclesMember_lbl" xml:lang="en-US">Motor Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MotorVehiclesMember" xlink:to="nivf_MotorVehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenIvfLimitedMember" xlink:href="nivf-20241231.xsd#nivf_NewGenIvfLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NewGenIvfLimitedMember_lbl" xml:lang="en-US">NewGenIvf Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NewGenIvfLimitedMember" xlink:to="nivf_NewGenIvfLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsidiarieMember" xlink:href="nivf-20241231.xsd#nivf_SubsidiarieMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SubsidiarieMember_lbl" xml:lang="en-US">Subsidiaries [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubsidiarieMember" xlink:to="nivf_SubsidiarieMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EWIHLMember" xlink:href="nivf-20241231.xsd#nivf_EWIHLMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_EWIHLMember_lbl" xml:lang="en-US">EWIHL [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EWIHLMember" xlink:to="nivf_EWIHLMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_COVIRIXMember" xlink:href="nivf-20241231.xsd#nivf_COVIRIXMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_COVIRIXMember_lbl" xml:lang="en-US">COVIRIX [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_COVIRIXMember" xlink:to="nivf_COVIRIXMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenMember" xlink:href="nivf-20241231.xsd#nivf_NewGenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NewGenMember_lbl" xml:lang="en-US">NewGen [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NewGenMember" xlink:to="nivf_NewGenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SeniorConvertibleNotesMember" xlink:href="nivf-20241231.xsd#nivf_SeniorConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SeniorConvertibleNotesMember_lbl" xml:lang="en-US">Senior Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeniorConvertibleNotesMember" xlink:to="nivf_SeniorConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Class A Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonClassAMember_lbl0" xml:lang="en-US">Common Class A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Class B Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AdditionalNotesMember" xlink:href="nivf-20241231.xsd#nivf_AdditionalNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AdditionalNotesMember_lbl" xml:lang="en-US">Additional Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AdditionalNotesMember" xlink:to="nivf_AdditionalNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SecuritiesPurchaseAgreementMember" xlink:href="nivf-20241231.xsd#nivf_SecuritiesPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SecuritiesPurchaseAgreementMember" xlink:to="nivf_SecuritiesPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConversionRateMember" xlink:href="nivf-20241231.xsd#nivf_ConversionRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ConversionRateMember_lbl" xml:lang="en-US">Conversion Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConversionRateMember" xlink:to="nivf_ConversionRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SeriesAWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesAWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SeriesAWarrantMember_lbl" xml:lang="en-US">Series A Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeriesAWarrantMember" xlink:to="nivf_SeriesAWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SeriesBWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesBWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SeriesBWarrantMember_lbl" xml:lang="en-US">Series B Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeriesBWarrantMember" xlink:to="nivf_SeriesBWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_JAKOpportunitiesVILLCJAKMember" xlink:href="nivf-20241231.xsd#nivf_JAKOpportunitiesVILLCJAKMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_JAKOpportunitiesVILLCJAKMember_lbl" xml:lang="en-US">JAK Opportunities VI LLC (&#8220;JAK&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKOpportunitiesVILLCJAKMember" xlink:to="nivf_JAKOpportunitiesVILLCJAKMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SecondAdditionalMandatoryNoteMember" xlink:href="nivf-20241231.xsd#nivf_SecondAdditionalMandatoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SecondAdditionalMandatoryNoteMember_lbl" xml:lang="en-US">Second Additional Mandatory Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SecondAdditionalMandatoryNoteMember" xlink:to="nivf_SecondAdditionalMandatoryNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SecondAdditionalNoteMember" xlink:href="nivf-20241231.xsd#nivf_SecondAdditionalNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SecondAdditionalNoteMember_lbl" xml:lang="en-US">Second Additional Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SecondAdditionalNoteMember" xlink:to="nivf_SecondAdditionalNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WhiteLionCapitalLLCMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionCapitalLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_WhiteLionCapitalLLCMember_lbl" xml:lang="en-US">White Lion Capital, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WhiteLionCapitalLLCMember" xlink:to="nivf_WhiteLionCapitalLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OSLGroupMember" xlink:href="nivf-20241231.xsd#nivf_OSLGroupMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OSLGroupMember_lbl" xml:lang="en-US">OSL Group [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OSLGroupMember" xlink:to="nivf_OSLGroupMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CustomerMember" xlink:href="nivf-20241231.xsd#nivf_CustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CustomerMember" xlink:to="nivf_CustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Trade Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CustomerTwoMember" xlink:href="nivf-20241231.xsd#nivf_CustomerTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CustomerTwoMember_lbl" xml:lang="en-US">Customer Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CustomerTwoMember" xlink:to="nivf_CustomerTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SuppliersTwoMember" xlink:href="nivf-20241231.xsd#nivf_SuppliersTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SuppliersTwoMember_lbl" xml:lang="en-US">Suppliers Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SuppliersTwoMember" xlink:to="nivf_SuppliersTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SuppliersOneMember" xlink:href="nivf-20241231.xsd#nivf_SuppliersOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SuppliersOneMember_lbl" xml:lang="en-US">Suppliers One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SuppliersOneMember" xlink:to="nivf_SuppliersOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember" xlink:href="nivf-20241231.xsd#nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember_lbl" xml:lang="en-US">Convertible Promissory Note was Converted into Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember" xlink:to="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNoteMember" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNoteMember" xlink:to="nivf_ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_UnsecuredPromissoryNotesMember" xlink:href="nivf-20241231.xsd#nivf_UnsecuredPromissoryNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_UnsecuredPromissoryNotesMember_lbl" xml:lang="en-US">Unsecured Promissory Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_UnsecuredPromissoryNotesMember" xlink:to="nivf_UnsecuredPromissoryNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SeriesCWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesCWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SeriesCWarrantMember_lbl" xml:lang="en-US">Series C Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeriesCWarrantMember" xlink:to="nivf_SeriesCWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_FreeStandingInstrumentsWarrantsMember" xlink:href="nivf-20241231.xsd#nivf_FreeStandingInstrumentsWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_FreeStandingInstrumentsWarrantsMember_lbl" xml:lang="en-US">Free Standing Instruments Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FreeStandingInstrumentsWarrantsMember" xlink:to="nivf_FreeStandingInstrumentsWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_BestLendingRateMember" xlink:href="nivf-20241231.xsd#nivf_BestLendingRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_BestLendingRateMember_lbl" xml:lang="en-US">Best Lending Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BestLendingRateMember" xlink:to="nivf_BestLendingRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProfessionalPartyMember" xlink:href="nivf-20241231.xsd#nivf_ProfessionalPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ProfessionalPartyMember_lbl" xml:lang="en-US">Professional Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProfessionalPartyMember" xlink:to="nivf_ProfessionalPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DoubleClickServicesLimitedMember" xlink:href="nivf-20241231.xsd#nivf_DoubleClickServicesLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DoubleClickServicesLimitedMember_lbl" xml:lang="en-US">DoubleClick Services Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DoubleClickServicesLimitedMember" xlink:to="nivf_DoubleClickServicesLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MAMember" xlink:href="nivf-20241231.xsd#nivf_MAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MAMember_lbl" xml:lang="en-US">M&amp;A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MAMember" xlink:to="nivf_MAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WhiteLionPurchaseAgreementMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_WhiteLionPurchaseAgreementMember_lbl" xml:lang="en-US">White Lion Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WhiteLionPurchaseAgreementMember" xlink:to="nivf_WhiteLionPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WhiteLionMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_WhiteLionMember_lbl" xml:lang="en-US">White Lion [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WhiteLionMember" xlink:to="nivf_WhiteLionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OccupationalRiskSchemeMember" xlink:href="nivf-20241231.xsd#nivf_OccupationalRiskSchemeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OccupationalRiskSchemeMember_lbl" xml:lang="en-US">Occupational Risk Scheme [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OccupationalRiskSchemeMember" xlink:to="nivf_OccupationalRiskSchemeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_HealthCareSchemeMember" xlink:href="nivf-20241231.xsd#nivf_HealthCareSchemeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_HealthCareSchemeMember_lbl" xml:lang="en-US">Health Care Scheme [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HealthCareSchemeMember" xlink:to="nivf_HealthCareSchemeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PensionSchemeMember" xlink:href="nivf-20241231.xsd#nivf_PensionSchemeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PensionSchemeMember_lbl" xml:lang="en-US">Pension Scheme [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PensionSchemeMember" xlink:to="nivf_PensionSchemeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_HKSARMember" xlink:href="nivf-20241231.xsd#nivf_HKSARMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_HKSARMember_lbl" xml:lang="en-US">HK SAR [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HKSARMember" xlink:to="nivf_HKSARMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ASPACIMember" xlink:href="nivf-20241231.xsd#nivf_ASPACIMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ASPACIMember_lbl" xml:lang="en-US">A SPAC I [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ASPACIMember" xlink:to="nivf_ASPACIMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityBishkekLLCFFBMember" xlink:href="nivf-20241231.xsd#nivf_FirstFertilityBishkekLLCFFBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_FirstFertilityBishkekLLCFFBMember_lbl" xml:lang="en-US">First Fertility Bishkek LLC (&#8220;FFB&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityBishkekLLCFFBMember" xlink:to="nivf_FirstFertilityBishkekLLCFFBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_BiClinicLtdMember" xlink:href="nivf-20241231.xsd#nivf_BiClinicLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_BiClinicLtdMember_lbl" xml:lang="en-US">Bi Clinic Ltd (&#8220;Bi Clinic&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BiClinicLtdMember" xlink:to="nivf_BiClinicLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MicroSortAcquisitionMember" xlink:href="nivf-20241231.xsd#nivf_MicroSortAcquisitionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MicroSortAcquisitionMember_lbl" xml:lang="en-US">MicroSort Acquisition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MicroSortAcquisitionMember" xlink:to="nivf_MicroSortAcquisitionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_GeneticsIVFInstituteIncMember" xlink:href="nivf-20241231.xsd#nivf_GeneticsIVFInstituteIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_GeneticsIVFInstituteIncMember_lbl" xml:lang="en-US">Genetics &amp; IVF Institute, Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_GeneticsIVFInstituteIncMember" xlink:to="nivf_GeneticsIVFInstituteIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:href="nivf-20241231.xsd#nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">2025 Securities Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:to="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SeniorConvertibleNoteMember" xlink:href="nivf-20241231.xsd#nivf_SeniorConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SeniorConvertibleNoteMember_lbl" xml:lang="en-US">Senior Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeniorConvertibleNoteMember" xlink:to="nivf_SeniorConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl" xml:lang="en-US">Subsidiary of LLC or LP [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl" xml:lang="en-US">Schedule of Company&apos;s subsidiaries [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntercompanyForeignCurrencyBalanceNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain_lbl" xml:lang="en-US">Intra-Entity Foreign Currency Balance, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" xlink:to="nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntercompanyForeignCurrencyBalanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceLineItems_lbl" xml:lang="en-US">Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Accounts and Financing Receivables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Schedule of Accounts Receivable, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain_lbl" xml:lang="en-US">Financial Asset, Aging [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable_lbl" xml:lang="en-US">Accounts Receivable, Net - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" xlink:to="nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl0" xml:lang="en-US">Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable_lbl" xml:lang="en-US">Accounts Receivable, Net - Schedule of Movement Allowances for Expected Credit Loss (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" xlink:to="nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl1" xml:lang="en-US">Schedule of Movement Allowances for Expected Credit Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable_lbl" xml:lang="en-US">Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Movement of Allowances for Expected Credit Loss (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" xlink:to="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems_lbl" xml:lang="en-US">Schedule of Movement of Allowances for Expected Credit Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:to="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Plant and Equipment, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable_lbl" xml:lang="en-US">Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" xlink:to="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems_lbl" xml:lang="en-US">Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable_lbl" xml:lang="en-US">Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Promissory Notes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" xlink:to="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems_lbl" xml:lang="en-US">Schedule of Promissory Notes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:to="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable" xlink:href="nivf-20241231.xsd#nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Additional Paid-in Capital (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable" xlink:to="nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable_lbl" xml:lang="en-US">Provision for Income Taxes - Schedule of the Provisions for Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" xlink:to="nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionsForIncomeTaxesLineItems" xlink:href="nivf-20241231.xsd#nivf_ProvisionsForIncomeTaxesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProvisionsForIncomeTaxesLineItems_lbl" xml:lang="en-US">Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProvisionsForIncomeTaxesLineItems" xlink:to="nivf_ProvisionsForIncomeTaxesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xml:lang="en-US">Segment Reporting, Revenue from External Customer, Product and Service [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xml:lang="en-US">Schedule of Business Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable_lbl" xml:lang="en-US">Disaggregated Revenues - Schedule of Geographical Information (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" xlink:to="nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl0" xml:lang="en-US">Schedule of Geographical Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Schedule of Revenue Information Based on the Locations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xml:lang="en-US">Condensed Financial Statements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" xlink:to="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_OrganizationandPrincipalActivitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OrganizationandPrincipalActivitiesDetailsTable_lbl" xml:lang="en-US">Organization and Principal Activities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="nivf_OrganizationandPrincipalActivitiesDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl0" xml:lang="en-US">Organization and Principal Activities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable_lbl" xml:lang="en-US">Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" xlink:to="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems_lbl" xml:lang="en-US">Deposits, Prepayment, Other Receivables And Deferred IPO Cost, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockNameDomain_lbl" xml:lang="en-US">Conversion of Stock, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable_lbl" xml:lang="en-US">Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems_lbl" xml:lang="en-US">Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_LeasesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LeasesDetailsTable" xlink:to="nivf_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US">Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsTable" xlink:href="nivf-20241231.xsd#nivf_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EquityDetailsTable" xlink:to="nivf_EquityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl0" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EmployeeBenefitPlansDetailsTable" xlink:href="nivf-20241231.xsd#nivf_EmployeeBenefitPlansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EmployeeBenefitPlansDetailsTable_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EmployeeBenefitPlansDetailsTable" xlink:to="nivf_EmployeeBenefitPlansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Employee Benefit Plans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ProvisionforIncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProvisionforIncomeTaxesDetailsTable_lbl" xml:lang="en-US">Provision for Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:to="nivf_ProvisionforIncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLineItems_lbl" xml:lang="en-US">Provision for Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExaminationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_RisksDetailsTable" xlink:href="nivf-20241231.xsd#nivf_RisksDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RisksDetailsTable_lbl" xml:lang="en-US">Risks (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RisksDetailsTable" xlink:to="nivf_RisksDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Risks [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_RelatedPartyBalancesandTransactionsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_RelatedPartyBalancesandTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RelatedPartyBalancesandTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Balances and Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="nivf_RelatedPartyBalancesandTransactionsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl0" xml:lang="en-US">Related Party Balances and Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_DisposalofSubsidiaryDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DisposalofSubsidiaryDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DisposalofSubsidiaryDetailsTable_lbl" xml:lang="en-US">Disposal of Subsidiary (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisposalofSubsidiaryDetailsTable" xlink:to="nivf_DisposalofSubsidiaryDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Disposal of Subsidiary [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_BusinessAcquisitionDetailsTable" xlink:href="nivf-20241231.xsd#nivf_BusinessAcquisitionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_BusinessAcquisitionDetailsTable_lbl" xml:lang="en-US">Business Acquisition (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BusinessAcquisitionDetailsTable" xlink:to="nivf_BusinessAcquisitionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsequentEventsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="nivf_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AccountsReceivableAfterAllowanceForCreditLoss_lbl0" xml:lang="en-US">The amount of shareholders amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableAfterAllowanceForCreditLoss" xlink:to="nivf_AccountsReceivableAfterAllowanceForCreditLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AggregateAmount_lbl0" xml:lang="en-US">The amout of aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AggregateAmount" xlink:to="nivf_AggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AllowancesForExpectedCreditLoss_lbl1" xml:lang="en-US">Represent the amount of allowances for expected credit loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLoss" xlink:to="nivf_AllowancesForExpectedCreditLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl0" xml:lang="en-US">Repressent the amount of reversal of provision (Provision).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:to="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AmortisationOfShareBasedCompensationExpense_lbl0" xml:lang="en-US">Amount of amortization expense attributable to share based compensation expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AmortisationOfShareBasedCompensationExpense" xlink:to="nivf_AmortisationOfShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AnnualTurnover_lbl0" xml:lang="en-US">The annual turn over of the company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AnnualTurnover" xlink:to="nivf_AnnualTurnover_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_BidPricePerShare_lbl0" xml:lang="en-US">Per share of bid price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BidPricePerShare" xlink:to="nivf_BidPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_CashConsideration_lbl0" xml:lang="en-US">Cash consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CashConsideration" xlink:to="nivf_CashConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_CashInBank_lbl0" xml:lang="en-US">The amount of cash in bank.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CashInBank" xlink:to="nivf_CashInBank_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_CommonStockPotentialValue_lbl0" xml:lang="en-US">The amount of common stock potential value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CommonStockPotentialValue" xlink:to="nivf_CommonStockPotentialValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ConsultingServiceTerm_lbl0" xml:lang="en-US">Consulting service term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConsultingServiceTerm" xlink:to="nivf_ConsultingServiceTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ConvertibleInstrumentsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for convertible instruments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleInstrumentsPolicyTextBlock" xlink:to="nivf_ConvertibleInstrumentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_CustomerDeposit_lbl0" xml:lang="en-US">Customer deposit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CustomerDeposit" xlink:to="nivf_CustomerDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DebtInstrumentCouponRatePercentage_lbl0" xml:lang="en-US">Percentage of debt instrument coupon rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DebtInstrumentCouponRatePercentage" xlink:to="nivf_DebtInstrumentCouponRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals_lbl0" xml:lang="en-US">Decrease in subscription receivable due to reduction of work by professionals.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" xlink:to="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DeemedExcessTaxPayable_lbl0" xml:lang="en-US">The amount of deemed excess tax payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DeemedExcessTaxPayable" xlink:to="nivf_DeemedExcessTaxPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DeemedValuePerShare_lbl0" xml:lang="en-US">Deemed value per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DeemedValuePerShare" xlink:to="nivf_DeemedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_Deposit_lbl0" xml:lang="en-US">Deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_Deposit" xlink:to="nivf_Deposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for deposits, prepayment, other receivables and deferred ipo cost, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax_lbl0" xml:lang="en-US">Amount of reversal on excess tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" xlink:to="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DueFromShareholders_lbl0" xml:lang="en-US">Due from shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholders" xlink:to="nivf_DueFromShareholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DueFromtoshareholdersRelatedParty_lbl0" xml:lang="en-US">The amount of related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromtoshareholdersRelatedParty" xlink:to="nivf_DueFromtoshareholdersRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DueToARelatedParty_lbl0" xml:lang="en-US">The amount of due to a related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToARelatedParty" xlink:to="nivf_DueToARelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent_lbl0" xml:lang="en-US">Percentage of provision on double tax treaty (DTT).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" xlink:to="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_GainOnPromissoryNote_lbl0" xml:lang="en-US">Represent the amount of gain on promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_GainOnPromissoryNote" xlink:to="nivf_GainOnPromissoryNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear_lbl0" xml:lang="en-US">The amount of over provision of tax in prior year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" xlink:to="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_IndependentDirectorFeePayable_lbl0" xml:lang="en-US">Independent director fee payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IndependentDirectorFeePayable" xlink:to="nivf_IndependentDirectorFeePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_IndicativeRateOfBorrowingCost_lbl0" xml:lang="en-US">Indicative rate of borrowing cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IndicativeRateOfBorrowingCost" xlink:to="nivf_IndicativeRateOfBorrowingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_InterestRateOtherVariablesPercentage_lbl0" xml:lang="en-US">Interest rate other variables, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_InterestRateOtherVariablesPercentage" xlink:to="nivf_InterestRateOtherVariablesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_LoanToASPAC_lbl0" xml:lang="en-US">Represents amount of loans to ASPAC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LoanToASPAC" xlink:to="nivf_LoanToASPAC_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_MaturityTerm_lbl0" xml:lang="en-US">Duration of maturity, term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MaturityTerm" xlink:to="nivf_MaturityTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_MergerActivityDrawn_lbl0" xml:lang="en-US">The amount of merger activity drawn.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MergerActivityDrawn" xlink:to="nivf_MergerActivityDrawn_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_NetTangibleAssets_lbl0" xml:lang="en-US">Amount of net tangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NetTangibleAssets" xlink:to="nivf_NetTangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_NonCashDiscountOnConvertibleNotes_lbl0" xml:lang="en-US">The amount of non cash discount on convertible notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonCashDiscountOnConvertibleNotes" xlink:to="nivf_NonCashDiscountOnConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_NonControllingInterestsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for non-controlling interests.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonControllingInterestsPolicyTextBlock" xlink:to="nivf_NonControllingInterestsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_OtherPrepaidExpenseNonCurrent_lbl0" xml:lang="en-US">Prepayment, non current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherPrepaidExpenseNonCurrent" xlink:to="nivf_OtherPrepaidExpenseNonCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_OutstandingPercentage_lbl0" xml:lang="en-US">Percentage of outstanding amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OutstandingPercentage" xlink:to="nivf_OutstandingPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_PaymentofInterest_lbl0" xml:lang="en-US">Cash outflow during the period as interest paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PaymentofInterest" xlink:to="nivf_PaymentofInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl0" xml:lang="en-US">Percentage of allowance on deferred tax assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:to="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_PercentageOfConversionExceeds_lbl0" xml:lang="en-US">Percentage of conversion exceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PercentageOfConversionExceeds" xlink:to="nivf_PercentageOfConversionExceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ProceedsFromAmountDueFromASPACI_lbl0" xml:lang="en-US">The cash outflow paid to A SPAC I.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProceedsFromAmountDueFromASPACI" xlink:to="nivf_ProceedsFromAmountDueFromASPACI_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ProfitTaxDescription_lbl0" xml:lang="en-US">Profit tax Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProfitTaxDescription" xlink:to="nivf_ProfitTaxDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_PromissoryNotesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy related to promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PromissoryNotesPolicyTextBlock" xlink:to="nivf_PromissoryNotesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ReceivableFromAgents_lbl0" xml:lang="en-US">Receivable from agents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ReceivableFromAgents" xlink:to="nivf_ReceivableFromAgents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_RelatedPartiesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for policy related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RelatedPartiesPolicyTextBlock" xlink:to="nivf_RelatedPartiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_RevenueRate_lbl0" xml:lang="en-US">The percentage of revenue rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueRate" xlink:to="nivf_RevenueRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ReverseCapitalization_lbl0" xml:lang="en-US">The amount of reverse capitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ReverseCapitalization" xlink:to="nivf_ReverseCapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of schedule of additional paid-in capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:to="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of estimated useful lives of property plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" xlink:to="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of movement allowances for expected credit loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfPromissoryNotesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfPromissoryNotesTableTextBlock" xlink:to="nivf_ScheduleOfPromissoryNotesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of balance due from shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:to="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of transaction costs on issuance of notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" xlink:to="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ServicesRanging_lbl0" xml:lang="en-US">Services ranging term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ServicesRanging" xlink:to="nivf_ServicesRanging_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit_lbl0" xml:lang="en-US">Value of shares issued during the period to issuance of shares through equity line of credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" xlink:to="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_StockIssuedDuringPeriodValueReverseCaptialization_lbl0" xml:lang="en-US">Represent the amount of reverse captialization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueReverseCaptialization" xlink:to="nivf_StockIssuedDuringPeriodValueReverseCaptialization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl0" xml:lang="en-US">Value of shares issued during the period to settlement of subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_SubscriptionReceivable_lbl0" xml:lang="en-US">Amount of subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubscriptionReceivable" xlink:to="nivf_SubscriptionReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_TerminationClauses_lbl0" xml:lang="en-US">Termination clauses term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TerminationClauses" xlink:to="nivf_TerminationClauses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_WaiverOfLiability_lbl0" xml:lang="en-US">Waiver of liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfLiability" xlink:to="nivf_WaiverOfLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_WaiverOfRelatedPartyBalance_lbl1" xml:lang="en-US">Waiver of related party balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalance" xlink:to="nivf_WaiverOfRelatedPartyBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_convertiblePromissoryNoteDiscountPercentage_lbl0" xml:lang="en-US">Convertible promissory note discount percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_convertiblePromissoryNoteDiscountPercentage" xlink:to="nivf_convertiblePromissoryNoteDiscountPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeTermOfLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember_lbl" xml:lang="en-US">the lesser of useful life or term of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UsefulLifeTermOfLeaseMember" xlink:to="us-gaap_UsefulLifeTermOfLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl1" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SubscriptionReceivable_lbl1" xml:lang="en-US">Subscription Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubscriptionReceivable" xlink:to="nivf_SubscriptionReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DeemedValuePerShare_lbl1" xml:lang="en-US">Deemed Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DeemedValuePerShare" xlink:to="nivf_DeemedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear_lbl1" xml:lang="en-US">Income Tax Reconciliation Over Provision Of Tax In Prior Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" xlink:to="nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_JAKAffiliatedHoldersThreeMember_lbl0" xml:lang="en-US">JAKAffiliated Holders Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKAffiliatedHoldersThreeMember" xlink:to="nivf_JAKAffiliatedHoldersThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl0" xml:lang="en-US">Common Class B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract_lbl" xml:lang="en-US">Schedule Of Movement Allowances For Expected Credit Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SeriesCWarrantMember_lbl0" xml:lang="en-US">Series CWarrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeriesCWarrantMember" xlink:to="nivf_SeriesCWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ReceivableFromAgents_lbl1" xml:lang="en-US">Receivable From Agents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ReceivableFromAgents" xlink:to="nivf_ReceivableFromAgents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl1" xml:lang="en-US">HONG KONG</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DisposalOfSubsidiaryTextBlock_lbl0" xml:lang="en-US">Disposal Of Subsidiary Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisposalOfSubsidiaryTextBlock" xlink:to="nivf_DisposalOfSubsidiaryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConversionRateMember_lbl0" xml:lang="en-US">Conversion Rate Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConversionRateMember" xlink:to="nivf_ConversionRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_HKD_lbl0" xml:lang="en-US">Hong Kong, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_HKD" xlink:to="currency_HKD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RelatedPartiesPolicyTextBlock_lbl1" xml:lang="en-US">Related Parties Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RelatedPartiesPolicyTextBlock" xlink:to="nivf_RelatedPartiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl0" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeCapInterestRate_lbl0" xml:lang="en-US">Derivative, Cap Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCapInterestRate" xlink:to="us-gaap_DerivativeCapInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_InterestRateOtherVariablesPercentage_lbl1" xml:lang="en-US">Interest Rate Other Variables Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_InterestRateOtherVariablesPercentage" xlink:to="nivf_InterestRateOtherVariablesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MicroSortAcquisitionMember_lbl0" xml:lang="en-US">Micro Sort Acquisition Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MicroSortAcquisitionMember" xlink:to="nivf_MicroSortAcquisitionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl0" xml:lang="en-US">Equity Method Investment, Aggregate Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WhiteLionMember_lbl0" xml:lang="en-US">White Lion Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WhiteLionMember" xlink:to="nivf_WhiteLionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl0" xml:lang="en-US">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl2" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0" xml:lang="en-US">Prepayment Fees on Advances, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Domestic, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAccountsReceivableNetAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAccountsReceivableNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAccountsReceivableNetAbstract_lbl" xml:lang="en-US">Schedule Of Accounts Receivable Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAccountsReceivableNetAbstract" xlink:to="nivf_ScheduleOfAccountsReceivableNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CashConsideration_lbl1" xml:lang="en-US">Cash Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CashConsideration" xlink:to="nivf_CashConsideration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OSLGroupMember_lbl0" xml:lang="en-US">OSLGroup Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OSLGroupMember" xlink:to="nivf_OSLGroupMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MotorVehiclesMember_lbl0" xml:lang="en-US">Motor Vehicles Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MotorVehiclesMember" xlink:to="nivf_MotorVehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementAndServiceFeesRate_lbl0" xml:lang="en-US">Management and Service Fees, Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementAndServiceFeesRate" xlink:to="us-gaap_ManagementAndServiceFeesRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_convertiblePromissoryNoteDiscountPercentage_lbl1" xml:lang="en-US">convertible Promissory Note Discount Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_convertiblePromissoryNoteDiscountPercentage" xlink:to="nivf_convertiblePromissoryNoteDiscountPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment_lbl0" xml:lang="en-US">Line of Credit Facility, Periodic Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AmortisationOfShareBasedCompensationExpense_lbl1" xml:lang="en-US">Amortisation Of Share Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AmortisationOfShareBasedCompensationExpense" xlink:to="nivf_AmortisationOfShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl0" xml:lang="en-US">Contractual Obligation, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_TH_lbl0" xml:lang="en-US">THAILAND</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_TH" xlink:to="country_TH_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl0" xml:lang="en-US">Deposits Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_FreeStandingInstrumentsWarrantsMember_lbl0" xml:lang="en-US">Free Standing Instruments Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FreeStandingInstrumentsWarrantsMember" xlink:to="nivf_FreeStandingInstrumentsWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl0" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl1" xml:lang="en-US">Deposits Prepayment Other Receivables And Deferred IPOCost Net Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SeriesBWarrantMember_lbl0" xml:lang="en-US">Series BWarrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeriesBWarrantMember" xlink:to="nivf_SeriesBWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl0" xml:lang="en-US">Workers&apos; Compensation Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SeriesAWarrantMember_lbl0" xml:lang="en-US">Series AWarrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeriesAWarrantMember" xlink:to="nivf_SeriesAWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl0" xml:lang="en-US">Deferred Costs, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OtherPrepaidExpenseNonCurrent_lbl1" xml:lang="en-US">Other Prepaid Expense Non Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherPrepaidExpenseNonCurrent" xlink:to="nivf_OtherPrepaidExpenseNonCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl1" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WhiteLionCapitalLLCMember_lbl0" xml:lang="en-US">White Lion Capital LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WhiteLionCapitalLLCMember" xlink:to="nivf_WhiteLionCapitalLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl0" xml:lang="en-US">Deposit Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl0" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MovementOfAllowancesMember_lbl0" xml:lang="en-US">Movement Of Allowances Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MovementOfAllowancesMember" xlink:to="nivf_MovementOfAllowancesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule Of Consolidated Financial Statements Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract_lbl" xml:lang="en-US">Schedule Of Movement Of Allowances For Expected Credit Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_UnsecuredPromissoryNotesMember_lbl0" xml:lang="en-US">Unsecured Promissory Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_UnsecuredPromissoryNotesMember" xlink:to="nivf_UnsecuredPromissoryNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ASPACIMember_lbl0" xml:lang="en-US">ASPACIMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ASPACIMember" xlink:to="nivf_ASPACIMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems_lbl0" xml:lang="en-US">Deposits Prepayment Other Receivablesand Deferred IPOCost Net Scheduleof Movementof Allowancesfor Expected Credit Loss Details Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:to="nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_HarcourtLimitedMember_lbl0" xml:lang="en-US">Harcourt Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HarcourtLimitedMember" xlink:to="nivf_HarcourtLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProfitTaxDescription_lbl1" xml:lang="en-US">Profit Tax Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProfitTaxDescription" xlink:to="nivf_ProfitTaxDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NewGenIvfLimitedMember_lbl0" xml:lang="en-US">New Gen Ivf Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NewGenIvfLimitedMember" xlink:to="nivf_NewGenIvfLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Subscriptions Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SuppliersTwoMember_lbl0" xml:lang="en-US">Suppliers Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SuppliersTwoMember" xlink:to="nivf_SuppliersTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_GeneticsIVFInstituteIncMember_lbl0" xml:lang="en-US">Genetics IVFInstitute Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_GeneticsIVFInstituteIncMember" xlink:to="nivf_GeneticsIVFInstituteIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl0" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_BiClinicLtdFFBiMember_lbl0" xml:lang="en-US">Bi Clinic Ltd FFBi Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BiClinicLtdFFBiMember" xlink:to="nivf_BiClinicLtdFFBiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfPromissoryNotesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfPromissoryNotesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfPromissoryNotesAbstract_lbl" xml:lang="en-US">Schedule Of Promissory Notes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfPromissoryNotesAbstract" xlink:to="nivf_ScheduleOfPromissoryNotesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MrSiuWingFungAlfredMember_lbl0" xml:lang="en-US">Mr Siu Wing Fung Alfred Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MrSiuWingFungAlfredMember" xlink:to="nivf_MrSiuWingFungAlfredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AllowancesForExpectedCreditLoss_lbl2" xml:lang="en-US">Allowances For Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLoss" xlink:to="nivf_AllowancesForExpectedCreditLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_HKSARMember_lbl0" xml:lang="en-US">HKSARMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HKSARMember" xlink:to="nivf_HKSARMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl0" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Other Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl0" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl0" xml:lang="en-US">Contractual Obligation, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl0" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl0" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EWIHLMember_lbl0" xml:lang="en-US">EWIHLMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EWIHLMember" xlink:to="nivf_EWIHLMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl0" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ServicesRanging_lbl1" xml:lang="en-US">Services Ranging</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ServicesRanging" xlink:to="nivf_ServicesRanging_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SeniorConvertibleNotesMember_lbl0" xml:lang="en-US">Senior Convertible Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeniorConvertibleNotesMember" xlink:to="nivf_SeniorConvertibleNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AtCostAbstract_lbl0" xml:lang="en-US">At Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AtCostAbstract" xlink:to="nivf_AtCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract_lbl0" xml:lang="en-US">The Convertible Notes Are Repayable As Follows Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract" xlink:to="nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl1" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SuppliersOneMember_lbl0" xml:lang="en-US">Suppliers One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SuppliersOneMember" xlink:to="nivf_SuppliersOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConsultingServiceTerm_lbl1" xml:lang="en-US">Consulting Service Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConsultingServiceTerm" xlink:to="nivf_ConsultingServiceTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PeriodAverageMember_lbl0" xml:lang="en-US">Period Average Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PeriodAverageMember" xlink:to="nivf_PeriodAverageMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract_lbl0" xml:lang="en-US">Convertible Notes At Amortised Cost Are As Follows Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract" xlink:to="nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_Deposit_lbl1" xml:lang="en-US">Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_Deposit" xlink:to="nivf_Deposit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl1" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockHeldBySubsidiary_lbl0" xml:lang="en-US">Common Stock Held by Subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockHeldBySubsidiary" xlink:to="us-gaap_CommonStockHeldBySubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl0" xml:lang="en-US">Contractual Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl0" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl0" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Estimated Useful Lives Of The Plan And Equipment Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" xlink:to="nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AccountsReceivableAfterAllowanceForCreditLoss_lbl1" xml:lang="en-US">Accounts Receivable After Allowance For Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableAfterAllowanceForCreditLoss" xlink:to="nivf_AccountsReceivableAfterAllowanceForCreditLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl0" xml:lang="en-US">Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SpecialAssessmentBond_lbl0" xml:lang="en-US">Special Assessment Bond</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SpecialAssessmentBond" xlink:to="us-gaap_SpecialAssessmentBond_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfPlantAndEquipmentNetAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Plant And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfPlantAndEquipmentNetAbstract" xlink:to="nivf_ScheduleOfPlantAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl2" xml:lang="en-US">Business Combination, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Reclassifications_lbl0" xml:lang="en-US">Reclassifications [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl0" xml:lang="en-US">Investment Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl0" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl1" xml:lang="en-US">Common Stock, No Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl0" xml:lang="en-US">Short-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleInstrumentsPolicyTextBlock_lbl1" xml:lang="en-US">Convertible Instruments Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleInstrumentsPolicyTextBlock" xlink:to="nivf_ConvertibleInstrumentsPolicyTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl0" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SecuritiesPurchaseAgreementMember_lbl0" xml:lang="en-US">Securities Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SecuritiesPurchaseAgreementMember" xlink:to="nivf_SecuritiesPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleBondsAbstract_lbl0" xml:lang="en-US">Convertible Bonds Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleBondsAbstract" xlink:to="nivf_ConvertibleBondsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Additional Paidin Capital Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:to="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PeriodEndMember_lbl0" xml:lang="en-US">Period End Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PeriodEndMember" xlink:to="nivf_PeriodEndMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ReverseCapitalization_lbl1" xml:lang="en-US">Reverse Capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ReverseCapitalization" xlink:to="nivf_ReverseCapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember_lbl0" xml:lang="en-US">Directors Remuneration To Ms Fong Hei Yue Tina Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:to="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl1" xml:lang="en-US">Percentage Of Allowance On Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:to="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl0" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CashInBank_lbl1" xml:lang="en-US">Cash In Bank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CashInBank" xlink:to="nivf_CashInBank_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WaiverOfLiability_lbl1" xml:lang="en-US">Waiver Of Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfLiability" xlink:to="nivf_WaiverOfLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl0" xml:lang="en-US">Repayments of Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember_lbl0" xml:lang="en-US">Shenzhen Qianhai Fengtai Renhui Health Technology Co Ltd SZQian Hai Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember" xlink:to="nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl1" xml:lang="en-US">Allowances For Expected Credit Loss Reversal Of Provision Provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:to="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl1" xml:lang="en-US">Stock Issued During Period Value Settlement Of Subscription Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Finance Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations_lbl0" xml:lang="en-US">Increase (Decrease) in Obligation, Pension Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:to="us-gaap_IncreaseDecreaseInPensionPlanObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_FirstFertilityPhnomPenhLimitedFFPPMember_lbl0" xml:lang="en-US">First Fertility Phnom Penh Limited FFPPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" xlink:to="nivf_FirstFertilityPhnomPenhLimitedFFPPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember_lbl0" xml:lang="en-US">Convertible Promissory Note Was Converted Into Ordinary Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember" xlink:to="nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DoubleClickServicesLimitedMember_lbl0" xml:lang="en-US">Double Click Services Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DoubleClickServicesLimitedMember" xlink:to="nivf_DoubleClickServicesLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PercentageOfConversionExceeds_lbl1" xml:lang="en-US">Percentage Of Conversion Exceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PercentageOfConversionExceeds" xlink:to="nivf_PercentageOfConversionExceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProfessionalPartyMember_lbl0" xml:lang="en-US">Professional Party Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProfessionalPartyMember" xlink:to="nivf_ProfessionalPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestCostsCapitalized_lbl0" xml:lang="en-US">Interest Costs Capitalized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsCapitalized" xlink:to="us-gaap_InterestCostsCapitalized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl0" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl0" xml:lang="en-US">Other Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DebtInstrumentCouponRatePercentage_lbl1" xml:lang="en-US">Debt Instrument Coupon Rate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DebtInstrumentCouponRatePercentage" xlink:to="nivf_DebtInstrumentCouponRatePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember_lbl0" xml:lang="en-US">Waiver Of Related Party Balance Of Mr Siu Wing Fung Alfred Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:to="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_BiClinicLtdMember_lbl0" xml:lang="en-US">Bi Clinic Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BiClinicLtdMember" xlink:to="nivf_BiClinicLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl3" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl0" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_BestLendingRateMember_lbl0" xml:lang="en-US">Best Lending Rate Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BestLendingRateMember" xlink:to="nivf_BestLendingRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CustomerTwoMember_lbl0" xml:lang="en-US">Customer Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CustomerTwoMember" xlink:to="nivf_CustomerTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl0" xml:lang="en-US">Investment Income, Investment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CommonStockPotentialValue_lbl1" xml:lang="en-US">Common Stock Potential Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CommonStockPotentialValue" xlink:to="nivf_CommonStockPotentialValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl0" xml:lang="en-US">Notes Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfOutstandingConvertibleNotesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfOutstandingConvertibleNotesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfOutstandingConvertibleNotesAbstract_lbl" xml:lang="en-US">Schedule Of Outstanding Convertible Notes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfOutstandingConvertibleNotesAbstract" xlink:to="nivf_ScheduleOfOutstandingConvertibleNotesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl2" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl0" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule Of Currency Exchange Rates That Were Used In Preparing The Accompanying Consolidated Financial Statements Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:to="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl0" xml:lang="en-US">Common Stock, Voting Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract_lbl0" xml:lang="en-US">Due From Shareholders Consist Of The Following Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" xlink:to="nivf_DueFromShareholdersConsistOfTheFollowingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl1" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule Of The Provisions For Income Taxes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:to="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl0" xml:lang="en-US">Postemployment Benefit Plans, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NonCurrentAbstract_lbl0" xml:lang="en-US">Non Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonCurrentAbstract" xlink:to="nivf_NonCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_FirstFertilityBishkekLLCFFBMember_lbl0" xml:lang="en-US">First Fertility Bishkek LLCFFBMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityBishkekLLCFFBMember" xlink:to="nivf_FirstFertilityBishkekLLCFFBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueFromtoshareholdersRelatedParty_lbl1" xml:lang="en-US">Due Fromtoshareholders Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromtoshareholdersRelatedParty" xlink:to="nivf_DueFromtoshareholdersRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl0" xml:lang="en-US">CHINA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember_lbl0" xml:lang="en-US">Conversion Of Convertible Note To Shares To JAKOpportunities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember" xlink:to="nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedAmortizationDeferredFinanceCosts_lbl0" xml:lang="en-US">Accumulated Amortization, Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="us-gaap_AccumulatedAmortizationDeferredFinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl1" xml:lang="en-US">Schedule Of The Balance Due From Shareholders Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:to="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProceedsFromAmountDueFromASPACI_lbl1" xml:lang="en-US">Proceeds From Amount Due From ASPACI</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProceedsFromAmountDueFromASPACI" xlink:to="nivf_ProceedsFromAmountDueFromASPACI_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerRefundLiability_lbl0" xml:lang="en-US">Contract with Customer, Refund Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiability" xlink:to="us-gaap_ContractWithCustomerRefundLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CNY_lbl0" xml:lang="en-US">China, Yuan Renminbi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CNY" xlink:to="currency_CNY_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CurrentTaxProvisionCambodiaMember_lbl0" xml:lang="en-US">Current Tax Provision Cambodia Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentTaxProvisionCambodiaMember" xlink:to="nivf_CurrentTaxProvisionCambodiaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_IndicativeRateOfBorrowingCost_lbl1" xml:lang="en-US">Indicative Rate Of Borrowing Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IndicativeRateOfBorrowingCost" xlink:to="nivf_IndicativeRateOfBorrowingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl0" xml:lang="en-US">Gain (Loss) on Termination of Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PensionSchemeMember_lbl0" xml:lang="en-US">Pension Scheme Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PensionSchemeMember" xlink:to="nivf_PensionSchemeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl2" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Transaction Costs On Issuance Of Notes Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" xlink:to="nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_StockIssuedDuringPeriodValueReverseCaptialization_lbl1" xml:lang="en-US">Stock Issued During Period Value Reverse Captialization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueReverseCaptialization" xlink:to="nivf_StockIssuedDuringPeriodValueReverseCaptialization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueFromShareholders_lbl1" xml:lang="en-US">Due From Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholders" xlink:to="nivf_DueFromShareholders_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleNotesMember_lbl0" xml:lang="en-US">Convertible Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNotesMember" xlink:to="nivf_ConvertibleNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_COVIRIXMember_lbl0" xml:lang="en-US">COVIRIXMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_COVIRIXMember" xlink:to="nivf_COVIRIXMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfCompanySSubsidiariesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfCompanySSubsidiariesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfCompanySSubsidiariesAbstract_lbl" xml:lang="en-US">Schedule Of Company SSubsidiaries Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfCompanySSubsidiariesAbstract" xlink:to="nivf_ScheduleOfCompanySSubsidiariesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MedHoldingsLimitedMedHoldingsMember_lbl0" xml:lang="en-US">Med Holdings Limited Med Holdings Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedHoldingsLimitedMedHoldingsMember" xlink:to="nivf_MedHoldingsLimitedMedHoldingsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfBusinessOperationsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfBusinessOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfBusinessOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Business Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfBusinessOperationsAbstract" xlink:to="nivf_ScheduleOfBusinessOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_TerminationClauses_lbl1" xml:lang="en-US">Termination Clauses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TerminationClauses" xlink:to="nivf_TerminationClauses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAdditionalPaidInCapitalAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAdditionalPaidInCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAdditionalPaidInCapitalAbstract_lbl" xml:lang="en-US">Schedule Of Additional Paid In Capital Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAdditionalPaidInCapitalAbstract" xlink:to="nivf_ScheduleOfAdditionalPaidInCapitalAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAdditionalCapital_lbl0" xml:lang="en-US">Other Additional Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAdditionalCapital" xlink:to="us-gaap_OtherAdditionalCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-Term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfGeographicalInformationAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfGeographicalInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfGeographicalInformationAbstract_lbl" xml:lang="en-US">Schedule Of Geographical Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfGeographicalInformationAbstract" xlink:to="nivf_ScheduleOfGeographicalInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NewGenivfLimitedMember_lbl0" xml:lang="en-US">New Genivf Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NewGenivfLimitedMember" xlink:to="nivf_NewGenivfLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl1" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl1" xml:lang="en-US">Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PaymentofInterest_lbl1" xml:lang="en-US">Paymentof Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PaymentofInterest" xlink:to="nivf_PaymentofInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RevenueRate_lbl1" xml:lang="en-US">Revenue Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueRate" xlink:to="nivf_RevenueRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl0" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MaturityTerm_lbl1" xml:lang="en-US">Maturity Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MaturityTerm" xlink:to="nivf_MaturityTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0" xml:lang="en-US">Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl0" xml:lang="en-US">Other Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl2" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_FirstFertilityPGSCenterLimitedFFCMember_lbl0" xml:lang="en-US">First Fertility PGSCenter Limited FFCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityPGSCenterLimitedFFCMember" xlink:to="nivf_FirstFertilityPGSCenterLimitedFFCMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfRevenueInformationBasedOnTheLocationsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfRevenueInformationBasedOnTheLocationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfRevenueInformationBasedOnTheLocationsAbstract_lbl" xml:lang="en-US">Schedule Of Revenue Information Based On The Locations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfRevenueInformationBasedOnTheLocationsAbstract" xlink:to="nivf_ScheduleOfRevenueInformationBasedOnTheLocationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NetTangibleAssets_lbl1" xml:lang="en-US">Net Tangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NetTangibleAssets" xlink:to="nivf_NetTangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl2" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_HealthCareSchemeMember_lbl0" xml:lang="en-US">Health Care Scheme Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HealthCareSchemeMember" xlink:to="nivf_HealthCareSchemeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl1" xml:lang="en-US">Common Class A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueToARelatedParty_lbl1" xml:lang="en-US">Due To ARelated Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToARelatedParty" xlink:to="nivf_DueToARelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OutstandingPercentage_lbl1" xml:lang="en-US">Outstanding Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OutstandingPercentage" xlink:to="nivf_OutstandingPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuanceDate1_lbl0" xml:lang="en-US">Debt Instrument, Issuance Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuanceDate1" xlink:to="us-gaap_DebtInstrumentIssuanceDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CurrentAbstract_lbl0" xml:lang="en-US">Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentAbstract" xlink:to="nivf_CurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl0" xml:lang="en-US">Investment Owned, Balance, Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_IVFTreatmentServiceMember_lbl0" xml:lang="en-US">IVFTreatment Service Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IVFTreatmentServiceMember" xlink:to="nivf_IVFTreatmentServiceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SurrogacyAncillaryCaringAndOtherServicesMember_lbl0" xml:lang="en-US">Surrogacy Ancillary Caring And Other Services Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" xlink:to="nivf_SurrogacyAncillaryCaringAndOtherServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SecondAdditionalMandatoryNoteMember_lbl0" xml:lang="en-US">Second Additional Mandatory Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SecondAdditionalMandatoryNoteMember" xlink:to="nivf_SecondAdditionalMandatoryNoteMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense, Operating and Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MergerActivityDrawn_lbl1" xml:lang="en-US">Merger Activity Drawn</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MergerActivityDrawn" xlink:to="nivf_MergerActivityDrawn_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AdditionalNotesMember_lbl0" xml:lang="en-US">Additional Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AdditionalNotesMember" xlink:to="nivf_AdditionalNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Reversal Of Excess Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" xlink:to="nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WaiverOfRelatedPartyBalance_lbl2" xml:lang="en-US">Waiver Of Related Party Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalance" xlink:to="nivf_WaiverOfRelatedPartyBalance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_IndependentDirectorFeePayable_lbl1" xml:lang="en-US">Independent Director Fee Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IndependentDirectorFeePayable" xlink:to="nivf_IndependentDirectorFeePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PromissoryNotesPolicyTextBlock_lbl1" xml:lang="en-US">Promissory Notes Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PromissoryNotesPolicyTextBlock" xlink:to="nivf_PromissoryNotesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WellImageLimitedMember_lbl0" xml:lang="en-US">Well Image Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WellImageLimitedMember" xlink:to="nivf_WellImageLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyCommittedCapital_lbl0" xml:lang="en-US">Investment Company, Committed Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyCommittedCapital" xlink:to="us-gaap_InvestmentCompanyCommittedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl0" xml:lang="en-US">Other Receivables, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Movement Allowances For Expected Credit Loss Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract_lbl" xml:lang="en-US">Schedule Of Accounts Receivable Net Of Allowance For Expected Credit Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:to="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SecondAdditionalNoteMember_lbl0" xml:lang="en-US">Second Additional Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SecondAdditionalNoteMember" xlink:to="nivf_SecondAdditionalNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_JAKOPPORTUNITIESVILLCMember_lbl0" xml:lang="en-US">JAKOPPORTUNITIESVILLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKOPPORTUNITIESVILLCMember" xlink:to="nivf_JAKOPPORTUNITIESVILLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_Within90DaysMember_lbl0" xml:lang="en-US">Within90 Days Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_Within90DaysMember" xlink:to="nivf_Within90DaysMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CurrentTaxProvisionKyrgyzstanMember_lbl0" xml:lang="en-US">Current Tax Provision Kyrgyzstan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentTaxProvisionKyrgyzstanMember" xlink:to="nivf_CurrentTaxProvisionKyrgyzstanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember_lbl0" xml:lang="en-US">Directors Remuneration To Mr Siu Wing Fung Alfred Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:to="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl0" xml:lang="en-US">Accounts and Nontrade Receivable [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MedicalInstrumentsMember_lbl1" xml:lang="en-US">Medical Instruments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedicalInstrumentsMember" xlink:to="nivf_MedicalInstrumentsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AnnualTurnover_lbl1" xml:lang="en-US">Annual Turnover</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AnnualTurnover" xlink:to="nivf_AnnualTurnover_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation Provision For Double Tax Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" xlink:to="nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CustomerDeposit_lbl1" xml:lang="en-US">Customer Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CustomerDeposit" xlink:to="nivf_CustomerDeposit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NonCashDiscountOnConvertibleNotes_lbl1" xml:lang="en-US">Non Cash Discount On Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonCashDiscountOnConvertibleNotes" xlink:to="nivf_NonCashDiscountOnConvertibleNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl0" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Premium Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Movement Of Allowances For Expected Credit Loss Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl0" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals_lbl1" xml:lang="en-US">Decrease In Subscription Receivable Due To Reduction Of Work By Professionals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" xlink:to="nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PromissoryNotesMember_lbl0" xml:lang="en-US">Promissory Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PromissoryNotesMember" xlink:to="nivf_PromissoryNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AggregateAmount_lbl1" xml:lang="en-US">Aggregate Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AggregateAmount" xlink:to="nivf_AggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl0" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl0" xml:lang="en-US">Product Warranty, Liquidation Proceeds, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_FFPGSHKLimitedMember_lbl0" xml:lang="en-US">FFPGSHKLimited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FFPGSHKLimitedMember" xlink:to="nivf_FFPGSHKLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NonControllingInterestsPolicyTextBlock_lbl1" xml:lang="en-US">Non Controlling Interests Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonControllingInterestsPolicyTextBlock" xlink:to="nivf_NonControllingInterestsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl0" xml:lang="en-US">Two Thousand Twenty Five Securities Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:to="nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_LoanToASPAC_lbl1" xml:lang="en-US">Loan To ASPAC</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LoanToASPAC" xlink:to="nivf_LoanToASPAC_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_BidPricePerShare_lbl1" xml:lang="en-US">Bid Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_BidPricePerShare" xlink:to="nivf_BidPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Shares Through Equity Line Of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" xlink:to="nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_JAKAffiliatedHoldersTwoMember_lbl0" xml:lang="en-US">JAKAffiliated Holders Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKAffiliatedHoldersTwoMember" xlink:to="nivf_JAKAffiliatedHoldersTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Amount Due From And Due To Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:to="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_THB_lbl0" xml:lang="en-US">Thailand, Baht</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_THB" xlink:to="currency_THB_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl1" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_JAKOpportunitiesVILLCJAKMember_lbl0" xml:lang="en-US">JAKOpportunities VILLCJAKMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKOpportunitiesVILLCJAKMember" xlink:to="nivf_JAKOpportunitiesVILLCJAKMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfPromissoryNotesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Promissory Notes Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfPromissoryNotesTableTextBlock" xlink:to="nivf_ScheduleOfPromissoryNotesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl2" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CustomerMember_lbl0" xml:lang="en-US">Customer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CustomerMember" xlink:to="nivf_CustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WhiteLionPurchaseAgreementMember_lbl0" xml:lang="en-US">White Lion Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WhiteLionPurchaseAgreementMember" xlink:to="nivf_WhiteLionPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OccupationalRiskSchemeMember_lbl0" xml:lang="en-US">Occupational Risk Scheme Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OccupationalRiskSchemeMember" xlink:to="nivf_OccupationalRiskSchemeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember_lbl0" xml:lang="en-US">Over Provision Of Tax In Prior Year Kyrgyzstan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember" xlink:to="nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_GainOnPromissoryNote_lbl1" xml:lang="en-US">Gain On Promissory Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_GainOnPromissoryNote" xlink:to="nivf_GainOnPromissoryNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SeniorConvertibleNoteMember_lbl0" xml:lang="en-US">Senior Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeniorConvertibleNoteMember" xlink:to="nivf_SeniorConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl0" xml:lang="en-US">Debt Issuance Costs, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ConvertibleNoteMember_lbl0" xml:lang="en-US">Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ConvertibleNoteMember" xlink:to="nivf_ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl0" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DeemedExcessTaxPayable_lbl1" xml:lang="en-US">Deemed Excess Tax Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DeemedExcessTaxPayable" xlink:to="nivf_DeemedExcessTaxPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MsFongHeiYueTinaMember_lbl0" xml:lang="en-US">Ms Fong Hei Yue Tina Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MsFongHeiYueTinaMember" xlink:to="nivf_MsFongHeiYueTinaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NewGenMember_lbl0" xml:lang="en-US">New Gen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NewGenMember" xlink:to="nivf_NewGenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl0" xml:lang="en-US">Contractual Obligation, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_JAKAffiliatedHoldersOneMember_lbl0" xml:lang="en-US">JAKAffiliated Holders One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKAffiliatedHoldersOneMember" xlink:to="nivf_JAKAffiliatedHoldersOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract_lbl0" xml:lang="en-US">Due To ARelated Party Consist Of The Following Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract" xlink:to="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl0" xml:lang="en-US">Receivables from Stockholder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl0" xml:lang="en-US">Provision for Other Credit Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MAMember_lbl0" xml:lang="en-US">MAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MAMember" xlink:to="nivf_MAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl0" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0" xml:lang="en-US">Property, Plant and Equipment, Salvage Value, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl1" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityOther_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SubsidiarieMember_lbl0" xml:lang="en-US">Subsidiarie Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubsidiarieMember" xlink:to="nivf_SubsidiarieMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl2" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_JAKAffiliatedHoldersMember_lbl0" xml:lang="en-US">JAKAffiliated Holders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_JAKAffiliatedHoldersMember" xlink:to="nivf_JAKAffiliatedHoldersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KH_lbl0" xml:lang="en-US">CAMBODIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KH" xlink:to="country_KH_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KG_lbl0" xml:lang="en-US">KYRGYZSTAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KG" xlink:to="country_KG_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl0" xml:lang="en-US">Proceeds from Other Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0" xml:lang="en-US">Short-Term Debt, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>nivf-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 01 09:22:09 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedBalanceSheet" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedIncomeStatement" roleURI="http://www.newgenivf.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ShareholdersEquityType2or3" roleURI="http://www.newgenivf.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConsolidatedCashFlow" roleURI="http://www.newgenivf.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_OrganizationandPrincipalActivities" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivities"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_GoingConcern" roleURI="http://www.newgenivf.com/role/GoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccountsReceivableNet" roleURI="http://www.newgenivf.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_Inventories" roleURI="http://www.newgenivf.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_PropertyandEquipmentNet" roleURI="http://www.newgenivf.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccruedLiabiltiesandOtherPayables" roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ContractLiabilities" roleURI="http://www.newgenivf.com/role/ContractLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants" roleURI="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_Leases" roleURI="http://www.newgenivf.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_Equity" roleURI="http://www.newgenivf.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_EmployeeBenefitPlans" roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ProvisionforIncomeTaxes" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DisaggregatedRevenues" roleURI="http://www.newgenivf.com/role/DisaggregatedRevenues"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_Risks" roleURI="http://www.newgenivf.com/role/Risks"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_RelatedPartyBalancesandTransactions" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_LoantoaSPACI" roleURI="http://www.newgenivf.com/role/LoantoaSPACI"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_CommitmentsContingencies" roleURI="http://www.newgenivf.com/role/CommitmentsContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DisposalofSubsidiary" roleURI="http://www.newgenivf.com/role/DisposalofSubsidiary"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_BusinessAcquisition" roleURI="http://www.newgenivf.com/role/BusinessAcquisition"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SubsequentEvents" roleURI="http://www.newgenivf.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ReclassificationandComparativeFigures" roleURI="http://www.newgenivf.com/role/ReclassificationandComparativeFigures"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccountingPoliciesByPolicy" roleURI="http://www.newgenivf.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_OrganizationandPrincipalActivitiesTables" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccountsReceivableNetTables" roleURI="http://www.newgenivf.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_InventoriesTables" roleURI="http://www.newgenivf.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_PropertyandEquipmentNetTables" roleURI="http://www.newgenivf.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_AccruedLiabiltiesandOtherPayablesTables" roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ContractLiabilitiesTables" roleURI="http://www.newgenivf.com/role/ContractLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables" roleURI="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_LeasesTables" roleURI="http://www.newgenivf.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_EquityTables" roleURI="http://www.newgenivf.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ProvisionforIncomeTaxesTables" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DisaggregatedRevenuesTables" roleURI="http://www.newgenivf.com/role/DisaggregatedRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_RelatedPartyBalancesandTransactionsTables" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofCompanysSubsidiariesTable" roleURI="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" roleURI="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAccountsReceivableNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofMovementAllowancesforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofInventoriesTable" roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofPlantandEquipmentNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAccruedLiabiltiesandOtherPayablesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofContractLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofConvertibleNotesTable" roleURI="http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofOutstandingConvertibleNotesTable" roleURI="http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofTransactionCostsonIssuanceofNotesTable" roleURI="http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofContractualObligationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofContractualObligationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofPromissoryNotesTable" roleURI="http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofLeaseLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAdditionalPaidinCapitalTable" roleURI="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleoftheProvisionsforIncomeTaxesTable" roleURI="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofIncomeTaxesTable" roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable" roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofBusinessOperationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofGeographicalInformationTable" roleURI="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofRevenueInformationBasedontheLocationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofAmountDuefromandDuetoRelatedPartiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofBalanceDuefromShareholdersTable" roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable0" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ScheduleofConsolidatedFinancialStatementsTable" roleURI="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_OrganizationandPrincipalActivitiesDetails" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_GoingConcernDetails" roleURI="http://www.newgenivf.com/role/GoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_PropertyandEquipmentNetDetails" roleURI="http://www.newgenivf.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails" roleURI="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_LeasesDetails" roleURI="http://www.newgenivf.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_EquityDetails" roleURI="http://www.newgenivf.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_EmployeeBenefitPlansDetails" roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_ProvisionforIncomeTaxesDetails" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_RisksDetails" roleURI="http://www.newgenivf.com/role/RisksDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_RelatedPartyBalancesandTransactionsDetails" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_LoantoaSPACIDetails" roleURI="http://www.newgenivf.com/role/LoantoaSPACIDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_DisposalofSubsidiaryDetails" roleURI="http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_BusinessAcquisitionDetails" roleURI="http://www.newgenivf.com/role/BusinessAcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#nivf_r_SubsequentEventsDetails" roleURI="http://www.newgenivf.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20241231.xsd#DocumentAndEntityInformation" roleURI="http://www.newgenivf.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivableFromAgents" xlink:href="nivf-20241231.xsd#nivf_ReceivableFromAgents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="ReceivableFromAgents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanToASPAC" xlink:href="nivf-20241231.xsd#nivf_LoanToASPAC"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="LoanToASPAC" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueFromShareholders" xlink:href="nivf-20241231.xsd#nivf_DueFromShareholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="DueFromShareholders" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherNotesPayableCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_CostOfRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_GrossProfit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="7.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueReverseCaptialization" xlink:href="nivf-20241231.xsd#nivf_StockIssuedDuringPeriodValueReverseCaptialization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueReverseCaptialization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20241231.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="AmortisationOfShareBasedCompensationExpense" xlink:href="nivf-20241231.xsd#nivf_AmortisationOfShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortisationOfShareBasedCompensationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCashDiscountOnConvertibleNotes" xlink:href="nivf-20241231.xsd#nivf_NonCashDiscountOnConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NonCashDiscountOnConvertibleNotes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WaiverOfRelatedPartyBalance" xlink:href="nivf-20241231.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="WaiverOfRelatedPartyBalance" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnPromissoryNote" xlink:href="nivf-20241231.xsd#nivf_GainOnPromissoryNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainOnPromissoryNote" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LegalFees" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInFinanceReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromAmountDueFromASPACI" xlink:href="nivf-20241231.xsd#nivf_ProceedsFromAmountDueFromASPACI"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromAmountDueFromASPACI" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentofInterest" xlink:href="nivf-20241231.xsd#nivf_PaymentofInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentofInterest" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivable" xlink:href="nivf-20241231.xsd#nivf_SubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="SubscriptionReceivable" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/GoingConcern" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="GoingConcernAbstract" xlink:href="nivf-20241231.xsd#nivf_GoingConcernAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccountsReceivableNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/Inventories" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ContractLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DisaggregatedRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/Risks" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/LoantoaSPACI" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/CommitmentsContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DisposalofSubsidiary" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisposalOfSubsidiaryAbstract" xlink:href="nivf-20241231.xsd#nivf_DisposalOfSubsidiaryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisposalOfSubsidiaryTextBlock" xlink:href="nivf-20241231.xsd#nivf_DisposalOfSubsidiaryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalOfSubsidiaryAbstract" xlink:to="DisposalOfSubsidiaryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/BusinessAcquisition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ReclassificationandComparativeFigures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Reclassifications" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Reclassifications"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_Reclassifications" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleInstrumentsPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_ConvertibleInstrumentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConvertibleInstrumentsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNotesPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_PromissoryNotesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PromissoryNotesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_RelatedPartiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RelatedPartiesPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonControllingInterestsPolicyTextBlock" xlink:href="nivf-20241231.xsd#nivf_NonControllingInterestsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NonControllingInterestsPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccountsReceivableNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/InventoriesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ContractLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPromissoryNotesTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfPromissoryNotesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="ScheduleOfPromissoryNotesTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ScheduleOfAdditionalPaidinCapitalTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DisaggregatedRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySSubsidiariesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfCompanySSubsidiariesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySSubsidiariesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NewGenivfLimitedMember" xlink:href="nivf-20241231.xsd#nivf_NewGenivfLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="NewGenivfLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FFPGSHKLimitedMember" xlink:href="nivf-20241231.xsd#nivf_FFPGSHKLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FFPGSHKLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellImageLimitedMember" xlink:href="nivf-20241231.xsd#nivf_WellImageLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="WellImageLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedHoldingsLimitedMedHoldingsMember" xlink:href="nivf-20241231.xsd#nivf_MedHoldingsLimitedMedHoldingsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="MedHoldingsLimitedMedHoldingsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstFertilityPGSCenterLimitedFFCMember" xlink:href="nivf-20241231.xsd#nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FirstFertilityPGSCenterLimitedFFCMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstFertilityPhnomPenhLimitedFFPPMember" xlink:href="nivf-20241231.xsd#nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FirstFertilityPhnomPenhLimitedFFPPMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BiClinicLtdFFBiMember" xlink:href="nivf-20241231.xsd#nivf_BiClinicLtdFFBiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="BiClinicLtdFFBiMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember" xlink:href="nivf-20241231.xsd#nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntercompanyForeignCurrencyBalanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PeriodEndMember" xlink:href="nivf-20241231.xsd#nivf_PeriodEndMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="PeriodEndMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PeriodAverageMember" xlink:href="nivf-20241231.xsd#nivf_PeriodAverageMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="PeriodAverageMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" xlink:to="srt_CurrencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_HKD" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_THB" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_THB"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_THB" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_CNY" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableNetAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:to="AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="Within90DaysMember" xlink:href="nivf-20241231.xsd#nivf_Within90DaysMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="Within90DaysMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" xlink:to="AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MovementOfAllowancesMember" xlink:href="nivf-20241231.xsd#nivf_MovementOfAllowancesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="MovementOfAllowancesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofInventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="CurrentAbstract" xlink:href="nivf-20241231.xsd#nivf_CurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="CurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Deposit" xlink:href="nivf-20241231.xsd#nivf_Deposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="Deposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivableFromAgents" xlink:href="nivf-20241231.xsd#nivf_ReceivableFromAgents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="ReceivableFromAgents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCurrentAbstract" xlink:href="nivf-20241231.xsd#nivf_NonCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="NonCurrentAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherPrepaidExpenseNonCurrent" xlink:href="nivf-20241231.xsd#nivf_OtherPrepaidExpenseNonCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAbstract" xlink:to="OtherPrepaidExpenseNonCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable"/>
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable" xlink:to="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLoss" xlink:href="nivf-20241231.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:to="AllowancesForExpectedCreditLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:href="nivf-20241231.xsd#nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:to="AllowancesForExpectedCreditLossReversalOfProvisionProvision" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLoss_0" xlink:href="nivf-20241231.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems" xlink:to="AllowancesForExpectedCreditLoss_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPlantAndEquipmentNetAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalInstrumentsMember" xlink:href="nivf-20241231.xsd#nivf_MedicalInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MedicalInstrumentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerDeposit" xlink:href="nivf-20241231.xsd#nivf_CustomerDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="CustomerDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IndependentDirectorFeePayable" xlink:href="nivf-20241231.xsd#nivf_IndependentDirectorFeePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="IndependentDirectorFeePayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerRefundLiability" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertibleNotesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfConvertibleNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleNotesAbstract" xlink:to="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable" xlink:to="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract" xlink:to="us-gaap_DeferredFinanceCostsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract" xlink:to="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="TheConvertibleNotesAreRepayableAsFollowsAbstract" xlink:href="nivf-20241231.xsd#nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems" xlink:to="TheConvertibleNotesAreRepayableAsFollowsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheConvertibleNotesAreRepayableAsFollowsAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheConvertibleNotesAreRepayableAsFollowsAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheConvertibleNotesAreRepayableAsFollowsAbstract" xlink:to="us-gaap_ConvertibleNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingConvertibleNotesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfOutstandingConvertibleNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingConvertibleNotesAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesMember" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNotesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JAKAffiliatedHoldersMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JAKAffiliatedHoldersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JAKAffiliatedHoldersOneMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JAKAffiliatedHoldersOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JAKAffiliatedHoldersTwoMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JAKAffiliatedHoldersTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JAKAffiliatedHoldersThreeMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JAKAffiliatedHoldersThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentCouponRatePercentage" xlink:href="nivf-20241231.xsd#nivf_DebtInstrumentCouponRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentCouponRatePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:to="us-gaap_InterestCostsCapitalized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofContractualObligationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfContractualObligationsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfContractualObligationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInFourthYear" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfContractualObligationsAbstract" xlink:to="us-gaap_ContractualObligationDueInFifthYear" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPromissoryNotesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfPromissoryNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPromissoryNotesAbstract" xlink:to="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PromissoryNotesMember" xlink:href="nivf-20241231.xsd#nivf_PromissoryNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNotesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable" xlink:to="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:to="us-gaap_NotesIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WaiverOfLiability" xlink:href="nivf-20241231.xsd#nivf_WaiverOfLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:to="WaiverOfLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91Jey1KbBNr08lrF9bNZYdTx/rA/SBVS10LyurQW5OboqYQWmZFkzLw3/d47HSjYGzqO9ETKAZNCuSd9bzJkSVkcGU94k1fhDc4tXQqjibaNNszh6F9ORmGKLPAlHqyPWSx7sNc84Mf0+16i2rCxXhF9wNubAv6aR1RG7s0EacW1eI] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems" xlink:to="us-gaap_NotesPayableCurrent_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalPaidInCapitalAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAdditionalPaidInCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofAdditionalPaidinCapitalDetailsTable" xlink:href="nivf-20241231.xsd#nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalPaidInCapitalAbstract" xlink:to="EquityScheduleofAdditionalPaidinCapitalDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofAdditionalPaidinCapitalDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofAdditionalPaidinCapitalDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdditionalPaidInCapital_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" xlink:href="nivf-20241231.xsd#nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" xlink:href="nivf-20241231.xsd#nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseCapitalization" xlink:href="nivf-20241231.xsd#nivf_ReverseCapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ReverseCapitalization" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ProvisionsForIncomeTaxesLineItems" xlink:href="nivf-20241231.xsd#nivf_ProvisionsForIncomeTaxesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:to="ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CurrentTaxProvisionKyrgyzstanMember" xlink:href="nivf-20241231.xsd#nivf_CurrentTaxProvisionKyrgyzstanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="CurrentTaxProvisionKyrgyzstanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OverProvisionOfTaxInPriorYearKyrgyzstanMember" xlink:href="nivf-20241231.xsd#nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="OverProvisionOfTaxInPriorYearKyrgyzstanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentTaxProvisionCambodiaMember" xlink:href="nivf-20241231.xsd#nivf_CurrentTaxProvisionCambodiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="CurrentTaxProvisionCambodiaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable" xlink:to="ProvisionsForIncomeTaxesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionsForIncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" xlink:href="nivf-20241231.xsd#nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="IncomeTaxReconciliationOverProvisionOfTaxInPriorYear" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBusinessOperationsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfBusinessOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessOperationsAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IVFTreatmentServiceMember" xlink:href="nivf-20241231.xsd#nivf_IVFTreatmentServiceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="IVFTreatmentServiceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SurrogacyAncillaryCaringAndOtherServicesMember" xlink:href="nivf-20241231.xsd#nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="SurrogacyAncillaryCaringAndOtherServicesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfGeographicalInformationAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfGeographicalInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeographicalInformationAbstract" xlink:to="DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KG" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KH" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TH" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueInformationBasedOnTheLocationsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfRevenueInformationBasedOnTheLocationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueInformationBasedOnTheLocationsAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KG" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KH" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TH" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MrSiuWingFungAlfredMember" xlink:href="nivf-20241231.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrSiuWingFungAlfredMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MsFongHeiYueTinaMember" xlink:href="nivf-20241231.xsd#nivf_MsFongHeiYueTinaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MsFongHeiYueTinaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HarcourtLimitedMember" xlink:href="nivf-20241231.xsd#nivf_HarcourtLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HarcourtLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JAKAffiliatedHoldersMember" xlink:href="nivf-20241231.xsd#nivf_JAKAffiliatedHoldersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JAKAffiliatedHoldersMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <loc xlink:type="locator" xlink:label="DueToARelatedParty" xlink:href="nivf-20241231.xsd#nivf_DueToARelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="DueToARelatedParty" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="DueFromtoshareholdersRelatedParty" xlink:href="nivf-20241231.xsd#nivf_DueFromtoshareholdersRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="DueFromtoshareholdersRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableAfterAllowanceForCreditLoss" xlink:href="nivf-20241231.xsd#nivf_AccountsReceivableAfterAllowanceForCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="AccountsReceivableAfterAllowanceForCreditLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20241231.xsd#nivf_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:href="nivf-20241231.xsd#nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DirectorsRemunerationToMrSiuWingFungAlfredMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:href="nivf-20241231.xsd#nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DirectorsRemunerationToMsFongHeiYueTinaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:href="nivf-20241231.xsd#nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JAKOPPORTUNITIESVILLCMember" xlink:href="nivf-20241231.xsd#nivf_JAKOPPORTUNITIESVILLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JAKOPPORTUNITIESVILLCMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember" xlink:href="nivf-20241231.xsd#nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WaiverOfRelatedPartyBalance" xlink:href="nivf-20241231.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="WaiverOfRelatedPartyBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalInstrumentsMember" xlink:href="nivf-20241231.xsd#nivf_MedicalInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MedicalInstrumentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MotorVehiclesMember" xlink:href="nivf-20241231.xsd#nivf_MotorVehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MotorVehiclesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandPrincipalActivitiesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_OrganizationandPrincipalActivitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandPrincipalActivitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementMember" xlink:href="nivf-20241231.xsd#nivf_SecuritiesPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SecuritiesPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EWIHLMember" xlink:href="nivf-20241231.xsd#nivf_EWIHLMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="EWIHLMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JAKOpportunitiesVILLCJAKMember" xlink:href="nivf-20241231.xsd#nivf_JAKOpportunitiesVILLCJAKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JAKOpportunitiesVILLCJAKMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NewGenIvfLimitedMember" xlink:href="nivf-20241231.xsd#nivf_NewGenIvfLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="NewGenIvfLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_OwnershipAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubsidiarieMember" xlink:href="nivf-20241231.xsd#nivf_SubsidiarieMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="SubsidiarieMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="COVIRIXMember" xlink:href="nivf-20241231.xsd#nivf_COVIRIXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="COVIRIXMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewGenMember" xlink:href="nivf-20241231.xsd#nivf_NewGenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="NewGenMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeniorConvertibleNotesMember" xlink:href="nivf-20241231.xsd#nivf_SeniorConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SeniorConvertibleNotesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalNotesMember" xlink:href="nivf-20241231.xsd#nivf_AdditionalNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="AdditionalNotesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionRateMember" xlink:href="nivf-20241231.xsd#nivf_ConversionRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConversionRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondAdditionalMandatoryNoteMember" xlink:href="nivf-20241231.xsd#nivf_SecondAdditionalMandatoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SecondAdditionalMandatoryNoteMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondAdditionalNoteMember" xlink:href="nivf-20241231.xsd#nivf_SecondAdditionalNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SecondAdditionalNoteMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WhiteLionCapitalLLCMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionCapitalLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="WhiteLionCapitalLLCMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesAWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="SeriesAWarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesBWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="SeriesBWarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_LongTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetTangibleAssets" xlink:href="nivf-20241231.xsd#nivf_NetTangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="NetTangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAmount" xlink:href="nivf-20241231.xsd#nivf_AggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="AggregateAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_InvestmentCompanyCommittedCapital" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityTerm" xlink:href="nivf-20241231.xsd#nivf_MaturityTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="MaturityTerm" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_LineOfCredit" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockHeldBySubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockHeldBySubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_CommonStockHeldBySubsidiary" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockPotentialValue" xlink:href="nivf-20241231.xsd#nivf_CommonStockPotentialValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="CommonStockPotentialValue" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerActivityDrawn" xlink:href="nivf-20241231.xsd#nivf_MergerActivityDrawn"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="MergerActivityDrawn" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerMember" xlink:href="nivf-20241231.xsd#nivf_CustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerTwoMember" xlink:href="nivf-20241231.xsd#nivf_CustomerTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SuppliersTwoMember" xlink:href="nivf-20241231.xsd#nivf_SuppliersTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SuppliersTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SuppliersOneMember" xlink:href="nivf-20241231.xsd#nivf_SuppliersOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SuppliersOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OSLGroupMember" xlink:href="nivf-20241231.xsd#nivf_OSLGroupMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="OSLGroupMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_Deposits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueRate" xlink:href="nivf-20241231.xsd#nivf_RevenueRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="RevenueRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/GoingConcernDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="GoingConcernAbstract" xlink:href="nivf-20241231.xsd#nivf_GoingConcernAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="us-gaap_LineOfCreditFacilityAverageOutstandingAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashInBank" xlink:href="nivf-20241231.xsd#nivf_CashInBank"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="CashInBank" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="us-gaap_DepositsAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:href="nivf-20241231.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable" xlink:to="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServicesRanging" xlink:href="nivf-20241231.xsd#nivf_ServicesRanging"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:to="ServicesRanging" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TerminationClauses" xlink:href="nivf-20241231.xsd#nivf_TerminationClauses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems" xlink:to="TerminationClauses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember" xlink:href="nivf-20241231.xsd#nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNoteMember" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnsecuredPromissoryNotesMember" xlink:href="nivf-20241231.xsd#nivf_UnsecuredPromissoryNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="UnsecuredPromissoryNotesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesAWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="SeriesAWarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesBWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="SeriesBWarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCWarrantMember" xlink:href="nivf-20241231.xsd#nivf_SeriesCWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="SeriesCWarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_CommonClassAMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FreeStandingInstrumentsWarrantsMember" xlink:href="nivf-20241231.xsd#nivf_FreeStandingInstrumentsWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="FreeStandingInstrumentsWarrantsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable" xlink:to="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="convertiblePromissoryNoteDiscountPercentage" xlink:href="nivf-20241231.xsd#nivf_convertiblePromissoryNoteDiscountPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="convertiblePromissoryNoteDiscountPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCapInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeCapInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_DerivativeCapInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfConversionExceeds" xlink:href="nivf-20241231.xsd#nivf_PercentageOfConversionExceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="PercentageOfConversionExceeds" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyLiquidationProceedsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="dei_LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BestLendingRateMember" xlink:href="nivf-20241231.xsd#nivf_BestLendingRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="BestLendingRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IndicativeRateOfBorrowingCost" xlink:href="nivf-20241231.xsd#nivf_IndicativeRateOfBorrowingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="IndicativeRateOfBorrowingCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="nivf-20241231.xsd#nivf_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NewGenIvfLimitedMember" xlink:href="nivf-20241231.xsd#nivf_NewGenIvfLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="NewGenIvfLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MAMember" xlink:href="nivf-20241231.xsd#nivf_MAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="MAMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WhiteLionPurchaseAgreementMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="WhiteLionPurchaseAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ProfessionalPartyMember" xlink:href="nivf-20241231.xsd#nivf_ProfessionalPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ProfessionalPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DoubleClickServicesLimitedMember" xlink:href="nivf-20241231.xsd#nivf_DoubleClickServicesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DoubleClickServicesLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WhiteLionMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="WhiteLionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockNoParValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingServiceTerm" xlink:href="nivf-20241231.xsd#nivf_ConsultingServiceTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ConsultingServiceTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAdditionalCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_OtherAdditionalCapital" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsTable" xlink:href="nivf-20241231.xsd#nivf_EmployeeBenefitPlansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="EmployeeBenefitPlansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PensionSchemeMember" xlink:href="nivf-20241231.xsd#nivf_PensionSchemeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="PensionSchemeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OccupationalRiskSchemeMember" xlink:href="nivf-20241231.xsd#nivf_OccupationalRiskSchemeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="OccupationalRiskSchemeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HealthCareSchemeMember" xlink:href="nivf-20241231.xsd#nivf_HealthCareSchemeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="HealthCareSchemeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TH" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KH" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KG" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementAndServiceFeesRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementAndServiceFeesRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_ManagementAndServiceFeesRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SpecialAssessmentBond" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SpecialAssessmentBond"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_SpecialAssessmentBond" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ProvisionforIncomeTaxesDetailsTable" xlink:href="nivf-20241231.xsd#nivf_ProvisionforIncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ProvisionforIncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KH" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HKSARMember" xlink:href="nivf-20241231.xsd#nivf_HKSARMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="HKSARMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxExaminationLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProfitTaxDescription" xlink:href="nivf-20241231.xsd#nivf_ProfitTaxDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="ProfitTaxDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" xlink:href="nivf-20241231.xsd#nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualTurnover" xlink:href="nivf-20241231.xsd#nivf_AnnualTurnover"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="AnnualTurnover" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedExcessTaxPayable" xlink:href="nivf-20241231.xsd#nivf_DeemedExcessTaxPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="DeemedExcessTaxPayable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAllowanceOnDeferredTaxAssets" xlink:href="nivf-20241231.xsd#nivf_PercentageOfAllowanceOnDeferredTaxAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="PercentageOfAllowanceOnDeferredTaxAssets" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/RisksDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RisksDetailsTable" xlink:href="nivf-20241231.xsd#nivf_RisksDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="RisksDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ASPACIMember" xlink:href="nivf-20241231.xsd#nivf_ASPACIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="ASPACIMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksDetailsTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateOtherVariablesPercentage" xlink:href="nivf-20241231.xsd#nivf_InterestRateOtherVariablesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="InterestRateOtherVariablesPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPensionPlanObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_IncreaseDecreaseInPensionPlanObligations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyBalancesandTransactionsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_RelatedPartyBalancesandTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyBalancesandTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyBalancesandTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/LoantoaSPACIDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DisposalofSubsidiaryDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisposalOfSubsidiaryAbstract" xlink:href="nivf-20241231.xsd#nivf_DisposalOfSubsidiaryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisposalofSubsidiaryDetailsTable" xlink:href="nivf-20241231.xsd#nivf_DisposalofSubsidiaryDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalOfSubsidiaryAbstract" xlink:to="DisposalofSubsidiaryDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalofSubsidiaryDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstFertilityBishkekLLCFFBMember" xlink:href="nivf-20241231.xsd#nivf_FirstFertilityBishkekLLCFFBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="FirstFertilityBishkekLLCFFBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalofSubsidiaryDetailsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" xlink:href="nivf-20241231.xsd#nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionDetailsTable" xlink:href="nivf-20241231.xsd#nivf_BusinessAcquisitionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="BusinessAcquisitionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BiClinicLtdMember" xlink:href="nivf-20241231.xsd#nivf_BiClinicLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="BiClinicLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionDetailsTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="nivf-20241231.xsd#nivf_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GeneticsIVFInstituteIncMember" xlink:href="nivf-20241231.xsd#nivf_GeneticsIVFInstituteIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GeneticsIVFInstituteIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" xlink:href="nivf-20241231.xsd#nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeniorConvertibleNoteMember" xlink:href="nivf-20241231.xsd#nivf_SeniorConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SeniorConvertibleNoteMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesMember" xlink:href="nivf-20241231.xsd#nivf_ConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNotesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNotesMember" xlink:href="nivf-20241231.xsd#nivf_PromissoryNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNotesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MicroSortAcquisitionMember" xlink:href="nivf-20241231.xsd#nivf_MicroSortAcquisitionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="MicroSortAcquisitionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewGenMember" xlink:href="nivf-20241231.xsd#nivf_NewGenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="NewGenMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WhiteLionMember" xlink:href="nivf-20241231.xsd#nivf_WhiteLionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="WhiteLionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashConsideration" xlink:href="nivf-20241231.xsd#nivf_CashConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="CashConsideration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedValuePerShare" xlink:href="nivf-20241231.xsd#nivf_DeemedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="DeemedValuePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingPercentage" xlink:href="nivf-20241231.xsd#nivf_OutstandingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="OutstandingPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BidPricePerShare" xlink:href="nivf-20241231.xsd#nivf_BidPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="BidPricePerShare" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherNotesPayable" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="nivf-20241231.xsd#nivf_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>108
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /HXH5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( /HXH5JFT 6$\P   "L"   1
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M\N%;SD5U*Z[OWD;7'WX78>NUV9G_9;RLOQF?!=L&?OV+]A-02P,$%     @
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M3@H\W/[O#;#"Q([A[8N_ 5!+ P04    " #Z.*%:XC#)ELL$   =%   &
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M2NTBC=H?1UWM9&DBQ25IQWAD&DBI,,*#1$_?13A*[F">5W)7GN9QN;G8U7Z
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M*UQE9U'9C9';]/SG41HCP_32$]P5*FD []=2FK>;Y /YB>#@/U!+ P04
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MTE/2B%8H"+]0N*HW2B*-*;/[M:E?.!A-().]LV2[X.V]2TA.%NBB%JX>&-(
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MP=!6 !E%D0D()M!H#-)D:)X<?#B. (*AL2!_AN;/4GB2HIC!A^)]!L@H/@*
MC&'(8&Z]?+KG8+8?]5'TB4T'SP=ZFJ$]+0"U0%%#HFB>'-KG>/LP P0Z RBT
M3_'VH6\$WC?0#D/;L<F@K8 'Q3UB<(G1;*!]CK9/P8>B/@SR9&B>'#J-H[T&
MPXF.)H=D.)H--(\CAE <C46A=8J/&03C>"X0C>'1($N*CR;X4,QG+* =@:,&
M /77D>UNMOF,]1^R?,R*BN3J 7:VX'T,>WRY^3)T<V'TJOY6\EX;HY?USX62
MH,:L 3Q_T+"--A>V@>WWN1?_ U!+ P04    " #Z.*%:?#22<GL#  "*"@
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MZ+*(R@;0^$;2Q^X:-D%__9S]#5!+ P04    " #Z.*%:.I_\,Z@'  "T(0
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M  Y3CD/:Q2T 7,(83H(#KD,A/% (!RG,2J7MK)0#5&H/_*CI,>4!9S%VN$!
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M!M^LPR 3KP,IO47?YMN\-EJ,=E[ E$O>4U*M6U=R#)J+ZDK'=0)?VW@%RN'
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M;TY+&;"%ETJ8]@P5J#:5!+T'4!6,02DZ*CAA:FU\&!%_HB#(A4P5:)6WIH>
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M;&S'6S+'8?R\OWUWU_/4B7TF\TP,!#)-YJG+A+;:8'/F\L D&7,_6'H=(O0
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M)CCP":H1\OAKS7Z /%4A-AM+=>_];U"'N*RDZ9$%TUVCK[76 D6TR63_)B<
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M_L$JLQ#7UA3DS/DXP"1_&!>]^E52GSVA/IV)C]:$VHMWIJ1RU\ 86#: 9FM
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M:)<%OQ*LEX<D'T'U.,!!),<FYGD\;P=I)"X14X<5EQW-AI/)A/]2; CI5.[
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M;"]W;W)K<VAE971S+W-H965T,3(N>&ULM5;;;N)($'WW5Y0\T2@C.<$7;DD
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M=BMR?,T/HB3THG0 (85(TM0)O4%(E$)R\>*4WI+8^0VU'I&@Y&W5EMQ@03I
M;<\%[Y3FE]!C4>9%+( /]A"%F<>"(7QPUM(0VQM@P\@+LL0FGC O' SA_A(
MGTES-:5+HNO8 K\@5QK0#A5<5K@;BZY"MLIP0*K7#44;!*R[O2&;D&*1?.H&
M.P$L7VYA*=_Z4_H7*E*AVG5:J:EO;6UZ03G?GN5XUJO0JWFOY0NN=M03*'%+
MKL'M<.""ZO6Q/QC9=)JTD884KMONZ9."RAK0^U9*<SK8 .>/U/1?4$L#!!0
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MG9U6+.E!0V4-:'\KJ1O'A0UP?B*G_P%02P,$%     @ ^CBA6F#!;<R, P
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M2=P!75]1ZA>K2G<MF"J+EPSWF.&MCFO:@.LSA3EM7DC!^IXX_A=02P,$%
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M[_SR;C^$"RJD0PH690,F;-DJ3,E"R#Y5 -V*ZYHO;=0I*N2!++EZ4MI[OW^
M/&!DPCA.76RS$CY!.R&H]=L3_44?-P[Y:%V\[30Q,WK#%24R+I'37-E0)S0/
M9":BN1!V'UU*YEW//?1'DZ-U\BU$*0Q7:L.2@]<Q$S\RL7*^,#IRUTN9+8DZ
M&;[V=]!6(P*F+I&";QA?K0#BNVKD0A&&01C,9+FNR$@2Z[#;N0W;N[B[V^^C
M*Q8SG4ONM;,.BG*3MVJVX8NZX:/AD@[?(HK^*GF[[U7>IJOO'@([54G='7Z$
MAZ5=%KX3KI?:IVVFX'TYE[Z(6"%R616>4W&S\)+0\-&\VQS!EA;](QFV@*NW
MP*$KP(K:C\0 ORT0>(L66S_UH1R^IOSR6F NW6-UC.I.P,L2'8VYRI3HDJ9I
M$'46QSMI#"\7#?+'#S<)_4S8QXU9;/Z@$'2*?T/6;U,\XKLK*G09:1A?0/T%
MO:V%UD2"FY)&>M,A^NR++G]IQA-3X%';1KVMN\IM"\\OV)X *8;.OE@BL9X)
M 65^QZ!'TR\TFH[FC9K<.2-G%?6H>HQOA0;7HK&V(J.'4>^SB\KXF@??!A:'
M@K)AG"#FOLZ!\FH\G<2'PPE;H\@Q4$41Y&&F8$]0&*<(4D-/>68$PF8IB;8S
MI5]/;O9DCD1^)+73"+E#)?A,8)3WK,+9"?!8JBM_F($MMVB&R-R,PYF4"[KT
MF:WGC^M[[OM,DPK"MG.57("8 I1ASQ;%#%8UNW;H7+@:!2=P8B,M[)NH2QP1
ML:>+SNMES3NSW;,[07[5;IWM571%^;ZE;CH?ECDCH:97L0.QUT1FOT78+;9M
M6XW(AOQ.TY+IVU1PRCZ2 "=<;(BONO!;%7>;2S]IM/=)6_3T^B Q$S2D:B\#
M[6@RC*?#0X^6#*?Q.)GB:C0>Q4?3:40+78:E!BFR5ZNP3WN!WQ_F<^&/JYU-
M9R\Y/(JGDQ'@DF%\.$KQ!($Z.$K8O@<+3%0Q)6H7C _FUC2)1RDQ[XV.XN1P
MU''A4^8ZT8B_5@W3)87XSM%A- '.,(G.E]2N*&;W7%4\G+4I53@M PF\=@05
M4Y@_3IX163FIY!^!M4X!I6GTDHF'\4&:;+6%_I,8LFNC:[JJ],:&(@UP2.LD
MG<1'P_0O9=DV]A[W+V8'KE)$-H%I%V(N#"VIA$V+ [:#4KCG"Y4^'CSBL'%$
M+"^6W(-BC;[>7C#\14^E@\TKF;S%V0UN1EN$A]'^R&6AA5,K6-,\QTDU'B.C
M0I2B3V@Z;W:&<Z^A1![5(=W?)3N8_JCXV)DW^TFSH5Y#E36J)VX]V9980<L_
MTYS:]=%A&H^2B6]9KY+).#Y,D[!.-5 SH21Z-'8%1[W8-U4EOPE%IT->^F62
M9D?D#R9!'O7.YAS3)->\HEVLSB^_$^^((<9!."_4(^K/;.B37SB=["KEO NB
M1F^?L]2@DR'&Q#8,B,DNP52]3X3U=WV"&'2^&!4"^Q1]%X->NBI=^'C4/FT_
MO9V%+TY;\O#=[C/6,3JR*S$'Z[!_>-!C)GP+"S=.K_SWIYEV3A?^<BDX-E$B
MP/NYUJZY(0'M!\G3_P-02P,$%     @ ^CBA6K[@BH Z!   +0D  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&ULE5;;<MLV$'WG5^PPG4P[ TL$P8MD
M2YKQ17$\:5*/Y+@/G3Y %$1Q0A(, %E6O[X+2*+E1%:G+R0NNP=G#W8!#-92
M?=-+(0P\5V6MA_[2F.:\V]794E1<=V0C:IQ92%5Q@UV5=W6C!)\[IZKLAD&0
M="M>U/YHX,;NU6@@5Z8L:G&O0*^JBJO-E2CE>NA3?S\P*?*EL0/=T:#AN9@*
M\[6Y5]CKMBCSHA*U+F0-2BR&_B4]OXJLO3-X+,1:'[3!1C*3\IOMW,V'?F )
MB5)DQB)P_#V):U&6%@AI?-]A^NV2UO&PO4?_X&+'6&9<BVM9_EG,S7+H]WR8
MBP5?E68BUQ_%+I[8XF6RU.X+ZZTMBWS(5MK(:N>,#*JBWO[Y\TZ' X=>\(9#
MN',('>_M0H[E#3=\-%!R#<I:(YIMN%"=-Y(K:KLI4Z-PMD _,[HI-,]S)7)N
MQ!PFXDG4*Z$'78/8UJ*;[7"NMCCA&S@TA,^R-DL-XWHNYJ\!NDBJ91;NF5V%
M)Q%O1-8!1@F$01B=P&-MI,SAL?\5*?QU.=-&87+\?2SH+61T'-(6S+EN>":&
M/E:$%NI)^*/W[V@27)P@'+6$HU/HHYN[Z>7M[61\>_DPOH')^''\Y>MX>HSE
M:9PO?SR,@<;P_ETOI.$%',>%AZ6 :UDUO-XXR_1"@ZUJF*TT(FH->!(H;FM)
M U?",Q(:)9^*N3B'7XO?X.[Q Q@\& S6K &K1I&)"^#U'*=Q7J^4DCG/-FZ(
MUUE1EG@.0,954>=[!]WQL-S ()N-X J$32=OMUVP4+("\6R$JGFYJP^AM,L1
M^V'V$WI'J< O$).(,<+2&-L1"4)*DGZ"[9#T:)_0A'G3/4GR,T-+6R(QU7)M
M-:6$THA$<0J,T#!&Z-1[D 8YJGVBO5X])I0EA,;,M?M11&@_@%LA<\6;99&A
M9U%OSUP4W,-B$-4,5\:"^$\QI"KRHG9I[DQ^$.?C)YA>3G#=/7F&4K#>RX#W
M::/RS3_:\!J52>*$Q*B2#8QABR'?( E(/V7>-:]F<EYP2 )*XC"!Q$I*^\#2
ME"1!SWM8\J*TNH6$IC$),5Y*&"+V \0)8C3JGQ+JN$PV57?FARH!G\DG'-'N
MG,:]JFT:>:7,=EF[QKT3+K7VWB]2=5YK_+NL\[,2+PS,5*V%T>!@;->\*2@C
M08]:IKVHU?)ZB?C0PVB"5O C.O\P!6%(8GH@<)2B9"%0EI(H#7&ZCVO%+_HR
M&A)&&;  #:,>A'%$TBCVD%2*6Y+8+(^BA 1!A+HGA$7L:,67/\6=H7*%-IY<
M0(-+&5<&XONJ:&QQ$:C%=FAW.F"=E +EUZ#LA7@F%V<K+79@SKIS[&SL'EQA
MF,2YNZCMXJO:;&^S=K1]"UQNK\ 7\^U#XC-7N*<8BEB@:]!)8W_+9=\QLG$7
MXDP:K!C77.)[1BAK@/,+*<V^8Q=H7TBC?P%02P,$%     @ ^CBA6HDR[4)?
M"0  ]1@  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULM5E=<]NX%7WG
MK\!HW9UV1I8LV4F\B>T9.TD;3R:MQ_:V#YT^0"0DH@8)+@!:UO[ZGGM!4I1#
M*Y[.[(O,#^!^GGON!7VVMN[!YTH%\528TI^/\A"J]].I3W-52#^QE2KQ9FE=
M(0-NW6KJ*Z=DQIL*,YT?';V=%E*7HXLS?G;C+LYL'8PNU8T3OBX*Z397RMCU
M^6@V:A_<ZE4>Z,'TXJR2*W6GPJ_5C</=M).2Z4*57MM2.+4\'UW.WE^=T'I>
M\$^MUKYW+<B3A;4/='.=G8^.R"!E5!I(@L2?1_51&4."8,9OC<Q1IY(V]J];
MZ7]EW^'+0GKUT9I_Z2SDYZ/3D<C44M8FW-KU%]7X\X;DI=9X_A7KN';V;B32
MV@=;-)MA0:'+^%<^-7'H;3@]>F'#O-DP9[NC(K;RDPSRXLS9M7"T&M+H@EWE
MW3!.EY24N^#P5F-?N+C5_L&?30-$T8-IVFR[BMOF+VR;S<4W6X;<B\]EIK)=
M 5/8T!DR;PVYFN^5^$FE$W$\&XOYT?QDC[SCSK%CEG>\SS'Q[\N%#PZI_\^0
MCU'"R; $*H?WOI*I.A\![UZY1S6Z^/FGV=NC#WOL.^GL.]DG_>+V^N[KW9!1
M^[?]_1_WG\7LK?CYI]/Y;/Y!L!AQ.1$?G<IT$ YNB\LTM749/*HF5?I1+HP2
MUZ6P+E-.!$LXTH7^78F0JR3=;AS3 Z"K1#FB\(*P2W[RT1:5+#>BL*4.UGDA
MRTR@,&N$!0MD$$MK4-Z'=<5EAFK3>"$?5$GJ8(5]A&;ZR6J%HEF 2,3]5G*2
M6I0YK/.LKW)V(1?:Z+ A$YHB$W5%@F&"EH:%KN@:S[!&>@\&([O6N8(,1X*<
M$KGT8J%@AQ1>8_U2IQ*.Z1)NHYAQ(7H!2(@G(*]<65VNJ-S)C]S9>I6#T822
M:0[-E76!WE?*:9O!$\OZO7^F')M?I7:\$^64_B*R"3WD?))_711LFM;.D7H8
M2TL:UZ$K\/W6ODP&!3X)N>B+:@5M=_ ZO!F([22Y#F*;'?DHM6$\D1^VY$N*
MNJ\KUOJH@ 6WEBX[-*!BLD*7L7= VACK$$%H_MNG&[%"R< V1]I)1FD!3*BG
M=PBM2&6E@YPD5XA8UGJK$1SM&)TQYGR)Y:0$RQ:;?C!C9#,-CQBXK2?\V%AD
M3!)P99FRW4 O5TZO<#Q9B]B GU2Q4"YI.8I-QL4Q07RAQ,'L%U2A]#F_2.E"
M_59#B%%4BH3V7LK)':/Q/DN6=9EYPHI!409R0:6R]ER=@LU1#H (FFP!JA:R
M!+-Q6G/TG$ZJI)R3N82X& E->TL./>(:%Q[&A0(U7J:0.4EZA4AFJ*?*4L#A
M%L*5PGHGVS(;]$!$#]:YIMPZ*G!(8%?82J]0^-"_W_ )0LS;(KU8KJ->'L9"
M%IP;4$BR=+80/H>RW)J(3.PQ5C+A7(J[F\N/XKI/,0U:R"^07@]%E/;L!YJ)
MM;Y7J<M,/^JL!H0V/!HP2)N8FUWW6#)"SG7+K.I50D1(J.3(C8D4*.6V0AW&
M<.^ =PPR0WF5]C64@C6$Z:&*%B_44_('U-/_%=ADM^*ZJ8# >7 R9ED'LW?C
MT]GI&.)\I7BT,YO84_Y@,X[9C-E^.ZXF:+C @?(AX70P,2QA4\0'GD?>XY<O
M%F"2[MO6-*;($[DL5XHPN;N29@ CJ11I0@=.41Z]?/(8\>Z#%X_2:0K&8=Q$
MI8H?0Q'<;=6"N@\@ E&919,J;8BX9.-WC,Q5MN(V:8U.Z66TA; -*Y: '=2:
M6@WYUG'H"\Y'FSH@)LUH,N@;QY-GE:'VSC.#-F:+Y=9N+H\=S1Y3@&$&$:5"
M3!$T3_&YHU,*<D\#"Z8GLR'!9* ?>)$LZ"BTG4PR!17H?+'84(1U$;6C.\LF
ML0-YS676S )D2&SDBN"]?#8%Q"F%_:0]<1JJ*J-5EC1H:"-$>7FFALIGB;:,
M7@$>T27&Z;K@C@:3U)/V05&5L0'XH5%B(F9_VO(2EU_+45[4A&R,2>76PF0@
M_RV+1L0^J$U_+(5'F#U*9=@IR*'QG$S:KNF2WR.U+C+-Y+(!,M$L:82)44Z^
MBS+*>#D4> IB B^IC]%DZ\ Z:UPPRP-+D6/:H@+#\RRJ@!U"60!QCP>A6F*2
M^S,1V%\H@+:(]$4K-TJ";Q6=MO;-(FL&*!=DFX&LGX*(L0H3]I/&3 :R$@?S
MM^/37UC&P9N3V7,JP^$71]NRJ7O4,>=G^*GN#:T,![HC.FW:WO+Y+IY=?:P_
MN5Q"ZV!8M@!D'N?C/,W6L)1'XN5.H31:DDZ+>FI>-CF]'U ! E%!NDW2F,3S
MA(ZGD';R:B@T4W%2)5:%NB]?#\;B_LL5;[G]=M4;A,@7+PN:T?D:@U+:#F/1
M.!+=X=*H1VKIF(OK*@%B6?-$?*$*^^%X\.RP%O&UFQZL^/7N@*JPY3KVH#=.
MO$#U"5&]V%+]]XE\QO6H647C+ 5)]/+0$#%\0KE@*GP^3_1IO&U<SW4E'5NE
MJ!1"\,L4WI^4OK-YVQ<&>1W3_$1\AD@D.V4=Y%R ,,,]W0_BR(*<N,=A?MA"
M!E*R.FT <Y_3(:K,QI@*BH7-M&3I7S=NM?F=R&'")WA'56,VPT2QJ#'@@=C&
MO=H@)3H>LR(O4G'X!%G?&@6#-G1:P:$,G1>X8D+H30]\_F[]' O5^!]%&K6"
M'E4^:F?+K@N\PI\?1.HU0KB@?+WX+Y,$AF!P5.,UY[SQCP^CO:QSIM@ GI%3
M4V>1H+@U6(AHSRGC! <,XBGB;C]^*1+#@>"G PB+D1T.0).@-B4R0T$0GI/(
MA/M3$QVUNXE_73IB+G=EK^CC#'O")(LB!O4D?%9KV@'%W,BU;["UJN,H1^<R
M,-4A 2H>-!UZ-5H-%=9X&PK82.XQ.IW"03?P;"GDPEF9-8CE_DI7A0JYS1B[
M03XUWPYZZ4$L^+ ;$TJ5#J:IZ9"9:2\QDS0GPC6:)@Z6-(TWYD4F_+8=)KJ/
M6DTT"(R5TV0;^%@9(BM,.=91U,U&=([R!$><2'T4C9Y?(L.<N:&:):0BLEED
MM:YLD9+ IO@/Z)4-+?8@G+2-? L",H_8W,@%DR4Z+5:2+<!1)7US?!\T@K\I
M*SZ[$>=UJ&ML']PT2"63H:^@T]ZG:&A9\0=W'S]CQ*_2W=/NF_YE_)2]71[_
M(?!-.G X96&)K4>3=V]&2!Y_9(\WP5;\87MA USBRUQ)4 $MP/NEM:&](07=
M?SHN_@=02P,$%     @ ^CBA6HET"_U'!0  SPP  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&ULI5=MC]HX$/[.KQC17@52!$F A7U#@GU1>[?=KH"[
MJCK=!T,FQ&IBYVQGZ?[[&SLO"UMV5>F^$#OQ///VS'BXV$GU72>(!GYDJ="7
M[<28_*S?UYL$,Z9[,D=!7V*I,F9HJ[9]G2MDD1/*TG[H^R?]C''1GEZX=P]J
M>B$+DW*!#PITD65,/<TQE;O+=M"N7RSX-C'V17]ZD;,M+M'\F3\HVO4;E(AG
M*#27 A3&E^U9<#8?VO/NP%\<=WIO#=:3M93?[>93=-GVK4&8XL98!$:/1[S"
M-+5 9,:_%6:[46D%]]<U^JWSG7Q9,XU7,OW*(Y-<MB=MB#!F16H6<O<1*W]&
M%F\C4^U^85>>'9'&3:&-S"IAVF=<E$_VHXK#GL#$?T4@K 1"9W>IR%EYS0R;
M7BBY V5/$YI=.%>=-!G'A4W*TBCZRDG.3!>8,H,1/#!EGF#.4B8VJ(&)"%:*
M"<U<\/1%WY R*]+?5,#S$CA\!3@(X;,4)M%P(R*,#@'Z9&5C:EB;.@_?1+S&
M30\&@0>A'P[?P!LTK@\<WN#_N0Y_S];:*-K]<RP*I8[A<1VVI,YTSC9XV:::
MT:@>L3W]\"XX\<_?\&#8>#!\"WVZN+F;K6ZNX6&V6'V#^>QN=G]ULX39_36L
M%K/[Y>QJ]>G+_?*8V6\"'S?[_LOJ!H(Q?'@W"8/P''Y1.ZP2K&L>9 PLDX4P
M$!4(L9*9B[?=&$E%[C+2RBDCW*9"@R'A6*;4.[C8G@%Q +,U*L<#ET";HH3G
MCA3V9P#7-;).F,)$IA$J#1LZQ[6Q%KS _*QZL.0%?*4=W!9BZ\$LC14QHV-=
M#?WSZH3;!>==6.X#._NYHBXC:?<>AO[0&PU/:348#;UP,G(&D7>L]@]RQ[@W
M+-(]N)5D#345^%:@!RLNV+,YU>=?L:<CI$$(NM 9GHX]:M70A8],;62A#-SQ
MC%M[9B\L*X7"+OG0.0F\B1^"7=>)_WWV!WQ@67X.+(YYRIUDK7[T&T@%F52X
M'W\8>,'(]WS27Z/<DXXSZ)!IC;N\S+?.9:'1QJ4*?,]QJ"+)05;79=6VB"ET
M_( =CA [^O#^-/1.1@'L$IZB4Q =94B%!<>Q!B56E=,>="@\SJHFU#;P!X"$
M\E.HZ7-#."M0^^[]?)0LI1O*!C*I"F$CLXQN,KIP.-U'"&L4&/,-9RG(G; J
M=]PD[NB5S'(FGLK(U9X=]_N0AZUG'K;V8]!J"JQ5%U@?.D9V]['Z+XA$_ DH
M8,/1P!%H, Z]P!^T[E#K,V!6C[.+G 3\D5,<27)#E<<-I%+KABN=8.Q-@@ET
M6R\1JQ*S7F;R$6E<<(XTV/H8>,N!<]=@2G=?]75>D\)0M+=<"-LDJHI]0J:<
MBY5QU=H?G9*A"WRD@-C,Q/"@Y"-W8PR%K-ETH1+LC)T$W9,6O$[6<[WMJ_A$
M@TQ$+E@P*@9KAMF[K%J64^OZ*HO0,.)\!)AJW%DZ 1=61J/+NDQYY+(54WL1
MCD?:T L;1>WM\X@H&!UVJ0.U)>_V<T_M^[68VI^P=5W7C?-R?$[264$<9K5K
MK[?E]Q"<EKV$5N&H6;EWOP!\O+O6F#5BC?>5T=BH;!H/N5WGZ;E-'3&U(?!D
M0@TPH 16;UI7LLC)'BX,I86JSU)4:-?A;'_]DN=2F4)P=Q$._(DW)O$:[AE$
M6)99Q\B,C=L9OJ8VYSIXW2WU<53;%@][<OT\-IOT]X;,#-76C=*V>]!M7LZ;
MS=MF6I^50^KS\7+4_\P4E9*&%&,2]7OC41M4.3Z7&R-S-[*NI:$!V"T3^L>!
MRAZ@[[$D]ZJ-5=#\AYG^!U!+ P04    " #Z.*%:*F!F4O0#  "&"   &0
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MP3<=8IP&ONE;,5YEEW![!5D?(_R7Y<Y;*HC_7PNW(YN]3L:7Y,@UHL!%1+?
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M>/_AT[F83L5//SR93J9/Q0Y)\2E3XLP4E2QOA;J6>2.=2A&8K9HBY=4DRU1
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M9&Q=TP(\7QJ(%+[0 =U;D2_^!U!+ P04    " #Z.*%:LM7_5(,$   -"@
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M&5%#WCF@YK[0@I0:4J"D>1KN#NVX?=H#2K8F;23BC*1K(V$$*<777.N, [@
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M(_BAH!WY (]XKDM3+JMDLX)Y..+1>C;$2]=?LTA9+BNSY'$FKWSM:A;:GZ,
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MU3C<#\K@/"VLFOG!;:(LC8'^,:.Y&[43H/=310%9+9R#:I+O_ =02P,$%
M  @ ^CBA6DHYJ$"C P  G @  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&ULI59M;]LV$/Z>7W%0BV(#.NO-=FS7-A"G"3*L08TXW3X,^\!()XLH1:HD
M%2?_?D=*5IW6,P+LB_AV=\\]Q^.=YCNEOYH2T<)3):19!*6U]2P,359BQ<Q
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MM3.@_;E2=C=Q <I?E]%O4$L#!!0    ( /HXH5JTH#ZA9 (  %$%   9
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M?V&S6YLD(>1K8U6S-T8&3=7N_N)Q'X<#@V'T@@';&S#/>^?(LWPGK)B.M=J
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MM/N%7;%WZG<ARK61:2E,#%(NBG_V7/JA(3!_2R L!4+'NU#D6%XSPQ;G2NY
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MQZIVLG7Y 2"A_.1D^ERGFA6H;/=^WDI,J<U8%V[+(Q#)-*5V1%V#4U-!6*'
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MUXT;;NDYB<INH.]K2>:5$ZN@?J N_@-02P,$%     @ ^CBA6D2B^A5F$
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M$NS!2U=I_YG/[^;A112:6J-:@FHIJ@E4DZBF4$VCFJ$TOR5<O#TXQHVT!V@
MCFH)JJ6H)E!-HII"-8UJAM+\IG$!^""\R?A[6][8,LK6#?(MFI;9U\7.OGAZ
MQ^;GWDL>GO+@HD<#;%03J"913:&:1C5#:5[1#UV /0P'V._SQ8N+IS!QZ'$
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MYLKH^I"JCTE@M&=<:!AO0P@/=JZP/%'5]QG5C9$C]XG#K31&ENXR9]"%RF:
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M@!7O,10G@F;JR?Z<"KE94(=KD!L"EM\@OU]2*O8G>0'5VR3C[U!+ P04
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M7 BI70CQ'UR<*#T_N$=ZX=9IO/NR,:9JSC*-.*06*KJXM*)6ZX\%ZPLC\_*
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M+?"L'_[3O^GQ$':%#FN6\)\*_?-\KK3$37]CJV_#%-F9S$F0J#7-8>K@JZY
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M_BM6-DVMU#;DA3 81*)$TR9M5576[4/5#R8YP*H39[9YV;_?V4E3H('UP[Z
M?;GG\7/G\]UP(^236@)HLLUYH4;.4NMRX+HJ74).U94HH< O<R%SJG$K%ZXJ
M)=#,@G+N^IU.Y.:4%4X\M+9;&0_%2G-6P*TD:I7G5/ZY!BXV(\=SG@UW;+'4
MQN#&PY(N8 KZOKR5N',;EHSE4"@F"B)A/G+&WB#I&7_K\)/!1NVLB8ED)L23
MV7S-1D['" (.J38,%/_6, '.#1'*^%US.LV1!KB[?F;_;&/'6&94P43P7RS3
MRY'ST2$9S.F*ZSNQ^0)U/%W#EPJN["_9U+X=AZ0KI45>@U%!SHKJGV[K/.P
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M3HRB74XX$U\FB5P41L,])LB7;"KP!+Y3]7R$"55,NA (<@9;P^R>H%)@18)
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M)M<B@^PE@8]Y:)(1[),Q#8XRSB&]((/^&0EZP;!#T.SM\,$1.8.F-@/'-SC
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MS/'"!&4#\/M*2K.?V V:*SC^ U!+ P04    " #Z.*%:&/Q%9:T"   ?!P
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M?X=&3\_RY9)K]TO6=>QY[)%\J8TL&S!64#)1_]/GI@];@##Y ! U@.A00-P
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MI@K.SK&[JA['M6%DY0;45!H<=VZYP"\8*!N ^S.)NAK#)FB_B=E?4$L#!!0
M   ( /HXH5H;B>W=, ,  *,-   9    >&PO=V]R:W-H965T<R]S:&5E=#4U
M+GAM;,5776_:,!3]*U8V39W4-5] :0>1"FQ:I;&BLFX/U1Y,<B%6G3BS#;3_
M?K83 E0A7=M(?4ELQ^?DG.O/VULS?B=B (GN$YJ*OA5+F9W;M@AC2+ X81FD
MZLN<\01+5>4+6V0<<&1 ";4]Q^G8"2:I%?1,VX0'/;:4E*0PX4@LDP3SAP%0
MMNY;KK5IN":+6.H&.^AE> %3D#?9A*N:7;)$)(%4$)8B#O.^=>&>#UU/ TR/
M7P368J>,M)498W>Z<AGU+4<K @JAU!18O58P!$HUD]+QMR"URG]JX&YYP_[5
MF%=F9EC D-'?)))QW^I:*((Y7E)YS=;?H##4UGPAH\(\T;KHZU@H7 K)D@*L
M%"0DS=_XO@C$#L#M' !X!<![#&@= /@%P#=&<V7&U@A+'/0X6R.N>RLV73"Q
M,6CEAJ1Z&*>2JZ]$X60P@HP)(L4QFG#(\(,:(7F,KF0,'%U#"&2%9Q0$PFF$
M1C 'SB%"EY,K-&1"=?RA)MK1""0F5'Q$G]#-=(2.WG_LV5)ITW^PPT+'(-?A
M'=#A>FC,4AD+]"6-(-HGL)6ITIFW<3;P:AE'$)X@WSU&GN.U*@0-_Q_NU\CQ
MRT#[AL]_9: O#@?Z]KOB1)<2$O&G*L*Y@%:U +T?G(L,A]"WU((7P%=@!1_>
MN1WG<U5T&B+;BU6KC%6KCCW81@@=D12-&*68B\I9E1.U#9'>LE:!IW8PIV>O
M=LU4].KZ9VV_4_;;T]DN=;9K=8Y)2I)E@F['D,R 5PY*+<-S!Z4ALCVSG=)L
MYZTG<*?)6#5$MA>KTS)6I[438ZKX2 B(XW1!TD65UWH"'SV FO)5OFJ!+_35
M+7UU:V7]!*[.(&P.X)#BI8 JB8-Z$M=XJ[)6BWNAM;/2VEG]6L;W3Z[E6H;G
MSL^&R/;,NL[VV'?>>C47"AH*5U-L^_':N2:YKUW13S"XSN$U70]]J3EO:\YK
M8ED_P5*S9]4CG^O/WKGN)L 7)@L0*&3+5.;WP[(USS0&.M/0U^5'[2H#N3#W
M;GM+DZ<O8\S5, M$8:XHG9-3=?+R/"/(*Y)EYE(]8U)=T4TQ5ED4<-U!?9\S
M)C<5_8,R+PO^ 5!+ P04    " #Z.*%:6_V[=Q@$  "@#@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-BYX;6RM5]]OVS@,_E<$[S!L0%M;_IFT28 MP6$#
M[KJ@Q;:'PSVHMI((LRV?I"3=?W^4[#J.H[AY:!Y:6^9'\2,ID9SLN?@E-Y0J
M]%SDI9PZ&Z6J6]>5Z8861-[PBI;P9<5%012\BK4K*T%)9D!%[OJ>%[L%8:4S
MFYBUI9A-^%;EK*1+@>2V*(CX_9GF?#]UL/.R\,#6&Z47W-FD(FOZ2-7W:BG@
MS6VU9*R@I62\1(*NILXG?+O D088B1^,[F7G&6DJ3YS_TB]?LZGC:8MH3E.E
M51#XMZ-SFN=:$]CQ7Z/4:??4P.[SB_8_#7D@\T0DG?/\)\O49NJ,')31%=GF
MZH'OO]"&D#$PY;DT?]&^D?4<E&ZEXD4#!@L*5M;_R7/CB X AV< ?@/P+P4$
M#2#H X(S@+ !A,8S-17CAP519#81?(^$E@9M^L$XTZ"!/BMUW!^5@*\,<&JV
MH!673,DKM!2T(K\AI.H*?5,;*M #32G;D:><2D3*#"WHB@I!,_1U^0W-N03!
M>\C,:_0(V9AM<XKX"KV!P@\+J@C+Y4=0_?UQ@3[\\7'B*B"K37;3AMCGFIA_
MEEAZ@P)\A7S/#RWP^>7PX!CN@HM;/_NMGWVC+SBC;[X%HJ6R\:B!H1VHS_VM
MK$A*IPX<;$G%CCJS]^]P[-W96+V1LB..0<LQ&-(^JX,L#D&VL:U51$:%OI1V
M,^SC*  ?[[H\+&+1&'NMU)&!86M@.&C@2V[:[*J1<6?#)!CCI&?6J13V \\;
MV>V*6KNB5^QJS@$KF6(D1]7V*6<I'"=89^4:O7\W\GWO#HZ)><)W*(738J,Q
MN)$]_LB61]$)T2 )XB2Q$XU;HO$@T;^HE+>(Y%!M2)E2!'4+T><*:@"03\$#
M3*&<2VN XA.+KL->="PB.+1;G+06)Q>ES!6J.M<9[V>ZN<ZR[G66FNNLI-8H
M):=I-([",.[Q.16+L!^-\+'88IC!/_C?@;,]:OTPNL0/4)W4!A&4L353D*A$
M2KBPE2"93M,J)TJW(C;*HU/*GOGU. ^:<5$"'_$;M_S&@_P.I0FM!"\0]#RE
M_:(8GQ+!<%&,HQZ1P?TN/XF+8;N'HXN]0QO@#>HY%&LKZ09]G+%)XO4SUB;G
MQ[[OG[DA<:=/P8,%])Z7U^GY(MJ@WZB*OI6V8ZZ'7@$/ENE.,*Q4_=.[6?_Z
MH3@5P]$(:FU\)A2',H^'ZWRWL2M?"<MI';?::BOWQ[;6A^$5RUXY#;I/.%XY
M5&@\7*)!,[2OUR;<I:Y61"+M 9A=3-U&]UQ19&\5W4Y[7E"Q-F..A JQ+57=
M7;6K]2@UUZ.4;N][ZY]P"!]"ZY?H9?IR#UO4L]O?1*Q9*5%.5["==Y, 4U&/
M0_6+XI49$)ZX@G'#/&Y@A*1""\#W%0=NS8O>H!U*9_\#4$L#!!0    ( /HX
MH5IAS6HQWP(  '@'   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;*U5
M:V_:,!3]*U8V3:W4-@\@G3J(Q*/3*JTK G7[,.V#22Y@U;$SVX3VW^_:"1EE
M 4W:OB1^W'-\[K%]W=]*]:37 (8\YUSH@;<VIKCQ?9VN(:?Z2A8@<&8I54X-
M=M7*UX4"FCE0SOTH"&(_ITQX2=^-3572EQO#F8"I(GJ3YU2]C(#+[< +O=W
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M88D_"] N /<72MGMQ"7H?C_93U!+ P04    " #Z.*%:41AI=DT$  ".%0
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M*4OOL#/!GD)*L:7)GE!$1$%8GF./01)JCZ[9&)9@,5Q7&K&_5* THIE(V9!
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M>^%2KF@,5QTM? GB"3J3GW[ @^"7M@QY FODJU?EJ^=";^1K91.5Z42U\2[
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M*#"-C(/112<SD)BDXE2%WR]FZ.3MZ="6"DJG9D<5P*0$<(\ =%QTRZA,!/I
M8XB?"]BJ&G5)W%U))FZKX@RB"^1USI#KN-V&A*8O#_=:TO'J$_*,GG=$[R\*
M^VT<"LF5W_>F>I;;=9NWT[?&0.0X@I&EK@4!? U6\.Y-QW?>-]7B/XD]JTRW
MKDRW33V8X-1P8XE"6!%*"5WI(L@$T!8P;X)O56S.%S5Q_[O.,^1>C=QK11['
M\0!%."<2I^0GQ"@NN*9N0RX5?:.H+_5U<.5>]1QG:*_WB5HW?CV17Q/YK40W
M(,0 X8RI2^B%0/X?0.?N9<?U+P^(6C=^/5&_)NJW$JE[2!.$Y=O9!%#&]_8
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M[W2HTH*7;QYE1;*->068,RE9;HIK( O@>H#J7S+%K:KH">J7I^1_4$L#!!0
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M*&N ZRN)L:@'=H.FWY]] U!+ P04    " #Z.*%:G*Y+3<T"  "6"   &0
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M+97#C?EP &47F/LK*?%I8GM3\RD2_P%02P,$%     @ ^CBA6LR(F?$!"P
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MQ8JJ'I0+>$K2SYN/X/*_4$L#!!0    ( /HXH5IC2?8Z_ ,  )\-   9
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M6_ D:Z!^7PHAOW_(GK&M'L*>_0]02P,$%     @ ^CBA6HB4=LBZ!@  Y2P
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MFDO"HEC>KP1FDM(X[LE=L;)0*#N"+HK4>4J%3,2+YEP65\"4@9R?42K6';5
M7:YY_P%02P,$%     @ ^CBA6II)/Y+> P  D10  !D   !X;"]W;W)K<VAE
M971S+W-H965T-SDN>&ULO5A1;]LV$/XKA#8,+=!%HBC)5F8;2*RU#;H 0;RN
M#\4>:.LL"Y5$CZ3M9K]^I*3(EJUH#L+TQ1:I^S[>?>*)IQOM&/\F5@ 2?<^S
M0HRME93K2]L6BQ7D5%RP-13JSI+QG$HUY(DMUAQH7(+RS'8=)[!SFA;69%3.
MW?')B&UDEA9PQY'8Y#GE#]>0L=W8PM;CQ'V:K*2>L">C-4U@!O+S^HZKD=VP
MQ&D.A4A9@3@LQ]85OHQPH &EQ5\I[,3!-=*AS!G[I@<W\=ARM$>0P4)J"JK^
MMC"%+--,RH]_:E*K65,##Z\?V=^7P:M@YE3 E&5?TEBNQM;00C$LZ2:3]VSW
M$>J ?,VW8)DH?]&NMG4LM-@(R?(:K#S(TZ+ZI]]K(0X *M!N@%L#W&. ]P2
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M:P-U?\F8?!SH!9HNY.0_4$L#!!0    ( /HXH5H! V[Q*@0   89   9
M>&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;,6976_B.!2&_XJ5':UFI)DFSB=T
M :G@'4TUK525F=V+T5X88D(T2<S&!J;[Z]=.0CX@6*6RQ$V;F',>^[SQ&VPS
MVM/\)UL3PL&O-,G8V%ASOKDU3;9<DQ2S&[HAF?AD1?,4<W&;1R;;Y 2'15*:
MF+9E^6:*X\R8C(JVIWPRHEN>Q!EYR@';IBG.7Z8DH?NQ 8U#PW,<K;EL,">C
M#8[(G/#OFZ=<W)DU)8Q3DK&89B GJ[%Q!V\1',J$(N*OF.Q9ZQK(4A:4_I0W
M]^'8L.2(2$*67"*P^+<C,Y(DDB3&\6\%->H^96+[^D#_7!0OBEE@1F8T^3L.
M^7IL# P0DA7>)OR9[K^0JB!/\I8T8<5?L*]B+0,LMXS3M$H6(TCCK/R/?U5"
MM!*@?R;!KA+LXP3W3()3)3BO37"K!+=0IBRET %ACB>CG.Y!+J,%35X48A;9
MHOPXD\]]SG/Q:2SR^ 3%#$=13B+,20B>R8YD6\+ )S 7,RS<)@30U:$9W&?E
M1),/;"K$#H&XX&L"'NBR:&7@/2(<QPG[(!#?YPB\?_=A9'(Q4-F=N:P&-2T'
M99\9%+3!(\WXFH$_LY"$78 I*JS+M ]E3FTE$9'E#7#@1V!;MMLSH-GKTYV>
M=/3Z=%M1C5,_-*?@.6=X;WPV/QX$!]QSDK)_^AY*V:G;WZE\ =VR#5Z2L2'>
M,(SD.V),?O\-^M8??8+JA"%-L([8;BVVJZ)/'F@6?4K$RRD$F#'"V4? *<=)
MGX(ER2M(\HV[FS@!]'U_9.[:VIR&N:YO66XW#)V&>9;ON$X=UJG'J^OQE/5\
M^0KF=\_@QR-)%R3OG0A*P*4302<,:8)UA/-KX?QKN,[7*;9.&-($ZX@=U&('
MVEQ7DORVZZP!//+<:9 W.#:<<DC]!0-%K8.ZUH&RUMDZSK#2D,K\2^>(3AC2
M!.OH-JQU&U[#D$.=8NN$(4VPCMC0:E:*EC9+5JBVW09.8!UY4MWAJPQ7"J,!
MU!6EM7R&2E&^ON31RW^,XTQI8#7ETDFEE89TT;H*VHV"]C5<7/6J2W&=-*2+
MUE6\V3U Y7KY,B._8>G=9]&9+A"J0.U7BVU[\,RJ&#;+?*A>Y\]PNJ!AK/XB
M5C,NGE4Z:4@7K:M?LZV WE5\K'4SHI6&=-&ZBC?[$:A<@5_F8__$-6XPM.SC
M;^33,.@$;G 4AWKB;'MH#;PS+FR6_5"][O^VQG&"LU#MPC<LU!5S0B<-Z:)U
M]6NV$G!P%1=JW8%HI2%=M*[BS28$*I?=E[EP>'I !&VG]>55"=039P5#=W!L
MP],XVW,#]]B&9NN ."5Y5!RT,["DVXR7AZAU:WF8/Y6'^?* ^:C]#M[>%4?;
M9H,I?R%XQ'D4BYF4D)5 6C>!&%1>'KJ7-YQNBF/H!>6<IL7EFN"0Y#) ?+ZB
ME!]N9 ?U3Q^3_P%02P,$%     @ ^CBA6MR;(UX@ P  %0L  !D   !X;"]W
M;W)K<VAE971S+W-H965T.#$N>&ULK59M;YLP$/XK%INF5NH")H0D78*4ETV+
MM&I1HVX?JGUPX!*L LYL)^G^_6Q#*$DI[:9\ =O</7Z>L^^XP9[Q!Q$#2/28
M)ID86K&4FVO;%F$,*1$MMH%,?5DQGA*IIGQMBPT'$AFG-+%=Q_'ME-#,"@9F
M;<Z# =O*A&8PYTALTY3P/V-(V'YH8>NP<$O7L=0+=C#8D#4L0-YMYES-[!(E
MHBED@K(,<5@-K1&^GF#C8"Q^4-B+RAAI*4O&'O1D%@TM1S."!$*I(8AZ[6 "
M2:*1%(_?!:A5[JD=J^,#^A<C7HE9$@$3EORDD8R'5L]"$:S(-I&W;/\5"D$=
MC1>R1)@GVN>VGFNA<"LD2PMGQ2"E6?XFCT4@*@[8?\'!+1S<4P?O!8=VX= V
M0G-F1M:42!(,.-LCKJT5FAZ8V!AOI89F^A@7DJNO5/G)X):*!X$NIB )3<0E
M^HCN%E-T\?YR8$L%KXWLL( :YU#N"U#813<LD[% G[,(HF, 6_$JR;D'<F.W
M$7$*80NU\15R'=>K(31YNWN[@4Z[C%7;X+4;8W7_32VCF814_*H+4H[AU6/H
MK+P6&Q+"T%)I)X#OP H^O,.^\ZE.X)G CN1ZI5RO"3T8)2K'218"4M5"Y5O(
MMIE4J1L"W9%E J).?0[9,9"ZA.P"W!_8NZJF1I,CIIV2::>1Z2P+50D3@"XB
MR$>7B&825$P4875JB!,)=71SW%Z%B]-R\ GAQLW_\Q#\4IK_BK2##*4 ,1D#
M1SO"J3F *[0!'D(F5<&M4^>_15WC_O^IKENJZ[[IX**GDXLN$4GU3:L3U'UV
M=5R_U_=.%.56?L6JX^'Z&]8KB?::<P$MYJ,)FJ'[&TB7P&LSOQ'B7S/_3&!'
M:ONEVOX9"EW_G'+/!'8D%SM//T'G_*6NP*S>L].;6&."O?J;B"M_;-Q(]KLI
M J^1P\^K;+>'>Z<$7S/+.=J5!B,%OC9]ET F3/GOO%S->[NQ[NUT@W*RKGJ^
MD>ET[">8O&&\(7Q-,X$26"E(I]55G'C>@^43R3:FC5DRJ9HB,XQ5WPI<&ZCO
M*\;D8:(W*#OAX"]02P,$%     @ ^CBA6H8TD6IQ @  )0@  !D   !X;"]W
M;W)K<VAE971S+W-H965T.#(N>&ULO59K;]HP%/TK5C9-K;21D-<Z%B(-T-1*
M0T*P;A^J?C#)A5BUX\PVC_[[V4Z(0*.TW="^$%_;Y_B>X\<EV7#Q( L A;:,
MEK+O%$I5/=>560$,RPZOH-0C"RX85CH42U=6 G!N08RZON?%+L.D=-+$]DU$
MFO"5HJ2$B4!RQ1@6CP.@?--WNLZN8TJ6A3(=;II4> DS4+?51.C(;5ERPJ"4
MA)=(P*+O?.GVAK&9;R?\(+"1>VUDE,PY?S#!3=YW/),04,B48<#ZLX8A4&J(
M=!J_&DZG7=( ]]L[]J]6N]8RQQ*&G/XDN2KZSI6#<EC@%553OKF&1D]D^#).
MI?U%FV:NYZ!L)15G#5AGP$A9?_&V\6$/T V? /@-P'\I(&@ @15:9V9EC;#"
M:2+X!@DS6[.9AO7&HK4:4II=G"FA1XG&J70*%"O(T00+]8@&F.(R XEPF:/O
M I<26[<ENAB!PH3*2_0!'6+NQL#F(.[UP.ULA"[>7B:NTID9?C=KLAC46?A/
M9#&"K(."[GOD>WYX!#Y\.3PXA+O:C]84OS7%MWS!/YIR]TT#T8T")N^/B:Y7
M"8^O8NYG3U8X@[ZC+Z $L08G??>F&WN?CUEP)K(#0X+6D. 4>SI: 5(<R0(+
M*#C-0<AC>FN2R)*8YV.=?O+CJ)NXZWTA)Y?Z2R%A*R0\*62,MX2M6'MHCZDX
MR?#:73L3V8'8J!4;_9=C')W3D#.1'1@2MX;$SQ[CA>#LV8-\DN:UBN,_;D40
MA?Y5U%Z+6HN[]XB; CK&8DGT[E!8:*#7^:@91%V4ZD#QRK[K<ZYTE;#-0M=Q
M$&:"'E]PKG:!*17M/X/T-U!+ P04    " #Z.*%:BIFRZ?8$  !N%@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6RU6%%OXC@0?K]?,6+WJE9B(0F!
M0@M(+5RU>[>5JM*]U:FZ!Y,88FT2YVRG;*7[\6<[(9 23.FE+Q GGL\S7\:3
MSS-<4?:#!Q@+^!F%,1\U B&2BW:;>P&.$&_1!,?RR8*R" DY9,LV3QA&OC:*
MPK9C6;UVA$C<& _UO3LV'M)4A"3&=PQX&D6(/5_CD*Y&#;NQOG%/EH%0-]KC
M88*6>(;%M^2.R5&[0/%)A&-.: P,+T:-*_MBZEC*0,_XD^ 5W[H&%<J<TA]J
M\,4?-2SE$0ZQ)Q0$DG]/>(+#4"%)/_[)01O%FLIP^WJ-?J.#E\',$<<3&GXG
MO@A&C7X#?+Q :2CNZ>HSS@/J*CR/AES_PBJ?:S7 2[F@46XL/8A(G/VCGSD1
M6P9V9X^!DQLX+PPZO3T&G=R@\W(%=X^!FQNXFIDL%,W#% DT'C*Z J9F2S1U
MH<G4UC)\$JOW/A-,/B723HSO<8@$]N$.,?$,URA$L8<YH-B'!X9BCO3KX? )
M9C+E_#3$0!=P%=$T%C!-,2P8C?1T-1 4M@&)1#J=8H%(R,\DQ+?9%$X_G@W;
M0GJNUF][N9>3S$MGCY>V [<T%@&'WV(?^V6 M@RYB-M9QSUQC(A3[+6@8S?!
ML9Q.A4/3UYN[!G<ZQ6OH:#QW#]XM:\&,I/"=Q$NX2>-E$Z["!9,\GIY\Z#N.
M=9G/T"/[\DQ3?LM;<$.EA4QO^"O%37@@,=J8Y(\+F\=;',TQ^[OJ!1C]4]7G
M@B?(PZ.&+"\<LR?<&)]\L'O6915Y-8&5J'0+*EV-WGE51F\E,3Q^E5/AB\ 1
MKZ3 K9."FL!*%'0+"KK&;-(4J&T;D*0J4+/U+$ ,!S3T,<L*@4^8K-*4\:HX
MC5AOC+-7Q-DS>EK4'[[E<E7 &4Q7PZ@OX=.XTW6=?G?8?MJ.97>::[E==U!,
M*WEY7GAY;M[;->Y2XTK'IFA-8"52^@4I_7?:I?TZ*:@)K$3!H*!@\']VZ;79
M^M&N9,=LM']KPVE,!0:[ZN,\-8*^D27;VB@4Z^ NE\("29F9Y4RB<J:*L0-
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M!A>7*$K5_;\VC"Q="UU)@PW9#7-\,D%9!UQ?2VGVAMV@?823GU!+ P04
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MX_[S _JE31Z261!%9R*Y9;'>3+R1AV*Z(GFB;\3V-UHFU#=X2Y$H^Q]M2]O
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M!O!^)6 1*1LF0%5SG_X'4$L#!!0    ( /HXH5K<JXR"> (  '@&   9
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MSIK*,<\*LJPC69S6-!,F5864-N>JB$6N%ZCY*6-RW=$.BK*X^P=02P,$%
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M0E2+4"U&M832NFG8MFI&TD/.KZX7:5DJGY7GW8V/:XG2@R3EY-'9B/9J4,U
M-1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42VAM&Z(MKV:T>,A[-Q!DB.T68-J
M.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEE-:-T+:E,Y*W=%Y_W5UT
M#II\;_<EVMI!-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+=UKG0O2OFXSHC#&J
M)936S<BVBS.2'JC^=-ZTP[_509LXJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J
MX4[KQ.+X8J2-M=?9B)9L4"VAM&XVMB6;D;R8\=Y^3.7?RF_SK!**E^4K^=Y-
MM(>#:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J)936B=9Q6\T9#^"]
MFV.TIH-J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEE-:-T+;,,_YO
ME'GDZ-$QBI9Y4,U -1/5+%2SQ_M%HV'/V==Z'M931W)['G8Q?OTHKV_.?<Q'
M7VB :B&J1:@6HUI":=VDTMJDDA=9#MB.U@;:6$G$=%-D55;_*MH4TWE:"N7S
M72'$\KU3K,F?P-&IAEX.!]4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-42
M2NM&;EO5&0_I[6NTKH-J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HE
ME-:-T+;34]^4;U]G=_7JZD)9%]EJFJWK6V]7>^36T>E):CJJ&:AF[K3.%;NT
MGI-16^BT-JHYJ.:BFH=J/JH%J!:B6H1J,:HEE-8-QK;>,_YS]9YZ<_ZH\Z/+
MISLZ.]'J#ZH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEE-8-V+;Z,Z:K
M/V.T^H-J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEE-:-T+;Z,SZN
M^G/@E^-HYP?5=%0SQONMB;XK+YOHK!:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6
M4%HW()O>3_>>]FCWL?QH]V_JOY1_S,538J:ELIUXU72#YNF]4&Z$6"GI[/\V
M97-7(:HB+]=B6F7W8O%#N<T+)56>KDNQ#5DE::Y+H8C;V_I1]9 Z? UQ4VR:
M7-Y^X9_?*NKC?-OAS=CF-XKX(RNKYEQ*C[_;A7<L?FZ?4?WTFJ,"LGSU"#<7
M/U>T8=][<UK.A:B^IE5Z=;D4Q9VX%HM%J4R;?;G-KL<7]]:OZK;^%*H??U%/
M3O?NK]_!CW']+N[_)M(^_J+UC5 _?NF]?WQ>2^?-;T[;IW1UN4[OA)\6=]FJ
M5!;BMGYZ@P]G]<9(D=W-GW^H\O6G$_5$N<FK*E]N;\Y%.A-%\X#Z][=Y_5[L
M?F@F>,B+[]NWX.K_ 5!+ P04    " #Z.*%:56BUG:4#  #+&0  #0   'AL
M+W-T>6QE<RYX;6S=6=U.VS 4?I4HC FDB33-2)O15MHJ(4W:)B2XV!UR&Z>U
MY/S,<5G+Y5YC%WL-[O8JVYYD/G&:I,6G BY&LU80^WSYOO/9/DZP&.1RQ>GE
MG%)I+6.>Y$-[+F7VQG'RZ9S&)#]),YHH)$I%3*3JBIF39X*2, =2S)UNI^,[
M,6&)/1HDB_@\EKDU31>)'-JN5\4L?7D?JJC_VK:TWC@-Z="^/GKY99'*LQ>6
MOAZ\.CCH7!^?;<>/"N#8=HRBIP\0/>G@N@K#I/U-Z>+V0R6DB8<8K6>@J2PU
M$SH8N?^PX>P<#SJ@P.BLX0LA]CKF(76:7#QOST7H&VR,W$7(&_.)3FC/,T_H
MK[N?2-G5R,["ZSVDFD]VK1,FC%3TGV]WB.,:V>W8-PO__O$=$:Z1AK!3[O;1
M($J3>M/#GH> RDQB:MT0/K3'A+.)8,"*2,SX2H>[$)BF/!665$\;9<6%2'ZK
M85?WX$%4ZL0L24616V?0OR?E[5O N@<&&>>5P:ZM Z-!1J2D(CE7G>+F(G@/
MLLKVU2I3#F>"K-SNJ5T3BHM*,DE%2$7]\+/7H=& TPCL"#:;PU6FF0.@E&FL
M&B$CLS0AA8<UHVPHV2GE_!*>TI^C#>UEU%C38E\F55,9*IM:1G= OZFFM9NR
MP9-TK8S=I/+=0@TG*?I0*?1"T(@MB_XRJ@Q@ZBZN3K*,K]YR-DMBJ@?_X(2C
M 5GSK'DJV*W*!J4R50$J;.N&"LFFS<A70;(KNI3K<EI&N.=N"SW_VWF>T80*
MPINF5>WO\RP_V7'Y5\US>"X>*]N.C2:]WOY[+/^2VW>3?AM,MF*Y^VTP&;3
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M[V'\.I;AUO.]QN?_)-7CY;OE]OCK\OLBOB]65YSK^XKAZ2]02P,$%     @
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " #Z.*%:F5R<(Q &  "<)P  $P
M            @ 'E 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M /HXH5KB,,F6RP0  !T4   8              " @28(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #Z.*%:3SV0KV,)  "K*P  &
M            @($G#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ ^CBA6GPTDG)[ P  B@H  !@              ("!P!8  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( /HXH5HZG_PSJ <  +0A
M   8              " @7$:  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " #Z.*%:EN8Q:J()  "%0@  &               @(%/(@
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ^CBA6J7+/:6^
M"P  U40  !@              ("!)RP  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( /HXH5KU'5$KK!<  +=#   8              "
M@1LX  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #Z.*%:
M+3P[H_4G   _=@  &               @(']3P  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ ^CBA6F0U=)P7!@  S0T  !@
M     ("!*'@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M /HXH5I"S0BM&0,  $,'   9              " @75^  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ ^CBA6A>9N]EO @  5P4  !D
M             ("!Q8$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " #Z.*%:;.:R4.H#  !^"   &0              @(%KA   >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( /HXH5I>A34$4 ,
M + &   9              " @8R(  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ ^CBA6NA2X+!J P  +@<  !D              ("!
M$XP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #Z.*%:
M8,%MS(P#  !9!P  &0              @(&TCP  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( /HXH5I:\.'Q/0@  +\4   9
M      " @7>3  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ ^CBA6F>T-,;J!   ^ L  !D              ("!ZYL  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #Z.*%:X\NJ4@X&   S#@
M&0              @($,H0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( /HXH5I/Z[BSUP0  ( ,   9              " @5&G  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ ^CBA6C)7K96&
M"   G!0  !D              ("!7ZP  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " #Z.*%:ON"*@#H$   M"0  &0
M@($<M0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /HX
MH5J),NU"7PD  /48   9              " @8VY  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ ^CBA6HET"_U'!0  SPP  !D
M         ("!(\,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " #Z.*%:*F!F4O0#  "&"   &0              @(&AR   >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( /HXH5J<Z+/%T0(  #P&
M   9              " @<S,  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ ^CBA6J",16!G!   50D  !D              ("!U,\
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #Z.*%:T*0(
M<,4$  !Q"@  &0              @(%RU   >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( /HXH5K3NI;?91   "$I   9
M  " @6[9  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M^CBA6K+5_U2#!   #0H  !D              ("!"NH  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " #Z.*%:S,J9I'\I  #I@P  &0
M            @('$[@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( /HXH5JES*?9[00  -4+   9              " @7H8 0!X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ ^CBA6DHYJ$"C P
MG @  !D              ("!GAT! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " #Z.*%:JK_$]CH#  #&"   &0              @(%X
M(0$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( /HXH5JT
MH#ZA9 (  %$%   9              " @>DD 0!X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ ^CBA6L9Z7(2^ P  U@@  !D
M     ("!A"<! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /HXH5H^113FE ,  +0(   9              "
M@0X[ 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ ^CBA
M6CV;RPX0!0  ^PL  !D              ("!V3X! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " #Z.*%:Q+[ZGR\$  #,"@  &0
M        @($@1 $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( /HXH5JP]HDH,@0  ",*   9              " @89( 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ ^CBA6H@K^&9_!0  K X
M !D              ("![TP! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " #Z.*%:1*+Z%680  !   $ &0              @(&E4@$
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( /HXH5J+]D%(
MW@8  #$C   9              " @4)C 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ ^CBA6A( A1+Y!   62(  !D
M ("!5VH! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #Z
M.*%:NVN;TRD$  !I&P  &0              @(&';P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( /HXH5KH?]$U^P,  +X9   9
M          " @>=S 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#
M%     @ ^CBA6L@W%51/ P  /@L  !D              ("!&7@! 'AL+W=O
M<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #Z.*%:&;^YT<P"  #8
M!P  &0              @(&?>P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM
M;%!+ 0(4 Q0    ( /HXH5KB/NO5@P(  % (   9              " @:)^
M 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ ^CBA6JLC
MB/'- @  C@<  !D              ("!7($! 'AL+W=O<FMS:&5E=',O<VAE
M970U,RYX;6Q02P$"% ,4    " #Z.*%:&/Q%9:T"   ?!P  &0
M    @(%@A $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M /HXH5H;B>W=, ,  *,-   9              " @42' 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ ^CBA6EO]NW<8!   H X  !D
M             ("!JXH! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " #Z.*%:8<UJ,=\"  !X!P  &0              @('ZC@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( /HXH5JGWM-9<@(
M (H&   9              " @1"2 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ ^CBA6E$8:79-!   CA4  !D              ("!
MN90! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #Z.*%:
M,).;P.$#   [#   &0              @($]F0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( /HXH5J3+\EAY@,  /<*   9
M      " @56= 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ ^CBA6@28C*;X!0  5RD  !D              ("!<J$! 'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #Z.*%:MKV>'A #  "="@
M&0              @(&AIP$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( /HXH5I#,?4F;@0  %D5   9              " @>BJ 0!X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ ^CBA6H1_= #Y
M @  T@@  !D              ("!C:\! 'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    " #Z.*%:7"#.\'T"  "0!@  &0
M@(&]L@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( /HX
MH5J&;YZQY@(  *X(   9              " @7&U 0!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ ^CBA6L&4UC3" P  A1(  !D
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M=#<R+GAM;%!+ 0(4 Q0    ( /HXH5H@&(^"K@8  ) ]   9
M  " @;W2 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @
M^CBA6HB4=LBZ!@  Y2P  !D              ("!HMD! 'AL+W=O<FMS:&5E
M=',O<VAE970W-"YX;6Q02P$"% ,4    " #Z.*%:EZ^R "8$  #B%0  &0
M            @(&3X $ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4
M Q0    ( /HXH5KQE4^"600  'L0   9              " @?#D 0!X;"]W
M;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ ^CBA6KTW[6][ @
MP@8  !D              ("!@.D! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX
M;6Q02P$"% ,4    " #Z.*%:PW<HMU #  "Z#0  &0              @($R
M[ $ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( /HXH5J:
M23^2W@,  )$4   9              " @;GO 0!X;"]W;W)K<VAE971S+W-H
M965T-SDN>&UL4$L! A0#%     @ ^CBA6@$#;O$J!   !AD  !D
M     ("!SO,! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /HXH5H5MU*AS0(  ) '   9              "
M@5(& @!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ ^CBA
M6ORU7.9%!   ?Q<  !D              ("!5@D" 'AL+W=O<FMS:&5E=',O
M<VAE970X-BYX;6Q02P$"% ,4    " #Z.*%:W*N,@G@"  !X!@  &0
M        @('2#0( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0
M   ( /HXH5KN"C3D*P,  "(+   9              " @8$0 @!X;"]W;W)K
M<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ ^CBA6NVDI^ = @  T 0
M !D              ("!XQ," 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q0
M2P$"% ,4    " #Z.*%:@L$R4#D1  !=* $ &0              @($W%@(
M>&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( /HXH5I5:+6=
MI0,  ,L9   -              "  :<G @!X;"]S='EL97,N>&UL4$L! A0#
M%     @ ^CBA6I>*NQS     $P(   L              ( !=RL" %]R96QS
M+RYR96QS4$L! A0#%     @ ^CBA6@K&[CUH!@  ^CH   \
M ( !8"P" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /HXH5KFXJ30H (
M  4U   :              "  ?4R @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( /HXH5K"@ QK.@(  &@S   3              "
M <TU @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !B &( Y1H  #@X @
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001213900-25-038045-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-038045-xbrl.zip
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M 6L@#T^BI%*HT*#3 W0>,]B2Y\Q@/?1*%J#WX81@X#7]"(9=*3 #4/,J3N=
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MWAS8-_\X]^H%$QXVOZ&$A_M4ASLDB\Y4V,1J-+D#A-N1+H):\@!+A;JJAC*
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MB<>87$\7\AAS93\G;JHO4SW4C.^V6.*J1)<FXN#1/]!P5 C283PQXH8D*\?
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M9GA0O3>N*.-\Q(>+Q1(O]ZSTT8#21R^3;FQ%W)),YD<72D'M!X=GIEHL3]J
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M))<^IU)%CIX8TLYG"CC>U%;7*\B7U+]U599SI3&-8'U1FHP6&(4T+_+OR;Q
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M-JU;=(9)81I^5VD?>FEP&C:22%CM$L7K+WD$#4 T11A52,%I2[&] 4Z*Z_I
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M)N"D:4:-#?$KACSJR;6'J<[^I\26P'D3^ :=9/:K@+H-D=A@1)EQE8Y$R9N
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MYR$&9TV7),PCR)5S[%@\=]F=GB19=;NYK/>)<XDX7D5QT%R1^F,]4$/%(<L
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MR*I2ZCSDI J>[K=[S H\\1$=9TY/VR/T$G929KV4^</)\? D!<3IP")&G,/
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MCOK%"P*W"0G"&%V<:<JM!2.'WPF*.%,P<CX>Z*#WFM@NEN J^@OTR_[KEP]
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M46?'OYM?F+U*M/8H03Z.I:(%%I1;ME5.@S;.?5+'PY<O!B]?O'GI.1JY\LY
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ML91*])-)QK(/OY[(8X.+<9=K7L@.:(3#2-YAN_WG$!A). <D#X,F0- ^O?^
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M=8[3;LI,O*2S+^,I=<N5C3SO#HK!.UHKF18X#:LH) U0?%[) 7^&$2;JG\[
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MS 4Y%ED"FA#]P7594)(8QZW@)_C"L$ 2H59,2)H-A!4K !,#Y\XO]7:I5$+
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MV@VZB+EOCB$^A&CP+XH8V'XCU<,?C1#J\ZOP?L')^*&[1!#I^&1 *%CKJ^=
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MP\G$$:@0V)>[?4G0J'XO;#O^"EMJ_N?G%PN)NASMP5]TI[S7X9I(X21Z7#<
MP!_5U)TAAD,W2>CM.'4.?<Q-R*\XZ+XPZ2H6CI!/A58<"1^C;K-IR[GQ7@7#
M@R*#$M!+ YMX84XZ]@:LJXMGU2%!2">'F;9JW%34^98R-$?,<?&ES/&/0B3X
MHVSO7>TH7;8],/\(O?J@@<<V$+-S_L #O?3.;#F1LGA5K'/T48^%OJN;V();
MYNTEF+#3 ^W4:/_IY&<<F+E'[>F&KUK\E*BA+J3U%]V\7: ;#XWOX8BQ^:\K
MZF;LA'\#9I(YTT%''$#5ADE*66=C?ML8-.E#(R.V9%)M8WF)(2OPF#HM=0!#
MN5/U@"QCDO8FQB?!K28EM;9%%?AI+HJ$"HN:,[<%T-+CWV$R$TD<O^DZ64Z!
MO;$8O(K#: %RIEM4;^+S;NL<= 1ES:H\5)"%UQB=(G U56/-C,@SZ$R*/I5T
M_5#9R_G5?I<VRR_$H7(K)/?C$Y)[%LG]]0G)_>?R:^+1)F3<[5!+80>A#JI"
M*L-J39J@K/DY\#)5EB0Y5D0H0?;(ME\3(11MN7I!ZL!>$I4L)#S@3F4# N[)
MX"OQ:_48>4^/,[063_[1I_*/;FQ$HI@)9H8HW#<P)\WE1,.*5D6Y'7KMJG!F
M;N<B#4@;K-7RMF_SBUI@)?U^0W0'*2E!<*FBWLA0;47P^]/BD716NUZXE:)4
MJM"6L(!(]!9&XFTVA<6/@N)^'#3*^]'#C.J%]*2Y(%G\C\<Q0W $PW3PQ3AR
MT5D.K!6C1<Q2)\2M&\)N=#'$^<83,/% 5P@3GW>24<5 B2)S)"1(_#3;L\6;
M&E26]D[$Y1,I@K8'/%2Q$K6T]E)5 _AVWD_S-EUN#U&?3)\LWV;!W()L.6R+
M/'@7"/8-C_N"E,TZYNCP)AFT<.B(]W-#1H'-C1\[VB_H4RNSM9%T&W%7K ]S
MKIQ]"JN2 &,KBK>1V9J>OPV/-^:R!K$X"!&;8:!!N;KX?<A<1;LYF["/8S[M
M(JH]):* ET$L,%$9LUG0A!LNC2-J3*3H:I'!=ZT3<PS&:JH 1XZ"&9$&(<%0
M7FZ3#Z)=QP1E874FF!ABK&*U9M:MUTSSLJD?)"IF&J[=,C7.V<OMX8:'IIL\
M-"4'845$]7ND_MF^1^JP>%<0Y@Z_$[Z1%E26FP"2F]]*/O;A?/=\I+OOQ;U!
M&0!T0,Y$X5L&,>PIM]YTA]!AULH)HBDMI-LI$9_^DDC/BB*J?=Z:/N9]-C*S
M8M-\Y>+DKWTZ?VW+X"MPX@H*Z_T$H="::P"U!;&H$=EK0*+7L8J"6)U8H=]4
M?RP;[\O\2!5OG#*O_O9Z\0(QK4MN#!TZ;S94>5J5*VQ7K+;0*' Q\9F82HOO
M5E_[[;Z]+/>P9;AL1*(>JD"K>MFS21>0W5E*.JML%@TQ++:4SV+S1\$H3(W_
M\_SXI61'8>^\UP2/J>RB/-Q%0I$IT@+;;4'=49G;YM>M/^!;P] ;J'B]QQN5
MXN:'Q7-C7@KM\&%7D >C8Y!=2,Z($:&7=V'D!;A5'>?_RMO>:H$\'0T*$[;0
M^<()-C\6D_?#A>7?@XL84P2K&P%?0*KHPM3 E$ ]?UDV*X!8_*E\HQM/;&KR
M'HK*3\.RP(F8G'=Z=.'C%1G'5;Y4US8,EOT/IMEEYV=50N^%)E+62$K':1GL
ML^FXQKM)?:.7)5=]6;?8+1UKT;SYZ?GCQ8XX&L6-#[\5U[PA5 \E/>4A0\(Q
M>%8X$:3\S9=7G>]3V?*CC?/GRL58SV3.M8#-"T+V3&QN)I( U[+N547@1$P7
M36*+%$ )S[I?*X-UX<SF@$*&'OV:U:>F-^_1ANK6\[S:O*W?+EX6G=]B"4_@
MG_09"W 0 Y3PW3Y_^4S9;@$;4&6WF(Y_Q4R /Z%V[Y[Y_>CYV0]GB_.GCY\N
M[CWZ[KOS^PF![JN?P@5UX;P6+JEO'@4>P)^>'5OYC+" (GF@T$]HB5'%+=NZ
MTA( +ZRO%_?:\MU]4O7M+E7I=4W-@.$K?NT]?4@J4-B=+^H@QOORF8(+".F"
MS/"Q$5*@V-5[%[,$]B5@5[Z6N@7K>YOM0"9!OEP>VWQE3+0/(%O"=)2TN1)Q
M.]L ^U]G;GZ7.G+]FVQ;BUMN6^ZT;7W&<:8J.T3U7+/!C]WZN)S(,Z&M"HV*
M5;ZC:(!T3WZLJ?(EZB<+4C_)@OYC'I8C7?V83V5*D\6V]#N:V(B:NCMZW(=1
MVH2#'QS//X\02;.:\H.;OMQV@6\IOR!L!V56:--E]>W@J-E- QNZ,UTX3+[\
M'O#&/$YC(DYJ90>X*%A+ FBW-DPS]GOY@#*?]?8*[HVF:5;YX4%7/U@A@*MR
M+CL?G_DYZGB2NWE=]ME8\T9IK."FNH%BB1A(8DMA:R;BW]('&2"P# ^JF0FR
MR46Z-VZ:NM]'S8-J=,1-/(@SR1V<;#)?%OSG9Y-U2S-*7E-J9Z5;:Z"1;XN.
M-C$6G"Y$H2;L<[)= SGD[[51+]$;"S4\.KMK8:<\4:I^W,KNDU-E=[:R^\VI
MLOOGR@G&)$\47*:-K*H-Z!@Z!32WXPK<J4[Z24#T>=NR&!V)OJ(SEV2I=J0X
M2B#F6-4KIUR(JNBNZ^8M_!:BQ&D9+Q5;@K8EEW#*PNA\E=4EIR*$RAQA)O43
MD8Q35&QX*8.(U0Q[-9,L894+E2&Y.!B#4D=@XH& G<O)Z+9YN<,#%N\H!'$J
M?S<V2P*4\[=CD9,U R?N+2SYTMO$_)DXZ'-%[=(-MWWHI+I&K&&&ZVXZ_RSV
MX<-XGO]92*B"\)<'A@;W%89+K]\[!3PG$9%F1! <!TTZG2N6L>"@+]0=4^SH
MI(;YK3S-4_#T49?Z5&_'#26X($M(CJ1?P47>^'?:D@QTRPIXIAJ:]I DG?SA
M-F[N-O%@0 TY>,4:J#Q0.91X!V43L,'9JBY:7I7A>@$0&GYYYN;2XA9,,+,1
MDB7KTH-_;4($K5.S"GNXL5Y(MS"S4;BIVFG-R?*Z[U(M$E$+C(WJ5%,'>F$
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MX5<%;9#8;'Q\W#!W2L;IW>*=)-N\$<3OE80;W'']-^Q,![5VP'OZ/:CK@YW
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M8$,P%T,.Z.A, IZ9YU8OEU$5L&1W;Q0W\'206^2///S8VP'RE]YGXZZY>HE
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M?Z(4:DJT,;_%Z6:*F"X*+E!H;SI' /EU3H2 [%#O!Y>-FI3O)4?T ;J(HML
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M7D-KKQ,[8A\P6%PDD"0V$^Q4%K5C&+*<(BVD4#DKMRTNQT?K@TH=D-:UN4I
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MO$-RK+PS<A5(MKEU9B>Q8O%NKP ]9>;V@4QU"<@ _97URBFMO,SW 9\_"&J
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MS 1"/5"3; V8KJ%)5][4!74V$-29[VC."%*,O$3R \@2D0AU"!_AE_7C"H>
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MCH0_*Y]ZY<+GOG3[^P?G/?=3BC".F)"7X;F'&=;LSOT&[[_P>5H1+QY682U
MF!@A([^D6>Z^12F#^7[.IY^OW4MB0_<RZ<&4\J!7SN*H5QT5,6M#'!<CBQ.1
MP<_,_7(@1ZFDN]3,+\O90?&-)2B\!8_A[;%SG0L,?0;N;S&C]N4(+_(TU,:E
MN"VQPS9@\R=GC#GWM5>=XONLY^#'-?H61C/5"'K.X6HE:'=%@G8J!-U$R5F/
M5K L%;MW4[$>L:1@F3H+B'-B5D_)#:#)P3H7'76N=:I;P#1D!CG*#.+=(IG'
MEE&-5^:[6+1H;T5['X%>!_#7P;X'=-@_JH^,&5ONX;Y+\-^8:W";I)2\8&&"
M "U>9*'HN;_ OY$/,"$H'(8P(X5[K3HX"48707[$+C^@I%)L+N?^@F3_:X+L
M:;T]B1"LQ_U)<0 RU3MQZR@&()HO:9V^3>) PYV#;&@1_58#&7R2-T:-]P[^
M2;^S1W[YVZ^OK&UQ1)0E9G:MK[GBP@D%O8MO^L1[<3'$QB@*V-RLW&9;W$<0
M/]2G"+68+V#,E"LA/U'+C3\PN6B<8#[52Y5)].GV4F4.O:ILJ1:9L?MG$B(,
M@G#C JN$*'E4@[,33CFV5"JF52PE;!J'='6+Y>O"-!]T++R8/Y,!Y3RI="Z&
MJ$= #Q)- D0H9GKPE: %D93+2,+[)T6L,Z/_QL4FJF">L&GS$*4V[<A8!$1\
MDLP:AR%P0@I$Q )83H2WR'K7\+R8HMC'0=Z+2,R -G5;/FX7@?A/.:(JWV Z
MS8B/:&[9D2+S)"O2DLB?5"(\:BORQ4*I*6ZHA).#O')1W"F90LOW-*J3Q=+%
M- TC]]"627,#4BN(+ LSDBL5O$ Z/M">QES@AEVP=A^3I[%")(</DV@*/)$#
MK\9)'&;(CA%1[3L%;<:3>2]FJ*-/E62QM?P__WC_LWOYZ4+_P@,=KV6?YG<C
M^S)'+:X8P0XKM?^+M#L@:@+GU5$K;].)$\T?F#6#B[N7O3]Z%'QS_Z^83/_.
M1L6BE[/ N<:&H<C^#KQ^']G^/0$#&$L:]YF;!RCI,T[BI$BQ4=$T D*J-8NM
M2;'K,9AW_X))V?*3NH.FL#J50YJ5/W#,#RX30J)_I5*&+2.>12SN]K5O%(X-
M;%VJ%]_ $,E&W6!62&J*JR7A6^K[52[BR@! 8F^015O*G3405"OQ0Y/20&1)
M'^C^(F,4YNB]E:-9PVQ IFR'J&@-6[ 0F0LH.V5 F45)LPCY_>WR(N3@F&3(
M,=K7S"[&JNDKJP9/J&+-. HVSP)%0\1W! FB',<J'"#20%1\*T"HC).,P(0H
M%3,;*VN(6E7&;B0%)E<"[09I2%T8P.*\S1F3PVY>*K]AA@G.I>=<:P?AF%T.
MLP)LS/=.#%#845*GEG!&#@E,WLY";$LQX_XT$LT;D(6IN"4W]I_)#,;^&<S>
M*25L8K[WF)I*8*.081$QA#V<&.7C!TZ)N@BKPX:'F,Q,W5H'J8@#TV<B"$=A
M'OY'!F4?5D^EHE+:JX5;KQN]\5:@_Z5%(6\@=>I0W2) IF/3F-S]_?)R?KUO
M<N"U3UQJ&NJV$Y<I"ISWPA>%I_95M31K/4[C5?$(OU]],D6#/1!ODBT_IVJ7
M_E(>O%O"W+(L0J</6RG\3R'!Y, 60;9H0K,"K2;XK=#BY"*X09,T +>712Z-
M\T<(DQ<3X)41^*59*:70*O]R\?8-N(]1H0#\+F%SDUAB&NU[ZF ;QKR>-_3K
ML45- VR30=XK,"AG %/76]7N&(T>]Y/P\<34YBBYYVH,3]_E/M&,WDF@DDCB
MTE:]=I=! J@);/)7-+?)A-YMD(>K)/7"9+NDWK:DWL,NJ?=9N!%?0)ZIF\"J
M]X!?/,!]^  :EVR[_KGM0N"HZ$]SQ5/$M3\^Q4=*[T_EKGH.U[>QFLFTXV#U
M<>4V3!DI0+O'$UM\&.(DV?D[MEB:L9ZM.1:OP<SE:>[W#\LIW@KJ*(RN"6A=
M_".N+!;[)Y:YMK8[\G.*_=S>@(L^JK\1M&/_R'(]#FKOPZ#&ZMNQW&Y\DBEU
ME^$952,CRN7*S$1)V;T%DZ+ \<GO B]%GZC#6X763,;]1:VF7!AZ*4,:6- "
MNDXM'B?Y'A%33.87?G*=)R $WWQ3?5H9;(H^\Y, QC@!%_3\])R6>7C8/Z'&
M/U)UL.\YX+S=*E^M^4"(#C"$ :M&,#8R"^Y<\OXY+KD\JV,TY_3>WU(1FUK\
MK<1^2PL6689#S"+56\OS-^Z>#F?I,!;\7D/H@U$R"<%'SE5#[P8W"^V0ZUD0
MRUF%VXBR+&?K/HZ61S[V2V,IL9=8^;E9J%-Z6[:/Y=IB9<+7 L!7.K2IXY("
MJ["HXA!];S8#C;?K83V_[@]&1SD0\5<=2:PS!S9/1G]^6\/PCZP%%ET'O(E4
MRW'LZJ!J!Q[U5F!;-JE)57YL*:T 4C=:PATHS40*TU7EB%BWFDJUL5Y+WNOC
MD>>V;/(B2GQ+.1*J?ZS"(.PH45%B6T("Q5G1H9R[X"4E/"ZR ;NV 6C8H>RY
M'\M6""(C,HV23!?*5BJ"J!>DB:N5I41)$T\X8[J&Y3R7"HXDO48.2<OAY4PN
M)^[1_@&.^YD;GB*37._]NHW<\'3\\.1[ 1P)AE,2W9C6!)<,-N#@/7Z$ 1_5
M[;'C4LVE7]B0'R#VKT*GQ,![)(.1]!S-3OCQ'>R$II+G!D6J6VQ/P3J$5\9L
M,GG</3KD\PET;T[JFFNUX43& S44#O@1;!XJ4C%*Q73LO!R^PKDL8$?W8V6>
M%"LMIW?#/38:YP&68IQ5N@L7&?<_,:"=IEMPAI 4)HJ?J1Z97)2O*N496Z(4
M5=,BS0H1FZ[F::%;/J=F!:;<\?K-I258GG5:W")6?FW"GN]%GH;?T&.8-T@Z
M1M:,3" +U4)<[G<N,X?5H=Y/#&0C3+=O2([VU:N#/7P&*G6/3_9/]&,?1!:(
M?X-/R!C?^#WVW-@N4EU8=[N@3K92:+O\U-=27@NSP-7\]U^.ZS-M#<"JU-M;
MR<6U@R1JJ:IDGJES$^6@D>%/DV@IL5XVJWO1@LQYK3)4$Z^EH\'+_OZ1US\\
M\_K'QZ]:RY//L"!WOO/()3KF?+_U";04HOI$<VFN2,_5IB-6>:RUDI97'S2^
MV=Z!N9^<OV@^M_6E9'\9BS"J@[G=8^H/.;P_6% NRI[G%[Y-4B!IO)T+;Y H
MK[*LP/1QGO.B(UAVWS>[V?^2V1+=:]:[N7=SQOR[7[-Q@ME*8!>/PP$%%W\C
M3)]?L%>E9I=WXG9W=O]#\NB;OS1E?TFP== 'DT]GV3";W=[C^VU&I3ICDVA%
MF[NOW45;0#VGP3/,C2*J_B4TQ8KE2RVOF;,M[OD68P?TUV_8M$_HK9P(!']X
MLF4_Y\U]WVWMIK;V0Q+O_13&U#A[*S?X,7>S<>L&C:]^'0;NAR1W_S%(_\9O
M5=:-M#[Z&2_$4XX7;&:]]W&4;*-GV</[)-+<O?I!K<B]HB[B>2/-K.V\UJ5W
M'N]'W2JZ5=R?11\4@#CNOZ@%Z?;.441K&8,V-SC^B^6+Y1XLJ !?*W97<PA@
M#0/78QR$"+=HY/Y3SO;9[>9BL*1N-U?;3<HI[#_IG+L]?<"<-Q'MN</TQTD^
M7".PW0>&WVLY2>A.-/2QLD!-<7W:NC5,M*[1EJ"'QYG<%DRAVY]N?Y[=_CSR
M=<;#92M=?)AD=!D00L9-&&"+$:J0MVY$_EFD8::Z8CPOHKA3"7_O7--M4+=!
M6[U!&[O*?(!L???S3U_^Y_]UQ]C1>;=!W09MRP;MG(FJ;[G,W=;W$ ;HN*3;
MH&Z#=GF#6O+)=@"M8U40CH,.A*,5A..H ^%X5)R9194UB+(CXTQP_&HS]3/;
M7"K3+KV:BFBPFYW#W>RHYG^"44"-AZFWT;-0+!%LTLU$1  @954UHC4,DABK
M5+'&)I_5!B @2=74>"!C.0P5=A)]$0X**A)S\L34IMI?N--(Q-1+%8O1$&=B
M*L( 7B72F$$P_T8M7OT4T92L,KTA3!#>R+@&F% 4E$@CAP<,B$+30"P-#]OZ
MP9C^V%$E02W-^_"Q.63OJ08 IY(CC14!U#@(&>%C'M*IRQ!>(6=L*8712OO<
M3,_2VPO?M.'TP*52*1^V7@3ZH^Q MR(/Z9/?KO_:LA6;2;[\#O;Z:&OV>O4L
MS66RM$@ EG DE05M)&?N'G=\*V?+[?#4'R71[_1DQ6R4NUH];G&JSQJR? [.
M][W]_?V[%KS^F3ZK3>P?/\HF/D)-W#U4V\*FEALJ7ZA:@TN6+#R(-E9[U0/Y
M;HE*LP<MICN*I;EW,T>Q656XA,%ZM/B\J3#V_N;P':/?DYI@5#=("O .[RSL
MNNM(VNS;A[[W[KSOLU7X_JC1N%XC*W5G^8"S[!]OP5FVA/)W/![*""F?,/B&
M"""/'A*%*>B%;^;-RT1&[V[#!:[[),QS*3,G:>N+WL$QJ1CS'[)L<XB 8!IN
M6.\@0>>7F_@#=0:A#B[F(=.MZ8(^-]NO.S<ASJ\=3BF?,+]L_EH/X# R?YQ,
M*/YJD&G3:8)8_>X(.U]PPZOY27VH_NK2_.KG\E?FC:]Z[A^2(=A$D$QS@@_V
M&7K7T2%EC3)5WZN>^P:_]>WI$Z8WHP1SY&58Q J]#8'82A"Y@8R2VZ?LP[3=
M9-HN_?\1_EBC.P1=[SD(L5?[ B\BL+,2P8DA[&=3PR=L(N&Y[6W!&9%6XRXK
MG/>2; ()I#*A:P]L'.&(*"K!O$.3JYVY2.S9D-':%:F6<.B^IGV-<X9 D33M
M#Q?7KR_^QT">'=-LZ*^#_8N]0[?D5P.-?>'GO!TL!L>$&EJ99>MFN/^&N2)^
M=>8R8GN=]4M(=6HVDZM>9*K34]E1"5C'/&JW6>-?A; W-J8;+T(!*)Z^#%Z]
M/'[U,@P9(!O^$;YJ E7\8II+E?.COAW(Z!DB?Q>I-2>2*N7\4PER@>9J^KM8
M./!!F!L0NO(WU&G%' T.K^"R>3)U\J/)#"3!K2,E@FF"0L7#NSK<(X4?B_"2
M/\S=,#WQ%=/R;ZO<."VXF6J^8KJKH7N#Q !7;SZP='0V_?:7OS5$G/I'\)Z[
M[,L'83O]W_]S?G)ZWN9<-"Y@?2^W6[R2S['L__F1%*D[#NG"=9I$H8]<3SIO
M,HV2F90$-,IMS^S/F"GL5@[$+F!D51T@,LK_L8E6VAL%CN^XXAEP!3;@DK>K
MLH1JV@?R6W+G*)T20'H464-,$;I41 Q#KX#K36NU\D_D'%#B^"AVYEME$BW,
M!4ICB$TMR*0!BJ$.8)2($6-B!FA5Y%2R;B6\M1"Z$T%MO-4VA-_]6'Q-_PLD
M.Y>3W*>P0<?*WR,K,\NMRLH$9BTG1:R:_;%I!S8P-TJ,1]H@;5=G])-I*O?,
M#%PP[E?G'^V)8L,C\X'NQH>,2]:BQN96C,Q QTVMYQ[(RX2N"ZH_RY7HB&8[
MQ]YKLXWO.Z-.U#Q+4<,MI%:V&MS;%#DX5BYEV55J >L:(:,B0B@3)@)&23/5
M\F-5@9>0.6"'%$CJD$-/.9W<!9V<W:  EW3GV+YCM>?#:O<ST*D!1EU=IW*$
MK>-2:F=!/=?LSMYA.J%F&1PH NH'XIF09QN$F!171-AH=V4WH0QI&>Y641[9
M\57'5T_&5YC67V39O1EK"975%+[T%H5-5YI)&6*U2Q=NQY+>AIP,:E)B6T+X
MFEQ>,N^S<5)$0:6YC4<]= (TN+&I9++2-$)$]T>>'H'K3Q9\*5/H=DH;\E/N
MV*#;YDSU96TG!3HIL&/:E>C:]G5174X3[H8+)BDJ6)'FU:947D-3.J:MH_VC
MZJT-?WR]]^M*LRHON*ZE7X"EC6'J"S_O&*QCL!UDL&I\N>UV$6/-I/TRU%VH
MG55GW[I^!O<.<Q6BV4H3P>([:FH'?"V%N?FL1[O+&<#;K6 S^[F=BNLX<.<,
M73)3F8K)A)-!,P.206SE+>C,@(6.YVK"H.JD[BHS=?-I"PDO0F3H=X@,K8@,
MQQTB0Z<".Q6X*2/4I/J0BL.@I?2I_V\:9E^Q?;#,,J/RZ+-2#>ZJDNK(_;LE
M=S+X E B"/F!)(W9KCXV5B60#Q6KK+M5M6A?B#HO!FUI;M$4$ZWL_I77;QQN
MB6<N,B!;GW*:N;GX*C%:Z4Z2V&0AZ-=.Q)]V8BVSI_PVI7:9G3_6<>?3<><4
M/D\"W+858Q&&K55XA#60CHX8UE6,6F9ZJRJ-CN@[HM^QW#0[_J#AL9#V*=(-
M\I]Y8=G,3J69:+25IJ$KDYZ<@[I4[>^9A^Y=P( LHRI]3!4/6U88NT;F&,,C
M$54C,2A>),)88=<!965Y) >,J->Q0,<"3\@"$RE7SO?+Y%1@66O$7HUM?M6#
MUUZ#IM# 8.TQ[=6""HV)5QU;=6SUE&S%'O3*A7&H*4*RMUK3HOPD0(A1=Z#!
M0L%##PJ?@V8R'X=^)7UI4Z$+O).U]%Z>N#+&4  E;LC46DK'BATK/FGL3A5;
MKZ95;*5F9R?\'=FAH^B.HI^.HK/"'Z]$S)PNJVL\"(4!$4$H^CM4-![(2(Z$
M*@9KTCMUA &N$5MI'BJ]AVI48(GT)OAO;V?9Z1%122Z K:8F%EG#GM"'Y/A%
MFJ(MK2*4;@BF]HT((V)[.';&C="P-+=RD,'Z\(O;V]M>+&]',@YOACT8N+?1
M+ >]XSN'8;00'*896JC$B'D0,M$<HDP3;BXBRO3<.4!0!223.>U8,PPC O\*
M,>!G7TXUS!C("F< +U0_8UG1C/<"$\(7*!0:O+E:$8<&(6?XZ!&%YJ7_ZF7_
M%?^M9OE!9('XMWN=)S[BRJ1?9>Z^@ZW"#<(?9^4LYQ?CB(RWM4Q #./:U4"9
MFFSW)P R2,'P!J/7-K@Q>1FCIEF]'X(IKFN1L$Y0P<V6WZ1?H,5M^@E4]MK(
M93A$.73?F*<5WC90^,R-DYP*>[F#*_(YGE)YD:&\?]W[@!HEX.F$:77F(1YK
M% ZPHADQ<Z9)O&A+\7D+>,9=&GBFPYWI[)]-9D#K2PQUPU=GI9+E*M2/OS3=
M1TP."ZA*8(<GK&%?J*XZ%Z%CD8<7":"V ,T&%#7'% C6Q"U[U#4B:,A1*KB^
ME:5\%L+D10J^1HK@<*3/.V;IF&7;F.61\D=:;*4G3B;I&*-CC-9 DXPPZ'^/
M2PQ#Y^BT%E$N\"H0 TR8QUC$,'"I)D1P$V;PWR3&"T5"&E.9*&$,GI)&':/Q
M5E-GZ(D)]JBPVNP&9L&^%SA"4\(=;2@V]R5'J)X^];ACS8XUOX-;C0V1^99-
ML^/#9\F'CW<7TV Z*I@^XN#5\B^WY0IF2WG_WO<R]D$YEW/H_/>]GOGA$>]G
MMJ=W^&%7J=I:J7K25:H^:J^<Y2\(PQ_;VH X36U Z':P\6)GI6XB^G;PSLM!
MI^URL*4M0_.]X&IS:[DN=-K:0UP4Y67AJDTK[G-9Z#1<%JZVPOD[1+L#$%XH
M&E^ZTIE#][Q 3>\,,/0J&V\FJE>#,)S>-AUL0J<[R4*[/J-A'O3C/*LTDJDN
MUEGN.)>[W>OZ272V]$H^;7GUL)(Y2]V:)&>A5F&$F.GXNB*5>^9/^T%/]9JP
M,?7Q@6&X*N1V/'-OA _<,L,AP5P#6]X'18N6O.'@<3@%015;OO?SLKT[5GP6
MK'@O?(>Y2I"2&TE):?>G35DI7 @$OB1F1C])^(BY"2OT5RMY1\\< 0+_+((1
MEZ)0 Z@0C0>O; ;E 6=B)1?>9-)%OZ'W'>5+&ZQ^.V?828YG+3GNJ<0KNAM3
MY]*0P';GP&)T;T;6ZI7.-T/3_U!5J*P>&INSEWUT??B?M<%+*[J\S&KL%*FB
M?:L9$QEE\%$+-]6J;EJD6:'NL-#6N'YSB2^^,_O1,].[!8&WXET>7[ZA 2.S
M,.5 E<Z(G,+QY$]6W]-)H4X*;58*X;]B@6\&CB]=<'@&>^A0'TE+).0-;1AU
MG6LE+KS*?,Q0!'9\"U2)_[U?%";/9#3LN+7CUFWCUGLG8.T4;$_' 1T'M+9_
M,F B#ZX7;[1 1T6(!1RQPGY;HH;\[ZLR8L=5'5<]#ZY")HBD,##Y:#;MS>-?
MF5HQ*@NQH+(Z9NB88?N8H8+@L6HH0@"))-&CI0DM?=^^2[E!*UVR/CAEJ"%C
M:)=RA58M#?_'X,?7!?7GP;U]J_ %,\<.Y_WC;X.MF>\64.=OIKM1)&Y-3.$G
M;'.4C9W?0QS5O<HBV-#,NR,K(;G%;C)@0H8BG;D!GT2US-FND88'*/]8@,DY
M3D @Y0I+#-XX2I+ '0HT9\/8N<6<$!RE?-< #%EY(U738M6<9@!C,,Z8S,H^
M<+Y^M7ZA_"93/\RD.X49IPS7)S1DT;1(L>443:1\738&M]3!2FJ8+852Q2B5
M4DV?.[VI""]GL!!BLB YRSOZ^Q4VC7(5,N![.0%>!7-[0B^Z0%46<8CI(LL2
MV$&DW(8I(]J&+U*ZL8+C-6U6LZ]A%*E,4O*&DYB$@UZ">TO]Z<PX:L?\,/6+
M29:CW%$HH.98;I*0D)^'4>CS;NJM[;E7L3,L(KP<5_91F/(/,6:/J:SU8U],
M.1,@40T=M0S\5;E]SL+M0Z6% 4 9J"@!=5AI0A^90S"@!M[A:)QSI$]^=0,Q
M$2-X23B$+>;%WG*;;+#]K+I]$,Z86.>/98 ;Y4;AA/J\R&^^G.*\L/ZEMN](
M8*D$[1JHHOVQN)&+YM#8C<G!.&7#_!9O?F6^N T:F%5U%&0FJ=F[R,2RL1.C
M\S)4N59 .\  2""5U3'< /4!I^O9G"2;8GSZ!.1;+%7_\TA@EW)U((::]95$
MYL82OL]0X' S8[Z>P%GH:032CP1!&U#*E21)!E_K[]7E$3]@9%EJ$!>8*ZJI
M5D#NIID[/Y=I"N.4*&!.%'\>T>?+\*9\E\*0P.50'[LA5CT->8OJ>/"VN.2.
M\HR.J#!%:;/4#UOZ<]&WCO[=!K3_ENN\1;;"%WV"QCB@TU+8&60I/)5NWOZ4
M]Z9DU9)C0(Y3FA7+'U)0?%FB]7CFIY+N06RYTG/?@!@JN1PEAA[5@.HBWX&9
M\:T4;4#^251HK]R2-9E6M]4GK#Q*P_K..)RX"!T:E4()I<X8I"-\@#(FH9)$
M:28$?_,/\ U2I&"0$">/"2A%Y&,/WPL[*<KDLTER ]*?U(\:!=90SLZIS([4
M'ZIN^&]2@$TABHQ>2_?!,%2Y!95%XTZI9[&:$@_ W@&60:@2<U(4$35G1U,E
MT,T>X-SS @[/T=@PZI2J>UL157HF8HC(JX*P FZ2G"*,:#=%&&',$0+H]/B%
M_BT^D%4&SUS$&<@C+GNA 5"YR 2MP! .!I11!<L&?ZEG2<#*^#W^3BDSR\@
MM:K ;_AT^?#I RX$5=:D*"E0AJS:.!$0OE&I?0Y:@!FAI)<-?ID0OJE;=_/B
MGOL'KJ!FP)JWZW>+4B?/O\\K29],4=I2-"C@C,PW9/T!80A*I+X=2U8):GSP
MW<FP\;'A8C"_U/)S/&!%GCWWPF0SAAJ\B!=KZ4H?_-/,8;M##Q>$5D8$IASP
M"[+:"[!_,2^8-V\:IB:^AHQ$"S-*MM-?MOZZ4N8XG-H7JR-NI[<6AV,,B8)
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MOX;E+X$",+1.94; .R-PX&(J=$:9[ #39SD5S@S2Y*ND\JX1EJ+I[N)@^S)
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M]LDRE90J*61OQQ%Q(>9&&DM[/)4W0B5&ZA2%66^9BU_Z7W@5B_@']'(P0:.
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M7[A2C9)_8+R;!-_$YE9L'SU2ZKSI5H+V6.8ME_G*;P+5JBUDV)I&,9$5 ]1
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M';!007+@G0+EM4T0_:&2V56+ (RJX9B*Z4/'/$Q4)B_2V6JT\OA(2-MSO?"
M&;XM#0N';ARS/.MBD8\0B^3*^3)>I3+I=>XH?>V9F^!1@L(*00<0-R4R]ZML
MII&R!S\ESA0SZ6I9MEPF,")?6-Y(\QPB)@#W1N0#E/5%F<2B&;RF!4VR.9ZB
M_STZPQN0RF;N]8^6J+>K,E;+%#<"P;U>I.T\F;;#;)]-OZU(_4VPOPI6^ZAY
ML'M#6^,)G)^<GE>/X(Y.'PL$T_TFHCZXE:AX]$TBS>Z2N(@F0YS4PWFZ#;N)
M_RY_.:]K;':TN!4K_3BI',&:B@%&/3C)D(*-A!7J80XGZ#>:!3F7YJ8_!]V&
M22#"9%\.DAA#,Q/%[R5#J@@H)IQ:((<4N].@(>"-ILE(^#,KIGZ55^=.D\ $
M>,R<IA18VV(%:@/[TG./CWNG+^9<,C9DF=@6H2L>:9OEL([7>)%9Z9PXDQ%X
M%079AYS)J;"0?947@Z^W,MHX6FU2OJO!RK"V4MHU$[6Q4\VUK9O@6!+% \V%
M/7,=26&0D]+'@UT:AKE*$RD%XET@U1N2DPLU42<\.^&Y%N$);$13J1@>]Q>A
M<S9,FR"=:F2H$H;?B' 20U>_ORV#G]70:2D$.5+M Q]C49HO4CLUZWXBEF;1
M_'(E:N?7V"YL#PYZ)^SN\;^4=W67O*5):)G+W]XI>.=CZF'S;!?+21V]%*Q'
MP-<K!3C&%#);860JQF8R]#';,7-CF6.BV3,0H1MV.NXUX96ROLZ[K*_6K*]^
ME_7U]"S4F1^;,S^,[;%U=H>"QJ39- <W[FV#W!$S:;!'M %$EVD1Y6P+_0-5
MC[IXS';]?XBQ?/S5/MX3W.EMT4Q6];B:%?\=4[:- (1 R<N4>%;G2OMKE4YV
M%_EL58>M5LSQ_%5^)Z^>K[PBT?1S:T"5N;,BG^;%SQ+QV#:?*$ Q@O?YBK'*
MN_>(^)0@M_>2X5Z1\5PTGL'GC[\9/ .191+#R5%#^(D/MO2XJ+)8^S7+3+Q5
MT-%TC@_TW5;_J'>\B>!2LZBS9LX*I67V-<<GPMQ5*GK"04CJD0^(@K#W: +L
M.[X@<>8<U1)P"_40UCAI[:12LFR'DW^G44*KD4>3PLC03/SC^2HODT6&F0W.
M/'4QQ12I03.C'##&0:Z4I1&=BUMS&\XXVP5CFF*N,H.1J AGJ5*-9J[D1CCY
M&%-<>^Y[\"P23B-)**Z,&7L-R ,:*=7D>^>U)92E_6,I I]QM*F5JE]$A,"@
MD]0B,> 4D"(%*9-+,=&5]+@/6*&):7XD5E0,M@07^GY*O):8S,5 (S:4B4M
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MNQTG[JUJNT.XQKKPS2-J':92$H::8B[8Z'<___0%YU5,-?:(&@E]8'2BP1L
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M#4W7J>=U>^3<J]#H7%-R#'0+.L3 >S&;5UO 4#M@N>"\O+JK>= [;58Q2L.
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M5(2%+N>^U'[$*\^-9?UNMSO6;D.V.&Q?Q4G<]8,Z/SWP#L_7D6CS7$CWX.#
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M5%)5@GLW)W> 7GO&KU6G32/81AC$: IX) 898*@FK0OE3O^4:S[X1[;*S"
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M;,SU.KS@W!R=$VQY-7'1]&4@20A(>../XI:/I5!')I79&0+:5>F:](MD9C@
M<,&&&YNI1O837_AE=Z/4Y&.&0EN2;+" [HHK3G_N'AULLC>W,,*76O(C3L1H
M$6S\\#LYWW2> S//JKB]G#*?"*:'5J.CXZ75,<UE["#%XS&Z95?WJ#N!.$P&
M]RYVM>-TW\ _*5>>D9J:LHU2ORN?W2Q50%YRVJ"Q6A>60ZD>FC,27QI?H>=P
M+EX[&W_[UX]\]?O?GGI9.JY%C-%W79MZRY%)@\GZ<OF^.=NE0#:8<"4W=_]Q
MI\%OL%*N#,/C@Z6T?E>ZZ7O2U!!R+\E/1I$+VGLU)^O#&*L2NA3'0&\WDHB8
M&U^,-<Q [V.:S)O>$(7.A?2'KNX&M?900H9S:'V PL]&K+U/W1^U^*(U? ^M
M".T%32W)^DB(VDOLA1&J8$BH-K[7?:@EKQ_)TT#:N23ZY\K6C$%XR@7YM#/R
M19\I.6QK\N-J>CMW8%F4AT@+]FT5K#<D5"0/<7:-<XZ^L+'HQ:FY9LU(312F
M*DV1:-=T0L])B_.L*@OKFUW]-AMYNQ]YN\YBL%!Z:"'P E1Z6"/'CA'=U\FL
M/P0-9#&';.1\[I:CC%4_EY9(2;6V(_W./.RG,YJ,D8SA+_*QR-4.7[05C9D3
ME)QQ1DU^J@]PM^1J%:Z)@#FG58BH5HG6R6C0*Z*AULKWVVF#GKUE-HYNE3@!
MX J?7FPT7KYE>!#\#MZ&O-[*R![KWEO:8? >;)'2D9V9[GYUX+"&IDG'KZN/
M E1U;V&C2S$/&4HS<@]QC$9N(GP\&=<@@![(JHP3&9+XQ?AKEC;3,A$C*/ZH
M)9"K2_1 -OQM=!I_-1KF>M;!^XK,PMQOY=LDC^^J3-VKHPM&><;'I>T'@VV>
MTX-30S+3\0@\772>%BVIJ5?=LCR]'=O "*W*LM)?5W=]<MRI2F.&J0D-8DB$
M4"F=#*M#N,*>>2![_1N4&5E4[?B]^EPWQY5W2,5AT3(&%\(AL=9_N2:XO(1G
M@-M,\G*H!XRX"]P38<Y5=XXMH?T@ =TVG);3OD/(5<H8/^YS@3CBHE?!,8HG
M6=G60$#C6#T&'N=UR6=I2P:"9W?DZ)\C04L#=C_36:R)!SLWW+:,TE>:;>1
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M7!-)ESG4PVHV6+0+F(<R(+3G"_2D22ZC-6/>[75)/R(]S>@[[BGN#8SQ(7K
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M+60T&E#>BU K<MHAQV5)5G8.B\@HO7JSE!. )%;_U9)([>S*3531:07NH5>
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M408CFK-).D'AMNR3Y2C =3D2@F?2@()\M:D9DE-&JHOJGS@TNEIJ%"U]WBT
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M.# Z<;4#:(WAV<5M1<U;5B _#$!N@%HEZ18MT03)TK^MZ>MWM'&VFP.#/(F
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MDG,61,=%#MI/]]=&THN(=W\]+$_1RKHE7$MH_7]KD"S^,/!@D/8J)5\+::S
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M$%JR;GQG2UV^7"78[O*:?:DD)H+,XU(J/#L-.X$!ZN]O,:V]XI/=[9T=^-2
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MOV4^Z'Z[AX/#>VOMNV>91OZ"/OR5">YX=C14LMG9O_PNFU2$:$MSH/.VX[=
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M_"=@)3BE%9ZAEJ3Z@%8E0,O%_JW$=J9@B]_4$K^!5RG3=SH8=FHPOX%O$O$
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M"UI4$RH+;.Y)/XM-R2@P@=?NCA?0T!60TP OLO4D<CHRAF=,L?1\!HP)N=P
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M<NFQ9Y@=Q;10*^YAG&J8IWY-X?KGV7OT%E,XL&D$#QE(BPJ#E3>!=Q41K9I
MDK&BW2^:=K8U?:ILDM1T%I1F(%T=T[SW)Y #=4V7T)U8[F+XKN#L5FRUOS.M
MREJC_4Y=/2(WC"N]VT$K<HAHI,10)TZ,S;>0.BD)BI?]3^KS@:P\Q";&E\ 4
ML1%7"O(2LZKB. L9V3)$)/MO$?92 P;\*MC:VD(''36-M[N/H]N;-2_VB:NT
MTM?*-&3&[^HNE5;ONI L@WX2]3!J@,T\<,X29Z6KLOT+S_X32WGDO 5!2<Q5
MMP%I=HB@+PYF3:Y&Z^T)7KB(53(R5P8*=B.CS*VQ4IGD526)X<"K;(BY0(]R
MDJ&_=^/FEVTR;U,R[^NM-IGWH<F;_@G]:/"/G\+_W=IZC>0:_KH2[MU<$%'J
MWW!^].'#\:??O/.CP\]GQQ=_O#_Y\/;HS.G=\'0D]8-(L(NKB (AU#XXEX0>
ME7HZI3-..=B=* Q)^Y6>@*A#XX/GBG7@<P6\%S2IJWA$O:R!]^=3?+B[O1-L
MO]PCR70X"L$2//!/L&4IZFSG5\#789G<TDIZA*;>1K0)WYO['3]*TYRS?4".
M@,+59\4/4Z&.)[ E&69CEM-!/T;])#Y'*7B:)_TKD,+^@<[2_85ZCOK=O:WB
MO=Z\]QZ<GQX<5EYQR!E'O">B5+KOH,712Q8ND*1=/HTG%-"B1M^)3K3="#?I
MA6=J+#'S@T(+_12C)-\@F3VD'%X0L_'-9N!O]/AKJ9I$'%HC=P.^:$)?4M^P
M^_0E!Q*DE.X5ZS?>AHC[(WF&WZ/3J6#P/@^NOJFDCPU%89Y(PK@'8(5A@\Z,
M7 %3O?U-JZ>D+WF;&>&+C&!>Z&T,&E_XYMXO?%-]H;^A*B_TY/'#N[_0[&?I
MA=P#+;Y49,Y($I#R*QM"-K?U23%S3MF7UU270ZUVA[PDY#Z';^#V1)C,\HNT
MX;W>]'>6I]7>S.-+@(;7#/>! $O\#TBTA^$4%+A1X'_X<.AK4BH^U[-"M;(P
MM8M5PZ!C^/T\BT'=J-Y??T#N!NH'YWT")9-!Q$VK9.G!#N;^#6:,V]/$OUOS
MM$_&^G/UE2:/T/^B)$T(\>15(ADLWAES3]DES.L$73P=SD!R)9CI(E\0#9U3
M]ED/OE&<IW2)!\;\9@Z[_9Y1XEIA=#_15I)B%W/D#-KC%>'D<6]MRG\E#PR<
M,78@'(U,\(N'P;N2*NHO#D1&+++$T!TIB=XR()T;R3;5AV*X1NT4A4@\\F\Y
MPP4XTEB%3(S<^!=[A*<9)R'@7\G@27EJ1?/&Z4@-+JGP8P!&)"4-2A=FQ>W9
M,257218NNE_10V;\(JF'K851WI.+A+8-)\O[-)Q':#HZ0!4QF*<"TXSSQ-[/
M<)A1 HJB"\GCN;OX RI;<I":Q&#K,-;BV7EK:.-+*_<Y]*XIH,19D&7 GV=T
M'YCZJRI;/AEP79%S&AZI@CP]^D1QH91))K G^742WY!G(]>=-Z5^^#6QV3WN
M[UE4;Z4B'YB8^_$H'QN?P<?P6S3.QSY76*.WH"Q6,NQH[9\C:9Z6;^6I68&6
ME3!QV5?[IC>)++UE#3OM%1M9OVU^,U>B0R#&D\+M"G@VB:D=HAQ@:U^BE%\$
M Y$@&<3D?\>M]JZ 6C W9,Y,04#"^'1_B;/QR&R2TBR$I,;,/H#EB)=D-&,1
M,XF+4C5D'M1&75(W8UF^3DU)/4L)J9V-2\9$I.BG*C@+3_"[]F?=?MG9VYL7
M^5L+KO$&[!I)7X5+!V=P%4WAAGH#A55^I-2CN['?CQ..M-+1G.6PX]V=P8L=
MU(TQSI"/+DDSTA;;T:$A:>4;S?.@GS&!:"NL\>;@:SQ,B,:$.[B.;+R%302!
ME237<:9+FB*P-U+.0YC&-RKABP3"#XUY\6HVO;EG=@1H%_=DX,TU0]TR17W)
M@ *1B=D"5OARE!9<SW&\PIQ>!CM;V\&K[NO*K)S*Q$:>. 0QF5UI%@CKR\<J
M=>^(I9[(R#ACZ^0:%EEBC9XC:I]:]N MKLZ%I<(CRTW4O_.(LD.5U[!7J(+G
ME,-NMMXD1+DBU=E[UU>"!CE35)]9:=_P.$J89]DR#K]2 0&(@@QHB"B^J@/Z
M7'4"+[<,@7/S!6QYG'- DQ:)M@7P WW[8LGTE94S/=&%QK6C_-4CI:Q_@GP$
M^=+/F;NC\I;(MN!TK<=YJK'S.$JE<92.5(BTON:1R=6;)<V<^[-AKUR/;0BL
MZJGQV%.CU;K";)^C6N YB-]FD0<(",1X*NSQ-4^$96$Z^T8O!V+"=';G[YM<
MQ*>G4OL>M*M8N%/,:3B,1A&%D6[B?#2HL&Q, BEKA_ 3,$<OUGQ5_LQRA8=1
MW_H*+N/KSNO7)N_<XKO62+9=;QOR6ML\-9*FL-X+G=6KZ*Q@V<241DE\&^P^
MS/5.Y2J-HG'$Q85+*H2P#0%IA;9""&-%24DE] J5\%R919R.0O+]O45>@0GQ
M&&66=:RZ]FO5\=EJ>(?\(3_C!*KQ'I=5C-0PNVU8[%4;%FL,BW7;L-A#A\7F
M)A,*Z0"3&873%(;4/Y6R!Y>?^EWR#/DDJJF&M-0;Q;>Q!QQM*5IOKJP*Q^*G
MKW5Q.%E_<R<A&UE04(>,NCO!K<&&XU__\=/V3W/>6'<+[[,5QI2@]B!:]>1?
MWEB2DZ=)?SY!LX=_/-76C7PB$N/O:3[]=:.[">O,I[\V;&?MW@GFFKWFG_[V
M' ^A+D9L*P8XPWAH[WK)YK,/AX_$=\]D_I'T[GTLMT,-?WXGZ'9B%-V.-_V3
MT2_=LRM:\#CWC)V,<@%A>G*.A5$MCX%2IH]8&V_M(3[\-=2G95V^QCO''Q^/
MJ<X6,^#X#P<4@3@7MPK_34C$IA!]S5UR$/V[[OYNM_?WD3FPU35K,0-NH .A
M(::&98EA(2UT-[\C.2Q& >87W@X(N%Q9@@IGV<@J%]"\QN7H5>(#8%A5B*\*
M^W_P3_^$LE'S"04-:0J_'U-B ._OSGSU16O%?[TCG9>'J34G[W9#9<S7I3')
MF)TWZ*N=G6!G:W_1@NMGFD]KQ]QX*=MH%0@][UU$#]'=MK!IQ+\N,\_GM(56
M<MK#$N.K'XT8=7_$>?_><8_OLX[GM,5-VW>K&_Y@PK74G:MI,@\C1:N9=9;\
MW*V7GP^&17^OPW[T$ZZ=S1/<BZ5'^E$V9&>!I/H1]Z3=BW45#XMMK]5("E,A
MP0WEG!J)0+IJ]CLB.?9:R?$,+\*+=B\L V>O%1GM37D2(N-1+8H#GTK:-M['
M(TKVW03K8AQA[BB+AOU6-#Q#@F^-BK)\V&M-BO:Z/+Y\6$FWNE6F+=T/ ZTN
MV^FAX=$0]JRFD^##]23DI(ZE2-3)0FZ>3J5R+$2<X#Z=@ULFT:LO$/%A;_KY
MB&L^+$18FANC)1<IN.6D6REOIUK!(K\V@'=AJM;+8&_K5;#U>E<_'IJ<V^9B
MO\>C].\ Y+<N1.Q&6K;G$F5II";<^,;ASXI".^I?1-VXZHB)*YFQ/*VG_"LU
M6E#)0O/D\E%$T1HIW;; J9%S48ZID&::%9!Q"(O !7?.7&SXMYJ/N2)JA/T<
M^)I<";8!UX:;K'Q=X(VX=HCA'8X,$H93REV4?"#\'"6REPL_\+<PX0=DBU+8
M!JG)[VW2/":Q0)E9J?*EF6/=>=BG^H\!9I7C((LJAG3BX)QM[MA!JO?QC0**
M#<S>- P<<9&(M)?CLG6=]ZXK!3#L;_6**R]'U]W,*\-N><H3$(P[#RT8[S6=
MYN*,P*^DH^A4%(U1@0_\?ER@9D34$6LTFKV@(D2\;0<77TIC? R14?CO<D2E
M.0[\#YW3CE.1@I\4-2@XP*GT\:F,- FY()>A,Q"LD&4OM:PL"BJIYTR!2T"O
MMM]X,+B.4LQUL@M?Z"E=?R1/",RA/\"J8+K%5"E,5W1@5W,.HG0:IPPM3^6<
M7(1J58<ZY8S(<,;$'A'#HUK.N8!O<7.:TLQZ7-E45H:$OZ2FX-@_F&3Q)(K]
MLSSZSXO?@%PFZC\TY#]5 OSG-(FG4P$"57IS31>?,<&)&&U'[Y-;823/?N1G
MW6TN?QI(@5&$+?7P5F-3I[3R6.F% :V?\/JJQV-1 IQ+/V'&CBN4$^,3PF9$
M#WDL!1D%SMYHFJHLB=J-X@Q'830FF5"KR6(I%I:?78DWBM\#S#8Q*/9P$9LE
M4?]O\2UN5>!W_5,UF:2ST74XP68+H_ _(3"4'*/LNZ^Z6X3@Z/\1)U_AIS^
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M^#SIZ@(%$<C9"9[#)"8S.J&@/MJ 'E[2IDLL/ W=*)/9DMJB=8[E2K;Z:&"
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MYWNT%_7<]=-# P72GB34SXR&&$W43[]JL8,*(O_\IB*"S#ZM",NK9\YC92_
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MI"VK.LP/F75XR$A(12E,(2N;P$W+-+OM!@W-I=3&7C+/^DNU^1<@$^,8'$Z
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MF"74^1R)"VL=L3\(R.G_*':/C^+)Y0M,&T$G,J:H9\9Q_WF")BBO\QSY:TN
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M,ZK^U^YP:M"Q:=+^BYZOC4@@&^J;SG++="4(0PULMK3<TO+M:+G<X/C@_/#
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M1NPR(?R]>)2#:A.V]ZJ]5X\B 23MV:JY-27RD1/1:[HX3-%4#XL5C=SZ1]K
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MK_&3J\4?^CQ<4L RT#]-' L'&T2)XH*XD&#.,'(O5<@:\2/5#0WA*E%Y!05
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M  W;B-?JJZ=>FR-@JX/8-8+";AZGTF.K(_N^TNX#'$V^6_O"6)1,IHD?I#9
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MU1:_][]'/6 CF+P4V1Q_;SX] U?&G^K^OK?H +];4K9KCQR%#(XS1Q'BX,M
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M^CPY"J?<>ZY+/#<N[IX4;+^Z QX9TDW1*;_6H F:T#JM!6$%>[)2'H"F25)
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M0'7BIE=CYL))_+\%OX+#8)L$7N'GIR.4Z9\]AXMV;^2_GG8DT,_",RS[Q3'
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M(K6L$FH,G7*(PDTP?SF>3X01F-F6F\WTXB:703,\(CS-]'BP!DO,X0 GE!@
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MO)F[EF/$,#\S[\X_0H.R/=.$(Z8#D+;H4<Z$ =W9L#AO<!WRTV K-.D2+ /
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MF+VM3 X1T"ZHIC2[ ^_!%$$Z)= \ZG9:LJAVZKD&>1M+(RNH<%:@+(MM=?.
MH2J":AL3(RNH<'>O*DJQ:T*JHUI2209_/-%N')*RY,*5]0/N@(W7#(T;ARY%
MT-DYZC;%3HK>B2K2_18B8BNHM:2CKBYO+JNN(LRVD!7;P4P&P;&M)JK88-%
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MHR[+6Y)1PR&>8[LS,L3EJ9-7I'K!(0 +%ZQ7SQ[^+;BSB>DQ='K/AB>\&*Y
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MV0]$84 <<_Q)F!K.DPEOD>"C4M2\&Q*\V@+R,_]U_&7T"/"IR83[.2R5%CZ
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M*&+Q8(XP :$&X"&Y0&<,9/58"J:9>Y[[\*/)1HX[5F1H7R>+,>EE)S95-V%
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MF.Z(.#RM0W#.?8[E%+9["0XM'/"11I(J\'QX--B?$K*;PC1_CKHO8HXI?T9
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M(NPZ[_:L9PPF6 EO@X+ XAP%&+3PZE\_$G<\?OEH46M4S\/)1 1V3G(YGE$
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M?HO%F;+C"K8F.ZX,Q3 (V@)+0Z$F9; 2EC3C%X&O1]A)XH2P!*H!=9/&8$O
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M LUNSA-2JF=3_4ZYJS[Y]@QY98>I=Y8ZA(.8,R@RCK4B3AAD"C\01,*GI$[
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MCD3U =,(6X2U]!!WTYHV7M-,*2F1?A1\4?:9&%_46#WU51X<2^8\3J4CF.U
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M<*9\^@SNP8<)T%/5MBN"A)CFRB53YO+'8A&7EQ^7>Y)@J7=;N[Z2=C=!^$G
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M^;1=G>4*D<K=G"7!#YXF AQ>1F?CW9];T#/U59H^?[QI (=A?UVLU.2YRBB
M^?'?+8(4BL39)J,\VN25(0BO\0.(E;CE=Z__.W*'& Y9,"C@HK*)L,SR"(07
M:03"A\?[A^O'YW\CQ*!Y_;^_W3XP!N$10@O./(D9]*]O+RQ&2Z"4@",7<0(*
M/,7!3G&P4QQLWW$PC35:,140?)A;>+L*5%Z>@MZUG[L;)V("C&9!/'#D>N1D
MN ,,2SA9M;L'A@!7JC37FCJ7K7'SP]SCX)Y2LVXURVM.Z,R^^8=&[>I:E57K
M4[MY=MDL6]7*X@:3P\'<FXD$=79Y,PIAJV!BDZW5 R+"W_>*RU>JEO9ZPE6<
MOUJS*LW%<;@]]6$L(-]:I</KDZ^$Y"M:U>;B"N)#B'$MO"$TP\?V3"Q?"D>I
M#LO]G.]:-<?KGV_Y[/*B4;,N+A;7'1_F_:CNEWZ5L\M&M6HUBHO5]>&JC2]!
M'(3FJ]-W.YZSW^-<;^;OVL>)&9MJV6IFE"H?QW58J])[??K5-D6_@U 7,]WB
M^UX/ZU)5,.O[SLF5JA?[Y:KZV66E7K(JC>712G[H9&JIVMCOP6$J!:S'>F/Y
M!OY=#VH[ .F]9U.?4($0 [%:.D[MMV=3&I%%K&H#Y%2.,6?[U'ZYU9Q D.YT
M1H.19V/=<M<9AD!!2J4=O>S<&FYT*Z'8)XU@\'?/P;\ @[4& 1SH7_3SF<R7
MB^]JC)-2:5J5\@:+C8Z_9FQKR-*[/5Z<J&!52DVK7-Q@^='NJA9%,<IS$-O>
M\1:N[%QQY^VOK97/+LL7%:O8W#F@U9&>UC;,A-RGA17'=>SS7_XN;Z;/_[MK
M\]=%,#58^1%W6QEQW^%54<>MR?VN<UK-WYS06=!(OT:Z2E]G/E[!8%33JA7+
M&6WSVVSY7WZE-7#02U;I8CI)8*7:E@L[+.O95B.N7EPV%R@4QT4M\>D2(I&I
M&C-&=G '0]L-J9F06@6Y"1N;M8&3L:$PS>)&FL55L0WQN:48?0=-TU2')X^C
MG=&]O'I9FYS8\6"/::A'IP,?ZGYV[;;KN=@%+X< :#]*:@]%:VAF"5RCMI\2
MQ$:Z!+%U=?7XV_4G\_-MZ^/MY^=;GG?,4Y"-A]:_:03RL14C)OV_D^<'QO+4
M$<YN_6W4MEBF*!9B>LE*Z-+P[.,A+SB218O&J6CQ@$KO3D6+AU7&=RI:/++F
M72G\I E]X*5CZX7G)O3-,N"+J(#*Q9)5K2W.1AU_A=YZ8;)UR'QQ=EFM6/5-
MSAW>0K1K^H57X*T&8"!AK!P'U1Q91HD:JN0>EAG]6FN<7=:M2G7=0ICM42KO
MA ><"KK2X-3=IFW.+O]PXWX_X!+KV/XF+=0CX[@)><' 7L_VMR7E11/DA56I
M+^[F_\Y2E^N1K8XSK3=P:W<B6F_!(QHZY!:973=T.EBVUG.<(V5\$K7:GCZ)
M+=TXCG".\QTAUNCFFVUV\)*W<B22]TI''17<9[Z["V(1CBN]/QI>9$[Z3ZG4
M^ \>PJ1X^2,(OSIAI&]86G3C18+FLE0L6HV,^/6A\.7&1+(B8G,+1*Q6K6)I
ML;.Q=P$]NUPR%3\[^L*"+1I >F14AS+,IP@P852_L"[JBV_<J4YR8];7>F=6
M [.U;M5SE-P= ;3,:8Y#7D91DZK7"I+4<6HUZ-B+'-VBIP$/F[SH&SJ_"S#=
MJR6X_EL:T#%1#K+U,0_;R%%E):*R$E;9.:IYHB\.AO2!R4AB,1U\S?I$8;H8
M@&+[/7O@>N,/B_9$GXW<OQPF :;^8\<L?5!IW8G79I3#,*OW@B#V\;O" JW_
M1_[DS/PV\#YX-I(='*S?GC:YW$S_)\2ZD0A;*DT;YQ:X _B1!Y_!\%1@PJN=
MP= +Q@ZBP!N$3#]J1V[7M<-QP;SWS=8P=#VS7*&"!?C3-B,GCCU&4[9?0H?_
MAE40E'JAV1[P9!Z:@,#UXOD6_ZB3M4K"F2^5J0/4]J@#U( /PE^0;>0:N$Q"
M'(9&Y\OD7LTLLLHNK=A0907_64CZE>1%/!<\.0O2:>LO7A*BOG:"J,^ J"\7
M3Q#UF^/YU>M59E<099:E-.O-O90.-=.E0U?W=\^/K:MG43MTB\5#QU8I= 6?
M11L(DQLR#T5(_F!RJ:#)[ *AYD5U>P5"<FVI"J$3AMFI'.A4#G0J!_J^RH%F
M8?D?!H[_MKS\+.6CE$X^E[Z!"=5F97%_QW=0'+1&.\0&*$T-MY5ZT2K5#Q._
MZU+.1]LKQM"V#NG6[X"O$3F@%^G_-T$H/]_J_'?DAEB4\'$4@;4:8>JK+:;B
MY3K<"ZQ+J%F5ZN$FM;?4?;-'FF.K:0EGC1XV>LOTNQ^3,8)Q0&,*_9%C=M/#
M$+?,#_/;C;=U"1]YKPD!E@,[ORA3C]E%#H".F3W$>Z+HMJ[8NA3%#L]RV:KG
M2,+.).D^D_6PJY'/ W0%:2*N;#%+QX\)D+\2J3JS$NE'2YUO$$=!ELF4BYEE
M,EGWDMEQL66(IF"U9-4N-H@1M8';N DT%DJU:OZ8XW=G>6+?199VC2S[^E[%
M1>WLLEZQJHU31OW@?>V+>EY?^Y0\/R7/%R?/+W:3/,^RL.R0QIQSOAPN&?SR
MJ@_.VWG;QH'K'<^EO/I;/S"'H3.TW:Z!_?_1* R#%[LSYCGN?L>% PW'9L<F
MUT<,4(_,]BB&9_]WY$2Q0 X(>1&@1WH.?" *P$\"W0+.TAA8%IXW' :N3S]P
M0S-X\^6[8IQPC-FQ"!=,13&AZT0&_..M[W8X$8_U 3B:OAO LX&@*#2ZHTX,
M"V'?M& ^:Q_#H@%.GL":(BH6$.4V9M?MQ 0]UN;9])(2-%_>"0?HX,)OQ4Z-
MCLS0B)J (%)?.<Q\_II("6*$E--M@=#]SR>GG35G29M\/3?U-N/KFLPM%Q'K
M8P^)SE)Q*M/Y^_7C\^W'S]<F?N#),A\>[[_</CW=/_Y;_N33]>/M[ZWGV]^O
M#9D0Y<%.?[0>'UMWSUO(C68<Y[K94!*\P)=X.C/SGN5B?4/@%>ZE]DX316L$
M%V!S]#GE+4]YR^/)Y)WREKMA#5WFH%Z&NPW6B$TPBF0 !5%,1I(=B0J+Z#2G
M:<FD;L)IC'O>Y$K."<)/T_W LY"EVAHCFSXY/2<,G>X-V)%^Q[F"[4;Y,7\O
M+LXN*U:QUK1JS4-%@YC[X%GTSATFK:6=U^D_9P11#PFS888$SKPN#(DLN0;8
MKAV;;A2-*#:7=5EV$^[-%^A9#TQ^G6NF0>;JT+A9MR_?Q4.PB2H(P<JIU6WU
MRUO?;(YCWW'R\LQ;FV%=^,["JWJ4 =F-:\.\T+8733 AK6H)2W*VU,VTTZ-:
MXD8N.J_<%_(B]X7<5P#[Y+^?_/=C\FA/_OMN6 .C^9UI5S*DKD#1>7=RW3?L
MNG.GL6I&&7_/CKIFPE%,6O1A+]-MW0#MU0 3I7JHM=G;==4;LUWU[\Q)OPO\
M\\ZBRW%\?MTN[M;GP']Y=L*!?L?R72Y$(;,JY8;5W!:6R3&?7>Y;VCPFGSR_
M!YYK_,^/YW#/T&KY;ESYY'"OZ7"7-7]V6U[W] B>C7OAFQC+@-4%M\E0],P:
M@Q+F.U8&44@7O4WMJ!5A,=+4>!XK54_4M[OI)FLS&,51;/MX3,:4 [*I%NQ#
MC'KD<<^6\=JGJ_8R_*6<KNA#Z/H==R@D_N0J\CAC\DG_:(O@;403)]M35W2K
M^[@*1L/I09>KQPIF5D;F7,^MR#1M_45?['@4*J.9J^/RL=L:80U1R/DK_!7.
M>R.!EZT'75H#+%-<BLV7,R"UBP"W"H\^QQTX"-(\VO$4H^XE^K8F6\Z(RF;L
M[A!7E^_NYC/_,P(9E6IF<."?K7^9_V,/AC^;=J\'[C?5Z/:S+W9VX&0_$:IZ
M:75;?G77N8(HCK,!O#-)L9A8*\:3EJ!/9<GDHFYA:IY/HN!)PI5F$>T!/M2W
M0R=*4Z]Z=EDL-"J+&\779+1M4[.:'S1^DI1HI:"X!0JA!+!?$L8[+VM$'(Y"
M)TV\&N)+%W(TS<TES4^KD[KVTPQ]-\>I*=7+:5IU8>_G _A('XETWK7'Y]@=
M=^[X\YE0VE,H+DMIPM1!MQ,4(*,15J>; HYRQ]*PPQVG-PRNW7TG#M#W*M.6
M&]E;7EVAB$CO_.[P/)IC%H6WA>90JJ_1YK:Z6FA@4RM"Z,_5#)/$V,Z>#T/4
M-Q>)^CUSQCY$>+.85X3/D=MYZ)9/3E6W+9F;)9#,HY=1%(N"B/GR^>!V-E,"
M-\MGES=..QQA Q^+X.:F1?!\F_Y8I'%M#]*X66&H]?W(XMK!R>(FF=W-VB')
MXMK>97%N<WHGLKB^=5E<E[+8K!1W)8<WM*O9<O@"XY]AIV^6MB.$<]C!,P-'
MRP16-AU[VF-U0_UB'R*?#/!-"?T<Z?L52'$8NH#L<O"95ZO[F,F2VZ@269OB
M>] K%\7<-GYNDDV%;)8[FFFQ/5-DS9?FC2WKJ(MB"?-*KYQ5+I7R17..FQBS
M5-M%L8RJ;6R6BOMP+V:0)%=IT#'KKC7J@U;571?%"G:FEA:E%3:NNU:MU]N+
MV%_Y^^O5)JXH.O;XNKGP.%LH:%IS3HL ><J'O?4IC1*+Z'I@4F?4(=EFC)+*
M"'KFW[:(7Z?#O>2[ZN")UZS&##,5BZKTNJAA& S<* K"L>C1>',0>@K4)^R:
M0)-LL^M&A+Z$W\V/:EO.;QAI"WI0ZT$9]TF\>7D+"3SOZ;+^GPAF*A(P-M2.
M$@=FVQ%SI0A4Z@WT(=+(COIF$!+V5=N1I60,*'SEV5%DMN#7<%$P.L<V,&-8
M=93I+": 1'KW2S1J_^ET8@+[@N?9")D%JAEX-O C[(A!?0U_IU%6HM1-T<:@
M>IB6''P%S,X(6Z[?\49=!TZJ[?A.S^VXC/DU7'A@Y75\A]!]M6/WU;FRA[<T
M?BN*'\G"^/_9>_OFQ)%D7_A_/H7"9^=$]Q/8@\1[S[F.P+0][1UWV\=VS]Q]
M_MF0H0!M"XF5A-W>3W\SLTIOJ$ ")! V-^[9:=L@565EY7O^,ML)M4[.NV=)
M5,5?<-%$4#'*W@TIP8O^X)# [3WC(XAD4%QY87%)I4AQ$[66O&[-.5JMXQPM
MV1PM]3A':UO^AJLFX.4X)B%>Y@P0<P6M<XGZ7E8V7%FMH]5&/E7[V;4TCOJL
MMI88Y(M:.J*:0TU$LPY3>A&VPYD7BNQV].#!F3Z0ENO[[Y<'A9+AH':-1J#4
MM%JU*XE8+&I1']B1@#AY))-JOAT&?S#XO ->Z.V$:@).&FXTN+@5\6T7MH*P
M16 [G.4[=VOY;2GJ'4LX'8T--AJ!-0$Z&)F!-+#"?N*,2^ 3W1QPA!5$<$IA
M$W5]PRT]AJ@[SBN<%"^)O1W!>B_IC%"/@X63K4NS7<.Q+JVS;C*8J/PB3IA;
M9:LO^!87P3=N+CEE,ZU:Q7DEK695;2>MT IBE?XM!G>YLBNE#C+4,DP!3DEH
MK6G>"<&A+OZVKL N9IQ?S-="KT4Q(P')5PA;5!X=W7(Y30F9Y-;RHWZW(S+P
MEZ-CUE5MQWH);ZL7+IBPH="RI;[48075J0\;)08'ACX*4,( 3Y/FF1"N;P#'
M1L-K\<,(?;OPQ6AW_7Y/NA38U>L!&,@")*MWG!\>]&."31:X0X"PANC6,D2.
M-;!(GC*V'.2VP_]YDJ&88"/#ZCUE;E^5@Y1D(]/2UH=]D(DG)](I<YA;J^=Z
MZ+(,Q'_U^Y>75U<1?LAO#\M&(H8#IC*>67Y+^IOLG:L*:#(;(9HJ7K?ITDZW
M8>$]DF@91L8:I-.*)MU65^1E84AA?J3N#8>?8L9+8@+;%D(M(U-O)Z4*]BC(
M;.V'!,KF6H [T-6Z6(@B2>1M<<>VH/)J_J^7FO\3*F*A0:/=^25/GN*(L=R$
MSW@G5O>4I$ M2%1[SL_I+.EURHUDA8U2C&+/WHXXRB4<1F;<V3:ZD5I'K6K2
MB;.93C(_,GU\H[RS6K@TBA N*<V3Y52WEX1Z :\T.29 1O]PU9$UZ,@XM$J>
MK+K2"$M=2<'BIJAD_A9HNFVUO@K@>GLSZDV=_FJ!T=R9-;*T0.:0@JZNXP6C
M^>:Z>?L$[R2%>64@W_X#;!:_OM /S:Z(NV*;R,[CKB$Z$(]$NLQS<5R:%QM.
M1O.DVK^YRB#<K6('VZ6(JBRU*(:TX=-M/I*L*-BA?0=@=PG+O&YW4*EQ>'-"
M'5X_^KF<BE$(_"?;&KJGLLZ< \/*[2R:DWRO< +-Q1/8%SQKP8-N8Q+Z\YQ=
M6]_@\8\OS'QF7[%R/*-?@S6$:@NHO0:,1@E08>FL6RLYN>"NPT+.\('AO$Q4
MM=E.KWERWFBV,YU><4>V_@@/.KWVFSN]QXGAK'%XK3(<WCKWK?/F3NS*GH-Q
MF/W(VM@+ON\CRV-DCC"1>"_0NHT%9<-8WCW;&*-UN*:#+3E:JUMM:3DV\NU8
M B1YJ+%/?.<<08-WR3[9&*:+C1T:")I-&"8?K.+]0Q4O%('%^T56E'PU&GE,
MJEY6HV^<APO)?4ARELK3 W3QB_7DCY.7WF0,Y$!VN^/)2WGY7^DE39M8^@E(
M5IFZS8S1OWQ*99HYL,]5+Q_EMW<3CN.(RTH1BG7K=I.P4]M;&&NDR3EUEF*@
MQ&PTG""A5AO->K734E=FZ@KCV^P'D)EY.WM@WO6GS0AI_Y=N8%4\2*TW-.NI
MQ'>%#').]-O1C4_R;+<%2]G6NRO'25'++FF))D4M43S1B8;26,!B!<O21$/N
MD83U(.6S/FXC%/!V8TM]M?XHQ+:FI:!99CN&-8=(O9T#S7I)Z[6EEW1;LNY@
MS%39.F"7]GK'1T2YT:%0"M#DU&^6/7T",Q=_.;?@U.8.V,!)/!2.@4)8+_!7
M,<C(EU&X@.\/*;WES:V*QJ+MM5?Z@/%^VFS7>@5(K0\>\@+T$? GE='<-+')
M6@EQAVM:\^ ;J"D^%^*5A':ALN,@W2XOQ]W<P8Y!@IKI/?25CMI$S**AC P3
M?5B!B^ R2QD!_Y,'&&TX'"P6BPC>F>CP&/RP/?,$X,T3P_L4@\NQ'87]'$QT
M:PP_8_?R$OP<1?<J>&,]( !?!P+>X4/]M7"$'>D6#*S/<IGK\G<^,=KKDZ<X
M" S@B/(L^/63,9H[ ^J+#_8ZL5TO*/O"%MN*PP:H$JAWG@;,Z8:C/".NRL'?
MAB7\\L5^8<\":R$"8E2A XR?$]!:@F.$+<@N]2<+1"-=X:*%1*C \ G BQ:P
MBUSL3?= 4?E\%(%1,BC^5(EC B51(A0.SL([I$>>:(R./ >8D#'@W>R9G36P
M/4.$JMM1B)QQR5^9$1)):Q DD@03J8JD=-@S-GV?*2M'(WH3H"12!#5?Y8G!
MG9XR(#>193"@LQR;G'J1F[1P?^AF6_8;87E2 %? >4I@!ACA;$N%*C]5,/)T
MQP&)N>O4S:[+81>EN:('B&)Q!#+]R7YFE3'2A T7KUO*/5*;6\Q((05Q._J+
MG\>M<X]F]FUHQ&5%GM&:)^>M*GA4U597 K+C C$9*B)Q\-6T+6WAF>6VI=;)
MN=JI5<%E6[JA"W]#=.E3]K3%\(3<]M2F2HAFO5I3E^^J'QZ3'M1S T_Z>Q5L
MB0H+)"O8&R[H G"D\"%@L"\W.H!*H!M ?H-T10N?VSQI-GUK<^@\*=TNQ0H(
M<#OXHRO^ZJX'P=W&D&WMK*LF!T%74W>V!:#X+G9&X.*U6C)BJ'!<G=6;ZY1Z
M<Q@?@&,+ :G#S>T,NV??D%;^30S0,WVU7(G;G7KNAIQ_T'>./9P//'&6KS<&
M>!!#JM.!OY!!MS8>*6(XR4V[$+/3Q%[YJ*7GV\B^:>P*9X6L77)>N$F+DC"!
MF(E_<ET_>8M@H-P$KXC R#IFI)*?&4D$B,((OD',SF4(0>L!>;:/0)XR($_M
M".294V/8GM!KUR_Y"]#O4:ZPVQESJ-_NAH&)YTJ+_9J->@[%?@13%$N]TA:'
M&!LBV?5I#L1U3,-B)^??;A\O%57ESJ0F0&)N+GL/EP]!*O,I9[=R9=/?KA5W
M-.#^K#N&/0?]XI]5Q:3#HO#?  AF#'BHR!Z-T-[&.D(?0)L^&?5)AS;ZG0J:
M/[ ";JW/3-"87HAZ"6\1T<'%;D[8)MPY?!)H,=-@SPQ<A(D(Z\6^GXJ6K;:W
MF+LF8UX?WGP-V.RZ!B[M61(,\Y<,OEY["Y\EK^5C1N(L6;W\"^4A\$BF&(L%
M_C(&W*+P3T;6J0MZS^&.(.+D!<B8/O1IB,%>F<$I(PN0(>(_CG/:3'\E/LO9
MJ-[%W<R8$"/6P*)$;MI1TO+4'IW.7<97A2:;AYZSIR,*?F'C#.+LP\,%H^\N
MZ^'[,V6TZA@B[52;;5E"*]W_VR(FE</:FP@64Z]V&DE,V&J1_MT6B #"4F?#
M'E#IG[1UQ*V(E]E'P+Y3]+?TZS'%W<P1F'7]Z\$E@I]5,D!5P+Y<P_5\D1%
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M0I4/87Y?$?G].$9RH$TISW),F;PM4)^DS?3D_'JN[![O.%_,X*!TZ9OM*3A
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M*)"7_YY32Y!'M#)M%^BQ-EY!Y@=&B_4(S7(?T$-:''KH\G^_7S_^HS#H(0G
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M8$&O6*YD6".3(C-DY47"O52%YQ]I56'BJ/DC33:&]S#KV7!L*_ >T_=S9(J
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MZXEA ;G%,%Z!7[B8O\*KRLT@DL//]N+'>-, !5;X'''C/\Q=L/,-D$,#K[+
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M(3Z&-$7-OQ R"+!%>I],#![TM%5\0GBEZ=4\.4\:7LK4,$WJU^=^+3JB+KS
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M^XR"1J#W0#%@3(=7@,'%06[E,(8T\XY$((<#I/9Z8G9@QKZ 3F*^-TY_J?J
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M@H.%1.E3%5(BL:!@)0&"88SJ5(5 Y9WX \6'*B/=<,(&-*KH$AZ/B+&Y\=?
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M VGV6ZP,C=(C:V5H[$MYNN&M_<1BMDY/UUJ%L-1!!B5<Q_MT^V(Q!X?A103
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M%*!'!1OFD!!)NZO2G8!+Q(AYGT$/+9V H@]JCSALA(\$&XU5[K31.NT\C-F
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M^_ZO#Z]]_>NK\.=8^E=;_P=02P,$%     @ ^#BA6K8B6H0W*@  14<! !L
M  !E83 R,SDX,#$P,65X-2TQ7VYE=V=E;BYH=&WM/6E3VTB;WUWE_]";JG<*
M9AV"(>0BDUK(,6'>7 O,3,U^V6K+;;LGLN31 ?'^^GV.[E9+ED$0$Q.BK:V\
M@RSU^=SG\[>G[]^]Z':>OWU]\ K^5^#_/3\].GWW^L7S!_R_\.L#\_/SPX^O
M_A(GIW^]>_W+O5$<9<]$?WN6B5,]5:GXH,[%<3R548\?],2)2O3H'GP(GWZR
MWV7J2W9?AGH</1.)'D^R?=%TJ'TQE<E8PX?XZO:]%\\/7[S^,M$#G8F]K?[S
M!X>PZD^5^:X]^$_1()WM+P[H;R!04::2J^_@?A;/:"+W8!!G63RE9["OH_>_
MBI/CE[_<4U_V[O?_=WN[O_7W;'Q/'+P[_>7>O1O<Y>G!X;O7XN7K=^]./AV\
M//KPZR_WMN_1WY\.7KVR?U]YTG,]S";XZO:_]L4@3H8JN1_$82AGJ8)3-/]U
MCT#P^>FQG>!,)9D.9&B/&T[MG@'3YZ>OQ/''/V&5'WZYM^>69";:V_Z7>_%K
MSVA?^#<>JA%<$'SYJXJ.SD;BUR3.9^*=GNI,#9\?'L.LQSH#H!!OXSQ5/?&G
M#CY/Y%2\E'-Q=,1O?-KZN"4.XR]BM_]XVWP4RZ$XC<\C_O,T3K(XE#WQQZ_]
M?M^\<YCH3*<3\8?&Y8FC-)31,,6[ V1]Y1U,Y3#^55SS!:\]W/M7>:M_YVFF
M1W, MS<?/YSZIWA_)*<ZG#^[[!SIW53_G^)C)X1]]4S\YY.]';'[:.^1>+2]
M]U \*#V S1(>XYR\+_CG^&J04;O=5<$#_=M_N/48L;?FO,Q#'0T5CG^?7V5B
M]4Q$,IO(:&L6GZLP_*]XK%6R%<13ON!$!A,5;DUR&8V]WPQ=6^EA> ]7->3J
MP.18C52BH@ >?'C_Z<'Q7V\?[&T_W>OO;&T#*=R]">"X@?.H?;B[+0YFB0[%
MSO;.7F6Z!T1]7]PH][KV@*^43,2)3M)OP&*_1B!80IK%QLMX.I/17$3Y=*"2
M9V*GWW_T],F33;&1390POVZN5(A80D]7O.TEL_RIQ$2>*2$#W+Y,@<WF4:I"
M_,\L%F5FTNT8;B)">8X_>V<B@-<$<12I(--Q!+P\F_@__Y2D_^3Q?BH2-=9I
MEDAZ*\UDIJ9  <5(AS"_^^I$!3E.#=N#^<3K+P'0PS&--M5I"M]V.W0C<)?%
M,[R639$#34UHE-\CNM03G"7UQSP(,A&/1/_I[FX/=RIA#4.\?C-D^54:MB=@
MO6_B9"K>W._W1)H'D])>NIUB,SH*PGRHH[&08<B#X_-4Q E\.)N%BO^$$Z1Q
M1CALY02*7;E5'?M'=V)GH]5MB5-XY[BT'O<&K#.D$S WEJA4ADH,YO077':(
M2TUYS_-)',+YI=Y9\.\GY=_YK#6R+SW2L'*X_ZRRAF*1W0X<-^ 9K*"_L]O;
M>;S7 R(M@E"F<,1P+G!:,IF+=")A=7P*42QF0$W.9)@KO"T?V-S=FP%.Z#M>
M$T!A"DO -<-7&WH3IN3IZ.UNQ[XNX'QS6#DL"HB! M*=BI_D=+8OCOYX(XXB
M&"/+,Y#.CJ)@2VS =+_"#V;C]=#^*4\ 4E,E#L:)XL,?2H-9L)B=OOA-1CGL
MM-M!TM[#2T  'ZCL7*FHM$=\CA.ZS;[701*?@,Q7,PVM:A]VB]O=VRZV*VIV
M"X] ;@?9,T0@A1-A(O@R3F:\SP/\?>E&)1UQ'F8,-LF9#A!/ZW?\4+Q1@P2W
M+"[;<;>#/]#<;L_\5\TV89\R$G(XU+@P&<(ETZZ7[5P. .1A[[\=_%M\G,W@
M%/.(,?R/(_'NW<OR1KL=LU./$BR]V\?B(!\#0<4-/G0K?P-<,+OX^TV!^\%-
MRRB&SY*ZUP%>*_/U/>$ 9]K 40K*%<-X%TYKR.0,28O<I!N CT!X(6IC,.U#
MC!1C VYQJ$8Z4L-N!T[H!$3/80XGV=^D6]P8\/?JBTH"G3H\_5,FB402YPT@
MRM_O\P#Z;%/L7GIQAE8Y0(&+_',"Q!T8-RSYI9SI3(:]Q7LLTU.B2''P>?E5
M H)^B,\4\GZ^S8OQL]M9M@I'H !^F4+?&7D!;D:,\B0"N0 )0#;1@.DS'>$9
MP&T;6TN*QA;&Z)W=K5W+>^K9P^H.A__=VM-1([6+WB2)T!Z?)]@59@[?K%$U
M>Y3U8S9>K-K2<ZF*L:BHHVV#-8?%G]RFC36L_%:]=@\Z>1SD)+<4'Z%24B@D
MW_SZMG$;*X;[:ZP I$*"[5F>S.)4(=_K=L;ZK(H=/7%NI&WU!71>)(EQHF%J
M&<)B G@+%P6##1,YRE)+2X?VW('79B@K D4KD=(M$% <)UR<!*@E47A8'."=
M(GK&W*88&9\AX\A)#6"Q4 *-A,V$@*]5XKTEK-X ? O.;XBCSHMO8 \J^B?7
M"3(@&#=00"ZB<8_I@?O0'0-^7"R&S*4T)1 -(, PFAR-D*#3@3H*3&>%G_)N
M9L# </\I#C\R=V*7U/,61(2;YR8Z!#-^F0&[2<,YR,8CE20L)I6W?"M)5+N6
M6[:6)0RDL9W\R8V9R3W[V1-D-%5.PAS'MYPO^=!:@OM+K><#4"R:[*1BE_F(
MMDP^O+I1KS[@IR0^TZR'#U%)016^WCS>0\L[#&C_9N4K![*5JCDO)Y3GZ2H7
MY_.MU8SX)HR!ZO7[XB5 90(JT6E\OMH#W7DB_CL'.=A9<\@A8:9;Y40W,.3;
M&.#@W_#/[;[$TY*?8WM[I0!2'KN_?.QK8K#GC5CF;EI"3?I[JZ8FGV2212I9
M*<Y^T,$D!A55? KC<WA]I6.3ST=\(I_/*@<^B+))#%+21_E9K?0T/H8:F(CX
M).>16N6X_T8I]6T\3..5'O K"<P W@Y7/.YO*!-$ H=?Z?'^%LLH0F$W#%66
MK?0D5 3:NWBG5XFFUR'R@0ZUA'7\_/,JMW=,#E+Q%AVDJQWYK_RS%G_):+6C
M M\F/Z9X"03@Y^<GOW]Z\=,K.1ZK!#@+_K72PP$2)I.A. 08 +#Z^:;G^TWB
MVX<J&:=9 HSA9F=[#]I>#I"M5*IN>*K5L_YBQ"OAY,[3%>+DSR J3S$TA31^
M_.I_E$21>)4;_;D\R^MH'+(1?"C^E.%JF50-%)#MP;B<-.G\*?FQ<"TE*?'&
M/.]W0-6UT__'_?OBC5;A\!D( F.U#W/\DW-41E_<OV_O\=71'W:=OLFSOU-C
M\WR$SXQB:Y\=AC+X+/I;>[#8- [U$)90V7D4)U/T S4X@+KHO&:66((*V$S-
MO@:)DI_O#]0(J/DS,:/#\ =]5#,H[M_?B7<S-9-Y9_T #YO/]Y;!X]VWFN]<
MQ6I^D*;Y=$9FQINVF^_N;3W<6Q)O=C-V\HMG/(I$C17<V:<3%6JT3I,C$FVU
MLCBJLJF;/I_)1(X3.9N('?+JQ7F&X^#P@4P2#$' 1QR*,E0S%1F:?J9@/6/V
M.,4)VKWT"("!_H;!@?K/5, 1"C!J6EK'L]6>5_]J"+8T[/9[Q"S+-RY"K@VY
MV0BO,*S&NDY\QX'U)PSF J1 =%3*'" K@B4:%\=T!LJ4VK])-&PO^9)+'C2_
M9':*H2=LZ2UOG$\4^7\ ET<R2/54AZHG5 A(G<01W#P@/7N(,,Z*XH,HX(H]
MTH#WU@='(,(DP'O6 M&M!**@.1"E\$AF>8*+3Q4Y6S': __*Y'3&]PZK_XS!
M4 4\$;LP- 9 "$#1<U)N$F",590#*+:0L$Y(&#:#!"6#B0LCQ!60$$ 12T=1
M@.&^43 W),#&J5 <)'VX-(Q)@&@B@R"WKO5NQ]('"BS-V(5O)O+EH!9HU@DT
MZCH\"*_21<%<$-I&M"%+<F7X19( +[+C6 @K!C(,B0+L%.QS#F<!H*>![ACA
MU$9/41AO5HD/2>54B5D2#_. XQ9RFJ0G@) E')BQL'82P <8T38C'ZG[$(.\
MTSP(5)IJ>,7,A,11#>]S "\ #V,.QV078<R../8H[IF>V7>*"=-BA&&+ ^O$
M@5$S'"#(T0C",9##8Y7&8<Y*V@48D*BIU*1?C7* !8#O@+%!420/_Z='D8=V
M J.'%6&6$R2C@3$5CN-X"%(>!G6: -TSK5PJP@"10U/T4%K@AQ]/C8/96%43
MYY3!<S2(P]N@1X+D.-1P &C!XFBE]+.&#603(.4:TQ<PBDC1ZQ,]1<' R)YR
M1JAD0I2R1$:I#/B<^*<B1K[^-"\XDF$,8(162\[5$'#D,@J00-C=XM!.SJ5X
M?QQSH@EC)2K/F2,#UUC;^40'DVX'CP^782G'3"4A"$4Z#<(XO62,&\7UQ]M;
M3QMFVOVPZ#YNSO(07#13]EKVP6!&_NI25D816DB_X3.&/(L^,B+B#QPGE^$F
M(!@P*" 9:+)Q 8K N9 =4G0D_/]81H2L2&P 6$,XD4&H-GN8&**'\*GZ8K(]
M<'9+(PBM\2%G ^&F "O4F8PRBN1IH7'-T#A9'31NU(/C)E-+"GZ5,QGH;-X3
MF%*;$*2@4A]C0A.,B^&@)H$!7M<)UQQ@D@PTCLT%]$,\"(TM,36@16*.6TP+
M5VN&*WUU;;!.+(X32@QDX &PF,HY_  R-0H# T.T# BE2+( @(*<\IX 9O((
M@ZE-9E(X!P:N*%:&C58QV18&:B+#$:ZA N.:F#GHE'$RE!@6P)(.9A(Z\D<T
MS ?\GN6]M-JRY-,SNL-Y(5S51T%NMO+X.D'W[^;R."6BPEUBEI:#7P><:/!"
M]ND#F<^G3385!\QOH"W+ ?)"IE5%I/,ENI[-]%N$>%$ _+)5M+"V3EC[O"I8
M(T)HB9\/$2625R)Q:);@] IKYT 2Z4P9Q&T-[0VE-7=4S/XM]*P3>L+FT.,+
M3";-AHU- ^-H7: YG'#)CTQFCX$<M(_5\6VTN=IL;1&J,29ADG;0$P/-:@ I
MUQ&9(8A_^LN"X4B(L],4*L,%#-?Q5%%FJ=W.]\-3U[&$)H%#._OBH_&_XTI.
M.)=W7_R!I0#@YSL85^2=ACV'?7$ZG\%V#Q(YT,&^^ #$D<_J0XPGL%.*![)?
MX2]W.4JII<V7T.9I,]H<Q9'3$XQ'RB?0R*-UY+B\'&)Y (4Z#]EO"Z+-)!!H
M= X4-0#]&OXU[A*2'__.0:X<:L[&KY#/>BV$TEF)%@=Y*$$/&^29B_@)L5 /
MQ^X8HR^L^$S'.88, <(A_;A1@GO5(+F[!(#]U>G?EX..N#KD,+BB@=K!:[?#
M %LR U'>L#/_5-020<'.+02M#X(:@E"DM $*9100$^%G-(\:2V$4N]?9VD?E
M/9R1.JZ:N4="HW1IK($VS9\-@F2:X3=JK(+PXA0=NUDBSU2D3%C1$HB_Q2+B
M=PUMS1AFU)AB)5S\)(J+8D=H!"G@!<@*UKT9JWK#M!_#5E]P -7@<CD5$^)*
M1LFR"KS)7I5"AS:\&9<QC8>PZ"HX)XON/P11-9V%LF#IZ-0$F%=IEFA#.,EJ
MGE;,YA6CDF9_S[EL+3MK!>>X.0.FBF"6W59*+VUX1>P6?V7]W504<P'<"U6D
MNATN(U4ENY4J49M8.B7-T3>W0(--!%4&1TS4%BM" >6EZ!;"+L"160*+U3-T
MA_..R,!>7E$/?3RFBB"6)_&6@OMSZ[1K@@GB/!R2- $[SL/,6M@MP,-P2M$!
M(0OP3*A<.Y+,"G1:7.G*GE*W<\&Q]THS\ H2%2B,Q:&Z=L!;6/JU!4XHO()'
MA&,(%)O78'!RV<,*: RX+- /X8#0AP92M))IQB:WHL2>_9 #E. M,HK8 S>+
ML1:_Q,3'H<T//^!?D9KH*%<&/OR7RH=7*0>I$O),3*GP5LL.UTH_9M=@AX%.
M %_1YQXP%@%3HN!)N-01L)K"1\]0B=XT%SYBO:MB(%/@?2,JZF--;UR,SSPC
MTPV]@,Z((HO#D!,+2Z( I=;G<(L@ZY_FG"DH G131^HJ/(B4O7(PO\!H2=@R
M24Z80H0F Y^N$1&V) V+/,(0A=.7*!L6P$7891^:L7*0S#1";C-&YP?Y-\ID
MT+YI:\(F2Y;=(]>R'J''K-CD$-@36:S%((X_W\?J)W-D/4:GL$,Y8FS!NE(N
M,:J,RKA5MTNJV65H,G&I,B5N<>:6X$S2U)J'B6[6,H9A>B:*P5GPZ,)K@@]\
M><-:U%@[U76FEJ($-$7]#M(@T0.U%-8S5TG4O&#%JQ:JU@E5:</@J[+LW8 "
M74-K(.==;?'92[6&FC 9%,6!B$W3U@K\G5B!R\J."W+F7($LR8//</',O8<
M.G%XQI&ALU &''(<ZG]R/93L(VRMM]^'];:P/[#:BAR$G/LEFF&)10$< _3P
MIVEA5"O5B">5E>29VQV(N:95-'&^[[9^]K*???>']+.WL<:7T[KL"J2.U%06
MSXF5.0-GD3WC&G+8*LHL[WQB<?Q8H:2S-.FJV^EOBG/)1GHO)[4'@A8<T/VA
M+?W,F5GHIV)KZ+":IUHR RJBP8+TBV('<5$[VEATK,KAASJSH<:K]U[RMBV+
MVJ>JSCRHGV]5"C>X*(B9I<Q5K(,7<6YRGEBR-<&-\DSJD.+"<' XSIGI-V"4
MIO*=W6Y>] ,@:GYU<71"O9"F,ZQ10ZI%SVG3]'C.^L;YA"PJ@&95/S" (;;T
M$1MY9 06/ZJ:>]Q@TEX1AH,-A/(L3MBU,'/#5,,HS<B;I43 1&5Y$O$R?$.H
MRR)<_,G82#G-$7\<J @("PT7GV/M5,P?]/&^ZJ8Y_.-('.8IT"+8(&_.]$SJ
MB9WM[:(9RN'+ ].ZY:;E\Q]7.F^&"F=7,>\SY:>\5E\]Q^Y?-4$ZO691.HZP
MHDR/.:5GG*2NI\[BSW69PE*<U](@M:V;A*>V*-JS9D71=J]2%.VCN<NVDTAY
M!1\CSQ%F7>BE3A4D?'AUTOSP$3F(SUC&2_/!WU[9"/3\.F_9LC8B.ZXR11%C
MZ;W;[0Q4&)]3>Q%4S,NAH^0P7G&QM*L=W6THCFD7\M+U6B&6GJY^2:W0M[):
M<J=^#%-*S>WXCX6\=);X0M,J--1RH$,,A"H:3H*80UBTD)J.CI.ZO/1F*LV6
M..+L>4!'+(-HLURP4PXNP*A\'M:G.6>1DE!Z'HE(3M6-\LG=ATT!\J:Q]>HK
M.:B&[I +-'4M)5O4O:45 JNH6]PC!E.2<5G"RK_H:4X9C'O;18O(I9U&J3J%
M[3Z531*%'BJT2;-%QGPGT2D? D-L'4W?@Z/IH7?SC9O.WJR/NKW9U3B2GC[M
M/=WS;_:PP<VV;L*UWV[#ZS57.W.*SK([;<6;)2OY@^+*BJ W8&*+;;-;&>>6
M%K ]=7YR4OU!Y,C([7)I_$V#:)UJK8_E@?Q-(W(XPB<>C<CQ0J8([-YE)EK2
M2KYJ5NYVG,5Q2=E-KPY8-;#1K\EC#1K5J#0RVIO(@DKM 3R"&Y7HFJ-&G4WJ
MN\:+!GSA^9N/'T[]8[Y_KC#YSD8'F",:HE^-+%3X0Z2,((@?-[1!7G>>F9Q/
M3:L8RKPPX%G.S2B"CXOZ.4OAUU2MJP:R4> =!K*Y..:O&*G;65YRDB+F$"&X
M,B=FFDS5%+8=#4%K(J*#]QN:Q-PTC0/MQUIYAWY#LM3VHZW=AMP$&U(0>%[W
M?BV^F5VMM%#&U^ZC=LF,V97M(9J5=W!!P,_#-N"G'/#S\(<,^/FFX%F/9BUW
M6\K=OA%[(^F.DD]<-YR*S(B&KQR3C6=2#T&9B!JF7O50<>-4!&,=-XF06.[5
M#4C\!I9RG^QM*?*UK;O&8FZ$N;1^ZH9^ZH=7\5._*SRAM\95?2<UYDMO[N%6
MO]&E_6FT3S0-&=_T+5'G[N2]K=(16Q/S8UVCURP'1/7(;;LYC.'$)#@,=YM7
MVL*1KX=R!W!&UJ3.E8TT\F")ZE+RVJ9*1CH:FTJ#5%P:4QA,"8X11V8H2HC6
MU?(?6+)*G6/S.YR7PO[PNI(\I/]1X]P4\.^!9CEDP\O?^9!#\TH5.*YW,FU
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ML[MVW\Y,>5 LA&H6WWZ;TYIR(QI4!GW4!F:5 [,>_6B!62UQO9RX-C/!GW*
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M["\J%?*7Y4J"7,>SW*/*8;_Y0J9I/C64C! %"8-,Y#B1LXG8 1!&!@[#H=;
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MB#TGYES9TL59)DJB==!.CI:]4&=SD+HCCD<(-7R-!!?IM;%K. J;L$2-(1@
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M)+H-H?9'9XNAZ145%F!NS0ZH3TYA3X&TF>M)*'4W)0:+A;X#IABQ2JG$@:9
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M<\I?AN%[&4A)"O#Q_(6F=L.IZPO!?4\B&B^VT]:I]_5]L%9G#FOU(%HX'PK
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MV A&/NHKWO-,LIREO\RE.=+7H52KZ]['6/7AM>3KN^8QG.2+Q"XK+&7W_SE
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MF36-D8OS<3Z-&PMFFF_S$6/4CRY?0>*W\4O^? ORN,29=6E3'MH/1H\AK4^
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M5[^C_0JO^G)15FW"F\!M9858['2I&3D@Q&3O0>D[S3>\I];#4;"HCXR3U3V
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M_4N*IMVB=&EX!Z$B0=,1)3  E=(:U2W5#3$:_E>\4BC$.VGQMCYHDHI*=GK
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ME#64#62?\Y[11OWZ5'MC<GJ[CB5;Y2S8[4[RZ&S3MOP6?K4.;'S#//T$7&+
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MW+-!R(L*.;'YH;4M4>XG%C*%7ZM5V@:!,];4TN&YIH6"Q2 BN ^AF^M24WA
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MPMR<]L,.I1Y[ R;V-SG^(0*=GR9OE49A:"W]G"VDU[R-S6I8(W&&FK_^4^I
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MG1"GAB@%JT)=Z:FSOMC1@HU^$_#+(/?$L<)0^>&%K -!W(F5JUB<8\S(\Z2
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MWB,+"<P$6W.@EM!0\[,Q@(8<AIF9BU/J=JLR"D'+)^4(-B9/<X29*<#85(=
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MA_LXQ0@CI?;,8W22HT,CZ.:>DIL^]J)Z9XZ7@._TH%88*TP;H:7]>E'@N@A
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MAM $.14L KP]=?U9\Q:.F#&3!@=P9U]FN_H95*:>TZ$ZOG9+"KZX_[L:7:3
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MYRA3#*#M00FJ/SD3F$*11^)B2^$H5$X5TX(,?_S_9>X8"0E W,QZ*GF9Q?C
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M*9Y;*,EL1UV]]AB^92S.GGJ_Y$K+.U].BPIMZ<O\R&('0W1A-F*[&LYHOBS
M<.%[S]>MA4,UPTL^Y:,&+1/7./:QMF8=S,''A&M?%,]+(<+W6(.%4<YW&1(1
M=9T6Y_T9PP!Z"I*/#AGJ:>9U^M.MBL 2^J-J29B[&3 GDZSOI<T;&3^JL1#^
MC1(M4I8_/#DW)OC?@&NFG%5B!^3H6=7V7XD"<6/F>*+YZ;XH7E8DY*59L?"W
M'\O7#30Y[5'C0A-*#.+<9Z%D@/;8]?$.4Y!<IX_Q3[:;0O-"-Z*EPA.XWNB)
M$JARMP-GV(1+5RT7],VNON_ULX3U0^W[.PD1$F*%E1Q?'FH9ZP_9L%7G=RQ_
M$!\QC@2<>934/HS(1BZ(-P6/9C"HJ8"@<> L#>RU9[)A?7FDZ%*J+JVU,A)=
M$+7QDP)-$JD X<5?Q<GY$3 3]9C LS>#9R<D&98R[=++T=@:>6=EJ/+E .=9
M=4+J7D2:F^>1A:JV9_;T'FV9@]3Z1A*BX$)^H.[+-]L4]KWRAE%P??@@$34*
MA0*+:[0%M!5H3[\?.Z8]-L*.V5M391DJH"ED"&X&.B5,Z;(_/6_$P\X-LWMO
M:AM=I)&B+-BJ\1;W^%"(4!?+SW+;P@6!':><_HPRH]O%7Q1@N'B=8+WIR_.D
M9MWQT3IWJF!.-F()#-HJ7^H7>/#.: =#+4[IK.=O/_-S/)U-2YBZUE5Q7K$8
MPS(Y^$UHM=B5,XR%M&''ACE9,2;*1 KCKMSV 8!3.@D-4<Y#J5*6.8WU 2HA
MDC!7J&NE&+[A/C_3'([5HT(-\&;Q%!OB5V61XD@'^S]N1ADY002NAOE&65<W
MZ[R"7U00I/T22-]!;Q>)%65D[W!39'3I$G;DM@S,JUI;IC755'_G0JC%^J)Q
M_E=4PP,[.+]GR:K?1ENU?]D(S)/S.NV>(<9-Z#GI\K'D3>955YD8)AA.@@#>
MF*H,V@JR=%(MLY1B[J=&EK^4BS^P. A]LJ@0?O$N'#!U<K2ID%I9$OV^(K1+
MG'6\L#A3T>I5J$5YS-[6\QIW\GP'^.8Q@!B0D<L7.0LU/Z5S(D!7DZK6.JW'
M;=A:KW00BX08"!V'"QE:;8?6+XHVQ539#(&M"VB+'0ET[V#W >BE<>.L)S30
MV3E-VIEXR\L3)7UW^$V9LFAL(^C^O1*<)DC7?O-Y+9<5<<#"%7WZ<OZZ2?U:
ML,XOPE0HP'':[4T62@HH%WEGR-7F=[W%HA@!QZ8Z_\*QSM1#8 %E>=O)_+VB
MEJ0'0^JH AHB]?M,PD\;UUDHXZ#]BE952W.?PJ7DM;';KH8@49**KV=KF3)*
M&^XY*[(<9D_+VU N3G??H^&_NJL9+\D;_YVR@8*A)^7?)5(HAX=@IK.89$EZ
ME3EU_3HZ3E6)^]'Z7(RMGEP64KTIB@'#+RM0])XW.R# $4V9V"4,0J7F(;KP
M9QU=K;KA6, '6!94?H\2'I](ME,I:2X2D#YX;8R-J5=<GV9K-6.8!KHXIXEN
M@]A2RWFZSSD)@>*3I8TC1\#O)%QU:Q\HPB-OXWXU+8Y<AOCH,;H^8\IK%J@&
M(V,2@M<S4<B\49--K"4\6AGYW6JO\S5V@"X&G'B0J36'"?@?&Q/O5Q%=@.PM
MZ*6?6=!Y?,6X7HX\9?S6?;F/!>$/[YX^6-2>-U=+N]0O<7 K2,+Y<N^7BQ8^
ML$S(S3H_]S8W_SJQ65]G9H5=+5NBC&21=8X@(_MDKI!;3/TN#45,%&!PM(Y3
M-T]?X+]MF2CVBUIRTO>R.:U8C]?YQ;*Y\&>92P27UGKK&)F4*6@+7M/(R..S
MT [_*S"[H!H^/]DW-U:R$Q,JG(_7MITZ2N]9I'^;5[[&>L=L=9^?->UY%N-!
M;=U&7K6=4_W#4QJ"'0\M#GQ6)-?@(/LD'1V-*;?R) C7'ZD:.@TI!;!W\H)O
M6K ^Y%(HSU[*GN9J4809,L5C3%[)%NTNRA"G]/'(#>2"^W,!^>IW>HO$X:JZ
MO&)>]: &>:D-ES7!YB0<6SO"3)+DU F>Y65>HY?'-\!OE*QHGH_VHMIVR+W-
MIV?5R+.3:[K"!'!0$J+?HH7(*]G;9,T0(WJ1;B#*5>H+E(:PNYUQ2[-VC_?=
MEN!(DT:1FEY:,72^9=_6B+M+F[R*INFU"\XT-X#\ X9?)/^Q(P@@BJ^H0N#+
MG*)%6];E$ OK3G0#&3G_='!8V4_)&+Q$6J<K*&.Y;'.96\3O?05^E8W\ ;RW
MU"I\^:DFG<. G&<Z2*1E[]ZY^1O%N[0@QY<[7;DKQ:P)JU6KXY<78:L-@<0#
M !N'H?-Y$1JVL/EB5?U)_$YW[72T/D/2+SJ:TQ\ <QDKQD+W P08>NM7KY<P
M:4X8%HLIC68-)'ERZS/]FX:K0*Q:W([B8@ [BQU&E230(3/>Q+XU#G14E(5B
M+GL1SJ.70<]0>?:3R#FVD==Q=X@"(S)M+O&B+?B% GMYV2-&3R1#.YY7S2$<
M>=.%O+I\F08Z?8:/#B7!Q@NY;G?P67=%=W# \C%*%1JGJT!T<TT D=!H&H->
M\:B)%:939;!KL;&3?7I*B.#Y0:U?6I:*89QR6JJNK.><%MJ./U)<J[38'5]N
M3N_,*]3\676EUR39F-?8N@0J_/V$%H1!)!MBX8;)O;9GBIH0Q@+6$!0.D?US
MZQNX"CKF5CB#-]S&R8BYB:7"9DZ9/P#&S;X&XP+FE&.:+!2@TH5+1J&WAQME
M[V7=G%^5?:I#5=IOA_F*E8.<Z4%-AM_]JUJ(JC*H\5 1:SS;]1 *VYEN/)>*
MD&:^E;.RP*+ZJSV ?U9<!IR>YUV!Y3HR>*;RYAC<T@2911GKS,Q(FIJUUP0F
M&0DS4T(X>!U!#.RIN.455,D2U_3'/!^).)2O$G;"C7+GOI,;EAUV3U_N,<;B
M&C:%G\92\4M5'9X?IQP<9"$)/H@S0*)B\C!MC+']/@OK.:X5<-K^<1]PI9OA
M="=0FB5K&=&EV"+K7;'5LJ=5L^QZ)GUXS&KO%"NU H[!=@4$4I>!GC6.H\4N
MRCE(O"ZDRZ\I%2X&S]W/I!U9D.ZPR<#CY35BTMP4M'RYE2*12P>6Q(6SW_&W
M9SW6]<:$FCAJQZJ>MQ9MFY'2I;K>:OQ6+Y')_2AQF!+8BF]$[\(+3Y6!:",:
M-AY3M34(J,G(2G,]UV6'D&D\*"T/J#1W!.UYWPM(.-LTODZ?ZJVG6^7] :#>
M:)[9[B&R&>V)9(Z(=XNRI(5^=*6XO:VH 0'Z&R9W@O6]#2NH$G?+>V'0.0P(
M]J$?2@H2MNCX/Z^NE$U/0,NR5<2])QWM<"= 29A6%")(J/1E6Z&:"6SKF^XS
M=+^W%]%@*7;P3XMJYOTP,]?*:UFVN*&EFT3KZL?"G.S[&VO''Y6]#J+(UA[T
M)A2G36?JX&*/N-'@DA]0RG*A>E B-M@_O9#5CSEDK[+/]0A$M0P;"5\CX$O:
M\BR(BP*,=2PX[@4HZN?7-?F>O=S\C#<+</P](UO57#,W(WAEO20-4GS R[)L
M5:,2@]=RN@Z1:LTE--"I?P _!64\*LWB^:;UF3G-Y!^M/YQ^\ ; A:M*OD 7
M3L P>U=<JC$(R/*A=R9&7,9*XE+[@8XAH@?R(VGF@X$>]@8-D5P[(:?0NYL8
M?K%R=(:>2E/_(QP@P-]P?_DNJ6U:!1; .1<0<]VI<$I?.@U7%]]&I M+E;"E
M%SM>D12I*K:&/5')Z/0'FD7_5:$[*Z(=8<)SX*L,HT?'U[!H219&UV<;BJA"
MM@.R2RQP*(S0:P+V(N'B6D3A*.+-(["HKMG_;HV1X3<JQNL\X1&."YUTL"K(
MQ4AW!P ]0MN#VCD)B[6J1RIIRQ<6:B):QX!AK<K > 9%+/?91FM!N3&=(L+$
M(J5;(X/= "HA&!?N<4$\YAAB4!Q<7=\HJ\'U=7[R"81E4 &GPU5V:5_:-[1F
MYACJJ&;0C%P;D]?)(P:S\KR:B!X(GQ9$8U3QWF9U>NSV"U.YS,)1W-X_K]YD
M(:&G'(M] Y>9?/JL[@OHNGH+*CZ</*[GX$!C (,N/1#MI6FO,8BYG_9:M&B@
M$S3J'DF6*&+/$ND";0,L]T<.9^JDV=OSEG^ 0+%L%PD8M39&3,D,$VW.37F#
MMUDH;CP74U^F?)^MJ!CRE02<(O.(@F^*JK<Q6Y81O PI8+]NN6&M/'=V1 KF
M.Z/I";//WDT-E[/A7&/ZH'BJ@@![9F\;01;3Y/1'L?U:8A^R)^-:#9Q)C+)
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M_API0NB!&V0VL(7QS$B84Q0BJ$@O -JO++*OC<;RY/D?L3)*5S__)+:*8-M
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M:G!GQ+MU5%S?MB5<N$.PX.X4$-S=);AK< WN$();X>[N4GCA&H);<">X6]
M 9K?O7U?OW[][NW[]3_?KC''J%%[[;G6/*?V.FO5'O6Z]+H)>"<O+2<-@(*"
M AB_O0"OJP ) "(\/ (\'"(" @(2$B(R*@X:*@H**@$6-@8."2$9*0DA,3$Y
M-0L=.243%3$Q/0\#$RL;)R<G&1V?$"^[( L')_M?)%"(2$BH**CX:&CX[!3$
M%.S_G\=K+P 3$4H/VA &BA( C0D%@PGU^AU !@! P4'];0#^YX""AH&%@T=
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M9 ]$Q!%/**CO0Z+B4+O$-7691GY/S;E%\^LO:7]3]N\)"_I_4O8?POZ7KA4
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MS_3&PP-KL(&FFD;'G(Q)32@W-UL(TLI+!P?O!&1H>KHX"SIC.GNW8I9L%H]
M_FR+?Y,5832Z!=Y-=6213'[(8!PJ>%1O?'':]XM1<0N+EZ9J60]PWGN,!M4U
M<S,5I"[ J_\(P>>:C*%3LXISX1FOKP[W-*! $(G$B;3S=N#LH)^1%=R[*E5;
M7GEWX/1X4[K]^-%@JA["-WU6)FNE8)Y0'Z#B6;'3-+NWWK " VG.6X]%,[?+
M])N8V 7#<O!ZJ6*;0'G"3TWDSBTTS*7>*.YUY/'&=_1X-NWD??8H7%3X^4<B
MXZ>9NF7*G83[[NH#3-4I_@FHCO.)&^9]_/7L+NX$&OJ= (-9*(F1M0'OAX2>
MKQH[1PKO,RJ9ZI@VOLZKE$RWD#SLM0E",US=I;MV#XFA-><XE12T! ;5BXNC
M%Y675OOHR]97<P\LQ5>^,]\!6QTVXZ7ZE(RG4602D&12$D4,^L;YZY4_VN^5
MK3IPYVTXN'^YQE2/%XY1M_)H"\Y8-2MXF6I\2UYO57>@S)U?WI]'B;>"%OE
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M37&P?+7SO;2&]0Z=4F-2Y5RI+DZ2#+A2BM,>0[N:@&T9_=S2HBHN<K7J!@#
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M/_4)]]P+ZZ4%=CX(">SU@QXW)K\U\T9;2]Q.I]>*BVMB]5:N];BU%9P:D(I
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M9&\G[!2+I^RHSIJ?#)C7S$0B+C1JP*<KW%J0J[W57NOAHY4N>C,*^G6.B8K
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M&1['.RP^."+$C3%;DS$ %QT@I%$BFB_Y2^%N1'F7X1'PH@_RE%KL/"43;H\
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MF[\'9:'-*D>8%,U<.S<SZ1T6L<RI@8%@!_<2RZ1+GI6"*O0(,Y!CDFM0=UQ
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MIA^N$"&N)K!5Q)O7_JO/DH[<?XCSGL:=?"Z(*WY35HZVT<NRM(.**T%)\2N
M=\,/+;6)D5^-^JL:GI;LN^> 8J8)Q:H7(UI5GUARK*@#)(D$8 @# KL\#F'&
MW$74*#%[UG%+DK:O$[WP^?NU33^IS]C.FV2^BI.)916'';SX;0VH-%Q<"F*7
MJV8*+V6CF)K59_SJGEM%P7I26]D7(U5*Q$B_AVN,9C:1._*2DXFSBE%ND%P>
M,!9G* EA37)TI*G!-'?XS'.U"]&9X=Z>=BU-8^E$VM-*QM*MC.YC-50C0B4
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M$8*&A8V->Q>7 @^/@O<A]4/>?_MS_05 B(4&09]#1Z,'W")$0R=$N^X T $
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M[2Q_FVQ@[8UV:L!P,@BZ15Q2/U:R:\[S.A*+7<D([_C6F8=&PZ-<X+?>MK#
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ME'O\<G5]RX#>,!.[/P63E"O9U4^\]%&ZG)D0#Y K8DZQ;C]-YT(@9_'V/N)
MX=!98BL9[LQ0^<G.@D(:#5UDD]U9\E#3\*TY[@"(I<^@B /&CGS(,?NB7P2L
MN:>UW:E;*#\B#S;?DMYT.**2.^Z_9?:"9;]7U^5A@$&$UL\)01$F=<TY&H(7
MUX 5*XU3O !,F!_FBT/4\X0>7.\X>>58&=T6Y**-(/A07?V^IG#[?VSI6?R!
MZD=H&KK7@!A4..]2[?N!)WN1YV4^$^ 52JG+L&9ZC>.?X$^.T-KU_O7HQ?MR
MN(I:"@YC(]4U$UQ,+R1Q.A1+@UP"CQZL'=W/WK14;3S$87PC+P(L#O Z^=K
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MQ7.F/[E:V"P0>PZ^QW\P^E/(2P/OB^0037:JHIM#PW[.AON!^!)_=!KR/?S
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M4J>"U(Z$1,I1IT0)%6Q(_&,)K&(Y&NWF?O7>M;=3^0;59N2(4A]*29EFTOB
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MGSJ+%M]OT2T[M(U=4E[Q[N;!B#Z$$?,\8)PRA3)IBD#A>XBB FX?PHI*2$A
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MUR[)[AFTRG%W%I<_X$8NB2HEAY\>W9>1$O %]3<VSONEXG\RJ#C,_P\MZK\
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M?^LEB]6 *CNJM#57CASD2/JO87QE!*VQN8P4RC1J,;[(%QK\W(S3H:^G?CX
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M??@2&RO)B&(AT'\(J!-,&<('(:0>B&-NK 1F6Q31 1TJ*Q<981'U,P$0MPS
M6TI/C..THYPXNB13U<W<>298)^M1Z4-7E1B:61?:V ,T5BR3BPV@2\Z!&Q.)
M'W.,H%A +"+J8_R+21K&4>S_-BSC%RC: VBK>N=B6/L X[;IL94R/.UN^1L-
MJ_L6OYO/1"%N,+B%IS__*_]\R@V("?9B-]&<(1$H=X/(\FQ+J58J#5\$H=R!
MNL1S"JY)WAMJ Q[R**/M8+MUEFL-U&CSC=Z2C5>Z78Q1;>XUE2VP+XHKA>-
M1]60&F'!.'T,]!%AC?G@K(!UU9N]L,8L:S7J1XA1,FZA#PDJX./]\&Z9N9L@
M8\ZB!K0=/P"<O5U!Q3596//ZB,?J.Z/2PKKW9#4[6J7=13C[?TO?/ GQ0;,C
MD+&,,?!I3GZX=YJSF.8*94C;!Y2B"V$[_ +Q1>/8'[JC:J%8^0"EP*B[,-<A
M/;(1W61:7EYI5/^([E3[S&A?G)9GZI$J$)G"D-9IQI 6/V5Z@+:$_5334>#
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MN9\M<+P^^#9T5W3]W:)XCEUYT"R>J.>+-VQ\F^@7V^9PO/NGR>GV0?WF'$.
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M8<3X%=::'KZ#BF2JZR29(T?O<Y?"<<T"HR=PIN)WG3/B  6>=XH>3PTCE%>
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M=5CFMQ# 1KY3RI:R6BB+QOF!I+&M&M+VDH_<1:0CA,L>0)I08=U-.LI+U!G
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M(7M":40\:"V,Z=+N:YC&.%-VE^DVIE;+(B:MT_^O>I'_D;3@_P:</XSW!GZ
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M@DD0H#X-5ZM(O9JF8'P386D0<STTV!3'6_B1: UG@@ER+J>$:,_(](=3BN$
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M!/(5%MV;1<8,NMVB)UQCD!.8._J"I61S:DRCEHV;;OI?VM0W)*U&T#^FE(2
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M1&M9!M%9@% E)*@8=JSU#N?Z&$+IXF2OUOWN*TQ'SBN0J@,@;LX\7W0JT\D
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MLFK /+/L"<'Z#)2M&'6Z.C[]YAC$<*"3*-&#J"^BKPC,65,+KJ?D!?'"$S\
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MU14*>1&V.H..6_]XL,(AV("'_4>CKH;41ON*XRNA)[,)BJCJ:!=I\,]GLPX
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M^QM_*VG'(U%M0\9 J]=3_0>5=M=WI>>GV9?H\U[^=0E3:/AQ>LA:?JR#)7O
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MYYW[B/B']'IC!50GP-S36QJ)=/@X?\,,+8DGOUO664HP/=6-L(?LZ 0OQY1
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MMA_9_:F[IN&BEBFL[N1O+]T,0'B;7 TZ)\"K2X^!HZ69B+M2]=P@O1W@^J?
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MMP=SC.X*N'0V7XEY%\0+6/%$=>'=D"*I61?Q0#GQ*,!XD_W,,3?(JNV>L3]
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MJLKIIDTN1]%.O##13"FU6F[EG#.!M,J_&LFHM,+.T%&)I9;))JEH OEM1LG
M&RHOU3?.3:L59-T,-8$"J$N:S)NE);\B9:V>*+>0N":>-(WJF,BS%#,PRF2K
M);M6/IM EO)2VF5**6@@RFW3N#VUL+:0YB86Z\;TC'RK4M+"=O+>:K6ID (G
MD'_N!Q-!ED]JQ"1J]\<P,TX@A-P/1D(H17[2@]"U$-;+RQ+[H(J2!CZ+\-B$
M)%&KEMQZZ5JBQ:.BG-'@*H5JQ/E;M6^YE>PB@03-:^F7^N63%8;I1G4<;CL[
M(&<P!,BKN@62UC(0<"F68[@+DC0AEF\MWG@?Q)W"4>3!8,SW=/T%6>:QI O
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MW^23O]'?7=.P3!UJA/M312>O,IH!8!\T2-&WU_W(2QC@<0K(-XE^+?)$BUI
MZR/_&O9QHYR#D8U_G@.C7"7C9;0^"J"RJUBSGFX^EJKAYLND:GSJ1EJKYNC
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M]J/SD^#]N4=K+>P.^\5SCY6$RZX[Q3$FDKV\67IVL G"^UMA>3?C9/GEHWW
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M:"J3ZY>O)U\=T#_YJ]$=73>;^QLJ+-R @_[#XS:'E(Z<GL!.O.&DX.YQ$+@
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M,U^-&X1;6&8G9<MQ6#4*M12%!U?+CJO: )O@K;.L9?=VOP3KE.-!U7( _:1
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M\,8^A#<[(;-S]V!;V$KQHD>A:8="W*".!98>ECS7C>,0_5Y>[=Y[%O)!G,?
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M"[3I#)(ZV6G><=_<1@@Q3$PIRN^^*2.K/>'52,$JG-(LKCME9/PWO^M3<ZA
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M!BJS#0+UR/6>I#,:+.=1&,2ML3V?NT#.757R9I0%LQDELR GDX9\+0/6F6@
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M,G*Z[0U790FP:;#_&\RAH"/!7#>9XN]7$4FGU@ZV**E( @D@YH\076]6D W
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MBXOCL[,CBZA2?2L'Z=&01(T:8(*S?CJ[KGK3/0ZR.=N^^7]._RC8D3[F(;/
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M+=FO6= +'XSECJE"'[QR).<G?TT<M-P".NME>, #J,S#1VK..L"JB/#)8%7
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MX$\D?9CNDS3:XKB@<1@)<6HTK;Z<46))P3A3!:"C?4Y+VLU$ZJKK8YH,4T;
M)OX&O^=5+F(A84KS$L[]$QDE<2H#3/  >/QK.&7.9#4MJ&1$Z>)^$Q(YZ_&M
M/^(X99Y\YMRG)NN6![7G-I9%;U8?3FQF">C!)VPI%2,B/A0+.XNV)$FB^%#\
MYH)^'X]>RDI!E9+G1OXG+XZ]K)##"6UM?4'50G^O%3=(5\ OP@MC8K&N<< I
M:\7[*@QC [^*O*@95DV\GD*>%'5AE8$.BHO1YP"9A79E+X,P"PY-AK_U@ZBX
M<%0!O"@HOC!3<\W;)4?QLE*I-4^$\'1'"E3J-%XE/'581QW/N[]848Q1]$O)
M7)7P)'H%? (!8\,N?)_GO&V5G&_VXQF=#2HN="? B^R]F_.#I4Q$@ EW-#?[
M?G<)-\+\X^UMRO'9<8!%'T,E*I2)EW D4HA'"P^5/_QR!=&KZN%#%*<K>AJZ
MP'?I2-&+8AH60TF$#$"'%-;V!6N,6.OGXOP#;BH<RF35J&P(SM<<*+=XP]/-
M4,OQL(J],&&EH49)/BNC9/420<((F+:"]T"\"ZKU.0T *<BP#J.N^1NZ"QDH
MYR$]'.]9 -T( !(0L!P7=,P!^$+O+D55RQ-)+0Q+J&FT"R=I]ABK\J/4D,;/
M 8MPGB1[=BQ8K/LXSM3'M; SF?*FX%FK:QT^&*(_%,.Q!J"[S2[8^HI=X(+3
M6\:^0"TN5/;>9G&W(?>\1D@/MZYL,(N)KE5YTK@]IP.@V@AB[#EU]BH(4NSR
M[5J@GM?GC9%'NC9OTA@ZA8R"Q^*8"R5_A<-+5Z%81)>MQ[,RM\ %]U4#(T)$
MP5'XA("5WKE%'0!&(K-&@5I@MJYB) !^M)*#?G&K;1S_<,5JBHX5SMD:W&:4
M0I,T])R3-SJ1H$RQ).JR%\RI1R4"/AHS-<<4?F-\JPZ0(_(*-A_OTQDNZ0H;
M(ED=P>-HQH9Z84%UK<<J?O%1QXI^A*BXN'X">#G=ZZ<.$36J1$KF9O_Z2<*-
M:)?.,EM&12>TX5]I[:T'CYI@WR]A]:!PDCIV50XC&$=75!*.Q)F[6\+X+7P3
M?2ZEQ,,2;K3QHJNLV,-(]8%U2%LM ZS!F,(V?;E/]S%&[TE(MOLM*@9!^S#
M,2J)(=B\.R%LRI'1#5C)*O8R#I,$8^ 3J=$;W&94).L@E:$J;]+\S-G>E:<S
M=/[45%?*36M38SE,7X2Q5!6C/?UJ#6Y3(39) XC)&IW(Z50LB3H@!'/J4R<O
M" CS.WJ;&X\$\W#J[0C]@ :& $1E--]5=ZDB,4<=_L/2>>BT0(I<9(V7S))9
MVDUPJ,"1+&H8MT*QOMAE'^.TT?W^'^9'=-:HFB.66_4%"9&?]7"]D0XC@S['
MCMEVMXD.&)_C$*]9(NLP6#YX,3ZGVW(PC;8L#2V_R!EK,]6F;W6_U>4.VI+S
M<5 ^$&(YM4[&2VB,@<8V;K14/7;Z>>A'6[SRGBY(XF^BA![M1JOL U.RZIN6
M, *G/7TD"0N+8:71LOZ(#G *P3 :@FQ6+)$O@J'CNAQVLD\?HIB:I-?>=HS(
M8 DAB^'!,!=@P:@".ZCL\ARQ3J<1Y]DM/R&(Q-,WWT_+@6\Q8YJ>:KG2H[]8
MXC3=8'Z\'5M/*=&V79I,@S<%7YZ"*G.*0AWQ"X&IO$[F5<]R2GFM@7SC'@N3
M+2HN;NH 7B#'&]5TSPCO\C4O*DI[N'4$=TA,""/!5.U?W$FX$1V2G[WUZ!$M
M"K]&3?,E$P9*V3=_,A]Z+UDX*KHKX4AT?F9?0K[VS_(/X6N7#J-AUOZ5FWM2
M"4>O0?=_*M5%7ZP(7AL86D?AR-M=%+)-<;$N7E0SLXX7S#&.2U<9T\K)SX0S
MI2#U8IRL:EM>28D;]WRL$S"I^@A:&+>NNG0]?!)' ]=N6\=+8 )1LQW6WL$/
M^!PL1Q]3<A[O=U+I3#ID*4KI(%N /J]1'W&XQY>42U%>LY$.E:I4;;IE%7F"
M $<2[_X^SLPDE(]U,LY832DWWZZJ+XN!DDOBE-6$"/9^NHB7.'XDOK)_C/:M
M@8W^JP(:.*R5#1:B#OM365.>0"YO[;*$3Y=(&#JD,]371FRX94H_'>:)>(NC
M^]C;/1#?VPP$!7AL:W@ 60! 46_F^#6SDG0*5,CGV6.C(LG/[/[G V4S3NE9
M?L3,WW):5C<E&2=0[@36YP1L;2W)-;:<SDGWL*:!7 RC0:F+W"DDXNA$5",;
M1QYNDE4UJ(]R.M:.FH@54G3T>H/<.BSFZW:1&5/\'OLAV@0X-G4I* SH()=I
M-U<*OH0BI(F.@IAP47T<YT'4QH(5N! 4E\O0IU54Z;@MZUQ/UBFUVHNJLI=1
MK%NH66M$BZ'1^MQ)@Z.3.N"\+1O58=5@$S%6-82U%\4PW.&8T#5.1Z]DUDW2
M;K&]3GX4]-_[Z)$;T;RN65D"FE]8%46@428SQ(1V(G'9.O(7U1+J7+0!TO.=
M1W$<?2;A_5@6GXR256-/P@CT!'TQN4:K!9J@Y<UDBN:G$\ZE(#YAWCY@ZL;)
M9+9;DF;1$F' W&%T9!SZ]'@R>KR@'FV[<3A:O('IQ\LQT.^][>Y[U!CG5,X6
M1A!H)K3172O=6!R^Y].Q=E'B;1;KY?XN(0'Q8N#I$F#G20>PE 6PDQ'8&<^[
ML-VSZG0:QP85P9266^?<3>.TSO<)"7&24#3>D5"6<*VWXI*2LIQ.4L8+]*HI
M[X(F_B][DI \">F)[(LJ<JQKG\X%,*X<RP"*?]E3O39['#$<%21CTRL+,0$9
M]F5SE+4_E<VL2V8-DTHVYSYO*S/;GVZ"TP>Z:)CMBC-JM,53:KKA47VS6J1M
MXDN',=!EZV^\)"%KXO.OG#MK6;B*%V=UJR[)/34T3NF>P 0)@E.D^JH9H#;
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MS^>4 ]AM(>0!L-*A0;76<-"=?\K22U!E_8FD#]-]DD9;')<E64='NISZ*=@
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M4%A->+3G:YZ&B.TKW-HF ;NA"A,\HA4A)F3[@1;,"OA6MCB-N+T7ZA;6D<D
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M5X_PH_<DY.Z'>?[X;O$YI O[0'8W.&9!!-X]/C_<>"R?Z\!:0H>R"V-*@S\
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MR'Z4%L0*@):W<92PN*RLFVNX=(NL]:I!-EG#*ACOO73/?),L;%G)K=/H8+L
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M]ZK*&^@6K'5'67_79R)=*3?#I#66P_3>=>;%(?.R%^_CQD5?%S7KI57E_ !
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MXJ.: $T:ME6&D(NNO3]O[/3V4$E4HOWF>*;FUN)RO]MMB*WMIHN:]0IV<G[
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M$]T1ZIG5,[$O=LR5?*KRM%WR+KN[_EY],4%+D,1IF523E*L\3[^1 $B"8N)
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MI'(ILT5E@,Z[ 7NZOD3].K,-Q(FW7^K\8-G'AND9YTGFF\*CUYB3_3$/L9.
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M! PF8+_7G5G;>UJP2?XY0S:[1R2T:;Q%+D91O4%::C7/5E M<@]7FT11LQJ
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MM=A^W4&LXY[WP;(S]]FH2E2])-1/O!*_-O)5^QM^;)VJD[X5H8K5*>,-@ Q
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M QB,F2HY49=?,2@<7Q@Q'G A/**/L7#A1,?^ :2/3O#&&!2@HWB5(WO+5("
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M%P/J%EP[75L"UN O&C?$#[PDR8LJE-6 ^$.J%^?!E1=TR59TYZNC72V/T[R
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M-%PV<''4UZZ'&'+6B%1J]470AQ=<_210>5Y'H7],D=;H85=YL!%K'3:XHDF
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M'X4PB0(ZY^0O:,CF2;U@%^CKZ-;80]2XFX+:J"954!M4YKQG1B]:-OE1&M3
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M]$*?70L=O-%W$'INXN_"M)(W@%=.L]&<E_+RIEL>+:!TNVY\\'RVZB8.E3@
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MG?PA!U,C%:1O$(ORF NFUVRJ81K3^RPOR\1&Y[F9091D,3E0>[""F<J$<?<
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M9#<MU"A'"[>+ #6+XE87-$[2"Q*G_*J[/:')ZBOY>G5U>G%QHA'0V#_*0-T
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M9C%A,5]N97=G96XN:'1M4$L! A0#%     @ ^#BA6E0*O:!]"   O#4  !P
M             ( !&!<$ &5A,#(S.3@P,3 Q97@M9F5E7VYE=V=E;BYH=&U0
M2P$"% ,4    " #X.*%:MB):A#<J  !%1P$ &P              @ '/'P0
M96$P,C,Y.# Q,#%E>#4M,5]N97=G96XN:'1M4$L! A0#%     @ ^#BA6GV4
M(>L.!P  F@<   T              ( !/TH$ &EM86=E7S P,2YJ<&=02P$"
M% ,4    " #X.*%:)S2?9=TY  !%0@  #0              @ %X400 :6UA
M9V5?,# R+FIP9U!+ 0(4 Q0    ( /@XH5IHECR9QCP  *=!   -
M      "  8"+! !I;6%G95\P,#,N:G!G4$L! A0#%     @ ^#BA6N;R$K7X
MA   *(\   T              ( !<<@$ &EM86=E7S P-"YJ<&=02P$"% ,4
M    " #X.*%:?R-@&HEM  #I=   #0              @ &4304 :6UA9V5?
M,# U+FIP9U!+ 0(4 Q0    ( /@XH5J C)G4[F<  &U[   -
M  "  4B[!0!I;6%G95\P,#8N:G!G4$L! A0#%     @ ^#BA6OI^S]?M#P$
MBTX!  T              ( !82,& &EM86=E7S P-RYJ<&=02P$"% ,4
M" #X.*%:_\P9.9H=  #+; $ $0              @ %Y,P< ;FEV9BTR,#(T
M,3(S,2YX<V102P$"% ,4    " #X.*%:B<O00WL3  "7_0  %0
M    @ %"40< ;FEV9BTR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @ ^#BA
M6B <CED;8P  LB\& !4              ( !\&0' &YI=F8M,C R-#$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( /@XH5K)G*QXV>$  ,/2"@ 5
M  "  3[(!P!N:79F+3(P,C0Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #X.*%:
M_Y2-F6!D   ?@08 %0              @ %*J@@ ;FEV9BTR,#(T,3(S,5]P
<<F4N>&UL4$L%!@     /  \ P@,  -T."0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>ea0239801-f1a1_newgen_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nivf="http://www.newgenivf.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nivf-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nivf:NewGenIvfLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-12</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2023-06-12</startDate>
            <endDate>2023-06-12</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2023-12-06</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:SubsidiarieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nivf:EWIHLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-17</startDate>
            <endDate>2024-04-17</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2024-04-17</startDate>
            <endDate>2024-04-17</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2024-04-17</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:COVIRIXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:NewGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:AdditionalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nivf:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConversionRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesAWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKOpportunitiesVILLCJAKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-28</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SecondAdditionalMandatoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-16</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SecondAdditionalMandatoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-16</startDate>
            <endDate>2024-08-16</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SecondAdditionalNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-16</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:WhiteLionCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-18</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2024-11-18</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:NewGenivfLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FFPGSHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:WellImageLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:MedHoldingsLimitedMedHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPGSCenterLimitedFFCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPhnomPenhLimitedFFPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:BiClinicLtdFFBiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:OSLGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodEndMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">nivf:PeriodAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">nivf:ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:UnsecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:SeriesCWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nivf:FreeStandingInstrumentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKAffiliatedHoldersThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nivf:BestLendingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nivf:BestLendingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:ProfessionalPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:ProfessionalPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:DoubleClickServicesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-04</startDate>
            <endDate>2023-12-04</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:DoubleClickServicesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-04</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nivf:NewGenIvfLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nivf:MAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nivf:WhiteLionPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-10</startDate>
            <endDate>2024-12-10</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-12</startDate>
            <endDate>2024-12-12</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-24</startDate>
            <endDate>2024-12-24</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:OverProvisionOfTaxInPriorYearKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:OverProvisionOfTaxInPriorYearKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:JAKAffiliatedHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKOPPORTUNITIESVILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKOPPORTUNITIESVILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:JAKOPPORTUNITIESVILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2023-06-12</instant>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:FirstFertilityBishkekLLCFFBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nivf:BiClinicLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-17</startDate>
            <endDate>2024-12-17</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-11</startDate>
            <endDate>2025-02-11</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2025-03-10</startDate>
            <endDate>2025-03-10</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-28</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nivf:MicroSortAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-28</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nivf:NewGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:GeneticsIVFInstituteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-28</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2025-02-28</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-02</startDate>
            <endDate>2025-04-02</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeniorConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-02</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2025-04-15</instant>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:WhiteLionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="thb">
        <measure>iso4217:THB</measure>
    </unit>
    <unit id="kzt">
        <measure>iso4217:KZT</measure>
    </unit>
    <unit id="hkd">
        <measure>iso4217:HKD</measure>
    </unit>
    <unit id="khr">
        <measure>iso4217:KHR</measure>
    </unit>
    <dei:AmendmentDescription contextRef="c0" id="ixv-44">Amendment No. 1</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-63">NEWGENIVF GROUP LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-77">D8</dei:EntityIncorporationStateCountryCode>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-112">Wing Fung Alfred Siu</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-122">36/39-36/40, 13th Floor, PS Tower Sukhumvit 21 Road (Asoke)</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-24160">Khlong Toei Nuea Sub-district</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c1" id="ixv-24161">Watthana District</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-24162">Bangkok</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-24163">10110</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-24164">TH</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-24165">+1 (212)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-24166">537-4406</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-24167">122 East 42nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-24168">18th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-24169">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-24170">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-24171">10168</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-24172">(212)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-24173">947-7200</dei:LocalPhoneNumber>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-245">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-253">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-24174" unitRef="usd">457740</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ix_4_fact" unitRef="usd">54104</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-24176" unitRef="usd">49245</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ix_5_fact" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-24178" unitRef="usd">80813</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ix_6_fact" unitRef="usd">126264</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-24180" unitRef="usd">195446</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ix_7_fact" unitRef="usd">512581</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c2" decimals="0" id="ixv-24182" unitRef="usd">1000000</us-gaap:DepositsAssetsCurrent>
    <nivf:ReceivableFromAgents contextRef="c2" decimals="0" id="ixv-24183" unitRef="usd">1191795</nivf:ReceivableFromAgents>
    <us-gaap:PrepaidExpenseCurrent contextRef="c2" decimals="0" id="ixv-24184" unitRef="usd">197706</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" id="ix_8_fact" unitRef="usd">1262228</us-gaap:PrepaidExpenseCurrent>
    <nivf:LoanToASPAC contextRef="c3" decimals="0" id="ix_9_fact" unitRef="usd">140000</nivf:LoanToASPAC>
    <nivf:DueFromShareholders contextRef="c3" decimals="0" id="ix_10_fact" unitRef="usd">354285</nivf:DueFromShareholders>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-24188" unitRef="usd">3172745</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ix_11_fact" unitRef="usd">2458836</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-24190" unitRef="usd">273096</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ix_12_fact" unitRef="usd">162157</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-24192" unitRef="usd">98570</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ix_13_fact" unitRef="usd">283847</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c2" decimals="0" id="ixv-24194" unitRef="usd">33333</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c3" decimals="0" id="ix_14_fact" unitRef="usd">1582156</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" id="ixv-24196" unitRef="usd">404999</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" id="ix_15_fact" unitRef="usd">2028160</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-24198" unitRef="usd">3577744</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ix_16_fact" unitRef="usd">4486996</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" id="ixv-24200" unitRef="usd">1298964</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" id="ix_17_fact" unitRef="usd">172626</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-24202" unitRef="usd">500729</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ix_18_fact" unitRef="usd">241613</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c2" decimals="0" id="ixv-24204" unitRef="usd">63489</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c3" decimals="0" id="ix_19_fact" unitRef="usd">7937</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-24206" unitRef="usd">154453</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-24207" unitRef="usd">108526</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ix_20_fact" unitRef="usd">207128</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ix_21_fact" unitRef="usd">6446</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c2" decimals="0" id="ixv-24210" unitRef="usd">82447</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OtherNotesPayableCurrent contextRef="c2" decimals="0" id="ixv-24211" unitRef="usd">500000</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" id="ixv-24212" unitRef="usd">11746</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" id="ix_22_fact" unitRef="usd">486706</us-gaap:TaxesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-24214" unitRef="usd">2720354</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ix_23_fact" unitRef="usd">1122456</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-24216" unitRef="usd">10231</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ix_24_fact" unitRef="usd">118979</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c2" decimals="0" id="ixv-24218" unitRef="usd">2328916</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="0" id="ixv-24219" unitRef="usd">2339147</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="0" id="ix_25_fact" unitRef="usd">118979</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-24221" unitRef="usd">5059501</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ix_26_fact" unitRef="usd">1241435</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-24223"
      unitRef="shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ix_27_fact"
      unitRef="shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ix_0_fact"
      unitRef="shares">1138519</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ix_1_fact"
      unitRef="shares">1138519</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ix_2_fact"
      unitRef="shares">507469</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ix_3_fact"
      unitRef="shares">507469</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c2" decimals="0" id="ixv-24229" unitRef="usd">204000</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c3" decimals="0" id="ix_28_fact" unitRef="usd">127564</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" id="ixv-24231" unitRef="usd">122505</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" id="ix_29_fact" unitRef="usd">4331815</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-24233" unitRef="usd">-985994</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ix_30_fact" unitRef="usd">-461351</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" id="ixv-24235" unitRef="usd">18875</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" id="ix_31_fact" unitRef="usd">-7288</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-24237" unitRef="usd">-1048614</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ix_32_fact" unitRef="usd">3735612</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c2" decimals="0" id="ixv-24239" unitRef="usd">-433143</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c3" decimals="0" id="ix_33_fact" unitRef="usd">-490051</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-24241" unitRef="usd">-1481757</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" id="ix_34_fact" unitRef="usd">3245561</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-24243" unitRef="usd">3577744</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ix_35_fact" unitRef="usd">4486996</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-24245" unitRef="usd">5433375</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="0" id="ixv-24246" unitRef="usd">5136153</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" id="ixv-24247" unitRef="usd">5944190</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" id="ixv-24248" unitRef="usd">3606481</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c6" decimals="0" id="ixv-24249" unitRef="usd">3454368</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c7" decimals="0" id="ixv-24250" unitRef="usd">4406421</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-24251" unitRef="usd">1826894</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c6" decimals="0" id="ixv-24252" unitRef="usd">1681785</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c7" decimals="0" id="ixv-24253" unitRef="usd">1537769</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="0" id="ixv-24254" unitRef="usd">206314</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="0" id="ixv-24255" unitRef="usd">18030</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c7" decimals="0" id="ixv-24256" unitRef="usd">36194</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-24257" unitRef="usd">2781075</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="0" id="ixv-24258" unitRef="usd">1621513</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="0" id="ixv-24259" unitRef="usd">1102870</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-24260" unitRef="usd">2987389</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="0" id="ixv-24261" unitRef="usd">1639543</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="0" id="ixv-24262" unitRef="usd">1139064</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-24263" unitRef="usd">-1160495</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="0" id="ixv-24264" unitRef="usd">42242</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="0" id="ixv-24265" unitRef="usd">398705</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome contextRef="c0" decimals="0" id="ixv-24266" unitRef="usd">971391</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c6" decimals="0" id="ixv-24267" unitRef="usd">111837</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c7" decimals="0" id="ixv-24268" unitRef="usd">23019</us-gaap:OtherIncome>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="0" id="ixv-24269" unitRef="usd">6953</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c6" decimals="0" id="ixv-24270" unitRef="usd">518</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c7" decimals="0" id="ixv-24271" unitRef="usd">21</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c0" decimals="0" id="ixv-24272" unitRef="usd">778656</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c6" decimals="0" id="ixv-24273" unitRef="usd">46179</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c7" decimals="0" id="ixv-24274" unitRef="usd">77757</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-24275" unitRef="usd">199688</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="0" id="ixv-24276" unitRef="usd">66176</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="0" id="ixv-24277" unitRef="usd">-54717</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-24278" unitRef="usd">-960807</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="0" id="ixv-24279" unitRef="usd">108418</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-24280" unitRef="usd">343988</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-24281" unitRef="usd">-486706</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-24282" unitRef="usd">208141</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-24283" unitRef="usd">-474101</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c6" decimals="0" id="ixv-24284" unitRef="usd">108418</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c7" decimals="0" id="ixv-24285" unitRef="usd">135847</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-24286" unitRef="usd">50542</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c6" decimals="0" id="ixv-24287" unitRef="usd">-21775</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-24288" unitRef="usd">-322820</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-24289" unitRef="usd">-524643</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-24290" unitRef="usd">130193</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-24291" unitRef="usd">458667</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" id="ixv-24292" unitRef="usd">32529</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c6" decimals="0" id="ixv-24293" unitRef="usd">-22704</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c7" decimals="0" id="ixv-24294" unitRef="usd">-1920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" id="ixv-24295" unitRef="usd">-441572</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c6" decimals="0" id="ixv-24296" unitRef="usd">85714</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="0" id="ixv-24297" unitRef="usd">133927</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-24298" unitRef="usd">56908</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c6" decimals="0" id="ixv-24299" unitRef="usd">-27621</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-24300" unitRef="usd">-323458</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-24301" unitRef="usd">-498480</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest contextRef="c6" decimals="0" id="ixv-24302" unitRef="usd">113335</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-24303" unitRef="usd">457385</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-24304"
      unitRef="usdPershares">-1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-24305"
      unitRef="usdPershares">3.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-24306"
      unitRef="usdPershares">4.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-24307"
      unitRef="usdPershares">-0.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-24308"
      unitRef="usdPershares">3.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-24309"
      unitRef="usdPershares">4.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ix_36_fact"
      unitRef="shares">358108</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ix_37_fact"
      unitRef="shares">30757</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ix_38_fact"
      unitRef="shares">28797</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-24313"
      unitRef="shares">743323</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-24314"
      unitRef="shares">30757</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-24315"
      unitRef="shares">28797</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ix_39_fact"
      unitRef="shares">507469</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c10" decimals="0" id="ix_40_fact" unitRef="usd">263421</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ix_41_fact" unitRef="usd">-1050211</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="0" id="ix_42_fact" unitRef="usd">10852</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="0" id="ix_43_fact" unitRef="usd">-775938</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="0" id="ixv-24321" unitRef="usd">-138972</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="0" id="ixv-24322" unitRef="usd">-914910</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c19" decimals="0" id="ixv-24323" unitRef="usd">458667</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c21" decimals="0" id="ixv-24324" unitRef="usd">458667</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c22" decimals="0" id="ixv-24325" unitRef="usd">-322820</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c7" decimals="0" id="ixv-24326" unitRef="usd">135847</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20" decimals="0" id="ixv-24327" unitRef="usd">-1282</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c21" decimals="0" id="ixv-24328" unitRef="usd">-1282</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c22" decimals="0" id="ixv-24329" unitRef="usd">-638</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c7" decimals="0" id="ixv-24330" unitRef="usd">-1920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c18" decimals="0" id="ixv-24331" unitRef="usd">240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c21" decimals="0" id="ixv-24332" unitRef="usd">240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c7" decimals="0" id="ixv-24333" unitRef="usd">240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c17" decimals="0" id="ixv-24334" unitRef="usd">-319872</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c18" decimals="0" id="ixv-24335" unitRef="usd">961538</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c21" decimals="0" id="ixv-24336" unitRef="usd">641666</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c7" decimals="0" id="ixv-24337" unitRef="usd">641666</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c23"
      decimals="INF"
      id="ix_44_fact"
      unitRef="shares">507469</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c24" decimals="0" id="ix_45_fact" unitRef="usd">-319872</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c25" decimals="0" id="ix_46_fact" unitRef="usd">1464959</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c26" decimals="0" id="ix_47_fact" unitRef="usd">-591544</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c27" decimals="0" id="ix_48_fact" unitRef="usd">9570</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c28" decimals="0" id="ix_49_fact" unitRef="usd">563113</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c29" decimals="0" id="ix_50_fact" unitRef="usd">-462430</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c30" decimals="0" id="ix_51_fact" unitRef="usd">100683</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c23"
      decimals="INF"
      id="ixv-24346"
      unitRef="shares">507469</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c24" decimals="0" id="ixv-24347" unitRef="usd">-319872</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c25" decimals="0" id="ixv-24348" unitRef="usd">1464959</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c26" decimals="0" id="ixv-24349" unitRef="usd">-591544</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c27" decimals="0" id="ixv-24350" unitRef="usd">9570</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c28" decimals="0" id="ixv-24351" unitRef="usd">563113</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c29" decimals="0" id="ixv-24352" unitRef="usd">-462430</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c30" decimals="0" id="ixv-24353" unitRef="usd">100683</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c34" decimals="0" id="ixv-24354" unitRef="usd">130193</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c36" decimals="0" id="ixv-24355" unitRef="usd">130193</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c37" decimals="0" id="ixv-24356" unitRef="usd">-21775</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c6" decimals="0" id="ixv-24357" unitRef="usd">108418</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c35" decimals="0" id="ixv-24358" unitRef="usd">-16858</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c36" decimals="0" id="ixv-24359" unitRef="usd">-16858</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c37" decimals="0" id="ixv-24360" unitRef="usd">-5846</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c6" decimals="0" id="ixv-24361" unitRef="usd">-22704</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c32" decimals="0" id="ixv-24362" unitRef="usd">192308</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c36" decimals="0" id="ixv-24363" unitRef="usd">192308</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c6" decimals="0" id="ixv-24364" unitRef="usd">192308</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c33" decimals="0" id="ixv-24365" unitRef="usd">2866856</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c36" decimals="0" id="ixv-24366" unitRef="usd">2866856</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c6" decimals="0" id="ixv-24367" unitRef="usd">2866856</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c38"
      decimals="INF"
      id="ix_52_fact"
      unitRef="shares">507469</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c39" decimals="0" id="ix_53_fact" unitRef="usd">-127564</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c40" decimals="0" id="ix_54_fact" unitRef="usd">4331815</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c41" decimals="0" id="ix_55_fact" unitRef="usd">-461351</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c42" decimals="0" id="ix_56_fact" unitRef="usd">-7288</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c43" decimals="0" id="ix_57_fact" unitRef="usd">3735612</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c44" decimals="0" id="ix_58_fact" unitRef="usd">-490051</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" id="ix_59_fact" unitRef="usd">3245561</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c38"
      decimals="INF"
      id="ixv-24376"
      unitRef="shares">507469</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c39" decimals="0" id="ixv-24377" unitRef="usd">-127564</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c40" decimals="0" id="ixv-24378" unitRef="usd">4331815</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c41" decimals="0" id="ixv-24379" unitRef="usd">-461351</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c42" decimals="0" id="ixv-24380" unitRef="usd">-7288</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c43" decimals="0" id="ixv-24381" unitRef="usd">3735612</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c44" decimals="0" id="ixv-24382" unitRef="usd">-490051</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" id="ixv-24383" unitRef="usd">3245561</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c48" decimals="0" id="ixv-24384" unitRef="usd">-524643</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c50" decimals="0" id="ixv-24385" unitRef="usd">-524643</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c51" decimals="0" id="ixv-24386" unitRef="usd">50542</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-24387" unitRef="usd">-474101</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c49" decimals="0" id="ixv-24388" unitRef="usd">26163</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c50" decimals="0" id="ixv-24389" unitRef="usd">26163</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c51" decimals="0" id="ixv-24390" unitRef="usd">6366</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" id="ixv-24391" unitRef="usd">32529</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <nivf:StockIssuedDuringPeriodValueReverseCaptialization contextRef="c47" decimals="0" id="ixv-24392" unitRef="usd">-6028690</nivf:StockIssuedDuringPeriodValueReverseCaptialization>
    <nivf:StockIssuedDuringPeriodValueReverseCaptialization contextRef="c50" decimals="0" id="ixv-24393" unitRef="usd">-6028690</nivf:StockIssuedDuringPeriodValueReverseCaptialization>
    <nivf:StockIssuedDuringPeriodValueReverseCaptialization contextRef="c0" decimals="0" id="ixv-24394" unitRef="usd">-6028690</nivf:StockIssuedDuringPeriodValueReverseCaptialization>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c46" decimals="0" id="ixv-24395" unitRef="usd">127564</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c50" decimals="0" id="ixv-24396" unitRef="usd">127564</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c0" decimals="0" id="ixv-24397" unitRef="usd">127564</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c47" decimals="0" id="ixv-24398" unitRef="usd">-2766856</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c50" decimals="0" id="ixv-24399" unitRef="usd">-2766856</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="0" id="ixv-24400" unitRef="usd">-2766856</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c45"
      decimals="INF"
      id="ixv-24401"
      unitRef="shares">631050</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c46" decimals="0" id="ixv-24402" unitRef="usd">-204000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c47" decimals="0" id="ixv-24403" unitRef="usd">4586236</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c50" decimals="0" id="ixv-24404" unitRef="usd">4382236</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c0" decimals="0" id="ixv-24405" unitRef="usd">4382236</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c52"
      decimals="INF"
      id="ixv-24406"
      unitRef="shares">1138519</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c53" decimals="0" id="ixv-24407" unitRef="usd">-204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c54" decimals="0" id="ixv-24408" unitRef="usd">122505</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c55" decimals="0" id="ixv-24409" unitRef="usd">-985994</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c56" decimals="0" id="ixv-24410" unitRef="usd">18875</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c57" decimals="0" id="ixv-24411" unitRef="usd">-1048614</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c58" decimals="0" id="ixv-24412" unitRef="usd">-433143</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-24413" unitRef="usd">-1481757</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-24414" unitRef="usd">-474101</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c6" decimals="0" id="ix_60_fact" unitRef="usd">108418</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c7" decimals="0" id="ix_61_fact" unitRef="usd">135847</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" id="ixv-24417" unitRef="usd">19502</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c6" decimals="0" id="ix_62_fact" unitRef="usd">31173</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c7" decimals="0" id="ix_63_fact" unitRef="usd">100533</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="0" id="ixv-24420" unitRef="usd">186762</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c6" decimals="0" id="ix_64_fact" unitRef="usd">198535</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c7" decimals="0" id="ix_65_fact" unitRef="usd">203411</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c7" decimals="0" id="ix_66_fact" unitRef="usd">-114013</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <nivf:AmortisationOfShareBasedCompensationExpense contextRef="c0" decimals="0" id="ixv-24424" unitRef="usd">33334</nivf:AmortisationOfShareBasedCompensationExpense>
    <nivf:NonCashDiscountOnConvertibleNotes contextRef="c0" decimals="0" id="ixv-24425" unitRef="usd">402500</nivf:NonCashDiscountOnConvertibleNotes>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c6" decimals="0" id="ix_67_fact" unitRef="usd">625</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c7" decimals="0" id="ix_68_fact" unitRef="usd">10777</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:InterestExpenseDebt contextRef="c0" decimals="0" id="ixv-24428" unitRef="usd">778656</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c6" decimals="0" id="ix_69_fact" unitRef="usd">46179</us-gaap:InterestExpenseDebt>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c6" decimals="0" id="ix_70_fact" unitRef="usd">88151</nivf:WaiverOfRelatedPartyBalance>
    <us-gaap:GainLossOnTerminationOfLease contextRef="c0" decimals="0" id="ixv-24431" unitRef="usd">13092</us-gaap:GainLossOnTerminationOfLease>
    <nivf:GainOnPromissoryNote contextRef="c0" decimals="0" id="ixv-24432" unitRef="usd">953861</nivf:GainOnPromissoryNote>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="0" id="ix_71_fact" unitRef="usd">240000</us-gaap:ShareBasedCompensation>
    <us-gaap:LegalFees contextRef="c6" decimals="0" id="ix_72_fact" unitRef="usd">27320</us-gaap:LegalFees>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-24435" unitRef="usd">-486706</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ix_73_fact" unitRef="usd">208141</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-24437" unitRef="usd">39871</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c6" decimals="0" id="ix_74_fact" unitRef="usd">-1166</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c7" decimals="0" id="ix_75_fact" unitRef="usd">-129922</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-24440" unitRef="usd">-45451</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c6" decimals="0" id="ix_76_fact" unitRef="usd">80665</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c7" decimals="0" id="ix_77_fact" unitRef="usd">7219</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c0" decimals="0" id="ixv-24443" unitRef="usd">2000851</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c6" decimals="0" id="ix_78_fact" unitRef="usd">448266</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c7" decimals="0" id="ix_79_fact" unitRef="usd">15197</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" id="ixv-24446" unitRef="usd">1126338</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c6" decimals="0" id="ix_80_fact" unitRef="usd">71362</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c7" decimals="0" id="ix_81_fact" unitRef="usd">58752</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-24449" unitRef="usd">-6750587</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c6" decimals="0" id="ix_82_fact" unitRef="usd">-51167</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c7" decimals="0" id="ix_83_fact" unitRef="usd">190689</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c0" decimals="0" id="ixv-24452" unitRef="usd">55552</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c6" decimals="0" id="ix_84_fact" unitRef="usd">-1352231</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c7" decimals="0" id="ix_85_fact" unitRef="usd">548010</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-24455" unitRef="usd">-204846</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c6" decimals="0" id="ix_86_fact" unitRef="usd">-230433</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c7" decimals="0" id="ix_87_fact" unitRef="usd">-175132</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInFinanceReceivables contextRef="c7" decimals="0" id="ix_88_fact" unitRef="usd">19476</us-gaap:IncreaseDecreaseInFinanceReceivables>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c0" decimals="0" id="ixv-24459" unitRef="usd">11746</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c7" decimals="0" id="ix_89_fact" unitRef="usd">-12170</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-24461" unitRef="usd">-8264074</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="0" id="ix_90_fact" unitRef="usd">-1766135</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="0" id="ix_91_fact" unitRef="usd">1710901</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-24464" unitRef="usd">53045</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="0" id="ix_92_fact" unitRef="usd">69848</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="0" id="ix_93_fact" unitRef="usd">94452</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-24467" unitRef="usd">-53045</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="0" id="ix_94_fact" unitRef="usd">-69848</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="0" id="ix_95_fact" unitRef="usd">-94452</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <nivf:ProceedsFromAmountDueFromASPACI contextRef="c0" decimals="0" id="ixv-24470" unitRef="usd">-140000</nivf:ProceedsFromAmountDueFromASPACI>
    <nivf:ProceedsFromAmountDueFromASPACI contextRef="c6" decimals="0" id="ix_96_fact" unitRef="usd">140000</nivf:ProceedsFromAmountDueFromASPACI>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="0" id="ixv-24472" unitRef="usd">6446</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c6" decimals="0" id="ix_97_fact" unitRef="usd">9317</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c7" decimals="0" id="ix_98_fact" unitRef="usd">19476</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c0" decimals="0" id="ixv-24475" unitRef="usd">8583597</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c7" decimals="0" id="ix_99_fact" unitRef="usd">128204</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c6" decimals="0" id="ix_100_fact" unitRef="usd">192308</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <nivf:PaymentofInterest contextRef="c0" decimals="0" id="ixv-24478" unitRef="usd">677663</nivf:PaymentofInterest>
    <nivf:PaymentofInterest contextRef="c6" decimals="0" id="ix_101_fact" unitRef="usd">24704</nivf:PaymentofInterest>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c0" decimals="0" id="ixv-24480" unitRef="usd">508738</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c6" decimals="0" id="ix_102_fact" unitRef="usd">1863206</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c7" decimals="0" id="ix_103_fact" unitRef="usd">-1742509</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <nivf:SubscriptionReceivable contextRef="c0" decimals="0" id="ixv-24483" unitRef="usd">-127564</nivf:SubscriptionReceivable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-24484" unitRef="usd">8675790</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="0" id="ix_104_fact" unitRef="usd">1881493</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="0" id="ix_105_fact" unitRef="usd">-1633781</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-24487" unitRef="usd">358671</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c6" decimals="0" id="ix_106_fact" unitRef="usd">45510</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c7" decimals="0" id="ix_107_fact" unitRef="usd">-17332</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" id="ixv-24490" unitRef="usd">44965</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c6" decimals="0" id="ix_108_fact" unitRef="usd">-18962</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="0" id="ix_109_fact" unitRef="usd">16124</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-24493" unitRef="usd">54104</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c30"
      decimals="0"
      id="ix_110_fact"
      unitRef="usd">27556</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c15"
      decimals="0"
      id="ix_111_fact"
      unitRef="usd">28764</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-24496" unitRef="usd">457740</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ix_112_fact" unitRef="usd">54104</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c30"
      decimals="0"
      id="ix_113_fact"
      unitRef="usd">27556</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c7" decimals="0" id="ix_114_fact" unitRef="usd">12170</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-24500" unitRef="usd">768068</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="0" id="ix_115_fact" unitRef="usd">24704</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="0" id="ix_116_fact" unitRef="usd">55469</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-20269">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 1 &#x2014;&#160;ORGANIZATION AND PRINCIPAL ACTIVITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Prior to the Business Combination,
on April 29, 2021, A SPAC I Acquisition Corp. (&#x201c;ASCA&#x201d;), was incorporated as a British Virgin Islands business company, specifically
a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or similar business combination with one or more target businesses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;The Business Combination&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On February 15, 2023,
ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &#x201c;Merger Agreement,&#x201d; and
the transactions contemplated thereunder, the &#x201c;Business Combination&#x201d;) with A SPAC I Mini Acquisition Corp., Merger Sub,
NewGenIvf Limited, a Cayman Islands exempted company (&#x201c;Legacy NewGenIvf&#x201d;) and certain shareholders of Legacy NewGenIvf.
Pursuant to the Merger Agreement, the Business Combination was effected in two steps: (i) ASCA was reincorporated to the British
Virgin Islands by merging with and into A SPAC I Mini Acquisition Corp. (such transaction, the &#x201c;Reincorporation Merger&#x201d;)
 and then the listed company was renamed as NewGenIvf Group
Limited; and (ii) Merger Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the
Company (such second step in isolation, the &#x201c;Acquisition Merger&#x201d;). The surviving entity of the Business Combination,
together with its subsidiaries is referred to in this prospectus as &#x201c;NewGenIvf,&#x201d; the &#x201c;Company,&#x201d;
&#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us,&#x201d; unless the context otherwise requires.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On June 12, 2023, the
parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the &#x201c;First Amendment&#x201d;), pursuant to
which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the &#x201c;Loan&#x201d;)
to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA&#x2019;s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from Legacy NewGenIvf, ASCA
agreed to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&#x2019;s failure to deliver audited
financial statements by no later than February 28, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On December 6, 2023, the
parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &#x201c;Second Amendment&#x201d;) which amended
and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&#x2019;s board of directors following the consummation
of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf and three (3)
of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii) provide for the
conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary Shares in
connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible assets immediately
after the consummation of the Business Combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On April 3, 2024, the Business
Combination was consummated with the Company as the surviving entity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The following is an organization chart of the
Company and its subsidiaries as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;img alt="" src="image_007.jpg" style="height: 322px; width: 700px"/&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s subsidiaries are detailed
in the table as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 22%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 30%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 36%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NewGenivf Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Cayman Islands company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on 16 January, 2019&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FFPGS (HK) Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on December&#160;19, 2019&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketing and administrative services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Image Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on July&#160;11, 2008&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Med Holdings Limited (&#x201c;Med Holdings&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on January&#160;21, 2015&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49%*&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility PGS Center Limited (&#x201c;FFC&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on March&#160;6, 2014&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;74%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Phnom Penh Limited (&#x201c;FFPP&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Cambodia company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on August&#160;10, 2015&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bi Clinic Ltd (&#x201c;FFBi&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;A Kyrgyzstan company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on December 16, 2021&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;Acquired on December 17, 2024&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment, surrogacy and ancillary caring services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd. (&#x201c;SZ QianHai&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;A Shenzhen China, PRC company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on October 24, 2024&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;Marketing and administrative services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Note:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;According to Thailand&#x2019;s
Foreign Business Act (the &#x201c;FBA&#x201d;), the majority shareholdings of limited company incorporated in Thailand is required to be
owned by Thai nationals.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;With reference to the capital
structure and voting rights structure of ordinary shares and preference shares (the &#x201c;Share Structure&#x201d;) of Med Holdings and
FFC, all the preference share capital shall be owned by a Thai national. No preference shares, however, have been issued to date. The
ordinary shares and preference shares have the same rights and status in all respects except for the distribution of profits by way of
dividends with details as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed 15% of the total amount of dividends declared from time to time;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After allocation of dividends as per (a)&#160;above, the rest of the dividends shall be distributed equally amongst the holders of ordinary shares according to their shareholding ratio;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The holders of preferred shares shall be entitled to dividends only in respect of the&#160;years for which the Company has declared a dividend payment, and there shall be no cumulative dividends; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends allocated to the holders of preferred shares in each year shall be limited at the rate as stated in (a)&#160;only. No additional dividends shall be paid to the holders of preferred shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Based upon the management&#x2019;s
judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board meeting, the Company accounts
for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings and FFC by exercising its majority
voting power in any board meetings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On April 17, 2024, the Company entered into a non-binding term sheet
(the &#x201c;Non-Binding Term Sheet&#x201d;) with European Wellness Investment Holdings Limited (&#x201c;EWIHL&#x201d;) for (i) the potential
acquisition of the entire equity interest of EWIHL by the Company for a consideration of US$268,000,000 to be payable by issuing 53,600,000
ordinary shares of the of the Company to the shareholder(s) of EWIHL or its associate and (ii) the fund-raising activity by the Company
from public or private shareholders, and in a form mutually acceptable to the parties, including structured equity investment for up to
US$30 million. On December 11, 2024, NewGenIvf announced its entry into a binding term sheet with European Wellness Investment Holdings
Limited (&#x201c;EWIHL&#x201d;) for the above proposed reverse merger, completion of which was subject to, among other conditions, the completion
of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On May 24, 2024, the Company
received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) notifying
the Company of its non-compliance with two (2) listing requirements for continued listing on Nasdaq pursuant to Nasdaq Listing Rules.
On November 21, 2024, a delisting notice was received from the continued non-compliance. The Company had filed to appeal the delisting
determination and undertook several strategic actions to regain compliance with Nasdaq&#x2019;s listing require. On February 27, 2025.
received approval for the transfer the Company&#x2019;s securities from the Nasdaq Global Market to the Nasdaq Capital Market and on March
10, 2025 its compliance with the listing requirements thereof.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On June 3, 2024, the Company announced the execution of a non-binding
term sheet (the &#x201c;Term Sheet&#x201d;) regarding a proposed reverse merger (the &#x201c;Proposed Transaction&#x201d;) with pharmaceutical
company COVIRIX Medical Pty Ltd (&#x201c;COVIRIX&#x201d;). The consideration was to be settled by way of the issuance of issue 102,890,000
of its ordinary shares to the shareholder(s) of COVIRIX or their respective nominees (the &#x201c;COVIRIX Shareholders&#x201d;) in exchange
for 100% equity interest of COVIRIX, at a deemed price per share of US$6, representing an aggregate amount of US$617,340,000. Simultaneously,
it is proposed that COVIRIX undertakes to introduce investors to raise US$6 million at US$6 per share for NIVF, in a form mutually acceptable
to both NewGen and COVIRIX. Following stockholder approval of the Proposed Transaction, COVIRIX Shareholders are expected to hold approximately
85.8% equity interest in NewGen. However, on September 21, 2024, COVIRIX withdrew from the Proposed Transaction, as such the Proposed
Transaction was terminated with no cost to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On August 7, 2024, the
Company entered into a Securities Purchase Agreement with certain investors named therein (collectively, the &#x201c;Buyers&#x201d;), pursuant
to which, amongst other things: (i) the Company agreed to sell, at an initial closing with JAK Opportunities VI LLC (&#x201c;JAK&#x201d;
and such initial closing, the &#x201c;Initial Closing&#x201d;), pursuant to which the Company agreed to sell to JAK (a) a senior convertible
note (the &#x201c;Initial Note&#x201d;) in the aggregate original principal amount of $1,100,000, and which terms are further set forth
below under the subheading &#x201c;(ii) Initial Closing with JAK&#x201d;, (b) a warrant to purchase 1,325,301 Class A Ordinary Shares of
the Company, no par value (&#x201c;Class A Shares&#x201d; and such warrant, the Series A Warrant), and (c) a warrant to purchase 180,722
Class B Ordinary Shares of the Company, no par value (&#x201c;Class B Shares&#x201d; and such warrant, the Series B Warrant, and the Series
B Warrants, together with the Series A Warrants, the &#x201c;Warrants&#x201d;); and (ii) the Company may require each Buyer (or each Buyer
may require the Company, as applicable) to participate in the sale of (a) one or more additional convertible notes (which aggregate original
principal amount for all additional convertible notes shall not exceed $9,500,000) (the &#x201c;Additional Notes,&#x201d; and, together
with the Initial Note, the &#x201c;Notes&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On August 12, 2024, the Company
and JAK consummated the Initial Closing. The Initial Note sold to JAK in connection with the Securities Purchase Agreement bears an interest
rate of 14.75% per annum and is convertible into the Company&#x2019;s Class A Shares as follows: the Conversion Amount (as defined below)
into validly issued, fully paid and non-assessable Class A at the Conversion Rate determined by dividing the aggregate of the principal
sum plus the interest rates (including late interest charges, if any) and the Make-Whole Amount, if any, by conversion price of $0.83.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;At the Initial Closing, the
Company also sold to JAK a Series A Warrant to purchase 1,325,301 Class A Shares and a Series B Warrant to purchase 180,722 Class B Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Additionally, in connection
with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with certain holders of its convertible
promissory notes (the &#x201c;Existing Notes&#x201d; and each of such amendment and exchange agreements, &#x201c;Amendment and Exchange Agreement&#x201d;),
pursuant to which the Company will exchange the Existing Notes by issuing, among other things, (i) senior convertible notes in the aggregate
principal amount of $2,700,000 (the &#x201c;Exchange Notes&#x201d;) and (b) a series of warrants to initially acquire up to a certain number
of ordinary shares to the holders of the Existing Notes set forth therein or in the Amendment and Exchange Agreement (the &#x201c;Exchange
Warrants&#x201d;)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On August 28, 2024, the Company
consummated the second tranche of its debt financing under the terms of the Securities Purchase Agreement. At the closing of the second
tranche, the Company sold to JAK Opportunities VI LLC (&#x201c;JAK&#x201d;) a senior convertible note (the &#x201c;Note&#x201d;) in the principal
amount of $500,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On November 11, 2024, the Company consummated the third tranche of
its debt financing under the terms of the Securities Purchase Agreement (&#x201c;SPA&#x201d;) referenced in the current report on Form 6-K
filed with the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on August 16, 2024. The Form 6-K filed with the
SEC on August 16, 2024 is incorporated by reference herein. Pursuant to the terms of the SPA, the Company may elect at the second additional
mandatory closing to sell and the institutional investor party to the SPA shall be required to purchases, subject to certain conditions,
an additional note (&#x201c;Second Additional Mandatory Note&#x201d;) in the principal amount of $1,500,000, after the effective date of
the Registration Statement (as defined in the SPA). The sale of the Second Additional Mandatory Note resulted in $1,395,000 of gross proceeds
to the company before fees and expenses. The Notes bears an interest rate of 14.75% per annum and may be adjustable from time to time
pursuant to its terms, with maturity at the 4.5 years anniversary of the date of issuance, subject to extension at the option of the holders
in certain circumstances. The Second Additional Note are convertible at any time, at an initial conversion price of $0.658.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On November. 18, 2024, the
Company entered into a binding term sheet (the &#x201c;Term Sheet&#x201d;) with White Lion Capital, LLC, (&#x201c;White Lion&#x201d;) a California-based
institutional investor focused on high-growth, early-stage public companies, setting out the principal terms and conditions for a $100
million equity line of credit, expandable to $500 million. Pursuant to the Term Sheet, NewGen will have the option, but not the obligation,
to sell to White Lion up to $100.0 million in shares of common stock over an initial 36-month period, with the potential to increase to
$300.0 million upon substantial M&amp;amp;A or merger activity, and further to $500.0 million after $250.0 million has been drawn.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On November 29, 2024, the
Company appointed Tam, Chun Wa to the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;). Mr. Tam will serve as an independent
director. In addition, Mr. Tam has been named to the Audit Committee of the Board. Following the appointment of Mr. Tam, the Board consists
of five members.&#160;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:LongTermDebt contextRef="c59" decimals="0" id="ixv-24503" unitRef="usd">560000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c60" decimals="0" id="ixv-24504" unitRef="usd">140000</us-gaap:RepaymentsOfShortTermDebt>
    <nivf:NetTangibleAssets contextRef="c61" decimals="0" id="ixv-24505" unitRef="usd">5000000</nivf:NetTangibleAssets>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c0" id="ixv-20306">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s subsidiaries are detailed
in the table as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 22%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 30%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 36%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NewGenivf Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Cayman Islands company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on 16 January, 2019&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FFPGS (HK) Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on December&#160;19, 2019&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketing and administrative services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Image Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on July&#160;11, 2008&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Med Holdings Limited (&#x201c;Med Holdings&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on January&#160;21, 2015&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49%*&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility PGS Center Limited (&#x201c;FFC&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on March&#160;6, 2014&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;74%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Phnom Penh Limited (&#x201c;FFPP&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Cambodia company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on August&#160;10, 2015&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bi Clinic Ltd (&#x201c;FFBi&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;A Kyrgyzstan company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on December 16, 2021&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;Acquired on December 17, 2024&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment, surrogacy and ancillary caring services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd. (&#x201c;SZ QianHai&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;A Shenzhen China, PRC company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on October 24, 2024&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;Marketing and administrative services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c88" id="ixv-20331">&#x25cf;&#160;&#160;&#160;A Cayman Islands company &#x25cf;&#160;&#160;&#160;Incorporated on 16 January, 2019</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c88" decimals="2" id="ixv-24506" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c88" id="ixv-20339">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c89" id="ixv-20346">&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company &#x25cf;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c89" decimals="2" id="ixv-24507" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c89" id="ixv-20354">Marketing and administrative services</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c90" id="ixv-20361">&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company &#x25cf;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c90" decimals="2" id="ixv-24508" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c90" id="ixv-20369">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c91" id="ixv-20376">&#x25cf;&#160;&#160;&#160;A Thailand company &#x25cf;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c91"
      decimals="2"
      id="ix_117_fact"
      unitRef="pure">0.49</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c91" id="ixv-20384">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c92" id="ixv-20391">&#x25cf;&#160;&#160;&#160;A Thailand company &#x25cf;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c92" decimals="2" id="ixv-24510" unitRef="pure">0.74</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c92" id="ixv-20399">Provision of IVF treatment</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c93" id="ixv-20406">&#x25cf;&#160;&#160;&#160;A Cambodia company &#x25cf;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c93" decimals="2" id="ixv-24511" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c93" id="ixv-20414">Provision of IVF treatment</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c94" id="ixv-20421">&#x25cf;&#160;&#160;&#160;A Kyrgyzstan company &#x25cf;&#160;&#160;&#160;Incorporated on December 16, 2021 &#x25cf;&#160;&#160;&#160;Acquired on December 17, 2024</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c94" decimals="2" id="ixv-24512" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c94" id="ixv-20430">Provision of IVF treatment, surrogacy and ancillary caring services</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c95" id="ixv-20437">&#x25cf;&#160;&#160;&#160;A Shenzhen China, PRC company &#x25cf;&#160;&#160;&#160;Incorporated on October 24, 2024</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c95" decimals="2" id="ixv-24513" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c95" id="ixv-24514">Marketing and administrative services</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c62" decimals="2" id="ixv-24515" unitRef="pure">0.50</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PreferredStockDividendRatePercentage contextRef="c0" decimals="2" id="ixv-24516" unitRef="pure">0.15</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c63" decimals="0" id="ixv-24517" unitRef="usd">268000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c64"
      decimals="0"
      id="ixv-24518"
      unitRef="shares">53600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentAggregateCost contextRef="c65" decimals="-6" id="ixv-24519" unitRef="usd">30000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c66"
      decimals="0"
      id="ixv-24520"
      unitRef="shares">102890000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c67" decimals="2" id="ixv-24521" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c68"
      decimals="0"
      id="ixv-24522"
      unitRef="usdPershares">6</us-gaap:SaleOfStockPricePerShare>
    <nivf:AggregateAmount contextRef="c66" decimals="0" id="ixv-24523" unitRef="usd">617340000</nivf:AggregateAmount>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c66" decimals="-6" id="ixv-24524" unitRef="usd">6000000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c68"
      decimals="0"
      id="ixv-24525"
      unitRef="usdPershares">6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c69" decimals="3" id="ixv-24526" unitRef="pure">0.858</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c70" decimals="0" id="ixv-24527" unitRef="usd">1100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c71"
      decimals="0"
      id="ixv-24528"
      unitRef="shares">1325301</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c72"
      decimals="0"
      id="ixv-24529"
      unitRef="shares">180722</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ConvertibleNotesPayable contextRef="c73" decimals="0" id="ixv-24530" unitRef="usd">9500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:InvestmentInterestRate contextRef="c74" decimals="4" id="ixv-24531" unitRef="pure">0.1475</us-gaap:InvestmentInterestRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c75"
      decimals="2"
      id="ixv-24532"
      unitRef="usdPershares">0.83</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c76"
      decimals="0"
      id="ixv-24533"
      unitRef="shares">1325301</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c77"
      decimals="0"
      id="ixv-24534"
      unitRef="shares">180722</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c78" decimals="0" id="ixv-24535" unitRef="usd">2700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c79" decimals="0" id="ixv-24536" unitRef="usd">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c80" decimals="0" id="ixv-24537" unitRef="usd">1500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c81" decimals="0" id="ixv-24538" unitRef="usd">1395000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:InvestmentInterestRate contextRef="c80" decimals="4" id="ixv-24539" unitRef="pure">0.1475</us-gaap:InvestmentInterestRate>
    <nivf:MaturityTerm contextRef="c81" id="ixv-24540">P4Y6M</nivf:MaturityTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c82"
      decimals="3"
      id="ixv-24541"
      unitRef="usdPershares">0.658</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c83" decimals="-6" id="ixv-24542" unitRef="usd">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCredit contextRef="c83" decimals="-6" id="ixv-24543" unitRef="usd">500000000</us-gaap:LineOfCredit>
    <us-gaap:CommonStockHeldBySubsidiary contextRef="c84" decimals="-5" id="ixv-24544" unitRef="usd">100000000</us-gaap:CommonStockHeldBySubsidiary>
    <nivf:CommonStockPotentialValue contextRef="c85" decimals="-5" id="ixv-24545" unitRef="usd">300000000</nivf:CommonStockPotentialValue>
    <nivf:MergerActivityDrawn contextRef="c86" decimals="-5" id="ixv-24546" unitRef="usd">500000000</nivf:MergerActivityDrawn>
    <nivf:MergerActivityDrawn contextRef="c87" decimals="-5" id="ixv-24547" unitRef="usd">250000000</nivf:MergerActivityDrawn>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-20556">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 2 &#x2014;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Principles of consolidation and basis of preparation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Management has prepared the
accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the United&#160;States
of America (&#x201c;U.S.&#160;GAAP&#x201d;). The Company maintains its general ledger and journals with the accrual method accounting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The business combination
transaction between Legacy NewGenIvf and SPAC I was accounted for as a reverse recapitalization under ASC 805, Business Combinations,
with NewGenIvf Group Limited, and deemed to be the accounting acquirer. As SPAC I did not meet the definition of a business under ASC
805, the transaction was not treated as a business combination. Instead, it was accounted for as a recapitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accordingly, the consolidated assets, liabilities
and results of operations of the accounting acquirer will become the historical financial statements of the Company, and the accounting
acquirer&#x2019;s assets, liabilities and results of operations will be consolidated with the Company beginning on the acquisition date.
The Legacy NewGenIvf was the legal acquiree but deemed to be the accounting acquirer. The Company was the legal acquirer but deemed to
be the accounting acquiree in the reverse merger. The historical financial statements prior to the acquisition are those of the accounting
acquirer (Legacy NewGenivf). After completion of the Share Exchange Transaction, the Company&#x2019;s consolidated financial statements
include the assets and liabilities, the operations and cash flow of the accounting acquirer. Any excess of the value of shares issued
by the Company over the net book value of the accounting acquirer will be recognized as a reduction to equity (APIC).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency translation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#x201c;$&#x201d;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#x201c;HK$&#x201d;).
Med Holdings and FFC use Thai baht (&#x201c;THB&#x201d;) as their functional currencies. First Fertility Phnom Penh Limited and Bi Clinic
Ltd (&#x201c;FFBi&#x201d;) uses United&#160;States dollar (&#x201c;USD&#x201d;) as their functional currencies. Shenzhen Qianhai Fengtai Renhui
Health Technology Co., Ltd. (&#x201c;SZ QianHai&#x201d;) uses Chinese Renminbi (&#x201c;CNY&#x201d;) as its functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Monetary assets and liabilities denominated in currencies other than the functional currency
are translated into the functional currency using the applicable exchange rates at the balance sheet dates&lt;/span&gt;. &lt;span style="font-family: Times New Roman, Times, Serif"&gt;Translation
gains and losses are recognized in the consolidated statements of operations and comprehensive income as other comprehensive income or
loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The value of foreign currencies
including, the HK$, THB and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#x2019;s financial condition in terms of reporting
in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Period-end&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;$: HK$&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: HK$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: THB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.3353&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.2265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.6153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: THB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.2262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.7867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.1428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: RMB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.9091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: RMB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.1946&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4569&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Deposits, other receivables and deferred legal
&amp;amp; IPO cost, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Deposits, other receivables and deferred Initial Public Offering (&#x201c;IPO&#x201d;)
cost, net primarily include deposits paid to suppliers, prepaid expenses, the prepaid professional fee which meets the definition of deferred
IPO cost, and a cash deposit of US$1,000,000 with OSL Group, a digital asset trading platform listed in Hong Kong Stock Exchange, for
the Company&#x2019;s future digital asset diversification strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to additional paid-in capital upon the completion of the Initial Public Offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Legal and professional fees
incurred in connection with issuing convertible debt are deferred and amortized over the life of the debt. These costs are presented as
a direct deduction from the carrying amount of the debt liability on the balance sheet (per ASC 835-30).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Share based compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company accounts for stock-based compensation
in accordance with ASC Topic 718-10, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which requires the measurement and recognition of compensation
expense for all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees
based on fair values of the shares to be issued estimated at grant date. The stock-based compensation expense recognized during the period
is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Fair value is determined based on the estimated
market prices of the Company&#x2019;s Common Stock at the respective issuance date in accordance with ASC 718, taking into consideration
the volatility of the market price of the shares, the terms of the instruments and the conditions upon which they were granted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Plant and equipment are stated
at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 81%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-102"&gt;the lesser of useful life or&#160;term of lease&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical instruments&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#x2019;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of&#160;long-lived&#160;assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete inventory
will be made based primarily on products approaching expiry period and forecasts of product demand. The excess balance above the product
demand as determined by this analysis becomes the basis for excess inventory charge and the written-down&#160;value of the inventory becomes
its cost. Written-down&#160;inventory would not be reversed if market conditions improve.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Other borrowings&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Convertible Instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Convertible Instruments are
categorized as equity or debt based on the terms of the notes. Convertible Notes are recorded at amounts equal to the proceeds of the
issuance, including the embedded conversion feature, and net of discounts and unamortized debt issuance in accordance with ASC 480-10-55-44
on the consolidated balance sheets. An evaluation of all conversion, purchase and redemption features contained in a debt instrument is
performed to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is recorded
separately as a derivative liability at its fair value, calculated using the Black-Scholes model.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Debt issuance and offering
costs are amortized over the contractual term of the Convertible Notes, to the consolidated statements of operations in accordance with
ASC 835-30-45-1A.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The convertible notes are
subsequently recorded at amortized cost, with interest expense recognized using the effective interest method. The derivative liability,
if any is remeasured at fair value at each reporting date and any gain or loss on fair value is recognized in the statement of comprehensive
income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Promissory Notes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Promissory notes, originated from ASCA&#x2019;s transaction and being
taken over by NewGenIVF Group Limited upon merger, are of non-interest bearing and recorded at original cost. They are subsequently measured
at amortised cost, with interest expense recognized using the effective interest method in the consolidated statement of income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary shares&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s ordinary
shares are stated at no par value. The difference between the consideration received, net of issuance cost, is recorded in additional
paid-in&#160;capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On January 21, 2025, the
Board of Directors of the Company approved a reverse stock split of all of the Company&#x2019;s issued and unissued shares, including the
Class A ordinary shares with no par value (the &#x201c;Class A Ordinary Shares&#x201d;), Class B ordinary shares with no par value and preferred
shares with no par value, at an exchange ratio of one (1) share for twenty (20) shares (the &#x201c;Reverse Stock Split&#x201d;). Upon the
opening of the market on February 11, 2025, the Company&#x2019;s Class A Ordinary Shares will begin trading on the Nasdaq Global Market
(&#x201c;Nasdaq&#x201d;) on a post-Reverse Stock Split basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In accordance with ASC 505,
the reverse stock split is to be accounted for retrospectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company adopted ASC Topic&#160;606,
Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using the full retrospective
method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had been applied to all prior
periods. The Company derives revenue principally from provision of In vitro fertilization (&#x201c;IVF&#x201d;) treatment and surrogacy
and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify its contracts with customers;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify its performance obligations under those contracts;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine the transaction prices of those contracts;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate the transaction prices to its performance obligations in those contracts; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services are inter dependant. All the contracts have commercial substance, and it is probable that
the Company will collect considerations from its customers for service component as settlement is predominantly required prior to performance
of the promised service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company derives its revenues
from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from IVF treatment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In vitro fertilization (&#x201c;IVF&#x201d;) treatment is an assisted
reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized embryo is then implanted
to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment as well as procedures and
brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized at a point in time
when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the various procedures and
treatments are evidenced by treatment cards and reports included within the patient files indicating successful completion of the service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from surrogacy and ancillary caring
services&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#x2019;s result of operations
can be found in Note&#160;8 below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from egg freezing and storage facility&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company provides access
the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the customer,
the Company makes available access to the facility with no further substantial involvement. Revenue is recognized at a point in time when
the facility is made available to the customer at the agreed consideration by the provision of specific address within the facility as
maintained in the patient file. The receipt of consideration is assured as payment is required upfront.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Principal versus agency considerations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company follows the guidance provided in ASC 606, Revenue from
Contracts with Customers, for determining whether the Company is the principal or an agent in arrangements with customers that involve
another party that contributes to the provision of services to a customer. In these instances, the Company determines whether it has promised
to provide the service itself (as principal) or to arrange for the specified service to be provided by another party (as an agent). This
determination is a matter of judgment that depends on the facts and circumstances of each arrangement. The Company recognizes revenue
from the performance of the procedures and treatment on a gross basis as the Company is responsible for the fulfillment, controls the
delivery of the promised service, and has full discretion in establishing prices and therefore is the principal in the arrangement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Contract related assets and
liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Account receivables, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#x2019;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#x2019;s customers&#x2019; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Contract liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#x2019;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Expected credit loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;ASU No.&#160;2016-13, Financial
Instruments&#160;&#x2014;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of credit
losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due to the
entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective interest
rate of the financial asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Retirement benefits&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Segment information&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company determines its
reportable segments using the management approach based on internal reporting used by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;),
comprising the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), for decision-making, resource allocation, and performance
assessment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company does not distinguish
revenues, costs, or expenses by segments, operational or geographical, but reports them in aggregate. Based on this assessment, management
has determined that the Company operates as a single reportable segment under ASC 280. Accordingly, all required segment financial information
is included in the consolidated financial statements. However, we segregate IVF revenue from surrogacy revenue as these two revenue types
are critical to our business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s CODM
is Mr. Siu Wing Fund Alfred, its CEO. Geographic disclosures of long-lived assets and revenue from external customers as of December 31,
2024 and 2023 are presented in Note 15.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company measured the
lease in accordance to ASU&#160;2016-02, &#x201c;Leases&#x201d; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of &lt;span style="-sec-ix-hidden: hidden-fact-103"&gt;twelve&lt;/span&gt;&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the differences
are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not realizable
or recoverable in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions in
income tax expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Comprehensive Income&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;&lt;i&gt;Comprehensive Income&lt;/i&gt;. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Earnings per share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company computes earnings
per share (&#x201c;EPS&#x201d;) following ASC Topic&#160;260, &#x201c;Earnings per share&#x201d;. Basic EPS is measured as the income or loss
available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents the dilutive
effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and or warrants; the
dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive effect of
options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those that increase
income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive securities
that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2024, 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and contingencies&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In the normal course of business,
the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range
of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency if it determines
it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors in making
these assessments including historical and the specific facts and circumstances of each matter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling&#160;interests&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of risks&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Concentration of credit risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers. Furthermore, the risk is mitigated by ascertaining upfront payments for
services prior to their performance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Concentration of customers&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2024 and
2023, one and two customers respectively which individually contributed more than 10% of trade receivable, and accounted for &lt;span style="-sec-ix-hidden: hidden-fact-104"&gt;89%&lt;/span&gt; and 96.3%
of the Company&#x2019;s trade receivable respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;None of the customers contributed
more than 10% of revenue for&#160;years ended December&#160;31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Concentration of suppliers&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2024 and
2023, nil and one supplier respectively which individually contributed more than 10% of trade payable, accounted for &lt;span style="-sec-ix-hidden: hidden-fact-105"&gt;nil&lt;/span&gt; % and 30.6% of
the Company&#x2019;s trade payable respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;For both the years ended
December 31, 2024 and 2023, no vendor contributed more than 10% of total purchases of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Financial instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net, loan
to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that approximate
their fair values due to their short maturities. ASC Topic&#160;820, &#x201c;Fair Value Measurements and Disclosures&#x201d; requires disclosing
the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#x201c;Financial Instruments&#x201d; defines fair value
and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts and
other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify as financial
instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments
and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#160;&#x2014;&#160;inputs to the valuation methodology used quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#160;&#x2014;&#160;inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#x2019;s full term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#160;&#x2014;&#160;inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#x201c;Distinguishing Liabilities from Equity&#x201d;
and ASC&#160;815.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recently issued accounting pronouncements &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The FASB has introduced expanded
income tax disclosure requirements under ASU 2023-09 to improve transparency. Companies will now need to provide a detailed reconciliation
of their effective tax rate, breaking down federal, state, and foreign taxes, as well as specific categories like tax credits and foreign
earnings. Additionally, businesses must disclose income taxes paid by jurisdiction, offering investors greater clarity on tax obligations.
These changes apply to both public and private companies, with annual reporting periods beginning after December 15, 2024 (2025 for calendar-year
entities). This update aims to reduce ambiguity in tax reporting and align disclosures with investor needs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;A major shift in digital
asset accounting, ASU 2023-08 requires companies to measure certain crypto assets (e.g., Bitcoin, Ethereum) at fair value rather than
applying the previous impairment-only model. This means entities must recognize quarterly fair value adjustments in their financial statements,
increasing volatility in reported earnings but improving transparency. The standard applies to fiscal years beginning after December 15,
2024, and impacts both corporate treasuries and investment firms holding cryptocurrencies. This change aligns GAAP closer to fair value
accounting seen in other investment holdings, addressing criticisms of the old impairment approach.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#x2019;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-20561">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Principles of consolidation and basis of preparation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Management has prepared the
accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the United&#160;States
of America (&#x201c;U.S.&#160;GAAP&#x201d;). The Company maintains its general ledger and journals with the accrual method accounting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The business combination
transaction between Legacy NewGenIvf and SPAC I was accounted for as a reverse recapitalization under ASC 805, Business Combinations,
with NewGenIvf Group Limited, and deemed to be the accounting acquirer. As SPAC I did not meet the definition of a business under ASC
805, the transaction was not treated as a business combination. Instead, it was accounted for as a recapitalization.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accordingly, the consolidated assets, liabilities
and results of operations of the accounting acquirer will become the historical financial statements of the Company, and the accounting
acquirer&#x2019;s assets, liabilities and results of operations will be consolidated with the Company beginning on the acquisition date.
The Legacy NewGenIvf was the legal acquiree but deemed to be the accounting acquirer. The Company was the legal acquirer but deemed to
be the accounting acquiree in the reverse merger. The historical financial statements prior to the acquisition are those of the accounting
acquirer (Legacy NewGenivf). After completion of the Share Exchange Transaction, the Company&#x2019;s consolidated financial statements
include the assets and liabilities, the operations and cash flow of the accounting acquirer. Any excess of the value of shares issued
by the Company over the net book value of the accounting acquirer will be recognized as a reduction to equity (APIC).&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-20597">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-20604">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#x201c;$&#x201d;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#x201c;HK$&#x201d;).
Med Holdings and FFC use Thai baht (&#x201c;THB&#x201d;) as their functional currencies. First Fertility Phnom Penh Limited and Bi Clinic
Ltd (&#x201c;FFBi&#x201d;) uses United&#160;States dollar (&#x201c;USD&#x201d;) as their functional currencies. Shenzhen Qianhai Fengtai Renhui
Health Technology Co., Ltd. (&#x201c;SZ QianHai&#x201d;) uses Chinese Renminbi (&#x201c;CNY&#x201d;) as its functional currency.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Monetary assets and liabilities denominated in currencies other than the functional currency
are translated into the functional currency using the applicable exchange rates at the balance sheet dates&lt;/span&gt;. &lt;span style="font-family: Times New Roman, Times, Serif"&gt;Translation
gains and losses are recognized in the consolidated statements of operations and comprehensive income as other comprehensive income or
loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The value of foreign currencies
including, the HK$, THB and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#x2019;s financial condition in terms of reporting
in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Period-end&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;$: HK$&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: HK$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: THB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.3353&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.2265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.6153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: THB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.2262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.7867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.1428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: RMB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.9091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: RMB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.1946&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4569&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="c0" id="ixv-24548">The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Period-end&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;$: HK$&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: HK$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: THB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.3353&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.2265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.6153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: THB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.2262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.7867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.1428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: RMB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.9091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$: RMB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.1946&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4569&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c103"
      decimals="4"
      id="ixv-24549"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c104"
      decimals="4"
      id="ixv-24550"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c105"
      decimals="4"
      id="ixv-24551"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c106"
      decimals="4"
      id="ixv-24552"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c107"
      decimals="4"
      id="ixv-24553"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c108"
      decimals="4"
      id="ixv-24554"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c109"
      decimals="4"
      id="ixv-24555"
      unitRef="pure">34.3353</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c110"
      decimals="4"
      id="ixv-24556"
      unitRef="pure">34.2265</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c111"
      decimals="4"
      id="ixv-24557"
      unitRef="pure">34.6153</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c112"
      decimals="4"
      id="ixv-24558"
      unitRef="pure">35.2262</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c113"
      decimals="4"
      id="ixv-24559"
      unitRef="pure">34.7867</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c114"
      decimals="4"
      id="ixv-24560"
      unitRef="pure">35.1428</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c115"
      decimals="4"
      id="ixv-24561"
      unitRef="pure">7.2994</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c116"
      decimals="4"
      id="ixv-24562"
      unitRef="pure">7.0971</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c117"
      decimals="4"
      id="ixv-24563"
      unitRef="pure">6.9091</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c118"
      decimals="4"
      id="ixv-24564"
      unitRef="pure">7.1946</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c119"
      decimals="4"
      id="ixv-24565"
      unitRef="pure">7.0835</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c120"
      decimals="4"
      id="ixv-24566"
      unitRef="pure">6.4569</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-20736">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <nivf:DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock contextRef="c0" id="ixv-20743">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Deposits, other receivables and deferred legal
&amp;amp; IPO cost, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Deposits, other receivables and deferred Initial Public Offering (&#x201c;IPO&#x201d;)
cost, net primarily include deposits paid to suppliers, prepaid expenses, the prepaid professional fee which meets the definition of deferred
IPO cost, and a cash deposit of US$1,000,000 with OSL Group, a digital asset trading platform listed in Hong Kong Stock Exchange, for
the Company&#x2019;s future digital asset diversification strategy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to additional paid-in capital upon the completion of the Initial Public Offering.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Legal and professional fees
incurred in connection with issuing convertible debt are deferred and amortized over the life of the debt. These costs are presented as
a direct deduction from the carrying amount of the debt liability on the balance sheet (per ASC 835-30).&lt;/p&gt;</nivf:DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock>
    <us-gaap:Deposits contextRef="c96" decimals="0" id="ixv-24567" unitRef="usd">1000000</us-gaap:Deposits>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-20756">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Share based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company accounts for stock-based compensation
in accordance with ASC Topic 718-10, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which requires the measurement and recognition of compensation
expense for all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees
based on fair values of the shares to be issued estimated at grant date. The stock-based compensation expense recognized during the period
is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Fair value is determined based on the estimated
market prices of the Company&#x2019;s Common Stock at the respective issuance date in accordance with ASC 718, taking into consideration
the volatility of the market price of the shares, the terms of the instruments and the conditions upon which they were granted.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-20782">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Plant and equipment are stated
at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment are as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 81%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-102"&gt;the lesser of useful life or&#160;term of lease&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical instruments&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#x2019;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="c2" decimals="2" id="ixv-24568" unitRef="pure">0</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <nivf:ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock contextRef="c0" id="ixv-24569">The estimated useful lives of the plan and equipment are as follows:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 81%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-102"&gt;the lesser of useful life or&#160;term of lease&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical instruments&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</nivf:ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c121" id="ixv-24570">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c122" id="ixv-24571">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c124" id="ixv-24572">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c125" id="ixv-24573">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c126" id="ixv-24574">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c127" id="ixv-24575">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c128" id="ixv-24576">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c129" id="ixv-24577">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-20827">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of&#160;long-lived&#160;assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-20838">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete inventory
will be made based primarily on products approaching expiry period and forecasts of product demand. The excess balance above the product
demand as determined by this analysis becomes the basis for excess inventory charge and the written-down&#160;value of the inventory becomes
its cost. Written-down&#160;inventory would not be reversed if market conditions improve.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c0" id="ixv-20845">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Other borrowings&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <nivf:ConvertibleInstrumentsPolicyTextBlock contextRef="c0" id="ixv-20852">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Convertible Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Convertible Instruments are
categorized as equity or debt based on the terms of the notes. Convertible Notes are recorded at amounts equal to the proceeds of the
issuance, including the embedded conversion feature, and net of discounts and unamortized debt issuance in accordance with ASC 480-10-55-44
on the consolidated balance sheets. An evaluation of all conversion, purchase and redemption features contained in a debt instrument is
performed to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is recorded
separately as a derivative liability at its fair value, calculated using the Black-Scholes model.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Debt issuance and offering
costs are amortized over the contractual term of the Convertible Notes, to the consolidated statements of operations in accordance with
ASC 835-30-45-1A.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The convertible notes are
subsequently recorded at amortized cost, with interest expense recognized using the effective interest method. The derivative liability,
if any is remeasured at fair value at each reporting date and any gain or loss on fair value is recognized in the statement of comprehensive
income.&lt;/p&gt;</nivf:ConvertibleInstrumentsPolicyTextBlock>
    <nivf:PromissoryNotesPolicyTextBlock contextRef="c0" id="ixv-20865">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Promissory Notes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Promissory notes, originated from ASCA&#x2019;s transaction and being
taken over by NewGenIVF Group Limited upon merger, are of non-interest bearing and recorded at original cost. They are subsequently measured
at amortised cost, with interest expense recognized using the effective interest method in the consolidated statement of income.&lt;/p&gt;</nivf:PromissoryNotesPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c0" id="ixv-20887">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary shares&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s ordinary
shares are stated at no par value. The difference between the consideration received, net of issuance cost, is recorded in additional
paid-in&#160;capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On January 21, 2025, the
Board of Directors of the Company approved a reverse stock split of all of the Company&#x2019;s issued and unissued shares, including the
Class A ordinary shares with no par value (the &#x201c;Class A Ordinary Shares&#x201d;), Class B ordinary shares with no par value and preferred
shares with no par value, at an exchange ratio of one (1) share for twenty (20) shares (the &#x201c;Reverse Stock Split&#x201d;). Upon the
opening of the market on February 11, 2025, the Company&#x2019;s Class A Ordinary Shares will begin trading on the Nasdaq Global Market
(&#x201c;Nasdaq&#x201d;) on a post-Reverse Stock Split basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In accordance with ASC 505,
the reverse stock split is to be accounted for retrospectively.&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c97"
      decimals="0"
      id="ixv-24578"
      unitRef="shares">20</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-20900">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company adopted ASC Topic&#160;606,
Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using the full retrospective
method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had been applied to all prior
periods. The Company derives revenue principally from provision of In vitro fertilization (&#x201c;IVF&#x201d;) treatment and surrogacy
and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify its contracts with customers;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify its performance obligations under those contracts;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine the transaction prices of those contracts;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate the transaction prices to its performance obligations in those contracts; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services are inter dependant. All the contracts have commercial substance, and it is probable that
the Company will collect considerations from its customers for service component as settlement is predominantly required prior to performance
of the promised service.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company derives its revenues
from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from IVF treatment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In vitro fertilization (&#x201c;IVF&#x201d;) treatment is an assisted
reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized embryo is then implanted
to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment as well as procedures and
brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized at a point in time
when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the various procedures and
treatments are evidenced by treatment cards and reports included within the patient files indicating successful completion of the service.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from surrogacy and ancillary caring
services&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#x2019;s result of operations
can be found in Note&#160;8 below.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from egg freezing and storage facility&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company provides access
the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the customer,
the Company makes available access to the facility with no further substantial involvement. Revenue is recognized at a point in time when
the facility is made available to the customer at the agreed consideration by the provision of specific address within the facility as
maintained in the patient file. The receipt of consideration is assured as payment is required upfront.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Principal versus agency considerations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company follows the guidance provided in ASC 606, Revenue from
Contracts with Customers, for determining whether the Company is the principal or an agent in arrangements with customers that involve
another party that contributes to the provision of services to a customer. In these instances, the Company determines whether it has promised
to provide the service itself (as principal) or to arrange for the specified service to be provided by another party (as an agent). This
determination is a matter of judgment that depends on the facts and circumstances of each arrangement. The Company recognizes revenue
from the performance of the procedures and treatment on a gross basis as the Company is responsible for the fulfillment, controls the
delivery of the promised service, and has full discretion in establishing prices and therefore is the principal in the arrangement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Contract related assets and
liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Account receivables, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#x2019;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#x2019;s customers&#x2019; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Contract liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#x2019;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Expected credit loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;ASU No.&#160;2016-13, Financial
Instruments&#160;&#x2014;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of credit
losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due to the
entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective interest
rate of the financial asset.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <nivf:RevenueRate contextRef="c2" decimals="2" id="ixv-24579" unitRef="pure">0.40</nivf:RevenueRate>
    <us-gaap:PostemploymentBenefitPlansPolicy contextRef="c0" id="ixv-21046">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Retirement benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.&lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-21053">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Segment information&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company determines its
reportable segments using the management approach based on internal reporting used by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;),
comprising the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), for decision-making, resource allocation, and performance
assessment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company does not distinguish
revenues, costs, or expenses by segments, operational or geographical, but reports them in aggregate. Based on this assessment, management
has determined that the Company operates as a single reportable segment under ASC 280. Accordingly, all required segment financial information
is included in the consolidated financial statements. However, we segregate IVF revenue from surrogacy revenue as these two revenue types
are critical to our business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s CODM
is Mr. Siu Wing Fund Alfred, its CEO. Geographic disclosures of long-lived assets and revenue from external customers as of December 31,
2024 and 2023 are presented in Note 15.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-21067">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company measured the
lease in accordance to ASU&#160;2016-02, &#x201c;Leases&#x201d; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of &lt;span style="-sec-ix-hidden: hidden-fact-103"&gt;twelve&lt;/span&gt;&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-21090">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the differences
are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not realizable
or recoverable in the future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions in
income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0" id="ixv-21100">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Comprehensive Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;&lt;i&gt;Comprehensive Income&lt;/i&gt;. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-21109">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Earnings per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company computes earnings
per share (&#x201c;EPS&#x201d;) following ASC Topic&#160;260, &#x201c;Earnings per share&#x201d;. Basic EPS is measured as the income or loss
available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents the dilutive
effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and or warrants; the
dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive effect of
options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those that increase
income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive securities
that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2024, 2023 and 2022.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <nivf:RelatedPartiesPolicyTextBlock contextRef="c0" id="ixv-21116">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Related parties&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.&lt;/p&gt;</nivf:RelatedPartiesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-21123">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In the normal course of business,
the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range
of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency if it determines
it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors in making
these assessments including historical and the specific facts and circumstances of each matter.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <nivf:NonControllingInterestsPolicyTextBlock contextRef="c0" id="ixv-21130">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling&#160;interests&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.&lt;/p&gt;</nivf:NonControllingInterestsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-21137">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of risks&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Concentration of credit risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers. Furthermore, the risk is mitigated by ascertaining upfront payments for
services prior to their performance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Concentration of customers&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2024 and
2023, one and two customers respectively which individually contributed more than 10% of trade receivable, and accounted for &lt;span style="-sec-ix-hidden: hidden-fact-104"&gt;89%&lt;/span&gt; and 96.3%
of the Company&#x2019;s trade receivable respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;None of the customers contributed
more than 10% of revenue for&#160;years ended December&#160;31, 2024 and 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Concentration of suppliers&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2024 and
2023, nil and one supplier respectively which individually contributed more than 10% of trade payable, accounted for &lt;span style="-sec-ix-hidden: hidden-fact-105"&gt;nil&lt;/span&gt; % and 30.6% of
the Company&#x2019;s trade payable respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;For both the years ended
December 31, 2024 and 2023, no vendor contributed more than 10% of total purchases of the Company.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c99" decimals="3" id="ixv-24580" unitRef="pure">0.963</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c101"
      decimals="3"
      id="ixv-24581"
      unitRef="pure">0.306</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c102"
      decimals="3"
      id="ixv-24582"
      unitRef="pure">0.306</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c0" id="ixv-21192">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net, loan
to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that approximate
their fair values due to their short maturities. ASC Topic&#160;820, &#x201c;Fair Value Measurements and Disclosures&#x201d; requires disclosing
the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#x201c;Financial Instruments&#x201d; defines fair value
and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts and
other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify as financial
instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments
and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#160;&#x2014;&#160;inputs to the valuation methodology used quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#160;&#x2014;&#160;inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#x2019;s full term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#160;&#x2014;&#160;inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#x201c;Distinguishing Liabilities from Equity&#x201d;
and ASC&#160;815.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-21244">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recently issued accounting pronouncements &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The FASB has introduced expanded
income tax disclosure requirements under ASU 2023-09 to improve transparency. Companies will now need to provide a detailed reconciliation
of their effective tax rate, breaking down federal, state, and foreign taxes, as well as specific categories like tax credits and foreign
earnings. Additionally, businesses must disclose income taxes paid by jurisdiction, offering investors greater clarity on tax obligations.
These changes apply to both public and private companies, with annual reporting periods beginning after December 15, 2024 (2025 for calendar-year
entities). This update aims to reduce ambiguity in tax reporting and align disclosures with investor needs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;A major shift in digital
asset accounting, ASU 2023-08 requires companies to measure certain crypto assets (e.g., Bitcoin, Ethereum) at fair value rather than
applying the previous impairment-only model. This means entities must recognize quarterly fair value adjustments in their financial statements,
increasing volatility in reported earnings but improving transparency. The standard applies to fiscal years beginning after December 15,
2024, and impacts both corporate treasuries and investment firms holding cryptocurrencies. This change aligns GAAP closer to fair value
accounting seen in other investment holdings, addressing criticisms of the old impairment approach.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#x2019;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c0" id="ixv-21260">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 3 &#x2014; GOING CONCERN.&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated financial statements have been prepared
assuming that the Company will continue as a going concern. The Company has generated a loss and suffered from an accumulated deficit
of $985,994 as of December 31, 2024. These matters raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.
Management&#x2019;s plans with regards to these include but not limited to issuance of share through equity line of credit with White Lion
Capital and conversion of JAK&#x2019;s promissory notes. These financial statements do not include any adjustments that might result from
the outcome of this uncertainty.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company closely monitors
the market for opportunities and has also been carrying out various fundraising projects to improve the Company&#x2019;s cash flow position.
As of this report date, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising the Initial Note,
the First Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the Company. A further
$2,000,000 of the Third Mandatory Additional Note was issued subsequent to year end and remains outstanding. Moreover, the Company has
access to an equity line of credit facility of up to $100,000,000 from White Lion Capital, of which approximately $7.1 million has been
drawn and become equity to date. As of this report date, the Company holds $2.48m cash in bank and a cash deposit of $1m with a trading
platform company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company can make no assurance
that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one
or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there
would likely be a material adverse effect on the Company and its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The consolidated financial
statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-24583" unitRef="usd">-985994</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="c0" decimals="0" id="ixv-24584" unitRef="usd">2000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
    <us-gaap:LineOfCreditFacilityPeriodicPayment contextRef="c0" decimals="0" id="ixv-24585" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:ProceedsFromOtherEquity contextRef="c0" decimals="-5" id="ixv-24586" unitRef="usd">7100000</us-gaap:ProceedsFromOtherEquity>
    <nivf:CashInBank contextRef="c2" decimals="-4" id="ixv-24587" unitRef="usd">2480000</nivf:CashInBank>
    <us-gaap:DepositsAssets contextRef="c2" decimals="-9" id="ixv-24588" unitRef="usd">1000000000</us-gaap:DepositsAssets>
    <us-gaap:AccountsAndNontradeReceivableTextBlock contextRef="c0" id="ixv-21277">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 4 &#x2014;&#160;ACCOUNTS RECEIVABLE, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Accounts receivable, net consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in"&gt;As of the end of each of the financial year, the
aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Within 90&#160;days&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;49,245&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The movement of allowances for expected credit
loss is as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Reversal of expected credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0" id="ixv-21282">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Accounts receivable, net consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c2" decimals="0" id="ixv-24589" unitRef="usd">49264</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c3" decimals="0" id="ixv-24590" unitRef="usd">9393</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="0" id="ixv-24591" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="0" id="ixv-24592" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-24593" unitRef="usd">49245</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-24594" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="c0" id="ixv-21343">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in"&gt;As of the end of each of the financial year, the
aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Within 90&#160;days&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;49,245&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c130" decimals="0" id="ixv-24595" unitRef="usd">49245</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c131" decimals="0" id="ixv-24596" unitRef="usd">9374</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c2" decimals="0" id="ixv-24597" unitRef="usd">49245</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c3" decimals="0" id="ixv-24598" unitRef="usd">9374</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock contextRef="c0" id="ixv-21381">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The movement of allowances for expected credit
loss is as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Reversal of expected credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c132" decimals="0" id="ixv-24599" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c133" decimals="0" id="ixv-24600" unitRef="usd">26</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c135" decimals="0" id="ixv-24601" unitRef="usd">7</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c136" decimals="0" id="ixv-24602" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c132" decimals="0" id="ixv-24603" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-21433">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 5 &#x2014;&#160;INVENTORIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Inventories consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Medicines, consumables and reagents for clinical and laboratory analyses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;80,813&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;126,264&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;80,813&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;126,264&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-21438">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Inventories consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Medicines, consumables and reagents for clinical and laboratory analyses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;80,813&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;126,264&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;80,813&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;126,264&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryGross contextRef="c2" decimals="0" id="ixv-24604" unitRef="usd">80813</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c3" decimals="0" id="ixv-24605" unitRef="usd">126264</us-gaap:InventoryGross>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-24606" unitRef="usd">80813</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-24607" unitRef="usd">126264</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-21478">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 6 &#x2014;&#160;DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND
DEFERRED IPO COST, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Other receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;121,533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,917&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Deferred initial public offering &#x201c;IPO&#x201d; cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;195,446&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;512,581&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Deposit with a digital asset trading platform&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Receivable from agents&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,191,795&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt"&gt;Prepayments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;197,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,262,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline"&gt;Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Prepayment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,582,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,582,156&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Included in prepayment is
an amount of $&lt;span&gt;22,000&lt;/span&gt; and $2,839,536 as of December 31, 2024 and 2023 respectively, being
share-based compensation cost paid to consultants for services ranging from three to ten years and with termination clauses of one to
three years respectively without any penalties. During the year, the scope of service was amended and accordingly the excess compensation
was reversed against Additional Paid in Capital and the remaining value of service is recognized over the period of service in the Statement
of Income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The movement of allowances for expected credit
loss is as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Reversal of provision (Provision)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-21483">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Other receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;121,533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,917&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Deferred initial public offering &#x201c;IPO&#x201d; cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;195,446&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;512,581&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Deposit with a digital asset trading platform&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Receivable from agents&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,191,795&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt"&gt;Prepayments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;197,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,262,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline"&gt;Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Prepayment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,582,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,582,156&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="c2" decimals="0" id="ixv-24608" unitRef="usd">121533</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="c3" decimals="0" id="ixv-24609" unitRef="usd">15910</us-gaap:OtherReceivablesGrossCurrent>
    <nivf:Deposit contextRef="c2" decimals="0" id="ixv-24610" unitRef="usd">73917</nivf:Deposit>
    <nivf:Deposit contextRef="c3" decimals="0" id="ixv-24611" unitRef="usd">123008</nivf:Deposit>
    <us-gaap:DeferredCostsCurrent contextRef="c3" decimals="0" id="ixv-24612" unitRef="usd">373677</us-gaap:DeferredCostsCurrent>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts contextRef="c2" decimals="0" id="ixv-24613" unitRef="usd">4</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts contextRef="c3" decimals="0" id="ixv-24614" unitRef="usd">14</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-24615" unitRef="usd">195446</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-24616" unitRef="usd">512581</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DepositAssets contextRef="c2" decimals="0" id="ixv-24617" unitRef="usd">1000000</us-gaap:DepositAssets>
    <nivf:ReceivableFromAgents contextRef="c2" decimals="0" id="ixv-24618" unitRef="usd">1191795</nivf:ReceivableFromAgents>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c2" decimals="0" id="ixv-24619" unitRef="usd">197706</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="0" id="ixv-24620" unitRef="usd">1262228</us-gaap:OtherPrepaidExpenseCurrent>
    <nivf:OtherPrepaidExpenseNonCurrent contextRef="c2" decimals="0" id="ixv-24621" unitRef="usd">33333</nivf:OtherPrepaidExpenseNonCurrent>
    <nivf:OtherPrepaidExpenseNonCurrent contextRef="c3" decimals="0" id="ixv-24622" unitRef="usd">1582156</nivf:OtherPrepaidExpenseNonCurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c2" decimals="0" id="ixv-24623" unitRef="usd">33333</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c3" decimals="0" id="ixv-24624" unitRef="usd">1582156</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c0" decimals="0" id="ixv-24625" unitRef="usd">22000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c6" decimals="0" id="ixv-24626" unitRef="usd">2839536</us-gaap:PrepaymentFeesOnAdvancesNet>
    <nivf:ServicesRanging contextRef="c138" id="ixv-24627">P10Y</nivf:ServicesRanging>
    <nivf:TerminationClauses contextRef="c137" id="ixv-24628">P1Y</nivf:TerminationClauses>
    <nivf:TerminationClauses contextRef="c138" id="ixv-24629">P3Y</nivf:TerminationClauses>
    <nivf:ServicesRanging contextRef="c137" id="ixv-24630">P3Y</nivf:ServicesRanging>
    <nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock contextRef="c0" id="ixv-21680">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The movement of allowances for expected credit
loss is as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Reversal of provision (Provision)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c3" decimals="0" id="ixv-24632" unitRef="usd">-14</nivf:AllowancesForExpectedCreditLoss>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c30" decimals="0" id="ixv-24633" unitRef="usd">-141</nivf:AllowancesForExpectedCreditLoss>
    <nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision contextRef="c0" decimals="0" id="ixv-24634" unitRef="usd">10</nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision>
    <nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision contextRef="c6" decimals="0" id="ixv-24635" unitRef="usd">127</nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c2" decimals="0" id="ixv-24636" unitRef="usd">-4</nivf:AllowancesForExpectedCreditLoss>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c3" decimals="0" id="ixv-24637" unitRef="usd">-14</nivf:AllowancesForExpectedCreditLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-21731">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 7 &#x2014;&#160;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Plant and equipment, net consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;At cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Building improvement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,493&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Medical instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;785,776&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;361,385&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150,688&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,512,416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,481,364&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,239,320&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,319,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;273,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;162,157&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Depreciation expenses for
the&#160;years ended December 31, 2024 and 2023 were $19,502 and $31,173, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-110"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-111"&gt;No&lt;/span&gt;&lt;/span&gt; impairment loss was recorded for the&#160;years
ended December&#160;31, 2024, and 2023.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-21736">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Plant and equipment, net consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;At cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Building improvement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,493&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Medical instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;785,776&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;361,385&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150,688&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,512,416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,481,364&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,239,320&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,319,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;273,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;162,157&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c139" decimals="0" id="ixv-24638" unitRef="usd">196929</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c140" decimals="0" id="ixv-24639" unitRef="usd">92438</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c141" decimals="0" id="ixv-24640" unitRef="usd">25390</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c142" decimals="0" id="ixv-24641" unitRef="usd">250493</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c143" decimals="0" id="ixv-24642" unitRef="usd">785776</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c144" decimals="0" id="ixv-24643" unitRef="usd">844809</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c145" decimals="0" id="ixv-24644" unitRef="usd">142936</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c146" decimals="0" id="ixv-24645" unitRef="usd">142936</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c147" decimals="0" id="ixv-24646" unitRef="usd">361385</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c148" decimals="0" id="ixv-24647" unitRef="usd">150688</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" id="ixv-24648" unitRef="usd">1512416</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" id="ixv-24649" unitRef="usd">1481364</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-24650" unitRef="usd">1239320</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-24651" unitRef="usd">1319207</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-24652" unitRef="usd">273096</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-24653" unitRef="usd">162157</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-24654" unitRef="usd">19502</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="0" id="ixv-24655" unitRef="usd">31173</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0" id="ixv-21851">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 8 &#x2014;&#160;ACCRUED LIABILTIES AND OTHER
PAYABLES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Accrued liabilities and other payables consist
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;201,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,633&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer deposit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Withholding tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,361&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Independent director fee payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Compensation payable (Note&#160;1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;167,762&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;500,729&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;241,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation payable represents a claim relating to an employee of
the subsidiary. On April 23, 2023, a settlement agreement was entered into with the employee, with compensation payable over 12 instalments
commencing April 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-21856">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Accrued liabilities and other payables consist
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;201,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,633&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer deposit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Withholding tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,361&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Independent director fee payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Compensation payable (Note&#160;1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;167,762&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;500,729&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;241,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation payable represents a claim relating to an employee of
the subsidiary. On April 23, 2023, a settlement agreement was entered into with the employee, with compensation payable over 12 instalments
commencing April 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-24656" unitRef="usd">201455</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-24657" unitRef="usd">43633</us-gaap:AccruedLiabilitiesCurrent>
    <nivf:CustomerDeposit contextRef="c2" decimals="0" id="ixv-24658" unitRef="usd">6349</nivf:CustomerDeposit>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="0" id="ixv-24659" unitRef="usd">4361</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c3" decimals="0" id="ixv-24660" unitRef="usd">7349</us-gaap:AccruedIncomeTaxesCurrent>
    <nivf:IndependentDirectorFeePayable contextRef="c2" decimals="0" id="ixv-24661" unitRef="usd">20000</nivf:IndependentDirectorFeePayable>
    <us-gaap:WorkersCompensationLiabilityCurrent contextRef="c2" decimals="0" id="ix_118_fact" unitRef="usd">100802</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent contextRef="c3" decimals="0" id="ix_119_fact" unitRef="usd">144015</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c2" decimals="0" id="ixv-24664" unitRef="usd">167762</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="0" id="ixv-24665" unitRef="usd">46616</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-24666" unitRef="usd">500729</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-24667" unitRef="usd">241613</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-21969">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 9 &#x2014;&#160;CONTRACT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Contract liabilities consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,360,168&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,006&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Recognized to revenue during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,788&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(122,662&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Refund to customers (Note 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,341,575&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;63,489&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Refund to customers are in relation to China-based clients who prepaid
for surrogacy and ancillary caring services but requested for refund of fees so that they may appoint their own surrogate mothers in countries
in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service
contract with those clients.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c0" id="ixv-21974">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Contract liabilities consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,360,168&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,006&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Recognized to revenue during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,788&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(122,662&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Refund to customers (Note 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,341,575&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;63,489&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Refund to customers are in relation to China-based clients who prepaid
for surrogacy and ancillary caring services but requested for refund of fees so that they may appoint their own surrogate mothers in countries
in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service
contract with those clients.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c3" decimals="0" id="ixv-24668" unitRef="usd">7937</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c30" decimals="0" id="ixv-24669" unitRef="usd">1360168</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination contextRef="c0" decimals="0" id="ixv-24670" unitRef="usd">75340</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination contextRef="c6" decimals="0" id="ixv-24671" unitRef="usd">112006</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c0" decimals="0" id="ixv-24672" unitRef="usd">-19788</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c6" decimals="0" id="ixv-24673" unitRef="usd">-122662</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerRefundLiability contextRef="c3" decimals="0" id="ix_120_fact" unitRef="usd">1341575</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c2" decimals="0" id="ixv-24675" unitRef="usd">63489</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c3" decimals="0" id="ixv-24676" unitRef="usd">7937</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-22055">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 10 &#x2014;&#160;CONVERTIBLE NOTES, PROMISSORY NOTES, DERIVATIVE
LIABILITY AND WARRANTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Convertible notes, at amortised cost are as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Convertible notes at amortised cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,059,595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Less: Deferred debt issuance cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;648,232&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Convertible notes, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,411,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;The convertible notes are repayable as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Current liability&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;82,447&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Non-current liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,328,916&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,411,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0"&gt;As of December 31, 2024, the Company had the following outstanding
convertible notes:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Principal&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Conversion&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Coupon&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;Issuance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;Maturity&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Note Holders&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%; text-align: left"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50,000&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.830&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 15%; text-align: center"&gt;April 3, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 15%; text-align: center"&gt;October 2, 2028&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,100,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.830&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;August&#160;3, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;February 2, 2029&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.950&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;August 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;March 1, 2029&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,500,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.686&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;14.75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;November 11, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;May 10, 2029&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,150,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in"&gt;During the year ended December 31, 2024, a total
of $5,800,000 of convertible promissory notes were issued with a discount of 7%. These Notes are to be settled by way of cash or may be
converted to Class A ordinary shares. The conversion of these notes are subject to certain criterions as mentioned in the Convertible
Note Agreements, which include a beneficiary cap of 9.9% of shareholdings in the Company by JAK.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2024,
$2,650,000 of convertible notes were converted into 7,020,975 ordinary shares by the note holder, thereby increasing our shareholder equity
by the same amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The effective interest expense calculated at 16.96 % amounted to $765,177
and $&lt;span style="-sec-ix-hidden: hidden-fact-131"&gt;nil&lt;/span&gt; for the year ended December 31, 2024 and December 31, 2023 respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The transaction costs incurred
on issuance of the Notes are capitalized and amortised over the term of the Notes as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transaction costs on issuance of Notes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add: capitalized during the year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;929,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: amortized during the year&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(281,268&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;648,232&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The following table sets
forth the Company&#x2019;s contractual obligations as of December 31, 2024 relating to the convertible notes:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Convertible bonds-&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;516,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,269,625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,207,625&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Promissory Notes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Issued during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,453,861&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Waiver of liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;953,861&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2024,
the Company has outstanding non-interest-bearing unsecured promissory notes with a total principal balance of US$500,000, which was settled
fully in February 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Derivative liability &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Pursuant to ASC 815, a derivative liability had
arisen from the issuance of convertible bonds which have the option of being converted to or exchanged for Class A ordinary shares at
any time from date of issuance. The derivative liability is assessed to be a debt requiring to be bifurcated from the host contract and
recorded at the fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;However, the conversion
to ordinary shares is subject to certain terms and criteria as set within the Agreement, which includes restriction of conversion if the
shareholdings by the note holder before and after the conversion exceeds 9.99%, as revised. As of December 31, 2024, the threshold has
been met, and accordingly the derivative is assessed to have no value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Free standing instruments &#x2013; warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The convertible bond agreements as mentioned above
granted the note holders 6,174,690 series A warrant, 180,722 series B warrant and 3,253,012 series C warrant, allowing the warrant holders
to purchase additional Class A ordinary shares at an exercise price of $0.913, $0.001 and $0.924 respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The exercise of these warrants
is subject to a 9.99% beneficial cap, as revised, which restricts the holder from exceeding shareholdings in excess of the cap in the
Company. As of December 31, 2024, the threshold has been met, and accordingly the derivative is assessed to have no value.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c0" id="ixv-22061">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Convertible notes, at amortised cost are as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Convertible notes at amortised cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,059,595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Less: Deferred debt issuance cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;648,232&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Convertible notes, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,411,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;The convertible notes are repayable as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Current liability&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;82,447&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Non-current liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,328,916&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,411,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DeferredFinanceCostsGross contextRef="c159" decimals="0" id="ixv-24677" unitRef="usd">3059595</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:AccumulatedAmortizationDeferredFinanceCosts contextRef="c159" decimals="0" id="ixv-24678" unitRef="usd">648232</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
    <us-gaap:DeferredFinanceCostsNet contextRef="c159" decimals="0" id="ixv-24679" unitRef="usd">2411363</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c159" decimals="0" id="ixv-24680" unitRef="usd">82447</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c159" decimals="0" id="ixv-24681" unitRef="usd">2328916</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="c159" decimals="0" id="ixv-24682" unitRef="usd">2411363</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c0" id="ixv-22177">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0"&gt;As of December 31, 2024, the Company had the following outstanding
convertible notes:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Principal&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;Conversion&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Coupon&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;Issuance&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;Maturity&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Note Holders&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%; text-align: left"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50,000&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.830&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 15%; text-align: center"&gt;April 3, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 15%; text-align: center"&gt;October 2, 2028&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,100,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.830&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;August&#160;3, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;February 2, 2029&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.950&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;August 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;March 1, 2029&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,500,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.686&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;14.75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;November 11, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;May 10, 2029&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,150,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermNotesPayable contextRef="c161" decimals="0" id="ixv-24683" unitRef="usd">50000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c161"
      decimals="3"
      id="ixv-24684"
      unitRef="usdPershares">0.83</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nivf:DebtInstrumentCouponRatePercentage
      contextRef="c161"
      decimals="4"
      id="ixv-24685"
      unitRef="pure">0.1475</nivf:DebtInstrumentCouponRatePercentage>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c162" id="ixv-24686">2024-04-03</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c162" id="ixv-24687">2028-10-02</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermNotesPayable contextRef="c163" decimals="0" id="ixv-24688" unitRef="usd">1100000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c163"
      decimals="3"
      id="ixv-24689"
      unitRef="usdPershares">0.83</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nivf:DebtInstrumentCouponRatePercentage
      contextRef="c163"
      decimals="4"
      id="ixv-24690"
      unitRef="pure">0.1475</nivf:DebtInstrumentCouponRatePercentage>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c164" id="ixv-24691">2024-08-03</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c164" id="ixv-24692">2029-02-02</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermNotesPayable contextRef="c165" decimals="0" id="ixv-24693" unitRef="usd">500000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c165"
      decimals="3"
      id="ixv-24694"
      unitRef="usdPershares">0.95</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nivf:DebtInstrumentCouponRatePercentage
      contextRef="c165"
      decimals="4"
      id="ixv-24695"
      unitRef="pure">0.1475</nivf:DebtInstrumentCouponRatePercentage>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c166" id="ixv-24696">2024-08-30</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c166" id="ixv-24697">2029-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermNotesPayable contextRef="c167" decimals="0" id="ixv-24698" unitRef="usd">1500000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c167"
      decimals="3"
      id="ixv-24699"
      unitRef="usdPershares">0.686</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nivf:DebtInstrumentCouponRatePercentage
      contextRef="c167"
      decimals="4"
      id="ixv-24700"
      unitRef="pure">0.1475</nivf:DebtInstrumentCouponRatePercentage>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c168" id="ixv-24701">2024-11-11</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c168" id="ixv-24702">2029-05-10</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermNotesPayable contextRef="c169" decimals="0" id="ixv-24703" unitRef="usd">3150000</us-gaap:LongTermNotesPayable>
    <us-gaap:ConvertibleDebt contextRef="c2" decimals="0" id="ixv-24704" unitRef="usd">5800000</us-gaap:ConvertibleDebt>
    <nivf:convertiblePromissoryNoteDiscountPercentage contextRef="c0" decimals="2" id="ixv-24705" unitRef="pure">0.07</nivf:convertiblePromissoryNoteDiscountPercentage>
    <us-gaap:DerivativeCapInterestRate contextRef="c2" decimals="3" id="ixv-24706" unitRef="pure">0.099</us-gaap:DerivativeCapInterestRate>
    <us-gaap:ConvertibleDebt contextRef="c149" decimals="0" id="ixv-24707" unitRef="usd">2650000</us-gaap:ConvertibleDebt>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c150"
      decimals="0"
      id="ixv-24708"
      unitRef="shares">7020975</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="c151" decimals="2" id="ixv-24709" unitRef="usd">16.96</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" id="ixv-24710" unitRef="usd">765177</us-gaap:InterestExpense>
    <nivf:ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock contextRef="c0" id="ixv-22312">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The transaction costs incurred
on issuance of the Notes are capitalized and amortised over the term of the Notes as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transaction costs on issuance of Notes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add: capitalized during the year&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;929,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: amortized during the year&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(281,268&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;648,232&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock>
    <us-gaap:InterestCostsCapitalized contextRef="c0" decimals="0" id="ixv-24711" unitRef="usd">929500</us-gaap:InterestCostsCapitalized>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="0" id="ixv-24712" unitRef="usd">281268</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredFinanceCostsNet contextRef="c2" decimals="0" id="ixv-24713" unitRef="usd">648232</us-gaap:DeferredFinanceCostsNet>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="c0" id="ixv-22394">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The following table sets
forth the Company&#x2019;s contractual obligations as of December 31, 2024 relating to the convertible notes:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Convertible bonds-&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;516,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,269,625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,207,625&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="c2" decimals="0" id="ixv-24714" unitRef="usd">516250</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear contextRef="c2" decimals="0" id="ixv-24715" unitRef="usd">457250</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear contextRef="c2" decimals="0" id="ixv-24716" unitRef="usd">457250</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear contextRef="c2" decimals="0" id="ixv-24717" unitRef="usd">507250</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear contextRef="c2" decimals="0" id="ixv-24718" unitRef="usd">3269625</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligation contextRef="c2" decimals="0" id="ixv-24719" unitRef="usd">5207625</us-gaap:ContractualObligation>
    <nivf:ScheduleOfPromissoryNotesTableTextBlock contextRef="c0" id="ixv-22445">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Promissory Notes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Issued during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,453,861&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Waiver of liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;953,861&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfPromissoryNotesTableTextBlock>
    <us-gaap:NotesIssued1 contextRef="c172" decimals="0" id="ixv-24720" unitRef="usd">1453861</us-gaap:NotesIssued1>
    <nivf:WaiverOfLiability contextRef="c172" decimals="0" id="ixv-24721" unitRef="usd">953861</nivf:WaiverOfLiability>
    <us-gaap:NotesPayableCurrent contextRef="c174" decimals="0" id="ixv-24722" unitRef="usd">500000</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c152" decimals="0" id="ixv-24723" unitRef="usd">500000</us-gaap:DebtInstrumentFaceAmount>
    <nivf:PercentageOfConversionExceeds contextRef="c2" decimals="4" id="ixv-24724" unitRef="pure">0.0999</nivf:PercentageOfConversionExceeds>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c153"
      decimals="0"
      id="ixv-24725"
      unitRef="shares">6174690</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c154"
      decimals="0"
      id="ixv-24726"
      unitRef="shares">180722</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c155"
      decimals="0"
      id="ixv-24727"
      unitRef="shares">3253012</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c156"
      decimals="3"
      id="ixv-24728"
      unitRef="usdPershares">0.913</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c157"
      decimals="3"
      id="ixv-24729"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c158"
      decimals="3"
      id="ixv-24730"
      unitRef="usdPershares">0.924</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProductWarrantyLiquidationProceedsPercentage contextRef="c2" decimals="4" id="ixv-24731" unitRef="pure">0.0999</us-gaap:ProductWarrantyLiquidationProceedsPercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-22543">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 11 &#x2014;&#160;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company has various operating
leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The Company&#x2019;s management believes
that the interest rate of 6.6% and 5.5% was the most indicative rate of the Company&#x2019;s borrowing cost for the calculation of the
present value of the lease payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of December 31, 2024 and 2023, the right-of-use&#160;assets
totaled $98,570, and $283,847, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of December 31, 2024 and 2023, lease liabilities
consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Operating lease&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lease liabilities&#160;&#x2013;&#160;current portion&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;207,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&#160;&#x2013;&#160;non-current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,231&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;118,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;326,107&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Finance lease&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lease liabilities&#160;&#x2013;&#160;current portion&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,446&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The following is a schedule of future minimum
payments under operating leases as of December&#160;31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Not later than 1 year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,321&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Between 1 to 2&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,864&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total operating lease liabilities, net of interest&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;118,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Other lease information is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.75 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.92&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 76%; text-align: left"&gt;Weighted-average discount rate&#160;&#x2013;&#160;operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Short term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;234,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2024 and
2023, there were $98,570 and $283,847 right of use (&#x201c;ROU&#x201d;) assets and $118,757 and $326,107 lease liabilities based on the
present value of the future minimum rental payments of leases, respectively. The Company&#x2019;s management believes that using an incremental
borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate (&#x201c;BLR&#x201d;) minus 0.125%&#160;was the
most indicative rate of the Company&#x2019;s borrowing cost for the calculation of the present value of the lease payments; the rate used
by the Company was 6.6% and 5.5% respectively.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c175"
      decimals="3"
      id="ixv-24732"
      unitRef="pure">0.066</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c176"
      decimals="3"
      id="ixv-24733"
      unitRef="pure">0.055</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-24734" unitRef="usd">98570</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-24735" unitRef="usd">283847</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-22552">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of December 31, 2024 and 2023, lease liabilities
consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Operating lease&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lease liabilities&#160;&#x2013;&#160;current portion&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;207,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&#160;&#x2013;&#160;non-current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,231&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;118,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;326,107&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Finance lease&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lease liabilities&#160;&#x2013;&#160;current portion&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,446&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Other lease information is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.75 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.92&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 76%; text-align: left"&gt;Weighted-average discount rate&#160;&#x2013;&#160;operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Short term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;234,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-24736" unitRef="usd">108526</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-24737" unitRef="usd">207128</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-24738" unitRef="usd">10231</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-24739" unitRef="usd">118979</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" id="ixv-24740" unitRef="usd">118757</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" id="ixv-24741" unitRef="usd">326107</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-24742" unitRef="usd">6446</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-22626">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The following is a schedule of future minimum
payments under operating leases as of December&#160;31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Not later than 1 year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,321&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Between 1 to 2&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,864&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total operating lease liabilities, net of interest&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;118,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="0" id="ixv-24743" unitRef="usd">111321</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="0" id="ixv-24744" unitRef="usd">10300</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="0" id="ixv-24745" unitRef="usd">121621</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="0" id="ixv-24746" unitRef="usd">2864</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" id="ixv-24747" unitRef="usd">118757</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-24748">P2Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3" id="ixv-24749">P0Y11M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="2" id="ixv-24750" unitRef="pure">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="2" id="ixv-24751" unitRef="pure">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ShortTermLeaseCost contextRef="c0" decimals="0" id="ixv-24752" unitRef="usd">234767</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c6" decimals="0" id="ixv-24753" unitRef="usd">114937</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-24754" unitRef="usd">98570</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-24755" unitRef="usd">283847</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" id="ixv-24756" unitRef="usd">118757</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" id="ixv-24757" unitRef="usd">326107</us-gaap:OperatingLeaseLiability>
    <nivf:IndicativeRateOfBorrowingCost contextRef="c2" decimals="5" id="ixv-24758" unitRef="pure">0.00125</nivf:IndicativeRateOfBorrowingCost>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c177"
      decimals="3"
      id="ixv-24759"
      unitRef="pure">0.066</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c178"
      decimals="3"
      id="ixv-24760"
      unitRef="pure">0.055</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-22727">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 12 &#x2014;&#160;EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Ordinary shares&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As at December&#160;31, 2023
and December 31, 2024, the Company is authorized to issue 10,000,000 ordinary shares. Each ordinary share is entitled to one vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board
of Directors of the Company.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The equity of the Company
as of December 31, 2024 and 2023 represents 1,138,519 and 507,469 ordinary shares with par value of $&lt;span style="-sec-ix-hidden: hidden-fact-133"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-134"&gt;Nil&lt;/span&gt;&lt;/span&gt;. The number of shares as above
have taken into consideration the reverse stock split effected on February 11, 2025 at an exchange ratio of one (1) share for twenty (20)
shares. Pursuant to ASC 505 the reverse stock split has been applied retrospectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Additional paid-in capital&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance as at January 1,2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,464,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of shares&#160;as compensation for services (&lt;i&gt;Note 1&lt;/i&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,866,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,331,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of shares through Equity Line of Credit (&lt;i&gt;Note 2&lt;/i&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,936,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of shares through conversion of convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,650,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Decrease in subscription receivable due to reduction of work by professionals &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,766,856&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Business Combination (&lt;i&gt;Note 3&lt;/i&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,028,690&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;122,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;- the number of shares below have been amended to apply the
reverse stock split in February 2025 retrospectively.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Note 1:&#160;On January 10, 2023, the Company issued 1,365 ordinary
shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4,
2023, the Company issued additional 3,450 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional
paid-in capital by $2,054,556. During 2024, the service scope and duration were reduced and the service value was adjusted accordingly
pursuant to addendums to respective agreements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Note 2:&lt;/span&gt; On November 21, 2024, the Company
entered into a Common Shares Purchase Agreement (the &#x201c;White Lion Purchase Agreement&#x201d;) with White Lion Capital, LLC (&#x201c;White
Lion&#x201d;) and a related Registration Rights Agreement (the &#x201c;RRA&#x201d;). Pursuant to the White Lion Purchase Agreement, the Company
has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One
Hundred Million Dollars ($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to
Three Hundred Million Dollars ($300,000,000) upon any substantial M&amp;amp;A or Material Transaction (as defined in the White Lion Purchase
Agreement) and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars
($250,000,000) has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions
set forth in the White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration
statement filed on December 5, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 10, 2024, 35,000 Class A Ordinary
Shares were issued to White Lion amounting $276,850, in consideration for White Lion&#x2019;s commitment pursuant to the White Lion Purchase
Agreement. In addition, on December 12, 2024, pursuant to this Agreement, the Company issued 9,500 Class A Ordinary Shares for a purchase
price of $1,572,186. On December 24, 2024, the Company issued 25,000 Class A Ordinary Shares for a purchase price of $160,050. On December
31, 2024, the Company issued 30,000 Class A Ordinary Shares for a purchase price of $204,000.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;Note 3: Upon de-spac business combination, additional paid-in capital
and capital reserve of Legacy NewGenIvf was combined with additional paid-in capital and accumulated net losses of the A SPAC I Acquisition
Corp and added into the additional paid-in capital of NewGenIvf Group upon the reverse take-over.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c38"
      decimals="0"
      id="ixv-24761"
      unitRef="shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c52"
      decimals="0"
      id="ixv-24762"
      unitRef="shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockVotingRights contextRef="c0" id="ixv-24763">one</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-24764"
      unitRef="shares">1138519</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-24765"
      unitRef="shares">507469</us-gaap:CommonStockSharesIssued>
    <nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock contextRef="c0" id="ixv-22755">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Additional paid-in capital&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Balance as at January 1,2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,464,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of shares&#160;as compensation for services (&lt;i&gt;Note 1&lt;/i&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,866,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,331,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of shares through Equity Line of Credit (&lt;i&gt;Note 2&lt;/i&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,936,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Issuance of shares through conversion of convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,650,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Decrease in subscription receivable due to reduction of work by professionals &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,766,856&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Business Combination (&lt;i&gt;Note 3&lt;/i&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,028,690&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;122,505&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Note 1:&#160;On January 10, 2023, the Company issued 1,365 ordinary
shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4,
2023, the Company issued additional 3,450 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional
paid-in capital by $2,054,556. During 2024, the service scope and duration were reduced and the service value was adjusted accordingly
pursuant to addendums to respective agreements&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Note 2:&lt;/span&gt; On November 21, 2024, the Company
entered into a Common Shares Purchase Agreement (the &#x201c;White Lion Purchase Agreement&#x201d;) with White Lion Capital, LLC (&#x201c;White
Lion&#x201d;) and a related Registration Rights Agreement (the &#x201c;RRA&#x201d;). Pursuant to the White Lion Purchase Agreement, the Company
has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One
Hundred Million Dollars ($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to
Three Hundred Million Dollars ($300,000,000) upon any substantial M&amp;amp;A or Material Transaction (as defined in the White Lion Purchase
Agreement) and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars
($250,000,000) has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions
set forth in the White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration
statement filed on December 5, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 10, 2024, 35,000 Class A Ordinary
Shares were issued to White Lion amounting $276,850, in consideration for White Lion&#x2019;s commitment pursuant to the White Lion Purchase
Agreement. In addition, on December 12, 2024, pursuant to this Agreement, the Company issued 9,500 Class A Ordinary Shares for a purchase
price of $1,572,186. On December 24, 2024, the Company issued 25,000 Class A Ordinary Shares for a purchase price of $160,050. On December
31, 2024, the Company issued 30,000 Class A Ordinary Shares for a purchase price of $204,000.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;Note 3: Upon de-spac business combination, additional paid-in capital
and capital reserve of Legacy NewGenIvf was combined with additional paid-in capital and accumulated net losses of the A SPAC I Acquisition
Corp and added into the additional paid-in capital of NewGenIvf Group upon the reverse take-over.&lt;/p&gt;</nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock>
    <us-gaap:AdditionalPaidInCapital contextRef="c30" decimals="0" id="ixv-24766" unitRef="usd">1464959</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c6" decimals="0" id="ix_121_fact" unitRef="usd">2866856</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" id="ixv-24768" unitRef="usd">4331815</us-gaap:AdditionalPaidInCapital>
    <nivf:StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit contextRef="c0" decimals="0" id="ix_123_fact" unitRef="usd">1936236</nivf:StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c0" decimals="0" id="ixv-24770" unitRef="usd">2650000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <nivf:DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals contextRef="c0" decimals="0" id="ix_122_fact" unitRef="usd">2766856</nivf:DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals>
    <nivf:ReverseCapitalization contextRef="c0" decimals="0" id="ix_124_fact" unitRef="usd">6028690</nivf:ReverseCapitalization>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" id="ixv-24773" unitRef="usd">122505</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c179"
      decimals="0"
      id="ixv-24775"
      unitRef="shares">1365</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <nivf:ConsultingServiceTerm contextRef="c179" id="ixv-24776">P10Y</nivf:ConsultingServiceTerm>
    <us-gaap:OtherAdditionalCapital contextRef="c180" decimals="0" id="ixv-24777" unitRef="usd">812300</us-gaap:OtherAdditionalCapital>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c181"
      decimals="0"
      id="ixv-24778"
      unitRef="shares">3450</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <nivf:ConsultingServiceTerm contextRef="c181" id="ixv-24779">P10Y</nivf:ConsultingServiceTerm>
    <us-gaap:OtherAdditionalCapital contextRef="c182" decimals="0" id="ixv-24780" unitRef="usd">2054556</us-gaap:OtherAdditionalCapital>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c183" decimals="0" id="ixv-24781" unitRef="usd">-100000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c184" decimals="0" id="ixv-24782" unitRef="usd">-300000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c185" decimals="0" id="ixv-24783" unitRef="usd">-500000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c186" decimals="0" id="ixv-24784" unitRef="usd">-250000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c187"
      decimals="0"
      id="ixv-24785"
      unitRef="shares">35000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c187" decimals="0" id="ixv-24786" unitRef="usd">276850</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c188"
      decimals="0"
      id="ixv-24787"
      unitRef="shares">9500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c188" decimals="0" id="ixv-24788" unitRef="usd">1572186</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c189"
      decimals="0"
      id="ixv-24789"
      unitRef="shares">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c189" decimals="0" id="ixv-24790" unitRef="usd">160050</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c190"
      decimals="0"
      id="ixv-24791"
      unitRef="shares">30000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c190" decimals="0" id="ixv-24792" unitRef="usd">204000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c0" id="ixv-22839">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 13 &#x2014;&#160;EMPLOYEE BENEFIT PLANS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;HK SAR&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 5% of the employees&#x2019;
basic salaries on monthly basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Thailand&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company is obliged to
make social security payments within the first 15&#160;days of the month over which it is accrued. In 2024, the Company and its employees
are each required to make contributions to the scheme calculated at 5% of the employee&#x2019;s salary with a cap of &lt;span style="-sec-ix-hidden: hidden-fact-137"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-138"&gt;THB750&lt;/span&gt;&lt;/span&gt; per month.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Cambodia&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Every business employing
one or more workers must register its business and workers with the National Social Security Fund (the &#x201c;NSSF&#x201d;) for the Occupational
Risk Scheme (for work-related&#160;accidents and occupational diseases), the Health Care Scheme and the Pension Scheme.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Once registered, the business
must pay to the NSSF:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A monthly contribution equivalent to 0.8% of each worker&#x2019;s monthly average wages (between $0.40 and $2.40 per month per worker) for the Occupational Risk Scheme.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A monthly contribution equivalent to 2.6% of a worker&#x2019;s monthly average wages (between $1.30 and $7.80 per month per worker) for the Health Care Scheme.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of 2% (total of 4%) of the contributable wage for the first five&#160;years. The contributable wage for the Pension Scheme ranges from between &lt;span style="-sec-ix-hidden: hidden-fact-136"&gt;KHR400,000&lt;/span&gt; (approximately $100) up to &lt;span style="-sec-ix-hidden: hidden-fact-135"&gt;KHR1,200,000&lt;/span&gt; (approximately $300).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Kyrgyzstan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 15% and 8%, respectively
of the employees&#x2019; basic salaries on monthly basis.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:ManagementAndServiceFeesRate
      contextRef="c191"
      decimals="2"
      id="ixv-24794"
      unitRef="pure">0.05</us-gaap:ManagementAndServiceFeesRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c192"
      decimals="2"
      id="ixv-24795"
      unitRef="pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c193"
      decimals="3"
      id="ixv-24796"
      unitRef="pure">0.008</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="c194" decimals="2" id="ixv-24797" unitRef="usd">0.4</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="c195" decimals="2" id="ixv-24798" unitRef="usd">2.4</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c196"
      decimals="3"
      id="ixv-24799"
      unitRef="pure">0.026</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="c197" decimals="2" id="ixv-24800" unitRef="usd">1.3</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="c198" decimals="2" id="ixv-24801" unitRef="usd">7.8</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c199"
      decimals="2"
      id="ixv-24802"
      unitRef="pure">0.02</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c200"
      decimals="2"
      id="ixv-24803"
      unitRef="pure">0.04</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c201" decimals="0" id="ixv-24804" unitRef="usd">100</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c202" decimals="0" id="ixv-24805" unitRef="usd">300</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:ManagementAndServiceFeesRate
      contextRef="c203"
      decimals="2"
      id="ixv-24806"
      unitRef="pure">0.15</us-gaap:ManagementAndServiceFeesRate>
    <us-gaap:ManagementAndServiceFeesRate contextRef="c0" decimals="2" id="ixv-24807" unitRef="pure">0.08</us-gaap:ManagementAndServiceFeesRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-22919">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 14 &#x2014;&#160;PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Cayman Islands&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;NewGenIvf Limited was incorporated
in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law. In addition, upon payment
of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;HK SAR&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived from
Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accordingly, the HK SAR profits
tax is calculated at 8.25% on the first HK$2&#160;million of the estimated assessable profits and at 16.5% on the remaining estimated
assessable profits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Thailand&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The companies incorporated
in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from or in consequence of the
business carried on in Thailand. The corporate income tax (CIT) rate is 20%. A foreign company not carrying on business in Thailand is
subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends, royalties, rentals, and service
fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%, while other rates may apply under
the provisions of a double tax treaty (DTT).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Cambodia&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The standard rate of corporate
income tax (&#x201c;CIT&#x201d;) for companies and permanent establishments who are classified as medium and large taxpayers is 20%. For
companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive rates from 0% to 20%. In view
of the annual turnover of the company, the annual turnover ranges from &lt;span style="-sec-ix-hidden: hidden-fact-152"&gt;KHR1&lt;/span&gt;&#160;billion to &lt;span style="-sec-ix-hidden: hidden-fact-153"&gt;KHR6&lt;/span&gt;&#160;billion for service and commercial
sectors, the company shall consider as the medium-sized&#160;company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Kyrgyzstan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The company is subject to
a corporate income tax on their aggregate annual income earned worldwide. Non-resident&#160;legal entities carrying out business activities
through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that permanent
establishments. During the year, excess tax payable of $486,706 were deemed to be no longer payable and reversed accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Profit tax is calculated
at a rate of 10% of aggregate annual income less allowed deductions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Significant components of
the provisions for income taxes for the year ended December&#160;31, 2024, and 2023 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Current tax provision Kyrgyzstan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Over provision of tax in prior year Kyrgyzstan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(486,706&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;Current tax provision Cambodia&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total tax (income) expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(486,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; padding-bottom: 1.5pt"&gt;(Loss) Income before taxes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(960,807&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;108,418&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;343,988&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Tax credit (expense) at the effective tax rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(179,863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(124,591&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Tax effect on non-taxable income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(81,323&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,173&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Tax effect on non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Tax effect on utilization of tax losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(127,521&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,369&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Tax losses unable to be utilized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,902&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Over provision of tax in prior year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Tax (income) expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(486,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;208,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred tax asset, net&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"&gt;Significant components of deferred tax assets,
net were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&#x2013; Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;160,432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(160,432&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2024 and
2023, the Company had net operating loss carry forward of $972,316 and $164,721. The Company believes it is less likely than not that
its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry forward. As a result, the
Company provided 100% allowance on deferred tax assets on net operating loss.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <nivf:ProfitTaxDescription contextRef="c0" id="ixv-24808">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived from
Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.</nivf:ProfitTaxDescription>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c0" decimals="4" id="ixv-24809" unitRef="pure">0.0825</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="c204"
      decimals="-6"
      id="ixv-24810"
      unitRef="hkd">2000000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign contextRef="c0" decimals="3" id="ixv-24811" unitRef="pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic contextRef="c0" decimals="2" id="ixv-24812" unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c0" decimals="2" id="ixv-24813" unitRef="pure">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <nivf:EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent contextRef="c0" decimals="2" id="ixv-24814" unitRef="pure">0.10</nivf:EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic
      contextRef="c205"
      decimals="2"
      id="ixv-24815"
      unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c137"
      decimals="2"
      id="ixv-24816"
      unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c138"
      decimals="2"
      id="ixv-24817"
      unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <nivf:DeemedExcessTaxPayable contextRef="c0" decimals="0" id="ixv-24818" unitRef="usd">486706</nivf:DeemedExcessTaxPayable>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="c0" decimals="2" id="ixv-24819" unitRef="pure">0.10</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-22960">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Significant components of
the provisions for income taxes for the year ended December&#160;31, 2024, and 2023 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Current tax provision Kyrgyzstan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Over provision of tax in prior year Kyrgyzstan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(486,706&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;Current tax provision Cambodia&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total tax (income) expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(486,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c208" decimals="0" id="ixv-24820" unitRef="usd">-486706</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-24821" unitRef="usd">-486706</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-23024">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; padding-bottom: 1.5pt"&gt;(Loss) Income before taxes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(960,807&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;108,418&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;343,988&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Tax credit (expense) at the effective tax rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(179,863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(124,591&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Tax effect on non-taxable income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(81,323&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,173&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Tax effect on non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Tax effect on utilization of tax losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(127,521&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,369&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Tax losses unable to be utilized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,902&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Over provision of tax in prior year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(486,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Tax (income) expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(486,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;208,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-24822" unitRef="usd">-960807</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="0" id="ixv-24823" unitRef="usd">108418</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-24824" unitRef="usd">343988</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c0" decimals="0" id="ixv-24825" unitRef="usd">-179863</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c6" decimals="0" id="ixv-24826" unitRef="usd">10732</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c7" decimals="0" id="ixv-24827" unitRef="usd">-124591</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c0" decimals="0" id="ixv-24828" unitRef="usd">-81323</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c6" decimals="0" id="ixv-24829" unitRef="usd">-39173</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c0" decimals="0" id="ixv-24830" unitRef="usd">129814</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c7" decimals="0" id="ixv-24831" unitRef="usd">369101</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" id="ixv-24832" unitRef="usd">131991</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c6" decimals="0" id="ixv-24833" unitRef="usd">28441</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c0" decimals="0" id="ixv-24834" unitRef="usd">-127521</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c7" decimals="0" id="ixv-24835" unitRef="usd">-36369</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c0" decimals="0" id="ixv-24836" unitRef="usd">126902</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <nivf:IncomeTaxReconciliationOverProvisionOfTaxInPriorYear contextRef="c0" decimals="0" id="ixv-24837" unitRef="usd">-486706</nivf:IncomeTaxReconciliationOverProvisionOfTaxInPriorYear>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-24838" unitRef="usd">-486706</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-24839" unitRef="usd">208141</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-23191">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"&gt;Significant components of deferred tax assets,
net were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&#x2013; Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;160,432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(160,432&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="0" id="ixv-24840" unitRef="usd">160432</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-24841" unitRef="usd">28441</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="0" id="ixv-24842" unitRef="usd">160432</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" id="ixv-24843" unitRef="usd">28441</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c2" decimals="0" id="ixv-24844" unitRef="usd">972316</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-24845" unitRef="usd">164721</us-gaap:OperatingLossCarryforwards>
    <nivf:PercentageOfAllowanceOnDeferredTaxAssets contextRef="c0" decimals="2" id="ixv-24846" unitRef="pure">1</nivf:PercentageOfAllowanceOnDeferredTaxAssets>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-23258">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 15 &#x2014;&#160;DISAGGREGATED REVENUES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s main business operations are
to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;IVF treatment service&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,433,375&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,021,696&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,819,163&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Surrogacy, ancillary caring and other services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,114,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,125,027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,433,375&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,136,153&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,944,190&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Geographical information&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Revenue from external customers originated from&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;HK SAR&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34,038&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Kyrgyzstan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,656,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,123,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,060,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;601,526&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;621,619&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;377,608&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thailand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,175,253&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,356,903&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;505,609&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,433,375&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,136,153&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,944,190&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The revenue information above is based on the
locations where the revenue originated.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Long-lived assets located at&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;HK SAR&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,081&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;584&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,370&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Kyrgyzstan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,513&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,902&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,472&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,085&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thailand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;312,313&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;307,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;254,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;371,666&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;446,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;506,343&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s long-lived&#160;assets consist
of plant and equipment, net and operating leases right-of-use&#160;assets, net.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c0" id="ixv-23263">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s main business operations are
to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;IVF treatment service&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,433,375&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,021,696&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,819,163&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Surrogacy, ancillary caring and other services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,114,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,125,027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,433,375&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,136,153&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,944,190&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues contextRef="c212" decimals="0" id="ixv-24847" unitRef="usd">5433375</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c213" decimals="0" id="ixv-24848" unitRef="usd">4021696</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c214" decimals="0" id="ixv-24849" unitRef="usd">2819163</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c216" decimals="0" id="ixv-24850" unitRef="usd">1114457</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c217" decimals="0" id="ixv-24851" unitRef="usd">3125027</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-24852" unitRef="usd">5433375</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="0" id="ixv-24853" unitRef="usd">5136153</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" id="ixv-24854" unitRef="usd">5944190</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0" id="ixv-23328">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Geographical information&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Revenue from external customers originated from&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;HK SAR&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34,038&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Kyrgyzstan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,656,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,123,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,060,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;601,526&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;621,619&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;377,608&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thailand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,175,253&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,356,903&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;505,609&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,433,375&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,136,153&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,944,190&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c218" decimals="0" id="ixv-24855" unitRef="usd">34038</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c203" decimals="0" id="ixv-24856" unitRef="usd">2656596</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c220" decimals="0" id="ixv-24857" unitRef="usd">3123593</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c221" decimals="0" id="ixv-24858" unitRef="usd">5060973</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c205" decimals="0" id="ixv-24859" unitRef="usd">601526</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c222" decimals="0" id="ixv-24860" unitRef="usd">621619</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c223" decimals="0" id="ixv-24861" unitRef="usd">377608</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c224" decimals="0" id="ixv-24862" unitRef="usd">2175253</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c225" decimals="0" id="ixv-24863" unitRef="usd">1356903</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c226" decimals="0" id="ixv-24864" unitRef="usd">505609</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-24865" unitRef="usd">5433375</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="0" id="ixv-24866" unitRef="usd">5136153</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" id="ixv-24867" unitRef="usd">5944190</us-gaap:Revenues>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0" id="ixv-23424">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The revenue information above is based on the
locations where the revenue originated.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Long-lived assets located at&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;HK SAR&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,081&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;584&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,370&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Kyrgyzstan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,513&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,902&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,472&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,085&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thailand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;312,313&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;307,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;254,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;371,666&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;446,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;506,343&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c191" decimals="0" id="ixv-24868" unitRef="usd">3081</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c218" decimals="0" id="ixv-24869" unitRef="usd">584</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c227" decimals="0" id="ixv-24870" unitRef="usd">8370</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c221" decimals="0" id="ixv-24871" unitRef="usd">22513</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c205" decimals="0" id="ixv-24872" unitRef="usd">47902</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c222" decimals="0" id="ixv-24873" unitRef="usd">137472</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c223" decimals="0" id="ixv-24874" unitRef="usd">229085</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c224" decimals="0" id="ixv-24875" unitRef="usd">312313</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c225" decimals="0" id="ixv-24876" unitRef="usd">307948</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c226" decimals="0" id="ixv-24877" unitRef="usd">254745</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-24878" unitRef="usd">371666</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c6" decimals="0" id="ixv-24879" unitRef="usd">446004</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c7" decimals="0" id="ixv-24880" unitRef="usd">506343</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0" id="ixv-23553">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 16 &#x2014;&#160;RISKS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"&gt;A. Credit risk&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Accounts receivable&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In order to minimize the
credit risk, the management of the Company monitors and ensures that follow-up&#160;action is taken to recover overdue debts. The Company
considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk
on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Company compares
the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition.
It considers available reasonable and supportive forward-looking&#160;information, such as GDP growth rate and nominal GDP per capita.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account receivables as of December
31, 2024 and 2023 to be $19.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The credit risk on liquid
funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&#160;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Deposits and other receivables, amount due
from shareholders and loan to A SPAC I&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company assessed the
impairment for deposits and other receivables, due from shareholders individually based on internal credit rating and ageing of these
debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition. Based on the impairment
assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables, due from shareholders
as of December&#160;31, 2024 is $4, and $17,818, respectively. The loss allowance for deposits and other receivables, due from shareholders
as of December&#160;31, 2023 is $14, and $17,818, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;B.&#160;Interest
risk&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Cash flow interest rate risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company is exposed to
cash flow interest rate risk through the changes in interest rates related mainly to the Company&#x2019;s variable-rates&#160;bank balances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company currently does
not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk. The directors
monitor the Company&#x2019;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Sensitivity analysis&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The sensitivity analysis
below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period and had been applied
to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is used when reporting
interest rate risk internally to key management personnel and represents management&#x2019;s assessment of the reasonably possible change
in interest rates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;If interest rates had been
1% higher or lower and all other variables were held constant, the Company&#x2019;s net (loss) income for the&#160;years ended December
31, 2024 and 2023 would have increased or decreased by approximately $26,894 and$541, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Foreign currency risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Foreign currency risk is
the risk that the holding of foreign currency assets will affect the Company&#x2019;s financial position as a result of a change in foreign
currency exchange rates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s monetary
assets and liabilities are mainly denominated in HK$, THB and RMB which are the same as the functional currencies of the relevant group
entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered insignificant. The Company currently
does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related foreign currency
exposure closely and will consider hedging significant foreign currency exposures should the need arise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;C. Economic and political
risks&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s operations
are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&#x2019;s business, financial condition, and results
of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s operations
in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include risks associated with,
among others, the political, economic and legal environment and foreign currency exchange. The Company&#x2019;s results may be adversely
affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies
with respect to laws and regulations, anti-inflationary&#160;measures, currency conversion, remittances abroad, and rates and methods
of taxation, among other things including natural disasters and wars.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;D. Inflation risk&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Management monitors changes
in prices levels. Historically inflation has not materially impacted the Company&#x2019;s consolidated financial statements; however, significant
increases in the price of labor that cannot be passed to the Company&#x2019;s customers could adversely impact the Company&#x2019;s results
of operations.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="0" id="ixv-24881" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="0" id="ixv-24882" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c230" decimals="0" id="ixv-24883" unitRef="usd">4</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNet contextRef="c230" decimals="0" id="ixv-24884" unitRef="usd">17818</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c231" decimals="0" id="ixv-24885" unitRef="usd">14</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNet contextRef="c231" decimals="0" id="ixv-24886" unitRef="usd">17818</us-gaap:AccountsReceivableNet>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="c0" decimals="2" id="ixv-24887" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <nivf:InterestRateOtherVariablesPercentage contextRef="c0" decimals="2" id="ixv-24888" unitRef="pure">0.01</nivf:InterestRateOtherVariablesPercentage>
    <us-gaap:IncreaseDecreaseInPensionPlanObligations contextRef="c0" decimals="0" id="ixv-24889" unitRef="usd">26894</us-gaap:IncreaseDecreaseInPensionPlanObligations>
    <us-gaap:IncreaseDecreaseInPensionPlanObligations contextRef="c6" decimals="0" id="ixv-24890" unitRef="usd">541</us-gaap:IncreaseDecreaseInPensionPlanObligations>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-23629">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 17 &#x2014;&#160;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The summary of amount due from and due to related
parties as the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;Due from shareholders consist of the following:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 45%; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Mr.&#160;Siu Wing Fung, Alfred (&#x201c;Mr.&#160;Siu&#x201d;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 30%; text-align: left; padding-bottom: 1.5pt"&gt;Shareholders and directors&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;404,549&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;354,285&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Due to a related party consist of the following:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Ms.&#160;Fong Hei Yue, Tina (&#x201c;Ms. Fong&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Shareholders and directors (note 1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(497,200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Harcourt Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;A related party (note&#160;2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(61,802&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;5% or more shareholder&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,150,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note:&lt;/span&gt;
&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Ms. Fong is the spouse of Mr.&#160;Siu. The due to shareholders balance
as of December 31, 2024 was $92,651 while the due from shareholders balance as of December 31, 2023 was $354,285.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The balance due from shareholders consist of the
following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Due from/ (to)shareholders/ related party&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(154,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372,103&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(154,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;354,285&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The movement of allowances for expected credit
loss is as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Reversal of Provision / (Provision)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Directors&#x2019; remuneration to Mr.&#160;Siu Wing Fung, Alfred&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;190,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;125,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;120,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Directors&#x2019; remuneration to Ms. Fong Hei Yue, Tina&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Waiver of related party balance of Mr. Siu Wing Fung, Alfred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(88,151&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Coupon interest expense  to JAK Opportunities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308,751&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Conversion of convertible note to shares to JAK Opportunities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,650,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-23634">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The summary of amount due from and due to related
parties as the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;Due from shareholders consist of the following:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 45%; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Mr.&#160;Siu Wing Fung, Alfred (&#x201c;Mr.&#160;Siu&#x201d;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 30%; text-align: left; padding-bottom: 1.5pt"&gt;Shareholders and directors&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;404,549&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;354,285&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Due to a related party consist of the following:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Ms.&#160;Fong Hei Yue, Tina (&#x201c;Ms. Fong&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Shareholders and directors (note 1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(497,200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Harcourt Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;A related party (note&#160;2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(61,802&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;JAK &amp;amp; affiliated holders&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;5% or more shareholder&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,150,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Ms. Fong is the spouse of Mr.&#160;Siu. The due to shareholders balance
as of December 31, 2024 was $92,651 while the due from shareholders balance as of December 31, 2023 was $354,285.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c234" id="ixv-24891">Shareholders and directors</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c235" decimals="0" id="ixv-24892" unitRef="usd">404549</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c236" decimals="0" id="ixv-24893" unitRef="usd">354285</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c237" id="ix_125_fact">Shareholders and directors (note 1)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <nivf:DueToARelatedParty
      contextRef="c238"
      decimals="0"
      id="ix_126_fact"
      unitRef="usd">497200</nivf:DueToARelatedParty>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c239" id="ix_127_fact">A related party (note&#160;2)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <nivf:DueToARelatedParty
      contextRef="c240"
      decimals="0"
      id="ix_128_fact"
      unitRef="usd">61802</nivf:DueToARelatedParty>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c242" id="ixv-24898">5% or more shareholder</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <nivf:DueToARelatedParty contextRef="c243" decimals="0" id="ixv-24899" unitRef="usd">-3150000</nivf:DueToARelatedParty>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c232" decimals="0" id="ixv-24901" unitRef="usd">92651</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c233" decimals="0" id="ixv-24902" unitRef="usd">354285</us-gaap:OtherReceivablesNetCurrent>
    <nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock contextRef="c0" id="ixv-23776">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The balance due from shareholders consist of the
following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Due from/ (to)shareholders/ related party&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(154,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372,103&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(154,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;354,285&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock>
    <nivf:DueFromtoshareholdersRelatedParty contextRef="c2" decimals="0" id="ixv-24903" unitRef="usd">-154453</nivf:DueFromtoshareholdersRelatedParty>
    <nivf:DueFromtoshareholdersRelatedParty contextRef="c3" decimals="0" id="ixv-24904" unitRef="usd">372103</nivf:DueFromtoshareholdersRelatedParty>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" id="ixv-24905" unitRef="usd">17818</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <nivf:AccountsReceivableAfterAllowanceForCreditLoss contextRef="c2" decimals="0" id="ixv-24906" unitRef="usd">-154453</nivf:AccountsReceivableAfterAllowanceForCreditLoss>
    <nivf:AccountsReceivableAfterAllowanceForCreditLoss contextRef="c3" decimals="0" id="ixv-24907" unitRef="usd">354285</nivf:AccountsReceivableAfterAllowanceForCreditLoss>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c0" id="ixv-23825">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The movement of allowances for expected credit
loss is as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Reversal of Provision / (Provision)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" id="ixv-24908" unitRef="usd">17818</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c30" decimals="0" id="ixv-24909" unitRef="usd">17059</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" id="ixv-24910" unitRef="usd">17818</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c6" decimals="0" id="ixv-24911" unitRef="usd">-759</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" id="ixv-24912" unitRef="usd">17818</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="c0" id="ixv-23874">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Directors&#x2019; remuneration to Mr.&#160;Siu Wing Fung, Alfred&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;190,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;125,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;120,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Directors&#x2019; remuneration to Ms. Fong Hei Yue, Tina&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Waiver of related party balance of Mr. Siu Wing Fung, Alfred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(88,151&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Coupon interest expense  to JAK Opportunities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308,751&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Conversion of convertible note to shares to JAK Opportunities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,650,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c245" decimals="0" id="ixv-24913" unitRef="usd">190000</nivf:WaiverOfRelatedPartyBalance>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c246" decimals="0" id="ixv-24914" unitRef="usd">125000</nivf:WaiverOfRelatedPartyBalance>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c247" decimals="0" id="ixv-24915" unitRef="usd">120000</nivf:WaiverOfRelatedPartyBalance>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c248" decimals="0" id="ixv-24916" unitRef="usd">190000</nivf:WaiverOfRelatedPartyBalance>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c249" decimals="0" id="ixv-24917" unitRef="usd">125000</nivf:WaiverOfRelatedPartyBalance>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c250" decimals="0" id="ixv-24918" unitRef="usd">120000</nivf:WaiverOfRelatedPartyBalance>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c252" decimals="0" id="ixv-24919" unitRef="usd">-88151</nivf:WaiverOfRelatedPartyBalance>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c254" decimals="0" id="ixv-24920" unitRef="usd">308751</nivf:WaiverOfRelatedPartyBalance>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c257" decimals="0" id="ixv-24921" unitRef="usd">2650000</nivf:WaiverOfRelatedPartyBalance>
    <us-gaap:ShortTermDebtTextBlock contextRef="c0" id="ixv-23974">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 18 &#x2014;&#160;LOAN TO A SPAC&#160;I&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On June&#160;12, 2023, NewGenIvf
Limited (the &#x201c;Legacy NewGenIvf&#x201d;) and A SPAC&#160;I Acquisition Corp (&#x201c;A SPAC&#160;I&#x201d;) entered into a First Amendment
to Merger Agreement, pursuant to which the Legacy NewGenIvf agreed to provide non-interest&#160;bearing loans in an aggregate principal
amount of up to $560,000 (the &#x201c;Loan&#x201d;) to A SPAC&#160;I to fund amounts required to further extend the period of time available
for A SPAC&#160;I to consummate a business combination, and for working capital and payment of professional, administrative and operational
expenses, and other purposes as mutually agreed by A SPAC&#160;I and the Legacy NewGenIvf. The Loan will only become repayable upon the
closing of the Acquisition Merger. As of December 31, 2023, $140,000 was outstanding under the loan. The Legacy NewGenIvf completed the
business combination with A SPAC I Acquisition Corp on April 3, 2024. After the combination, the balance of loan to ACSA was eliminated
in the subsequent period.&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="c260" decimals="0" id="ixv-24922" unitRef="usd">560000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c6" decimals="0" id="ixv-24923" unitRef="usd">140000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-23983">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 19 &#x2014;&#160;COMMITMENTS &amp;amp; &lt;span style="text-transform: uppercase"&gt;CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2024 and
2023, the Company was not a party to any legal or administrative proceedings. As of December 31, 2024, the Company had commitment as described
in Notes 10 and 11 to the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company is also committed
to honor its obligations pursuant to the convertible note agreements as described in Note 10&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <nivf:DisposalOfSubsidiaryTextBlock contextRef="c0" id="ixv-24007">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 20 &#x2014;&#160;&lt;span style="text-transform: uppercase"&gt;DISPOSAL
OF SUBSIDIARY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On December 18, 2024, the
Company completed the sale of its First Fertility Bishkek LLC to an unrelated third party for total consideration of US$11, consisting
of cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As part of the disposal,
all the outstanding account payables and receivables as well as all outstanding balances between the First Fertility Bishkek LLC and Harcourt,
FFPGS, and the Director were transferred to the Seller. Any tax liabilities in Kyrgyzstan arising from the transfer of these balances
shall be borne by the Buyer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the financial impact
of the disposal:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consideration received: Cash of $11 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;Net assets acquired of&#160;$486,706&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reversal of excess tax of $486,706&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"&gt;The disposal was accounted for in accordance with ASC 810, Consolidation.
As a result, the Company deconsolidated First Fertility Bishkek LLC and recognized a write back of tax (after netting against the cash
consideration received) in the amount of US$486,706 in the consolidated statements of operations for the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"&gt;The disposal did not represent a strategic shift
and, therefore, was not classified as a discontinued operation under ASC 205-20.&lt;/p&gt;</nivf:DisposalOfSubsidiaryTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="c261" decimals="0" id="ixv-24924" unitRef="usd">11</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c2" decimals="0" id="ixv-24925" unitRef="usd">11</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c0" decimals="0" id="ixv-24926" unitRef="usd">486706</us-gaap:FairValueOfAssetsAcquired>
    <nivf:DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax contextRef="c0" decimals="0" id="ixv-24927" unitRef="usd">486706</nivf:DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax>
    <us-gaap:TaxesPayableCurrentAndNoncurrent contextRef="c2" decimals="0" id="ixv-24928" unitRef="usd">486706</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c0" id="ixv-24048">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 21 &#x2014;&#160;&lt;span style="text-transform: uppercase"&gt;BUSINESS
ACQUISITION&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"&gt;On December 17, 2024, the Company acquired Bi
Clinic Ltd (&#x201c;Bi Clinic&#x201d;), which holds a license for the provision of IVF treatment, surrogacy, and ancillary caring services,
for total consideration of $15,000. The acquisition enhances the Company&#x2019;s position in healthcare fertility sector. The transaction
was accounted for as a business combination under ASC 805, Business Combinations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"&gt;At the acquisition date, Bi Clinic had not yet
commenced revenue-generating activities but had established the necessary regulatory approvals and licensing framework to operate as an
IVF and surrogacy service provider. These approvals, along with the Company&#x2019;s planned integration of medical personnel and operational
processes, provide the necessary inputs and substantive processes required to meet the definition of a business under ASC 805.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"&gt;Since Bi Clinic had no other assets or liabilities,
the entire purchase price was allocated to intangible assets, specifically the IVF license and regulatory approvals. No goodwill was recognized
in connection with the transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"&gt;As Bi Clinic had no prior operations, its financial
results have been included in the consolidated financial statements from the acquisition date, with no historical revenue or expenses
impacting the Company&#x2019;s consolidated results. Pro forma financial information has been omitted, as the acquisition is not considered
material to the Company&#x2019;s financial results.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c262" decimals="0" id="ixv-24929" unitRef="usd">15000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-24065">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 22 &#x2014;&#160;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company evaluated subsequent
events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon
this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or
disclosure in the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On February 11, 2025, the
Company carried out a 1-for-20 reverse stock split of its issued and unissued shares. The effect of the reverse stock split was to consolidate
every 20 issued and unissued shares into one share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On February 24, 2025, the
Company entered into a Consulting Services Agreement with A SPAC (Holdings) Group Corp (&#x201c;ASPAC&#x201d;), pursuant to which the Company
engaged ASPAC for the provision of certain consulting services. It was agreed that the Company would provide consideration in the form
of cash and shares. On March 3, 2025, the Company issued the 150,000 Class A Ordinary Shares to ASPAC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On February 27, 2025, the
Company received a confirmation from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved
and that the Company&#x2019;s securities were transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025.
On March 10, 2025, the Company received a confirmation letter from Nasdaq confirming that it has demonstrated compliance with all of Nasdaq&#x2019;s
listing requirements, including shareholder equity of more than $2.5m, as required in the Panel&#x2019;s decision letter dated February
19, 2025&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On February 28, 2025, the
Company completed its acquisition of the MicroSort technology from Genetics &amp;amp; IVF Institute, Inc. (&#x201c;GIVF&#x201d;). Pursuant to
a Purchase Agreement dated January 21, 2025 between the Company and GIVF (&#x201c;Purchase Agreement&#x201d;), the Company purchased all
of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort
technology from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Ordinary Shares (&#x201c;MicroSort Acquisition&#x201d;).
Under the terms of the agreement, the Company acquired the technology for US$5 million, which was satisfied through a combination of US$750,000
in cash and the issuance of 2,500,000 ordinary shares (as was adjusted to 125,000 ordinary shares after the Reverse Stock Split on February
11, 2025) at a deemed value of US$1.70 per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On February 18, 2025, the
Company entered into a cooperation agreement with FERTILITY GROUP LLC (&#x201c;BOBCARE&#x201d;) to jointly develop fertility services in
the Kyrgyzstan market. The collaboration aims to combine NewGen&#x2019;s technical expertise in fertility treatments with BOBCARE&#x2019;s
market resources in the region. This strategic partnership is anticipated to contribute to NewGen&#x2019;s market presence over the next
three years, improving the competitive position of both parties in the Kyrgyzstan market. Both companies will work together on several
initiatives, including enhancing clinical protocols and patient management systems, knowledge exchange between fertility specialists,
coordinated marketing and brand-building activities in Kyrgyzstan, and developing specialized fertility treatment options for the regional
market.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On March 31, 2025, the Company
terminated the binding term sheet with healthcare company European Wellness Investment Holdings Limited (&#x201c;EWIHL&#x201d;) regarding
their previously announced reverse merger transaction. On the grounds of non fulfilment of certain criteria as contained in the term sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On March 31, 2025, the Company&#x2019;s Board approved certain amendments
to its Share Incentive Plan of 2024, the awards of which are valid for a period of 10 years from March 28, 2025, whereby the maximum aggregate
number of shares with respect to which Awards may be granted under the Plan shall be 1,054,260 Shares, which may be increased from time
to time as determined by the Board or Committee of the Board, in an amount equal to 20% of the then outstanding ordinary shares of the
Company at the time of such increase. Shares may be made available from Shares held in treasury or authorized but unissued shares of the
Company not reserved for any other purpose. To date, no shares have been awarded under this Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On April 1, 2025, the
Company entered into a new Securities Purchase Agreement (&#x201c;2025 Securities Purchase Agreement&#x201d;) with JAK, pursuant to which,
amongst other things: (i) the Company agreed to sell, at an initial closing, a senior convertible note in the aggregate original principal
amount of $3,200,000, convertible into Class A Ordinary Shares pursuant to its terms; and (ii) the Company may require JAK (or JAK may
require the Company, as applicable) to participate in the sale of one or more additional convertible notes (which aggregate original
principal amount for all additional convertible notes shall not exceed $25,600,000).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On April 2, 2025, the Company
consummated the fourth tranche of its debt financing under the terms of its existing Securities Purchase Agreement with the investor,&#160;At
the closing of the fourth tranche, the Company sold&#160;to&#160;the investor a senior convertible note in the principal amount of $2,000,000.
The Note&#160;bears an interest rate of 14.75% per annum and may be adjustable from time to time pursuant to its terms. The funding from
these arrangements with the investor is intended to be used to finance the establishment of a fertility clinic in Dubai.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span&gt;Mr.
Yip Eng Jeremy Foo, a director of NewGenIvf Group Limited (the &#x201c;Company&#x201d;), has resigned from the Board of Directors of the
Company, the Audit Committee of the Company, and the Compensation Committee of the Company due to personal reasons, effective April 4,
2025. Mr. Foo&#x2019;s resignation did not result from any disagreement with the Board or the Company on any matter relating to the Company&#x2019;s
operations, policies or practices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Ms. Florianna Ann Chi Wan
Chan will be appointed as a director of the Company, effective April 15, 2025, to fill the vacancy on the Audit Committee and the Compensation
Committee created by Mr. Foo&#x2019;s resignation. Ms Chan has over 20 years of experience in project management, real estate development,
and luxury hospitality, and is a proven leader in driving growth and operational excellence. Since 2015, Ms. Chan has led Lab Concept
Company Limited, a subsidiary of The Lane Crawford Joyce Group, where she successfully restructured operations, spearheaded rebranding,
and digitized processes, achieving significant revenue growth. Previously, she held senior roles at VCC Company Limited, Eton Properties,
and Crown Macau, excelling in real estate development, marketing, and VIP services. She holds a Bachelor of Hospitality Management from
Central Queensland University in Australia and an Advanced Diploma from William Angliss Institute of TAFE. Fluent in Cantonese, Mandarin,
and English, Ms. Chan brings a deep understanding of Asia Pacific markets and a strategic vision that will drive the Company&#x2019;s
continued growth and success.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On April 15, 2025, the Board
of Directors approved another reverse stock split of all of the Company&#x2019;s issued and unissued shares, including the Class A ordinary
shares with no par value (the &#x201c;Class A Ordinary Shares&#x201d;), Class B ordinary shares with no par value and preferred shares with
no par value, at an exchange ratio of one (1) share for ten (10) shares. The Company expects that the Reverse Stock Split will become
effective on or around May 2, 2025, and that its Class A Ordinary Shares will begin trading on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;)
on a post-Reverse Stock Split basis on such date. The Reverse Stock Split is intended for the Company to remain compliant with a minimum
bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;No fractional shares will
be issued in connection with the Reverse Stock Split. Instead, the Company will issue one full post-Reverse Stock Split Class A Ordinary
Share to any shareholder at a participant level who would have been entitled to receive a fractional share as a result of the process.
After the Reverse Stock Split, all options, warrants and other convertible securities of the Company outstanding immediately prior to
the Reverse Stock Split will be adjusted by dividing the number of Class A Ordinary Shares into which the options, warrants and other
convertible securities are exercisable or convertible by ten (10) in accordance with the terms of the plans, agreements or arrangements
governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Subsequent to the year end
and to the date of this report, $3,150,000 convertible notes outstanding as of December 31, 2024 had been converted to additional 2,594,252
Class A ordinary shares while Promissory Notes of $500,000 outstanding as of December 31, 2024 were settled. A further 1,660,000 shares
totaling $5,193,763 were issued under the Equity Line of Credit with White Lion.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Other than the events mentioned
above, there have been no other subsequent events noted till the date of these financial statements.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c263" id="ixv-24930">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c264"
      decimals="0"
      id="ixv-24931"
      unitRef="shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockholdersEquityOther
      contextRef="c265"
      decimals="-5"
      id="ixv-24932"
      unitRef="usd">2500000</us-gaap:StockholdersEquityOther>
    <nivf:CashConsideration contextRef="c266" decimals="0" id="ixv-24933" unitRef="usd">750000</nivf:CashConsideration>
    <us-gaap:CommonStockSharesIssued
      contextRef="c267"
      decimals="0"
      id="ixv-24934"
      unitRef="shares">125000</us-gaap:CommonStockSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="c268"
      decimals="-6"
      id="ixv-24935"
      unitRef="usd">5000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c269" decimals="0" id="ixv-24936" unitRef="usd">750000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c270"
      decimals="0"
      id="ixv-24937"
      unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c271"
      decimals="0"
      id="ixv-24938"
      unitRef="shares">125000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <nivf:DeemedValuePerShare
      contextRef="c271"
      decimals="2"
      id="ixv-24939"
      unitRef="usdPershares">1.7</nivf:DeemedValuePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c272" id="ixv-24940">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c272"
      decimals="0"
      id="ixv-24941"
      unitRef="shares">1054260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <nivf:OutstandingPercentage
      contextRef="c272"
      decimals="2"
      id="ixv-24942"
      unitRef="pure">0.20</nivf:OutstandingPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c273" decimals="0" id="ixv-24943" unitRef="usd">3200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c274" decimals="0" id="ixv-24944" unitRef="usd">25600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c275" decimals="0" id="ixv-24945" unitRef="usd">2000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c276"
      decimals="4"
      id="ixv-24946"
      unitRef="pure">0.1475</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <nivf:BidPricePerShare
      contextRef="c277"
      decimals="2"
      id="ixv-24947"
      unitRef="usdPershares">1</nivf:BidPricePerShare>
    <us-gaap:ConvertibleNotesPayable contextRef="c169" decimals="0" id="ixv-24948" unitRef="usd">3150000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c97"
      decimals="0"
      id="ixv-24949"
      unitRef="shares">2594252</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:OtherNotesPayable contextRef="c174" decimals="0" id="ixv-24950" unitRef="usd">500000</us-gaap:OtherNotesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c278"
      decimals="0"
      id="ixv-24951"
      unitRef="shares">1660000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c278" decimals="0" id="ixv-24952" unitRef="usd">5193763</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:Reclassifications contextRef="c0" id="ixv-24137">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 23 &#x2014;&#160;RECLASSIFICATION
AND COMPARATIVE FIGURES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;Certain prior year amounts
have been reclassified to conform to the current year&#x2019;s presentation. These include the re-presentation of share-based compensation
to consultants pursuant to service agreements. In the prior year, compensation for future services to be rendered were recorded as subscription
receivables in the Statement of Equity. In the current year, these compensation for services has been reclassified and measured at the
fair value of the shares issued as compensation at grant date in accordance with ASC 718. This reclassification had no effect on previously
reported&#160;net&#160;income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt"&gt;The comparative figures in the consolidated balance sheets, statement
of equity, consolidated statements of cash flows, together with the accompanying notes, where relevant reflect those of the Company after
the reverse takeover and reorganization process in 2024, and accordingly differs from those audited and reported on by the predecessor
auditor on NewGenIvf Limited, the legal acquiree and accounting acquirer, arising from the application of ASC 805, which requires retrospective
application. The difference mainly impacts the equity in the consolidated balance sheets, the statement of equity and the consolidated
statements of cash flows, including the relevant notes.&lt;/p&gt;</us-gaap:Reclassifications>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">F-1/A</dei:DocumentType>
    <us-gaap:DepositsAssetsCurrent
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:ReceivableFromAgents
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:LoanToASPAC
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:DueFromShareholders
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="c3"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="c3"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="c3"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c2"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c3"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c2"
      id="hidden-fact-12"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c3"
      id="hidden-fact-13"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c9"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c16"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c17"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c18"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c20"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c16"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c17"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c18"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c19"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c16"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c17"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c19"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c22"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c19"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c22"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c23"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c31"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c32"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c33"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c35"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c31"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c32"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c33"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c34"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c31"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c33"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c34"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c35"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c37"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c32"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c34"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c35"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c37"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c38"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c45"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c46"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c47"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c49"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c46"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c47"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c48"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueReverseCaptialization
      contextRef="c46"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueReverseCaptialization
      contextRef="c48"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueReverseCaptialization
      contextRef="c49"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c47"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c48"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c49"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c46"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c48"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c49"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c45"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c48"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c49"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c52"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c6"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:AmortisationOfShareBasedCompensationExpense
      contextRef="c6"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:AmortisationOfShareBasedCompensationExpense
      contextRef="c7"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:NonCashDiscountOnConvertibleNotes
      contextRef="c6"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:NonCashDiscountOnConvertibleNotes
      contextRef="c7"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="c0"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseDebt
      contextRef="c7"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c0"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c7"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="c6"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="c7"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:GainOnPromissoryNote
      contextRef="c6"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:GainOnPromissoryNote
      contextRef="c7"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c0"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c6"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LegalFees
      contextRef="c0"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LegalFees
      contextRef="c7"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInFinanceReceivables
      contextRef="c0"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInFinanceReceivables
      contextRef="c6"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="c6"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:ProceedsFromAmountDueFromASPACI
      contextRef="c7"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="c6"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c0"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c7"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:PaymentofInterest
      contextRef="c7"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:SubscriptionReceivable
      contextRef="c6"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:SubscriptionReceivable
      contextRef="c7"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c6"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration contextRef="c123" id="hidden-fact-102">http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c2" id="hidden-fact-103">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c98"
      id="hidden-fact-104"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c100"
      id="hidden-fact-105"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="c134"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredCostsCurrent
      contextRef="c2"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepositAssets
      contextRef="c3"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:ReceivableFromAgents
      contextRef="c3"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c0"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c6"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:CustomerDeposit
      contextRef="c3"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:IndependentDirectorFeePayable
      contextRef="c3"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="c2"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="c160"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedAmortizationDeferredFinanceCosts
      contextRef="c160"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="c160"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="c160"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="c160"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayable
      contextRef="c160"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="c3"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="c30"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestCostsCapitalized
      contextRef="c6"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c6"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="c3"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c170"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c171"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesIssued1
      contextRef="c173"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfLiability
      contextRef="c173"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c170"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="c6"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c2"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c2"
      id="hidden-fact-133"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      id="hidden-fact-134"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c202"
      decimals="0"
      id="hidden-fact-135"
      unitRef="kzt">1200000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c201"
      decimals="0"
      id="hidden-fact-136"
      unitRef="kzt">400000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SpecialAssessmentBond
      contextRef="c175"
      decimals="0"
      id="hidden-fact-137"
      unitRef="thb">750</us-gaap:SpecialAssessmentBond>
    <us-gaap:SpecialAssessmentBond
      contextRef="c176"
      decimals="0"
      id="hidden-fact-138"
      unitRef="thb">450</us-gaap:SpecialAssessmentBond>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c206"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c207"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c209"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c210"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c211"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c7"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="c6"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c7"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="c6"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:AnnualTurnover
      contextRef="c137"
      decimals="-9"
      id="hidden-fact-152"
      unitRef="khr">1000000000</nivf:AnnualTurnover>
    <nivf:AnnualTurnover
      contextRef="c138"
      decimals="-9"
      id="hidden-fact-153"
      unitRef="khr">6000000000</nivf:AnnualTurnover>
    <us-gaap:Revenues
      contextRef="c215"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c191"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c219"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c219"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c228"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c229"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c203"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c220"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:DueToARelatedParty
      contextRef="c241"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:DueToARelatedParty
      contextRef="c244"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="c2"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="c2"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c251"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c253"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c255"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c256"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c258"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c259"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-25128">0001981662</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-25129">true</dei:AmendmentFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares as presented have been adjusted retrospectively for a Reverse Share Split effected in February 2025 of 1 share for every 20 existing share issued</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-7"
          xlink:label="hidden-fact-7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-2"
          xlink:label="hidden-fact-2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_35_fact"
          xlink:label="ix_35_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_32_fact"
          xlink:label="ix_32_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-9"
          xlink:label="hidden-fact-9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-11"
          xlink:label="hidden-fact-11"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-1"
          xlink:label="hidden-fact-1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-8"
          xlink:label="hidden-fact-8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-5"
          xlink:label="hidden-fact-5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-13"
          xlink:label="hidden-fact-13"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_33_fact"
          xlink:label="ix_33_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_34_fact"
          xlink:label="ix_34_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_31_fact"
          xlink:label="ix_31_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-7"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-2"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_35_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_32_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-9"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-11"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-1"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-8"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-5"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-13"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_33_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_34_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_31_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_36_fact"
          xlink:label="ix_36_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_37_fact"
          xlink:label="ix_37_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_38_fact"
          xlink:label="ix_38_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Adjusted
retrospectively for reverse stock split&#160;that was effected in February 2025 of 1 share for every 20 existing share issued.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_36_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_37_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_38_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_51_fact"
          xlink:label="ix_51_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_44_fact"
          xlink:label="ix_44_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_57_fact"
          xlink:label="ix_57_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_52_fact"
          xlink:label="ix_52_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_45_fact"
          xlink:label="ix_45_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_59_fact"
          xlink:label="ix_59_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_41_fact"
          xlink:label="ix_41_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_47_fact"
          xlink:label="ix_47_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_54_fact"
          xlink:label="ix_54_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_55_fact"
          xlink:label="ix_55_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_42_fact"
          xlink:label="ix_42_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_56_fact"
          xlink:label="ix_56_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_46_fact"
          xlink:label="ix_46_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_39_fact"
          xlink:label="ix_39_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_53_fact"
          xlink:label="ix_53_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_48_fact"
          xlink:label="ix_48_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-32"
          xlink:label="hidden-fact-32"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_50_fact"
          xlink:label="ix_50_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_49_fact"
          xlink:label="ix_49_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_40_fact"
          xlink:label="ix_40_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_43_fact"
          xlink:label="ix_43_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_58_fact"
          xlink:label="ix_58_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-15"
          xlink:label="hidden-fact-15"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_51_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_44_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_57_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_52_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_45_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_59_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_41_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_47_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_54_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_55_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_42_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_56_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_46_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_39_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_53_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_48_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-32"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_50_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_49_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_40_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_43_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_58_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-15"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-101"
          xlink:label="hidden-fact-101"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_88_fact"
          xlink:label="ix_88_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_90_fact"
          xlink:label="ix_90_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_108_fact"
          xlink:label="ix_108_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_85_fact"
          xlink:label="ix_85_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-97"
          xlink:label="hidden-fact-97"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_100_fact"
          xlink:label="ix_100_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_116_fact"
          xlink:label="ix_116_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-80"
          xlink:label="hidden-fact-80"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_102_fact"
          xlink:label="ix_102_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_87_fact"
          xlink:label="ix_87_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_74_fact"
          xlink:label="ix_74_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_67_fact"
          xlink:label="ix_67_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_72_fact"
          xlink:label="ix_72_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_76_fact"
          xlink:label="ix_76_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_64_fact"
          xlink:label="ix_64_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_71_fact"
          xlink:label="ix_71_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-86"
          xlink:label="hidden-fact-86"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_111_fact"
          xlink:label="ix_111_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_77_fact"
          xlink:label="ix_77_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_97_fact"
          xlink:label="ix_97_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_93_fact"
          xlink:label="ix_93_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-98"
          xlink:label="hidden-fact-98"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_63_fact"
          xlink:label="ix_63_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-75"
          xlink:label="hidden-fact-75"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-99"
          xlink:label="hidden-fact-99"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_99_fact"
          xlink:label="ix_99_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_75_fact"
          xlink:label="ix_75_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_73_fact"
          xlink:label="ix_73_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_82_fact"
          xlink:label="ix_82_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_114_fact"
          xlink:label="ix_114_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-88"
          xlink:label="hidden-fact-88"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_86_fact"
          xlink:label="ix_86_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_89_fact"
          xlink:label="ix_89_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_61_fact"
          xlink:label="ix_61_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_69_fact"
          xlink:label="ix_69_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_83_fact"
          xlink:label="ix_83_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_106_fact"
          xlink:label="ix_106_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_80_fact"
          xlink:label="ix_80_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_65_fact"
          xlink:label="ix_65_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-73"
          xlink:label="hidden-fact-73"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_92_fact"
          xlink:label="ix_92_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_94_fact"
          xlink:label="ix_94_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_62_fact"
          xlink:label="ix_62_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_107_fact"
          xlink:label="ix_107_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_84_fact"
          xlink:label="ix_84_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_68_fact"
          xlink:label="ix_68_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_105_fact"
          xlink:label="ix_105_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-96"
          xlink:label="hidden-fact-96"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-82"
          xlink:label="hidden-fact-82"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_109_fact"
          xlink:label="ix_109_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-78"
          xlink:label="hidden-fact-78"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-84"
          xlink:label="hidden-fact-84"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-94"
          xlink:label="hidden-fact-94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_113_fact"
          xlink:label="ix_113_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_96_fact"
          xlink:label="ix_96_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_60_fact"
          xlink:label="ix_60_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_79_fact"
          xlink:label="ix_79_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-81"
          xlink:label="hidden-fact-81"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-92"
          xlink:label="hidden-fact-92"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_78_fact"
          xlink:label="ix_78_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-74"
          xlink:label="hidden-fact-74"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_101_fact"
          xlink:label="ix_101_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-72"
          xlink:label="hidden-fact-72"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_98_fact"
          xlink:label="ix_98_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_112_fact"
          xlink:label="ix_112_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_110_fact"
          xlink:label="ix_110_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-89"
          xlink:label="hidden-fact-89"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_95_fact"
          xlink:label="ix_95_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-83"
          xlink:label="hidden-fact-83"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-76"
          xlink:label="hidden-fact-76"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_81_fact"
          xlink:label="ix_81_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_70_fact"
          xlink:label="ix_70_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-93"
          xlink:label="hidden-fact-93"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_115_fact"
          xlink:label="ix_115_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_91_fact"
          xlink:label="ix_91_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_104_fact"
          xlink:label="ix_104_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_66_fact"
          xlink:label="ix_66_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-91"
          xlink:label="hidden-fact-91"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_103_fact"
          xlink:label="ix_103_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-101"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_88_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_90_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_108_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_85_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-97"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_100_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_116_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-80"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_102_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_87_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_74_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_67_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_72_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_76_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_64_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_71_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-86"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_111_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_77_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_97_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_93_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-98"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_63_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-75"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-99"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_99_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_75_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_73_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_82_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_114_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-88"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_86_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_89_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_61_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_69_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_83_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_106_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_80_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_65_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-73"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_92_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_94_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_62_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_107_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_84_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_68_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_105_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-96"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-82"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_109_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-78"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-84"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-94"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_113_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_96_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_60_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_79_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-81"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-92"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_78_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-74"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_101_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-72"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_98_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_112_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_110_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-89"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_95_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-83"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-76"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_81_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_70_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-93"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_115_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_91_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_104_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_66_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-91"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_103_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_117_fact"
          xlink:label="ix_117_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_117_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_119_fact"
          xlink:label="ix_119_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_118_fact"
          xlink:label="ix_118_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represents a claim relating to an employee of
the subsidiary. On April 23, 2023, a settlement agreement was entered into with the employee, with compensation payable over 12 instalments
commencing April 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_119_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_118_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-114"
          xlink:label="hidden-fact-114"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_120_fact"
          xlink:label="ix_120_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund to customers are in relation to China-based clients who prepaid
for surrogacy and ancillary caring services but requested for refund of fees so that they may appoint their own surrogate mothers in countries
in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service
contract with those clients.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-114"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_120_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_122_fact"
          xlink:label="ix_122_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_121_fact"
          xlink:label="ix_121_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On January 10, 2023, the Company issued 1,365 ordinary
shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4,
2023, the Company issued additional 3,450 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional
paid-in capital by $2,054,556. During 2024, the service scope and duration were reduced and the service value was adjusted accordingly
pursuant to addendums to respective agreements</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_122_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_121_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_123_fact"
          xlink:label="ix_123_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On November 21, 2024, the Company entered into a Common Shares Purchase Agreement (the &#x201c;White Lion Purchase Agreement&#x201d;) with White Lion Capital, LLC (&#x201c;White Lion&#x201d;) and a related Registration Rights Agreement (the &#x201c;RRA&#x201d;). Pursuant to the White Lion Purchase Agreement, the Company has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One Hundred Million Dollars ($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to Three Hundred Million Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase Agreement) and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000) has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth in the White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration statement filed on December 5, 2024.
On December 10, 2024, 35,000 Class A Ordinary Shares were issued to White Lion amounting $276,850, in consideration for White Lion&#x2019;s commitment pursuant to the White Lion Purchase Agreement. In addition, on December 12, 2024, pursuant to this Agreement, the Company issued 9,500 Class A Ordinary Shares for a purchase price of $1,572,186. On December 24, 2024, the Company issued 25,000 Class A Ordinary Shares for a purchase price of $160,050. On December 31, 2024, the Company issued 30,000 Class A Ordinary Shares for a purchase price of $204,000.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_123_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_124_fact"
          xlink:label="ix_124_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_10_footnote" xlink:label="ix_10_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Upon de-spac business combination, additional paid-in capital
and capital reserve of Legacy NewGenIvf was combined with additional paid-in capital and accumulated net losses of the A SPAC I Acquisition
Corp and added into the additional paid-in capital of NewGenIvf Group upon the reverse take-over.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_124_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_126_fact"
          xlink:label="ix_126_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_125_fact"
          xlink:label="ix_125_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_11_footnote" xlink:label="ix_11_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Ms. Fong is the spouse of Mr.&#160;Siu. The due to shareholders balance
as of December 31, 2024 was $92,651 while the due from shareholders balance as of December 31, 2023 was $354,285.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_126_fact"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_125_fact"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_128_fact"
          xlink:label="ix_128_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_127_fact"
          xlink:label="ix_127_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-162"
          xlink:label="hidden-fact-162"
          xlink:type="locator"/>
        <link:footnote id="ix_12_footnote" xlink:label="ix_12_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_128_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_127_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-162"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001981662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment No. 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">F-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEWGENIVF
GROUP LIMITED<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">122
East 42nd Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">18th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">947-7200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Wing
Fung Alfred Siu<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">36/39-36/40, 13th
Floor, PS Tower
Sukhumvit 21 Road (Asoke)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Khlong Toei Nuea Sub-district<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Watthana District<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bangkok<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">TH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+1 (212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">537-4406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 457,740<span></span>
</td>
<td colspan="2" class="nump">$ 54,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">49,245<span></span>
</td>
<td colspan="2" class="nump">9,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">80,813<span></span>
</td>
<td colspan="2" class="nump">126,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Deposits, other receivables and deferred legal &amp; IPO cost, net</a></td>
<td class="nump">195,446<span></span>
</td>
<td colspan="2" class="nump">512,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposit with a digital asset trading platform</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ReceivableFromAgents', window );">Receivable from agents</a></td>
<td class="nump">1,191,795<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayments</a></td>
<td class="nump">197,706<span></span>
</td>
<td colspan="2" class="nump">1,262,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_LoanToASPAC', window );">Loan to A SPAC I</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="nump">140,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueFromShareholders', window );">Due from shareholders</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="nump">354,285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,172,745<span></span>
</td>
<td colspan="2" class="nump">2,458,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Plant and equipment, net</a></td>
<td class="nump">273,096<span></span>
</td>
<td colspan="2" class="nump">162,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">98,570<span></span>
</td>
<td colspan="2" class="nump">283,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepayments</a></td>
<td class="nump">33,333<span></span>
</td>
<td colspan="2" class="nump">1,582,156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">404,999<span></span>
</td>
<td colspan="2" class="nump">2,028,160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">3,577,744<span></span>
</td>
<td colspan="2" class="nump">4,486,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,298,964<span></span>
</td>
<td colspan="2" class="nump">172,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued liabilities and other payables</a></td>
<td class="nump">500,729<span></span>
</td>
<td colspan="2" class="nump">241,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">63,489<span></span>
</td>
<td colspan="2" class="nump">7,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">108,526<span></span>
</td>
<td colspan="2" class="nump">207,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="nump">6,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes</a></td>
<td class="nump">82,447<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Promissory note</a></td>
<td class="nump">500,000<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">11,746<span></span>
</td>
<td colspan="2" class="nump">486,706<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,720,354<span></span>
</td>
<td colspan="2" class="nump">1,122,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">10,231<span></span>
</td>
<td colspan="2" class="nump">118,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes, non-current</a></td>
<td class="nump">2,328,916<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">2,339,147<span></span>
</td>
<td colspan="2" class="nump">118,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,059,501<span></span>
</td>
<td colspan="2" class="nump">1,241,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, no par value, 10,000,000 shares authorized and 1,138,519* and 507,469* shares issued and outstanding as of December 31, 2024 and 2023 respectively</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="num">(204,000)<span></span>
</td>
<td colspan="2" class="num">(127,564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">122,505<span></span>
</td>
<td colspan="2" class="nump">4,331,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(985,994)<span></span>
</td>
<td colspan="2" class="num">(461,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="nump">18,875<span></span>
</td>
<td colspan="2" class="num">(7,288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity attributable to the shareholders of the Company</a></td>
<td class="num">(1,048,614)<span></span>
</td>
<td colspan="2" class="nump">3,735,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="num">(433,143)<span></span>
</td>
<td colspan="2" class="num">(490,051)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="num">(1,481,757)<span></span>
</td>
<td colspan="2" class="nump">3,245,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">3,577,744<span></span>
</td>
<td colspan="2" class="nump">4,486,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 154,453<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueFromShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due from shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueFromShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_LoanToASPAC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of loans to ASPAC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_LoanToASPAC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ReceivableFromAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ReceivableFromAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,000,000<span></span>
</td>
<td colspan="2" class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,138,519<span></span>
</td>
<td colspan="2" class="nump">507,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares ,shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,138,519<span></span>
</td>
<td colspan="2" class="nump">507,469<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares as presented have been adjusted retrospectively for a Reverse Share Split effected in February 2025 of 1 share for every 20 existing share issued</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,433,375<span></span>
</td>
<td class="nump">$ 5,136,153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,944,190<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,606,481)<span></span>
</td>
<td class="num">(3,454,368)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,406,421)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,826,894<span></span>
</td>
<td class="nump">1,681,785<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,537,769<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(206,314)<span></span>
</td>
<td class="num">(18,030)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(36,194)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,781,075)<span></span>
</td>
<td class="num">(1,621,513)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,102,870)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,987,389)<span></span>
</td>
<td class="num">(1,639,543)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,139,064)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,160,495)<span></span>
</td>
<td class="nump">42,242<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">398,705<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expenses), net</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">971,391<span></span>
</td>
<td class="nump">111,837<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23,019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,953<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(778,656)<span></span>
</td>
<td class="num">(46,179)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(77,757)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199,688<span></span>
</td>
<td class="nump">66,176<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(54,717)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) Income before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(960,807)<span></span>
</td>
<td class="nump">108,418<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">343,988<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax income (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">486,706<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(208,141)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(474,101)<span></span>
</td>
<td class="nump">108,418<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">135,847<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income (loss) attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,542<span></span>
</td>
<td class="num">(21,775)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(322,820)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to the shareholders of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(524,643)<span></span>
</td>
<td class="nump">130,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">458,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,529<span></span>
</td>
<td class="num">(22,704)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,920)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(441,572)<span></span>
</td>
<td class="nump">85,714<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">133,927<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Less: total comprehensive (loss) income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,908<span></span>
</td>
<td class="num">(27,621)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(323,458)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest', window );">Total comprehensive (loss) income attributable to the shareholders of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (498,480)<span></span>
</td>
<td class="nump">$ 113,335<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 457,385<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">&#8211; diluted (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">358,108<span></span>
</td>
<td class="nump">30,757<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">28,797<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">743,323<span></span>
</td>
<td class="nump">30,757<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">28,797<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Adjusted
retrospectively for reverse stock split&#160;that was effected in February 2025 of 1 share for every 20 existing share issued.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares</div></th>
<th class="th" colspan="2"><div>Subscription receivable</div></th>
<th class="th" colspan="2"><div>Additional paid-in capital</div></th>
<th class="th" colspan="2"><div>Accumulated deficit</div></th>
<th class="th" colspan="2"><div>Accumulated other comprehensive income/(loss)</div></th>
<th class="th" colspan="2"><div>Total attributable to the shareholders of the Company</div></th>
<th class="th" colspan="2"><div>Non- controlling interests</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 263,421<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1,050,211)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 10,852<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (775,938)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (138,972)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (914,910)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">507,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">458,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">458,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(322,820)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">135,847<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,282)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,282)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(638)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,920)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Capital injection by directors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">240,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">240,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">240,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(319,872)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">961,538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">641,666<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">641,666<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(319,872)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,464,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(591,544)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,570<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">563,113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(462,430)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">507,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21,775)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">108,418<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16,858)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16,858)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,846)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22,704)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable', window );">Settlement of subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">192,308<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">192,308<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">192,308<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,866,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,866,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,866,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(127,564)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,331,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(461,351)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,288)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,735,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(490,051)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,245,561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">507,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">507,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(524,643)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(524,643)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,542<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (474,101)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,366<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32,529<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueReverseCaptialization', window );">Reverse capitalization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,028,690)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,028,690)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,028,690)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable', window );">Settlement of subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">127,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">127,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">127,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Remeasurement of share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,766,856)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,766,856)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,766,856)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of shares under ELOC/Note Conversion arrangement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(204,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,586,236<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,382,236<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,382,236<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares under ELOC/Note Conversion arrangement (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">631,050<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (204,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 122,505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (985,994)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18,875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,048,614)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (433,143)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,481,757)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,138,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,138,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr><td colspan="17"></td></tr>
<tr><td colspan="17"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares as presented have been adjusted retrospectively for a Reverse Share Split effected in February 2025 of 1 share for every 20 existing share issued</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_StockIssuedDuringPeriodValueReverseCaptialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of reverse captialization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_StockIssuedDuringPeriodValueReverseCaptialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to settlement of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (474,101)<span></span>
</td>
<td class="nump">$ 108,418<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 135,847<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,502<span></span>
</td>
<td class="nump">31,173<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100,533<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">186,762<span></span>
</td>
<td class="nump">198,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">203,411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">114,013<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AmortisationOfShareBasedCompensationExpense', window );">Amortisation of share based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,334<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_NonCashDiscountOnConvertibleNotes', window );">Non cash discount on convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">402,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Provision of expected credit loss allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,777<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">778,656<span></span>
</td>
<td class="nump">46,179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_WaiverOfRelatedPartyBalance', window );">Waiver of related party balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(88,151)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on lease modification</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,092)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_GainOnPromissoryNote', window );">Gain on promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(953,861)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Directors&#8217; remuneration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">240,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,320<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Gain on) Provision for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(486,706)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">208,141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39,871)<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">129,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,451<span></span>
</td>
<td class="num">(80,665)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,219)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Deposit and other receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,000,851)<span></span>
</td>
<td class="num">(448,266)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(15,197)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,126,338<span></span>
</td>
<td class="nump">71,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58,752<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,750,587)<span></span>
</td>
<td class="num">(51,167)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">190,689<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,552<span></span>
</td>
<td class="num">(1,352,231)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">548,010<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(204,846)<span></span>
</td>
<td class="num">(230,433)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(175,132)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFinanceReceivables', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(19,476)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Tax paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,746<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(12,170)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,264,074)<span></span>
</td>
<td class="num">(1,766,135)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,710,901<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITY</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(53,045)<span></span>
</td>
<td class="num">(69,848)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(94,452)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(53,045)<span></span>
</td>
<td class="num">(69,848)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(94,452)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProceedsFromAmountDueFromASPACI', window );">Amount due from A SPAC I</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140,000<span></span>
</td>
<td class="num">(140,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,446)<span></span>
</td>
<td class="num">(9,317)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(19,476)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Other borrowings, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,583,597<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">128,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of shares (net of reverse capitalization effect)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">192,308<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_PaymentofInterest', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(677,663)<span></span>
</td>
<td class="num">(24,704)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Amount with related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">508,738<span></span>
</td>
<td class="nump">1,863,206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,742,509)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubscriptionReceivable', window );">Subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127,564<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,675,790<span></span>
</td>
<td class="nump">1,881,493<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,633,781)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">358,671<span></span>
</td>
<td class="nump">45,510<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(17,332)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign currency translation on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,965<span></span>
</td>
<td class="num">(18,962)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,124<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">54,104<span></span>
</td>
<td class="nump">27,556<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">28,764<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">457,740<span></span>
</td>
<td class="nump">54,104<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,556<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplementary cash flow information:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(12,170)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (768,068)<span></span>
</td>
<td class="num">$ (24,704)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (55,469)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AmortisationOfShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to share based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AmortisationOfShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_GainOnPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of gain on promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_GainOnPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_NonCashDiscountOnConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non cash discount on convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_NonCashDiscountOnConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_PaymentofInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow during the period as interest paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_PaymentofInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ProceedsFromAmountDueFromASPACI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to A SPAC I.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ProceedsFromAmountDueFromASPACI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_SubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_SubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_WaiverOfRelatedPartyBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Waiver of related party balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_WaiverOfRelatedPartyBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFinanceReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in outstanding loans including accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFinanceReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Principal Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND PRINCIPAL ACTIVITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION AND PRINCIPAL ACTIVITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to the Business Combination,
on April 29, 2021, A SPAC I Acquisition Corp. (&#8220;ASCA&#8221;), was incorporated as a British Virgin Islands business company, specifically
a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or similar business combination with one or more target businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>The Business Combination</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 15, 2023,
ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &#8220;Merger Agreement,&#8221; and
the transactions contemplated thereunder, the &#8220;Business Combination&#8221;) with A SPAC I Mini Acquisition Corp., Merger Sub,
NewGenIvf Limited, a Cayman Islands exempted company (&#8220;Legacy NewGenIvf&#8221;) and certain shareholders of Legacy NewGenIvf.
Pursuant to the Merger Agreement, the Business Combination was effected in two steps: (i) ASCA was reincorporated to the British
Virgin Islands by merging with and into A SPAC I Mini Acquisition Corp. (such transaction, the &#8220;Reincorporation Merger&#8221;)
 and then the listed company was renamed as NewGenIvf Group
Limited; and (ii) Merger Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the
Company (such second step in isolation, the &#8220;Acquisition Merger&#8221;). The surviving entity of the Business Combination,
together with its subsidiaries is referred to in this prospectus as &#8220;NewGenIvf,&#8221; the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us,&#8221; unless the context otherwise requires.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 12, 2023, the
parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the &#8220;First Amendment&#8221;), pursuant to
which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the &#8220;Loan&#8221;)
to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA&#8217;s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from Legacy NewGenIvf, ASCA
agreed to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&#8217;s failure to deliver audited
financial statements by no later than February 28, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 6, 2023, the
parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &#8220;Second Amendment&#8221;) which amended
and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&#8217;s board of directors following the consummation
of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf and three (3)
of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii) provide for the
conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary Shares in
connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible assets immediately
after the consummation of the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 3, 2024, the Business
Combination was consummated with the Company as the surviving entity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is an organization chart of the
Company and its subsidiaries as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg" style="height: 322px; width: 700px"/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s subsidiaries are detailed
in the table as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenivf Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Cayman Islands company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on 16 January, 2019</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%*</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Cambodia company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bi Clinic Ltd (&#8220;FFBi&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;A Kyrgyzstan company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;Incorporated on December 16, 2021</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;Acquired on December 17, 2024</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment, surrogacy and ancillary caring services</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd. (&#8220;SZ QianHai&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;A Shenzhen China, PRC company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;Incorporated on October 24, 2024</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;Marketing and administrative services</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">According to Thailand&#8217;s
Foreign Business Act (the &#8220;FBA&#8221;), the majority shareholdings of limited company incorporated in Thailand is required to be
owned by Thai nationals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With reference to the capital
structure and voting rights structure of ordinary shares and preference shares (the &#8220;Share Structure&#8221;) of Med Holdings and
FFC, all the preference share capital shall be owned by a Thai national. No preference shares, however, have been issued to date. The
ordinary shares and preference shares have the same rights and status in all respects except for the distribution of profits by way of
dividends with details as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed 15% of the total amount of dividends declared from time to time;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After allocation of dividends as per (a)&#160;above, the rest of the dividends shall be distributed equally amongst the holders of ordinary shares according to their shareholding ratio;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of preferred shares shall be entitled to dividends only in respect of the&#160;years for which the Company has declared a dividend payment, and there shall be no cumulative dividends; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends allocated to the holders of preferred shares in each year shall be limited at the rate as stated in (a)&#160;only. No additional dividends shall be paid to the holders of preferred shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based upon the management&#8217;s
judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board meeting, the Company accounts
for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings and FFC by exercising its majority
voting power in any board meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 17, 2024, the Company entered into a non-binding term sheet
(the &#8220;Non-Binding Term Sheet&#8221;) with European Wellness Investment Holdings Limited (&#8220;EWIHL&#8221;) for (i) the potential
acquisition of the entire equity interest of EWIHL by the Company for a consideration of US$268,000,000 to be payable by issuing 53,600,000
ordinary shares of the of the Company to the shareholder(s) of EWIHL or its associate and (ii) the fund-raising activity by the Company
from public or private shareholders, and in a form mutually acceptable to the parties, including structured equity investment for up to
US$30 million. On December 11, 2024, NewGenIvf announced its entry into a binding term sheet with European Wellness Investment Holdings
Limited (&#8220;EWIHL&#8221;) for the above proposed reverse merger, completion of which was subject to, among other conditions, the completion
of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May 24, 2024, the Company
received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying
the Company of its non-compliance with two (2) listing requirements for continued listing on Nasdaq pursuant to Nasdaq Listing Rules.
On November 21, 2024, a delisting notice was received from the continued non-compliance. The Company had filed to appeal the delisting
determination and undertook several strategic actions to regain compliance with Nasdaq&#8217;s listing require. On February 27, 2025.
received approval for the transfer the Company&#8217;s securities from the Nasdaq Global Market to the Nasdaq Capital Market and on March
10, 2025 its compliance with the listing requirements thereof.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 3, 2024, the Company announced the execution of a non-binding
term sheet (the &#8220;Term Sheet&#8221;) regarding a proposed reverse merger (the &#8220;Proposed Transaction&#8221;) with pharmaceutical
company COVIRIX Medical Pty Ltd (&#8220;COVIRIX&#8221;). The consideration was to be settled by way of the issuance of issue 102,890,000
of its ordinary shares to the shareholder(s) of COVIRIX or their respective nominees (the &#8220;COVIRIX Shareholders&#8221;) in exchange
for 100% equity interest of COVIRIX, at a deemed price per share of US$6, representing an aggregate amount of US$617,340,000. Simultaneously,
it is proposed that COVIRIX undertakes to introduce investors to raise US$6 million at US$6 per share for NIVF, in a form mutually acceptable
to both NewGen and COVIRIX. Following stockholder approval of the Proposed Transaction, COVIRIX Shareholders are expected to hold approximately
85.8% equity interest in NewGen. However, on September 21, 2024, COVIRIX withdrew from the Proposed Transaction, as such the Proposed
Transaction was terminated with no cost to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-sec-ix-redline:true;-keep: true">On August 7, 2024, the
Company entered into a Securities Purchase Agreement with certain investors named therein (collectively, the &#8220;Buyers&#8221;), pursuant
to which, amongst other things: (i) the Company agreed to sell, at an initial closing with JAK Opportunities VI LLC (&#8220;JAK&#8221;
and such initial closing, the &#8220;Initial Closing&#8221;), pursuant to which the Company agreed to sell to JAK (a) a senior convertible
note (the &#8220;Initial Note&#8221;) in the aggregate original principal amount of $1,100,000, and which terms are further set forth
below under the subheading &#8220;(ii) Initial Closing with JAK&#8221;, (b) a warrant to purchase 1,325,301 Class A Ordinary Shares of
the Company, no par value (&#8220;Class A Shares&#8221; and such warrant, the Series A Warrant), and (c) a warrant to purchase 180,722
Class B Ordinary Shares of the Company, no par value (&#8220;Class B Shares&#8221; and such warrant, the Series B Warrant, and the Series
B Warrants, together with the Series A Warrants, the &#8220;Warrants&#8221;); and (ii) the Company may require each Buyer (or each Buyer
may require the Company, as applicable) to participate in the sale of (a) one or more additional convertible notes (which aggregate original
principal amount for all additional convertible notes shall not exceed $9,500,000) (the &#8220;Additional Notes,&#8221; and, together
with the Initial Note, the &#8220;Notes&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 12, 2024, the Company
and JAK consummated the Initial Closing. The Initial Note sold to JAK in connection with the Securities Purchase Agreement bears an interest
rate of 14.75% per annum and is convertible into the Company&#8217;s Class A Shares as follows: the Conversion Amount (as defined below)
into validly issued, fully paid and non-assessable Class A at the Conversion Rate determined by dividing the aggregate of the principal
sum plus the interest rates (including late interest charges, if any) and the Make-Whole Amount, if any, by conversion price of $0.83.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the Initial Closing, the
Company also sold to JAK a Series A Warrant to purchase 1,325,301 Class A Shares and a Series B Warrant to purchase 180,722 Class B Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, in connection
with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with certain holders of its convertible
promissory notes (the &#8220;Existing Notes&#8221; and each of such amendment and exchange agreements, &#8220;Amendment and Exchange Agreement&#8221;),
pursuant to which the Company will exchange the Existing Notes by issuing, among other things, (i) senior convertible notes in the aggregate
principal amount of $2,700,000 (the &#8220;Exchange Notes&#8221;) and (b) a series of warrants to initially acquire up to a certain number
of ordinary shares to the holders of the Existing Notes set forth therein or in the Amendment and Exchange Agreement (the &#8220;Exchange
Warrants&#8221;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 28, 2024, the Company
consummated the second tranche of its debt financing under the terms of the Securities Purchase Agreement. At the closing of the second
tranche, the Company sold to JAK Opportunities VI LLC (&#8220;JAK&#8221;) a senior convertible note (the &#8220;Note&#8221;) in the principal
amount of $500,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 11, 2024, the Company consummated the third tranche of
its debt financing under the terms of the Securities Purchase Agreement (&#8220;SPA&#8221;) referenced in the current report on Form 6-K
filed with the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) on August 16, 2024. The Form 6-K filed with the
SEC on August 16, 2024 is incorporated by reference herein. Pursuant to the terms of the SPA, the Company may elect at the second additional
mandatory closing to sell and the institutional investor party to the SPA shall be required to purchases, subject to certain conditions,
an additional note (&#8220;Second Additional Mandatory Note&#8221;) in the principal amount of $1,500,000, after the effective date of
the Registration Statement (as defined in the SPA). The sale of the Second Additional Mandatory Note resulted in $1,395,000 of gross proceeds
to the company before fees and expenses. The Notes bears an interest rate of 14.75% per annum and may be adjustable from time to time
pursuant to its terms, with maturity at the 4.5 years anniversary of the date of issuance, subject to extension at the option of the holders
in certain circumstances. The Second Additional Note are convertible at any time, at an initial conversion price of $0.658.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November. 18, 2024, the
Company entered into a binding term sheet (the &#8220;Term Sheet&#8221;) with White Lion Capital, LLC, (&#8220;White Lion&#8221;) a California-based
institutional investor focused on high-growth, early-stage public companies, setting out the principal terms and conditions for a $100
million equity line of credit, expandable to $500 million. Pursuant to the Term Sheet, NewGen will have the option, but not the obligation,
to sell to White Lion up to $100.0 million in shares of common stock over an initial 36-month period, with the potential to increase to
$300.0 million upon substantial M&amp;A or merger activity, and further to $500.0 million after $250.0 million has been drawn.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 29, 2024, the
Company appointed Tam, Chun Wa to the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). Mr. Tam will serve as an independent
director. In addition, Mr. Tam has been named to the Audit Committee of the Board. Following the appointment of Mr. Tam, the Board consists
of five members.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Principles of consolidation and basis of preparation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management has prepared the
accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the United&#160;States
of America (&#8220;U.S.&#160;GAAP&#8221;). The Company maintains its general ledger and journals with the accrual method accounting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The business combination
transaction between Legacy NewGenIvf and SPAC I was accounted for as a reverse recapitalization under ASC 805, Business Combinations,
with NewGenIvf Group Limited, and deemed to be the accounting acquirer. As SPAC I did not meet the definition of a business under ASC
805, the transaction was not treated as a business combination. Instead, it was accounted for as a recapitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, the consolidated assets, liabilities
and results of operations of the accounting acquirer will become the historical financial statements of the Company, and the accounting
acquirer&#8217;s assets, liabilities and results of operations will be consolidated with the Company beginning on the acquisition date.
The Legacy NewGenIvf was the legal acquiree but deemed to be the accounting acquirer. The Company was the legal acquirer but deemed to
be the accounting acquiree in the reverse merger. The historical financial statements prior to the acquisition are those of the accounting
acquirer (Legacy NewGenivf). After completion of the Share Exchange Transaction, the Company&#8217;s consolidated financial statements
include the assets and liabilities, the operations and cash flow of the accounting acquirer. Any excess of the value of shares issued
by the Company over the net book value of the accounting acquirer will be recognized as a reduction to equity (APIC).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency translation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#8220;$&#8221;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#8220;HK$&#8221;).
Med Holdings and FFC use Thai baht (&#8220;THB&#8221;) as their functional currencies. First Fertility Phnom Penh Limited and Bi Clinic
Ltd (&#8220;FFBi&#8221;) uses United&#160;States dollar (&#8220;USD&#8221;) as their functional currencies. Shenzhen Qianhai Fengtai Renhui
Health Technology Co., Ltd. (&#8220;SZ QianHai&#8221;) uses Chinese Renminbi (&#8220;CNY&#8221;) as its functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Monetary assets and liabilities denominated in currencies other than the functional currency
are translated into the functional currency using the applicable exchange rates at the balance sheet dates</span>. <span style="font-family: Times New Roman, Times, Serif">Translation
gains and losses are recognized in the consolidated statements of operations and comprehensive income as other comprehensive income or
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The value of foreign currencies
including, the HK$, THB and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#8217;s financial condition in terms of reporting
in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Period-end</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">$: HK$</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: HK$</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Period-end</td><td>&#160;</td>
    <td style="text-align: center">$: THB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.3353</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.2265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.6153</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: THB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.2262</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.7867</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.1428</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Period-end</td><td>&#160;</td>
    <td style="text-align: center">$: RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9091</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.1946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0835</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4569</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cash and cash equivalents</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Deposits, other receivables and deferred legal
&amp; IPO cost, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deposits, other receivables and deferred Initial Public Offering (&#8220;IPO&#8221;)
cost, net primarily include deposits paid to suppliers, prepaid expenses, the prepaid professional fee which meets the definition of deferred
IPO cost, and a cash deposit of US$1,000,000 with OSL Group, a digital asset trading platform listed in Hong Kong Stock Exchange, for
the Company&#8217;s future digital asset diversification strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to additional paid-in capital upon the completion of the Initial Public Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Legal and professional fees
incurred in connection with issuing convertible debt are deferred and amortized over the life of the debt. These costs are presented as
a direct deduction from the carrying amount of the debt liability on the balance sheet (per ASC 835-30).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share based compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company accounts for stock-based compensation
in accordance with ASC Topic 718-10, <i>Compensation-Stock Compensation</i>, which requires the measurement and recognition of compensation
expense for all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees
based on fair values of the shares to be issued estimated at grant date. The stock-based compensation expense recognized during the period
is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Fair value is determined based on the estimated
market prices of the Company&#8217;s Common Stock at the respective issuance date in accordance with ASC 718, taking into consideration
the volatility of the market price of the shares, the terms of the instruments and the conditions upon which they were granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and equipment, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Plant and equipment are stated
at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 81%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-102">the lesser of useful life or&#160;term of lease</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical instruments</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;10&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor vehicle</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#8217;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of&#160;long-lived&#160;assets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Inventories</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete inventory
will be made based primarily on products approaching expiry period and forecasts of product demand. The excess balance above the product
demand as determined by this analysis becomes the basis for excess inventory charge and the written-down&#160;value of the inventory becomes
its cost. Written-down&#160;inventory would not be reversed if market conditions improve.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other borrowings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Convertible Instruments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Convertible Instruments are
categorized as equity or debt based on the terms of the notes. Convertible Notes are recorded at amounts equal to the proceeds of the
issuance, including the embedded conversion feature, and net of discounts and unamortized debt issuance in accordance with ASC 480-10-55-44
on the consolidated balance sheets. An evaluation of all conversion, purchase and redemption features contained in a debt instrument is
performed to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is recorded
separately as a derivative liability at its fair value, calculated using the Black-Scholes model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Debt issuance and offering
costs are amortized over the contractual term of the Convertible Notes, to the consolidated statements of operations in accordance with
ASC 835-30-45-1A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The convertible notes are
subsequently recorded at amortized cost, with interest expense recognized using the effective interest method. The derivative liability,
if any is remeasured at fair value at each reporting date and any gain or loss on fair value is recognized in the statement of comprehensive
income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Promissory Notes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Promissory notes, originated from ASCA&#8217;s transaction and being
taken over by NewGenIVF Group Limited upon merger, are of non-interest bearing and recorded at original cost. They are subsequently measured
at amortised cost, with interest expense recognized using the effective interest method in the consolidated statement of income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s ordinary
shares are stated at no par value. The difference between the consideration received, net of issuance cost, is recorded in additional
paid-in&#160;capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 21, 2025, the
Board of Directors of the Company approved a reverse stock split of all of the Company&#8217;s issued and unissued shares, including the
Class A ordinary shares with no par value (the &#8220;Class A Ordinary Shares&#8221;), Class B ordinary shares with no par value and preferred
shares with no par value, at an exchange ratio of one (1) share for twenty (20) shares (the &#8220;Reverse Stock Split&#8221;). Upon the
opening of the market on February 11, 2025, the Company&#8217;s Class A Ordinary Shares will begin trading on the Nasdaq Global Market
(&#8220;Nasdaq&#8221;) on a post-Reverse Stock Split basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with ASC 505,
the reverse stock split is to be accounted for retrospectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC Topic&#160;606,
Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using the full retrospective
method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had been applied to all prior
periods. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;) treatment and surrogacy
and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its contracts with customers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its performance obligations under those contracts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction prices of those contracts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction prices to its performance obligations in those contracts; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services are inter dependant. All the contracts have commercial substance, and it is probable that
the Company will collect considerations from its customers for service component as settlement is predominantly required prior to performance
of the promised service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company derives its revenues
from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from IVF treatment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In vitro fertilization (&#8220;IVF&#8221;) treatment is an assisted
reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized embryo is then implanted
to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment as well as procedures and
brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized at a point in time
when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the various procedures and
treatments are evidenced by treatment cards and reports included within the patient files indicating successful completion of the service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from surrogacy and ancillary caring
services</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result of operations
can be found in Note&#160;8 below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from egg freezing and storage facility</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides access
the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the customer,
the Company makes available access to the facility with no further substantial involvement. Revenue is recognized at a point in time when
the facility is made available to the customer at the agreed consideration by the provision of specific address within the facility as
maintained in the patient file. The receipt of consideration is assured as payment is required upfront.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Principal versus agency considerations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company follows the guidance provided in ASC 606, Revenue from
Contracts with Customers, for determining whether the Company is the principal or an agent in arrangements with customers that involve
another party that contributes to the provision of services to a customer. In these instances, the Company determines whether it has promised
to provide the service itself (as principal) or to arrange for the specified service to be provided by another party (as an agent). This
determination is a matter of judgment that depends on the facts and circumstances of each arrangement. The Company recognizes revenue
from the performance of the procedures and treatment on a gross basis as the Company is responsible for the fulfillment, controls the
delivery of the promised service, and has full discretion in establishing prices and therefore is the principal in the arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract related assets and
liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Account receivables, net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#8217;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#8217;s customers&#8217; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contract liabilities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#8217;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expected credit loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ASU No.&#160;2016-13, Financial
Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of credit
losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due to the
entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective interest
rate of the financial asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Retirement benefits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Segment information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines its
reportable segments using the management approach based on internal reporting used by the Chief Operating Decision Maker (&#8220;CODM&#8221;),
comprising the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), for decision-making, resource allocation, and performance
assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company does not distinguish
revenues, costs, or expenses by segments, operational or geographical, but reports them in aggregate. Based on this assessment, management
has determined that the Company operates as a single reportable segment under ASC 280. Accordingly, all required segment financial information
is included in the consolidated financial statements. However, we segregate IVF revenue from surrogacy revenue as these two revenue types
are critical to our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s CODM
is Mr. Siu Wing Fund Alfred, its CEO. Geographic disclosures of long-lived assets and revenue from external customers as of December 31,
2024 and 2023 are presented in Note 15.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company measured the
lease in accordance to ASU&#160;2016-02, &#8220;Leases&#8221; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of <span style="-sec-ix-hidden: hidden-fact-103">twelve</span>&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income Taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the differences
are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not realizable
or recoverable in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions in
income tax expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Comprehensive Income</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;<i>Comprehensive Income</i>. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Earnings per share</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company computes earnings
per share (&#8220;EPS&#8221;) following ASC Topic&#160;260, &#8220;Earnings per share&#8221;. Basic EPS is measured as the income or loss
available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents the dilutive
effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and or warrants; the
dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive effect of
options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those that increase
income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive securities
that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2024, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Commitments and contingencies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the normal course of business,
the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range
of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency if it determines
it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors in making
these assessments including historical and the specific facts and circumstances of each matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Non-controlling&#160;interests</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of risks</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of credit risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers. Furthermore, the risk is mitigated by ascertaining upfront payments for
services prior to their performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of customers</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, one and two customers respectively which individually contributed more than 10% of trade receivable, and accounted for <span style="-sec-ix-hidden: hidden-fact-104">89%</span> and 96.3%
of the Company&#8217;s trade receivable respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of the customers contributed
more than 10% of revenue for&#160;years ended December&#160;31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of suppliers</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, nil and one supplier respectively which individually contributed more than 10% of trade payable, accounted for <span style="-sec-ix-hidden: hidden-fact-105">nil</span> % and 30.6% of
the Company&#8217;s trade payable respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For both the years ended
December 31, 2024 and 2023, no vendor contributed more than 10% of total purchases of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Financial instruments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net, loan
to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that approximate
their fair values due to their short maturities. ASC Topic&#160;820, &#8220;Fair Value Measurements and Disclosures&#8221; requires disclosing
the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#8220;Financial Instruments&#8221; defines fair value
and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts and
other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify as financial
instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments
and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8212;&#160;inputs to the valuation methodology used quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#160;&#8212;&#160;inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#8217;s full term</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#160;&#8212;&#160;inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities from Equity&#8221;
and ASC&#160;815.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recently issued accounting pronouncements </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FASB has introduced expanded
income tax disclosure requirements under ASU 2023-09 to improve transparency. Companies will now need to provide a detailed reconciliation
of their effective tax rate, breaking down federal, state, and foreign taxes, as well as specific categories like tax credits and foreign
earnings. Additionally, businesses must disclose income taxes paid by jurisdiction, offering investors greater clarity on tax obligations.
These changes apply to both public and private companies, with annual reporting periods beginning after December 15, 2024 (2025 for calendar-year
entities). This update aims to reduce ambiguity in tax reporting and align disclosures with investor needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A major shift in digital
asset accounting, ASU 2023-08 requires companies to measure certain crypto assets (e.g., Bitcoin, Ethereum) at fair value rather than
applying the previous impairment-only model. This means entities must recognize quarterly fair value adjustments in their financial statements,
increasing volatility in reported earnings but improving transparency. The standard applies to fiscal years beginning after December 15,
2024, and impacts both corporate treasuries and investment firms holding cryptocurrencies. This change aligns GAAP closer to fair value
accounting seen in other investment holdings, addressing criticisms of the old impairment approach.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 3 &#8212; GOING CONCERN.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated financial statements have been prepared
assuming that the Company will continue as a going concern. The Company has generated a loss and suffered from an accumulated deficit
of $985,994 as of December 31, 2024. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
Management&#8217;s plans with regards to these include but not limited to issuance of share through equity line of credit with White Lion
Capital and conversion of JAK&#8217;s promissory notes. These financial statements do not include any adjustments that might result from
the outcome of this uncertainty.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company closely monitors
the market for opportunities and has also been carrying out various fundraising projects to improve the Company&#8217;s cash flow position.
As of this report date, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising the Initial Note,
the First Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the Company. A further
$2,000,000 of the Third Mandatory Additional Note was issued subsequent to year end and remains outstanding. Moreover, the Company has
access to an equity line of credit facility of up to $100,000,000 from White Lion Capital, of which approximately $7.1 million has been
drawn and become equity to date. As of this report date, the Company holds $2.48m cash in bank and a cash deposit of $1m with a trading
platform company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company can make no assurance
that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one
or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there
would likely be a material adverse effect on the Company and its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial
statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNontradeReceivableTextBlock', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 4 &#8212;&#160;ACCOUNTS RECEIVABLE, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accounts receivable, net consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49,264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,393</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,374</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">As of the end of each of the financial year, the
aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Within 90&#160;days</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">49,245</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">9,374</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,374</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(19</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(26</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Reversal of expected credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNontradeReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/326/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNontradeReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 5 &#8212;&#160;INVENTORIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Inventories consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Medicines, consumables and reagents for clinical and laboratory analyses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">80,813</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">126,264</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">80,813</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">126,264</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract', window );"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND DEFERRED IPO COST, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 6 &#8212;&#160;DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND
DEFERRED IPO COST, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Other receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">121,533</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,917</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Deferred initial public offering &#8220;IPO&#8221; cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,677</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">195,446</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">512,581</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Deposit with a digital asset trading platform</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Receivable from agents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,191,795</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt">Prepayments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">197,706</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,262,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline">Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Prepayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,582,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,582,156</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Included in prepayment is
an amount of $<span>22,000</span> and $2,839,536 as of December 31, 2024 and 2023 respectively, being
share-based compensation cost paid to consultants for services ranging from three to ten years and with termination clauses of one to
three years respectively without any penalties. During the year, the scope of service was amended and accordingly the excess compensation
was reversed against Additional Paid in Capital and the remaining value of service is recognized over the period of service in the Statement
of Income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(141</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Reversal of provision (Provision)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 7 &#8212;&#160;PROPERTY AND EQUIPMENT, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Plant and equipment, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>At cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Building improvement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">196,929</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,493</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">785,776</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,809</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,936</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">361,385</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,688</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,512,416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,481,364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,239,320</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,319,207</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">273,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">162,157</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Depreciation expenses for
the&#160;years ended December 31, 2024 and 2023 were $19,502 and $31,173, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="-sec-ix-hidden: hidden-fact-110"><span style="-sec-ix-hidden: hidden-fact-111">No</span></span> impairment loss was recorded for the&#160;years
ended December&#160;31, 2024, and 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilties and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilties and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED LIABILTIES AND OTHER PAYABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 8 &#8212;&#160;ACCRUED LIABILTIES AND OTHER
PAYABLES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued liabilities and other payables consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">201,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,633</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,349</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,361</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,349</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Independent director fee payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compensation payable (Note&#160;1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,802</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,015</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">167,762</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">500,729</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">241,613</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0%">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represents a claim relating to an employee of
the subsidiary. On April 23, 2023, a settlement agreement was entered into with the employee, with compensation payable over 12 instalments
commencing April 2023.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositContractsLiabilitiesAbstract', window );"><strong>Contract Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">CONTRACT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 9 &#8212;&#160;CONTRACT LIABILITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Contract liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,937</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,360,168</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,006</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recognized to revenue during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,788</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122,662</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Refund to customers (Note 1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,341,575</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">63,489</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0%">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund to customers are in relation to China-based clients who prepaid
for surrogacy and ancillary caring services but requested for refund of fees so that they may appoint their own surrogate mothers in countries
in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service
contract with those clients.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES, PROMISSORY NOTES, DERIVATIVE LIABILITY AND WARRANTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 10 &#8212;&#160;CONVERTIBLE NOTES, PROMISSORY NOTES, DERIVATIVE
LIABILITY AND WARRANTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Convertible notes, at amortised cost are as follows:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Convertible notes at amortised cost</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,059,595</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: Deferred debt issuance cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">648,232</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Convertible notes, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,411,363</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>The convertible notes are repayable as follows:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Current liability</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">82,447</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,328,916</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,411,363</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#160;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0">As of December 31, 2024, the Company had the following outstanding
convertible notes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Principal</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><b>Conversion</b></td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Coupon</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Issuance</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Maturity</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Note Holders</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td> <td>&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Price</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left">JAK &amp; affiliated holders</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td><td style="width: 9%; text-align: right">0.830</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14.75</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center">April 3, 2024</td><td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center">October 2, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">JAK &amp; affiliated holders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,100,000</td> <td>&#160;</td> <td>&#160;</td><td style="text-align: right">0.830</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14.75</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">August&#160;3, 2024</td><td>&#160;</td> <td style="text-align: center">February 2, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">JAK &amp; affiliated holders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td> <td>&#160;</td> <td>&#160;</td><td style="text-align: right">0.950</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14.75</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">August 30, 2024</td><td>&#160;</td> <td style="text-align: center">March 1, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">JAK &amp; affiliated holders</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,500,000</td> <td>&#160;</td> <td>&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.686</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">14.75</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">November 11, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">May 10, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,150,000</td> <td>&#160;</td> <td>&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">During the year ended December 31, 2024, a total
of $5,800,000 of convertible promissory notes were issued with a discount of 7%. These Notes are to be settled by way of cash or may be
converted to Class A ordinary shares. The conversion of these notes are subject to certain criterions as mentioned in the Convertible
Note Agreements, which include a beneficiary cap of 9.9% of shareholdings in the Company by JAK.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
$2,650,000 of convertible notes were converted into 7,020,975 ordinary shares by the note holder, thereby increasing our shareholder equity
by the same amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The effective interest expense calculated at 16.96 % amounted to $765,177
and $<span style="-sec-ix-hidden: hidden-fact-131">nil</span> for the year ended December 31, 2024 and December 31, 2023 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The transaction costs incurred
on issuance of the Notes are capitalized and amortised over the term of the Notes as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs on issuance of Notes</span></td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at beginning of the year</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add: capitalized during the year</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">929,500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: amortized during the year</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(281,268</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">648,232</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth the Company&#8217;s contractual obligations as of December 31, 2024 relating to the convertible notes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Convertible bonds-</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">516,250</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2029</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,269,625</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,207,625</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Promissory Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Balance at beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,453,861</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Waiver of liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">953,861</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; padding-bottom: 4pt">Ending balance</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">500,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
the Company has outstanding non-interest-bearing unsecured promissory notes with a total principal balance of US$500,000, which was settled
fully in February 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Derivative liability </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to ASC 815, a derivative liability had
arisen from the issuance of convertible bonds which have the option of being converted to or exchanged for Class A ordinary shares at
any time from date of issuance. The derivative liability is assessed to be a debt requiring to be bifurcated from the host contract and
recorded at the fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">However, the conversion
to ordinary shares is subject to certain terms and criteria as set within the Agreement, which includes restriction of conversion if the
shareholdings by the note holder before and after the conversion exceeds 9.99%, as revised. As of December 31, 2024, the threshold has
been met, and accordingly the derivative is assessed to have no value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Free standing instruments &#8211; warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The convertible bond agreements as mentioned above
granted the note holders 6,174,690 series A warrant, 180,722 series B warrant and 3,253,012 series C warrant, allowing the warrant holders
to purchase additional Class A ordinary shares at an exercise price of $0.913, $0.001 and $0.924 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The exercise of these warrants
is subject to a 9.99% beneficial cap, as revised, which restricts the holder from exceeding shareholdings in excess of the cap in the
Company. As of December 31, 2024, the threshold has been met, and accordingly the derivative is assessed to have no value.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 11 &#8212;&#160;LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has various operating
leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The Company&#8217;s management believes
that the interest rate of 6.6% and 5.5% was the most indicative rate of the Company&#8217;s borrowing cost for the calculation of the
present value of the lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024 and 2023, the right-of-use&#160;assets
totaled $98,570, and $283,847, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024 and 2023, lease liabilities
consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Operating lease</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lease liabilities&#160;&#8211;&#160;current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,526</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">207,128</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities&#160;&#8211;&#160;non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,231</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,979</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">118,757</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">326,107</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Finance lease</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lease liabilities&#160;&#8211;&#160;current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,446</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is a schedule of future minimum
payments under operating leases as of December&#160;31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Not later than 1 year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">111,321</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Between 1 to 2&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,621</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,864</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total operating lease liabilities, net of interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">118,757</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other lease information is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.75 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92&#160;years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Weighted-average discount rate&#160;&#8211;&#160;operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term lease cost</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">234,767</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">114,937</td><td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, there were $98,570 and $283,847 right of use (&#8220;ROU&#8221;) assets and $118,757 and $326,107 lease liabilities based on the
present value of the future minimum rental payments of leases, respectively. The Company&#8217;s management believes that using an incremental
borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate (&#8220;BLR&#8221;) minus 0.125%&#160;was the
most indicative rate of the Company&#8217;s borrowing cost for the calculation of the present value of the lease payments; the rate used
by the Company was 6.6% and 5.5% respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Ordinary shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As at December&#160;31, 2023
and December 31, 2024, the Company is authorized to issue 10,000,000 ordinary shares. Each ordinary share is entitled to one vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board
of Directors of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The equity of the Company
as of December 31, 2024 and 2023 represents 1,138,519 and 507,469 ordinary shares with par value of $<span style="-sec-ix-hidden: hidden-fact-133"><span style="-sec-ix-hidden: hidden-fact-134">Nil</span></span>. The number of shares as above
have taken into consideration the reverse stock split effected on February 11, 2025 at an exchange ratio of one (1) share for twenty (20)
shares. Pursuant to ASC 505 the reverse stock split has been applied retrospectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional paid-in capital</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance as at January 1,2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,464,959</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of shares&#160;as compensation for services (<i>Note 1</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,866,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,331,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of shares through Equity Line of Credit (<i>Note 2</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,936,236</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of shares through conversion of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,650,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease in subscription receivable due to reduction of work by professionals <i>(Note 1)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,766,856</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Combination (<i>Note 3</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,028,690</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Balance as at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">122,505</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">- the number of shares below have been amended to apply the
reverse stock split in February 2025 retrospectively.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 1:&#160;On January 10, 2023, the Company issued 1,365 ordinary
shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4,
2023, the Company issued additional 3,450 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional
paid-in capital by $2,054,556. During 2024, the service scope and duration were reduced and the service value was adjusted accordingly
pursuant to addendums to respective agreements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Note 2:</span> On November 21, 2024, the Company
entered into a Common Shares Purchase Agreement (the &#8220;White Lion Purchase Agreement&#8221;) with White Lion Capital, LLC (&#8220;White
Lion&#8221;) and a related Registration Rights Agreement (the &#8220;RRA&#8221;). Pursuant to the White Lion Purchase Agreement, the Company
has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One
Hundred Million Dollars ($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to
Three Hundred Million Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase
Agreement) and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars
($250,000,000) has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions
set forth in the White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration
statement filed on December 5, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 10, 2024, 35,000 Class A Ordinary
Shares were issued to White Lion amounting $276,850, in consideration for White Lion&#8217;s commitment pursuant to the White Lion Purchase
Agreement. In addition, on December 12, 2024, pursuant to this Agreement, the Company issued 9,500 Class A Ordinary Shares for a purchase
price of $1,572,186. On December 24, 2024, the Company issued 25,000 Class A Ordinary Shares for a purchase price of $160,050. On December
31, 2024, the Company issued 30,000 Class A Ordinary Shares for a purchase price of $204,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Note 3: Upon de-spac business combination, additional paid-in capital
and capital reserve of Legacy NewGenIvf was combined with additional paid-in capital and accumulated net losses of the A SPAC I Acquisition
Corp and added into the additional paid-in capital of NewGenIvf Group upon the reverse take-over.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 13 &#8212;&#160;EMPLOYEE BENEFIT PLANS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>HK SAR</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 5% of the employees&#8217;
basic salaries on monthly basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Thailand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is obliged to
make social security payments within the first 15&#160;days of the month over which it is accrued. In 2024, the Company and its employees
are each required to make contributions to the scheme calculated at 5% of the employee&#8217;s salary with a cap of <span style="-sec-ix-hidden: hidden-fact-137"><span style="-sec-ix-hidden: hidden-fact-138">THB750</span></span> per month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cambodia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Every business employing
one or more workers must register its business and workers with the National Social Security Fund (the &#8220;NSSF&#8221;) for the Occupational
Risk Scheme (for work-related&#160;accidents and occupational diseases), the Health Care Scheme and the Pension Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once registered, the business
must pay to the NSSF:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to 0.8% of each worker&#8217;s monthly average wages (between $0.40 and $2.40 per month per worker) for the Occupational Risk Scheme.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to 2.6% of a worker&#8217;s monthly average wages (between $1.30 and $7.80 per month per worker) for the Health Care Scheme.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of 2% (total of 4%) of the contributable wage for the first five&#160;years. The contributable wage for the Pension Scheme ranges from between <span style="-sec-ix-hidden: hidden-fact-136">KHR400,000</span> (approximately $100) up to <span style="-sec-ix-hidden: hidden-fact-135">KHR1,200,000</span> (approximately $300).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Kyrgyzstan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 15% and 8%, respectively
of the employees&#8217; basic salaries on monthly basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Provision for Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;PROVISION FOR INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cayman Islands</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NewGenIvf Limited was incorporated
in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law. In addition, upon payment
of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>HK SAR</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived from
Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, the HK SAR profits
tax is calculated at 8.25% on the first HK$2&#160;million of the estimated assessable profits and at 16.5% on the remaining estimated
assessable profits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Thailand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The companies incorporated
in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from or in consequence of the
business carried on in Thailand. The corporate income tax (CIT) rate is 20%. A foreign company not carrying on business in Thailand is
subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends, royalties, rentals, and service
fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%, while other rates may apply under
the provisions of a double tax treaty (DTT).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cambodia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The standard rate of corporate
income tax (&#8220;CIT&#8221;) for companies and permanent establishments who are classified as medium and large taxpayers is 20%. For
companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive rates from 0% to 20%. In view
of the annual turnover of the company, the annual turnover ranges from <span style="-sec-ix-hidden: hidden-fact-152">KHR1</span>&#160;billion to <span style="-sec-ix-hidden: hidden-fact-153">KHR6</span>&#160;billion for service and commercial
sectors, the company shall consider as the medium-sized&#160;company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Kyrgyzstan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company is subject to
a corporate income tax on their aggregate annual income earned worldwide. Non-resident&#160;legal entities carrying out business activities
through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that permanent
establishments. During the year, excess tax payable of $486,706 were deemed to be no longer payable and reversed accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Profit tax is calculated
at a rate of 10% of aggregate annual income less allowed deductions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Significant components of
the provisions for income taxes for the year ended December&#160;31, 2024, and 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Current tax provision Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: justify">Over provision of tax in prior year Kyrgyzstan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(486,706</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: justify">Current tax provision Cambodia</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total tax (income) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(486,706</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-bottom: 1.5pt">(Loss) Income before taxes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(960,807</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">108,418</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">343,988</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax credit (expense) at the effective tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(179,863</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(124,591</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax effect on non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,323</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,173</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax effect on non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369,101</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,991</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax effect on utilization of tax losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(127,521</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,369</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax losses unable to be utilized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Over provision of tax in prior year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486,706</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Tax (income) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(486,706</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">208,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax asset, net</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">Significant components of deferred tax assets,
net were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">&#8211; Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">160,432</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,441</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(160,432</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,441</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, the Company had net operating loss carry forward of $972,316 and $164,721. The Company believes it is less likely than not that
its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry forward. As a result, the
Company provided 100% allowance on deferred tax assets on net operating loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Disaggregated Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">DISAGGREGATED REVENUES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 15 &#8212;&#160;DISAGGREGATED REVENUES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s main business operations are
to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">IVF treatment service</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,433,375</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,021,696</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,819,163</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Surrogacy, ancillary caring and other services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,114,457</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,125,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,433,375</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,136,153</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,944,190</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Geographical information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers originated from</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34,038</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,656,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,123,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,060,973</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">601,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">621,619</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">377,608</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,175,253</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,356,903</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">505,609</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,433,375</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,136,153</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,944,190</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The revenue information above is based on the
locations where the revenue originated.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Long-lived assets located at</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 9%; text-align: right">3,081</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 9%; text-align: right">584</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="width: 1%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>China</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">8,370</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">22,513</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">47,902</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">137,472</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">229,085</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">312,313</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">307,948</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">254,745</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">$</td><td style="border-bottom: Black 4pt double; text-align: right">371,666</td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">$</td><td style="border-bottom: Black 4pt double; text-align: right">446,004</td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">506,343</td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s long-lived&#160;assets consist
of plant and equipment, net and operating leases right-of-use&#160;assets, net.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">RISKS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 16 &#8212;&#160;RISKS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">A. Credit risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Accounts receivable</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to minimize the
credit risk, the management of the Company monitors and ensures that follow-up&#160;action is taken to recover overdue debts. The Company
considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk
on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Company compares
the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition.
It considers available reasonable and supportive forward-looking&#160;information, such as GDP growth rate and nominal GDP per capita.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account receivables as of December
31, 2024 and 2023 to be $19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash and cash equivalents</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The credit risk on liquid
funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&#160;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Deposits and other receivables, amount due
from shareholders and loan to A SPAC I</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company assessed the
impairment for deposits and other receivables, due from shareholders individually based on internal credit rating and ageing of these
debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition. Based on the impairment
assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables, due from shareholders
as of December&#160;31, 2024 is $4, and $17,818, respectively. The loss allowance for deposits and other receivables, due from shareholders
as of December&#160;31, 2023 is $14, and $17,818, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">B.&#160;Interest
risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cash flow interest rate risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is exposed to
cash flow interest rate risk through the changes in interest rates related mainly to the Company&#8217;s variable-rates&#160;bank balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company currently does
not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk. The directors
monitor the Company&#8217;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sensitivity analysis</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The sensitivity analysis
below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period and had been applied
to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is used when reporting
interest rate risk internally to key management personnel and represents management&#8217;s assessment of the reasonably possible change
in interest rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If interest rates had been
1% higher or lower and all other variables were held constant, the Company&#8217;s net (loss) income for the&#160;years ended December
31, 2024 and 2023 would have increased or decreased by approximately $26,894 and$541, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Foreign currency risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign currency risk is
the risk that the holding of foreign currency assets will affect the Company&#8217;s financial position as a result of a change in foreign
currency exchange rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s monetary
assets and liabilities are mainly denominated in HK$, THB and RMB which are the same as the functional currencies of the relevant group
entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered insignificant. The Company currently
does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related foreign currency
exposure closely and will consider hedging significant foreign currency exposures should the need arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">C. Economic and political
risks</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s operations
are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&#8217;s business, financial condition, and results
of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s operations
in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include risks associated with,
among others, the political, economic and legal environment and foreign currency exchange. The Company&#8217;s results may be adversely
affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies
with respect to laws and regulations, anti-inflationary&#160;measures, currency conversion, remittances abroad, and rates and methods
of taxation, among other things including natural disasters and wars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">D. Inflation risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management monitors changes
in prices levels. Historically inflation has not materially impacted the Company&#8217;s consolidated financial statements; however, significant
increases in the price of labor that cannot be passed to the Company&#8217;s customers could adversely impact the Company&#8217;s results
of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Balances and Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 17 &#8212;&#160;RELATED PARTY BALANCES AND TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The summary of amount due from and due to related
parties as the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Due from shareholders consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 30%; text-align: left; padding-bottom: 1.5pt">Shareholders and directors</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">404,549</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">354,285</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Due to a related party consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</td><td>&#160;</td> <td style="text-align: left">Shareholders and directors (note 1)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(497,200</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Harcourt Limited</td><td>&#160;</td> <td style="text-align: left">A related party (note&#160;2)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(61,802</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">JAK &amp; affiliated holders</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt">5% or more shareholder</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:</span>
</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms. Fong is the spouse of Mr.&#160;Siu. The due to shareholders balance
as of December 31, 2024 was $92,651 while the due from shareholders balance as of December 31, 2023 was $354,285.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The balance due from shareholders consist of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Due from/ (to)shareholders/ related party</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(154,453</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">372,103</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(154,453</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">354,285</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,818</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,059</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Reversal of Provision / (Provision)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,818</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(759</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(17,818</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Directors&#8217; remuneration to Mr.&#160;Siu Wing Fung, Alfred</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">190,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">125,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Waiver of related party balance of Mr. Siu Wing Fung, Alfred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(88,151</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Coupon interest expense  to JAK Opportunities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,751</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Conversion of convertible note to shares to JAK Opportunities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,650,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan to a SPAC I<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>LOAN TO A SPAC I [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">LOAN TO A SPAC I</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 18 &#8212;&#160;LOAN TO A SPAC&#160;I</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June&#160;12, 2023, NewGenIvf
Limited (the &#8220;Legacy NewGenIvf&#8221;) and A SPAC&#160;I Acquisition Corp (&#8220;A SPAC&#160;I&#8221;) entered into a First Amendment
to Merger Agreement, pursuant to which the Legacy NewGenIvf agreed to provide non-interest&#160;bearing loans in an aggregate principal
amount of up to $560,000 (the &#8220;Loan&#8221;) to A SPAC&#160;I to fund amounts required to further extend the period of time available
for A SPAC&#160;I to consummate a business combination, and for working capital and payment of professional, administrative and operational
expenses, and other purposes as mutually agreed by A SPAC&#160;I and the Legacy NewGenIvf. The Loan will only become repayable upon the
closing of the Acquisition Merger. As of December 31, 2023, $140,000 was outstanding under the loan. The Legacy NewGenIvf completed the
business combination with A SPAC I Acquisition Corp on April 3, 2024. After the combination, the balance of loan to ACSA was eliminated
in the subsequent period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments &amp; Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments &amp; Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS &amp; CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 19 &#8212;&#160;COMMITMENTS &amp; <span style="text-transform: uppercase">CONTINGENCIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, the Company was not a party to any legal or administrative proceedings. As of December 31, 2024, the Company had commitment as described
in Notes 10 and 11 to the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is also committed
to honor its obligations pursuant to the convertible note agreements as described in Note 10</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of Subsidiary<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisposalOfSubsidiaryAbstract', window );"><strong>Disposal of Subsidiary [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisposalOfSubsidiaryTextBlock', window );">DISPOSAL OF SUBSIDIARY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 20 &#8212;&#160;<span style="text-transform: uppercase">DISPOSAL
OF SUBSIDIARY</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 18, 2024, the
Company completed the sale of its First Fertility Bishkek LLC to an unrelated third party for total consideration of US$11, consisting
of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As part of the disposal,
all the outstanding account payables and receivables as well as all outstanding balances between the First Fertility Bishkek LLC and Harcourt,
FFPGS, and the Director were transferred to the Seller. Any tax liabilities in Kyrgyzstan arising from the transfer of these balances
shall be borne by the Buyer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">The following table summarizes the financial impact
of the disposal:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration received: Cash of $11 </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt">Net assets acquired of&#160;$486,706</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reversal of excess tax of $486,706</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The disposal was accounted for in accordance with ASC 810, Consolidation.
As a result, the Company deconsolidated First Fertility Bishkek LLC and recognized a write back of tax (after netting against the cash
consideration received) in the amount of US$486,706 in the consolidated statements of operations for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">The disposal did not represent a strategic shift
and, therefore, was not classified as a discontinued operation under ASC 205-20.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DisposalOfSubsidiaryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DisposalOfSubsidiaryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DisposalOfSubsidiaryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DisposalOfSubsidiaryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS ACQUISITION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 21 &#8212;&#160;<span style="text-transform: uppercase">BUSINESS
ACQUISITION</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">On December 17, 2024, the Company acquired Bi
Clinic Ltd (&#8220;Bi Clinic&#8221;), which holds a license for the provision of IVF treatment, surrogacy, and ancillary caring services,
for total consideration of $15,000. The acquisition enhances the Company&#8217;s position in healthcare fertility sector. The transaction
was accounted for as a business combination under ASC 805, Business Combinations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">At the acquisition date, Bi Clinic had not yet
commenced revenue-generating activities but had established the necessary regulatory approvals and licensing framework to operate as an
IVF and surrogacy service provider. These approvals, along with the Company&#8217;s planned integration of medical personnel and operational
processes, provide the necessary inputs and substantive processes required to meet the definition of a business under ASC 805.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">Since Bi Clinic had no other assets or liabilities,
the entire purchase price was allocated to intangible assets, specifically the IVF license and regulatory approvals. No goodwill was recognized
in connection with the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">As Bi Clinic had no prior operations, its financial
results have been included in the consolidated financial statements from the acquisition date, with no historical revenue or expenses
impacting the Company&#8217;s consolidated results. Pro forma financial information has been omitted, as the acquisition is not considered
material to the Company&#8217;s financial results.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 22 &#8212;&#160;SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluated subsequent
events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon
this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or
disclosure in the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 11, 2025, the
Company carried out a 1-for-20 reverse stock split of its issued and unissued shares. The effect of the reverse stock split was to consolidate
every 20 issued and unissued shares into one share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 24, 2025, the
Company entered into a Consulting Services Agreement with A SPAC (Holdings) Group Corp (&#8220;ASPAC&#8221;), pursuant to which the Company
engaged ASPAC for the provision of certain consulting services. It was agreed that the Company would provide consideration in the form
of cash and shares. On March 3, 2025, the Company issued the 150,000 Class A Ordinary Shares to ASPAC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 27, 2025, the
Company received a confirmation from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved
and that the Company&#8217;s securities were transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025.
On March 10, 2025, the Company received a confirmation letter from Nasdaq confirming that it has demonstrated compliance with all of Nasdaq&#8217;s
listing requirements, including shareholder equity of more than $2.5m, as required in the Panel&#8217;s decision letter dated February
19, 2025</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 28, 2025, the
Company completed its acquisition of the MicroSort technology from Genetics &amp; IVF Institute, Inc. (&#8220;GIVF&#8221;). Pursuant to
a Purchase Agreement dated January 21, 2025 between the Company and GIVF (&#8220;Purchase Agreement&#8221;), the Company purchased all
of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort
technology from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Ordinary Shares (&#8220;MicroSort Acquisition&#8221;).
Under the terms of the agreement, the Company acquired the technology for US$5 million, which was satisfied through a combination of US$750,000
in cash and the issuance of 2,500,000 ordinary shares (as was adjusted to 125,000 ordinary shares after the Reverse Stock Split on February
11, 2025) at a deemed value of US$1.70 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 18, 2025, the
Company entered into a cooperation agreement with FERTILITY GROUP LLC (&#8220;BOBCARE&#8221;) to jointly develop fertility services in
the Kyrgyzstan market. The collaboration aims to combine NewGen&#8217;s technical expertise in fertility treatments with BOBCARE&#8217;s
market resources in the region. This strategic partnership is anticipated to contribute to NewGen&#8217;s market presence over the next
three years, improving the competitive position of both parties in the Kyrgyzstan market. Both companies will work together on several
initiatives, including enhancing clinical protocols and patient management systems, knowledge exchange between fertility specialists,
coordinated marketing and brand-building activities in Kyrgyzstan, and developing specialized fertility treatment options for the regional
market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 31, 2025, the Company
terminated the binding term sheet with healthcare company European Wellness Investment Holdings Limited (&#8220;EWIHL&#8221;) regarding
their previously announced reverse merger transaction. On the grounds of non fulfilment of certain criteria as contained in the term sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 31, 2025, the Company&#8217;s Board approved certain amendments
to its Share Incentive Plan of 2024, the awards of which are valid for a period of 10 years from March 28, 2025, whereby the maximum aggregate
number of shares with respect to which Awards may be granted under the Plan shall be 1,054,260 Shares, which may be increased from time
to time as determined by the Board or Committee of the Board, in an amount equal to 20% of the then outstanding ordinary shares of the
Company at the time of such increase. Shares may be made available from Shares held in treasury or authorized but unissued shares of the
Company not reserved for any other purpose. To date, no shares have been awarded under this Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-sec-ix-redline:true;-keep: true">On April 1, 2025, the
Company entered into a new Securities Purchase Agreement (&#8220;2025 Securities Purchase Agreement&#8221;) with JAK, pursuant to which,
amongst other things: (i) the Company agreed to sell, at an initial closing, a senior convertible note in the aggregate original principal
amount of $3,200,000, convertible into Class A Ordinary Shares pursuant to its terms; and (ii) the Company may require JAK (or JAK may
require the Company, as applicable) to participate in the sale of one or more additional convertible notes (which aggregate original
principal amount for all additional convertible notes shall not exceed $25,600,000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 2, 2025, the Company
consummated the fourth tranche of its debt financing under the terms of its existing Securities Purchase Agreement with the investor,&#160;At
the closing of the fourth tranche, the Company sold&#160;to&#160;the investor a senior convertible note in the principal amount of $2,000,000.
The Note&#160;bears an interest rate of 14.75% per annum and may be adjustable from time to time pursuant to its terms. The funding from
these arrangements with the investor is intended to be used to finance the establishment of a fertility clinic in Dubai.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span>Mr.
Yip Eng Jeremy Foo, a director of NewGenIvf Group Limited (the &#8220;Company&#8221;), has resigned from the Board of Directors of the
Company, the Audit Committee of the Company, and the Compensation Committee of the Company due to personal reasons, effective April 4,
2025. Mr. Foo&#8217;s resignation did not result from any disagreement with the Board or the Company on any matter relating to the Company&#8217;s
operations, policies or practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ms. Florianna Ann Chi Wan
Chan will be appointed as a director of the Company, effective April 15, 2025, to fill the vacancy on the Audit Committee and the Compensation
Committee created by Mr. Foo&#8217;s resignation. Ms Chan has over 20 years of experience in project management, real estate development,
and luxury hospitality, and is a proven leader in driving growth and operational excellence. Since 2015, Ms. Chan has led Lab Concept
Company Limited, a subsidiary of The Lane Crawford Joyce Group, where she successfully restructured operations, spearheaded rebranding,
and digitized processes, achieving significant revenue growth. Previously, she held senior roles at VCC Company Limited, Eton Properties,
and Crown Macau, excelling in real estate development, marketing, and VIP services. She holds a Bachelor of Hospitality Management from
Central Queensland University in Australia and an Advanced Diploma from William Angliss Institute of TAFE. Fluent in Cantonese, Mandarin,
and English, Ms. Chan brings a deep understanding of Asia Pacific markets and a strategic vision that will drive the Company&#8217;s
continued growth and success.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 15, 2025, the Board
of Directors approved another reverse stock split of all of the Company&#8217;s issued and unissued shares, including the Class A ordinary
shares with no par value (the &#8220;Class A Ordinary Shares&#8221;), Class B ordinary shares with no par value and preferred shares with
no par value, at an exchange ratio of one (1) share for ten (10) shares. The Company expects that the Reverse Stock Split will become
effective on or around May 2, 2025, and that its Class A Ordinary Shares will begin trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
on a post-Reverse Stock Split basis on such date. The Reverse Stock Split is intended for the Company to remain compliant with a minimum
bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No fractional shares will
be issued in connection with the Reverse Stock Split. Instead, the Company will issue one full post-Reverse Stock Split Class A Ordinary
Share to any shareholder at a participant level who would have been entitled to receive a fractional share as a result of the process.
After the Reverse Stock Split, all options, warrants and other convertible securities of the Company outstanding immediately prior to
the Reverse Stock Split will be adjusted by dividing the number of Class A Ordinary Shares into which the options, warrants and other
convertible securities are exercisable or convertible by ten (10) in accordance with the terms of the plans, agreements or arrangements
governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subsequent to the year end
and to the date of this report, $3,150,000 convertible notes outstanding as of December 31, 2024 had been converted to additional 2,594,252
Class A ordinary shares while Promissory Notes of $500,000 outstanding as of December 31, 2024 were settled. A further 1,660,000 shares
totaling $5,193,763 were issued under the Equity Line of Credit with White Lion.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than the events mentioned
above, there have been no other subsequent events noted till the date of these financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification and Comparative Figures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Reclassification and Comparative Figures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">RECLASSIFICATION AND COMPARATIVE FIGURES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 23 &#8212;&#160;RECLASSIFICATION
AND COMPARATIVE FIGURES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">Certain prior year amounts
have been reclassified to conform to the current year&#8217;s presentation. These include the re-presentation of share-based compensation
to consultants pursuant to service agreements. In the prior year, compensation for future services to be rendered were recorded as subscription
receivables in the Statement of Equity. In the current year, these compensation for services has been reclassified and measured at the
fair value of the shares issued as compensation at grant date in accordance with ASC 718. This reclassification had no effect on previously
reported&#160;net&#160;income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17.85pt">The comparative figures in the consolidated balance sheets, statement
of equity, consolidated statements of cash flows, together with the accompanying notes, where relevant reflect those of the Company after
the reverse takeover and reorganization process in 2024, and accordingly differs from those audited and reported on by the predecessor
auditor on NewGenIvf Limited, the legal acquiree and accounting acquirer, arising from the application of ASC 805, which requires retrospective
application. The difference mainly impacts the equity in the consolidated balance sheets, the statement of equity and the consolidated
statements of cash flows, including the relevant notes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Reclassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation and basis of preparation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Principles of consolidation and basis of preparation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management has prepared the
accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the United&#160;States
of America (&#8220;U.S.&#160;GAAP&#8221;). The Company maintains its general ledger and journals with the accrual method accounting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The business combination
transaction between Legacy NewGenIvf and SPAC I was accounted for as a reverse recapitalization under ASC 805, Business Combinations,
with NewGenIvf Group Limited, and deemed to be the accounting acquirer. As SPAC I did not meet the definition of a business under ASC
805, the transaction was not treated as a business combination. Instead, it was accounted for as a recapitalization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, the consolidated assets, liabilities
and results of operations of the accounting acquirer will become the historical financial statements of the Company, and the accounting
acquirer&#8217;s assets, liabilities and results of operations will be consolidated with the Company beginning on the acquisition date.
The Legacy NewGenIvf was the legal acquiree but deemed to be the accounting acquirer. The Company was the legal acquirer but deemed to
be the accounting acquiree in the reverse merger. The historical financial statements prior to the acquisition are those of the accounting
acquirer (Legacy NewGenivf). After completion of the Share Exchange Transaction, the Company&#8217;s consolidated financial statements
include the assets and liabilities, the operations and cash flow of the accounting acquirer. Any excess of the value of shares issued
by the Company over the net book value of the accounting acquirer will be recognized as a reduction to equity (APIC).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency translation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#8220;$&#8221;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#8220;HK$&#8221;).
Med Holdings and FFC use Thai baht (&#8220;THB&#8221;) as their functional currencies. First Fertility Phnom Penh Limited and Bi Clinic
Ltd (&#8220;FFBi&#8221;) uses United&#160;States dollar (&#8220;USD&#8221;) as their functional currencies. Shenzhen Qianhai Fengtai Renhui
Health Technology Co., Ltd. (&#8220;SZ QianHai&#8221;) uses Chinese Renminbi (&#8220;CNY&#8221;) as its functional currency.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Monetary assets and liabilities denominated in currencies other than the functional currency
are translated into the functional currency using the applicable exchange rates at the balance sheet dates</span>. <span style="font-family: Times New Roman, Times, Serif">Translation
gains and losses are recognized in the consolidated statements of operations and comprehensive income as other comprehensive income or
loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The value of foreign currencies
including, the HK$, THB and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#8217;s financial condition in terms of reporting
in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Period-end</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">$: HK$</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: HK$</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Period-end</td><td>&#160;</td>
    <td style="text-align: center">$: THB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.3353</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.2265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.6153</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: THB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.2262</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.7867</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.1428</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Period-end</td><td>&#160;</td>
    <td style="text-align: center">$: RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9091</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.1946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0835</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4569</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cash and cash equivalents</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock', window );">Deposits, other receivables and deferred legal &amp; IPO cost, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Deposits, other receivables and deferred legal
&amp; IPO cost, net</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deposits, other receivables and deferred Initial Public Offering (&#8220;IPO&#8221;)
cost, net primarily include deposits paid to suppliers, prepaid expenses, the prepaid professional fee which meets the definition of deferred
IPO cost, and a cash deposit of US$1,000,000 with OSL Group, a digital asset trading platform listed in Hong Kong Stock Exchange, for
the Company&#8217;s future digital asset diversification strategy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to additional paid-in capital upon the completion of the Initial Public Offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Legal and professional fees
incurred in connection with issuing convertible debt are deferred and amortized over the life of the debt. These costs are presented as
a direct deduction from the carrying amount of the debt liability on the balance sheet (per ASC 835-30).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share based compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share based compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company accounts for stock-based compensation
in accordance with ASC Topic 718-10, <i>Compensation-Stock Compensation</i>, which requires the measurement and recognition of compensation
expense for all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees
based on fair values of the shares to be issued estimated at grant date. The stock-based compensation expense recognized during the period
is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Fair value is determined based on the estimated
market prices of the Company&#8217;s Common Stock at the respective issuance date in accordance with ASC 718, taking into consideration
the volatility of the market price of the shares, the terms of the instruments and the conditions upon which they were granted.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and equipment, net</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Plant and equipment are stated
at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment are as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 81%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-102">the lesser of useful life or&#160;term of lease</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical instruments</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;10&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor vehicle</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#8217;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of&#160;long-lived&#160;assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Inventories</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete inventory
will be made based primarily on products approaching expiry period and forecasts of product demand. The excess balance above the product
demand as determined by this analysis becomes the basis for excess inventory charge and the written-down&#160;value of the inventory becomes
its cost. Written-down&#160;inventory would not be reversed if market conditions improve.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Other borrowings</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other borrowings</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleInstrumentsPolicyTextBlock', window );">Convertible Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Convertible Instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Convertible Instruments are
categorized as equity or debt based on the terms of the notes. Convertible Notes are recorded at amounts equal to the proceeds of the
issuance, including the embedded conversion feature, and net of discounts and unamortized debt issuance in accordance with ASC 480-10-55-44
on the consolidated balance sheets. An evaluation of all conversion, purchase and redemption features contained in a debt instrument is
performed to determine if there are any embedded features that require bifurcation as a derivative. The conversion feature is recorded
separately as a derivative liability at its fair value, calculated using the Black-Scholes model.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Debt issuance and offering
costs are amortized over the contractual term of the Convertible Notes, to the consolidated statements of operations in accordance with
ASC 835-30-45-1A.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The convertible notes are
subsequently recorded at amortized cost, with interest expense recognized using the effective interest method. The derivative liability,
if any is remeasured at fair value at each reporting date and any gain or loss on fair value is recognized in the statement of comprehensive
income.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_PromissoryNotesPolicyTextBlock', window );">Promissory Notes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Promissory Notes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Promissory notes, originated from ASCA&#8217;s transaction and being
taken over by NewGenIVF Group Limited upon merger, are of non-interest bearing and recorded at original cost. They are subsequently measured
at amortised cost, with interest expense recognized using the effective interest method in the consolidated statement of income.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Ordinary shares</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary shares</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s ordinary
shares are stated at no par value. The difference between the consideration received, net of issuance cost, is recorded in additional
paid-in&#160;capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 21, 2025, the
Board of Directors of the Company approved a reverse stock split of all of the Company&#8217;s issued and unissued shares, including the
Class A ordinary shares with no par value (the &#8220;Class A Ordinary Shares&#8221;), Class B ordinary shares with no par value and preferred
shares with no par value, at an exchange ratio of one (1) share for twenty (20) shares (the &#8220;Reverse Stock Split&#8221;). Upon the
opening of the market on February 11, 2025, the Company&#8217;s Class A Ordinary Shares will begin trading on the Nasdaq Global Market
(&#8220;Nasdaq&#8221;) on a post-Reverse Stock Split basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with ASC 505,
the reverse stock split is to be accounted for retrospectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC Topic&#160;606,
Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using the full retrospective
method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had been applied to all prior
periods. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;) treatment and surrogacy
and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its contracts with customers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its performance obligations under those contracts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction prices of those contracts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction prices to its performance obligations in those contracts; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services are inter dependant. All the contracts have commercial substance, and it is probable that
the Company will collect considerations from its customers for service component as settlement is predominantly required prior to performance
of the promised service.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company derives its revenues
from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from IVF treatment</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In vitro fertilization (&#8220;IVF&#8221;) treatment is an assisted
reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized embryo is then implanted
to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment as well as procedures and
brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized at a point in time
when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the various procedures and
treatments are evidenced by treatment cards and reports included within the patient files indicating successful completion of the service.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from surrogacy and ancillary caring
services</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result of operations
can be found in Note&#160;8 below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from egg freezing and storage facility</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides access
the facility to its customers. Upon request for the service, which is agreed verbally and followed by signed consent form from the customer,
the Company makes available access to the facility with no further substantial involvement. Revenue is recognized at a point in time when
the facility is made available to the customer at the agreed consideration by the provision of specific address within the facility as
maintained in the patient file. The receipt of consideration is assured as payment is required upfront.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Principal versus agency considerations</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company follows the guidance provided in ASC 606, Revenue from
Contracts with Customers, for determining whether the Company is the principal or an agent in arrangements with customers that involve
another party that contributes to the provision of services to a customer. In these instances, the Company determines whether it has promised
to provide the service itself (as principal) or to arrange for the specified service to be provided by another party (as an agent). This
determination is a matter of judgment that depends on the facts and circumstances of each arrangement. The Company recognizes revenue
from the performance of the procedures and treatment on a gross basis as the Company is responsible for the fulfillment, controls the
delivery of the promised service, and has full discretion in establishing prices and therefore is the principal in the arrangement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract related assets and
liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Account receivables, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#8217;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#8217;s customers&#8217; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contract liabilities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#8217;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expected credit loss</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ASU No.&#160;2016-13, Financial
Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of credit
losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due to the
entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective interest
rate of the financial asset.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitPlansPolicy', window );">Retirement benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Retirement benefits</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Segment information</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines its
reportable segments using the management approach based on internal reporting used by the Chief Operating Decision Maker (&#8220;CODM&#8221;),
comprising the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), for decision-making, resource allocation, and performance
assessment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company does not distinguish
revenues, costs, or expenses by segments, operational or geographical, but reports them in aggregate. Based on this assessment, management
has determined that the Company operates as a single reportable segment under ASC 280. Accordingly, all required segment financial information
is included in the consolidated financial statements. However, we segregate IVF revenue from surrogacy revenue as these two revenue types
are critical to our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s CODM
is Mr. Siu Wing Fund Alfred, its CEO. Geographic disclosures of long-lived assets and revenue from external customers as of December 31,
2024 and 2023 are presented in Note 15.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Leases</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company measured the
lease in accordance to ASU&#160;2016-02, &#8220;Leases&#8221; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of <span style="-sec-ix-hidden: hidden-fact-103">twelve</span>&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the differences
are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not realizable
or recoverable in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions in
income tax expense.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Comprehensive Income</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;<i>Comprehensive Income</i>. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Earnings per share</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company computes earnings
per share (&#8220;EPS&#8221;) following ASC Topic&#160;260, &#8220;Earnings per share&#8221;. Basic EPS is measured as the income or loss
available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents the dilutive
effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and or warrants; the
dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive effect of
options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those that increase
income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive securities
that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2024, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_RelatedPartiesPolicyTextBlock', window );">Related parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Related parties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Commitments and contingencies</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the normal course of business,
the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range
of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency if it determines
it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors in making
these assessments including historical and the specific facts and circumstances of each matter.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_NonControllingInterestsPolicyTextBlock', window );">Non-controlling interests</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Non-controlling&#160;interests</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of risks</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of risks</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of credit risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers. Furthermore, the risk is mitigated by ascertaining upfront payments for
services prior to their performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of customers</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, one and two customers respectively which individually contributed more than 10% of trade receivable, and accounted for <span style="-sec-ix-hidden: hidden-fact-104">89%</span> and 96.3%
of the Company&#8217;s trade receivable respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of the customers contributed
more than 10% of revenue for&#160;years ended December&#160;31, 2024 and 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of suppliers</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024 and
2023, nil and one supplier respectively which individually contributed more than 10% of trade payable, accounted for <span style="-sec-ix-hidden: hidden-fact-105">nil</span> % and 30.6% of
the Company&#8217;s trade payable respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For both the years ended
December 31, 2024 and 2023, no vendor contributed more than 10% of total purchases of the Company.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Financial instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net, loan
to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that approximate
their fair values due to their short maturities. ASC Topic&#160;820, &#8220;Fair Value Measurements and Disclosures&#8221; requires disclosing
the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#8220;Financial Instruments&#8221; defines fair value
and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements
for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts and
other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify as financial
instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments
and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8212;&#160;inputs to the valuation methodology used quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#160;&#8212;&#160;inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#8217;s full term</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#160;&#8212;&#160;inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities from Equity&#8221;
and ASC&#160;815.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recently issued accounting pronouncements </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FASB has introduced expanded
income tax disclosure requirements under ASU 2023-09 to improve transparency. Companies will now need to provide a detailed reconciliation
of their effective tax rate, breaking down federal, state, and foreign taxes, as well as specific categories like tax credits and foreign
earnings. Additionally, businesses must disclose income taxes paid by jurisdiction, offering investors greater clarity on tax obligations.
These changes apply to both public and private companies, with annual reporting periods beginning after December 15, 2024 (2025 for calendar-year
entities). This update aims to reduce ambiguity in tax reporting and align disclosures with investor needs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A major shift in digital
asset accounting, ASU 2023-08 requires companies to measure certain crypto assets (e.g., Bitcoin, Ethereum) at fair value rather than
applying the previous impairment-only model. This means entities must recognize quarterly fair value adjustments in their financial statements,
increasing volatility in reported earnings but improving transparency. The standard applies to fiscal years beginning after December 15,
2024, and impacts both corporate treasuries and investment firms holding cryptocurrencies. This change aligns GAAP closer to fair value
accounting seen in other investment holdings, addressing criticisms of the old impairment approach.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ConvertibleInstrumentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ConvertibleInstrumentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deposits, prepayment, other receivables and deferred ipo cost, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_NonControllingInterestsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_NonControllingInterestsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_PromissoryNotesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_PromissoryNotesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_RelatedPartiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for policy related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_RelatedPartiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Principal Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">Schedule of Company&#8217;s Subsidiaries</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s subsidiaries are detailed
in the table as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenivf Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Cayman Islands company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on 16 January, 2019</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%*</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Cambodia company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bi Clinic Ltd (&#8220;FFBi&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;A Kyrgyzstan company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;Incorporated on December 16, 2021</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;Acquired on December 17, 2024</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment, surrogacy and ancillary caring services</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd. (&#8220;SZ QianHai&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;A Shenzhen China, PRC company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;Incorporated on October 24, 2024</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;Marketing and administrative services</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</a></td>
<td class="text">The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Period-end</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">$: HK$</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: HK$</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Period-end</td><td>&#160;</td>
    <td style="text-align: center">$: THB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.3353</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.2265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.6153</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: THB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.2262</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.7867</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.1428</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Period-end</td><td>&#160;</td>
    <td style="text-align: center">$: RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9091</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Period average</td><td>&#160;</td>
    <td style="text-align: center">$: RMB</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.1946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0835</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4569</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives of the Plan and Equipment</a></td>
<td class="text">The estimated useful lives of the plan and equipment are as follows:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 81%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-102">the lesser of useful life or&#160;term of lease</span></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical instruments</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;10&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor vehicle</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accounts receivable, net consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49,264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,393</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,374</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">As of the end of each of the financial year, the
aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Within 90&#160;days</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">49,245</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">9,374</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,374</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock', window );">Schedule of Movement Allowances for Expected Credit Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(19</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(26</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Reversal of expected credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of movement allowances for expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Inventories consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Medicines, consumables and reagents for clinical and laboratory analyses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">80,813</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">126,264</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">80,813</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">126,264</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract', window );"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Other receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">121,533</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,917</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Deferred initial public offering &#8220;IPO&#8221; cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,677</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">195,446</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">512,581</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Deposit with a digital asset trading platform</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Receivable from agents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,191,795</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt">Prepayments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">197,706</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,262,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline">Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Prepayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,582,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,582,156</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock', window );">Schedule of Movement of Allowances for Expected Credit Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(141</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Reversal of provision (Provision)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Plant and Equipment, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Plant and equipment, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>At cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Building improvement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">196,929</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,493</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">785,776</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,809</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,936</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">361,385</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,688</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,512,416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,481,364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,239,320</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,319,207</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">273,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">162,157</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilties and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilties and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilties and Other Payables</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued liabilities and other payables consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">201,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,633</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,349</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,361</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,349</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Independent director fee payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compensation payable (Note&#160;1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,802</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,015</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">167,762</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">500,729</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">241,613</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0%">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represents a claim relating to an employee of
the subsidiary. On April 23, 2023, a settlement agreement was entered into with the employee, with compensation payable over 12 instalments
commencing April 2023.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositContractsLiabilitiesAbstract', window );"><strong>Contract Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Contract liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,937</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,360,168</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,006</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recognized to revenue during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,788</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122,662</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Refund to customers (Note 1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,341,575</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">63,489</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0%">&#160;</td> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund to customers are in relation to China-based clients who prepaid
for surrogacy and ancillary caring services but requested for refund of fees so that they may appoint their own surrogate mothers in countries
in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service
contract with those clients.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Notes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Convertible notes, at amortised cost are as follows:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Convertible notes at amortised cost</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,059,595</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: Deferred debt issuance cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">648,232</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Convertible notes, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,411,363</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>The convertible notes are repayable as follows:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Current liability</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">82,447</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,328,916</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,411,363</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#160;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Convertible Notes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0">As of December 31, 2024, the Company had the following outstanding
convertible notes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Principal</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><b>Conversion</b></td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Coupon</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Issuance</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Maturity</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Note Holders</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td> <td>&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Price</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left">JAK &amp; affiliated holders</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td><td style="width: 9%; text-align: right">0.830</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14.75</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center">April 3, 2024</td><td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center">October 2, 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">JAK &amp; affiliated holders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,100,000</td> <td>&#160;</td> <td>&#160;</td><td style="text-align: right">0.830</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14.75</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">August&#160;3, 2024</td><td>&#160;</td> <td style="text-align: center">February 2, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">JAK &amp; affiliated holders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td> <td>&#160;</td> <td>&#160;</td><td style="text-align: right">0.950</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14.75</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">August 30, 2024</td><td>&#160;</td> <td style="text-align: center">March 1, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">JAK &amp; affiliated holders</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,500,000</td> <td>&#160;</td> <td>&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.686</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">14.75</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">November 11, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">May 10, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,150,000</td> <td>&#160;</td> <td>&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock', window );">Schedule of Transaction Costs on Issuance of Notes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The transaction costs incurred
on issuance of the Notes are capitalized and amortised over the term of the Notes as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs on issuance of Notes</span></td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at beginning of the year</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add: capitalized during the year</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">929,500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: amortized during the year</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(281,268</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">648,232</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Contractual Obligations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth the Company&#8217;s contractual obligations as of December 31, 2024 relating to the convertible notes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Convertible bonds-</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">516,250</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2029</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,269,625</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,207,625</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfPromissoryNotesTableTextBlock', window );">Schedule of Promissory Notes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Promissory Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Balance at beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,453,861</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Waiver of liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">953,861</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; padding-bottom: 4pt">Ending balance</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">500,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfPromissoryNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfPromissoryNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of transaction costs on issuance of notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Subparagraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2024 and 2023, lease liabilities
consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Operating lease</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lease liabilities&#160;&#8211;&#160;current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,526</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">207,128</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities&#160;&#8211;&#160;non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,231</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,979</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">118,757</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">326,107</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Finance lease</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lease liabilities&#160;&#8211;&#160;current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,446</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other lease information is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.75 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92&#160;years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left">Weighted-average discount rate&#160;&#8211;&#160;operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term lease cost</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">234,767</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">114,937</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments under Operating Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is a schedule of future minimum
payments under operating leases as of December&#160;31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Not later than 1 year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">111,321</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Between 1 to 2&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,621</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,864</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total operating lease liabilities, net of interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">118,757</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock', window );">Schedule of Additional Paid-in Capital</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional paid-in capital</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Balance as at January 1,2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,464,959</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of shares&#160;as compensation for services (<i>Note 1</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,866,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,331,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of shares through Equity Line of Credit (<i>Note 2</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,936,236</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of shares through conversion of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,650,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease in subscription receivable due to reduction of work by professionals <i>(Note 1)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,766,856</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Combination (<i>Note 3</i>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,028,690</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Balance as at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">122,505</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 1:&#160;On January 10, 2023, the Company issued 1,365 ordinary
shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4,
2023, the Company issued additional 3,450 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional
paid-in capital by $2,054,556. During 2024, the service scope and duration were reduced and the service value was adjusted accordingly
pursuant to addendums to respective agreements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Note 2:</span> On November 21, 2024, the Company
entered into a Common Shares Purchase Agreement (the &#8220;White Lion Purchase Agreement&#8221;) with White Lion Capital, LLC (&#8220;White
Lion&#8221;) and a related Registration Rights Agreement (the &#8220;RRA&#8221;). Pursuant to the White Lion Purchase Agreement, the Company
has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One
Hundred Million Dollars ($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to
Three Hundred Million Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase
Agreement) and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars
($250,000,000) has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions
set forth in the White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration
statement filed on December 5, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 10, 2024, 35,000 Class A Ordinary
Shares were issued to White Lion amounting $276,850, in consideration for White Lion&#8217;s commitment pursuant to the White Lion Purchase
Agreement. In addition, on December 12, 2024, pursuant to this Agreement, the Company issued 9,500 Class A Ordinary Shares for a purchase
price of $1,572,186. On December 24, 2024, the Company issued 25,000 Class A Ordinary Shares for a purchase price of $160,050. On December
31, 2024, the Company issued 30,000 Class A Ordinary Shares for a purchase price of $204,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Note 3: Upon de-spac business combination, additional paid-in capital
and capital reserve of Legacy NewGenIvf was combined with additional paid-in capital and accumulated net losses of the A SPAC I Acquisition
Corp and added into the additional paid-in capital of NewGenIvf Group upon the reverse take-over.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Provision for Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of the Provisions for Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Significant components of
the provisions for income taxes for the year ended December&#160;31, 2024, and 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Current tax provision Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: justify">Over provision of tax in prior year Kyrgyzstan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(486,706</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: justify">Current tax provision Cambodia</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total tax (income) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(486,706</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Taxes</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-bottom: 1.5pt">(Loss) Income before taxes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(960,807</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">108,418</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">343,988</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax credit (expense) at the effective tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(179,863</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(124,591</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax effect on non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,323</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,173</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax effect on non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369,101</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,991</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Tax effect on utilization of tax losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(127,521</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,369</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax losses unable to be utilized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Over provision of tax in prior year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(486,706</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Tax (income) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(486,706</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">208,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">Significant components of deferred tax assets,
net were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">&#8211; Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">160,432</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,441</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(160,432</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,441</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Disaggregated Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Business Operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s main business operations are
to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">IVF treatment service</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,433,375</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,021,696</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,819,163</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Surrogacy, ancillary caring and other services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,114,457</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,125,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,433,375</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,136,153</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,944,190</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Geographical Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Geographical information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers originated from</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34,038</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,656,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,123,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,060,973</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">601,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">621,619</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">377,608</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,175,253</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,356,903</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">505,609</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,433,375</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,136,153</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,944,190</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue Information Based on the Locations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The revenue information above is based on the
locations where the revenue originated.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Long-lived assets located at</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 9%; text-align: right">3,081</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">$</td><td style="width: 9%; text-align: right">584</td><td style="width: 1%; text-align: justify">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="width: 1%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>China</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">8,370</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">22,513</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">47,902</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">137,472</td><td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: right">229,085</td><td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">312,313</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">307,948</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">254,745</td><td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">$</td><td style="border-bottom: Black 4pt double; text-align: right">371,666</td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">$</td><td style="border-bottom: Black 4pt double; text-align: right">446,004</td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: justify">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">506,343</td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Balances and Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Amount Due from and Due to Related Parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The summary of amount due from and due to related
parties as the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Due from shareholders consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 45%; text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 30%; text-align: left; padding-bottom: 1.5pt">Shareholders and directors</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">404,549</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">354,285</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Due to a related party consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</td><td>&#160;</td> <td style="text-align: left">Shareholders and directors (note 1)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(497,200</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Harcourt Limited</td><td>&#160;</td> <td style="text-align: left">A related party (note&#160;2)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(61,802</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">JAK &amp; affiliated holders</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt">5% or more shareholder</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms. Fong is the spouse of Mr.&#160;Siu. The due to shareholders balance
as of December 31, 2024 was $92,651 while the due from shareholders balance as of December 31, 2023 was $354,285.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock', window );">Schedule of Balance Due from Shareholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The balance due from shareholders consist of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Due from/ (to)shareholders/ related party</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(154,453</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">372,103</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(154,453</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">354,285</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Movement of Allowances for Expected Credit Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,818</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,059</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Reversal of Provision / (Provision)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,818</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(759</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(17,818</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of Consolidated Financial Statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Directors&#8217; remuneration to Mr.&#160;Siu Wing Fung, Alfred</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">190,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">125,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Waiver of related party balance of Mr. Siu Wing Fung, Alfred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(88,151</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Coupon interest expense  to JAK Opportunities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,751</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Conversion of convertible note to shares to JAK Opportunities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,650,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of balance due from shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2024</div></th>
<th class="th"><div>Aug. 16, 2024</div></th>
<th class="th"><div>Jun. 03, 2024</div></th>
<th class="th"><div>Apr. 17, 2024</div></th>
<th class="th"><div>Jun. 12, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 28, 2024</div></th>
<th class="th"><div>Aug. 12, 2024</div></th>
<th class="th"><div>Dec. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Receipt of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_NetTangibleAssets', window );">Net tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividends preference shares rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,890,000<span></span>
</td>
<td class="nump">53,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Deemed price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AggregateAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 617,340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investors amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockHeldBySubsidiary', window );">Common stock selling value</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_CommonStockPotentialValue', window );">Common stock potential value</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesAWarrantMember', window );">Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,174,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesBWarrantMember', window );">Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_SeniorConvertibleNotesMember', window );">Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_SeniorConvertibleNotesMember', window );">Senior Convertible Notes [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_AdditionalNotesMember', window );">Additional Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_ConversionRateMember', window );">Conversion Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_SecondAdditionalMandatoryNoteMember', window );">Second Additional Mandatory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_MaturityTerm', window );">Maturity, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_SecondAdditionalNoteMember', window );">Second Additional Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_WhiteLionCapitalLLCMember', window );">White Lion Capital, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_SubsidiarieMember', window );">Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Equity investment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_COVIRIXMember', window );">COVIRIX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_NewGenMember', window );">NewGen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=nivf_NewGenIvfLimitedMember', window );">NewGenIvf Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate loans principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_MergerActivityDrawn', window );">Merger activity drawn</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_MergerActivityDrawn', window );">Merger activity drawn</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_JAKOpportunitiesVILLCJAKMember', window );">JAK Opportunities VI LLC (&#8220;JAK&#8221;) [Member] | Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nivf_EWIHLMember', window );">EWIHL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nivf_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,325,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,325,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares [Member] | Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amout of aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_CommonStockPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock potential value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_CommonStockPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_MaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Duration of maturity, term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_MaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_MergerActivityDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of merger activity drawn.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_MergerActivityDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_NetTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net tangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_NetTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockHeldBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of entity shares held by subsidiary, which are purchased for the purpose of granting the shares to senior employees as part of an employee stock option plan approved by the Entity's Board of Directors. Presented as a reduction of shareholders' equity at their cost to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockHeldBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_SeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_SeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_AdditionalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_AdditionalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_ConversionRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_ConversionRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_SecondAdditionalMandatoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_SecondAdditionalMandatoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_SecondAdditionalNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_SecondAdditionalNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_WhiteLionCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_WhiteLionCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_SubsidiarieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_SubsidiarieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_COVIRIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_COVIRIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_NewGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_NewGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=nivf_NewGenIvfLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=nivf_NewGenIvfLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_JAKOpportunitiesVILLCJAKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_JAKOpportunitiesVILLCJAKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nivf_EWIHLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nivf_EWIHLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nivf_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nivf_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities - Schedule of Company&#8217;s Subsidiaries (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_NewGenivfLimitedMember', window );">NewGenivf Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Company's subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Cayman Islands company &#9679;&#160;&#160;&#160;Incorporated on 16 January, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FFPGSHKLimitedMember', window );">FFPGS (HK) Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Company's subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Marketing and administrative services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_WellImageLimitedMember', window );">Well Image Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Company's subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_MedHoldingsLimitedMedHoldingsMember', window );">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Company's subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FirstFertilityPGSCenterLimitedFFCMember', window );">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Company's subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FirstFertilityPhnomPenhLimitedFFPPMember', window );">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Company's subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Cambodia company &#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_BiClinicLtdFFBiMember', window );">Bi Clinic Ltd (&#8220;FFBi&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Company's subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Kyrgyzstan company &#9679;&#160;&#160;&#160;Incorporated on December 16, 2021 &#9679;&#160;&#160;&#160;Acquired on December 17, 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Provision of IVF treatment, surrogacy and ancillary caring services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember', window );">Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd. (&#8220;SZ QianHai&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Company's subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Shenzhen China, PRC company &#9679;&#160;&#160;&#160;Incorporated on October 24, 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Marketing and administrative services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State in which the subsidiary of the limited liability company or limited partnership was organized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_NewGenivfLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_NewGenivfLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FFPGSHKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FFPGSHKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_WellImageLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_WellImageLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_MedHoldingsLimitedMedHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_MedHoldingsLimitedMedHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FirstFertilityPGSCenterLimitedFFCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FirstFertilityPGSCenterLimitedFFCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FirstFertilityPhnomPenhLimitedFFPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FirstFertilityPhnomPenhLimitedFFPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_BiClinicLtdFFBiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_BiClinicLtdFFBiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Salvage value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split shares (in Shares)</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_RevenueRate', window );">Contract revenue rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_OSLGroupMember', window );">OSL Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Deposits', window );">Cash deposit (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersTwoMember', window );">Suppliers Two [Member] | Supplier Concentration Risk [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersOneMember', window );">Suppliers One [Member] | Supplier Concentration Risk [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.60%<span></span>
</td>
<td class="nump">30.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_CustomerMember', window );">Customer [Member] | Customer Concentration Risk [Member] | Trade Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_CustomerTwoMember', window );">Customer Two [Member] | Customer Concentration Risk [Member] | Trade Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_RevenueRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of revenue rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_RevenueRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_OSLGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_OSLGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nivf_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nivf_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nivf_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nivf_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodEndMember', window );">Period End [Member] | HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodEndMember', window );">Period End [Member] | THB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">34.3353<span></span>
</td>
<td class="nump">34.2265<span></span>
</td>
<td class="nump">34.6153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodEndMember', window );">Period End [Member] | RMB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">7.2994<span></span>
</td>
<td class="nump">7.0971<span></span>
</td>
<td class="nump">6.9091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodAverageMember', window );">Period Average [Member] | HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodAverageMember', window );">Period Average [Member] | THB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">35.2262<span></span>
</td>
<td class="nump">34.7867<span></span>
</td>
<td class="nump">35.1428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodAverageMember', window );">Period Average [Member] | RMB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">7.1946<span></span>
</td>
<td class="nump">7.0835<span></span>
</td>
<td class="nump">6.4569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntercompanyForeignCurrencyBalanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodEndMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodEndMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_HKD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_HKD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_THB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_THB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=nivf_PeriodAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">the lesser of useful life or term of lease<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Medical Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Motor Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Medical Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Motor Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (985,994)<span></span>
</td>
<td colspan="2" class="num">$ (461,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Remains outstanding balance</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPayment', window );">Line of credit facility</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Equity</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_CashInBank', window );">Cash in bank</a></td>
<td class="nump">2,480,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Cash deposit</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_CashInBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash in bank.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_CashInBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments of both interest and principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Schedule of Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 49,264<span></span>
</td>
<td class="nump">$ 9,393<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for expected credit loss</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable net</a></td>
<td class="nump">$ 49,245<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable , net</a></td>
<td class="nump">$ 49,245<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=nivf_Within90DaysMember', window );">Within 90 days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable , net</a></td>
<td class="nump">$ 49,245<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=nivf_Within90DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=nivf_Within90DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net - Schedule of Movement Allowances for Expected Credit Loss (Details) - Movement of Allowances [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Schedule of Movement Allowances for Expected Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning of the year</a></td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Reversal of expected credit losses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=nivf_MovementOfAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=nivf_MovementOfAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Medicines, consumables and reagents for clinical and laboratory analyses</a></td>
<td class="nump">$ 80,813<span></span>
</td>
<td class="nump">$ 126,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 80,813<span></span>
</td>
<td class="nump">$ 126,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems', window );"><strong>Deposits, Prepayment, Other Receivables And Deferred IPO Cost, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment (in Dollars)</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 2,839,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems', window );"><strong>Deposits, Prepayment, Other Receivables And Deferred IPO Cost, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ServicesRanging', window );">Service ranging</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_TerminationClauses', window );">Termination clauses</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems', window );"><strong>Deposits, Prepayment, Other Receivables And Deferred IPO Cost, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ServicesRanging', window );">Service ranging</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_TerminationClauses', window );">Termination clauses</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ServicesRanging">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Services ranging term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ServicesRanging</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_TerminationClauses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination clauses term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_TerminationClauses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_CurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other receivables</a></td>
<td class="nump">$ 121,533<span></span>
</td>
<td class="nump">$ 15,910<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_Deposit', window );">Deposits</a></td>
<td class="nump">73,917<span></span>
</td>
<td class="nump">123,008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred initial public offering &#8220;IPO&#8221; cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">373,677<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts', window );">Less: allowance for expected credit loss</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Deposits, prepayment, other receivables and deferred IPO cost, net</a></td>
<td class="nump">195,446<span></span>
</td>
<td class="nump">512,581<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposit with a digital asset trading platform</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ReceivableFromAgents', window );">Receivable from agents</a></td>
<td class="nump">1,191,795<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepayments</a></td>
<td class="nump">197,706<span></span>
</td>
<td class="nump">1,262,228<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_NonCurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_OtherPrepaidExpenseNonCurrent', window );">Prepayment</a></td>
<td class="nump">33,333<span></span>
</td>
<td class="nump">1,582,156<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepayment, non-current</a></td>
<td class="nump">$ 33,333<span></span>
</td>
<td class="nump">$ 1,582,156<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_CurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_CurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_Deposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_Deposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_NonCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_NonCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_OtherPrepaidExpenseNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment, non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_OtherPrepaidExpenseNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ReceivableFromAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ReceivableFromAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Movement of Allowances for Expected Credit Loss (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems', window );"><strong>Schedule of Movement of Allowances for Expected Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLoss', window );">Balance at beginning of the year</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision', window );">Reversal of provision (Provision)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLoss', window );">Ending balance</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AllowancesForExpectedCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of allowances for expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AllowancesForExpectedCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repressent the amount of reversal of provision (Provision).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 19,502<span></span>
</td>
<td class="nump">$ 31,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Plant and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">$ 1,512,416<span></span>
</td>
<td class="nump">$ 1,481,364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,239,320)<span></span>
</td>
<td class="num">(1,319,207)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Plant and equipment, Net</a></td>
<td class="nump">273,096<span></span>
</td>
<td class="nump">162,157<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Plant and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">196,929<span></span>
</td>
<td class="nump">92,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Plant and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">25,390<span></span>
</td>
<td class="nump">250,493<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember', window );">Medical instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Plant and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">785,776<span></span>
</td>
<td class="nump">844,809<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Plant and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">142,936<span></span>
</td>
<td class="nump">142,936<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Plant and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">$ 361,385<span></span>
</td>
<td class="nump">$ 150,688<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilties and Other Payables - Schedule of Accrued Liabilties and Other Payables (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accrued Liabilities and Other Payables [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 201,455<span></span>
</td>
<td class="nump">$ 43,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_CustomerDeposit', window );">Customer deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,349<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Withholding tax payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,361<span></span>
</td>
<td class="nump">7,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_IndependentDirectorFeePayable', window );">Independent director fee payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Compensation payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100,802<span></span>
</td>
<td class="nump">144,015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">167,762<span></span>
</td>
<td class="nump">46,616<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued Liabilties and Other Payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 500,729<span></span>
</td>
<td class="nump">$ 241,613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represents a claim relating to an employee of
the subsidiary. On April 23, 2023, a settlement agreement was entered into with the employee, with compensation payable over 12 instalments
commencing April 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_CustomerDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_CustomerDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_IndependentDirectorFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Independent director fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_IndependentDirectorFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities - Schedule of Contract Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Schedule of Contract Liabilities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,937<span></span>
</td>
<td class="nump">$ 1,360,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,340<span></span>
</td>
<td class="nump">112,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized to revenue during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19,788)<span></span>
</td>
<td class="num">(122,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Refund to customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,341,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 63,489<span></span>
</td>
<td class="nump">$ 7,937<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund to customers are in relation to China-based clients who prepaid
for surrogacy and ancillary caring services but requested for refund of fees so that they may appoint their own surrogate mothers in countries
in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service
contract with those clients.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible promissory note</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_convertiblePromissoryNoteDiscountPercentage', window );">Convertible promissory note discount percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCapInterestRate', window );">Percentage of beneficiary cap</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 765,177<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_PercentageOfConversionExceeds', window );">Percentage of conversion exceeds</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyLiquidationProceedsPercentage', window );">Percentage of exercise warrants</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesAWarrantMember', window );">Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Convertible warrant shares (in Shares)</a></td>
<td class="nump">6,174,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesBWarrantMember', window );">Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Convertible warrant shares (in Shares)</a></td>
<td class="nump">180,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesCWarrantMember', window );">Series C Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Convertible warrant shares (in Shares)</a></td>
<td class="nump">3,253,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 0.913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_FreeStandingInstrumentsWarrantsMember', window );">Free Standing Instruments Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in Dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 0.924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_ConvertibleNoteMember', window );">Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying amount of the convertible notes</a></td>
<td class="nump">$ 16.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_UnsecuredPromissoryNotesMember', window );">Unsecured Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal balance</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible promissory note</a></td>
<td class="nump">$ 2,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember', window );">Convertible Promissory Note was Converted into Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems', window );"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted ordinary shares (in Shares)</a></td>
<td class="nump">7,020,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_PercentageOfConversionExceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of conversion exceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_PercentageOfConversionExceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_convertiblePromissoryNoteDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note discount percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_convertiblePromissoryNoteDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCapInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCapInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyLiquidationProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of proceeds from liquidation of asset held as collateral or by third party expected to cover maximum potential future payment for product warranty. Includes, but is not limited to, separately price extended warranty, product maintenance contract, and warranty obligation incurred in connection with agreed upon specification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyLiquidationProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesCWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nivf_SeriesCWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nivf_FreeStandingInstrumentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nivf_FreeStandingInstrumentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_UnsecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_UnsecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details) - Convertible Notes Payable [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract', window );"><strong>Convertible notes, at amortised cost are as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Convertible notes at amortised cost</a></td>
<td class="nump">$ 3,059,595<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts', window );">Less: Deferred debt issuance cost</a></td>
<td class="nump">648,232<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Convertible notes, net</a></td>
<td class="nump">2,411,363<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract', window );"><strong>The convertible notes are repayable as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Current liability</a></td>
<td class="nump">82,447<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Non-current liability</a></td>
<td class="nump">2,328,916<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total</a></td>
<td class="nump">$ 2,411,363<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Outstanding Convertible Notes (Details) - Convertible Notes [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 3,150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_ConvertibleNotesMember', window );">JAK &amp; affiliated holders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price | $ / shares</a></td>
<td class="nump">$ 0.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DebtInstrumentCouponRatePercentage', window );">Coupon Rate</a></td>
<td class="nump">14.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Apr.  03,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Oct.  02,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_ConvertibleNotesMember', window );">JAK &amp; affiliated holders One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price | $ / shares</a></td>
<td class="nump">$ 0.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DebtInstrumentCouponRatePercentage', window );">Coupon Rate</a></td>
<td class="nump">14.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Aug.  03,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Feb.  02,  2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_ConvertibleNotesMember', window );">JAK &amp; affiliated holders Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price | $ / shares</a></td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DebtInstrumentCouponRatePercentage', window );">Coupon Rate</a></td>
<td class="nump">14.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Aug. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Mar.  01,  2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_ConvertibleNotesMember', window );">JAK &amp; affiliated holders Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price | $ / shares</a></td>
<td class="nump">$ 0.686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DebtInstrumentCouponRatePercentage', window );">Coupon Rate</a></td>
<td class="nump">14.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Issuance Date</a></td>
<td class="text">Nov. 11,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">May 10,  2029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DebtInstrumentCouponRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of debt instrument coupon rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DebtInstrumentCouponRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_JAKAffiliatedHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_JAKAffiliatedHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_JAKAffiliatedHoldersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_JAKAffiliatedHoldersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_JAKAffiliatedHoldersTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_JAKAffiliatedHoldersTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_JAKAffiliatedHoldersThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_JAKAffiliatedHoldersThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Transaction Costs on Issuance of Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract', window );"><strong>Schedule of Transaction Costs on Issuance of Notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Balance at beginning of the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Add: capitalized during the year</a></td>
<td class="nump">929,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Less: amortized during the year</a></td>
<td class="num">(281,268)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Ending balance</a></td>
<td class="nump">$ 648,232<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Contractual Obligations (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfContractualObligationsAbstract', window );"><strong>Schedule of Contractual Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 516,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2026</a></td>
<td class="nump">457,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2027</a></td>
<td class="nump">457,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2028</a></td>
<td class="nump">507,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2029</a></td>
<td class="nump">3,269,625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 5,207,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfContractualObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfContractualObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Promissory Notes (Details) - Promissory Notes [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems', window );"><strong>Schedule of Promissory Notes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance at beginning of the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Issued during the year</a></td>
<td class="nump">1,453,861<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_WaiverOfLiability', window );">Waiver of liability</a></td>
<td class="nump">953,861<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Ending balance</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_WaiverOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Waiver of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_WaiverOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 98,570<span></span>
</td>
<td class="nump">$ 283,847<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 118,757<span></span>
</td>
<td class="nump">$ 326,107<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_IndicativeRateOfBorrowingCost', window );">Indicative rate of borrowing cost</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Interest rate</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Best Lending Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Interest rate</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Best Lending Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_IndicativeRateOfBorrowingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicative rate of borrowing cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_IndicativeRateOfBorrowingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nivf_BestLendingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nivf_BestLendingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities &#8211; current portion</a></td>
<td class="nump">$ 108,526<span></span>
</td>
<td class="nump">$ 207,128<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities &#8211; non-current portion</a></td>
<td class="nump">10,231<span></span>
</td>
<td class="nump">118,979<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">118,757<span></span>
</td>
<td class="nump">326,107<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Lease liabilities &#8211; current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,446<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average lease term &#8211; operating leases</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">11 months 1 day<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; operating leases</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease cost</a></td>
<td class="nump">$ 234,767<span></span>
</td>
<td class="nump">$ 114,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Payments under Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Minimum Payments under Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Not later than 1 year</a></td>
<td class="nump">$ 111,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Between 1 to 2 years</a></td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">121,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(2,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities, net of interest</a></td>
<td class="nump">$ 118,757<span></span>
</td>
<td class="nump">$ 326,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 24, 2024</div></th>
<th class="th"><div>Dec. 12, 2024</div></th>
<th class="th"><div>Dec. 10, 2024</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Jun. 03, 2024</div></th>
<th class="th"><div>Apr. 17, 2024</div></th>
<th class="th"><div>Dec. 04, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,138,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138,519<span></span>
</td>
<td class="nump">507,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Ordinary shares with par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares with par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (250,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,890,000<span></span>
</td>
<td class="nump">53,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Purchase price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,866,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 641,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_ProfessionalPartyMember', window );">Professional Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConsultingServiceTerm', window );">Consulting service term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAdditionalCapital', window );">Increase in paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_DoubleClickServicesLimitedMember', window );">DoubleClick Services Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ConsultingServiceTerm', window );">Consulting service term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAdditionalCapital', window );">Increase in paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,054,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | White Lion [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Purchase price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="nump">$ 160,050<span></span>
</td>
<td class="nump">$ 1,572,186<span></span>
</td>
<td class="nump">$ 276,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nivf_NewGenIvfLimitedMember', window );">NewGenIvf Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nivf_MAMember', window );">M&amp;A [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nivf_WhiteLionPurchaseAgreementMember', window );">White Lion Purchase Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares as presented have been adjusted retrospectively for a Reverse Share Split effected in February 2025 of 1 share for every 20 existing share issued</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ConsultingServiceTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting service term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ConsultingServiceTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAdditionalCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional paid-in capital (APIC) classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAdditionalCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_ProfessionalPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_ProfessionalPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_DoubleClickServicesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_DoubleClickServicesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_WhiteLionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_WhiteLionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nivf_NewGenIvfLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nivf_NewGenIvfLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nivf_MAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nivf_MAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nivf_WhiteLionPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nivf_WhiteLionPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Additional Paid-in Capital (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Balance beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,331,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,464,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of shares as compensation for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,866,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Balance ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122,505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,331,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit', window );">Issuance of shares through Equity Line of Credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,936,236<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of shares through conversion of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,650,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals', window );">Decrease in subscription receivable due to reduction of work by professionals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(2,766,856)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ReverseCapitalization', window );">Business Combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">$ (6,028,690)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On January 10, 2023, the Company issued 1,365 ordinary
shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4,
2023, the Company issued additional 3,450 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional
paid-in capital by $2,054,556. During 2024, the service scope and duration were reduced and the service value was adjusted accordingly
pursuant to addendums to respective agreements</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">On November 21, 2024, the Company entered into a Common Shares Purchase Agreement (the &#8220;White Lion Purchase Agreement&#8221;) with White Lion Capital, LLC (&#8220;White Lion&#8221;) and a related Registration Rights Agreement (the &#8220;RRA&#8221;). Pursuant to the White Lion Purchase Agreement, the Company has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One Hundred Million Dollars ($100,000,000) in aggregate gross purchase price of newly issued Ordinary Shares, with an automatic increase to Three Hundred Million Dollars ($300,000,000) upon any substantial M&amp;A or Material Transaction (as defined in the White Lion Purchase Agreement) and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000) has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth in the White Lion Purchase Agreement. The White Lion Purchase Agreement was included as Exhibit 10.27 of the Form F-1 registration statement filed on December 5, 2024.
On December 10, 2024, 35,000 Class A Ordinary Shares were issued to White Lion amounting $276,850, in consideration for White Lion&#8217;s commitment pursuant to the White Lion Purchase Agreement. In addition, on December 12, 2024, pursuant to this Agreement, the Company issued 9,500 Class A Ordinary Shares for a purchase price of $1,572,186. On December 24, 2024, the Company issued 25,000 Class A Ordinary Shares for a purchase price of $160,050. On December 31, 2024, the Company issued 30,000 Class A Ordinary Shares for a purchase price of $204,000.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Upon de-spac business combination, additional paid-in capital
and capital reserve of Legacy NewGenIvf was combined with additional paid-in capital and accumulated net losses of the A SPAC I Acquisition
Corp and added into the additional paid-in capital of NewGenIvf Group upon the reverse take-over.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in subscription receivable due to reduction of work by professionals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ReverseCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reverse capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ReverseCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to issuance of shares through equity line of credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - 12 months ended Dec. 31, 2024<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>KZT (&#8376;)</div></th>
<th class="th"><div>THB (&#3647;)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementAndServiceFeesRate', window );">Scheme calculated rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SpecialAssessmentBond', window );">Special concession amount (in Baht) | &#3647;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#3647; 750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SpecialAssessmentBond', window );">Special concession amount (in Baht) | &#3647;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#3647; 450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementAndServiceFeesRate', window );">Scheme calculated rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TH', window );">Thailand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of employee's salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KG', window );">Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementAndServiceFeesRate', window );">Scheme calculated rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nivf_OccupationalRiskSchemeMember', window );">Occupational Risk Scheme [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Contribution equivalent</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nivf_OccupationalRiskSchemeMember', window );">Occupational Risk Scheme [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Average wages per month (in Dollars)</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nivf_OccupationalRiskSchemeMember', window );">Occupational Risk Scheme [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Average wages per month (in Dollars)</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nivf_HealthCareSchemeMember', window );">Health Care Scheme [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Contribution equivalent</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nivf_HealthCareSchemeMember', window );">Health Care Scheme [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Average wages per month (in Dollars)</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nivf_HealthCareSchemeMember', window );">Health Care Scheme [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Average wages per month (in Dollars)</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_PensionSchemeMember', window );">Pension Scheme [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Contribution equivalent</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_PensionSchemeMember', window );">Pension Scheme [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Contribution equivalent</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_PensionSchemeMember', window );">Pension Scheme [Member] | Cambodia [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Contributable wage</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">&#8376; 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_PensionSchemeMember', window );">Pension Scheme [Member] | Cambodia [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Contributable wage</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">&#8376; 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementAndServiceFeesRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate for management and service fees under arrangement to manage operations, including, but not limited to, investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementAndServiceFeesRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SpecialAssessmentBond">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a type of municipal bond typically used to fund a development project. Also called special assessment limited liability bond, special district bond, special purpose bond, special tax bond and community development obligation. Interest owed to lenders is paid by taxes levied on the community benefiting from the particular bond-funded project. For example, if a bond of this sort was issued to pay for sidewalks to be repaved in a certain community, an additional tax would be levied on homeowners in the area benefiting from this project.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SpecialAssessmentBond</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nivf_OccupationalRiskSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nivf_OccupationalRiskSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nivf_HealthCareSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nivf_HealthCareSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nivf_PensionSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nivf_PensionSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Details)<br> $ in Millions, &#6107; in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>HKD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>KHR (&#6107;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Provision for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProfitTaxDescription', window );">Profit tax rate description</a></td>
<td class="text">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived from
Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.<span></span>
</td>
<td class="text">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived from
Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.<span></span>
</td>
<td class="text">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived from
Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Profit tax percent</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign', window );">Remaining estimated percentage</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic', window );">Corporate income tax, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">General tax rate, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent', window );">Other rates provisions percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DeemedExcessTaxPayable', window );">Deemed excess tax payable (in Dollars)</a></td>
<td class="nump">$ 486,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Aggregate annual income percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward (in Dollars)</a></td>
<td class="nump">$ 972,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_PercentageOfAllowanceOnDeferredTaxAssets', window );">Percentage of allowance on deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Provision for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Progressive rates percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AnnualTurnover', window );">Annual turnover ranges (in Riels) | &#6107;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#6107; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Provision for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Progressive rates percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AnnualTurnover', window );">Annual turnover ranges (in Riels) | &#6107;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#6107; 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HK [Member] | HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Provision for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Estimated assessable profits (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KH', window );">Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Provision for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic', window );">Corporate income tax, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AnnualTurnover">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The annual turn over of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AnnualTurnover</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DeemedExcessTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed excess tax payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DeemedExcessTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of provision on double tax treaty (DTT).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_PercentageOfAllowanceOnDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of allowance on deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_PercentageOfAllowanceOnDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ProfitTaxDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit tax Description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ProfitTaxDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in domestic income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in foreign income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=nivf_HKSARMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=nivf_HKSARMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes - Schedule of the Provisions for Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionsForIncomeTaxesLineItems', window );"><strong>Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax (income) expense</a></td>
<td class="num">$ (486,706)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">$ 208,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionKyrgyzstanMember', window );">Current tax provision Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionsForIncomeTaxesLineItems', window );"><strong>Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax (income) expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember', window );">Over provision of tax in prior year Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionsForIncomeTaxesLineItems', window );"><strong>Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax (income) expense</a></td>
<td class="num">(486,706)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionCambodiaMember', window );">Current tax provision Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionsForIncomeTaxesLineItems', window );"><strong>Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax (income) expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ProvisionsForIncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ProvisionsForIncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionKyrgyzstanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionKyrgyzstanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionCambodiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionCambodiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes - Schedule of Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract', window );"><strong>Schedule of Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) Income before taxes</a></td>
<td class="num">$ (960,807)<span></span>
</td>
<td class="nump">$ 108,418<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 343,988<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax credit (expense) at the effective tax rates</a></td>
<td class="num">(179,863)<span></span>
</td>
<td class="nump">10,732<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(124,591)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Tax effect on non-taxable income</a></td>
<td class="num">(81,323)<span></span>
</td>
<td class="num">(39,173)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Tax effect on non-deductible expenses</a></td>
<td class="nump">129,814<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">369,101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">131,991<span></span>
</td>
<td class="nump">28,441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Tax effect on utilization of tax losses</a></td>
<td class="num">(127,521)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(36,369)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Tax losses unable to be utilized</a></td>
<td class="nump">126,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear', window );">Over provision of tax in prior year</a></td>
<td class="num">(486,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax (income) expense</a></td>
<td class="num">$ (486,706)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 208,141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of over provision of tax in prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provision for Income Taxes - Schedule of Components of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 160,432<span></span>
</td>
<td class="nump">$ 28,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(160,432)<span></span>
</td>
<td class="num">(28,441)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues - Schedule of Business Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 5,433,375<span></span>
</td>
<td class="nump">$ 5,136,153<span></span>
</td>
<td class="nump">$ 5,944,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nivf_IVFTreatmentServiceMember', window );">IVF treatment service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">5,433,375<span></span>
</td>
<td class="nump">4,021,696<span></span>
</td>
<td class="nump">2,819,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nivf_SurrogacyAncillaryCaringAndOtherServicesMember', window );">Surrogacy, ancillary caring and other services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,114,457<span></span>
</td>
<td class="nump">$ 3,125,027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nivf_IVFTreatmentServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nivf_IVFTreatmentServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nivf_SurrogacyAncillaryCaringAndOtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nivf_SurrogacyAncillaryCaringAndOtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues - Schedule of Geographical Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 5,433,375<span></span>
</td>
<td class="nump">$ 5,136,153<span></span>
</td>
<td class="nump">$ 5,944,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">34,038<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KG', window );">Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2,656,596<span></span>
</td>
<td class="nump">3,123,593<span></span>
</td>
<td class="nump">5,060,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KH', window );">Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">601,526<span></span>
</td>
<td class="nump">621,619<span></span>
</td>
<td class="nump">377,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TH', window );">Thailand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,175,253<span></span>
</td>
<td class="nump">$ 1,356,903<span></span>
</td>
<td class="nump">$ 505,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues - Schedule of Revenue Information Based on the Locations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Revenue Information Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Long-lived assets, total</a></td>
<td class="nump">$ 371,666<span></span>
</td>
<td class="nump">$ 446,004<span></span>
</td>
<td class="nump">$ 506,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Revenue Information Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Long-lived assets, total</a></td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Revenue Information Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Long-lived assets, total</a></td>
<td class="nump">8,370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KG', window );">Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Revenue Information Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Long-lived assets, total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KH', window );">Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Revenue Information Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Long-lived assets, total</a></td>
<td class="nump">47,902<span></span>
</td>
<td class="nump">137,472<span></span>
</td>
<td class="nump">229,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TH', window );">Thailand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Revenue Information Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Long-lived assets, total</a></td>
<td class="nump">$ 312,313<span></span>
</td>
<td class="nump">$ 307,948<span></span>
</td>
<td class="nump">$ 254,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Risks [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for account receivables</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase (decrease) interest risk rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_InterestRateOtherVariablesPercentage', window );">Interest rate other variables, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPensionPlanObligations', window );">Increased (decreased) amount</a></td>
<td class="nump">$ 26,894<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nivf_ASPACIMember', window );">A SPAC I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Risks [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for account receivables</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Other receivables</a></td>
<td class="nump">$ 17,818<span></span>
</td>
<td class="nump">$ 17,818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_InterestRateOtherVariablesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate other variables, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_InterestRateOtherVariablesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPensionPlanObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for pension benefits. Includes, but is not limited to, defined benefit or defined contribution plans. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPensionPlanObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nivf_ASPACIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nivf_ASPACIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Related Party [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to shareholders</a></td>
<td class="nump">$ 92,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions - Schedule of Amount Due from and Due to Related Parties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember', window );">Mr. Siu Wing Fung, Alfred (&#8220;Mr. Siu&#8221;) and Ms. Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Shareholders and directors<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 354,285<span></span>
</td>
<td class="nump">$ 404,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MsFongHeiYueTinaMember', window );">Ms. Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Shareholders and directors (note 1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueToARelatedParty', window );">Due to a related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(497,200)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_HarcourtLimitedMember', window );">Harcourt Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">A related party (note&#160;2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueToARelatedParty', window );">Due to a related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(61,802)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_JAKAffiliatedHoldersMember', window );">JAK &amp; affiliated holders [Member] | Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5% or more shareholder<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueToARelatedParty', window );">Due to a related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,150,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Ms. Fong is the spouse of Mr.&#160;Siu. The due to shareholders balance
as of December 31, 2024 was $92,651 while the due from shareholders balance as of December 31, 2023 was $354,285.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueToARelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of due to a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueToARelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MsFongHeiYueTinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MsFongHeiYueTinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_HarcourtLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_HarcourtLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_JAKAffiliatedHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_JAKAffiliatedHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Balances and Transactions - Schedule of Balance Due from Shareholders (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfBalanceDueFromShareholdersAbstract', window );"><strong>Schedule of Balance Due from Shareholders [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueFromtoshareholdersRelatedParty', window );">Due from/ (to)shareholders/ related party</a></td>
<td class="num">$ (154,453)<span></span>
</td>
<td class="nump">$ 372,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less: allowance for expected credit loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(17,818)<span></span>
</td>
<td class="num">$ (17,059)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AccountsReceivableAfterAllowanceForCreditLoss', window );">Total shareholders amount</a></td>
<td class="num">$ (154,453)<span></span>
</td>
<td class="nump">$ 354,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AccountsReceivableAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of shareholders amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AccountsReceivableAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueFromtoshareholdersRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueFromtoshareholdersRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfBalanceDueFromShareholdersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfBalanceDueFromShareholdersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions - Schedule of Movement of Allowances for Expected Credit Loss (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrentAbstract', window );"><strong>Schedule of Movement of Allowances for Expected Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning of the year</a></td>
<td class="num">$ (17,818)<span></span>
</td>
<td class="num">$ (17,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Reversal of Provision / (Provision)</a></td>
<td class="nump">17,818<span></span>
</td>
<td class="num">(759)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (17,818)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions - Schedule of Consolidated Financial Statements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember', window );">Directors&#8217; remuneration to Mr. Siu Wing Fung, Alfred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_WaiverOfRelatedPartyBalance', window );">Transactions with related parties</a></td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMsFongHeiYueTinaMember', window );">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_WaiverOfRelatedPartyBalance', window );">Transactions with related parties</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember', window );">Waiver of related party balance of Mr. Siu Wing Fung, Alfred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_WaiverOfRelatedPartyBalance', window );">Transactions with related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(88,151)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_JAKOPPORTUNITIESVILLCMember', window );">Coupon interest payable to JAK Opportunities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_WaiverOfRelatedPartyBalance', window );">Transactions with related parties</a></td>
<td class="nump">308,751<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember', window );">Conversion of convertible note to shares to JAK Opportunities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_WaiverOfRelatedPartyBalance', window );">Transactions with related parties</a></td>
<td class="nump">$ 2,650,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_WaiverOfRelatedPartyBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Waiver of related party balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_WaiverOfRelatedPartyBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMsFongHeiYueTinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMsFongHeiYueTinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_JAKOPPORTUNITIESVILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_JAKOPPORTUNITIESVILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan to a SPAC I (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>LOAN TO A SPAC I [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalancePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Outstanding under the loan</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalancePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of investment owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalancePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of Subsidiary (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 18, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal Group, Including Discontinued Operation, Consideration</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair Value of Assets Acquired</a></td>
<td class="nump">486,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax', window );">Reversal of excess tax</a></td>
<td class="nump">486,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">Income tax provision</a></td>
<td class="nump">$ 486,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_FirstFertilityBishkekLLCFFBMember', window );">First Fertility Bishkek LLC (&#8220;FFB&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reversal on excess tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_FirstFertilityBishkekLLCFFBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_FirstFertilityBishkekLLCFFBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisition (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 17, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nivf_BiClinicLtdMember', window );">Bi Clinic Ltd (&#8220;Bi Clinic&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nivf_BiClinicLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nivf_BiClinicLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 10, 2025</div></th>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Feb. 11, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 24, 2024</div></th>
<th class="th"><div>Dec. 12, 2024</div></th>
<th class="th"><div>Dec. 10, 2024</div></th>
<th class="th"><div>Jun. 03, 2024</div></th>
<th class="th"><div>Apr. 17, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 15, 2025</div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,890,000<span></span>
</td>
<td class="nump">53,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Shareholder equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138,519<span></span>
</td>
<td class="nump">507,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Ordinary shares reverse stock (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DeemedValuePerShare', window );">Deemed value per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_BidPricePerShare', window );">Bid price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,866,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_WhiteLionMember', window );">White Lion [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,193,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nivf_MicroSortAcquisitionMember', window );">MicroSort Acquisition [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nivf_NewGenMember', window );">NewGen [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Business combination cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_GeneticsIVFInstituteIncMember', window );">Genetics &amp; IVF Institute, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember', window );">2025 Securities Purchase Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_SeniorConvertibleNoteMember', window );">Senior Convertible Note [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Bears an interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Promissory notes outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_CashConsideration', window );">Cash consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Valid period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Awarded shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,054,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_OutstandingPercentage', window );">Outstanding amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Ordinary shares reverse stock (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,594,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | White Lion [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | 2025 Securities Purchase Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="18"></td></tr>
<tr><td colspan="18"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares as presented have been adjusted retrospectively for a Reverse Share Split effected in February 2025 of 1 share for every 20 existing share issued</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re-presented as mentioned in Note 23</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">On January 10, 2023, the Company issued 1,365 ordinary
shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4,
2023, the Company issued additional 3,450 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional
paid-in capital by $2,054,556. During 2024, the service scope and duration were reduced and the service value was adjusted accordingly
pursuant to addendums to respective agreements</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_BidPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share of bid price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_BidPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_CashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_CashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DeemedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DeemedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_OutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_OutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_WhiteLionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_WhiteLionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nivf_MicroSortAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nivf_MicroSortAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nivf_NewGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nivf_NewGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_GeneticsIVFInstituteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_GeneticsIVFInstituteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_SeniorConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_SeniorConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>279</ContextCount>
  <ElementCount>387</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>114</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Shareholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Principal Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/OrganizationandPrincipalActivities</Role>
      <ShortName>Organization and Principal Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccountsReceivableNet</Role>
      <ShortName>Accounts Receivable, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accrued Liabilties and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables</Role>
      <ShortName>Accrued Liabilties and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Contract Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ContractLiabilities</Role>
      <ShortName>Contract Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants</Role>
      <ShortName>Convertible Notes, Promissory Notes, Derivative Liability and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Provision for Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ProvisionforIncomeTaxes</Role>
      <ShortName>Provision for Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Disaggregated Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DisaggregatedRevenues</Role>
      <ShortName>Disaggregated Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/Risks</Role>
      <ShortName>Risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Related Party Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions</Role>
      <ShortName>Related Party Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Loan to a SPAC I</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/LoantoaSPACI</Role>
      <ShortName>Loan to a SPAC I</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Commitments &amp; Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/CommitmentsContingencies</Role>
      <ShortName>Commitments &amp; Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Disposal of Subsidiary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DisposalofSubsidiary</Role>
      <ShortName>Disposal of Subsidiary</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Business Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/BusinessAcquisition</Role>
      <ShortName>Business Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Reclassification and Comparative Figures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ReclassificationandComparativeFigures</Role>
      <ShortName>Reclassification and Comparative Figures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Organization and Principal Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables</Role>
      <ShortName>Organization and Principal Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/OrganizationandPrincipalActivities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Accounts Receivable, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccountsReceivableNetTables</Role>
      <ShortName>Accounts Receivable, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccountsReceivableNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/Inventories</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Accrued Liabilties and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables</Role>
      <ShortName>Accrued Liabilties and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Contract Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ContractLiabilitiesTables</Role>
      <ShortName>Contract Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ContractLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables</Role>
      <ShortName>Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/Equity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Provision for Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</Role>
      <ShortName>Provision for Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Disaggregated Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DisaggregatedRevenuesTables</Role>
      <ShortName>Disaggregated Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DisaggregatedRevenues</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Related Party Balances and Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</Role>
      <ShortName>Related Party Balances and Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Organization and Principal Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails</Role>
      <ShortName>Organization and Principal Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Organization and Principal Activities - Schedule of Company???s Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable</Role>
      <ShortName>Organization and Principal Activities - Schedule of Company???s Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/GoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/GoingConcern</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable</Role>
      <ShortName>Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Accounts Receivable, Net - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable</Role>
      <ShortName>Accounts Receivable, Net - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Accounts Receivable, Net - Schedule of Movement Allowances for Expected Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable</Role>
      <ShortName>Accounts Receivable, Net - Schedule of Movement Allowances for Expected Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofInventoriesTable</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Movement of Allowances for Expected Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Movement of Allowances for Expected Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Property and Equipment, Net - Schedule of Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net - Schedule of Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Accrued Liabilties and Other Payables - Schedule of Accrued Liabilties and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable</Role>
      <ShortName>Accrued Liabilties and Other Payables - Schedule of Accrued Liabilties and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Contract Liabilities - Schedule of Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable</Role>
      <ShortName>Contract Liabilities - Schedule of Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails</Role>
      <ShortName>Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable</Role>
      <ShortName>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Outstanding Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable</Role>
      <ShortName>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Outstanding Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Transaction Costs on Issuance of Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable</Role>
      <ShortName>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Transaction Costs on Issuance of Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Contractual Obligations (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofContractualObligationsTable</Role>
      <ShortName>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Contractual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable</Role>
      <ShortName>Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LeasesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Leases - Schedule of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable</Role>
      <ShortName>Leases - Schedule of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Leases - Schedule of Future Minimum Payments under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable</Role>
      <ShortName>Leases - Schedule of Future Minimum Payments under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/EquityTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Equity - Schedule of Additional Paid-in Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable</Role>
      <ShortName>Equity - Schedule of Additional Paid-in Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails</Role>
      <ShortName>Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Provision for Income Taxes - Schedule of the Provisions for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable</Role>
      <ShortName>Provision for Income Taxes - Schedule of the Provisions for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Provision for Income Taxes - Schedule of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable</Role>
      <ShortName>Provision for Income Taxes - Schedule of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Provision for Income Taxes - Schedule of Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable</Role>
      <ShortName>Provision for Income Taxes - Schedule of Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Disaggregated Revenues - Schedule of Business Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable</Role>
      <ShortName>Disaggregated Revenues - Schedule of Business Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Disaggregated Revenues - Schedule of Geographical Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable</Role>
      <ShortName>Disaggregated Revenues - Schedule of Geographical Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Disaggregated Revenues - Schedule of Revenue Information Based on the Locations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable</Role>
      <ShortName>Disaggregated Revenues - Schedule of Revenue Information Based on the Locations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/RisksDetails</Role>
      <ShortName>Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/Risks</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Related Party Balances and Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails</Role>
      <ShortName>Related Party Balances and Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Related Party Balances and Transactions - Schedule of Amount Due from and Due to Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable</Role>
      <ShortName>Related Party Balances and Transactions - Schedule of Amount Due from and Due to Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Related Party Balances and Transactions - Schedule of Balance Due from Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable</Role>
      <ShortName>Related Party Balances and Transactions - Schedule of Balance Due from Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Related Party Balances and Transactions - Schedule of Movement of Allowances for Expected Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0</Role>
      <ShortName>Related Party Balances and Transactions - Schedule of Movement of Allowances for Expected Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Related Party Balances and Transactions - Schedule of Consolidated Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable</Role>
      <ShortName>Related Party Balances and Transactions - Schedule of Consolidated Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Loan to a SPAC I (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/LoantoaSPACIDetails</Role>
      <ShortName>Loan to a SPAC I (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LoantoaSPACI</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Disposal of Subsidiary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DisposalofSubsidiaryDetails</Role>
      <ShortName>Disposal of Subsidiary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DisposalofSubsidiary</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Business Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/BusinessAcquisitionDetails</Role>
      <ShortName>Business Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/BusinessAcquisition</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ea0239801-f1a1_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996060 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SubsequentEvents</ParentRole>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="F-1/A" isDefinitelyFs="true" isUsgaap="true" original="ea0239801-f1a1_newgen.htm">ea0239801-f1a1_newgen.htm</File>
    <File>nivf-20241231.xsd</File>
    <File>nivf-20241231_cal.xml</File>
    <File>nivf-20241231_def.xml</File>
    <File>nivf-20241231_lab.xml</File>
    <File>nivf-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="897">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>212
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0239801-f1a1_newgen.htm": {
   "nsprefix": "nivf",
   "nsuri": "http://www.newgenivf.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ea0239801-f1a1_newgen.htm"
     ]
    },
    "schema": {
     "local": [
      "nivf-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nivf-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nivf-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nivf-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nivf-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 323,
   "keyCustom": 64,
   "axisStandard": 33,
   "axisCustom": 0,
   "memberStandard": 34,
   "memberCustom": 75,
   "hidden": {
    "total": 174,
    "http://fasb.org/us-gaap/2024": 131,
    "http://www.newgenivf.com/20241231": 40,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 279,
   "entityCount": 1,
   "segmentCount": 114,
   "elementCount": 695,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 897,
    "http://xbrl.sec.gov/dei/2024": 24,
    "http://fasb.org/srt/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://www.newgenivf.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.newgenivf.com/role/ShareholdersEquityType2or3",
     "longName": "004 - Statement - Consolidated Statements of Changes in Shareholders\u2019 Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Shareholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c10",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c10",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.newgenivf.com/role/ConsolidatedCashFlow",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.newgenivf.com/role/OrganizationandPrincipalActivities",
     "longName": "006 - Disclosure - Organization and Principal Activities",
     "shortName": "Organization and Principal Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "007 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.newgenivf.com/role/GoingConcern",
     "longName": "008 - Disclosure - Going Concern",
     "shortName": "Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.newgenivf.com/role/AccountsReceivableNet",
     "longName": "009 - Disclosure - Accounts Receivable, Net",
     "shortName": "Accounts Receivable, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.newgenivf.com/role/Inventories",
     "longName": "010 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet",
     "longName": "011 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.newgenivf.com/role/PropertyandEquipmentNet",
     "longName": "012 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables",
     "longName": "013 - Disclosure - Accrued Liabilties and Other Payables",
     "shortName": "Accrued Liabilties and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.newgenivf.com/role/ContractLiabilities",
     "longName": "014 - Disclosure - Contract Liabilities",
     "shortName": "Contract Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants",
     "longName": "015 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants",
     "shortName": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.newgenivf.com/role/Leases",
     "longName": "016 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.newgenivf.com/role/Equity",
     "longName": "017 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.newgenivf.com/role/EmployeeBenefitPlans",
     "longName": "018 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.newgenivf.com/role/ProvisionforIncomeTaxes",
     "longName": "019 - Disclosure - Provision for Income Taxes",
     "shortName": "Provision for Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.newgenivf.com/role/DisaggregatedRevenues",
     "longName": "020 - Disclosure - Disaggregated Revenues",
     "shortName": "Disaggregated Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.newgenivf.com/role/Risks",
     "longName": "021 - Disclosure - Risks",
     "shortName": "Risks",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions",
     "longName": "022 - Disclosure - Related Party Balances and Transactions",
     "shortName": "Related Party Balances and Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.newgenivf.com/role/LoantoaSPACI",
     "longName": "023 - Disclosure - Loan to a SPAC I",
     "shortName": "Loan to a SPAC I",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.newgenivf.com/role/CommitmentsContingencies",
     "longName": "024 - Disclosure - Commitments & Contingencies",
     "shortName": "Commitments & Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.newgenivf.com/role/DisposalofSubsidiary",
     "longName": "025 - Disclosure - Disposal of Subsidiary",
     "shortName": "Disposal of Subsidiary",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nivf:DisposalOfSubsidiaryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nivf:DisposalOfSubsidiaryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.newgenivf.com/role/BusinessAcquisition",
     "longName": "026 - Disclosure - Business Acquisition",
     "shortName": "Business Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.newgenivf.com/role/SubsequentEvents",
     "longName": "027 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.newgenivf.com/role/ReclassificationandComparativeFigures",
     "longName": "028 - Disclosure - Reclassification and Comparative Figures",
     "shortName": "Reclassification and Comparative Figures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Reclassifications",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Reclassifications",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.newgenivf.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables",
     "longName": "996001 - Disclosure - Organization and Principal Activities (Tables)",
     "shortName": "Organization and Principal Activities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996002 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.newgenivf.com/role/AccountsReceivableNetTables",
     "longName": "996003 - Disclosure - Accounts Receivable, Net (Tables)",
     "shortName": "Accounts Receivable, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.newgenivf.com/role/InventoriesTables",
     "longName": "996004 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables",
     "longName": "996005 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.newgenivf.com/role/PropertyandEquipmentNetTables",
     "longName": "996006 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables",
     "longName": "996007 - Disclosure - Accrued Liabilties and Other Payables (Tables)",
     "shortName": "Accrued Liabilties and Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.newgenivf.com/role/ContractLiabilitiesTables",
     "longName": "996008 - Disclosure - Contract Liabilities (Tables)",
     "shortName": "Contract Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables",
     "longName": "996009 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Tables)",
     "shortName": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.newgenivf.com/role/LeasesTables",
     "longName": "996010 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.newgenivf.com/role/EquityTables",
     "longName": "996011 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables",
     "longName": "996012 - Disclosure - Provision for Income Taxes (Tables)",
     "shortName": "Provision for Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.newgenivf.com/role/DisaggregatedRevenuesTables",
     "longName": "996013 - Disclosure - Disaggregated Revenues (Tables)",
     "shortName": "Disaggregated Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables",
     "longName": "996014 - Disclosure - Related Party Balances and Transactions (Tables)",
     "shortName": "Related Party Balances and Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
     "longName": "996015 - Disclosure - Organization and Principal Activities (Details)",
     "shortName": "Organization and Principal Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c60",
      "name": "us-gaap:RepaymentsOfShortTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c60",
      "name": "us-gaap:RepaymentsOfShortTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
     "longName": "996016 - Disclosure - Organization and Principal Activities - Schedule of Company\u2019s Subsidiaries (Details)",
     "shortName": "Organization and Principal Activities - Schedule of Company\u2019s Subsidiaries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c88",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c88",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996017 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
     "longName": "996018 - Disclosure - Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment",
     "longName": "996019 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c121",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c121",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.newgenivf.com/role/GoingConcernDetails",
     "longName": "996020 - Disclosure - Going Concern (Details)",
     "shortName": "Going Concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LineOfCreditFacilityAverageOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable",
     "longName": "996021 - Disclosure - Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details)",
     "shortName": "Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
     "longName": "996022 - Disclosure - Accounts Receivable, Net - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss (Details)",
     "shortName": "Accounts Receivable, Net - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
     "longName": "996023 - Disclosure - Accounts Receivable, Net - Schedule of Movement Allowances for Expected Credit Loss (Details)",
     "shortName": "Accounts Receivable, Net - Schedule of Movement Allowances for Expected Credit Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c132",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c133",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.newgenivf.com/role/ScheduleofInventoriesTable",
     "longName": "996024 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails",
     "longName": "996025 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PrepaymentFeesOnAdvancesNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PrepaymentFeesOnAdvancesNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable",
     "longName": "996026 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OtherReceivablesGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OtherReceivablesGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable",
     "longName": "996027 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Movement of Allowances for Expected Credit Loss (Details)",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Movement of Allowances for Expected Credit Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "nivf:AllowancesForExpectedCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c30",
      "name": "nivf:AllowancesForExpectedCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.newgenivf.com/role/PropertyandEquipmentNetDetails",
     "longName": "996028 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
     "longName": "996029 - Disclosure - Property and Equipment, Net - Schedule of Plant and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable",
     "longName": "996030 - Disclosure - Accrued Liabilties and Other Payables - Schedule of Accrued Liabilties and Other Payables (Details)",
     "shortName": "Accrued Liabilties and Other Payables - Schedule of Accrued Liabilties and Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable",
     "longName": "996031 - Disclosure - Contract Liabilities - Schedule of Contract Liabilities (Details)",
     "shortName": "Contract Liabilities - Schedule of Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c30",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
     "longName": "996032 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Details)",
     "shortName": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable",
     "longName": "996033 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details)",
     "shortName": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c159",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c159",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable",
     "longName": "996034 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Outstanding Convertible Notes (Details)",
     "shortName": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Outstanding Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c169",
      "name": "us-gaap:LongTermNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c169",
      "name": "us-gaap:LongTermNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable",
     "longName": "996035 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Transaction Costs on Issuance of Notes (Details)",
     "shortName": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Transaction Costs on Issuance of Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestCostsCapitalized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestCostsCapitalized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable",
     "longName": "996036 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Contractual Obligations (Details)",
     "shortName": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Contractual Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable",
     "longName": "996037 - Disclosure - Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Promissory Notes (Details)",
     "shortName": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Promissory Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c172",
      "name": "us-gaap:NotesIssued1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfPromissoryNotesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c172",
      "name": "us-gaap:NotesIssued1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfPromissoryNotesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.newgenivf.com/role/LeasesDetails",
     "longName": "996038 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "nivf:IndicativeRateOfBorrowingCost",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable",
     "longName": "996039 - Disclosure - Leases - Schedule of Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable",
     "longName": "996040 - Disclosure - Leases - Schedule of Future Minimum Payments under Operating Leases (Details)",
     "shortName": "Leases - Schedule of Future Minimum Payments under Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.newgenivf.com/role/EquityDetails",
     "longName": "996041 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
     "longName": "996042 - Disclosure - Equity - Schedule of Additional Paid-in Capital (Details)",
     "shortName": "Equity - Schedule of Additional Paid-in Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AdditionalPaidInCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c30",
      "name": "us-gaap:AdditionalPaidInCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
     "longName": "996043 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ManagementAndServiceFeesRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c192",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
     "longName": "996044 - Disclosure - Provision for Income Taxes (Details)",
     "shortName": "Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nivf:ProfitTaxDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nivf:DeemedExcessTaxPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
     "longName": "996045 - Disclosure - Provision for Income Taxes - Schedule of the Provisions for Income Taxes (Details)",
     "shortName": "Provision for Income Taxes - Schedule of the Provisions for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c208",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable",
     "longName": "996046 - Disclosure - Provision for Income Taxes - Schedule of Income Taxes (Details)",
     "shortName": "Provision for Income Taxes - Schedule of Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable",
     "longName": "996047 - Disclosure - Provision for Income Taxes - Schedule of Components of Deferred Tax Assets (Details)",
     "shortName": "Provision for Income Taxes - Schedule of Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
     "longName": "996048 - Disclosure - Disaggregated Revenues - Schedule of Business Operations (Details)",
     "shortName": "Disaggregated Revenues - Schedule of Business Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c212",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
     "longName": "996049 - Disclosure - Disaggregated Revenues - Schedule of Geographical Information (Details)",
     "shortName": "Disaggregated Revenues - Schedule of Geographical Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c218",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable",
     "longName": "996050 - Disclosure - Disaggregated Revenues - Schedule of Revenue Information Based on the Locations (Details)",
     "shortName": "Disaggregated Revenues - Schedule of Revenue Information Based on the Locations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.newgenivf.com/role/RisksDetails",
     "longName": "996051 - Disclosure - Risks (Details)",
     "shortName": "Risks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtInstrumentInterestRateIncreaseDecrease",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails",
     "longName": "996052 - Disclosure - Related Party Balances and Transactions (Details)",
     "shortName": "Related Party Balances and Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c232",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c232",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
     "longName": "996053 - Disclosure - Related Party Balances and Transactions - Schedule of Amount Due from and Due to Related Parties (Details)",
     "shortName": "Related Party Balances and Transactions - Schedule of Amount Due from and Due to Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c234",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c234",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable",
     "longName": "996054 - Disclosure - Related Party Balances and Transactions - Schedule of Balance Due from Shareholders (Details)",
     "shortName": "Related Party Balances and Transactions - Schedule of Balance Due from Shareholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "nivf:DueFromtoshareholdersRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "nivf:DueFromtoshareholdersRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0",
     "longName": "996055 - Disclosure - Related Party Balances and Transactions - Schedule of Movement of Allowances for Expected Credit Loss (Details)",
     "shortName": "Related Party Balances and Transactions - Schedule of Movement of Allowances for Expected Credit Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable",
     "longName": "996056 - Disclosure - Related Party Balances and Transactions - Schedule of Consolidated Financial Statements (Details)",
     "shortName": "Related Party Balances and Transactions - Schedule of Consolidated Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c245",
      "name": "nivf:WaiverOfRelatedPartyBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c245",
      "name": "nivf:WaiverOfRelatedPartyBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.newgenivf.com/role/LoantoaSPACIDetails",
     "longName": "996057 - Disclosure - Loan to a SPAC I (Details)",
     "shortName": "Loan to a SPAC I (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c260",
      "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c260",
      "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails",
     "longName": "996058 - Disclosure - Disposal of Subsidiary (Details)",
     "shortName": "Disposal of Subsidiary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nivf:DisposalOfSubsidiaryTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nivf:DisposalOfSubsidiaryTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.newgenivf.com/role/BusinessAcquisitionDetails",
     "longName": "996059 - Disclosure - Business Acquisition (Details)",
     "shortName": "Business Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c262",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c262",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.newgenivf.com/role/SubsequentEventsDetails",
     "longName": "996060 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c265",
      "name": "us-gaap:StockholdersEquityOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0239801-f1a1_newgen.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "nivf_ASPACIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ASPACIMember",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A SPAC I [Member]",
        "label": "ASPACIMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification and Comparative Figures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndNontradeReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsAndNontradeReceivableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountsReceivableNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTS RECEIVABLE, NET",
        "label": "Accounts and Nontrade Receivable [Text Block]",
        "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r307"
     ]
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable , net",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Receivable, Net [Abstract]",
        "terseLabel": "Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]",
        "verboseLabel": "Schedule of Movement Allowances for Expected Credit Loss [Abstract]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r911"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r91"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED LIABILTIES AND OTHER PAYABLES",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued Liabilties and Other Payables",
        "terseLabel": "Accrued liabilities and other payables",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r836"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable [Member]",
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "nivf_AccountsReceivableAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "AccountsReceivableAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders amount",
        "documentation": "The amount of shareholders amount.",
        "label": "Accounts Receivable After Allowance For Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r304",
      "r792"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Member]",
        "verboseLabel": "Trade Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r772",
      "r856",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accounts receivable net",
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Movement of Allowances for Expected Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "AccountsReceivableNetScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "AccountsReceivableNetScheduleofMovementAllowancesforExpectedCreditLossDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net - Schedule of Movement Allowances for Expected Credit Loss (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Withholding tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r141"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilties and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedAmortizationDeferredFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedAmortizationDeferredFinanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable": {
       "parentTag": "us-gaap_DeferredFinanceCostsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Deferred debt issuance cost",
        "label": "Accumulated Amortization, Debt Issuance Costs",
        "documentation": "Amount of accumulated amortization of debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r985"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r208",
      "r618"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r95",
      "r217",
      "r612",
      "r643",
      "r644"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income/(loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16",
      "r21",
      "r513",
      "r516",
      "r556",
      "r639",
      "r640",
      "r883",
      "r884",
      "r885",
      "r897",
      "r898",
      "r899",
      "r901"
     ]
    },
    "nivf_AdditionalNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "AdditionalNotesMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Notes [Member]",
        "label": "Additional Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance beginning",
        "periodEndLabel": "Balance ending",
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r836",
      "r1034"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r897",
      "r898",
      "r899",
      "r901",
      "r977",
      "r1035"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital injection by directors",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of share based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r426"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AggregateAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "AggregateAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount",
        "documentation": "The amout of aggregate amount.",
        "label": "Aggregate Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable": {
       "parentTag": "nivf_AccountsReceivableAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable",
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Balance at beginning of the year",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedLabel": "Less: allowance for expected credit loss",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r305",
      "r310",
      "r311",
      "r313",
      "r1002"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: allowance for expected credit loss",
        "terseLabel": "Allowance for account receivables",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r305",
      "r310"
     ]
    },
    "nivf_AllowancesForExpectedCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "AllowancesForExpectedCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of the year",
        "periodEndLabel": "Ending balance",
        "documentation": "Represent the amount of allowances for expected credit loss.",
        "label": "Allowances For Expected Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "AllowancesForExpectedCreditLossReversalOfProvisionProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of provision (Provision)",
        "documentation": "Repressent the amount of reversal of provision (Provision).",
        "label": "Allowances For Expected Credit Loss Reversal Of Provision Provision"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AmortisationOfShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "AmortisationOfShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortisation of share based compensation expense",
        "documentation": "Amount of amortization expense attributable to share based compensation expense.",
        "label": "Amortisation Of Share Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: amortized during the year",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r370",
      "r889",
      "r984"
     ]
    },
    "nivf_AnnualTurnover": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "AnnualTurnover",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual turnover ranges (in Riels)",
        "documentation": "The annual turn over of the company.",
        "label": "Annual Turnover"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r973"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration amount",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r974",
      "r975",
      "r976"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r973"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r151",
      "r209",
      "r245",
      "r275",
      "r279",
      "r295",
      "r296",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r506",
      "r510",
      "r523",
      "r608",
      "r702",
      "r801",
      "r802",
      "r836",
      "r863",
      "r930",
      "r931",
      "r991"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r222",
      "r245",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r506",
      "r510",
      "r523",
      "r836",
      "r930",
      "r931",
      "r991"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r506",
      "r510",
      "r523",
      "r930",
      "r931",
      "r991"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455"
     ]
    },
    "nivf_BestLendingRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "BestLendingRateMember",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Best Lending Rate [Member]",
        "label": "Best Lending Rate Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_BiClinicLtdFFBiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "BiClinicLtdFFBiMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bi Clinic Ltd (\u201cFFBi\u201d) [Member]",
        "label": "Bi Clinic Ltd FFBi Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_BiClinicLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "BiClinicLtdMember",
     "presentation": [
      "http://www.newgenivf.com/role/BusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bi Clinic Ltd (\u201cBi Clinic\u201d) [Member]",
        "label": "Bi Clinic Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_BidPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "BidPricePerShare",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bid price (in Dollars per share)",
        "documentation": "Per share of bid price.",
        "label": "Bid Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building improvement [Member]",
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r500",
      "r820",
      "r821"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.newgenivf.com/role/BusinessAcquisitionDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r500",
      "r820",
      "r821"
     ]
    },
    "nivf_BusinessAcquisitionDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "BusinessAcquisitionDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/BusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/BusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/BusinessAcquisitionDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration amount",
        "verboseLabel": "Total consideration",
        "netLabel": "Business combination agreement",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r15"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/BusinessAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUSINESS ACQUISITION",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r501"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r866"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China [Member]",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CNY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "CNY",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RMB [Member]",
        "label": "China, Yuan Renminbi"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_COVIRIXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "COVIRIXMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVIRIX [Member]",
        "label": "COVIRIXMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r206",
      "r790"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r106",
      "r241"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r106"
     ]
    },
    "nivf_CashConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "CashConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration",
        "documentation": "Cash consideration.",
        "label": "Cash Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_CashInBank": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "CashInBank",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/GoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash in bank",
        "documentation": "The amount of cash in bank.",
        "label": "Cash In Bank"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r212",
      "r213",
      "r214",
      "r245",
      "r267",
      "r268",
      "r270",
      "r272",
      "r277",
      "r278",
      "r306",
      "r339",
      "r341",
      "r342",
      "r343",
      "r346",
      "r347",
      "r379",
      "r380",
      "r383",
      "r386",
      "r393",
      "r523",
      "r651",
      "r652",
      "r653",
      "r654",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r689",
      "r711",
      "r735",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r868",
      "r891",
      "r902"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r277",
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r391",
      "r393",
      "r651",
      "r652",
      "r653",
      "r654",
      "r811",
      "r868",
      "r891"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price per share (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant to purchase shares (in Shares)",
        "verboseLabel": "Convertible warrant shares (in Shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments &amp; Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/CommitmentsContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS &amp; CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r331",
      "r332",
      "r774",
      "r921",
      "r926"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r775"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Ordinary Shares [Member]",
        "verboseLabel": "Common Class A [Member]",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Ordinary Shares [Member]",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_CommonStockHeldBySubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockHeldBySubsidiary",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock selling value",
        "label": "Common Stock Held by Subsidiary",
        "documentation": "Value of entity shares held by subsidiary, which are purchased for the purpose of granting the shares to senior employees as part of an employee stock option plan approved by the Entity's Board of Directors. Presented as a reduction of shareholders' equity at their cost to the subsidiary."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary Shares [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860",
      "r897",
      "r898",
      "r901",
      "r977",
      "r1033",
      "r1035"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Ordinary shares with par value",
        "label": "Common Stock, No Par Value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares with par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "nivf_CommonStockPotentialValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "CommonStockPotentialValue",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock potential value",
        "documentation": "The amount of common stock potential value.",
        "label": "Common Stock Potential Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r689"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued",
        "verboseLabel": "Ordinary shares issued (in Shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Ordinary shares ,shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r83",
      "r689",
      "r708",
      "r1035",
      "r1036"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, no par value, 10,000,000 shares authorized and 1,138,519* and 507,469* shares issued and outstanding as of December 31, 2024 and 2023 respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r610",
      "r836"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFIT PLANS",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r224",
      "r226",
      "r232",
      "r604",
      "r625",
      "r626"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r58",
      "r59",
      "r301",
      "r773"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r58",
      "r59",
      "r301",
      "r646",
      "r773"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r58",
      "r59",
      "r301",
      "r773",
      "r872"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r159"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/Risks"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RISKS",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r58",
      "r59",
      "r301"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r58",
      "r59",
      "r301",
      "r773"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of consolidation and basis of preparation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r794"
     ]
    },
    "nivf_ConsultingServiceTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConsultingServiceTerm",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting service term",
        "documentation": "Consulting service term.",
        "label": "Consulting Service Term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ContractLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Liabilities",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of year",
        "periodEndLabel": "Balance at end of year",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r416"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Contract Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r416"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized to revenue during the year",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerRefundLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Refund to customers",
        "label": "Contract with Customer, Refund Liability",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Contractual Obligation, to be Paid, Year Five",
        "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInFourthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Contractual Obligation, to be Paid, Year Four",
        "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Contractual Obligation, to be Paid, Year One",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Contractual Obligation, to be Paid, Year Two",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInThirdYear",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractualObligationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Contractual Obligation, to be Paid, Year Three",
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contractual Obligations",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r876",
      "r896"
     ]
    },
    "nivf_ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConversionOfConvertibleNoteToSharesToJAKOpportunitiesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible note to shares to JAK Opportunities [Member]",
        "label": "Conversion Of Convertible Note To Shares To JAKOpportunities Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted ordinary shares (in Shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "nivf_ConversionRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConversionRateMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Rate [Member]",
        "label": "Conversion Rate Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible promissory note",
        "label": "Convertible Debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r142",
      "r1000"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt [Member]",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r349",
      "r350",
      "r360",
      "r361",
      "r362",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Convertible Notes",
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertibleInstrumentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleInstrumentsPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Instruments",
        "documentation": "Disclosure of accounting policy for convertible instruments.",
        "label": "Convertible Instruments Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable": {
       "parentTag": "us-gaap_ConvertibleNotesPayable",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, non-current",
        "verboseLabel": "Non-current liability",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleNoteMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Note [Member]",
        "label": "Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleNotesAtAmortisedCostAreAsFollowsAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes, at amortised cost are as follows:",
        "label": "Convertible Notes At Amortised Cost Are As Follows Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes [Member]",
        "label": "Convertible Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Convertible notes",
        "verboseLabel": "Convertible notes outstanding",
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r142",
      "r1000"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable": {
       "parentTag": "us-gaap_ConvertibleNotesPayable",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes",
        "verboseLabel": "Current liability",
        "label": "Convertible Notes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Payable [Member]",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r140"
     ]
    },
    "nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofConvertibleNotesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Convertible Notes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Promissory Notes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsScheduleofPromissoryNotesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes, Promissory Notes, Derivative Liability and Warrants - Schedule of Promissory Notes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ConvertiblePromissoryNoteWasConvertedIntoOrdinarySharesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Promissory Note was Converted into Ordinary Shares [Member]",
        "label": "Convertible Promissory Note Was Converted Into Ordinary Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of revenues",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r245",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r523",
      "r801",
      "r930"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "documentation": "Information by currency."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "nivf_CurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "CurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_CurrentTaxProvisionCambodiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "CurrentTaxProvisionCambodiaMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax provision Cambodia [Member]",
        "label": "Current Tax Provision Cambodia Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_CurrentTaxProvisionKyrgyzstanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "CurrentTaxProvisionKyrgyzstanMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax provision Kyrgyzstan [Member]",
        "label": "Current Tax Provision Kyrgyzstan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r301"
     ]
    },
    "nivf_CustomerDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "CustomerDeposit",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer deposit",
        "documentation": "Customer deposit.",
        "label": "Customer Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_CustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "CustomerMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Member]",
        "label": "Customer Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Two [Member]",
        "label": "Customer Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted shares (in Shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE NOTES, PROMISSORY NOTES, DERIVATIVE LIABILITY AND WARRANTS",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r243",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r337",
      "r338",
      "r348",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r364",
      "r371",
      "r372",
      "r374",
      "r536"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable",
      "http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r72",
      "r73",
      "r140",
      "r142",
      "r249",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r833",
      "r892",
      "r922",
      "r923",
      "r924",
      "r983",
      "r985"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount of the convertible notes",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Price",
        "verboseLabel": "Conversion price (in Dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r351"
     ]
    },
    "nivf_DebtInstrumentCouponRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DebtInstrumentCouponRatePercentage",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coupon Rate",
        "documentation": "Percentage of debt instrument coupon rate.",
        "label": "Debt Instrument Coupon Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "verboseLabel": "Total principal balance",
        "netLabel": "Original principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r536",
      "r537",
      "r807",
      "r808",
      "r833"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bears an interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r376",
      "r536",
      "r537",
      "r833"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) interest risk rate",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentIssuanceDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuanceDate1",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance Date",
        "label": "Debt Instrument, Issuance Date",
        "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r932"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r833",
      "r892",
      "r983",
      "r985"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity Date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r806",
      "r978",
      "r979"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r249",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r833",
      "r892",
      "r922",
      "r923",
      "r924",
      "r983",
      "r985"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r44",
      "r45",
      "r63",
      "r125",
      "r126",
      "r249",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r833",
      "r892",
      "r983",
      "r985"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "nivf_DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DecreaseInSubscriptionReceivableDueToReductionOfWorkByProfessionals",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in subscription receivable due to reduction of work by professionals",
        "documentation": "Decrease in subscription receivable due to reduction of work by professionals.",
        "label": "Decrease In Subscription Receivable Due To Reduction Of Work By Professionals"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DeemedExcessTaxPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DeemedExcessTaxPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed excess tax payable (in Dollars)",
        "documentation": "The amount of deemed excess tax payable.",
        "label": "Deemed Excess Tax Payable"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DeemedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DeemedValuePerShare",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed value per share (in Dollars per share)",
        "documentation": "Deemed value per share.",
        "label": "Deemed Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred initial public offering \u201cIPO\u201d cost",
        "label": "Deferred Costs, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable": {
       "parentTag": "us-gaap_DeferredFinanceCostsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes at amortised cost",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r985"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable",
      "http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Convertible notes, net",
        "periodStartLabel": "Balance at beginning of the year",
        "periodEndLabel": "Ending balance",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r982",
      "r983",
      "r985"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry forward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average wages per month (in Dollars)",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution equivalent",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_Deposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "Deposit",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "documentation": "Deposits.",
        "label": "Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit with a digital asset trading platform",
        "label": "Deposit Assets",
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_DepositContractsLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositContractsLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash deposit (in Dollars)",
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_DepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/GoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash deposit",
        "label": "Deposits Assets",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit with a digital asset trading platform",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits, Prepayment, Other Receivables And Deferred IPO Cost, Net [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits, other receivables and deferred legal &amp; IPO cost, net",
        "documentation": "Disclosure of accounting policy for deposits, prepayment, other receivables and deferred ipo cost, net.",
        "label": "Deposits Prepayment Other Receivables And Deferred IPOCost Net Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement of Allowances for Expected Credit Loss [Abstract]",
        "label": "Deposits Prepayment Other Receivablesand Deferred IPOCost Net Scheduleof Movementof Allowancesfor Expected Credit Loss Details Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetScheduleofMovementofAllowancesforExpectedCreditLossDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - Schedule of Movement of Allowances for Expected Credit Loss (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expenses",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r38"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of plant and equipment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r275",
      "r284",
      "r296",
      "r801",
      "r802"
     ]
    },
    "us-gaap_DerivativeCapInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeCapInterestRate",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of beneficiary cap",
        "label": "Derivative, Cap Interest Rate",
        "documentation": "Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DirectorsRemunerationToMrSiuWingFungAlfredMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 remuneration to Mr. Siu Wing Fung, Alfred [Member]",
        "label": "Directors Remuneration To Mr Siu Wing Fung Alfred Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DirectorsRemunerationToMsFongHeiYueTinaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DirectorsRemunerationToMsFongHeiYueTinaMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 remuneration to Ms. Fong Hei Yue, Tina [Member]",
        "label": "Directors Remuneration To Ms Fong Hei Yue Tina Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DisaggregatedRevenuesScheduleofGeographicalInformationDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregated Revenues - Schedule of Geographical Information (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DisaggregatedRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue Information Based on the Locations",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r66",
      "r67",
      "r118"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationReversalOfExcessTax",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of excess tax",
        "documentation": "Amount of reversal on excess tax.",
        "label": "Disposal Group Including Discontinued Operation Reversal Of Excess Tax"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DisposalOfSubsidiaryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DisposalOfSubsidiaryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal of Subsidiary [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DisposalOfSubsidiaryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DisposalOfSubsidiaryTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiary"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DISPOSAL OF SUBSIDIARY",
        "label": "Disposal Of Subsidiary Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DisposalofSubsidiaryDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DisposalofSubsidiaryDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal of Subsidiary (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DoubleClickServicesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DoubleClickServicesLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DoubleClick Services Limited [Member]",
        "label": "Double Click Services Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueFromShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DueFromShareholders",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from shareholders",
        "documentation": "Due from shareholders.",
        "label": "Due From Shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueFromtoshareholdersRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DueFromtoshareholdersRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable": {
       "parentTag": "nivf_AccountsReceivableAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from/ (to)shareholders/ related party",
        "documentation": "The amount of related party.",
        "label": "Due Fromtoshareholders Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueToARelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "DueToARelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due to a related party",
        "documentation": "The amount of due to a related party.",
        "label": "Due To ARelated Party"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_EWIHLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "EWIHLMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EWIHL [Member]",
        "label": "EWIHLMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share \u2013 basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r265",
      "r267",
      "r270",
      "r271",
      "r272",
      "r274",
      "r498",
      "r503",
      "r520",
      "r521",
      "r605",
      "r627",
      "r796"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u2013 diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r267",
      "r270",
      "r271",
      "r272",
      "r274",
      "r498",
      "r503",
      "r520",
      "r521",
      "r605",
      "r627",
      "r796"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r273"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign currency translation on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Progressive rates percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r824"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate annual income percentage",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r963",
      "r964"
     ]
    },
    "nivf_EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationProvisionForDoubleTaxPercent",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other rates provisions percentage",
        "documentation": "Percentage of provision on double tax treaty (DTT).",
        "label": "Effective Income Tax Rate Reconciliation Provision For Double Tax Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General tax rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r824",
      "r894",
      "r963"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate income tax, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Domestic, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in domestic income tax contingency."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r963"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining estimated percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in foreign income tax contingency."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r963"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit tax percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r475",
      "r894",
      "r963"
     ]
    },
    "nivf_EmployeeBenefitPlansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "EmployeeBenefitPlansDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Three",
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Operations [Line Items]",
        "terseLabel": "Schedule of Geographical Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r200",
      "r228",
      "r229",
      "r230",
      "r250",
      "r251",
      "r252",
      "r254",
      "r259",
      "r261",
      "r263",
      "r276",
      "r308",
      "r309",
      "r325",
      "r395",
      "r488",
      "r489",
      "r495",
      "r496",
      "r497",
      "r499",
      "r502",
      "r503",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r538",
      "r541",
      "r556",
      "r624",
      "r639",
      "r640",
      "r641",
      "r662",
      "r735"
     ]
    },
    "nivf_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment amount",
        "label": "Equity Method Investment, Aggregate Cost",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "nivf_EquityScheduleofAdditionalPaidinCapitalDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "EquityScheduleofAdditionalPaidinCapitalDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Additional Paid-in Capital (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_FFPGSHKLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "FFPGSHKLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FFPGS (HK) Limited [Member]",
        "label": "FFPGSHKLimited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Assets Acquired",
        "label": "Fair Value of Assets Acquired",
        "documentation": "The fair value of assets acquired in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities, current",
        "verboseLabel": "Lease liabilities \u2013 current portion",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance lease",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r548"
     ]
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, Aging [Axis]",
        "documentation": "Information by period in which financial asset is past due or not past due."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r314",
      "r805"
     ]
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, Aging [Domain]",
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r314",
      "r805"
     ]
    },
    "nivf_FirstFertilityBishkekLLCFFBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "FirstFertilityBishkekLLCFFBMember",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Fertility Bishkek LLC (\u201cFFB\u201d) [Member]",
        "label": "First Fertility Bishkek LLCFFBMember"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_FirstFertilityPGSCenterLimitedFFCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "FirstFertilityPGSCenterLimitedFFCMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Fertility PGS Center Limited (\u201cFFC\u201d) (Note) [Member]",
        "label": "First Fertility PGSCenter Limited FFCMember"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_FirstFertilityPhnomPenhLimitedFFPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "FirstFertilityPhnomPenhLimitedFFPPMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Fertility Phnom Penh Limited (\u201cFFPP\u201d) [Member]",
        "label": "First Fertility Phnom Penh Limited FFPPMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rates, period-end",
        "label": "Foreign Currency Exchange Rate, Translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "nivf_FreeStandingInstrumentsWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "FreeStandingInstrumentsWarrantsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Free Standing Instruments Warrants [Member]",
        "label": "Free Standing Instruments Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures [Member]",
        "verboseLabel": "Furniture and Fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on lease modification",
        "label": "Gain (Loss) on Termination of Lease",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "nivf_GainOnPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "GainOnPromissoryNote",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on promissory note",
        "documentation": "Represent the amount of gain on promissory note.",
        "label": "Gain On Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r714"
     ]
    },
    "nivf_GeneticsIVFInstituteIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "GeneticsIVFInstituteIncMember",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genetics &amp; IVF Institute, Inc [Member]",
        "label": "Genetics IVFInstitute Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_GoingConcernAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "GoingConcernAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r150",
      "r245",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r523",
      "r798",
      "r801",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r930"
     ]
    },
    "country_HK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "HK",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HK SAR [Member]",
        "verboseLabel": "HK [Member]",
        "label": "HONG KONG"
       }
      }
     },
     "auth_ref": []
    },
    "currency_HKD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "HKD",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HK [Member]",
        "label": "Hong Kong, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_HKSARMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "HKSARMember",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HK SAR [Member]",
        "label": "HKSARMember"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_HarcourtLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "HarcourtLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Harcourt Limited [Member]",
        "label": "Harcourt Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_HealthCareSchemeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "HealthCareSchemeMember",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Scheme [Member]",
        "label": "Health Care Scheme Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_IVFTreatmentServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "IVFTreatmentServiceMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IVF treatment service [Member]",
        "label": "IVFTreatment Service Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r116",
      "r828"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r119"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) Income before taxes",
        "terseLabel": "(Loss) Income before taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r146",
      "r150",
      "r606",
      "r620",
      "r798",
      "r801",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal of Subsidiary [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r467",
      "r468",
      "r479",
      "r485",
      "r824",
      "r970"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r467",
      "r468",
      "r479",
      "r485",
      "r824",
      "r970"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r970"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r970"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROVISION FOR INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r462",
      "r467",
      "r476",
      "r477",
      "r478",
      "r480",
      "r484",
      "r490",
      "r492",
      "r493",
      "r494",
      "r656",
      "r824"
     ]
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow",
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Tax (income) expense",
        "terseLabel": "(Gain on) Provision for income taxes",
        "negatedLabel": "Tax income (expense)",
        "verboseLabel": "Total tax (income) expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r165",
      "r262",
      "r263",
      "r275",
      "r285",
      "r296",
      "r466",
      "r467",
      "r491",
      "r629",
      "r824"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r464",
      "r465",
      "r480",
      "r481",
      "r483",
      "r487",
      "r650"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r824",
      "r963"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit (expense) at the effective tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r467",
      "r470",
      "r824"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effect on non-deductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r475",
      "r963"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effect on non-taxable income",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r963",
      "r965"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses unable to be utilized",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r963",
      "r964"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effect on utilization of tax losses",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r963",
      "r964"
     ]
    },
    "nivf_IncomeTaxReconciliationOverProvisionOfTaxInPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "IncomeTaxReconciliationOverProvisionOfTaxInPriorYear",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over provision of tax in prior year",
        "documentation": "The amount of over provision of tax in prior year.",
        "label": "Income Tax Reconciliation Over Provision Of Tax In Prior Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated assessable profits (in Dollars)",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r475",
      "r963"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxSettlementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes paid",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r108",
      "r890",
      "r968",
      "r969"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax paid",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r888"
     ]
    },
    "us-gaap_IncreaseDecreaseInFinanceReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInFinanceReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance lease liabilities",
        "label": "Increase (Decrease) in Finance Receivables",
        "documentation": "The increase (decrease) during the reporting period in outstanding loans including accrued interest."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r888"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other payables",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposit and other receivables, net",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInPensionPlanObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPensionPlanObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increased (decreased) amount",
        "label": "Increase (Decrease) in Obligation, Pension Benefits",
        "documentation": "Amount of increase (decrease) in obligation for pension benefits. Includes, but is not limited to, defined benefit or defined contribution plans. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "nivf_IndependentDirectorFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "IndependentDirectorFeePayable",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Independent director fee payable",
        "documentation": "Independent director fee payable.",
        "label": "Independent Director Fee Payable"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_IndicativeRateOfBorrowingCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "IndicativeRateOfBorrowingCost",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indicative rate of borrowing cost",
        "documentation": "Indicative rate of borrowing cost.",
        "label": "Indicative Rate Of Borrowing Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntercompanyForeignCurrencyBalanceByDescriptionAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intra-Entity Foreign Currency Balance by Description [Axis]",
        "documentation": "Information by foreign entity for which intra-entity foreign currency transaction that is considered to be long-term investment with settlement not planned or anticipated in foreseeable future, exists."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_IntercompanyForeignCurrencyBalanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntercompanyForeignCurrencyBalanceLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofTransactionCostsonIssuanceofNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add: capitalized during the year",
        "label": "Interest Costs Capitalized",
        "documentation": "Amount of interest capitalized during the period."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r279",
      "r283",
      "r286",
      "r296",
      "r534",
      "r801",
      "r802"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r368",
      "r377",
      "r809",
      "r810"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r238",
      "r239"
     ]
    },
    "nivf_InterestRateOtherVariablesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "InterestRateOtherVariablesPercentage",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate other variables, percentage",
        "documentation": "Interest rate other variables, percentage.",
        "label": "Interest Rate Other Variables Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORIES",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicines, consumables and reagents for clinical and laboratory analyses",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventories",
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r791",
      "r836"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r205",
      "r219",
      "r315",
      "r316",
      "r317",
      "r572",
      "r795"
     ]
    },
    "us-gaap_InvestmentCompanyCommittedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentCompanyCommittedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investors amount",
        "label": "Investment Company, Committed Capital",
        "documentation": "Amount of funds committed to investment company from investors."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r282",
      "r296",
      "r801",
      "r886"
     ]
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInvestmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Investment Income, Investment Expense",
        "documentation": "Amount of expenses related to the generation of investment income."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r861",
      "r1003"
     ]
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Investment Interest Rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r746",
      "r749",
      "r750",
      "r752",
      "r753",
      "r757",
      "r758",
      "r855",
      "r912",
      "r913"
     ]
    },
    "us-gaap_InvestmentOwnedBalancePrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalancePrincipalAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/LoantoaSPACIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount",
        "label": "Investment Owned, Balance, Principal Amount",
        "documentation": "Amount of principal of investment owned."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r679",
      "r747",
      "r755",
      "r759",
      "r855"
     ]
    },
    "nivf_JAKAffiliatedHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "JAKAffiliatedHoldersMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JAK &amp; affiliated holders [Member]",
        "label": "JAKAffiliated Holders Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_JAKAffiliatedHoldersOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "JAKAffiliatedHoldersOneMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JAK &amp; affiliated holders One [Member]",
        "label": "JAKAffiliated Holders One Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_JAKAffiliatedHoldersThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "JAKAffiliatedHoldersThreeMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JAK &amp; affiliated holders Three [Member]",
        "label": "JAKAffiliated Holders Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_JAKAffiliatedHoldersTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "JAKAffiliatedHoldersTwoMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JAK &amp; affiliated holders Two [Member]",
        "label": "JAKAffiliated Holders Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_JAKOPPORTUNITIESVILLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "JAKOPPORTUNITIESVILLCMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coupon interest payable to JAK Opportunities [Member]",
        "label": "JAKOPPORTUNITIESVILLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_JAKOpportunitiesVILLCJAKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "JAKOpportunitiesVILLCJAKMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JAK Opportunities VI LLC (\u201cJAK\u201d) [Member]",
        "label": "JAKOpportunities VILLCJAKMember"
       }
      }
     },
     "auth_ref": []
    },
    "country_KG": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "KG",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kyrgyzstan [Member]",
        "label": "KYRGYZSTAN"
       }
      }
     },
     "auth_ref": []
    },
    "country_KH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "KH",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cambodia [Member]",
        "label": "CAMBODIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Liabilities",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r553"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and professional fee",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Payments under Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not later than 1 year",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Between 1 to 2 years",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r72",
      "r73",
      "r74",
      "r78",
      "r79",
      "r80",
      "r81",
      "r245",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r507",
      "r510",
      "r511",
      "r523",
      "r688",
      "r797",
      "r863",
      "r930",
      "r991",
      "r992"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r144",
      "r615",
      "r836",
      "r893",
      "r914",
      "r980"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r204",
      "r245",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r507",
      "r510",
      "r511",
      "r523",
      "r836",
      "r930",
      "r991",
      "r992"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r78",
      "r79",
      "r80",
      "r81",
      "r245",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r507",
      "r510",
      "r511",
      "r523",
      "r930",
      "r991",
      "r992"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r142",
      "r1000"
     ]
    },
    "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAverageOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/GoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remains outstanding balance",
        "label": "Line of Credit Facility, Average Outstanding Amount",
        "documentation": "Average amount borrowed under the credit facility during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/GoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility",
        "label": "Line of Credit Facility, Periodic Payment",
        "documentation": "Amount of the required periodic payments of both interest and principal."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r77"
     ]
    },
    "nivf_LoanToASPAC": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "LoanToASPAC",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan to A SPAC I",
        "documentation": "Represents amount of loans to ASPAC.",
        "label": "Loan To ASPAC"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate loans principal amount",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r142",
      "r361",
      "r375",
      "r807",
      "r808",
      "r833",
      "r1000"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Amount",
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r922",
      "r923",
      "r924"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r41",
      "r922",
      "r923",
      "r924"
     ]
    },
    "nivf_MAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MAMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "M&amp;A [Member]",
        "label": "MAMember"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r815",
      "r846",
      "r850",
      "r935",
      "r1004",
      "r1005",
      "r1006",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_ManagementAndServiceFeesRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManagementAndServiceFeesRate",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheme calculated rate",
        "label": "Management and Service Fees, Rate",
        "documentation": "Rate for management and service fees under arrangement to manage operations, including, but not limited to, investment."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "nivf_MaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MaturityTerm",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity, term",
        "documentation": "Duration of maturity, term.",
        "label": "Maturity Term"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails",
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r172",
      "r174",
      "r175",
      "r177",
      "r198",
      "r199",
      "r333",
      "r334",
      "r335",
      "r336",
      "r423",
      "r460",
      "r522",
      "r570",
      "r637",
      "r638",
      "r645",
      "r680",
      "r681",
      "r745",
      "r749",
      "r753",
      "r754",
      "r757",
      "r785",
      "r786",
      "r804",
      "r811",
      "r822",
      "r829",
      "r830",
      "r831",
      "r832",
      "r847",
      "r932",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ]
    },
    "nivf_MedHoldingsLimitedMedHoldingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MedHoldingsLimitedMedHoldingsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Med Holdings Limited (\u201cMed Holdings\u201d) (Note) [Member]",
        "label": "Med Holdings Limited Med Holdings Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MedicalInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MedicalInstrumentsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical instruments [Member]",
        "verboseLabel": "Medical Instruments [Member]",
        "label": "Medical Instruments Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MergerActivityDrawn": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MergerActivityDrawn",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger activity drawn",
        "documentation": "The amount of merger activity drawn.",
        "label": "Merger Activity Drawn"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MicroSortAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MicroSortAcquisitionMember",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MicroSort Acquisition [Member]",
        "label": "Micro Sort Acquisition Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails",
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r172",
      "r174",
      "r175",
      "r177",
      "r198",
      "r199",
      "r333",
      "r334",
      "r335",
      "r336",
      "r423",
      "r460",
      "r522",
      "r570",
      "r637",
      "r638",
      "r645",
      "r680",
      "r681",
      "r745",
      "r749",
      "r753",
      "r754",
      "r757",
      "r785",
      "r786",
      "r804",
      "r811",
      "r822",
      "r829",
      "r830",
      "r831",
      "r847",
      "r932",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r143",
      "r245",
      "r306",
      "r339",
      "r341",
      "r342",
      "r343",
      "r346",
      "r347",
      "r523",
      "r614",
      "r691"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of equity interest",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment percentage",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MotorVehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MotorVehiclesMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor Vehicles [Member]",
        "label": "Motor Vehicles Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MovementOfAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MovementOfAllowancesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement of Allowances [Member]",
        "label": "Movement Of Allowances Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MrSiuWingFungAlfredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MrSiuWingFungAlfredMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Siu Wing Fung, Alfred (\u201cMr. Siu\u201d) and Ms. Fong Hei Yue, Tina (\u201cMs. Fong\u201d) [Member]",
        "label": "Mr Siu Wing Fung Alfred Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MsFongHeiYueTinaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "MsFongHeiYueTinaMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ms. Fong Hei Yue, Tina (\u201cMs. Fong\u201d) [Member]",
        "label": "Ms Fong Hei Yue Tina Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r815",
      "r846",
      "r850",
      "r935",
      "r1004",
      "r1005",
      "r1006",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activity",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITY",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r109"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income attributable to the shareholders of the Company",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r109",
      "r147",
      "r202",
      "r223",
      "r225",
      "r230",
      "r245",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r262",
      "r263",
      "r269",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r498",
      "r503",
      "r521",
      "r523",
      "r623",
      "r710",
      "r733",
      "r734",
      "r861",
      "r930"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: net income (loss) attributable to non-controlling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r136",
      "r223",
      "r225",
      "r259",
      "r262",
      "r263",
      "r622",
      "r885"
     ]
    },
    "nivf_NetTangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "NetTangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net tangible assets",
        "documentation": "Amount of net tangible assets.",
        "label": "Net Tangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently issued accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_NewGenIvfLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "NewGenIvfLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NewGenIvf Limited [Member]",
        "label": "New Gen Ivf Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_NewGenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "NewGenMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NewGen [Member]",
        "label": "New Gen Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_NewGenivfLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "NewGenivfLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NewGenivf Limited [Member]",
        "label": "New Genivf Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_NonCashDiscountOnConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "NonCashDiscountOnConvertibleNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non cash discount on convertible notes",
        "documentation": "The amount of non cash discount on convertible notes.",
        "label": "Non Cash Discount On Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_NonControllingInterestsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "NonControllingInterestsPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "documentation": "Disclosure of accounting policy for non-controlling interests.",
        "label": "Non Controlling Interests Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_NonCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "NonCurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current",
        "label": "Non Current Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r395",
      "r897",
      "r898",
      "r899",
      "r901",
      "r1035"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expenses), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued during the year",
        "label": "Notes Issued",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of the year",
        "periodEndLabel": "Ending balance",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "nivf_OSLGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "OSLGroupMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OSL Group [Member]",
        "label": "OSLGroup Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_OccupationalRiskSchemeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "OccupationalRiskSchemeMember",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Occupational Risk Scheme [Member]",
        "label": "Occupational Risk Scheme Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment [Member]",
        "verboseLabel": "Office Equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating (loss) income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r798",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Payments under Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Total operating lease liabilities, net of interest",
        "verboseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "verboseLabel": "Lease liabilities \u2013 current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Lease liabilities \u2013 non-current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, net",
        "verboseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate \u2013 operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r835"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average lease term \u2013 operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r835"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry forward (in Dollars)",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Principal Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND PRINCIPAL ACTIVITIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r134",
      "r647",
      "r648"
     ]
    },
    "nivf_OrganizationandPrincipalActivitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "OrganizationandPrincipalActivitiesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Principal Activities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAdditionalCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAdditionalCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in paid-in capital",
        "label": "Other Additional Capital",
        "documentation": "Amount of additional paid-in capital (APIC) classified as other."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r611"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: total comprehensive (loss) income attributable to non-controlling interests",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r16",
      "r135"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r624"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive (loss) income attributable to the shareholders of the Company",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r16",
      "r135"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND DEFERRED IPO COST, NET",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r712",
      "r760",
      "r761",
      "r762"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expenses), net",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "verboseLabel": "Due to shareholders",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r836"
     ]
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ContractLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTRACT LIABILITIES",
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r79",
      "r920"
     ]
    },
    "us-gaap_OtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory notes outstanding",
        "label": "Other Notes Payable",
        "documentation": "Amount of long-term notes payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r142",
      "r1000"
     ]
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note",
        "label": "Other Notes Payable, Current",
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r918"
     ]
    },
    "nivf_OtherPrepaidExpenseNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "OtherPrepaidExpenseNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment",
        "documentation": "Prepayment, non current.",
        "label": "Other Prepaid Expense Non Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Gross, Current",
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from shareholders",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_OutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "OutstandingPercentage",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding amount",
        "documentation": "Percentage of outstanding amount.",
        "label": "Outstanding Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_OverProvisionOfTaxInPriorYearKyrgyzstanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "OverProvisionOfTaxInPriorYearKyrgyzstanMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over provision of tax in prior year Kyrgyzstan [Member]",
        "label": "Over Provision Of Tax In Prior Year Kyrgyzstan Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total attributable to the shareholders of the Company",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_PaymentofInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "PaymentofInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "documentation": "Cash outflow during the period as interest paid.",
        "label": "Paymentof Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "nivf_PensionSchemeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "PensionSchemeMember",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Scheme [Member]",
        "label": "Pension Scheme Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_PercentageOfAllowanceOnDeferredTaxAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "PercentageOfAllowanceOnDeferredTaxAssets",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of allowance on deferred tax assets",
        "documentation": "Percentage of allowance on deferred tax assets.",
        "label": "Percentage Of Allowance On Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_PercentageOfConversionExceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "PercentageOfConversionExceeds",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of conversion exceeds",
        "documentation": "Percentage of conversion exceeds.",
        "label": "Percentage Of Conversion Exceeds"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_PeriodAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "PeriodAverageMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period Average [Member]",
        "label": "Period Average Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_PeriodEndMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "PeriodEndMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End [Member]",
        "label": "Period End Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962"
     ]
    },
    "us-gaap_PostemploymentBenefitPlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PostemploymentBenefitPlansPolicy",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement benefits",
        "label": "Postemployment Benefit Plans, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends preference shares rate",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r746",
      "r750",
      "r752",
      "r758"
     ]
    },
    "us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PremiumsReceivableAllowanceForDoubtfulAccounts",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: allowance for expected credit loss",
        "label": "Premium Receivable, Allowance for Credit Loss",
        "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r910",
      "r916",
      "r917",
      "r1002"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deposits, prepayment, other receivables and deferred IPO cost, net",
        "terseLabel": "Deposits, other receivables and deferred legal &amp; IPO cost, net",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r318",
      "r319",
      "r793"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "totalLabel": "Prepayment, non-current",
        "label": "Prepaid Expense, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_PrepaymentFeesOnAdvancesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaymentFeesOnAdvancesNet",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment (in Dollars)",
        "label": "Prepayment Fees on Advances, Net",
        "documentation": "Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ProceedsFromAmountDueFromASPACI": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ProceedsFromAmountDueFromASPACI",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amount due from A SPAC I",
        "documentation": "The cash outflow paid to A SPAC I.",
        "label": "Proceeds From Amount Due From ASPACI"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares (net of reverse capitalization effect)",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings, net",
        "label": "Proceeds from Issuance of Other Long-Term Debt",
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/GoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Proceeds from Other Equity",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount with related parties",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r196",
      "r298",
      "r573",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r788",
      "r813",
      "r845",
      "r847",
      "r848",
      "r851",
      "r852",
      "r877",
      "r927",
      "r928",
      "r935",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_ProductWarrantyLiquidationProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyLiquidationProceedsPercentage",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise warrants",
        "label": "Product Warranty, Liquidation Proceeds, Percentage",
        "documentation": "Percentage of proceeds from liquidation of asset held as collateral or by third party expected to cover maximum potential future payment for product warranty. Includes, but is not limited to, separately price extended warranty, product maintenance contract, and warranty obligation incurred in connection with agreed upon specification."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r196",
      "r298",
      "r573",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r788",
      "r813",
      "r845",
      "r847",
      "r848",
      "r851",
      "r852",
      "r877",
      "r927",
      "r928",
      "r935",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "nivf_ProfessionalPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ProfessionalPartyMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional Party [Member]",
        "label": "Professional Party Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow",
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Net (loss) income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r223",
      "r225",
      "r236",
      "r245",
      "r253",
      "r259",
      "r262",
      "r263",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r498",
      "r503",
      "r505",
      "r508",
      "r509",
      "r521",
      "r523",
      "r606",
      "r621",
      "r661",
      "r710",
      "r733",
      "r734",
      "r826",
      "r827",
      "r862",
      "r885",
      "r930"
     ]
    },
    "nivf_ProfitTaxDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ProfitTaxDescription",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit tax rate description",
        "documentation": "Profit tax Description.",
        "label": "Profit Tax Description"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_PromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "PromissoryNotesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Notes [Member]",
        "label": "Promissory Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_PromissoryNotesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "PromissoryNotesPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Notes",
        "documentation": "Disclosure of accounting policy related to promissory notes.",
        "label": "Promissory Notes Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r553"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r160",
      "r163",
      "r164"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plant and equipment, Gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r207",
      "r619"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Plant and Equipment, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Plant and equipment, Net",
        "terseLabel": "Plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r553",
      "r607",
      "r619",
      "r836"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r160",
      "r163",
      "r617"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salvage value percentage",
        "label": "Property, Plant and Equipment, Salvage Value, Percentage",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Plant and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r553"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Useful Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of expected credit losses",
        "verboseLabel": "Reversal of Provision / (Provision)",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r312"
     ]
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision of expected credit loss allowance",
        "label": "Provision for Other Credit Losses",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r145"
     ]
    },
    "nivf_ProvisionforIncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ProvisionforIncomeTaxesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ProvisionforIncomeTaxesScheduleoftheProvisionsforIncomeTaxesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Income Taxes - Schedule of the Provisions for Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ProvisionsForIncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ProvisionsForIncomeTaxesLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails",
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r172",
      "r174",
      "r175",
      "r177",
      "r198",
      "r199",
      "r333",
      "r334",
      "r335",
      "r336",
      "r420",
      "r423",
      "r452",
      "r453",
      "r454",
      "r460",
      "r522",
      "r568",
      "r569",
      "r570",
      "r637",
      "r638",
      "r645",
      "r680",
      "r681",
      "r745",
      "r749",
      "r753",
      "r754",
      "r757",
      "r785",
      "r786",
      "r804",
      "r811",
      "r822",
      "r829",
      "r830",
      "r831",
      "r832",
      "r847",
      "r855",
      "r925",
      "r932",
      "r978",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails",
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r172",
      "r174",
      "r175",
      "r177",
      "r198",
      "r199",
      "r333",
      "r334",
      "r335",
      "r336",
      "r420",
      "r423",
      "r452",
      "r453",
      "r454",
      "r460",
      "r522",
      "r568",
      "r569",
      "r570",
      "r637",
      "r638",
      "r645",
      "r680",
      "r681",
      "r745",
      "r749",
      "r753",
      "r754",
      "r757",
      "r785",
      "r786",
      "r804",
      "r811",
      "r822",
      "r829",
      "r830",
      "r831",
      "r832",
      "r847",
      "r855",
      "r925",
      "r932",
      "r978",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998"
     ]
    },
    "nivf_ReceivableFromAgents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ReceivableFromAgents",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from agents",
        "documentation": "Receivable from agents.",
        "label": "Receivable From Agents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesFromStockholderMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription receivable",
        "label": "Receivables from Stockholder [Member]",
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Reclassifications": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Reclassifications",
     "presentation": [
      "http://www.newgenivf.com/role/ReclassificationandComparativeFigures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RECLASSIFICATION AND COMPARATIVE FIGURES",
        "label": "Reclassifications [Text Block]",
        "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "nivf_RelatedPartiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "RelatedPartiesPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "documentation": "Disclosure of accounting policy for policy related parties.",
        "label": "Related Parties Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_RelatedPartyBalancesandTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "RelatedPartyBalancesandTransactionsDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances and Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r421",
      "r560",
      "r561",
      "r609",
      "r616",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r707",
      "r709",
      "r744"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r560",
      "r561",
      "r562",
      "r563",
      "r609",
      "r616",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r707",
      "r709",
      "r744"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561",
      "r990"
     ]
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relationship",
        "label": "Related Party Transaction, Description of Transaction",
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r211",
      "r552",
      "r554",
      "r555",
      "r559"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/ScheduleofOutstandingConvertibleNotesTable",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Balances and Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r715",
      "r716",
      "r719"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances and Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r421",
      "r560",
      "r561",
      "r609",
      "r616",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r707",
      "r709",
      "r744",
      "r990"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY BALANCES AND TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r561",
      "r564",
      "r657",
      "r658",
      "r659",
      "r717",
      "r718",
      "r719",
      "r740",
      "r742"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipt of loan",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/GoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r127",
      "r613",
      "r642",
      "r644",
      "r655",
      "r690",
      "r836"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r250",
      "r251",
      "r252",
      "r254",
      "r259",
      "r261",
      "r263",
      "r308",
      "r309",
      "r325",
      "r488",
      "r489",
      "r495",
      "r496",
      "r497",
      "r499",
      "r502",
      "r503",
      "r512",
      "r514",
      "r515",
      "r517",
      "r519",
      "r538",
      "r541",
      "r639",
      "r641",
      "r662",
      "r1035"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregated Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived assets, total",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r275",
      "r280",
      "r281",
      "r294",
      "r296",
      "r298",
      "r299",
      "r301",
      "r414",
      "r415",
      "r573"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r787"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DisaggregatedRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DISAGGREGATED REVENUES",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r418"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DisaggregatedRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Geographical Information",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "nivf_RevenueRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "RevenueRate",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract revenue rate",
        "documentation": "The percentage of revenue rate.",
        "label": "Revenue Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "verboseLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r231",
      "r245",
      "r275",
      "r280",
      "r281",
      "r294",
      "r296",
      "r298",
      "r299",
      "r301",
      "r306",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r523",
      "r606",
      "r801",
      "r930"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue Information Based on the Locations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ReverseCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ReverseCapitalization",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Business Combination",
        "documentation": "The amount of reverse capitalization.",
        "label": "Reverse Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_RisksDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "RisksDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributable wage",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r264",
      "r424",
      "r869",
      "r900"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r91",
      "r304",
      "r911"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilties and Other Payables",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAccountsReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfAccountsReceivableNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accounts Receivable Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accounts Receivable Net Of Allowance For Expected Credit Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAdditionalPaidInCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfAdditionalPaidInCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Additional Paid In Capital Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfAdditionalPaidinCapitalTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Paid-in Capital",
        "documentation": "Tabular disclosure of schedule of additional paid-in capital.",
        "label": "Schedule Of Additional Paidin Capital Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Amount Due From And Due To Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfBalanceDueFromShareholdersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfBalanceDueFromShareholdersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Balance Due from Shareholders [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfBusinessOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfBusinessOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Business Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfCompanySSubsidiariesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfCompanySSubsidiariesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SSubsidiaries Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfComponentsOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Provisions for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r195",
      "r249",
      "r870"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Financial Statements",
        "label": "Condensed Financial Statements [Table Text Block]",
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r896"
     ]
    },
    "nivf_ScheduleOfConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Consolidated Financial Statements Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfContractualObligationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfContractualObligationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Contractual Obligations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfConvertibleNotesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfConvertibleNotesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Notes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Currency Exchange Rates That Were Used In Preparing The Accompanying Consolidated Financial Statements Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Convertible Notes",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r44",
      "r45",
      "r63",
      "r125",
      "r126",
      "r807",
      "r809",
      "r896",
      "r983"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r824",
      "r963"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]",
        "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DisaggregatedRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Operations",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "nivf_ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfThePlanAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives of the Plan and Equipment",
        "documentation": "Tabular disclosure of estimated useful lives of property plant and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of The Plan And Equipment Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements",
        "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]",
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "nivf_ScheduleOfGeographicalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfGeographicalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Geographical Information Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r92",
      "r93",
      "r94"
     ]
    },
    "nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfMovementAllowancesForExpectedCreditLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Movement Allowances For Expected Credit Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement Allowances for Expected Credit Loss",
        "documentation": "Tabular disclosure of movement allowances for expected credit loss.",
        "label": "Schedule Of Movement Allowances For Expected Credit Loss Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Movement Of Allowances For Expected Credit Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement of Allowances for Expected Credit Loss",
        "label": "Schedule Of Movement Of Allowances For Expected Credit Loss Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfOutstandingConvertibleNotesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfOutstandingConvertibleNotesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding Convertible Notes Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Plant And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfPromissoryNotesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfPromissoryNotesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Promissory Notes Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfPromissoryNotesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfPromissoryNotesTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Promissory Notes",
        "documentation": "Tabular disclosure of promissory notes.",
        "label": "Schedule Of Promissory Notes Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r553"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r715",
      "r716",
      "r719"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount Due from and Due to Related Parties",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfRevenueInformationBasedOnTheLocationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfRevenueInformationBasedOnTheLocationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenue Information Based On The Locations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Subsidiaries",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]",
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of LLC or LP [Table]",
        "documentation": "Disclosure of information about subsidiary of limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfTheBalanceDueFromShareholdersTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Due from Shareholders",
        "documentation": "Tabular disclosure of balance due from shareholders.",
        "label": "Schedule Of The Balance Due From Shareholders Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfTheProvisionsForIncomeTaxesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of The Provisions For Income Taxes Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfTransactionCostsOnIssuanceOfNotesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Transaction Costs on Issuance of Notes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ScheduleOfTransactionCostsOnIssuanceOfNotesTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transaction Costs on Issuance of Notes",
        "documentation": "Tabular disclosure of transaction costs on issuance of notes.",
        "label": "Schedule Of Transaction Costs On Issuance Of Notes Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SecondAdditionalMandatoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SecondAdditionalMandatoryNoteMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Additional Mandatory Note [Member]",
        "label": "Second Additional Mandatory Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SecondAdditionalNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SecondAdditionalNoteMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Additional Note [Member]",
        "label": "Second Additional Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r173",
      "r176",
      "r178",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r299",
      "r300",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r676",
      "r677",
      "r678",
      "r748",
      "r751",
      "r756",
      "r763",
      "r771",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r789",
      "r814",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r849",
      "r855",
      "r935",
      "r1004",
      "r1005",
      "r1006",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r297",
      "r299",
      "r799",
      "r800",
      "r803"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Selling and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SeniorConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SeniorConvertibleNoteMember",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Convertible Note [Member]",
        "label": "Senior Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SeniorConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SeniorConvertibleNotesMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Convertible Notes [Member]",
        "label": "Senior Convertible Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SeriesAWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SeriesAWarrantMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Warrant [Member]",
        "label": "Series AWarrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SeriesBWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SeriesBWarrantMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Warrant [Member]",
        "label": "Series BWarrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SeriesCWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SeriesCWarrantMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Warrant [Member]",
        "label": "Series CWarrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ServicesRanging": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ServicesRanging",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service ranging",
        "documentation": "Services ranging term.",
        "label": "Services Ranging"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 remuneration",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of employee's salary",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r430",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valid period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "nivf_ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "ShenzhenQianhaiFengtaiRenhuiHealthTechnologyCoLtdSZQianHaiMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shenzhen Qianhai Fengtai Renhui Health Technology Co., Ltd. (\u201cSZ QianHai\u201d) [Member]",
        "label": "Shenzhen Qianhai Fengtai Renhui Health Technology Co Ltd SZQian Hai Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LOAN TO A SPAC I [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/LoantoaSPACI"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOAN TO A SPAC I",
        "label": "Short-Term Debt [Text Block]",
        "documentation": "The entire disclosure for short-term debt."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r922",
      "r923",
      "r924"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r922",
      "r923",
      "r924"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r835"
     ]
    },
    "us-gaap_ShorttermDebtAverageOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShorttermDebtAverageOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/LoantoaSPACIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding under the loan",
        "label": "Short-Term Debt, Average Outstanding Amount",
        "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r720"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r242"
     ]
    },
    "us-gaap_SpecialAssessmentBond": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SpecialAssessmentBond",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Special concession amount (in Baht)",
        "label": "Special Assessment Bond",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a type of municipal bond typically used to fund a development project. Also called special assessment limited liability bond, special district bond, special purpose bond, special tax bond and community development obligation. Interest owed to lenders is paid by taxes levied on the community benefiting from the particular bond-funded project. For example, if a bond of this sort was issued to pay for sidewalks to be repaved in a certain community, an additional tax would be levied on homeowners in the area benefiting from this project."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r72",
      "r1000"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r212",
      "r213",
      "r214",
      "r245",
      "r267",
      "r268",
      "r270",
      "r272",
      "r277",
      "r278",
      "r306",
      "r339",
      "r341",
      "r342",
      "r343",
      "r346",
      "r347",
      "r379",
      "r380",
      "r383",
      "r386",
      "r393",
      "r523",
      "r651",
      "r652",
      "r653",
      "r654",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r689",
      "r711",
      "r735",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r868",
      "r891",
      "r902"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r83",
      "r88",
      "r89",
      "r200",
      "r228",
      "r229",
      "r230",
      "r250",
      "r251",
      "r252",
      "r254",
      "r259",
      "r261",
      "r263",
      "r276",
      "r308",
      "r309",
      "r325",
      "r395",
      "r488",
      "r489",
      "r495",
      "r496",
      "r497",
      "r499",
      "r502",
      "r503",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r538",
      "r541",
      "r556",
      "r624",
      "r639",
      "r640",
      "r641",
      "r662",
      "r735"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r173",
      "r176",
      "r178",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r299",
      "r300",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r676",
      "r677",
      "r678",
      "r748",
      "r751",
      "r756",
      "r763",
      "r771",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r789",
      "r814",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r849",
      "r855",
      "r935",
      "r1004",
      "r1005",
      "r1006",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r276",
      "r541",
      "r573",
      "r649",
      "r674",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r713",
      "r714",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r735",
      "r856"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r264",
      "r424",
      "r869",
      "r871",
      "r900"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r276",
      "r303",
      "r541",
      "r573",
      "r649",
      "r674",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r713",
      "r714",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r735",
      "r856"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares under ELOC/Note Conversion arrangement (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r44",
      "r83",
      "r88",
      "r127",
      "r365"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for services",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (in Shares)",
        "verboseLabel": "Issuance of shares",
        "netLabel": "Ordinary shares issued (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r82",
      "r83",
      "r127",
      "r651",
      "r735",
      "r765"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in Shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split shares (in Shares)",
        "verboseLabel": "Ordinary shares reverse stock (in Shares)",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares under ELOC/Note Conversion arrangement",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r83",
      "r88",
      "r89",
      "r127"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares through conversion of convertible notes",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r83",
      "r88",
      "r89",
      "r127"
     ]
    },
    "nivf_StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesThroughEquityLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares through Equity Line of Credit",
        "documentation": "Value of shares issued during the period to issuance of shares through equity line of credit.",
        "label": "Stock Issued During Period Value Issuance Of Shares Through Equity Line Of Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares",
        "verboseLabel": "Purchase price",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r82",
      "r83",
      "r127",
      "r662",
      "r735",
      "r765",
      "r862"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares as compensation for services",
        "verboseLabel": "Shares issued value",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_StockIssuedDuringPeriodValueReverseCaptialization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "StockIssuedDuringPeriodValueReverseCaptialization",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse capitalization",
        "documentation": "Represent the amount of reverse captialization.",
        "label": "Stock Issued During Period Value Reverse Captialization"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of subscription receivable",
        "documentation": "Value of shares issued during the period to settlement of subscription receivable.",
        "label": "Stock Issued During Period Value Settlement Of Subscription Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Equity attributable to the shareholders of the Company",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r88",
      "r89",
      "r114",
      "r691",
      "r708",
      "r736",
      "r737",
      "r836",
      "r863",
      "r893",
      "r914",
      "r980",
      "r1035"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r56",
      "r200",
      "r201",
      "r229",
      "r250",
      "r251",
      "r252",
      "r254",
      "r259",
      "r261",
      "r308",
      "r309",
      "r325",
      "r395",
      "r488",
      "r489",
      "r495",
      "r496",
      "r497",
      "r499",
      "r502",
      "r503",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r526",
      "r527",
      "r531",
      "r539",
      "r556",
      "r640",
      "r641",
      "r660",
      "r691",
      "r708",
      "r736",
      "r737",
      "r769",
      "r862",
      "r893",
      "r914",
      "r980",
      "r1035"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r244",
      "r378",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r395",
      "r518",
      "r738",
      "r741",
      "r770"
     ]
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Subscription receivable",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r82",
      "r83",
      "r88",
      "r743"
     ]
    },
    "us-gaap_StockholdersEquityOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityOther",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholder equity",
        "label": "Stockholders' Equity, Other",
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r739"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "nivf_SubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SubscriptionReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Subscription receivable",
        "documentation": "Amount of subscription receivable.",
        "label": "Subscription Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r567"
     ]
    },
    "nivf_SubsidiarieMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SubsidiarieMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [Member]",
        "label": "Subsidiarie Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal activity",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose",
        "documentation": "Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company's subsidiaries [Line Items]",
        "terseLabel": "Organization and Principal Activities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership %",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest",
        "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Background",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, State",
        "documentation": "State in which the subsidiary of the limited liability company or limited partnership was organized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOING CONCERN",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement of Allowances for Expected Credit Loss",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "nivf_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofthePlanandEquipmentDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlanandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of the Plan and Equipment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary cash flow information:",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Concentration Risk [Member]",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "nivf_SuppliersOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SuppliersOneMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suppliers One [Member]",
        "label": "Suppliers One Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SuppliersTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SuppliersTwoMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suppliers Two [Member]",
        "label": "Suppliers Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SurrogacyAncillaryCaringAndOtherServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "SurrogacyAncillaryCaringAndOtherServicesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surrogacy, ancillary caring and other services [Member]",
        "label": "Surrogacy Ancillary Caring And Other Services Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_TH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "TH",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thailand [Member]",
        "label": "THAILAND"
       }
      }
     },
     "auth_ref": []
    },
    "currency_THB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "THB",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "THB [Member]",
        "label": "Thailand, Baht"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/DisposalofSubsidiaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "label": "Taxes Payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r141",
      "r999"
     ]
    },
    "nivf_TerminationClauses": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "TerminationClauses",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination clauses",
        "documentation": "Termination clauses term.",
        "label": "Termination Clauses"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_TheConvertibleNotesAreRepayableAsFollowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "TheConvertibleNotesAreRepayableAsFollowsAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConvertibleNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The convertible notes are repayable as follows:",
        "label": "The Convertible Notes Are Repayable As Follows Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r989"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "TwoThousandTwentyFiveSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Securities Purchase Agreement [Member]",
        "label": "Two Thousand Twenty Five Securities Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "nivf_UnsecuredPromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "UnsecuredPromissoryNotesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsecured Promissory Notes [Member]",
        "label": "Unsecured Promissory Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r157",
      "r158",
      "r161",
      "r162"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor vehicle [Member]",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_WaiverOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "WaiverOfLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPromissoryNotesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waiver of liability",
        "documentation": "Waiver of liability.",
        "label": "Waiver Of Liability"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_WaiverOfRelatedPartyBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "WaiverOfRelatedPartyBalance",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow",
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Waiver of related party balance",
        "terseLabel": "Transactions with related parties",
        "documentation": "Waiver of related party balance.",
        "label": "Waiver Of Related Party Balance"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waiver of related party balance of Mr. Siu Wing Fung, Alfred [Member]",
        "label": "Waiver Of Related Party Balance Of Mr Siu Wing Fung Alfred Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r272"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding - basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r272"
     ]
    },
    "nivf_WellImageLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "WellImageLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Well Image Limited [Member]",
        "label": "Well Image Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_WhiteLionCapitalLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "WhiteLionCapitalLLCMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "White Lion Capital, LLC [Member]",
        "label": "White Lion Capital LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_WhiteLionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "WhiteLionMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "White Lion [Member]",
        "label": "White Lion Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_WhiteLionPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "WhiteLionPurchaseAgreementMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "White Lion Purchase Agreement [Member]",
        "label": "White Lion Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_Within90DaysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "Within90DaysMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 90 days [Member]",
        "label": "Within90 Days Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabiltiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation payable",
        "label": "Workers' Compensation Liability, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "nivf_convertiblePromissoryNoteDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20241231",
     "localname": "convertiblePromissoryNoteDiscountPercentage",
     "presentation": [
      "http://www.newgenivf.com/role/ConvertibleNotesPromissoryNotesDerivativeLiabilityandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible promissory note discount percentage",
        "documentation": "Convertible promissory note discount percentage.",
        "label": "convertible Promissory Note Discount Percentage"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "9",
   "Subsection": "06",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310/tableOfContent"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/326/tableOfContent"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-25"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "80",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Subparagraph": "(a)",
   "Publisher": "SEC"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-27"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
